<?xml version="1.0" encoding="UTF-8" ?>
<xml>
    <records>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>407</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">407</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1568</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Aagaard, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Amarzguioui, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, G. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Santos, L. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ehsani, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Prydz, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Mol Biol, Duarte, CA 91010 USA. Univ Oslo, Biotechnol Ctr Oslo, Oslo,
                    Norway.&#xD;Rossi, JJ, City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol,
                    1450 E Duarte Rd, Duarte, CA 91010 USA.&#xD;jrossi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A facile lentiviral vector
                        system for expression of doxycycline-inducible shRNAs: knockdown of the
                        pre-miRNA processing enzyme Drosha</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">938-945</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA INTERFERENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICRORNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-0016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245999500012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">RNA interference (RNAi) is a
                    powerful genetic tool for loss-of-function studies in mammalian cells and is
                    also considered a potentially powerful therapeutic modality for the treatment of
                    a variety of human diseases. During the past 3 years a number of systems for
                    conditional RNAi have been developed that allow controlled expression of short
                    hairpin RNA (shRNA) triggers of RNAi. The simplest strategy relies on
                    tet-operable polymerase III-promoted shRNAs and co-expression of the
                    tetracycline regulatory protein, TetR. In this study we have combined these
                    features into a single lentiviral vector that upon delivery to target cells
                    allows robust induction of shRNAs, even with low levels of doxycycline;
                    importantly, we show minimal leakiness in the absence of inducer. We have
                    exploited the regulatory properties of our system by targeting an essential
                    cellular gene, the nuclear RNaseIII endonuclease Drosha. Drosha is the core
                    catalytic component of the &quot;microprocessor complex&quot; and cleaves the
                    primary microRNA ( miRNA) transcripts into their pre-miRNA hairpin
                    intermediates. We anticipate that our vector will facilitate functional studies
                    of miRNA biogenesis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    161FI&#xD;Times Cited: 0&#xD;Cited Reference Count: 29&#xD;Cited References:
                    &#xD; AAGAARD L, 2002, J GEN VIROL 2, V83, P439&#xD; AMAR L, 2006, NUCLEIC ACIDS
                    RES, V34&#xD; AMARZGUIOUI M, 2004, BIOCHEM BIOPH RES CO, V316, P1050&#xD; AN DS,
                    2006, MOL THER, V14, P494&#xD; BARTEL DP, 2004, CELL, V116, P281&#xD; BERNSTEIN
                    E, 2003, NAT GENET, V35, P215&#xD; CASTANOTTO D, 2002, RNA, V8, P1454&#xD; CHEN
                    YC, 2003, CANCER RES, V63, P4801&#xD; CZUDERNA F, 2003, NUCLEIC ACIDS RES, V31,
                    E127&#xD; DICKINS RA, 2005, NAT GENET, V37, P1289&#xD; GREGORY RI, 2004, NATURE,
                    V432, P235&#xD; GUPTA S, 2004, P NATL ACAD SCI USA, V101, P1927&#xD; HAN J,
                    2004, GENE DEV, V18&#xD; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345&#xD;
                    HOHJOH H, 2004, FEBS LETT, V557, P193&#xD; HOLEN T, 2005, NUCLEIC ACIDS RES,
                    V33, P4704&#xD; KLOOSTERMAN WP, 2006, DEV CELL, V11, P441&#xD; LEE Y, 2003,
                    NATURE, V425, P415&#xD; LI MJ, 2005, METH MOL B, V309, P261&#xD; LIN SK, 2004,
                    ASIAN J CONTROL, V6, P376&#xD; MATSUKURA S, 2003, NUCLEIC ACIDS RES, V31&#xD;
                    OHKAWA J, 2000, HUM GENE THER, V11, P577&#xD; SCHWARZ DS, 2003, CELL, V115,
                    P199&#xD; SIOLAS D, 2005, NAT BIOTECHNOL, V23, P227&#xD; STEGMEIER F, 2005, P
                    NATL ACAD SCI USA, V102, P13212&#xD; SZULC J, 2006, NAT METHODS, V3, P109&#xD;
                    VANDEWETERING M, 2003, EMBO REP, V4, P609&#xD; VENTURA A, 2004, P NATL ACAD SCI
                    USA, V101, P10380&#xD; WIZNEROWICZ M, 2003, J VIROL, V77, P8957</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245999500012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>557</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">557</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1953</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Aagaard, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">RNAi therapeutics: principles,
                        prospects and challenges</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Adv Drug Deliv Rev</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Advanced Drug Delivery
                        Reviews</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Adv. Drug Deliv. Rev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Adv Drug Deliv Rev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">75-86</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">59</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2-3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Biological</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nanoparticles/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Neoplasms/genetics/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA,
                        Messenger/genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small
                        Interfering/chemistry/ genetics/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Virus
                        Diseases/genetics/therapy</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar 30</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0169-409X (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17449137</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">RNA interference (RNAi) was
                    discovered less than a decade ago and already there are human clinical trials in
                    progress or planned. A major advantage of RNAi versus other antisense based
                    approaches for therapeutic applications is that it utilizes cellular machinery
                    that efficiently allows targeting of complementary transcripts, often resulting
                    in highly potent down-regulation of gene expression. Despite the excitement
                    about this remarkable biological process for sequence specific gene regulation,
                    there are a number of hurdles and concerns that must be overcome prior to making
                    RNAi a real therapeutic modality, which include off-target effects, triggering
                    of type I interferon responses, and effective delivery in vivo. This review
                    discusses mechanistic aspects of RNAi, the potential problem areas and solutions
                    and therapeutic applications. It is anticipated that RNAi will be a major
                    therapeutic modality within the next several years, and clearly warrants intense
                    investigation to fully understand the mechanisms involved.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>656</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">656</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1566</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Adamson, P. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Matthay, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Brien, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reaman, G. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sato, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Balis, F. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Childrens Hosp Philadelphia, Div
                    Clin Pharmacol &amp; Therapeut, Philadelphia, PA 19104 USA. Univ Calif San
                    Francisco, Sch Med, San Francisco, CA 94143 USA. NCI, Pediat Oncol Branch,
                    Bethesda, MD 20892 USA. Childrens Natl Med Ctr, Washington, DC 20010 USA. City
                    Hope Natl Med Ctr, Duarte, CA 91010 USA.&#xD;Adamson, PC, Childrens Hosp
                    Philadelphia, Div Clin Pharmacol &amp; Therapeut, ARC 916,3615 Civ Ctr Blvd,
                    Philadelphia, PA 19104 USA.&#xD;adamsonp@mail.med.upenn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A phase 2 trial of
                        all-trans-retinoic acid in combination with interferon-alpha 2A in children
                        with recurrent neuroblastoma or Wilms tumor: A pediatric oncology branch,
                        NCI and children&apos;s oncology group study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pediatric Blood &amp;
                        Cancer</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Pediatr. Blood Cancer</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatric Blood &amp;
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatr. Blood Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatr Blood Cancer</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatric Blood &amp;
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatr. Blood Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatr Blood Cancer</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">661-665</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">49</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">interferon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neuroblastoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase 2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">retinoic acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Wilms tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN NEURO-BLASTOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REFRACTORY
                        PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIGH-RISK NEUROBLASTOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">13-CIS-RETINOIC ACID</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">II TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERMITTENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SCHEDULE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALPHA-INTERFERON</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLINICAL-TRIAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1545-5009</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249085300011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background The combination of the
                    anti proliferative and differentiation-inducing effects of retinoids together
                    with the anti-proliferative, immunostimulatory, and differentiation-potentiating
                    effects of interferon-a (IFN-alpha) were the basis for the development of this
                    combination in pediatric patients with refractory neuroblastoma or Wilms tumor.
                    Procedure. A phase 2 trial of all-trans-retinoic acid (ATRA), administered
                    orally at a dose of 90 mg/m(2)/day in three divided doses for 3 consecutive days
                    per week, and IFN-alpha 2a, administered subcutaneously daily at a dose of 3 x
                    10(6) U/m(2)/day for 5 consecutive days per week, in 4 week cycles was
                    performed. A two-stage design was used for each disease stratum. Results.
                    Seventeen patients 0 6 evaluable) with neuroblastoma, median age 9 years, and 15
                    patients (14 evaluable) with Wilms tumor, median age 6 years, were enrolled.
                    Overall, the combination was well tolerated, with headache being the most common
                    toxicity observed. There were no complete or partial responses. The median
                    number of cycles administered was 1 (range 1-9). Four patients with
                    neuroblastoma had stable disease for 12 or more weeks. Conclusions. The
                    combination of ATRA and IFN-alpha 2a was inactive in children with relapsed or
                    refractory neuroblastoma and Wilms tumor. The lack of activity with this
                    combination in children with refractory neuroblastoma is similar to the
                    disappointing phase 2 results of single agent 13-cis-retinoic-acid (13cRA) and
                    does not support further development of ATRA for children with relapsed
                    neuroblastoma.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    205AO&#xD;Times Cited: 0&#xD;Cited Reference Count: 52</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249085300011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>805</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">805</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1565</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ai, C. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Digiusto, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, C. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Hematol
                    Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. City Hope Natl Med Ctr,
                    Dept Diabet Endocrinol &amp; Metab, Duarte, CA 91010 USA. City Hope Natl Med
                    Ctr, Dept Cytogenet, Duarte, CA 91010 USA.&#xD;Shih, CC, City Hope Natl Med Ctr,
                    Div Hematol Hematopoiet Cell Transplantat, Fox N Res Bldg,1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;cshih@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Human marrow-derived mesodermal
                        progenitor cells generate insulin-secreting islet-like clusters in
                        vivo</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Stem Cells and
                        Development</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Stem cells and
                        development</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Stem Cells Dev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Stem Cells Dev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">757-770</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">16</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATIC BETA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EX-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIFFERENTIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPANSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1547-3287</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251266900007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Transplantation of pancreatic islet
                    cells is the only known potential cure for diabetes mellitus. However, the
                    difficulty in obtaining sufficient numbers of purified islets for
                    transplantation severely limits its use. A renewable and clinically accessible
                    source of stem cells capable of differentiating into insulin-secreting
                    beta-cells might circumvent this limitation. Here, we report that human fetal
                    bone marrow (BM)-derived mesodermal progenitor cells (MPCs) possess the
                    potential to generate insulin-secreting islet-like clusters (ISILCs) when
                    injected into human fetal pancreatic tissues implanted in severe combined
                    immunodeficiency ( SCID) mice. Seven essential genes involved in pancreatic
                    endocrine development, including insulin, glucagon, somatostatin, pdx-1, glut-2,
                    nkx 2.2, and nkx 6.1, are expressed in these BM-MPC-derived ISILCs, suggesting
                    that ISILCs are generated through neogenesis of BM-MPCs. Our data further
                    suggest that differentiation of BM-MPCs into ISILCs is not mediated by cell
                    fusion. Insulin secretion from these ISILCs is regulated by glucose
                    concentration in vitro, and transplantation of purified ISILCs normalizes
                    hyperglycemia in streptozocin (STZ)induced nonobese diabetic (NOD)/SCID
                    mice.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    235XF&#xD;Times Cited: 0&#xD;Cited Reference Count: 50&#xD;Cited References:
                    &#xD; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977&#xD; ALVAREZDOLADO M,
                    2003, NATURE, V425, P968&#xD; BAUM CM, 1992, P NATL ACAD SCI USA, V89,
                    P2804&#xD; BJORNSON CRR, 1999, SCIENCE, V283, P534&#xD; BRAZELTON TR, 2000,
                    SCIENCE, V290, P1775&#xD; CASTRO RF, 2002, SCIENCE, V297, P1299&#xD; CHOI JB,
                    2003, DIABETOLOGIA, V46, P1366&#xD; CHOW WA, 2006, CANCER GENET CYTOGEN, V166,
                    P95&#xD; FIORETTO P, 1998, NEW ENGL J MED, V339, P69&#xD; FUCHS E, 2000, CELL,
                    V100, P143&#xD; HEGRE OD, 1973, DIABETES, V22, P577&#xD; HEGRE OD, 1975, ANAT
                    REC, V185, P209&#xD; HESS D, 2003, NAT BIOTECHNOL, V21, P763&#xD; HORI Y, 2002,
                    P NATL ACAD SCI USA, V99, P16105&#xD; IANUS A, 2003, J CLIN INVEST, V111,
                    P843&#xD; JIANG YH, 2002, EXP HEMATOL, V30, P896&#xD; JIANG YH, 2002, NATURE,
                    V418, P41&#xD; KODAMA S, 2003, SCIENCE, V302, P1223&#xD; KRAUSE DS, 2001, CELL,
                    V105, P369&#xD; KYOIZUMI S, 1992, BLOOD, V79, P1704&#xD; LAMMERT E, 2001,
                    SCIENCE, V294, P564&#xD; LAMMERT E, 2003, MECH DEVELOP, V120, P59&#xD; LAZZAROW
                    A, 1973, DIABETES, V22, P877&#xD; LECHNER A, 2004, DIABETES, V53, P616&#xD;
                    LUMELSKY N, 2001, SCIENCE, V292, P1389&#xD; MCCUNE JM, 1988, SCIENCE, V241,
                    P1632&#xD; MEZEY E, 2000, SCIENCE, V290, P1779&#xD; PEAR WS, 1998, BLOOD, V92,
                    P3780&#xD; PITTENGER MF, 1999, SCIENCE, V284, P143&#xD; POVLSEN CO, 1974,
                    NATURE, V248, P247&#xD; RAMIYA VK, 2000, NAT MED, V6, P278&#xD; REYES M, 2001,
                    BLOOD, V98, P2615&#xD; SHAPIRO AMJ, 2000, NEW ENGL J MED, V343, P230&#xD; SHIH
                    CC, 1999, BLOOD, V94, P1623&#xD; SHIH CC, 2000, BLOOD, V95, P1957&#xD; SHIH CC,
                    2000, EXP HEMATOL, V28, P1046&#xD; SHIH CC, 2001, BLOOD, V98, P2412&#xD; TERADA
                    N, 2002, NATURE, V416, P542&#xD; THOMSON JA, 1998, SCIENCE, V282, P1147&#xD;
                    TODOROV I, 2006, PANCREAS, V32, P130&#xD; TUCH BE, 1984, DIABETES, V33,
                    P1180&#xD; TUCH BE, 1986, DIABETES, V35, P464&#xD; USADEL KH, 1980, DIABETES S1,
                    V29, P74&#xD; VASSILOPOULOS G, 2003, NATURE, V422, P901&#xD; WAGERS AJ, 2002,
                    SCIENCE, V297, P2256&#xD; WANG X, 2003, NATURE, V422, P897&#xD; WEISSMAN IL,
                    2000, CELL, V100, P157&#xD; YAM PY, 2002, MOL THER, V5, P479&#xD; YING QL, 2002,
                    NATURE, V416, P545&#xD; ZULEWSKI H, 2001, DIABETES, V50, P521</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251266900007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>628</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">628</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1561</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Alberts, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, P. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilczynski, S. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jang, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moon, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ward, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Beck, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clouser, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Markman, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Arizona, Arizona Canc Ctr,
                    Tucson, AZ 85724 USA. SW Oncol Grp, Ctr Stat, Seattle, WA USA. City Hope Natl
                    Med Ctr, Duarte, CA 91010 USA. So Calif Permanente Med Grp, Riverside, CA USA.
                    Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA. Univ Arkansas Med Sci, Little
                    Rock, AR 72205 USA. Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030
                    USA.&#xD;Alberts, DS, Univ Arizona, Arizona Canc Ctr, Box 245024,1515 N Campbell
                    Ave, Tucson, AZ 85724 USA.&#xD;dalberts@azcc.arizona.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase II trial of imatinib
                        mesylate in recurrent, biomarker positive, ovarian cancer (Southwest
                        Oncology Group Protocol S0211)</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Gynecological Cancer</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Int. J. Gynecol. Cancer</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Gynecological Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Gynecol. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Gynecol Cancer</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Gynecological Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Gynecol. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Gynecol Cancer</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">784-788</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">imatinib mesylate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kit (CD117)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ovarian cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PDGFR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TYROSINE KINASE
                        INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-KIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EFFICACY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul-Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1048-891X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248302900005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Platinum-resistant ovarian cancer
                    continues to be a difficult therapeutic problem. Clearly, molecularly targeted
                    agents should be evaluated in this patient population. Patients were eligible
                    for this phase II study with stage III or IV ovarian cancer, whose tumor
                    expressed Kit (CD117) or platelet-derived growth factor receptor (PDGFR) and
                    with relapse of measurable disease within 6 months of completing frontline,
                    platinum- and taxane-based chemotherapy. Patients were treated daily with 400 mg
                    of imatinib mesylate orally. It was assumed that the agent would be of no
                    further interest if the population response rate was less than 10%. A two-stage
                    design was used for patient accrual. A total of 34 patients were registered to
                    the study. Of these, 15 were found to be ineligible or not evaluable (8 because
                    their tumor samples were negative for both DC117 and PDGFR). Of 19 evaluable
                    patients, 2 (11%) tested positively for c-Kit and 17 (89%) tested positively for
                    PDGFR. There were no objective responders. Thirteen patients (68%) had
                    increasing disease or symptomatic deterioration and six (32%) went off protocol
                    during the first month due to adverse events. Median progression-free survival
                    was 2 months (95% CI 1-3 months) and median overall survival was 10 months (95%
                    CI 6-18 months). Eleven percent of patients experienced grade 4
                    hematologic/metabolic toxicity and 37% experienced grade 3 nonhematologic
                    toxicity. We conclude that imatinib mesylate as a single agent does not appear
                    to have useful clinical activity in c-Kit and/or PDGFR positive, recurrent
                    ovarian cancer in heavily pretreated patients with ovarian cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    193VI&#xD;Times Cited: 0&#xD;Cited Reference Count: 20</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248302900005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>960</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">960</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1948</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Altilio, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gardia, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Otis-Green, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pain Medicine &amp;
                    Palliative Care, Beth Israel Medical Center, 350 East 17th Street, Baird 12, New
                    York, NY 10003, USA. taltilio@chpnet.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Social work practice in
                        palliative and end-of-life care: a report from the summit</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Soc Work End Life Palliat
                        Care</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">J Soc Work End Life Palliat
                        Care</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">68-86</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <edition>
                <style face="normal" font="default" size="100%">2008/10/22</style>
            </edition>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Attitude of Health
                        Personnel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clinical Competence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Consensus Development
                        Conferences as Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interdisciplinary
                        Communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interprofessional
                        Relations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/ organization
                        &amp; administration/standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Patient Care
                        Planning/organization &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Physician&apos;s Practice
                        Patterns</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Work/ organization &amp;
                        administration/standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Terminal Care/ organization
                        &amp; administration/standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1552-4256 (Print)&#xD;1552-4256
                    (Linking)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18928082</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In 2005 a Social Work Summit on
                    End-of-Life and Palliative Care was hosted by the National Association of Social
                    Workers (NASW) with support from the Project on Death in America (PDIA) and
                    National Hospice and Palliative Care Organization (NHPCO). Building on the work
                    of a first summit held in 2002, work groups focused on practice, research,
                    policy, and education with &quot;State of the Field&quot; presentations used as
                    a point of convergence for setting priorities and developing action plans. This
                    article describes a process of document selection and review which was designed
                    to isolate aspects of social work practice and to determine concordance with
                    domains and guidelines detailed in the interdisciplinary consensus document,
                    Clinical Practice Guidelines for Quality Palliative Care, a publication of the
                    National Consensus Project for Quality Palliative Care
                    (http://www.nationalconsensusproject.org). In addition, a group of documents
                    written by colleagues in medicine and nursing were chosen for evaluation as they
                    reflect the emerging and valued incorporation of palliative care principles into
                    specialties such as pediatrics and intensive care. This second review was
                    focused on determining the nature and scope of social work presence and
                    participation and on understanding if the role of the profession was clearly
                    articulated in these specialty areas. This article discusses the historical
                    context and relevant findings that may contribute to the growth of the
                    profession in this rich and burgeoning specialty.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">Altilio, Terry&#xD;Gardia,
                    Gary&#xD;Otis-Green, Shirley&#xD;United States&#xD;Journal of social work in
                    end-of-life &amp; palliative care&#xD;J Soc Work End Life Palliat Care.
                    2007;3(4):68-86.</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed</style>
            </custom1>
            <remote-database-provider>
                <style face="normal" font="default" size="100%">Nlm</style>
            </remote-database-provider>
            <language>
                <style face="normal" font="default" size="100%">eng</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>585</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">585</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1559</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Amador-Noguez, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dean, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, W. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Setchell, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Darlington, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Baylor Coll Med, Dept Human Mol
                    Genet, Houston, TX 77030 USA. Baylor Coll Med, Huffington Ctr Aging, Houston, TX
                    77030 USA. Baylor Coll Med, Dept Mol &amp; Cellular Biol, Houston, TX 77030 USA.
                    Beckman Res Inst, Dept Gene regulat &amp; Drug Discovery, Duarte, CA USA.
                    Childrens Hosp, Med Ctr, Dept CLin Mass Spect, Cincinnati, OH 45229
                    USA.&#xD;Amador-Noguez, D, Baylor Coll Med, Dept Human Mol Genet, One Baylor
                    Plaza,N803, Houston, TX 77030 USA.&#xD;da135453@bcm.tmc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Alterations in xenobiotic
                        metabolism in the long-lived Little mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Aging Cell</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Aging Cell</style>
                </alt-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">453-470</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">aging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bile acid metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Little mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mouse</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nuclear hormone
                        receptors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stress resistance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">xenobiotic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREGNANE-X-RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSTITUTIVE ANDROSTANE
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORPHAN NUCLEAR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BILE-ACID SYNTHESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OXIDATIVE STRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIFE-SPAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBON-TETRACHLORIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CAENORHABDITIS-ELEGANS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCED HEPATOTOXICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CALORIE RESTRICTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1474-9718</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248088000007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Our previous microarray expression
                    analysis of the long-lived Little mice (Ghrhr(lit/lit)) showed a concerted
                    up-regulation of xenobiotic detoxification genes. Here, we show that this
                    up-regulation is associated with a potent increase in resistance against the
                    adverse effects of a variety of xenobiotics, including the hepatotoxins
                    acetaminophen and bromobenzene and the paralyzing agent zoxazolamine. The
                    classic xenobiotic receptors Car (Constitutive Androstane Receptor) and Pxr
                    (Pregnane X Receptor) are considered key regulators of xenobiotic metabolism.
                    Using double and triple knockout/mutant mouse models we found, however, that Car
                    and Pxr are not required for the up-regulation of xenobiotic genes in Little
                    mice. Our results suggest instead that bile acids and the primary bile acid
                    receptor Fxr (farnesoid X receptor) are likely mediators of the up-regulation of
                    xenobiotic detoxification genes in Little mice. Bile acid levels are
                    considerably elevated in the bile, serum, and liver of Little mice. We found
                    that treatment of wild-type animals with cholic acid, one of the major bile
                    acids elevated in Little mice, mimics in large part the up-regulation of
                    xenobiotic detoxification genes observed in Little mice. Additionally, the loss
                    of Fxr had a major effect on the expression of the xenobiotic detoxification
                    genes up-regulated in Little mice. A large fraction of these genes lost or
                    decreased their high expression levels in double mutant mice for Fxr and Ghrhr.
                    The alterations in xenobiotic metabolism in Little mice constitute a form of
                    increased stress resistance and may contribute to the extended longevity of
                    these mice.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    190VF&#xD;Times Cited: 0&#xD;Cited Reference Count: 66</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248088000007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>868</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">868</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1558</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Anderson, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hellan, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lai, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Trisal, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pigazzi, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Gen
                    &amp; Oncol Surg, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Thorac
                    Surg, Duarte, CA 91010 USA.&#xD;Pigazzi, A, Duarte Rd, Duarte, CA 91010
                    USA.&#xD;apigazzi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Robotic surgery for
                        gastrointestinal malignancies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of Medical
                        Robotics and Computer Assisted Surgery</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">297-300</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">robotics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gastrointestinal
                        malignancies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gastric cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophageal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rectal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED
                        CLINICAL-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOTAL MESORECTAL
                        EXCISION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINIMALLY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INVASIVE ESOPHAGECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODE DISSECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTRIC-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBTOTAL GASTRECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LAPAROSCOPIC SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTERIOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISTAL GASTRECTOMY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1478-5951</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252867300003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background This report describes our
                    initial experience with the use of robotic-assisted surgery for the treatment of
                    gastrointestinal (GI) malignancies. Methods Between November 2004 and July 2007,
                    73 robotic procedures (26 female, 47 male) for GI cancer were performed and
                    retrospectively reviewed. Procedures included 25 oesophagectornies, 11
                    gastrectornies and 37 rectal resections. The median body mass index (BMI) for
                    this patient population was 26. Results The median operative times for rectal,
                    oesophageal and gastric resections were 285, 482 and 430 min, respectively.
                    There were three conversions. Major postoperative morbidity was 16% for rectal,
                    32% for oesophageal and 9% for gastric procedures. The leak rate was 11% for
                    rectal, 16% for oesophageal and 9% for gastric anastomoses. Median length of
                    stay was 4, 11 and 5 days, respectively. The median number of lymph nodes
                    harvested was 13, 22, and 26 for rectal, oesophageal and gastric
                    lymphadenectomies, respectively. At a median follow-up of 9 months, one patient
                    developed a port site recurrence; 30 day mortality was zero. Conclusion This
                    initial experience suggests that the robotic approach is safe and feasible for a
                    variety of radical oncological surgical procedures. Copyright (c) 2007 John
                    Wiley &amp; Sons, Ltd.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    258KR&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; AHLERING TE, 2003, J UROLOGY, V170, P1738&#xD; ANDERSON C, 2007, SURG
                    ENDOSC, V21, P1662&#xD; BODNER J, 2005, SWISS MED WKLY, V135, P674&#xD; BODNER
                    J, 2005, WORLD J SURG, V29, P982&#xD; BOTTGER T, 2006, ZBL CHIR, V131, P466&#xD;
                    BRAGA M, 2007, DIS COLON RECTUM, V50, P464&#xD; BRAGHETTO I, 2006, SURG ENDOSC,
                    V20, P1681&#xD; BRETAGNOL F, 2005, SURG ENDOSC, V19, P892&#xD; BREUKINK SO,
                    2005, INT J COLORECTAL DIS, V20, P428&#xD; CADIERE GB, 2001, WORLD J SURG, V25,
                    P1467&#xD; DRAAISMA WA, 2006, BRIT J SURG, V93, P1351&#xD; FLESHMAN JW, 1999,
                    DIS COLON RECTUM, V42, P930&#xD; FOLLIGUET T, 2006, EUR J CARDIO-THORAC, V29,
                    P362&#xD; GIULIANOTTI PC, 2003, ARCH SURG-CHICAGO, V138, P777&#xD; GUILLOU PJ,
                    2005, LANCET, V365, P1718&#xD; HASHIZUME M, 2004, JPN J CLIN ONCOL, V34,
                    P227&#xD; HUSCHER CGS, 2005, ANN SURG, V241, P232&#xD; JANSON M, 2004, BRIT J
                    SURG, V91, P409&#xD; JAYNE DG, 2005, BRIT J SURG, V92, P1124&#xD; KERNSTINE KH,
                    2004, J THORAC CARDIOV SUR, V127, P1847&#xD; LAW WL, 2006, DIS COLON RECTUM,
                    V49, P1108&#xD; MELVIN WS, 2005, SURGERY, V138, P553&#xD; MENON M, 2007, EUR
                    UROL, V51, P648&#xD; NIFONG LW, 2005, J THORAC CARDIOV SUR, V129, P1395&#xD;
                    PIGAZZI A, 2006, SURG ENDOSC, V20, P1521&#xD; RUURDA JP, 2005, DIGEST SURG, V22,
                    P313&#xD; SHIMIZU S, 2000, SURG ENDOSC-ULTRAS, V14, P27&#xD; SMITH JA, 2005, J
                    CLIN ONCOL, V23, P8170&#xD; SMITHERS BM, 2007, ANN SURG, V245, P232&#xD;
                    TALAMINI MA, 2003, SURG ENDOSC, V17, P1521&#xD; TANIMURA S, 2005, SURG ENDOSC,
                    V19, P1177</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252867300003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>415</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">415</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1557</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Anderson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palmer, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Remling, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yam, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yee, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zaia, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Akkina, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Colorado State Univ, Dept Microbiol
                    Immunol &amp; Pathol, Ft Collins, CO 80523 USA. City Hope Natl Med Ctr, Beckman
                    Res Inst, Div Mol Biol, Duarte, CA 91010 USA.&#xD;Akkina, R, Colorado State
                    Univ, Dept Microbiol Immunol &amp; Pathol, 1619 Campus Delivery, Ft Collins, CO
                    80523 USA.&#xD;akkina@colostate.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Safety and efficacy of a
                        lentiviral vector containing three anti-HIV genes - CCR5 ribozyme, tat-rev
                        siRNA, and TAR decoy - in SCID-hu mouse-derived T cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1182-1188</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">VIRUS TYPE-1 REPLICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMALL INTERFERING RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDIATED INHIBITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTI-CCR5 RIBOZYME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFECTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-0016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246555800021</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Gene therapeutic strategies show
                    promise in controlling human immunodeficiency virus (HIV) infection and in
                    restoring immunological function. A number of efficacious anti-HIV gene
                    constructs have been described so far, including small interfering RNAs
                    (siRNAs), RNA decoys, transdominant proteins, and ribozymes, each with a
                    different mode of action. However, as HIV is prone to generating escape mutants,
                    the use of a single anti-HIV construct would not be adequate to afford long
                    range-viral protection. On this basis, a combination of highly potent anti-HIV
                    genes - namely, a short hairpin siRNA (shRNA) targeting rev and tat, a
                    transactivation response (TAR) decoy, and a CCR5 ribozyme - have been inserted
                    into a third-generation lentiviral vector. Our recent in vitro studies with this
                    construct, Triple-R, established its efficacy in both T-cell lines and CD34 cell
                    - derived macrophages. In this study, we have evaluated this combinatorial
                    vector in vivo. Vector-transduced CD34 cells were injected into severe combined
                    immunodeficiency (SCID)-hu mouse thy/liv grafts to determine their capacity to
                    give rise to T cells. Our results show that phenotypically normal transgenic T
                    cells are generated that are able to resist HIV-1 infection when challenged in
                    vitro. These important attributes of this combinatorial vector show its promise
                    as an excellent candidate for use in human clinical trials.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    168WX&#xD;Times Cited: 0&#xD;Cited Reference Count: 46&#xD;Cited References:
                    &#xD; AKKINA R, 2003, ANTICANCER RES, V23, P1997&#xD; AKKINA RK, 1994, BLOOD,
                    V84, P1393&#xD; AN DS, 1997, J VIROL, V71, P1397&#xD; ANDERSON J, 2005, MOL
                    THER, V12, P687&#xD; ANDERSON J, 2005, RETROVIROLOGY, V2&#xD; BACHELER LT, 2000,
                    ANTIMICROB AGENTS CH, V44, P2475&#xD; BAI JR, 2000, MOL THER, V1, P244&#xD;
                    BANERJEA A, 2003, MOL THER, V8, P62&#xD; BANERJEA A, 2004, AIDS RES THER, V1,
                    P2&#xD; BERGER EA, 1999, ANNU REV IMMUNOL, V17, P657&#xD; BODEN D, 2003, J
                    VIROL, V77, P11531&#xD; CAGNON L, 2000, ANTISENSE NUCLEIC A, V10, P251&#xD;
                    CAPODICI J, 2002, J IMMUNOL, V169, P5196&#xD; COBURN GA, 2002, J VIROL, V76,
                    P9225&#xD; DAS AT, 2004, J VIROL, V78, P2601&#xD; DAVE RS, 2003, REV MED VIROL,
                    V13, P373&#xD; DROPULIC B, 2006, HUM GENE THER, V17, P577&#xD; ELBASHIR SM,
                    2001, NATURE, V411, P494&#xD; FAUCI AS, 1996, NATURE, V384, P529&#xD; FEDOROV Y,
                    2006, RNA, V12, P1188&#xD; FIRE A, 1998, NATURE, V391, P806&#xD; HUANG RD, 1996,
                    FINANCIAL MARKETS I, V5, P1&#xD; HUMEAU LM, 2004, MOL THER, V9, P902&#xD; JACQUE
                    JM, 2002, NATURE, V418, P435&#xD; JOSHI PJ, 2005, MOL THER, V11, P677&#xD; KOHN
                    DB, 1999, BLOOD, V94, P368&#xD; LAFEUILLADE A, 2001, HIV MED, V2, P231&#xD; LEE
                    NS, 2002, NAT BIOTECHNOL, V20, P500&#xD; LI MJ, 2003, MOL THER, V8, P196&#xD; LI
                    MJ, 2005, MOL THER, V12, P900&#xD; LIU R, 1996, CELL, V86, P367&#xD;
                    MARTINEZPICADO J, 2000, P NATL ACAD SCI USA, V97, P10948&#xD; MCCUNE JM, 2001,
                    NATURE, V410, P974&#xD; NAIF HM, 2002, J VIROL, V76, P3114&#xD; NALDINI L, 1996,
                    SCIENCE, V272, P263&#xD; NOVINA CD, 2002, NAT MED, V8, P681&#xD; QIN XF, 2003, P
                    NATL ACAD SCI USA, V100, P183&#xD; SCACHERI PC, 2004, P NATL ACAD SCI USA, V101,
                    P1892&#xD; STRAYER DS, 2005, MOL THER, V11, P823&#xD; SULLENGER BA, 1991, J
                    VIROL, V65, P6811&#xD; SWAN CH, 2006, GENE THER, V20, P1480&#xD; UCHIDA N, 1998,
                    P NATL ACAD SCI USA, V95, P11939&#xD; ULICH C, 1996, J VIROL, V70, P4871&#xD;
                    WESTERHOUT EM, 2005, NUCLEIC ACIDS RES, V33, P796&#xD; YAM P, 2006, MOL THER,
                    V14, P236&#xD; YAM PY, 2002, MOL THER, V5, P479</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246555800021 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>258</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">258</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1555</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Appelbaum, F. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenblum, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Arceci, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carroll, W. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Breitfeld, P. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Larson, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Murphy, S. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Brien, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Radich, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scher, N. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, F. O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stone, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tallman, M. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr, Div
                    Clin Res, Seattle, WA 98109 USA. NIH, Bethesda, MD 20892 USA. Johns Hopkins,
                    Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. Mt Sinai Sch Med, Sch Med,
                    New York, NY USA. NYU, Sch Med, New York, NY USA. Duke Univ, Sch Med, Durham, NC
                    USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Univ Chicago, Med Ctr,
                    Chicago, IL 60637 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Texas,
                    Hlth Sci Ctr, Childrens Canc Res Inst, San Antonio, TX 78285 USA. MD Anderson
                    Canc Ctr, Houston, TX USA. US FDA, Rockville, MD 20857 USA. Cincinnati Childrens
                    Hosp, Med Ctr, Cincinnati, OH USA. Northwestern Univ, Sch Med, Chicago, IL 60611
                    USA.&#xD;Appelbaum, FR, Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100
                    Fairview Ave N,D5-310,POB 19024, Seattle, WA 98109
                    USA.&#xD;fappelba@fhcrc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">End points to establish the
                        efficacy of new agents in the treatment of acute leukemia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1810-1816</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE-MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINIMAL RESIDUAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOGENOUS
                        LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELL
                        TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOLOGY-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RETROSPECTIVE ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GEMTUZUMAB OZOGAMICIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244641100011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Federal regulations provide 2
                    pathways for approval of new agents for the treatment of acute leukemia, regular
                    and accelerated approval. Regular approval requires evidence of clinical
                    benefit, which is generally defined as either prolongation of life or improved
                    quality of life, or an effect on an end point established as a surrogate for
                    clinical benefit. Accelerated approval can be obtained based on demonstration of
                    an effect on a surrogate measure &quot;reasonably likely&quot; to predict
                    clinical benefit, but requires demonstration of clinical benefit after approval
                    as well. The acute leukemias are a heterogeneous and relatively uncommon group
                    of diseases. The design and execution of prospective randomized clinical trials
                    demonstrating prolongation of life or improved quality of life for patients with
                    these disorders can be difficult and costly and require lengthy follow-up. Thus,
                    the development of novel trial design and inclusion of validated surrogate
                    markers for clinical benefit are needed. To explore some of the issues pertinent
                    to the choice of end points for drug approval in acute leukemia, the Food and
                    Drug Administration invited the American Society of Hematology to participate in
                    the organization and conduct of a joint workshop. In this report, we present the
                    results of that effort.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    142HW&#xD;Times Cited: 0&#xD;Cited Reference Count: 41&#xD;Cited References:
                    &#xD; *AM CANC SOC, 2006, CANC FACTS FIG&#xD; *US FDA, GUID IND AV THER&#xD; *US
                    FDA, 1998, GUID IND PROV CLIN E&#xD; APPELBAUM FR, 2004, CLIN ONCOLOGY,
                    P2825&#xD; APPELBAUM FR, 2005, AM SOC CLIN ONCOLOGY, P528&#xD; APPELBAUM FR,
                    2006, BLOOD, V107, P3481&#xD; BOROWITZ MJ, 2003, LEUKEMIA, V17, P1566&#xD;
                    CAMPANA D, 2001, LEUKEMIA, V15, P278&#xD; CHESON BD, 2003, J CLIN ONCOL, V21,
                    P4642&#xD; CHESON BD, 2004, J CLIN ONCOL, V22, P576&#xD; COUSTANSMITH E, 2002,
                    BLOOD, V100, P52&#xD; COUSTANSMITH E, 2004, LEUKEMIA, V18, P499&#xD; DEBOTTON S,
                    2005, J CLIN ONCOL, V23, P120&#xD; DEGREEF GE, 2005, BRIT J HAEMATOL, V128,
                    P184&#xD; ESTEY EH, 2002, BLOOD 1, V106, A161&#xD; FREIREICH EJ, 1961, J CHRON
                    DIS, V14, P593&#xD; HOELZER D, 2005, AM SOC CLIN ONCOLOGY, P533&#xD; KANTARJIAN
                    H, 2003, BLOOD, V102, P2379&#xD; KANTARJIAN HM, 2004, CLIN ONCOLOGY, P2793&#xD;
                    KREJCI O, 2003, BONE MARROW TRANSPL, V32, P849&#xD; LARSON RA, 1995, BLOOD, V85,
                    P2025&#xD; LARSON RA, 2005, CANCER, V104, P1442&#xD; LEITH CP, 1997, BLOOD, V89,
                    P3323&#xD; MIYAMOTO T, 1996, BLOOD, V87, P4789&#xD; NEMECEK ER, 2004, BONE
                    MARROW TRANSPL, V34, P799&#xD; PUI CH, 1998, NEW ENGL J MED, V339, P605&#xD;
                    RAVINDRANATH Y, 2005, LEUKEMIA, V19, P2101&#xD; RIES LAG, 1975, SEER CANC STAT
                    REV&#xD; SANMIGUEL JF, 2001, BLOOD, V98, P1746&#xD; SCOTT BL, 2006, LEUKEMIA,
                    V20, P128&#xD; SIERRA J, 1997, BLOOD, V89, P4226&#xD; SIEVERS EL, 2001, J CLIN
                    ONCOL, V19, P3244&#xD; SMITH FO, 2005, LEUKEMIA, V19, P2054&#xD; TALLMAN MS,
                    2005, AM SOC CLIN ONCOLOGY, P540&#xD; THIEDE C, 2006, BLOOD, V107, P4011&#xD;
                    VANDONGEN JJM, 1998, LANCET, V352, P1731&#xD; VARNI JW, 1999, MED CARE, V37,
                    P126&#xD; WHEATLEY K, 1999, BRIT J HAEMATOL, V107, P69&#xD; WILSON CS, 2006,
                    BLOOD, V108, P685&#xD; ZITTOUN R, 1997, BONE MARROW TRANSPL, V20, P307&#xD;
                    ZITTOUN R, 1999, PSYCHO-ONCOL, V8, P64</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244641100011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>667</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">667</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1550</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Arumugam, P. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scholes, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Perelman, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xia, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yee, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malik, P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Cincinnati Childrens Hosp Med Ctr,
                    Div Expt Hematol, Cincinnati, OH 45229 USA. Childrens Hosp Los Angeles, Saban
                    Res Inst, Div Hematol Oncol, Los Angeles, CA 90027 USA. City Hope Natl Med Ctr,
                    Beckman Res Inst, Dept Virol, Duarte, CA 91010 USA. USC Keck Sch Med, Dept
                    Pediat &amp; Pathol, Los Angeles, CA USA.&#xD;Malik, P, Cincinnati Childrens
                    Hosp Med Ctr, Div Expt Hematol, TCHRF 6564,ML 7013,3333 Burnet Ave, Cincinnati,
                    OH 45229 USA.&#xD;Punam.Malik@cchmc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Improved human beta-globin
                        expression from self-inactivating lentiviral vectors carrying the chicken
                        hypersensitive site-4 (cHS4) insulator element</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Ther</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Ther</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1863-1871</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">LOCUS-CONTROL REGION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MURINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ERYTHROLEUKEMIA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RETROVIRAL TRANSFER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHENOTYPIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CORRECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMATIN INSULATOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENHANCER BLOCKING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN GENOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-0016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249778000022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Effective gene therapy for
                    beta-thalassemia major (beta-TM) requires consistent, high expression of human
                    beta-globin (h beta-globin) in red blood cells (RBCs). Several groups have now
                    shown that lentiviral (LV) vectors stably transmit the h beta/h gamma-globin
                    genes and large elements of the locus control region, resulting in correction of
                    the murine thalassemia intermedia (TI) phenotype and survival of mice with the
                    TM phenotype. However, current LVs show variable h beta/h gamma-globin
                    expression and require a high number of vector copies/cell for a therapeutic
                    effect. To address this, we designed LVs flanked by the chicken hypersensitive
                    site-4 (cHS4) chromatin insulator element and compared them with their
                    &quot;un-insulated&quot; counterparts. We observed a consistent twofold-higher h
                    beta expression from insulated vectors in single-copy mouse erythroleukemia cell
                    clones, an increase that resulted from reduced position effect variegation (PEV)
                    and increased probability of expression from individual integrants. This effect
                    was confirmed in vivo: an approximately twofold increase in h beta expression
                    was seen in the RBC progeny of murine hematopoietic stem cells, with
                    significantly higher numbers of h beta-expressing cells in individual secondary
                    spleen colony-forming units. In summary, cHS4-insulated h beta-globin LVs showed
                    distinct chromatin barrier activity, resulting in higher, consistent h beta
                    expression. These studies have important implications for vector design for
                    clinical trials for gene therapy for hemoglobinopathies.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    214ZX&#xD;Times Cited: 0&#xD;Cited Reference Count: 48</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249778000022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>322</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">322</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1547</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ashing-Giwa, K. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tejero, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Padilla, G. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hellemann, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, CCARE, Div
                    Populat Sci, Duarte, CA 91010 USA. Univ Calif Los Angeles, Sch Med, Ctr Culture
                    &amp; Hlth, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept
                    Community Hlth Sci, Los Angeles, CA 90024 USA. Univ Calif San Francisco, Dept
                    Nursing, San Francisco, CA 94143 USA. Univ Calif Los Angeles, Semel Inst
                    Neuropsychiat Biostat Core, Los Angeles, CA USA.&#xD;Ashing-Giwa, KT, City Hope
                    Natl Med Ctr, CCARE, Div Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;kashing@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Examining predictive models of
                        HRQOL in a population-based, multiethnic sample of women with breast
                        carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Quality of Life Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Quality of Life Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Qual. Life Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Qual Life Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">413-428</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">16</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">culture</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ethnic minority</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health disparities</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HRQOL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">multiethnic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">social-ecology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASIAN-AMERICAN WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL-ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AFRICAN-AMERICAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TELEPHONE INTERVIEWS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOCIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUPPORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH SURVEY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WHITE WOMEN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0962-9343</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244692800005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: This study examined
                    health related quality of life (HRQOL) and its predictors among African-,
                    Asian-, Latina-, and European American breast cancer survivors (BCS) using a
                    socio-ecologically and culturally contextual theoretical model of HRQOL.
                    Methods: We employed a case-control, cross sectional design with a
                    population-based sample from the California Cancer Registry. Descriptive,
                    bivariate, and multivariate regression analyses were conducted. Results: The
                    sample included 703 BCS: 135 (19%) African-, 206 (29%) Asian-, 183 (26%)
                    Latina-, and 179 (26%) European Americans. Latinas reported the lowest HRQOL (p
                    &lt; 0.0001). The final regression model explained 70% of variance in HRQOL.
                    Years since diagnosis, number of comorbidities, role limitation, emotional
                    wellbeing, quality of doctor-patient relationship, social support, and life
                    stress are significant HRQOL determinants. Exploratory regression analyses
                    indicate ethnic differences in significant predictors for HRQOL. Conclusions:
                    HRQOL among this multiethnic sample ranged from fair to good. Bivariate analysis
                    suggests that ethnic differences in HRQOL exist. However, regression analyses
                    demonstrated that socio-ecological factors in conjunction with medical
                    characteristics are more salient to HRQOL outcomes, and that ethnic group
                    membership may be a proxy for socio-ecological context. Furthermore, the
                    influence of ethnicity, culture, and social-ecology are complex; research with
                    large, population-based samples are necessary to disentangle the impact of
                    contextual factors on HRQOL.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    143AQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 70&#xD;Cited References:
                    &#xD; *AM CANC SOC, 2003, CAL CANC FACTS FIG 2&#xD; *AM CANC SOC, 2003, CANC
                    PREV EARL DET F&#xD; *AM CANC SOC, 2004, CANC FACT FIG 2004&#xD; *AS PAC AM LEG
                    CTR, 2004, DIV FAC AS PAC ISL L&#xD; *SEER, SEER STAT DAT INC&#xD; *STATA, 2000,
                    STATA REF MAN&#xD; ANDERSON NB, 1995, PSYCHOSOM MED, V57, P213&#xD; ASHING K,
                    2006, PSYCHOSOC ONCOL, V24, P19&#xD; ASHING KT, 2003, PSYCHO-ONCOL, V12,
                    P38&#xD; ASHINGGIWA K, 1999, CANCER, V85, P418&#xD; ASHINGGIWA K, 2000,
                    PSYCHOSOC ONCOL, V17, P47&#xD; ASHINGGIWA KT, 2004, CANCER, V101, P450&#xD;
                    ASHINGGIWA KT, 2004, PSYCHO-ONCOL, V13, P408&#xD; ASHINGGIWA KT, 2005, ETHNIC
                    DIS, V15, P130&#xD; ASHINGGIWA KT, 2005, QUAL LIFE RES, V14, P297&#xD; AZIZ NM,
                    2002, J NUTR S, V132, S3494&#xD; AZIZ NM, 2002, ONCOL NURS FORUM, V29, P789&#xD;
                    BERRY JW, 1992, CROSS CULTURAL PSYCH&#xD; BOURJOLLY JN, 1998, SOC WORK HEALTH
                    CARE, V28, P21&#xD; BOURJOLLY JN, 1999, SOC WORK HEALTH CARE, V28, P1&#xD; BRADY
                    MJ, 1997, J CLIN ONCOL, V15, P974&#xD; BRAMBILLA DJ, 1987, AM J EPIDEMIOL, V126,
                    P962&#xD; CELLA D, 1998, MED CARE, V36, P1407&#xD; CELLA DF, 1993, CANCER
                    INVEST, V11, P327&#xD; CELLA DF, 1993, J CLIN ONCOL, V11, P570&#xD;
                    COSCARELLISCHAG A, 1993, J CLIN ONCOL, V11, P783&#xD; DEAPEN D, 2002, INT J
                    CANCER, V99, P747&#xD; DEIMLING GT, 2002, J PSYCHOSOC ONCOL, V20, P71&#xD;
                    DIMATTEO MR, 1993, PSYCHOL ASSESSMENT, V5, P102&#xD; DORVAL M, 1998, J CLIN
                    ONCOL, V16, P487&#xD; GANZ PA, 2002, J NATL CANCER I, V94, P39&#xD; GANZ PA,
                    2004, J NATL CANCER I, V96, P376&#xD; GIEDZINSKA AS, 2004, ANN BEHAV MED, V28,
                    P39&#xD; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619&#xD; GILLILAND FD, 1998,
                    CANCER, V82, P1769&#xD; GOTAY CC, 2002, PSYCHO-ONCOL, V11, P103&#xD; GUYATT GH,
                    1993, ANN INTERN MED, V118, P622&#xD; HARRIS LE, 1997, MED CARE, V35, P70&#xD;
                    HAYS RD, 1993, HEALTH ECON, V2, P217&#xD; JEMAL A, 2004, CANCER, V101, P3&#xD;
                    JUAREZ G, 1998, CANCER PRACT, V6, P3178&#xD; KAGAWASINGER M, 1997, CULT MED
                    PSYCHIAT, V21, P449&#xD; KAGAWASINGER M, 2000, CANCER, V89, P696&#xD;
                    KAGAWASINGER M, 2003, PSYCHO-ONCOL, V12, P24&#xD; KIM J, 2006, ONCOL NURS FORUM,
                    V33, P1071&#xD; KORNBLITH AB, 2003, CANCER, V98, P679&#xD; LI CI, 2003, ARCH
                    INTERN MED, V163, P49&#xD; MCQUELLON RP, 1997, BREAST J, V3, P178&#xD;
                    MEYEROWITZ BE, 1998, PSYCHOL BULL, V123, P47&#xD; MILLER B, 1996, NIH
                    PUBLICATION&#xD; NGOMETZGER Q, 2004, MED CARE, V42, P893&#xD; POLINSKY ML, 1994,
                    HEALTH SOC WORK, V19, P165&#xD; POWELL DR, 1994, ANN NY ACAD SCI, V736,
                    P131&#xD; REYNOLDS P, 1994, CANCER EPIDEM BIOMAR, V3, P253&#xD; RIES LAG, 2000,
                    CANCER, V88, P2398&#xD; RIES LAG, 2004, SEER CANC STAT REV 1&#xD; RIETMAN JS,
                    2003, EUR J SURG ONCOL, V29, P229&#xD; SEKARAN U, 1983, J INT BUS STUD, V14,
                    P61&#xD; SHAVERS VL, 2003, CANCER, V97, P134&#xD; SHERBOURNE CD, 1991, SOC SCI
                    MED, V32, P705&#xD; SIEMIATYCKI J, 1979, AM J PUBLIC HEALTH, V69, P238&#xD;
                    SPENCER SM, 1999, HEALTH PSYCHOL, V18, P159&#xD; VINOKUR AD, 1989, CANCER, V63,
                    P394&#xD; WARE JE, 1984, CANCER, V53, P2316&#xD; WARE JE, 1992, MED CARE, V30,
                    P473&#xD; WELLISCH D, 1999, PSYCHO-ONCOL, V8, P207&#xD; WENZEL LB, 1999, CANCER,
                    V86, P1768&#xD; WYATT GE, 1998, WOMENS HLTH, V4, P385&#xD; YU CLM, 2000, CANCER,
                    V88, P1715&#xD; ZASLAVSKY AM, 2002, MED CARE, V40, P485</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244692800005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>575</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">575</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1934</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Baker, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wuenschell, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xia, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Termini, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bates, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Connor, T. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Biology Division, Beckman Research
                    Institute, City of Hope National Medical Center, Duarte, California 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nucleotide excision repair
                        eliminates unique DNA-protein cross-links from mammalian cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">22592-604</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">31</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHO Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cricetinae</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cricetulus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA/ chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA
                        (Cytosine-5-)-Methyltransferase/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Methyltransferases/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proteins/ chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Site-Specific DNA
                        Methyltransferase (Cytosine-Specific)/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Substrate Specificity</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug 3</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17507378</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">DNA-protein cross-links (DPCs)
                    present a formidable obstacle to cellular processes because they are
                    &quot;superbulky&quot; compared with the majority of chemical adducts.
                    Elimination of DPCs is critical for cell survival because their persistence can
                    lead to cell death or halt cell cycle progression by impeding DNA and RNA
                    synthesis. To study DPC repair, we have used DNA methyltransferases to generate
                    unique DPC adducts in oligodeoxyribonucleotides or plasmids to monitor both in
                    vitro excision and in vivo repair. We show that HhaI DNA methyltransferase
                    covalently bound to an oligodeoxyribonucleotide is not efficiently excised by
                    using mammalian cell-free extracts, but protease digestion of the full-length
                    HhaI DNA methyltransferase-DPC yields a substrate that is efficiently removed by
                    a process similar to nucleotide excision repair (NER). To examine the repair of
                    that unique DPC, we have developed two plasmid-based in vivo assays for DPC
                    repair. One assay shows that in nontranscribed regions, DPC repair is greater
                    than 60% in 6 h. The other assay based on host cell reactivation using a green
                    fluorescent protein demonstrates that DPCs in transcribed genes are also
                    repaired. Using Xpg-deficient cells (NER-defective) with the in vivo host cell
                    reactivation assay and a unique DPC indicates that NER has a role in the repair
                    of this adduct. We also demonstrate a role for the 26 S proteasome in DPC
                    repair. These data are consistent with a model for repair in which the
                    polypeptide chain of a DPC is first reduced by proteolysis prior to NER.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/09/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>598</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">598</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1544</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Baker, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ness, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Steinberger, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Francisco, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burns, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sklar, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weisdorf, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gurney, J. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Minnesota, Dept Pediat,
                    Minneapolis, MN 55455 USA. Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
                    City Hope Natl Med Ctr, Div Populat Sci, Duarte, CA 91010 USA. Mem Sloan
                    Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA. City Hope Natl Med Ctr,
                    Div Hematol &amp; Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. Univ
                    Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.&#xD;Baker, KS, Univ Minnesota,
                    Dept Pediat, Minneapolis, MN 55455 USA.&#xD;baker084@umn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Diabetes, hypertension, and
                        cardiovascular events in survivors of hematopoietic cell transplantation: a
                        report from the bone marrow transplantation survivor study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1765-1772</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-REACTIVE PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NONENDOCRINE LATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLICATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUTRITION EXAMINATION
                        SURVEY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDHOOD-CANCER
                        SURVIVOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CORONARY-HEART-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOTAL-BODY IRRADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3RD NATIONAL-HEALTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METABOLIC SYNDROME</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244219400059</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We ascertained the prevalence of
                    self-reported late occurrence of diabetes, hypertension, and cardiovascular (CV)
                    disease in 1089 hematopoietic cell transplantation (HCT) survivors who underwent
                    HCT between 1974 and 1998, survived at least 2 years, and were not currently
                    taking immunosuppressant agents and compared them with 383 sibling controls. All
                    subjects completed a 255-item health questionnaire. The mean age at survey
                    completion was 39.3 years for survivors and 38.6 years for siblings; mean
                    follow-up was 8.6 years. Adjusting for age, sex, race, and body mass index
                    (BMI), survivors of allogeneic HCT were 3.65 times (95% confidence interval
                    [CI], 1.82-7.32) more likely to report diabetes than siblings and 2.06 times
                    (95% CI, 1.39-3.04) more likely to report hypertension compared with siblings
                    but did not report other CV outcomes with any greater frequency. Recipients of
                    autologous HCTs were no more likely than siblings to report any of the outcomes
                    studied. Allogeneic HCT survivors were also more likely to develop hypertension
                    (odds ratio [OR] = 2.31; 95% CI, 1.45-3.67) than autologous recipients. Total
                    body irradiation (TBI) exposure was associated with an increased risk of
                    diabetes (OR = 3.42; 95% CI, 1.55-7.52). Thus, HCT survivors have a higher age-
                    and BMI-adjusted risk of diabetes and hypertension, potentially leading to a
                    higher than expected risk of CV events with age. (Blood. 2007;109: 1765-1772).
                    (c) 2007 by The American Society of Hematology.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    136JW&#xD;Times Cited: 1&#xD;Cited Reference Count: 58</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244219400059 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>635</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">635</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1543</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Balajee, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lindsley, M. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lqbal, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ito, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pappas, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brandt, M. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Ctr Dis Control &amp; Prevent, Mycot
                    Dis Branch, Atlanta, GA 30333 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA.
                    Univ Alabama, Div Infect Dis, Birmingham, AL USA.&#xD;Balajee, SA, Ctr Dis
                    Control &amp; Prevent, Mycot Dis Branch, Mail Stop G 11,1600 Clifton Rd,
                    Atlanta, GA 30333 USA.&#xD;fir3@cdc.gov</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nonsporulating clinical isolate
                        identified as Petromyces alliaceus (Anamorph Aspergillus alliaceus) by
                        morphological and sequence-based methods</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Microbiology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Clin. Microbiol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Microbiology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Microbiol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Microbiol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Microbiology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Microbiol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Microbiol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">2701-2703</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">45</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC STEM-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIBED SPACER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUMIGATUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DESIGN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0095-1137</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248793300052</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Concerted morphological and
                    sequencing-based strategies revealed the identity of a nonsporulating clinical
                    isolate as Petromyces alliaceus (anamorph Aspergillus alliaceus). This rare
                    Aspergillus sp. was recovered as the etiological agent of invasive pulmonary
                    aspergillosis and had reduced in vitro susceptibilities to amphotericin B and
                    caspofungin, which correlated with clinical failure of therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    200WK&#xD;Times Cited: 0&#xD;Cited Reference Count: 14</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248793300052 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>594</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">594</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1541</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Battiwalla, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bajwa, R. P. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Radovic, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Almyroudis, N. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Segal, B. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wallace, P. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nakamura, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Padmanabhan, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hahn, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McCarthy, P. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Roswell Pk Canc Inst, Dept Med,
                    Buffalo, NY 14202 USA. Roswell Pk Canc Inst, Dept Pathol &amp; Lab Med, Buffalo,
                    NY 14202 USA. Div Hematol Hematopoiet Cell Transplantat, Duarte, CA
                    USA.&#xD;Battiwalla, M, Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14202
                    USA.&#xD;minoo.battiwalla@roswellpark.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ganciclovir inhibits lymphocyte
                        proliferation by impairing DNA synthesis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">765-770</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CMV</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ganciclovir</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA polymerase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >CYTOMEGALOVIRUS-INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CMV INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECIPIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >9-(1,3-DIHYDROXY-2-PROPOXYMETHYL)GUANINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROPHYLAXIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACYCLOVIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INVITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247861200003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Cytomegalovirus (CMV)
                    disease-related mortality in allogeneic hematopoietic stem cell transplant
                    (HSCT) recipients has dramatically declined because of ganciclovir prophylaxis
                    and preemptive therapeutic strategies. However, ganciclovir has not improved
                    overall survival in randomized studies despite effectively preventing overt CMV
                    disease. Moreover, recurrent posttransplant CMV antigenemia, associated with
                    prolonged ganciclovir exposure, is a predictor of increased relapse of
                    malignancy. We examined the hypothesis that ganciclovir itself may have a
                    negative impact on immune reconstitution by testing the effect of ganciclovir on
                    normal human lymphocytes in vitro. T-lymphocyte activation and proliferation, as
                    measured by PHA-induccd H-3-thymidine uptake, was greatly reduced at therapeutic
                    concentrations of ganciclovir (10 mu g/mL) but not for foscarnet (300 mu M/L).
                    Moreover, ganciclovir impaired bromodeoxyuridine incorporation in proliferating
                    lymphocytes, but did not impair lymphocyte survival or induce lymphocyte
                    apoptosis. Collectively, these results show that ganciclovir suppresses
                    T-lymphocyte proliferation in vitro by inhibiting DNA synthesis; with
                    implications for T-lymphocyte function following allogeneic BMT. (c) 2007
                    American Society for Blood and Marrow Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    187PV&#xD;Times Cited: 0&#xD;Cited Reference Count: 24</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247861200003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>806</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">806</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1929</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bedell, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaal, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pullarkat, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Cytogenetics, City of
                    Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Successful application of a
                        direct detection slide-based sequential phenotype/genotype assay using
                        archived bone marrow smears and paraffin embedded tissue sections</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Mol Diagn</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">589-97</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Bone Marrow/ pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">In Situ Hybridization,
                        Fluorescence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Diagnostic Techniques/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Paraffin Embedding/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tissue Banks</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tissue Fixation/ methods</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-1578 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17975026</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Identification of genetic
                    abnormalities in pathological samples is critical for accurate diagnosis, risk
                    stratification, detection of minimal residual disease, and assessment of
                    response to therapy. Interphase fluorescence in situ hybridization analysis is
                    the standard cytogenetic assay used by many laboratories to detect specific
                    clonal karyotypic aberrations in formalin-fixed, paraffin-embedded tissue.
                    However, direct correlation with immunophenotype or morphology in individual
                    cells is rarely performed because the procedural steps are labor intensive and
                    usually require extensive troubleshooting. In this study, we present a
                    sequential fluorescence in situ hybridization-based technique that uses the
                    identical archived bone marrow smears or paraffin-embedded tissue sections
                    previously evaluated by a pathologist for morphological or immunohistochemical
                    characteristics. This approach is relatively straightforward, using
                    uncomplicated pretreatment and hybridization conditions and basic equipment
                    attached to an automated image analyzer with image capture software to record
                    the location of targeted cells for genotypic/phenotype correlation. Furthermore,
                    the method has proved reliable and reproducible on test samples regardless of
                    specimen age, tissue type, or referring institution.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2008/01/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>410</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">410</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1535</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bates, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Biol, Duarte, CA 91010 USA.&#xD;Besaratinia, A, City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Biol, 1450 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;ania@coh.org gpfeifer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Riboflavin activated by
                        ultraviolet A1 irradiation induces oxidative DNA damage-mediated mutations
                        inhibited by vitamin C</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5953-5958</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">14</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ultraviolet A radiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">photosensitizer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antioxidant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">skin cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLOBUTANE PYRIMIDINE
                        DIMERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN SKIN CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYDROGEN-PEROXIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SINGLET OXYGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UVA RADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIPYRIMIDINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHOTOPRODUCTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WAVELENGTH DEPENDENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLAR MUTAGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIOLOGICAL ROLE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245657600046</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">An increasingly popular theory
                    ascribes UVA (&gt;320-400 nm) carcinogenicity to the ability of this wavelength
                    to trigger intracellular photosensitization reactions, thereby giving rise to
                    promutagenic oxidative DNA damage. We have tested this theory both at the
                    genomic and nucleotide resolution level in mouse embryonic fibroblasts carrying
                    the lambda phage cll transgene. We have also tested the hypothesis that
                    inclusion of a cellular photosensitizer (riboflavin) can intensify UVA-induced
                    DNA damage and mutagenesis, whereas addition of an antioxidant (vitamin Q can
                    counteract the induced effects. Cleavage assays with formamidopyrimidine DNA
                    glycosylase (Fpg) coupled to alkaline gel electrophoresis and ligation-mediated
                    PCR (LM-PCR) showed that riboflavin treatment (1 mu M) combined with UVA1
                    (340-400 nm) irradiation (7.68 J/cm(2)) or higher dose UVA1 irradiation alone
                    induced Fpg-sensitive sites (indicative of oxidized and/or ring-opened purines)
                    in the overall genome and in the cll transgene, respectively. Also, the combined
                    treatment with riboflavin and UVA1 irradiation gave rise to single-strand DNA
                    breaks in the genome and in the cll transgene determined by terminal
                    transferase-dependent PCR (TD-PCR). A cotreatment with vitamin C (11 mM)
                    efficiently inhibited the formation of the induced lesions. Mutagenicity
                    analysis showed that riboflavin treatment combined with UVA1 irradiation or
                    high-dose UVA1 irradiation alone significantly increased the relative frequency
                    of cll mutants, both mutation spectra exhibiting significant increases in the
                    relative frequency of G:C -&gt; T:A transversions, the signature mutations of
                    oxidative DNA damage. The induction of cll mutant frequency was effectively
                    reduced consequent to a cotreatment with vitamin C. Our findings support the
                    notion that UVA-induced photosensitization reactions are responsible for
                    oxidative DNA damage leading to mutagenesis.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    156OA&#xD;Times Cited: 0&#xD;Cited Reference Count: 54&#xD;Cited References:
                    &#xD; AGAR NS, 2004, P NATL ACAD SCI USA, V101, P4954&#xD; ALAPETITE C, 1996,
                    INT J RADIAT BIOL, V69, P359&#xD; BAIER J, 2006, BIOPHYS J, V91, P1452&#xD;
                    BESARATINIA A, 2004, BIOCHEMISTRY-US, V43, P15557&#xD; BESARATINIA A, 2004,
                    BIOCHEMISTRY-US, V43, P8169&#xD; BESARATINIA A, 2005, CARCINOGENESIS, V27,
                    P1526&#xD; BESARATINIA A, 2005, P NATL ACAD SCI USA, V102, P10058&#xD; BOITEUX
                    S, 1987, EMBO J, V6, P3177&#xD; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300,
                    P535&#xD; CADET J, 2006, PHOTOCHEM PHOTOBIOL, V82, P1219&#xD; CATANI MV, 2005,
                    NUTR REV, V63, P81&#xD; CHEN HH, 2001, SCI STKE&#xD; DEGRUIJL FR, 1993, CANCER
                    RES, V53, P53&#xD; DEGRUIJL FR, 2002, SKIN PHARMACOL APPL, V15, P316&#xD; DOUKI
                    T, 1999, INT J RADIAT BIOL, V75, P571&#xD; DOUKI T, 1999, PHOTOCHEM PHOTOBIOL,
                    V70, P184&#xD; DOUKI T, 2003, BIOCHEMISTRY-US, V42, P9221&#xD; DROBETSKY EA,
                    1995, P NATL ACAD SCI USA, V92, P2350&#xD; FAN XJ, 2006, P NATL ACAD SCI USA,
                    V103, P16912&#xD; FORAKER AB, 2003, ADV DRUG DELIVER REV, V55, P1467&#xD;
                    HOCKBERGER PE, 1999, P NATL ACAD SCI USA, V96, P6255&#xD; IKEHATA H, 2003,
                    MUTAGENESIS, V18, P511&#xD; IKEHATA H, 2004, MUTAT RES-FUND MOL M, V556,
                    P11&#xD; KALAM MA, 2006, NUCLEIC ACIDS RES, V34, P2305&#xD; KAPPES UP, 2005,
                    RADIAT RES 1, V164, P440&#xD; KAPPES UP, 2006, J INVEST DERMATOL, V126,
                    P667&#xD; KIELBASSA C, 1997, CARCINOGENESIS, V18, P811&#xD; KIM S, IN PRESS
                    MUTAT RES&#xD; KOZMIN S, 2005, P NATL ACAD SCI USA, V102, P13538&#xD; KRAMARENKO
                    GG, 2006, PHOTOCHEM PHOTOBIOL, V82, P1634&#xD; KRUTMANN J, 2000, J DERMATOL SCI,
                    V23, P22&#xD; KVAM E, 1997, CARCINOGENESIS, V18, P2379&#xD; LAMBERT LB, 2005,
                    MUTAT RES-REV MUTAT, V590, P1&#xD; LAN L, 2004, P NATL ACAD SCI USA, V101,
                    P13738&#xD; LEHMANN J, 1998, MUTAT RES-DNA REPAIR, V407, P97&#xD; MELLO AC,
                    1984, BIOCHEM J, V218, P273&#xD; MELLON I, 1987, CELL, V51, P241&#xD; MINAMI H,
                    1999, J INVEST DERMATOL, V113, P77&#xD; MOURET S, 2006, P NATL ACAD SCI USA,
                    V103, P13765&#xD; OUYANG H, 2004, J INVEST DERMATOL, V122, P1020&#xD; PERDIZ D,
                    2000, J BIOL CHEM, V275, P26732&#xD; PFEIFER GP, 2005, MUTAT RES-FUND MOL M,
                    V571, P19&#xD; ROCHETTE PJ, 2003, NUCLEIC ACIDS RES, V31, P2786&#xD; SAKAGAMI H,
                    1997, ANTICANCER RES, V17, P3513&#xD; SATO K, 1995, J INVEST DERMATOL, V105,
                    P608&#xD; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363&#xD; SHIBUTANI S,
                    1991, NATURE, V349, P431&#xD; SHINDO Y, 1994, J INVEST DERMATOL, V102, P122&#xD;
                    WONDRAK GT, 2004, J BIOL CHEM, V279, P30009&#xD; WOOD ML, 1990, BIOCHEMISTRY-US,
                    V29, P7024&#xD; WOODHEAD AD, 1999, J EPIDEMIOL S, V9, P102&#xD; WOOLLONS A,
                    1999, BRIT J DERMATOL, V140, P1023&#xD; YAJIMA H, 1995, EMBO J, V14, P2393&#xD;
                    ZHANG XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245657600046 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>398</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">398</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">990</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Biol,
                    Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Besaratinia, A, City Hope Natl Med
                    Ctr, Div Biol, Beckman Res Inst, 1450 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;ania@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A review of mechanisms of
                        acrylamide carcinogenicity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">519-528</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA ADDUCT FORMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIETARY ACRYLAMIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMOGLOBIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADDUCTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK-ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORTALITY PATTERNS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAILLARD REACTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRINKING-WATER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEONATAL MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-REGIONS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0143-3334</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245351100002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The fact that acrylamide, a proven
                    rodent carcinogen, is present in significant quantities (up to several mg/kg of
                    foodstuff) in a wide range of commonly consumed human foods is alarming.
                    Attempts to determine a possible involvement of dietary acrylamide in human
                    cancers have not been conclusive, however. To resolve the carcinogenicity of
                    acrylamide to humans, the as yet unknown mechanism of action of acrylamide needs
                    to be unraveled. The present review is a synopsis of research on the known and
                    hypothetical modes of action of acrylamide of relevance for carcinogenesis. Both
                    genotoxic and non-genotoxic modes of action of acrylamide are discussed with
                    special emphasis on DNA adduct-targeted mutagenesis. Mechanistic data are
                    presented from various experimental systems including in vitro experiments and
                    in vivo rodent and human studies with special focus on mouse models. Human
                    exposure data, including estimates of daily intake of dietary acrylamide in
                    different populations and the corresponding cancer risk assessments are
                    provided. The significant gaps in knowledge, which currently preclude a more
                    definitive evaluation of human cancer risk due to exposure to dietary
                    acrylamide, are highlighted. Future directions for research on acrylamide and
                    cancer are outlined, and potential challenges are underscored.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    152HB&#xD;Times Cited: 0&#xD;Cited Reference Count: 96&#xD;Cited References:
                    &#xD; *EUR COMM EUR CHEM, 2002, EUR UN RISK ASS REP&#xD; *INT AG RES CANC,
                    ACRYLAMIDE&#xD; *US EPA PROT AG, ASS HLTH RISKS EXP A&#xD; *WHO, GUID DRINK WAT
                    QUAL&#xD; *WHO, 2005, SURV PLANN FIN WHO R, P1&#xD; ABATE C, 1990, SCIENCE,
                    V249, P1157&#xD; ADLER PR, 2000, INT J RECIRCULATING, V1, P15&#xD; AGRAWAL AK,
                    1981, PHARMACOL BIOCH BEHA, V14, P527&#xD; AGRAWAL AK, 1981, TOXICOL APPL PHARM,
                    V58, P89&#xD; ALI SF, 1983, ARCH TOXICOL, V52, P35&#xD; ANWAY MD, 2005, SCIENCE,
                    V308, P1466&#xD; BANERJEE S, 1986, CANCER LETT, V32, P293&#xD; BERGMARK E, 1997,
                    CHEM RES TOXICOL, V10, P78&#xD; BESARATINIA A, 2003, J NATL CANCER I, V95,
                    P889&#xD; BESARATINIA A, 2004, J NATL CANCER I, V96, P1023&#xD; BESARATINIA A,
                    2005, MUTAT RES-GEN TOX EN, V580, P31&#xD; BESARATINIA A, 2006, CARCINOGENESIS,
                    V27, P1526&#xD; BOETTCHER MI, 2006, ARCH TOXICOL, V80, P55&#xD; BOLT HM, 2003,
                    TOXICOL LETT, V140, P43&#xD; BULL RJ, 1984, CANCER LETT, V24, P209&#xD; BULL RJ,
                    1984, CANCER RES, V44, P107&#xD; COLLINS JJ, 1989, J OCCUP MED, V31, P614&#xD;
                    DACOSTA GG, 2003, CHEM RES TOXICOL, V16, P1328&#xD; DEARFIELD KL, 1988, MUTAT
                    RES, V195, P45&#xD; DEARFIELD KL, 1995, MUTAT RES-FUND MOL M, V330, P71&#xD;
                    DERELANKO MJ, 2001, HDB TOXICOLOGY, P627&#xD; DOERGE DR, 2005, TOXICOL APPL
                    PHARM, V202, P258&#xD; ERDREICH LS, 2004, REGUL TOXICOL PHARM, V39, P150&#xD;
                    FEINBERG AP, 2004, NAT REV CANCER, V4, P143&#xD; FELSOT AS, 2002, ACRYLAMIDE
                    ANGST ANO&#xD; FENNELL TR, 2005, TOXICOL SCI, V85, P447&#xD; FRIEDMAN M, 2003, J
                    AGR FOOD CHEM, V51, P4504&#xD; FU PP, 2000, DRUG METAB REV, V32, P241&#xD; FUHR
                    U, 2006, CANCER EPIDEM BIOMAR, V15, P266&#xD; GHANAYEM BI, 2005, BIOL REPROD,
                    V72, P157&#xD; GHANAYEM BI, 2005, MUTAT RES-FUND MOL M, V578, P284&#xD; GLAAB
                    WE, 1999, MUTAT RES-FUND MOL M, V427, P67&#xD; GODIN AC, 2002, VET REC, V151,
                    P724&#xD; GRANATH F, 2001, OCCUP ENVIRON MED, V58, P608&#xD; HAGMAR L, 2001,
                    SCAND J WORK ENV HEA, V27, P219&#xD; HAGMAR L, 2003, BRIT J CANCER, V89,
                    P774&#xD; HARACSKA L, 2001, GENE DEV, V15, P945&#xD; HASHIMOTO K, 1985, MUTAT
                    RES, V158, P129&#xD; HOORN AJW, 1993, MUTAGENESIS, V8, P7&#xD; HUTT JA, 2005,
                    CARCINOGENESIS, V26, P1999&#xD; JAGERSTAD M, 2005, MUTAT RES-FUND MOL M, V574,
                    P156&#xD; JOHNSON KA, 1986, TOXICOL APPL PHARM, V85, P154&#xD; KOIZUMI A, 1993,
                    LAB INVEST, V68, P728&#xD; KOSKINEN M, 2000, CHEM-BIOL INTERACT, V129, P209&#xD;
                    LAMBERT LB, 2005, MUTAT RES-REV MUTAT, V590, P1&#xD; LEE YW, 1995, MOL CELL
                    BIOL, V15, P2547&#xD; LI EE, 1994, CARCINOGENESIS, V15, P1377&#xD; LOEB LA,
                    1986, ANNU REV GENET, V20, P201&#xD; MANENTI G, 2003, CARCINOGENESIS, V24,
                    P1143&#xD; MANJANATHA MG, 2006, ENVIRON MOL MUTAGEN, V47, P6&#xD; MARSH GM,
                    1999, OCCUP ENVIRON MED, V56, P181&#xD; MASS MJ, 1997, MUTAT RES-REV MUTAT,
                    V386, P263&#xD; MCCOLLISTER DD, 1964, TOXICOL APPLIED PHAR, V6, P172&#xD;
                    MOTTRAM DS, 2002, NATURE, V419, P448&#xD; MUCCI LA, 2003, BRIT J CANCER, V88,
                    P84&#xD; MUCCI LA, 2004, INT J CANCER, V109, P774&#xD; MUCCI LA, 2005, ADV EXP
                    MED BIOL, V561, P39&#xD; MUCCI LA, 2006, INT J CANCER, V118, P169&#xD;
                    NEUHAUSERKLAUS A, 1989, MUTAT RES, V226, P157&#xD; PAULSSON B, 2001,
                    CARCINOGENESIS, V22, P817&#xD; PAULSSON B, 2002, MUTAT RES-GEN TOX EN, V516,
                    P101&#xD; PELUCCHI C, 2003, INT J CANCER, V105, P558&#xD; PELUCCHI C, 2006, INT
                    J CANCER, V118, P467&#xD; PETERSEN BJ, 2005, ADV EXP MED BIOL, V561, P63&#xD;
                    RAY SS, 2004, J BIOL CHEM, V279, P27187&#xD; REYNOLDS T, 2002, J NATL CANCER I,
                    V94, P876&#xD; RICE JM, 2005, MUTAT RES-GEN TOX EN, V580, P3&#xD; ROBINSON M,
                    1986, ENV HLTH PERSPECT, V68, P141&#xD; RUSSELL LB, 1991, MUTAT RES, V262,
                    P101&#xD; SCHETTGEN T, 2004, INT ARCH OCC ENV HEA, V77, P213&#xD; SCHMID TE,
                    1999, MUTAGENESIS, V14, P173&#xD; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL,
                    V50, P735&#xD; SEGERBACK D, 1995, CARCINOGENESIS, V16, P1161&#xD; SHIMKIN MB,
                    1975, ADV CANCER RES, V21, P1&#xD; SMITH CJ, 2001, FOOD CHEM TOXICOL, V39,
                    P183&#xD; SOLOMON JJ, 1985, CANCER RES, V45, P3465&#xD; SONG SM, 2005, ONCOGENE,
                    V24, P8268&#xD; SORGEL F, 2002, CHEMOTHERAPY, V48, P267&#xD; SRIVASTAVA SP,
                    1986, BRAIN RES, V371, P319&#xD; STADLER RH, 2002, NATURE, V419, P449&#xD;
                    STONER GD, 1982, J AM COLL TOXICOL, V1, P145&#xD; SUMNER SCJ, 1997, CHEM RES
                    TOXICOL, V10, P1152&#xD; SUMNER SCJ, 1999, CHEM RES TOXICOL, V12, P1110&#xD;
                    TAREKE E, 2000, CHEM RES TOXICOL, V13, P517&#xD; TAREKE E, 2002, J AGR FOOD
                    CHEM, V50, P4998&#xD; TORNQVIST M, 2000, LEAKAGE ACRYLAMIDES, P1&#xD; TRITSCHER
                    AM, 2004, TOXICOL LETT, V149, P177&#xD; TSUDA H, 1993, MUTAGENESIS, V8, P23&#xD;
                    TYL RW, 2003, REPROD TOXICOL, V17, P1&#xD; USHIJIMA T, 2005, CANCER SCI, V96,
                    P206&#xD; ZHAO B, 2004, NUCLEIC ACIDS RES, V32, P3984</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245351100002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>807</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">807</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1530</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Francisco, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baker, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gurney, J. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McGlave, P. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Donnell, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ramsay, N. K. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robison, L. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snyder, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stein, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weisdorf, D. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Univ Minnesota, Minneapolis, MN USA. Univ Michigan, Ann Arbor, MI
                    48109 USA. St Jude Childrens Hosp, Memphis, TN 38105 USA.&#xD;Bhatia, S, City
                    Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;sbhatia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Late mortality after allogeneic
                        hematopoietic cell transplantation and functional status of long-term
                        survivors: report from the Bone Marrow Transplant Survivor Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3784-3792</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">110</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ADULT SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDHOOD-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APLASTIC-ANEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INSURANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250946300048</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We assessed late mortality in 1479
                    individuals who had survived 2 or more years after allogeneic hematopoietic cell
                    transplantation (HCT). Median age at HCT was 25.9 years and median length of
                    follow-up was 9.5 years. The conditional survival probability at 15 years from
                    HCT was 80.2% (SE = 1.9%) for those who were disease-free at entry into the
                    cohort, and the relative mortality was 9.9 (95% confidence interval, 8.7-11.2).
                    Relative mortality decreased with time from HCT, but remained significantly
                    elevated at 15 years after HCT (standardized mortality ratio = 2.2). Relapse of
                    primary disease (29%) and chronic graft-versus-host disease (cGVHD: 22%) were
                    the leading causes of premature death. Nonrelapserelated mortality was increased
                    among patients older than 18 years at HCT (118-45 years: relative risk [RR] =
                    1.7; 46+ years: RR 3.7) and among those with cGVHD (RR 2.7), and was lower among
                    patients who received methotrexate for GVHD prophylaxis (RR = 0.5). HCT
                    survivors were more likely to report difficulty in holding jobs (odds ratio [OR]
                    = 13.9), and in obtaining health (OR = 7.1) or life (OR = 9.9) insurance
                    compared with siblings. This study demonstrates that mortality rates remain
                    twice as high as that of the general population among 15-year survivors of HCT,
                    and that the survivors face challenges affecting their health and
                    well-being.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    231KS&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; ANDRYKOWSKI MA, 1989, BONE MARROW TRANSPL, V4, P75&#xD; ANDRYKOWSKI MA,
                    1990, TRANSPLANTATION, V50, P399&#xD; BHATIA S, 1996, BLOOD, V87, P3633&#xD;
                    BHATIA S, 2001, J CLIN ONCOL, V19, P464&#xD; BRESLOW NE, 1987, IARC SCI PUBL,
                    V82, P1&#xD; COX DR, 1972, J ROY STAT SOC B MET, V34, P187&#xD; CURB JD, 1985,
                    AM J EPIDEMIOL, V121, P754&#xD; DEEG HJ, 1998, BLOOD, V91, P3637&#xD; DUELL T,
                    1997, ANN INTERN MED, V126, P184&#xD; FLOWERS MED, 2004, THOMAS HEMATOPOIETIC,
                    P944&#xD; GLUCKMAN E, 1993, BONE MARROW TRANSPL, V12, S13&#xD; GREEN DM, 1991,
                    CANCER, V67, P206&#xD; HAYS DM, 1992, J CLIN ONCOL, V10, P1397&#xD; HOLMES GE,
                    1986, CANCER, V57, P190&#xD; HOROWITZ MM, 2004, HTOMAS HEMATOPOIETIC, P9&#xD;
                    KREISMAN H, 1992, SEMIN ONCOL, V19, P508&#xD; KRISHNAN A, 2000, BLOOD, V95,
                    P1588&#xD; MARSH G, 2000, MORTALITY POPULATION&#xD; METAYER C, 2003, BLOOD,
                    V101, P2015&#xD; SOCIE G, 1993, NEW ENGL J MED, V329, P1152&#xD; SOCIE G, 1999,
                    NEW ENGL J MED, V341, P14&#xD; SOCIE G, 2000, J CLIN ONCOL, V18, P348&#xD;
                    VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303&#xD; WINGARD JR, 1991, ANN
                    INTERN MED, V114, P113&#xD; WITHERSPOON RP, 1989, NEW ENGL J MED, V321,
                    P784</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250946300048 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>196</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">196</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1529</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krailo, M. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burden, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Askin, F. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dickman, P. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grier, H. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Link, M. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meyers, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Perlman, E. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rausen, A. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robison, L. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vietti, T. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miser, J. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Childrens Oncol Grp, Arcadia, CA
                    91006 USA. City Hope Natl Med Ctr, Div Pediat Oncol, Duarte, CA 91010 USA. Univ
                    So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA. Johns
                    Hopkins Med Ctr, Dept Pathol, Baltimore, MD USA. Phoenix Childrens Hosp, Dept
                    Pathol, Phoenix, AZ USA. Dana Farber Canc Inst, Dept &amp; Div Pediat Hematol
                    Oncol, Boston, MA USA. Childrens Hosp, Boston, MA 02115 USA. Stanford Univ, Sch
                    Med, Stanford, CA 94305 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021
                    USA. Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. NYU, Med
                    Ctr, Dept Pediat, New York, NY USA. Univ Minnesota, Div Pediat Epidemiol &amp;
                    Clin Res, Minneapolis, MN USA. Univ Washington, Med Ctr, Div Pediat Hematol
                    Oncol, St Louis, MO USA.&#xD;Bhatia, S, Childrens Oncol Grp, POB 60012, Arcadia,
                    CA 91006 USA.&#xD;sbhatia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Therapy-related myelodysplasia
                        and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal
                        tumor of bone: a report from the Children&apos;s Oncology Group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">46-51</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECURRENT SARCOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HODGKINS-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2ND NEOPLASMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IFOSFAMIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ETOPOSIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243153900017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">This study describes the magnitude
                    of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML)
                    in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children&apos;s
                    Oncology Group therapeutic protocol, INT0091. Between 1988 and 1992, patients
                    with or without metastatic disease were randomized to receive doxorubicin,
                    vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs
                    alternating with etoposide and ifosfamide (regimen B). Between 1992 and 1994,
                    patients with metastatic disease were non-randomly assigned to receive
                    high-intensity therapy (regimen C: regimen B therapy with higher doses of
                    doxorubicin, cyclophosphamide, and ifosfamide). Median age at diagnosis of Ewing
                    sarcoma was 12 years, and median length of follow-up, 8 years. Eleven patients
                    developed t-MDS/AML, resulting in a cumulative incidence of 2% at 5 years. While
                    patients treated on regimens A and B were at a low risk for development of
                    t-MDS/AML (cumulative incidence: 0.4% and 0.9% at 5 years, respectively),
                    patients treated on regimen C were at a 16-fold increased risk of developing
                    t-MDS/AML (cumulative incidence: 11% at 5 years), when compared with those
                    treated on regimen A. Increasing exposure to ifosfamide from 90 to 140 g/m(2),
                    cyclophosphamide from 9.6 to 17.6 g/m(2), and doxorubicin from 375 to 450
                    mg/m(2) increased the risk of t-MDS/AML significantly.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast; Top Tier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    121JM&#xD;Times Cited: 0&#xD;Cited Reference Count: 24&#xD;Cited References:
                    &#xD; ANTMAN KH, 1989, J CLIN ONCOL, V7, P126&#xD; BHATIA S, 1996, NEW ENGL J
                    MED, V334, P745&#xD; BHATIA S, 2001, P AN M AM SOC CLIN, V20, A369&#xD; BHATIA
                    S, 2002, BLOOD, V99, P4257&#xD; GRAY RJ, 1988, ANN STAT, V16, P1141&#xD; GRIER
                    HE, 2003, NEW ENGL J MED, V348, P694&#xD; HUSTU HO, 1972, CANCER, V30,
                    P1522&#xD; JURGENS H, 1988, CANCER, V61, P23&#xD; JURGENS H, 1989, CANCER
                    CHEMOTH PHARM, V24, P40&#xD; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI&#xD;
                    KUNG FH, 1993, CANCER, V71, P1898&#xD; MAGRATH I, 1986, CANCER CHEMOTH PHARM,
                    V18, S25&#xD; MISER JS, 1987, J CLIN ONCOL, V5, P1191&#xD; NESBIT ME, 1976, CA
                    CANC J CLIN, V26, P174&#xD; NESBIT ME, 1990, J CLIN ONCOL, V8, P1664&#xD;
                    PAULUSSEN M, 2001, ANN ONCOL, V12, P1619&#xD; PUI CH, 1991, NEW ENGL J MED,
                    V325, P1682&#xD; RELLING MV, 2003, BLOOD, V101, P3862&#xD; RODRIGUEZGALINDO C,
                    2000, J PEDIAT HEMATOL ONC, V22, P321&#xD; SMITH RE, 2003, J CLIN ONCOL, V21,
                    P1195&#xD; TALLMAN MS, 1995, J CLIN ONCOL, V13, P1557&#xD; TRAVIS LB, 1999, NEW
                    ENGL J MED, V340, P351&#xD; TRAVIS LB, 2000, J NATL CANCER I, V92, P1165&#xD;
                    VANLEEUWEN FE, 1994, J CLIN ONCOL, V12, P1063</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243153900017 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>276</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">276</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1524</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bobadilla, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Enriquez, E. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Alvarez, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaytan, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept
                    Cytogenet, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Biostat, Duarte,
                    CA 91010 USA.&#xD;Slovak, ML, City Hope Natl Med Ctr, Dept Cytogenet, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;mslovak@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An interphase fluorescence in
                        situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in
                        myeloid malignancies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">British Journal of
                        Haematology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">British Journal of
                        Haematology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Br. J. Haematol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Br J Haematol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">806-813</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">136</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ecotropic virus integration
                        site-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fluorescence in situ
                        hybridisation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute myeloid leukaemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">myelodysplastic syndrome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chronic myeloid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">leukaemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOGENOUS
                        LEUKEMIAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EVI1 LOCUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSLOCATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0007-1048</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244611600005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Chromosome rearrangements involving
                    band 3q26.2 are associated with myeloid malignancies, aberrant expression of the
                    human ecotropic virus integration site-1 (EVI1) gene, an unfavourable prognosis
                    and an aggressive clinical course. The 3q26.2 rearrangements are
                    characteristically heterogeneous and typically difficult to detect in poor
                    quality metaphases. To develop a dual-colour fluorescence in situ hybridisation
                    (FISH) assay for the detection of 3q26.2/EVI1 aberrations, a series of 10 BAC
                    clones corresponding to the EVI1 gene region were systematically evaluated and
                    narrowed down to two probe sets; one probe set encompassed the EVI1 gene
                    extending centromeric, while the second probe set covered the EVI1 gene and
                    extends telomeric. Both probe sets were evaluated on 35 patient samples with
                    cytogenetically defined 3q26.2 rearrangements collected at various treatment
                    time points, the inv(3)(q21q26.2) Kasumi-4 cell line, and 10 known negative
                    samples. The two-probe set strategy identified all samples, despite the vast
                    breakpoint heterogeneity observed. In samples from acute myeloid leukaemia and
                    myelodysplastic syndrome cases, the majority of inversion breakpoints were
                    3&apos; to EVI1 whereas 3q26.2 translocation breakpoints frequently mapped
                    5&apos; to EVI1. However, two 3q26.2 translocation samples had breakpoints
                    3&apos; to EVI1. Most inv(3q) chronic myeloid leukaemia samples showed
                    breakpoints within the EVI1 gene. This study demonstrated that, despite the
                    extensive breakpoint heterogeneity observed with 3q26.2 aberrations, this FISH
                    strategy is effective for the detection of 3q26.2 abnormalities in myeloid
                    malignancies.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    141XF&#xD;Times Cited: 0&#xD;Cited Reference Count: 19&#xD;Cited References:
                    &#xD; ASOU H, 1996, BRIT J HAEMATOL, V93, P68&#xD; CAMERON YC, 2006, CANCER,
                    V106, P1730&#xD; CHAKRABORTY S, 2003, ATLAS GENETICS CYTOG&#xD; CHARRIN C, 2002,
                    HEMATOL J, V3, P21&#xD; DOORNKHOSROVANI BV, 2003, BLOOD, V101, P837&#xD;
                    HALTRICH I, 2006, EUR J HAEMATOL, V76, P124&#xD; HUNTLY BJP, 2003, BLOOD, V102,
                    P1160&#xD; JOLKOWSKA J, 2000, LEUKEMIA RES, V24, P553&#xD; LEVY ER, 1994, BLOOD,
                    V83, P1348&#xD; MADRIGAL I, 2006, CANCER GENET CYTOGEN, V170, P115&#xD; MITANI
                    K, 1994, EMBO J, V13, P504&#xD; MORISHITA K, 1992, P NATL ACAD SCI USA, V89,
                    P3937&#xD; NUCIFORA G, 1997, LEUKEMIA, V11, P2022&#xD; NUCIFORA G, 2006, GENE,
                    V368, P1&#xD; POPPE B, 2006, GENE CHROMOSOME CANC, V45, P349&#xD; SLOVAK ML,
                    2005, CANCER GENET CYTOGEN, V158, P99&#xD; SUZUKAWA K, 1994, BLOOD, V84,
                    P2681&#xD; TRUBIA M, 2006, LEUKEMIA, V20, P48&#xD; WEISER R, 2003,
                    HAEMATOLOGICA, V88, P25</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244611600005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>900</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">900</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1915</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Borneman, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Piper, B. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, V. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koczywas, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Uman, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research &amp;
                    Education, Division of Population Sciences, Beckman Research Institute, City of
                    Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.
                    tborneman@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Implementing the Fatigue
                        Guidelines at one NCCN member institution: process and outcomes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">J Natl Compr Canc Netw</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1092-101</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">5</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Comorbidity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Disease Management</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fatigue/epidemiology/ etiology/
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Guideline Adherence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/ complications</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prognosis</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1540-1405 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18053431</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Fatigue, despite being the most
                    common and distressing symptom in cancer, is often unrelieved because of
                    numerous patient, provider, and system barriers. The overall purpose of this
                    5-year prospective clinical trial is to translate the NCCN Cancer-Related
                    Fatigue Clinical Practice Guidelines in Oncology and NCCN Adult Cancer Pain
                    Clinical Practice Guidelines in Oncology into practice and develop a
                    translational interventional model that can be replicated across settings. This
                    article focuses on one NCCN member institution&apos;s experience related to the
                    first phase of the NCCN Cancer-Related Fatigue Guidelines implementation,
                    describing usual care compared with evidence-based guidelines. Phase 1 of this
                    3-phased clinical trial compared the usual care of fatigue with that
                    administered according to the NCCN guidelines. Eligibility criteria included age
                    18 years or older; English-speaking; diagnosed with breast, lung, colon, or
                    prostate cancer; and fatigue and/or pain ratings of 4 or more on a 0 to 10
                    screening scale. Research nurses screened all available subjects in a cancer
                    center medical oncology clinic to identify those meeting these criteria.
                    Instruments included the Piper Fatigue Scale, a Fatigue Barriers Scale, a
                    Fatigue Knowledge Scale, and a Fatigue Chart Audit Tool. Descriptive and
                    inferential statistics were used in data analysis. At baseline, 45 patients had
                    fatigue only (&gt; or = 4) and 24 had both fatigue and pain (&gt; or = 4). This
                    combined sample (N = 69) was predominantly Caucasian (65%), female (63%), an
                    average of 60 years old, diagnosed with stage 3 or 4 breast cancer, and
                    undergoing treatment (82%). The most common barriers noted were patients&apos;
                    belief that physicians would introduce the subject of fatigue if it was
                    important (patient barrier); lack of fatigue documentation (professional
                    barrier); and lack of supportive care referrals (system barrier). Findings
                    showed several patient, professional, and system barriers that distinguish usual
                    care from that recommended by the NCCN Cancer-Related Fatigue Guidelines. Phase
                    2, the intervention model, is designed to decrease these barriers and improve
                    patient outcomes over time, and is in progress.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2008/04/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>673</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">673</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1522</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bowen, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fann, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Andersen, M. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rhew, I. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gralow, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lewis, F. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hunt, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palomares, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moinpour, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ankerst, D. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Washington, Sch Med, Seattle,
                    WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington,
                    Sch Nursing, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Div Publ Hlth
                    Sci, Duarte, CA USA. City Hope Natl Med Ctr, Canc Screening &amp; Prevent
                    Program, Duarte, CA 91010 USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA.
                    Univ Munich, D-80539 Munich, Germany. City Hope Natl Med Ctr, Div Populat Sci,
                    Duarte, CA 91010 USA.&#xD;dbowen@bu.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Recruiting patients with breast
                        cancer and their families to behavioral research in the post-HIPAA
                        period</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncol Nurs Forum</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1049-1054</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED
                        CLINICAL-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRIVACY RULE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRIMARY-CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERVENTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVORSHIP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHALLENGES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRAM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIET</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0190-535X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249351700015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose/Objectives: To describe a
                    process for, response rates of, and indicated interest in recruiting patients
                    with breast cancer and their spouses and family members from a clinical setting
                    into behavioral and psychiatric research studies since the Health Insurance
                    Portability and Accountability Act (HIPAA) regulations have taken effect. Data
                    Sources: Published articles, books and book chapters, MEDLINE (R), government
                    agency information and HIPAA regulatory Web sites, and survey data. Data
                    Synthesis: Response rates among the three target groups-patients, spouses and
                    partners, and female first-degree relatives-were 77%, 95%, and 88%,
                    respectively. Interest was high in the three target groups, with 77%, 87%, and
                    65% of responding patients, spouses and partners, and female first-degree
                    relatives, respectively. Conclusions: Taken together, these data indicate that
                    high participation rates can be expected from patients with breast cancer and
                    their families in clinical settings. Implications for Nursing: Regulations pose
                    barriers to patient and family recruitment, but thoughtful systems actually can
                    improve rates of recruitment.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    208XE&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; *HIPA ADV, 2003, HIPPA PRIM&#xD; *US DEP HHS, 2003, HIPAA PRIV RUL INF
                    R&#xD; ALBERT SM, 2005, GERONTOLOGIST, V45, P432&#xD; ANDERSEN BL, 1992, J
                    CONSULT CLIN PSYCH, V60, P552&#xD; ASHINGGIWA KT, 2004, CANCER, V101, P450&#xD;
                    ASHINGGIWA KT, 2005, ETHNIC DIS, V15, P130&#xD; BAUM A, 2001, PSYCHOSOCIAL
                    INTERVE&#xD; BENSON AB, 1991, J CLIN ONCOL, V9, P2067&#xD; BESKOW LM, 2006, AM J
                    PUBLIC HEALTH, V96, P1920&#xD; CHLEBOWSKI RT, 1993, J CLIN ONCOL, V11,
                    P2072&#xD; DONNELLY JM, 2000, PSYCHO-ONCOL, V9, P44&#xD; ELTING LS, 2006,
                    CANCER, V106, P2452&#xD; FRIEDMAN DS, 2006, AM J OPHTHALMOL, V141, P543&#xD;
                    GOTAY CC, 1991, SOC SCI MED, V33, P569&#xD; HEINEY SP, 2006, CANCER NURS, V29,
                    P291&#xD; HELMES AW, 2000, CANCER EPIDEM BIOMAR, V9, P1377&#xD; HUNTER CP, 1987,
                    CANCER TREAT REP, V71, P559&#xD; HUTCHINS LF, 1999, NEW ENGL J MED, V341,
                    P2061&#xD; KROENKE K, 2001, J GEN INTERN MED, V16, P606&#xD; LEE JY, 1980, CANC
                    CLIN TRIALS, V3, P381&#xD; LOVATO LC, 1997, CONTROL CLIN TRIALS, V18, P328&#xD;
                    MCTIERNAN A, 1998, CANCER EPIDEM BIOMAR, V7, P477&#xD; NEWCOMB PA, 1990, PREV
                    MED, V19, P61&#xD; PIERCE JP, 1997, NUTR CANCER, V28, P282&#xD; SANDS G, 2003,
                    WELC PRIVACY SECURIT&#xD; SEARS SR, 2003, CANCER EPIDEM BIOMAR, V12, P1087&#xD;
                    SHALOWITZ D, 2006, ANN INTERN MED, V144, P685&#xD; SPIRO SG, 2000, THORAX, V55,
                    P463&#xD; SPITZER RL, 1999, JAMA-J AM MED ASSOC, V282, P1737&#xD; TAYLOR KM,
                    1984, NEW ENGL J MED, V310, P1363&#xD; WOLF MS, 2006, CANCER, V106, P474</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249351700015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>775</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">775</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1521</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Bowers, C. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Singer-Sam, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Neurosci, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Biol, Duarte, CA 91010 USA.&#xD;Singer-Sam, J, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Neurosci, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;jsam@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Unique retrotransposon LINE-1
                        distribution at the Prader-Willi Angelman syndrome locus</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Molecular
                        Evolution</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Molecular
                        Evolution</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Mol. Evol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Mol Evol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">475-484</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">65</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">comparative genomics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genomic imprinting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">retrotransposons</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epigenetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN GENOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPOSABLE ELEMENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOUSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORGANIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPEATS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-2844</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250626400011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We analyzed the distribution of long
                    interspersed nuclear elements (LINE)-1 (L1) along mouse autosomes at a 1-Mb
                    scale, and found a unique combination of high density and strand asymmetry of L1
                    elements at the imprinted Prader-Willi syndrome/Angelman syndrome (PWS/AS) locus
                    on mouse chromosome 7. This L1 signature overlaps the paternally expressed
                    domain of the locus, excluding the maternally expressed Ube3a gene, and is
                    conserved in rat and human. Unlike the PWS/AS locus, other instances of high L1
                    density and strand asymmetry in the mouse are not associated with imprinted
                    regions and are not evolutionarily conserved in human. The evolutionary
                    conservation of the L1 signature at the PWS/AS locus despite differences in
                    composition of L1 elements between rodent and human, requires a mechanism for
                    active perpetuation of L1 asymmetry during bursts of L1 activity, and indicates
                    a possible functional role for L1 elements at this locus. Aside from the PWS/AS
                    locus, rodents have a far greater correlation of L1 densities between DNA
                    strands than do humans; we provide evidence that this difference in interstrand
                    correlation between the two taxa is due largely to the difference in average age
                    of the dominant L1 families.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    226ZG&#xD;Times Cited: 0&#xD;Cited Reference Count: 21&#xD;Cited References:
                    &#xD; ALLEN E, 2003, P NATL ACAD SCI USA, V100, P9940&#xD; BRANNAN CI, 1999,
                    CURR OPIN GENET DEV, V9, P164&#xD; BUETTNER VI, 2005, MAMM GENOME, V16,
                    P219&#xD; DELAVAL K, 2004, CURR OPIN GENET DEV, V14, P188&#xD; DORER DR, 1994,
                    CELL, V77, P993&#xD; FURANO AV, 2004, TRENDS GENET, V20, P9&#xD; GARRICK D,
                    1998, NAT GENET, V18, P56&#xD; GREALLY JM, 2002, P NATL ACAD SCI USA, V99,
                    P327&#xD; HOLMQUIST GP, 2006, CYTOGENET GENOME RES, V114, P96&#xD; LANDER ES,
                    2001, NATURE, V409, P860&#xD; LEMEUR E, 2005, DEV BIOL, V286, P587&#xD; LEWIS A,
                    2006, CYTOGENET GENOME RES, V113, P81&#xD; LOPES S, 2003, HUM MOL GENET, V12,
                    P295&#xD; LUEDI PP, 2005, GENOME RES, V15, P875&#xD; MEDSTRAND P, 2002, GENOME
                    RES, V12, P1483&#xD; NICHOLLS RD, 2001, ANNU REV GENOM HUM G, V2, P153&#xD;
                    RUNTE M, 2001, HUM MOL GENET, V10, P2687&#xD; SMIT AFA, 1999, CURR OPIN GENET
                    DEV, V9, P657&#xD; TILGHMAN SM, 1999, CELL, V96, P185&#xD; WALTER J, 2006,
                    CYTOGENET GENOME RES, V113, P109&#xD; YANG S, 2004, GENOME RES, V14,
                    P517</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250626400011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>638</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">638</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1518</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Brown, C. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vishwanath, R. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aguilar, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Starr, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Najbauer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Canc
                    Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010 USA. City Hope Natl Med
                    Ctr, Div Hematol &amp; Hematopoiet Cell Transplantat, Med Ctr, Duarte, CA 91010
                    USA. City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Brown,
                    CE, City Hope Natl Med Ctr, Div Canc Immunotherapeut &amp; Tumor Immunol, KCRB
                    3009,1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;chrown@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Tumor-derived chemokine
                        MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively
                        transferred T cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">3332-3341</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">179</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCYTE CHEMOATTRACTANT
                        PROTEIN-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTACTIC PROTEIN-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNIFICANT REDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSGENE EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MALIGNANT GLIOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SERUM-LEVELS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248991800076</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">To exert a therapeutic effect,
                    adoptively transferred tumor-specific CTLs must traffic to sites of tumor
                    burden, exit the circulation, and infiltrate the tumor microenvironment. In this
                    study, we examine the ability of adoptively transferred human CTL to traffic to
                    tumors with disparate chemokine secretion profiles independent of tumor Ag
                    recognition. Using a combination of in vivo tumor tropism studies and in vitro
                    biophotonic chemotaxis assays, we observed that cell lines derived from glioma,
                    medulloblastoma, and renal cell carcinoma efficiently chemoattracted ex
                    vivo-expanded primary human T cells. We compared the chemokines secreted by
                    tumor cell lines with high chernotactic activity with those that failed to
                    elicit T cell chemotaxis (Daudi lymphoma, 10HTB neuroblastoma, and A2058
                    melanoma cells) and found a correlation between tumorderived production of
                    MCP-1/CCL2 ( &gt;= 10 ng/ml) and T cell chemotaxis. Chemokine immunodepletion
                    studies confirmed that tumor-derived MCP-I elicits effector T cell chemotaxis.
                    Moreover, MCP-I is sufficient for in vivo T cell tumor tropism as evidenced by
                    the selective accumulation of Lv. administered firefly luciferase-expressing T
                    cells in intracerebral xenografts of tumor transfectants secreting MCP-1. These
                    studies suggest that the capacity of adoptively transferred T cells to home to
                    tumors may be, in part, dictated by the species and amounts of tumor-derived
                    chemokines, in particular MCP-1.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    203RN&#xD;Times Cited: 0&#xD;Cited Reference Count: 58</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248991800076 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>651</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">651</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1517</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Buettner, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gritsko, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Karras, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Enkemann, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mesa, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nam, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr,
                    Beckman Res Inst, Duarte, CA 91010 USA. H Lee Moffitt Canc Ctr &amp; Res Inst,
                    Tampa, FL USA. Res Inst, Tampa, FL USA. ISIS Pharmaceut, Antisense Drug
                    Discovery, Carlsbad, CA 92008 USA.&#xD;Buettner, R, City Hope Comprehens Canc
                    Ctr, Beckman Res Inst, Duarte, CA 91010 USA.&#xD;rbuettner@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Activated signal transducers and
                        activators of transcription 3 signaling induces CD46 expression and protects
                        human cancer cells from complement-dependent cytotoxicity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Mol. Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">823-832</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">5</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MEMBRANE COFACTOR
                        PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DECAY-ACCELERATING
                        FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-BINDING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSTITUTIVE ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STAT3 ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTITUMOR-ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULAR TARGETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-GAMMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SRC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOPROTEIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1541-7786</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248862100007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CD46 is one of the
                    complement-regulatory proteins expressed on the surface of normal and tumor
                    cells for protection against complement-dependent cytotoxicity. Cancer cells
                    need to access the blood circulation for continued growth and metastasis, thus
                    exposing themselves to destruction by complement system components. Previous
                    studies have established that the signal transducers and activators of
                    transcription 3 (STAT3) transcription factor is persistently activated in a wide
                    variety of human cancer cells and primary tumor tissues compared with their
                    normal counterparts. Using microarray gene expression profiling, we identified
                    the CD46 gene as a target for activated STAT3 signaling in human breast and
                    prostate cancer cells. The CD46 promoter contains two binding sites for
                    activated STAT3 and mutations introduced into the major site abolished STAT3
                    binding. Chromatin immunoprecipitation confirms binding of STAT3 to the CD46
                    promoter. CD46 promoter activity is induced by activation of STAT3 and blocked
                    by a dominant-negative form of STAT3 in luciferase reporter assays. CD46 mRNA
                    expression is induced by interleukin-6 and by transient transfection of normal
                    human epithelial cells with a persistently active mutant construct of STAT3,
                    STAT3C. Furthermore, we show that inhibition of STAT3-mediated CD46 cell surface
                    expression sensitizes DU145 prostate cancer cells to cytotoxicity in an in vitro
                    complement lysis assay using rabbit anti-DU145 antiserum and rabbit complement.
                    These results show that activated STAT3 signaling induces the CD46 promoter and
                    protects human cancer cells from complement-dependent cytotoxicity, suggesting a
                    potential mechanism whereby oncogenic signaling contributes to tumor cell
                    evasion of antibody-mediated immunity.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    201WA&#xD;Times Cited: 0&#xD;Cited Reference Count: 37</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248862100007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>418</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">418</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1512</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cai, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhu, L. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, Z. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91006 USA.&#xD;Chen, Y, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Immunol, 1500 Duarte Rd, Duarte, CA 91006
                    USA.&#xD;ychen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Determination of the
                        three-dimensional structure of the Mrf2-DNA complex using paramagnetic spin
                        labeling</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochemistry (Mosc).</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochemistry (Mosc)</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">4943-4950</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">46</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">17</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-BINDING DOMAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOCKING APPROACH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEAD RINGER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-V</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RELAXATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESTRAINTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOMOLOGY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NMR</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-2960</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245899900001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Understanding the mechanism of
                    protein-DNA interactions at the molecular level is one of the main focuses in
                    structural and molecular biological investigations. At present, NMR spectroscopy
                    is the only approach that can provide atomic details of protein-DNA recognition
                    in solution. However, determining the structures of protein-DNA complexes using
                    NMR spectroscopy has been dependent on the observation of intermolecular nuclear
                    Overhauser effects (NOE) and their assignments, which are difficult to obtain in
                    many cases. In this study, we have shown that intermolecular distance
                    constraints derived from a single spin-label in combination with docking
                    calculations have defined many specific contacts of the complex between the
                    AT-rich interaction domain (ARID) of Mrf2 and its target DNA. Mrf2 contacts DNA
                    mainly using the two flexible loops, L1 and L2. While the L1 loop contacts the
                    phosphate backbone, L2 and several residues in the adjacent helices interact
                    with AT base pairs in the major groove of DNA. Despite the structural diversity
                    in the ARID family of DNA-binding proteins, Mrf2 maintains contacts with DNA
                    similar to those observed in the homologous Dri-DNA complex.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    159XB&#xD;Times Cited: 0&#xD;Cited Reference Count: 20&#xD;Cited References:
                    &#xD; ARNESANO F, 2004, STRUCTURE, V12, P669&#xD; BATTISTE JL, 2000,
                    BIOCHEMISTRY-US, V39, P5355&#xD; CORNILESCU G, 1999, J BIOMOL NMR, V13,
                    P289&#xD; DOMINGUEZ C, 2003, J AM CHEM SOC, V125, P1731&#xD; DOMINGUEZ C, 2004,
                    STRUCTURE, V12, P633&#xD; FOLKERS PJM, 1993, BIOCHEMISTRY-US, V32, P9407&#xD;
                    FOLMER RHA, 1994, J MOL BIOL, V240, P341&#xD; GILLESPIE JR, 1997, J MOL BIOL,
                    V268, P170&#xD; IWAHARA J, 1999, EMBO J, V18, P6084&#xD; IWAHARA J, 2002, EMBO
                    J, V21, P1197&#xD; KIM S, 2004, J BIOL CHEM, V279, P16670&#xD; KORTSCHAK RD,
                    2000, TRENDS BIOCHEM SCI, V25, P294&#xD; KRUGH TR, 1976, SPIN LABELING THEORY,
                    P339&#xD; LEVENE SD, 1986, BIOCHEMISTRY-US, V25, P3988&#xD; RAMOS A, 1998, J AM
                    CHEM SOC, V120, P10992&#xD; SOLOMON I, 1956, J CHEM PHYS, V25, P261&#xD; SPOLAR
                    RS, 1994, SCIENCE, V263, P777&#xD; WILSKER D, 2004, NUCLEIC ACIDS RES, V32,
                    P1345&#xD; YUAN YC, 1998, NAT STRUCT BIOL, V5, P959&#xD; ZHU LY, 2001,
                    BIOCHEMISTRY-US, V40, P9142</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245899900001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>642</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">642</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1511</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cai, W. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olafsen, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, X. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cao, Q. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gambhir, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, X. Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Stanford Univ, Sch Med, MIPS,
                    Stanford, CA 94305 USA. Stanford Univ, Sch Med, Bio X Program, Dept Radiol,
                    Stanford, CA 94305 USA. Univ Calif Los Angeles, Crump Inst Mol Imaging, Dept Mol
                    &amp; Med Pharmacol, David Geffen Sch Med, Los Angeles, CA USA. Stanford Univ,
                    Sch Med, Dept Bioengn, Stanford, CA 94305 USA. City Hope Natl Med Ctr, Div
                    Radiol, Duarte, CA 91010 USA.&#xD;Chen, XY, Stanford Univ, Sch Med, MIPS, 1201
                    Welch Rd,P095, Stanford, CA 94305 USA.&#xD;shawchen@stanford.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">PET imaging of colorectal cancer
                        in xenograft-bearing mice by use of an F-18-labeled T84.66
                        anti-carcinoembryonic antigen diabody</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Nuclear
                        Medicine</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Nucl. Med.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Nuclear
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Nucl. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Nucl Med</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Nuclear
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Nucl. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Nucl Med</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">304-310</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">carcinoembryonic antigen
                        (CEA)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T84.66 diabody</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">F-18</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small-animal PET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">colorectal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-TUMOR ANGIOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIBODY FRAGMENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RGD PEPTIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CEA DIABODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROPET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOSIMETRY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINIBODY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0161-5505</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244115600038</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In this study, we investigated the
                    F-18-labeled anti-carcinoembryonic antigen (CEA) T84.66 diabody, a genetically
                    engineered noncovalent dimer of single-chain variable fragments, for
                    small-animal PET imaging of CEA expression in xenograft-bearing mice. Methods:
                    F-18 labeling of the anti-CEA T84.66 diabody (molecular mass, 55 kDa) was
                    achieved with N-succinimiclyl-4-F-18-fluorobenzoate (F-18-SFB). The
                    biodistribution of the F-18-fluorobenzyl-T84.66 diabody (F-18-FB-T84.66 diabody)
                    was evaluated in athymic nude mice bearing subcutaneous LS 174T human colon
                    carcinoma and C6 rat glioma tumors. Serial small-animal PET imaging studies were
                    performed to further evaluate in vivo targeting efficacy and pharmacokinetics.
                    Results: Radiolabeling required 35 +/- 5 (mean +/- SD) min starting from
                    F-18-SFB, and the tracer F-18-FB-T84.66 diabody was synthesized with a specific
                    activity of 1.83 +/- 1.71 TBq/mmol. The decay-corrected radiochemical yield was
                    1.40% 0.16% (n = 4), and the radiochemical purity was greater than 98%. The
                    radioimmunoreactivity was 57.1% +/- 2.0%. The F-18-FB-T84.66 diabody showed
                    rapid and high tumor uptake and fast clearance from the circulation in the LS
                    174T xenograft model, as evidenced by both small-animal PET imaging and
                    biodistribution studies. High-contrast small-animal PET images were obtained as
                    early as 1 h after injection of the F-18-FB-T84.66 diabody, and only a
                    background level of activity accumulation was found in CEA-negative C6 tumors.
                    The tracer exhibited predominantly renal clearance, with some activity in the
                    liver and spleen at early time points. Conclusion: The F-18-labeled diabody
                    represents a new class of tumor-specific probes for PET that are based on
                    targeting cell surface antigen expression. The F-18-FB-T84.66 diabody can be
                    used for high-contrast small-animal PET imaging of CEA-positive tumor
                    xenografts. It may be translated to the clinic for PET of CEA-positive
                    malignancies.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    134WR&#xD;Times Cited: 1&#xD;Cited Reference Count: 40</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244115600038 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>419</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">419</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1509</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cano, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Klitz, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mack, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maiers, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marsh, S. G. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Noreen, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reed, E. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Senitzer, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Setterholm, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fernandez-Vina, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas, MD Anderson Canc Ctr,
                    HLA Typing Lab, Houston, TX 77054 USA. Univ Calif Berkeley, Berkeley, CA 94720
                    USA. Inst Publ Hlth, Oakland, CA USA. Childrens Hosp, Oakland Res Inst, Oakland,
                    CA 94609 USA. Roche Mol Syst, Dept Human Genet, Alameda, CA USA. Natl Marrow
                    Donor Program, Minneapolis, MN USA. Royal Free Hosp, Anthony Nolan Res Inst,
                    London NW3 2QG, England. Univ Calif Los Angeles, David Geffen Sch Med,
                    Immunogenet Ctr, Dept Pathol, Minneapolis, MN USA. City Hope Natl Med Ctr,
                    Duarte, CA 91010 USA. Seattle Canc Care Alliance, Clin Immunogenet Lab, Seattle,
                    WA USA.&#xD;Fernandez-Vina, M, Univ Texas, MD Anderson Canc Ctr, HLA Typing Lab,
                    8515 Fannin,NA01-091C, Houston, TX 77054
                    USA.&#xD;MFernand@mdanderson.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Common and well-documented HLA
                        alleles - Report of the ad-hoc committee of the American Society for
                        Histocompatiblity and Immunogenetics</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Human Immunology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Immunol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">392-417</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">common allele</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">null allele</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">well-documented allele</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">proficiency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">testing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antigen recognition site</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical
                        histocompatibility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genotype ambiguity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLASS-II POLYMORPHISM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASHI MINORITY WORKSHOPS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DR-DQ HAPLOTYPES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">B-ALLELES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LINKAGE DISEQUILIBRIUM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIGH-RESOLUTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEQUENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYMORPHISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AFRICAN POPULATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPEDICION-HUMANA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA-DRB1 ALLELES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0198-8859</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246227800010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In histocompatibility testing some
                    genotype ambiguities are almost always resolved into the genotype with the most
                    common alleles. To achieve unambiguous assignments additional unwieldy tests are
                    performed. The American Society for Histocompatibility and Immunogenetics formed
                    a committee to define what human leukocyte antigen (HLA) genotypes do not need
                    to be resolved in external proficiency testing. The tasks included detailed
                    analysis of large datasets of high-resolution typing and thorough review of the
                    pertinent scientific literature. Strict criteria were used to create a catalogue
                    of common and well-documented (CWD) alleles. In total, 130, 245, 81, and 143 of
                    the highly polymorphic HLA-A, -B, -C, and DRB1 loci fell into the CWD category;
                    these represent 27%-30% of all alleles recognized. For the loci DRB3/4/5, DQA1,
                    DQB1, and DPB1, a total of 29, 16, 26, and 52 CWD alleles were identified. A
                    recommendation indicated that an acceptable report should only include one
                    possible genotype; multiple genotypes can only be reported if only one of these
                    includes two alleles of the CWD group. Exceptions in which resolution is not
                    necessary are ambiguities involving functional alleles with identical sequences
                    in the antigen recognition site. The criteria were established for proficiency
                    testing, which could be a valuable tool when making clinical histocompatibility
                    decisions.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    164IT&#xD;Times Cited: 0&#xD;Cited Reference Count: 75&#xD;Cited References:
                    &#xD; ADAMS EJ, 1995, TISSUE ANTIGENS, V45, P18&#xD; ARNAIZVILLENA A, 2001, HUM
                    IMMUNOL, V62, P1051&#xD; ARNAIZVILLENA A, 2002, TISSUE ANTIGENS, V60, P111&#xD;
                    BALDASSARRE LA, 2003, TISSUE ANTIGENS, V61, P249&#xD; BANNAI M, 2000, TISSUE
                    ANTIGENS, V55, P128&#xD; BANNAI M, 2000, TISSUE ANTIGENS, V55, P128&#xD;
                    BEGOVICH AB, 2001, TISSUE ANTIGENS, V57, P424&#xD; BEGOVICH AB, 2001, TISSUE
                    ANTIGENS, V58, P431&#xD; BELICH MP, 1992, NATURE, V357, P326&#xD; BUGAWAN TL,
                    1999, TISSUE ANTIGENS 1, V53, P311&#xD; BUGAWAN TL, 2000, TISSUE ANTIGENS, V56,
                    P392&#xD; CAO K, 1999, REV IMMUNOGENET, V1, P177&#xD; CAO K, 2001, HUM IMMUNOL,
                    V62, P109&#xD; CAO K, 2004, TISSUE ANTIGENS, V63, P293&#xD; DEPABLO R, 1997,
                    TISSUE ANTIGENS, V50, P593&#xD; ELLIS JM, 2000, TISSUE ANTIGENS, V56, P291&#xD;
                    ELLIS JM, 2001, TISSUE ANTIGENS, V57, P339&#xD; FERNANDEZVINA M, 1995, TISSUE
                    ANTIGENS, V45, P153&#xD; FERNANDEZVINA MA, 1991, IMMUNOGENETICS, V34, P299&#xD;
                    FERNANDEZVINA MA, 1997, TISSUE ANTIGENS, V50, P233&#xD; FORT M, 1998, TISSUE
                    ANTIGENS 1, V51, P327&#xD; GAO X, 1992, EUR J IMMUNOGENET, V19, P263&#xD; GAO X,
                    1992, TISSUE ANTIGENS, V40, P31&#xD; GAO XJ, 1992, HUM IMMUNOL, V34, P153&#xD;
                    GAO XJ, 1992, IMMUNOGENETICS, V36, P333&#xD; GARBER TL, 1995, IMMUNOGENETICS,
                    V42, P19&#xD; GARBER TL, 1995, IMMUNOGENETICS, V42, P308&#xD; GOMEZCASADO E,
                    2000, TISSUE ANTIGENS, V55, P239&#xD; HAMMOND MG, 1997, HLA GENETIC DIVERSIT,
                    V1, CH4&#xD; HOLLENBACH JA, 2001, HUM IMMUNOL, V62, P378&#xD; HORS J, 1997, HLA
                    GENETIC DIVERSIT, V1&#xD; IMANISHI T, 1991, HLA 1991 P 11 INT HI, V1&#xD;
                    IZAABEL H, 1998, TISSUE ANTIGENS, V51, P106&#xD; KEMPENICH JH, 2006, TISSUE
                    ANTIGENS, V67, P284&#xD; KLITZ W, 2003, TISSUE ANTIGENS, V62, P296&#xD; KRAUSA
                    P, 1999, EXP CLIN IMMUNOGENET, V16, P17&#xD; LAYRISSE Z, 2001, HUM IMMUNOL, V62,
                    P992&#xD; LAYRISSE Z, 2001, HUM IMMUNOL, V62, P992&#xD; LAZARO AM, 1999, HUM
                    IMMUNOL, V60, P1138&#xD; LEFFELL MS, 2002, HUM IMMUNOL, V63, P614&#xD; LEFFELL
                    MS, 2004, HUM IMMUNOL, V65, P78&#xD; LITTLE AM, 2001, HUM IMMUNOL, V62,
                    P170&#xD; LUO M, 2002, TISSUE ANTIGENS, V59, P370&#xD; MAGOR KE, 1997, J
                    IMMUNOL, V158, P5242&#xD; MAIN P, 2001, HUM BIOL, V73, P782&#xD; MARTINEZARENDS
                    A, 1998, TISSUE ANTIGENS, V52, P51&#xD; MEYER D, IN PRESS HLA 2004 IM&#xD;
                    MIDDLETON D, 2000, HUM IMMUNOL, V61, P1048&#xD; MIDDLETON D, 2000, HUM IMMUNOL,
                    V61, P1285&#xD; MIGOTNABIAS F, 1999, TISSUE ANTIGENS, V53, P580&#xD; MODIANO D,
                    2001, TISSUE ANTIGENS, V57, P128&#xD; NOVITSKY V, 2001, HUM IMMUNOL, V62,
                    P146&#xD; OUMHANI K, 2001, HUM IMMUNOL, V63, P626&#xD; OUMHANI K, 2002, HUM
                    IMMUNOL, V63, P129&#xD; PAUL P, 2001, TISSUE ANTIGENS, V57, P300&#xD;
                    PIMTANOTHAI N, 2001, TISSUE ANTIGENS, V58, P1&#xD; PINTO C, 2004, HUM IMMUNOL,
                    V65, P181&#xD; RENQUIN J, 2001, TISSUE ANTIGENS, V58, P211&#xD; ROBINSON J,
                    2000, TISSUE ANTIGENS, V55, P280&#xD; ROBINSON J, 2003, NUCLEIC ACIDS RES, V31,
                    P311&#xD; SAITO S, 2000, TISSUE ANTIGENS, V56, P522&#xD; SALAMON H, 1999,
                    GENETICS, V152, P393&#xD; SANCHEZMAZAS A, 2000, TISSUE ANTIGENS, V56, P303&#xD;
                    SANCHEZMAZAS A, 2001, HUM IMMUNOL, V62, P937&#xD; SCHIPPER RF, 1998, HUM
                    IMMUNOL, V59, P518&#xD; SCHNITTGER L, 1997, TISSUE ANTIGENS, V50, P546&#xD; TANG
                    JM, 2000, EXP CLIN IMMUNOGENET, V17, P185&#xD; TOKUNAGA K, 1997, IMMUNOGENETICS,
                    V46, P199&#xD; TRACHTENBERG EA, 1995, AM J HUM GENET, V57, P415&#xD;
                    TRACHTENBERG EA, 1996, TISSUE ANTIGENS, V48, P174&#xD; TRACHTENBERG EA, 1996,
                    TISSUE ANTIGENS, V48, P192&#xD; TURNER S, 1998, J IMMUNOL, V161, P1406&#xD;
                    WILLIAMS F, 1999, TISSUE ANTIGENS, V54, P59&#xD; WILLIAMS F, 2001, HUM IMMUNOL,
                    V62, P645&#xD; WILLIAMS F, 2001, HUM IMMUNOL, V62, P645</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246227800010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>394</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">394</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1505</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Carpenter, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snyder, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Flowers, M. E. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sanders, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gooley, T. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Martin, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Appelbaum, F. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Radich, J. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr, Div
                    Clin Res, Seattle, WA 98109 USA. Univ Washington, Dept Pediat, Seattle, WA 98195
                    USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. City Hope Natl Med Ctr,
                    Duarte, CA 91010 USA.&#xD;Carpenter, PA, Fred Hutchinson Canc Res Ctr, Div Clin
                    Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.&#xD;pcarpent@fhcrc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Prophylactic administration of
                        imatinib after hematopoietic cell transplantation for high-risk Philadelphia
                        chromosome-positive leukemia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2791-2793</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">1ST 100 DAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADAPTIVE IMMUNITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESYLATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RELAPSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PH+</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245639000027</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Relapse occurs frequently after
                    allogeneic hematopoietic cell transplantation (HCT) for treatment of high-risk
                    Philadelphia chromosome-positive (Ph+) leukemia. Administration of imatinib
                    early after HCT might provide an effective approach for preventing recurrent Ph+
                    leukemia, but the feasibility of this approach has not been systematically
                    tested. Twentytwo patients, 15 with Ph+ acute lympho- blastic leukemia and 7
                    with high-risk chronic myelogenous leukemia, were enrolled in a prospective
                    study and given imatinib from the time of engraftment until 365 days after HCT.
                    Before day 90, adults (n = 19) tolerated a median average daily imatinib dose of
                    400 mg/d (range, 200-500 mg/d), and children (n = 3) tolerated 265 mg/m(2)/d
                    (range, 200-290 mg/m(2)/d). The most common adverse events related to imatinib
                    administration were grade 1-3 nausea, emesis, and serum transaminase elevations.
                    We conclude that imatinib can be safely administered early after myeloablative
                    allogeneic HCT at a dose intensity comparable to that used in primary
                    therapy.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    156HP&#xD;Times Cited: 0&#xD;Cited Reference Count: 20&#xD;Cited References:
                    &#xD; ANDERLINI P, 2004, BIOL BLOOD MARROW TR, V10, P883&#xD; BORG C, 2004, J
                    CLIN INVEST, V114, P379&#xD; CHAN CW, 2006, NAT MED, V12, P207&#xD; KANTARJIAN
                    HM, 2002, BLOOD, V100, P1590&#xD; MARIN D, 2002, BLOOD, V100, A782&#xD; OBRIEN
                    SG, 2003, NEW ENGL J MED, V348, P994&#xD; OLAVARRIA E, 2003, LEUKEMIA, V17,
                    P1707&#xD; OTTMANN OG, 2002, BLOOD, V100, P1965&#xD; RADICH J, 1997, BLOOD, V89,
                    P2602&#xD; RADICH JP, 1995, BLOOD, V85, P2632&#xD; RADICH JP, 2001, HEMATOL
                    ONCOL CLIN N, V15, P21&#xD; RADICH JP, 2004, HEMATOL ONCOL CLIN N, V18,
                    P685&#xD; SHETH SR, 2002, BLOOD 1, V100, A635&#xD; SIERRA J, 1997, BLOOD, V90,
                    P1410&#xD; SMYTH MJ, 2006, NEW ENGL J MED, V354, P2282&#xD; STIREWALT DL, 2003,
                    BIOL BLOOD MARROW TR, V9, P206&#xD; TAIEB J, 2006, NAT MED, V12, P214&#xD;
                    WASSMANN B, 2005, BLOOD, V106, P458&#xD; WASSMANN B, 2006, BLOOD, V108,
                    P1469&#xD; YANADA M, 2006, J CLIN ONCOL, V24, P460</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245639000027 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>676</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">676</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1501</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Castanotto, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sakurai, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lingeman, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, H. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aagaard, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Soifer, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gatignol, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div Mol
                    Biol, Duarte, CA 91010 USA. Beckman Res Inst City Hope, Grad Sch Biol Sci,
                    Duarte, CA 91010 USA. Beckman Res Inst City Hope, Div Biol, Duarte, CA 91010
                    USA. McGill Univ, Lady Davis Inst Med Res, Virus Cell Interact Lab, Montreal,
                    PQ, Canada.&#xD;Rossi, JJ, Beckman Res Inst City Hope, Div Mol Biol, Duarte, CA
                    91010 USA.&#xD;jrossi@bricoh.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Combinatorial delivery of small
                        interfering RNAs reduces RNAi efficacy by selective incorporation into
                        RISC</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5154-5164</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">15</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">6</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOUBLE-STRANDED-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHORT HAIRPIN RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR EXPORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICRORNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRECURSORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ARGONAUTE2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRBP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0305-1048</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249612300020</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Despite the great potential of RNAi,
                    ectopic expression of shRNA or siRNAs holds the inherent risk of competition for
                    critical RNAi components, thus altering the regulatory functions of some
                    cellular microRNAs. In addition, specific siRNA sequences can potentially hinder
                    incorporation of other siRNAs when used in a combinatorial approach. We show
                    that both synthetic siRNAs and expressed shRNAs compete against each other and
                    with the endogenous microRNAs for transport and for incorporation into the RNA
                    induced silencing complex ( RISC). The same siRNA sequences do not display
                    competition when expressed from a microRNA backbone. We also show that TAR RNA
                    binding protein ( TRBP) is one of the sensors for selection and incorporation of
                    the guide sequence of interfering RNAs. These findings reveal that combinatorial
                    siRNA approaches can be problematic and have important implications for the
                    methodology of expression and use of therapeutic interfering RNAs.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    212QQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 35&#xD;Cited References:
                    &#xD; BOHNSACK MT, 2004, RNA, V10, P185&#xD; CASTANOTTO D, 2005, METHOD ENZYMOL,
                    V392, P173&#xD; CHATTERJEEKISHORE M, 2006, CURR OPIN DRUG DISC, V9, P231&#xD;
                    CHENDRIMADA TP, 2005, NATURE, V436, P740&#xD; CULLEN BR, 2006, NAT GENET S, V38,
                    S25&#xD; DAVIET L, 2000, EUR J BIOCHEM, V267, P2419&#xD; FIRE A, 1998, NATURE,
                    V391, P806&#xD; GITLIN L, 2002, NATURE, V418, P430&#xD; GITLIN L, 2003, J VIROL,
                    V77, P7159&#xD; GREGORY RI, 2005, CELL, V123, P631&#xD; GRIMM D, 2006, NATURE,
                    V441, P537&#xD; HAASE AD, 2005, EMBO REP, V6, P961&#xD; HANNON GJ, 2004, NATURE,
                    V431, P371&#xD; HUTVAGNER G, 2004, PLOS BIOL, V2, P465&#xD; KIM VN, 2004, TRENDS
                    CELL BIOL, V14, P156&#xD; KOLLER E, 2006, NUCLEIC ACIDS RES, V34, P4467&#xD;
                    LEWIS BP, 2005, CELL, V120, P15&#xD; LIM LP, 2005, NATURE, V433, P769&#xD; LIU
                    JD, 2004, SCIENCE, V305, P1437&#xD; LUND E, 2004, SCIENCE, V303, P95&#xD;
                    MEISTER G, 2004, MOL CELL, V15, P185&#xD; MEISTER G, 2004, NATURE, V431,
                    P343&#xD; MEISTER G, 2004, RNA, V10, P544&#xD; MOFFAT J, 2006, NAT REV MOL CELL
                    BIO, V7, P177&#xD; NISHITSUJI H, 2006, J VIROL, V80, P7658&#xD; OHRT T, 2006,
                    NUCLEIC ACIDS RES, V34, P1369&#xD; RAND TA, 2004, P NATL ACAD SCI USA, V101,
                    P14385&#xD; REYNOLDS A, 2004, NAT BIOTECHNOL, V22, P326&#xD; RIVAS FV, 2005, NAT
                    STRUCT MOL BIOL, V12, P340&#xD; SONG JJ, 2004, SCIENCE, V305, P1434&#xD; TOMARI
                    Y, 2005, GENE DEV, V19, P517&#xD; VARGASON JM, 2003, CELL, V115, P799&#xD; YI R,
                    2003, GENE DEV, V17, P3011&#xD; YI R, 2005, RNA, V11, P220&#xD; ZAMORE PD, 2005,
                    SCIENCE, V309, P1519</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249612300020 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>873</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">873</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1496</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McNamara, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aguilar, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ostberg, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Dept Pediat Hematol Oncol, Div Canc Immunotherapeut &amp; Tumor Immunol,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Clin &amp; Mol Pharmacol,
                    Duarte, CA USA.&#xD;Jensen, MC, City Hope Natl Med Ctr, Beckman Res Inst, Dept
                    Pediat Hematol Oncol, Div Canc Immunotherapeut &amp; Tumor Immunol, 1500 E
                    Duarte RD, Duarte, CA 91010 USA.&#xD;mjensen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Transgene-enforced
                        co-stimulation of CD4(+) T cells leads to enhanced and sustained anti-tumor
                        effector functioning</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">771-784</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CD4(+) T cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cellular immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chimeric Ag receptors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">co-stimulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gliomia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR ALPHA-2 CHAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHIMERIC RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIGEN RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COSTIMULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-13</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">4-1BB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD28</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1465-3249</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252534600009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background Thc role of
                    co-stimulation in CD4(+) T cell activation by professional APC is well
                    established, while less is known of the role co-stimulation plays when CD4+ T
                    cells interact directly with tumor cells. Methods Through generic engineering of
                    human CD4(+) T cells We tested the hypothesis that integration of co-stimulatory
                    signaling domains within a tumor-targeting chimeric Ag receptor (CAR), the
                    IL-13R alpha 2-specific IL-13-zetakine (IL13 zeta), would enhance CD4(+) T cell
                    mediated responses against tumors that fail to express ligands for
                    co-stimulatory receptors. Results Compared with CD3 zeta-mediated activation
                    alone, CD4(+) effector T cells expressing the IL13-CD28-41BB zeta CAR exhibited
                    augmented/ sustained MAPK and AKT activity, up-regulated Th1 cytokine
                    production, and enhanced cytolytic potency against tumor targets. Moreover, upon
                    recursive stimulation with tumor the IL13-CD28- 41BB zeta(+) cells
                    retained/recycled their lytic function, whereas IL-13C(+) CD4(+) cells became
                    anergic/exhausted. These in vitro observations correlated with enhanced in vivo
                    control of established orthotopic CNS gliomia xenografts in immunodeficient mice
                    mediated by adoptively transferred ex vivo-expanded CD4(+) T cells expressing
                    the co-stimulatory CAR. Discussion Together these studies demonstrate the
                    importance of integrating co-stimulation with CD3 zeta signaling events to
                    activate fully CD4(+) antitumor effector cells for sustained function in the
                    tumor microenvironment.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    253RF&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687&#xD; BROWN CE, 2005, J
                    IMMUNOL METHODS, V297, P39&#xD; CANNONS JL, 1999, J IMMUNOL, V163, P2990&#xD;
                    CATELLINO F, 2006, ANNU REV IMMUNOL, V24, P519&#xD; CHANG LF, 2006, CELL, V124,
                    P601&#xD; CHEN LP, 1992, CELL, V71, P1093&#xD; CHEUK ATC, 2004, CANCER GENE
                    THER, V11, P215&#xD; CHIALDA L, 2005, RESP RES, V6&#xD; COOPER LJ, 2005, CANC
                    CHEMOTHER BIOL, V22, P293&#xD; COOPER LJN, 2005, BLOOD, V105, P1622&#xD; CROFT
                    M, 2003, CYTOKINE GROWTH F R, V14, P265&#xD; DEBINSKI W, 1998, NAT BIOTECHNOL,
                    V16, P449&#xD; DONNELLY MLL, 2001, J GEN VIROL 5, V82, P1027&#xD; FINNEY HM,
                    2004, J IMMUNOL, V172, P104&#xD; GLIMCHER LH, 2000, GENE DEV, V14, P1693&#xD;
                    HIBI M, 1993, GENE DEV, V7, P2135&#xD; HUSAIN SR, 1997, CLIN CANCER RES, V3,
                    P151&#xD; IMAI C, 2004, LEUKEMIA, V18, P676&#xD; JANSSEN EM, 2003, NATURE, V421,
                    P852&#xD; KAHLON KS, 2004, CANCER RES, V64, P9160&#xD; KANE LP, 2001, NAT
                    IMMUNOL, V2, P37&#xD; KANE LP, 2003, IMMUNOL REV, V192, P7&#xD; KAWAKAMI K,
                    2006, CANCER RES, V66, P4434&#xD; KAWAKAMI M, 2003, CLIN CANCER RES, V9,
                    P6381&#xD; KAWAKAMI M, 2004, CANCER, V101, P1036&#xD; KIOI M, 2006, CANCER,
                    V107, P1407&#xD; KNUTSON KL, 2005, CANCER IMMUNOL IMMUN, V54, P721&#xD; KOWOLIK
                    CM, 2006, CANCER RES, V66, P10995&#xD; LEE SW, 2006, J IMMUNOL, V177, P4464&#xD;
                    MEISEL R, 2003, EXP HEMATOL, V31, P1215&#xD; MINN AJ, 2005, NATURE, V436,
                    P518&#xD; NASH KT, 2001, CRIT REV ONCOL HEMAT, V39, P87&#xD; PULE MA, 2005, MOL
                    THER, V12, P933&#xD; RINCON M, 2003, IMMUNOL REV, V192, P131&#xD; SERRANO LM,
                    2006, BLOOD, V107, P2643&#xD; SHEDLOCK DJ, 2003, SCIENCE, V300, P337&#xD; STARCK
                    L, 2005, EUR J IMMUNOL, V35, P1257&#xD; SU B, 1994, CELL, V77, P727&#xD;
                    TOWNSEND SE, 1993, SCIENCE, V259, P368&#xD; WHITMIRE JK, 2000, CURR OPIN
                    IMMUNOL, V12, P448</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252534600009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>283</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">283</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1490</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, C. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kirshner, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, W. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nguyen, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Dvi Informat Sci, Duarte, CA 91010 USA.&#xD;Shively, JE, 1450 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;jshively@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mutation analysis of the short
                        cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies
                        residues that orchestrate actin binding and lumen formation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5749-5760</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BILIARY GLYCOPROTEIN
                        CD66A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-CAM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOEMBRYONIC
                        ANTIGENS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL BASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORPHOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SYSTEM</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244482300071</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">CEACAM1-4S (carcinoembryonic antigen
                    cell adhesion molecule 1, with 4 ectodomains and a short, 12-14 amino acid
                    cytoplasmic domain) mediates lumen formation via an apoptotic and cytoskeletal
                    reorganization mechanism when mammary epithelial cells are grown in a
                    three-dimensional model of mammary morphogenesis. We show by quantitative yeast
                    two-hybrid, BIAcore, NMR HSQC and STD, and confocal analyses that amino acids
                    phenylalanine (Phe(454)) and lysine (Lys(456)) are key residues that interact
                    with actin orchestrating the cytoskeletal reorganization. A CEACAM1 membrane
                    model based on vitamin D-binding protein that predicts an interaction of Phe 454
                    at subdomain 3 of actin was supported by inhibition of binding of actin to
                    vitamin D-binding protein by the cytoplasmic domain peptide. We also show that
                    residues Thr(457) and/or Ser(419) are phosphorylated in CEACAM1-transfected
                    cells grown in three-dimensional culture and that mutation analysis of these
                    residues (T457A/S459A) or F454A blocks lumen formation. These studies
                    demonstrate that a short cytoplasmic domain membrane receptor can directly
                    mediate substantial intracellular signaling.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    140CZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; BLAU DM, 2001, J VIROL, V75, P8173&#xD; BOULTON IC, 2002, NAT IMMUNOL, V3,
                    P229&#xD; CHEN CJ, 2004, J IMMUNOL, V172, P3544&#xD; DAUBEROSGUTHORP.P, 1988,
                    PROTEINS, V4, P31&#xD; DOMINGUEZ R, 2004, TRENDS BIOCHEM SCI, V29, P572&#xD;
                    EDLUND M, 1996, J BIOL CHEM, V271, P1393&#xD; EDLUND M, 1998, FEBS LETT, V425,
                    P166&#xD; ERGUN S, 2000, MOL CELL, V5, P311&#xD; GRAYOWEN SD, 1997, EMBO J, V16,
                    P3435&#xD; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831&#xD; HELLER H, 1993,
                    J PHYS CHEM-US, V97, P8343&#xD; HOLMES KC, 2003, NATURE, V425, P423&#xD; HOLMES
                    KC, 2004, PHILOS T ROY SOC B, V359, P1819&#xD; HUANG J, 1998, ANTICANCER RES,
                    V18, P3203&#xD; HUANG J, 1999, J CELL SCI, V112, P4193&#xD; IIJIMA H, 2004, J
                    EXP MED, V199, P471&#xD; KAMMERER R, 2001, J IMMUNOL, V166, P6537&#xD; KANO K,
                    1978, BIOCHIM BIOPHYS ACTA, V509, P289&#xD; KIRSHNER J, 2003, J BIOL CHEM, V278,
                    P50338&#xD; KIRSHNER J, 2003, P NATL ACAD SCI USA, V100, P521&#xD; KIRSHNER J,
                    2004, J MOL HISTOL, V35, P287&#xD; KLEINERMAN DI, 1996, CANCER RES, V56,
                    P3431&#xD; LORENZ M, 1995, J MOL BIOL, V246, P108&#xD; LUO WP, 1997, ONCOGENE,
                    V14, P1697&#xD; LUO WP, 1999, CANCER GENE THER, V6, P313&#xD; MARKEL G, 2002, J
                    CLIN INVEST, V110, P943&#xD; MAYER M, 2001, J AM CHEM SOC, V123, P6108&#xD;
                    NAJJAR SM, 2002, TRENDS ENDOCRIN MET, V13, P240&#xD; NEUMAIER M, 1993, P NATL
                    ACAD SCI USA, V90, P10744&#xD; NITTKA S, 2004, ONCOGENE, V23, P9306&#xD; NOLLAU
                    P, 1997, CANCER RES, V57, P2354&#xD; OBRINK B, 1997, CURR OPIN CELL BIOL, V9,
                    P616&#xD; OTTERBEIN LR, 2002, P NATL ACAD SCI USA, V99, P8003&#xD; SCHUMANN D,
                    2001, J BIOL CHEM, V276, P47421&#xD; SPAAR A, 2003, BIOPHYS J, V85, P1576&#xD;
                    VIRJI M, 2000, MOL MICROBIOL, V36, P784&#xD; WALLACH DFH, 1976, J CELL PHYSIOL,
                    V89, P769&#xD; WATT SM, 2001, BLOOD, V98, P1469&#xD; YEUNG T, 2006, SCIENCE,
                    V313, P347&#xD; YU EW, 2003, SCIENCE, V300, P976</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244482300071 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>745</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">745</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1487</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Masri, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Phung, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, Y. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, X. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst, Dept Surg Res,
                    Duarte, CA 91010 USA. Beckman Res Inst, Div Informat Sci, Duarte, CA 91010
                    USA.&#xD;Chen, SA, Beckman Res Inst, Dept Surg Res, Duarte, CA 91010
                    USA.&#xD;schen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">New experimental models for
                        aromatase inhibitor resistance</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Steroid Biochemistry
                        and Molecular Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Steroid Biochemistry
                        and Molecular Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Steroid Biochem. Mol.
                        Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Steroid Biochem Mol
                        Biol</style>
                </abbr-2>
                <abbr-3>
                    <style face="normal" font="default" size="100%">The Journal of steroid
                        biochemistry &amp; molecular biology</style>
                </abbr-3>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">8-15</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">106</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1-5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aromatase inhibitor
                        resistance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SITE-DIRECTED
                        MUTAGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >TERM-ESTROGEN-DEPRIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTMENOPAUSAL WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING CHARACTERISTICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TAMOXIFEN THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MECHANISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LETROZOLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOCHROME-P450</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug-Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0960-0760</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250078300003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Clinical trials have demonstrated
                    the importance of aromatase inhibitor (AI) therapy in the effective treatment of
                    hormone-dependent breast cancers. In contrast to tamoxifen, an antagonist of the
                    estrogen receptor (ER), AIs have shown to be better tolerated along with
                    decreased recurrence rates of the disease. Currently, three third-generation AIs
                    are being used: exemestane, letrozole, and anastrozole. Our laboratory is
                    attempting to understand several aspects of AI functionality. In this paper, we
                    first review recent findings from our structure-function studies of aromatase as
                    well as the molecular characterization of the interaction between AIs and
                    aromatase. Based on these studies, we propose new evidence for the interaction
                    of letrozole and exemestane with aromatase. In addition, we will discuss recent
                    results generated from our AI-resistant cell lines. Our laboratory has generated
                    MCF-7aro cells that are resistant to letrozole, anastrozole, exemestane, and
                    tamoxifen. Basic functional characterization of aromatase and ER(x in these
                    resistant cell lines has been done and microarray analysis has been employed in
                    order to better understand the mechanism responsible for AI resistance on a
                    genome-wide scale. The results generated so far suggest the presence of at least
                    four types of resistant cell lines. Overall, the information presented in this
                    paper supplements our understanding of AI function, and such information can be
                    valuable for the development of treatment strategies against AI resistant breast
                    cancers. (C) 2007 Elsevier Ltd. All rights reserved.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    219IO&#xD;Times Cited: 0&#xD;Cited Reference Count: 44&#xD;Cited References:
                    &#xD; BAUM M, 2002, LANCET, V359, P2131&#xD; BECKER M, 2005, MOL CANCER THER,
                    V4, P151&#xD; BRODIE A, 2005, J STEROID BIOCHEM, V95, P41&#xD; BRODIE AMH, 1994,
                    J STEROID BIOCHEM, V49, P281&#xD; BRUEGGEMEIER RW, 2005, ENDOCR REV, V26,
                    P331&#xD; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622&#xD; CHEN S, 1992, J
                    BIOL CHEM, V267, P22587&#xD; CHEN S, 1997, J STEROID BIOCHEM, V61, P107&#xD;
                    CHEN S, 1998, FRONT BIOSCI, V3, P922&#xD; CHEN SA, 2003, J STEROID BIOCHEM, V86,
                    P231&#xD; CHEN SA, 2006, J STEROID BIOCHEM, V102, P232&#xD; COOMBES RC, 1984,
                    LANCET, V2, P1237&#xD; COOMBES RC, 2004, NEW ENGL J MED, V350, P1081&#xD;
                    DOWSETT M, 1989, CANCER RES, V49, P1306&#xD; DOWSETT M, 2005, J STEROID BIOCHEM,
                    V95, P167&#xD; ESTEBAN JM, 1992, AM J PATHOL, V140, P337&#xD; FAVIA AD, 2006,
                    PROTEINS, V62, P1074&#xD; GOSS PE, 2003, NEW ENGL J MED, V349, P1793&#xD; HARADA
                    N, 1997, J STEROID BIOCHEM, V61, P175&#xD; HONG YY, 2006, ANN NY ACAD SCI,
                    V1089, P237&#xD; HONG YY, 2007, MOL ENDOCRINOL, V21, P401&#xD; ITOH T, 2005, MOL
                    CANCER RES, V3, P203&#xD; JAMES VHT, 1987, STEROIDS, V50, P269&#xD; JELOVAC D,
                    2005, CANCER RES, V65, P5380&#xD; KAO YC, 1996, CANCER RES, V56, P3451&#xD; KAO
                    YC, 2001, EUR J BIOCHEM, V268, P243&#xD; LU Q, 1996, ENDOCRINOLOGY, V137,
                    P3061&#xD; MA CX, 2005, CANCER RES, V65, P11071&#xD; MACEDO LF, 2005, CANCER
                    RES, V66, P7775&#xD; MARTIN LA, 2005, ENDOCR-RELAT CANC S1, V12, S75&#xD; MILLER
                    WR, 1987, STEROIDS, V50, P537&#xD; NICHOLSON RI, 2004, ENDOCR-RELAT CANCER, V11,
                    P623&#xD; OMOTO Y, 2002, BREAST CANC, V9, P308&#xD; SABNIS GJ, 2005, CANCER RES,
                    V65, P3903&#xD; SANTEN RJ, 1981, BREAST CANCER RES TR, V1, P183&#xD; SANTEN RJ,
                    1994, J CLIN ENDOCR METAB, V79, P627&#xD; SANTEN RJ, 2005, J STEROID BIOCHEM,
                    V95, P155&#xD; SASANO H, 2005, J STEROID BIOCHEM, V95, P35&#xD; SMITH IE, 2003,
                    NEW ENGL J MED, V348, P2431&#xD; SUN XZ, 1997, J STEROID BIOCHEM, V63, P29&#xD;
                    THOMPSON EA, 1974, J BIOL CHEM, V249, P5364&#xD; TREECK O, 2004, ANTI-CANCER
                    DRUG, V15, P787&#xD; VERMEULEN A, 1986, EUR J CANCER CLIN ON, V22, P515&#xD;
                    WANG X, 2006, CANCER RES, V66, P10281&#xD;Sp. Iss. SI</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250078300003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>833</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">833</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1486</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, T. J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kaats, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Braverman, E. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eisenberg, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davis, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Comings, D. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wood, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pullin, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Arcuri, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Varshavski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mengucci, J. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, S. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Downs, B. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meshkin, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waite, R. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schoolfield, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Prihoda, T. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">White, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Wake Forest Univ, Bowman Gray Sch
                    Med, Dept Physiol &amp; Pharmacol, Winston Salem, NC 27157 USA. Chang Jung
                    Christian Univ, Tainan, Taiwan. Hlth &amp; Med Res Fdn San Antonio, San Antonio,
                    TX USA. Path Med Clin, New York, NY USA. Univ N Texas Hlth Sci, Ft Worth, TX
                    USA. Carlsbad Sci Fdn, City Hope Natl Med Ctr, Duarte, CA USA. Univ Texas Hlth
                    Sci Ctr San Antonio, Dept Informat, San Antonio, TX 78229 USA. Baylor Coll Med,
                    Sports Med Inst, Houston, TX 77030 USA. Synapatmine Inc, San Antonio, TX USA.
                    Allied Nutraceut Res, Lederach, PA USA. Salugen Inc, San Diego, CA USA.
                    GenWellness Inc, San Diego, CA USA. Univ Texas Hlth Sci Ctr San Antonio, Dept
                    Pathol, San Antonio, TX 78229 USA. DNA Serv Amer, Lafayette, LA USA. Baylor Coll
                    Med, Dept Mol Genet, Houston, TX 77030 USA.&#xD;Blum, K, Wake Forest Univ,
                    Bowman Gray Sch Med, Dept Physiol &amp; Pharmacol, Med Ctr Blvd, Winston Salem,
                    NC 27157 USA.&#xD;drd2gene@aol.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Chromium Picolinate (CrP) a
                        putative anti-obesity nutrient induces changes in body composition as a
                        function of the Taq1 dopamine D2 receptor polymorphisms in a randomized
                        double-blind placebo controlled study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy and Molecular
                        Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy and Molecular
                        Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther. Mol. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther Mol Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">161-170</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">11B</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">chromium picolinate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genotyping</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">body-composition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genotrim (R)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">and</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dopamine D2 receptor
                        gene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWING-FINISHING PIGS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">X-RAY ABSORPTIOMETRY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REWARD DEFICIENCY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WEIGHT-LOSS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PARENTERAL-NUTRITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMOSOME-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCASS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRAITS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOOD-PRESSURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OBESE WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1529-9120</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251610000007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">There is controversy regarding the
                    effects and safety of chromium salts (picolinate and nicotinate) on body
                    composition and weight loss in humans. Thus, we decided to test the hypothesis
                    that typing the obese patients by genotyping the dopamine D2 receptor (DRD2)
                    gene prior to treatment with Chromium Picolinate (CrP) would result in a
                    differential treatment outcome. We genotyped obese subjects for the DRD2 gene
                    utilizing standard PCR techniques. The subjects were assessed for scale weight
                    and for percent body fat using dual energy X-ray absorptiometry (DEXAR). The
                    subjects were divided into matched placebo and CrP groups (400 mu g. per day)
                    accordingly. The sample was separated into two independent groups. Those with
                    either an A1/A1 or A1/A2 allele or those with only the A2/A2 allelic pattern.
                    Each of these groups were tested separately for differences between placebo and
                    treatment means for a variety of measures of weight change. The measures of the
                    change in fat weight (p&lt;0.041), change in body weight (p&lt;0.017), the
                    percent change in weight (p&lt;0.044), and the body weight change in kilograms
                    (p&lt;0.012) were all significant for carriers of the DRD2 A2 genotype, whereas
                    no significance was found for any parameter for those subjects possessing a DRD2
                    A1 allele. These results suggest that the dopaminergic system, specifically the
                    density of the D2 receptors, confers a significant differential therapeutic
                    effect of CrP in terms of weight loss and change in body fat, thereby
                    strengthening the need for DNA testing.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    240TJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 85&#xD;Cited References:
                    &#xD; *WHO, 1973, TECH REP SER, V532&#xD; ANDERSON PW, 1995, PHYS WORLD, V8,
                    P37&#xD; ANDERSON RA, 1979, AM COLL NUTR, V16, P273&#xD; ANDERSON RA, 1995,
                    NUTRITION, V11, P83&#xD; ANDERSON RA, 1998, J TRACE ELEM EXP MED, V11, P241&#xD;
                    ANDERSON RA, 1998, NUTR REV, V56, P266&#xD; BAGCHI D, 2002, TOXICOLOGY, V180,
                    P5&#xD; BAHADORI B, 1997, ACTA MED AUST, V24, P185&#xD; BESHYAH SA, 1995, AM J
                    CLIN NUTR, V61, P1186&#xD; BLUM K, 1990, CURR THER RES, V43, P217&#xD; BLUM K,
                    1990, JAMA-J AM MED ASSOC, V263, P578&#xD; BLUM K, 1994, AM J MED GENET,
                    P55&#xD; BLUM K, 1996, AM SCI, V84, P132&#xD; BLUM K, 1996, J ROY SOC MED, V89,
                    P396&#xD; BLUM K, 1996, PHARMACOGENETICS, V6, P297&#xD; BLUM K, 1997, CURR THER
                    RES CLIN E, V58, P745&#xD; BROWN RO, 1986, DIGEST DIS SCI, V31, P661&#xD;
                    BULBULIAN R, 1996, MED SCI SPORTS EXERC, V39, P992&#xD; CAMPBELL WW, 1999, J
                    APPL PHYSIOL, V86, P29&#xD; CHEN TJH, 2004, MED HYPOTHESES, V63, P538&#xD; CHEN
                    TJH, 2007, GENE THER MOL BIOL A, V11, P61&#xD; CLANCY SP, 1994, INT J SPORT
                    NUTR, V4, P142&#xD; COMINGS DE, 1993, BIOCHEM MED METAB B, V50, P176&#xD;
                    COMINGS DE, 1996, AM J MED GENET, V67, P264&#xD; COMINGS DE, 1996, MOL
                    PSYCHIATR, V1, P325&#xD; CRAWFORD V, 1999, DIABETES OBES METAB, V1, P331&#xD;
                    DAVIDSON JRT, 2003, BIOL PSYCHIAT, V53, P261&#xD; DIAZ ML, 2007, IN PRESS J NUTR
                    BIOC, P23&#xD; EVANS GW, 1973, BIOCHEM BIOPH RES CO, V50, P718&#xD; EVANS GW,
                    1983, INT J SPORT NUTR, V3, P117&#xD; EVANS GW, 1989, INT J BIOSOCIAL MED, V11,
                    P163&#xD; EVANS GW, 1994, ADV SCI RES, V1, P19&#xD; FEKETE S, 2001, ACTA VET
                    HUNG, V49, P385&#xD; FREDI KE, 1991, AM J CLIN NUTR, V55, P764&#xD; GRANT KE,
                    1997, MED SCI SPORT EXER, V29, P992&#xD; GUDI R, 2005, MUTAT RES-GEN TOX EN,
                    V587, P140&#xD; HALLMARK MA, 1996, MED SCI SPORT EXER, V28, P139&#xD; HASTEN DL,
                    1992, INT J SPORT NUTR, V2, P343&#xD; JENKINSON CP, 2000, INT J OBESITY, V24,
                    P1233&#xD; JENSEN MD, 1993, MAYO CLIN PROC, V68, P867&#xD; KAATS GR, 1992, CURR
                    THER RES CLIN E, V51, P261&#xD; KAATS GR, 1996, CURR THER RES CLIN E, V57,
                    P747&#xD; KAATS GR, 1998, ADV THER, V15, P345&#xD; KAATS GR, 1998, CURR THER RES
                    CLIN E, V59, P379&#xD; KORNEGAY ET, 1997, J ANIM SCI, V75, P1319&#xD; LAWFORD
                    BR, 1995, NAT MED, V1, P337&#xD; LAWFORD BR, 2003, EUR NEUROPSYCHOPHARM, V13,
                    P313&#xD; LINDEMANN MD, 1995, J ANIM SCI, V73, P457&#xD; LOVEDAY KS, 1996,
                    EVALUATION CHROMIUM&#xD; LUKASKI HC, 1996, AM J CLIN NUTR, V63, P954&#xD;
                    LUKASKI HC, 1999, ANNU REV NUTR, V19, P279&#xD; LUKASKI HC, 2000, AM J CLIN
                    NUTR, V72, P585&#xD; LUKASKI HC, 2007, IN PRESS NUTRITION&#xD; LUVOLSI JM, 2000,
                    J STRENGTH COND RES, V15, P161&#xD; MAZESS RB, 1990, AM J CLIN NUTR, V51,
                    P1106&#xD; MCCARTY MF, 1996, FASEB J, V10, P365&#xD; MERTZ W, 1993, J NUTR,
                    V123, P626&#xD; MERTZ W, 1994, RISK ASSESSMENT ESSE&#xD; MIN JK, 1997, ASIAN
                    AUSTRAL J ANIM, V10, P8111&#xD; MOKDAD AH, 2003, JAMA-J AM MED ASSOC, V289,
                    P76&#xD; MOONEY KW, 1997, J ANIM SCI, V75, P2661&#xD; MUNOZ MJG, 2006, NUTR
                    HOSP, V21, P709&#xD; NOBLE EP, 1994, INT J EAT DISORDER, V15, P205&#xD; NOBLE
                    EP, 2003, AM J MED GENET B B, V116, P103&#xD; NORD RH, 1995, ASIA PACIFIC J
                    CLIN, V4, P173&#xD; PAGE TG, 1993, J ANIM SCI, V71, P656&#xD; PASSMAN WJ, 1997,
                    INT J OBES RELA META, V21, P1143&#xD; ROSEMOND R, 2001, J HUM HYPERTENS, V15,
                    P553&#xD; RUBIN MA, 1998, J NUTR, V128, P73&#xD; SLESINSKI R, 2004, CHROMIUM
                    PICOLINATE&#xD; SPITZ MR, 2000, NUTR RES, V20, P371&#xD; STALLINGS DM, 2006,
                    MUTAT RES-GEN TOX EN, V610, P101&#xD; STEARNS DM, 1995, FASEB J, V9, P1643&#xD;
                    STOECKER BJ, 1990, INT LIFE SCI I, P287&#xD; TATARANNI PA, 1995, AM J CLIN NUTR,
                    V62, P730&#xD; TATARANNI PA, 2001, DIABETES, V50, P901&#xD; THANOS PK, 2001, J
                    NEUROCHEM, V78, P1094&#xD; THOMAS GN, 2000, HYPERTENSION, V36, P177&#xD; THOMAS
                    GN, 2001, CLIN ENDOCRINOL, V55, P605&#xD; TRENT LK, 1995, J SPORT MED PHYS FIT,
                    V35, P273&#xD; VOLPE SL, 2001, J AM COLL NUTR, V20, P293&#xD; WALKER LS, 1998,
                    MED SCI SPORT EXER, V30, P1730&#xD; WANG GJ, 2001, LANCET, V357, P354&#xD; WANG
                    ZM, 1995, AM J CLIN NUTR, V61, P457&#xD; WARD TL, 1997, J ANIM SCI, V75,
                    P1001</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251610000007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>285</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">285</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1483</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, W. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Y. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, H. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Su, Z. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Dept Gene Regulat &amp; Drug Discovery, Duarte, CA 91010 USA. Chinese Acad
                    Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100080, Peoples R
                    China. Chinese Acad Sci, Inst Hydrobiol, Wuhan 430072, Peoples R
                    China.&#xD;Chen, WD, City Hope Natl Med Ctr, Beckman Res Inst, Dept Gene Regulat
                    &amp; Drug Discovery, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;wdchen999@yahoo.com.cn</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Hydrodynamics in an expanded bed
                        of large size ion-exchange resin, and natural product adsorption</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Chemical Technology
                        and Biotechnology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Chemical Technology
                        and Biotechnology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Chem. Technol.
                        Biotechnol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Chem Technol
                        Biotechnol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">135-142</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">82</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cation resin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hydrodynamics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dynamic binding capacity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">expanded bed</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adsorption</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">natural product</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">separations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUPERCRITICAL-FLUID
                        EXTRACTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADSORPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PURIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMATOGRAPHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PERFORMANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPANSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECOVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CULTURES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLUMN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0268-2575</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244615300003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Successful applications of expanded
                    bed adsorption (EBA) technology have been widely reported in the literature for
                    protein purification. Little has been reported on the recovery of natural
                    products and active components of Chinese herbal preparations using EBA
                    technology. In this study, the hydrodynamic behavior in an expanded bed of
                    cation resin, 001 x 7 Styrene-DVB, was investigated. Ephedrine hydrochloride
                    (EH) was used as a model natural product to test the dynamic binding capacity
                    (DBC) in the expanded bed. EBA of EH directly from a feedstock containing
                    powdered herbs has also been investigated. These particles are different from
                    commercially available expanded bed adsorbents by virtue of their large size
                    (20S to 1030 gm). When the adsorbent bed is expanded to approximately 1.3 to 1.5
                    times its settled bed height, the axial liquid-phase dispersion coefficient was
                    found to be of the order 10(-5) m(2) s(-1), which falls into the range 1.0 x
                    10(-6) to 1.0 X 10(-5) m(2) s(-1) observed previously in protein purification.
                    Because of the favorable column efficiency (low axial dispersion coefficient),
                    the recovery yield and purification factor values of EH directly from a
                    feedstock reached 86.5% and 18, respectively. The results suggest that EBA
                    technology holds promise for the recovery of natural products and active
                    components of Chinese herbal preparations.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    141YO&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; ANKLAM E, 1998, FOOD ADDIT CONTAM, V15, P729&#xD; BASCOUL A, 1988, CHEM
                    ENG J, V38, P69&#xD; BIRD RB, 1960, TRANSPORT PHENOMENA&#xD; CHANG YK, 1996,
                    BIOTECHNOL BIOENG, V49, P512&#xD; CHASE HA, 1994, TRENDS BIOTECHNOL, V12,
                    P296&#xD; CHEN WD, 2002, J CHROMATOGR A, V962, P29&#xD; CHEN WD, 2003,
                    BIOTECHNOL PROGR, V19, P880&#xD; CHEN WD, 2003, J CHROMATOGR A, V1012, P1&#xD;
                    CHEN WD, 2004, BIOTECHNOL LETT, V26, P1233&#xD; CLEMMITT RH, 2000, BIOTECHNOL
                    BIOENG, V67, P206&#xD; CORDOBA PR, 1996, BIOTECHNOL TECH, V10, P629&#xD; HJORTH
                    R, 1995, BIOSEPARATION, V5, P217&#xD; HJORTH R, 1997, TRENDS BIOTECHNOL, V15,
                    P230&#xD; HU HB, 2000, CHINESE J CHEM ENG, V8, P230&#xD; LALI AM, 1989, POWDER
                    TECHNOL, V57, P39&#xD; LANG QY, 2001, TALANTA, V53, P771&#xD; LUTKEMEYER D,
                    1999, BIOTECHNOL BIOENG, V65, P114&#xD; PALSSON E, 2000, BIOTECHNOL LETT, V22,
                    P245&#xD; PHILLIPSON JD, 2001, PHYTOCHEMISTRY, V56, P237&#xD; RICHARDSON JF,
                    1954, T I CHEM ENG-LOND, V32, P35&#xD; THOMMES J, 1995, BIOTECHNOL BIOENG, V45,
                    P205&#xD; THOMMES J, 1995, BIOTECHNOL BIOENG, V48, P367&#xD; TONG XD, 2002, J
                    CHROMATOGR A, V943, P63&#xD; WANG YD, 2004, BIOCHEM ENG J, V19, P259&#xD;
                    WEBSTER GH, 1990, AICHE S SER, V86, P104</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244615300003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>558</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">558</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1899</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ge, H. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Young, M. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, T. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stevens, S. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Graduate program in Microbiology,
                    City of Hope Beckman Research Institute, Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Proteomic analysis of in
                        vivo-assembled pre-mRNA splicing complexes expands the catalog of
                        participating factors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3928-44</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chickens/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclophilins/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hela Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Heterogeneous-Nuclear
                        Ribonucleoproteins/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mass Spectrometry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nuclear
                        Proteins/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Peptides/analysis/isolation
                        &amp; purification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proteomics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Helicases/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Precursors/isolation &amp;
                        purification/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Splicing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Messenger/isolation &amp;
                        purification/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small
                        Nuclear/analysis/isolation &amp; purification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-Binding
                        Proteins/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ribonucleoproteins/
                        analysis/isolation &amp; purification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ribonucleoproteins, Small
                        Nuclear/analysis/biosynthesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Spliceosomes/ chemistry</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1362-4962 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17537823</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Previous compositional studies of
                    pre-mRNA processing complexes have been performed in vitro on synthetic
                    pre-mRNAs containing a single intron. To provide a more comprehensive list of
                    polypeptides associated with the pre-mRNA splicing apparatus, we have determined
                    the composition of the bulk pre-mRNA processing machinery in living cells. We
                    purified endogenous nuclear pre-mRNA processing complexes from human and chicken
                    cells comprising the massive (&gt;200S) supraspliceosomes (a.k.a.
                    polyspliceosomes). As expected, RNA components include a heterogeneous mixture
                    of pre-mRNAs and the five spliceosomal snRNAs. In addition to known pre-mRNA
                    splicing factors, 5&apos; end binding factors, 3&apos; end processing factors,
                    mRNA export factors, hnRNPs and other RNA binding proteins, the protein
                    components identified by mass spectrometry include RNA adenosine deaminases and
                    several novel factors. Intriguingly, our purified supraspliceosomes also contain
                    a number of structural proteins, nucleoporins, chromatin remodeling factors and
                    several novel proteins that were absent from splicing complexes assembled in
                    vitro. These in vivo analyses bring the total number of factors associated with
                    pre-mRNA to well over 300, and represent the most comprehensive analysis of the
                    pre-mRNA processing machinery to date.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>677</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">677</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1481</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Han, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vora, N. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pezner, R. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Radiat
                    Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Thorac Surg, Duarte,
                    CA 91010 USA. City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA 91010
                    USA.&#xD;Chen, YJ, City Hope Natl Med Ctr, Div Radiat Oncol, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;yichen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Setup variations in radiotherapy
                        of esophageal cancer: Evaluation by daily megavoltage computed tomographic
                        localization</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Radiat. Oncol. Biol.
                        Phys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1537-1545</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">68</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">setup variation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophageal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MVCT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">helical</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tomotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONFORMAL RADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HELICAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONLINE CORRECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ERRORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMAGES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0360-3016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248629400033</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To use pretreatment
                    megavoltage computed tomography (MVCT) scans to evaluate setup variations in
                    anterior-posterior (AP), lateral, and superior-inferior (SI) directions and
                    rotational variations, including pitch, roll, and yaw, for esophageal cancer
                    patients treated with helical tomotherapy. Methods and Materials: Ten patients
                    with locally advanced esophageal cancer treated by combined chemoradiation using
                    helical tomotherapy were selected. After patients were positioned using their
                    skin tattoos/marks, MVCT scans were performed before every treatment and
                    automatically registered to planning kilovoltage CT scans according to bony
                    landmarks. Image registration data were used to adjust patient setups before
                    treatment. A total of 250 MVCT scans were analyzed. Correlations between setup
                    variations and body habitus, including height, weight, relative weight change,
                    body surface area, and patient age, were evaluated. Results: The standard
                    deviations for systematic setup corrections in AP, lateral, and SI directions
                    and pitch, roll, and yaw rotations were 1.5, 3.7, and 4.8 mm and 0.5 degrees,
                    1.2 degrees, and 0.8 degrees, respectively. The appropriate averages of random
                    setup variations in AP, lateral, and SI directions and pitch, roll, and yaw
                    rotations were 2.9, 5.2, and 4.4 mm, and 1.0 degrees, 1.2 degrees, and 1.1
                    degrees, respectively. Setup variations were stable throughout the entire course
                    of radiotherapy in all three translational and three rotational displacements,
                    with little change in magnitude. No significant correlations were found between
                    setup variations and body habitus variables. Conclusions: Daily MVCT scans
                    before each treatment can effectively detect setup errors and thereby reduce
                    planning target volume (PTV) margins. This will reduce radiation dose to
                    critical organs and may translate into lower treatment-related toxicities. (c)
                    2007 Elsevier Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    198LK&#xD;Times Cited: 0&#xD;Cited Reference Count: 30&#xD;Cited References:
                    &#xD; *INT COMM RAD UN M, 1993, 50 ICRU&#xD; ALASTI H, 2001, INT J RADIAT ONCOL,
                    V49, P869&#xD; BIJHOLD J, 1992, RADIOTHER ONCOL, V24, P261&#xD; BOSWELL S, 2006,
                    MED PHYS, V33, P4395&#xD; COOPER JS, 1999, JAMA-J AM MED ASSOC, V281, P1623&#xD;
                    DEBOER HCJ, 2001, INT J RADIAT ONCOL, V49, P857&#xD; DEKOSTE JRV, 2003, INT J
                    RADIAT ONCOL, V55, P804&#xD; DENEVE W, 1992, RADIOTHER ONCOL, V24, P45&#xD;
                    ERRIDGE SC, 2003, RADIOTHER ONCOL, V66, P75&#xD; EZZ A, 1992, INT J RADIAT
                    ONCOL, V22, P159&#xD; FORREST LJ, 2004, INT J RADIAT ONCOL, V60, P1639&#xD;
                    GASPAR LE, 2000, CANCER, V88, P988&#xD; HERSKOVIC A, 1992, NEW ENGL J MED, V326,
                    P1593&#xD; HUNT MA, 1995, INT J RADIAT ONCOL, V32, P227&#xD; LEE HK, 2003, INT J
                    RADIAT ONCOL, V57, P1317&#xD; LING CC, 1993, RADIOTHER ONCOL, V29, P129&#xD;
                    MACKIE TR, 1993, MED PHYS, V20, P1709&#xD; MACKIE TR, 2003, INT J RADIAT ONCOL,
                    V56, P89&#xD; MACKIE TR, 2003, INTENSITY MODULATED, P247&#xD; MEEKS SL, 2005,
                    MED PHYS, V32, P2673&#xD; MINSKY BD, 2002, J CLIN ONCOL, V20, P1167&#xD; PISANI
                    L, 2000, INT J RADIAT ONCOL, V47, P825&#xD; RUCHALA KJ, 2002, INT J RADIAT
                    ONCOL, V54, P592&#xD; SAMSON MJ, 1999, INT J RADIAT ONCOL, V43, P827&#xD;
                    SASIDHARAN S, 2005, INT J RADIAT ONCO S1, V63, S91&#xD; STAHL M, 2005, J CLIN
                    ONCOL, V23, P2310&#xD; STROOM JC, 1999, INT J RADIAT ONCOL, V43, P905&#xD;
                    VALICENTI RK, 1994, INT J RADIAT ONCOL, V30, P431&#xD; VANDESTEENE J, 1998, INT
                    J RADIAT ONCOL, V40, P967&#xD; YAN D, 1997, INT J RADIAT ONCOL, V38,
                    P197</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248629400033 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>648</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">648</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1480</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Han, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsai, P. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pezner, R. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vora, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lim, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Radiat
                    Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Med Oncol, Duarte, CA
                    91010 USA. City Hope Natl Med Ctr, Div Thorac Surg, Duarte, CA 91010 USA. Harbor
                    UCLA Med Ctr, Torrance, CA 90509 USA.&#xD;Chen, YJ, City Hope Natl Med Ctr, Div
                    Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;yichen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Helical tomotherapy for
                        radiotherapy in esophageal cancer: A preferred plan with better conformal
                        target coverage and more homogeneous dose distribution</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Medical Dosimetry</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Med. Dosim.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Medical Dosimetry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Med. Dosim.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Med Dosim</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Medical Dosimetry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Med. Dosim.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Med Dosim</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">166-171</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">helical tomotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMRT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophageal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTENSITY-MODULATED
                        RADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-III TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREOPERATIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMORADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMORADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0958-3947</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249163000003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We compare different radiotherapy
                    techniques-helical tomotherapy (tomotherapy), step-and-shoot IMRT (IMRT), and
                    3-dimensional conformal radiotherapy (3DCRT)-for patients with mid-distal
                    esophageal carcinoma on the basis of dosimetric analysis. Six patients with
                    locally advanced mid-distal esophageal carcinoma were treated with neoadjuvant
                    chemoradiation followed by surgery. Radiotherapy included 50 Gy to gross
                    planning target volume (PTV) and 45 Gy to elective PTV in 25 fractions.
                    Tomotherapy, IMRT, and 3DCRT plans were generated. Dose-volume histograms
                    (DVHs), homogeneity index (HI), volumes of lung receiving more than 10, 15, or
                    20 Gy (V-10, V-15, V-20) and volumes of heart receiving more than 30 or 45 Gy
                    (V-30, V-45) were determined. Statistical analysis was performed by paired
                    t-tests. By isodose distributions and DVHs, tomotherapy plans showed sharper
                    dose gradients, more conformal coverage, and better HI for both gross and
                    elective PTVs compared with IMRT or 3DCRT plans. Mean V-20 of lung was
                    significantly reduced in tomotherapy plans. However, tornotherapy and IMRT plans
                    resulted in larger V,0 of lung compared to 3DCRT plans. The heart was
                    significantly spared in tomotherapy and IMRT plans compared to 3DCRT plans in
                    terms of V-30 and V-45. We conclude that tornotherapy plans are superior in
                    terms of target conformity, dose homogeneity, and V-20 of lung. (C) 2007
                    American Association of Medical Dosimetrists.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    206DB&#xD;Times Cited: 0&#xD;Cited Reference Count: 26</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249163000003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>630</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">630</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1473</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Cho, Y. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guszczynski, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dressler, G. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Copeland, T. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kalkum, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ge, K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">NIDDK, NIH, Nucl Receptor Biol Sect,
                    Bethesda, MD 20892 USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol,
                    Duarte, CA 91010 USA. Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. NCI,
                    Natl Inst Hlth, Lab Prot Dynam &amp; Signaling, Frederick, MD 21702 USA.&#xD;Ge,
                    K, NIDDK, NIH, Nucl Receptor Biol Sect, Bethesda, MD 20892
                    USA.&#xD;kaig@niddk.nih.gov</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">PTIP associates with MLL3-and
                        MLL4-containing histone H3 lysine 4 methyltransferase complex</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">20395-20406</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">28</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SACCHAROMYCES-CEREVISIAE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DROSOPHILA-TRITHORAX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVE CHROMATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SET1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGET GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COACTIVATOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MLL2</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247819300042</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PTIP, a protein with tandem BRCT
                    domains, has been implicated in DNA damage response. However, its normal
                    cellular functions remain unclear. Here we show that while ectopically expressed
                    PTIP is capable of interacting with DNA damage response proteins including
                    53BP1, endogenous PTIP, and a novel protein PA1 are both components of a
                    Set1-like histone methyltransferase (HMT) complex that also contains ASH2L,
                    RBBP5, WDR5, hDPY-30, NCOA6, SET domain-containing HMTsMLL3 and MLL4, and
                    substoichiometric amount of JmjC domain-containing putative histone demethylase
                    UTX. PTIP complex carries robust HMT activity and specifically methylates lysine
                    4 (K4) on histone H3. Furthermore, PA1 binds PTIP directly and requires PTIP for
                    interaction with the rest of the complex. Moreover, we show that hDPY-30 binds
                    ASH2L directly. The evolutionarily conserved hDPY-30, ASH2L, RBBP5, and WDR5
                    likely constitute a subcomplex that is shared by all human
                    Set1-likeHMTcomplexes. In contrast, PTIP, PA1, and UTX specifically associate
                    with the PTIP complex. Thus, in cells without DNA damage agent treatment, the
                    endogenous PTIP associates with a Set1-like HMT complex of unique subunit
                    composition. As histone H3 K4 methylation associates with active genes, our
                    study suggests a potential role of PTIP in the regulation of gene
                    expression.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    187AI&#xD;Times Cited: 0&#xD;Cited Reference Count: 40</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247819300042 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>778</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">778</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1471</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chow, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenthal, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Karanes, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jaing, T. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Graham, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsukahara, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gjertson, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tan, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Petz, L. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">StemCyte Int Cord Blood Ctr, Covina,
                    CA 91722 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Chang Gung Univ, Tao
                    Yuan, Taiwan. Childrens Hosp, Tao Yuan, Taiwan. Univ Arizona, Med Ctr, Tucson,
                    AZ USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los
                    Angeles, Med Ctr, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Publ
                    Hlth, Los Angeles, CA 90024 USA. Mt Elizabeth Hosp, Singapore, Singapore.
                    StemCyte Natl Cord Blood Ctr, Linkou, Taiwan.&#xD;Chow, R, StemCyte Int Cord
                    Blood Ctr, 1589 W Ind Pk St, Covina, CA 91722
                    USA.&#xD;rchow@stemcyte.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Analysis of hematopoietic cell
                        transplants using plasma-depleted cord blood products that are not red blood
                        cell reduced</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1346-1357</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cord blood
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cord blood banking</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Plasma depletion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cord</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">blood processing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Volume reduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Postthaw wash</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BETA-THALASSEMIA MAJOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNRELATED DONORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNITS UCB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEDIATRIC-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADULT PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIVERSE ADULT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250813000009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Limited cell dose hampers wider use
                    of cord blood transplantation (CBT). By depleting plasma but not RBC during
                    processing, nucleated cell (NC) loss is reduced to &lt; 0. 1 % which increases
                    significantly the proportion of high cell dose products-3-fold for products with
                    NC &gt;= 200 x 10(7). Clinical outcome for plasma depleted (PD) CBT was
                    previously unavailable. A retrospective audited analysis was performed on 118 PD
                    CBT, with mean and median NC doses of 7.6 x 10(7)/kg and 5.6 x 10(7)/kg,
                    respectively, for this mostly pediatric population. The median times to
                    engraftment and engraftment rates for ANC 500 and platelet 20K were 22 and 50
                    days, respectively, and 90% +/- 3% and 77% +/- 5%, respectively. The incidences
                    of grade III-IV acute graft-versushost disease (aGVHD) and extensive chronic
                    GVHD (cGVHD) were 13% +/- 4% and 17% +/- 6%, respectively. Relapse rate for
                    malignancies was 25% +/- 6% and 100-day treatment-related mortality (TRM) was
                    16% +/- 3%. With a median follow-up of 557 days, the 1-year overall survival and
                    relapse-free survival are 65% +/- 5% and 51% +/- 6%, respectively. These results
                    demonstrate that PD CBT is safe and effective, and that eliminating RBC
                    reduction or depletion improves cell recovery during CB processing, resulting in
                    a larger proportion of the inventory with high NC number. (c) 2007 American
                    Society for Blood and Mai-row Transplantation</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    229OE&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; BALLEN KK, 2005, BLOOD 1, V106, A579&#xD; BALLEN KK, 2006, TRANSFUSION,
                    V46, P2063&#xD; BARKER JN, 2002, BIOL BLOOD MARROW TR, V8, P257&#xD; BARKER JN,
                    2002, CURR OPIN ONCOL, V14, P160&#xD; BARKER JN, 2003, CRIT REV ONCOL HEMAT,
                    V48, P35&#xD; BARKER JN, 2005, BLOOD, V105, P1343&#xD; BRUNSTEIN CG, 2006, ANNU
                    REV MED, V57, P403&#xD; CHOW R, 2005, BLOOD 2, V106, B405&#xD; CHOW R, 2005,
                    BLOOD 2, V106, B451&#xD; CHOW R, 2005, BLOOD, V106, S578&#xD; CHOW R, 2006, BIOL
                    BLOOD MARROW S1, V12, P87&#xD; CREER MH, 2005, BLOOD 2, V106, B386&#xD; DAVEY S,
                    2004, BRIT J HAEMATOL, V125, P358&#xD; FERNANDEZ MN, 2003, EXP HEMATOL, V31,
                    P535&#xD; GLUCKMAN E, 2000, EXP HEMATOL, V28, P1197&#xD; GOODWIN H, 2004,
                    CYTOTHERAPY, V5, P80&#xD; GREWAL SS, 2003, BLOOD, V101, P4233&#xD; HAHN T, 2003,
                    BONE MARROW TRANSPL, V32, P145&#xD; HUNG GY, 2005, INT J HEMATOL, V82, P159&#xD;
                    JAING T, 2006, PEDIATR TRANSPLANT, V10, P1&#xD; JAING TH, 2005, BIOL BLOOD
                    MARROW TR, V11, P349&#xD; JAING TH, 2005, J TROP PEDIATRICS, V51, P122&#xD;
                    JIANG T, 2006, BIOL BLOOD MARROW TR, V12, P1126&#xD; KERNAN NA, 2006, BIOL BLOOD
                    MARROW S1, V12, P14&#xD; KOEGLER G, 2005, NMDP COUNC M ABSTR&#xD; KURTZBERG J,
                    2005, BIOL BLOOD MARROW S1, V11, P2&#xD; KURTZBERG J, 2005, J CLIN INVEST, V115,
                    P2592&#xD; LAPIERRE V, 2005, TRANSFUSION S59A, V45&#xD; LAPIERRE V, 2007,
                    CYTOTHERAPY, V9, P163&#xD; LAROCHE V, 2005, TRANSFUSION, V45, P1909&#xD;
                    LAUGHLIN MJ, 2004, NEW ENGL J MED, V351, P2265&#xD; MAJHAIL NS, 2006, CURR OPIN
                    IMMUNOL, V18, P1&#xD; NAGAMURAINOUE T, 2003, TRANSFUSION, V43, P1285&#xD; PETZ
                    LD, 1987, TRANSFUS MED REV, V1, P85&#xD; ROCHA V, 2004, CURR OPIN HEMATOL, V11,
                    P375&#xD; ROCHA V, 2004, NEW ENGL J MED, V351, P2276&#xD; ROCHA V, 2006, BIOL
                    BLOOD MARROW S1, V12, P34&#xD; ROWLEY SD, 2004, THOMAS HEMATOPOIETIC, P599&#xD;
                    RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119&#xD; RUBINSTEIN P, 1998,
                    NEW ENGL J MED, V339, P1565&#xD; SAUERHEILBORN A, 2004, TRANSFUSION, V44,
                    P907&#xD; SCHOEMANS H, 2006, BONE MARROW TRANSPL, V38, P83&#xD; STIFF P, 2005,
                    BLOOD 1, V106, A580&#xD; TAKAHASHI S, 2004, BLOOD, V104, P3813&#xD; TAKAHASHI
                    TA, 2006, CYTOTHERAPY, V8, P254&#xD; WAGNER J, 2005, BIOL BLOOD MARROW TR, V11,
                    P921&#xD; WAGNER JE, 2002, BLOOD, V100, P1611&#xD; WINDRUM P, 2005, BONE MARROW
                    TRANSPL, V36, P601&#xD; YASUTAKE M, 2005, TRANSFUSION, V45, P1899</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250813000009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>610</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">610</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">988</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chow, W. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Med
                    Oncol &amp; Therapeut Res, Duarte, CA 91010 USA.&#xD;Chow, WA, City Hope Natl
                    Med Ctr, Div Med Oncol &amp; Therapeut Res, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;wchow@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Update on
                        chondrosarcomas</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Current Opinion in
                        Oncology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Curr. Opin. Oncol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Current Opinion in
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Curr. Opin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Curr Opin Oncol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Current Opinion in
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Curr. Opin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Curr Opin Oncol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">371-376</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">19</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">chondrosarcoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clear cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dedifferentiated</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mesenchymal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">myxoid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTRASKELETAL MYXOID
                        CHONDROSARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-SITU HYBRIDIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPARATIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENOMIC HYBRIDIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRANIAL BASE
                        CHONDROSARCOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLEAR-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHONDROSARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONVENTIONAL
                        CHONDROSARCOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDIAN HEDGEHOG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1040-8746</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247460300014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose of review This paper reviews
                    recent molecular, biologic, developmental therapeutic, and clinical findings in
                    conventional and variant chondrosarcomas. Recent findings The prognosis of
                    chondrosarcomas traditionally correlates with histologic grade and adequacy of
                    surgery. Newer markers of cell differentiation, activation, genetics, and cell
                    signaling may offer important prognostic information. Translational research has
                    validated platelet-derived growth factor receptor, estrogen signaling, matrix
                    metalloproteinase-1, histone deacetylase, methylthioadenosine phosphorylase, and
                    vascular endothelial growth factor-A as potential therapeutic targets.
                    Bisphosphonates may also possess important antitumoral effects. Molecular
                    studies have established that extraskeletal myxoid chondrosarcoma is a unique
                    entity defined by the presence of a fusion gene between the orphan nuclear
                    receptor, CHN/NOR1, and a promiscuous partner, most commonly EWSR1. Clinical
                    studies have shown that development of second malignancies is an uncommon but
                    real risk for chondrosarcoma survivors; the benefit of chemotherapy for
                    dedifferentiated chondrosarcomas remains questionable; and late recurrences of
                    clear cell chondrosarcomas emphasize the need for long-term follow up. Summary
                    Chondrosarcomas are a heterogeneous group of bone and soft tissue tumors. Recent
                    advances in molecular diagnostics, pathobiology, and developmental therapeutics
                    will aid both scientists and clinicians in improving the classification and
                    therapy of this diverse family of cartilaginous tumors.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    181TZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 52</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247460300014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>746</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">746</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">986</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, D. Z. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gibson, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">David, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Natl Med Ctr, Facey Med Grp, Dept
                    Surg, San Gabriel, CA 91778 USA. City Hope Natl Med Ctr, Dept Surg, Duarte, CA
                    91010 USA. City Hope Natl Med Ctr, Dept Gastroenterol, Duarte, CA 91010 USA.
                    City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA 91010 USA.&#xD;Chu, DZJ, Natl
                    Med Ctr, Facey Med Grp, Dept Surg, San Gabriel, CA 91778
                    USA.&#xD;davidzjchu@yahoo.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The surgeon&apos;s role in
                        cancer prevention. The model in colorectal carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Surg Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3054-3069</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILIAL ADENOMATOUS
                        POLYPOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROSATELLITE-INSTABILITY
                        STATUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED
                        CLINICAL-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION PROFILE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEUTZ-JEGHERS-SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ABERRANT CRYPT FOCI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLON-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYNCH-SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BETA-CAROTENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNITED-STATES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1068-9265</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250204500007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Cancer Prevention is an emerging
                    field, capturing the old traditional concept of anticipating the development of
                    a major disease and preventing its full impact by early detection, treatment, or
                    aborting the tumorigenic process by a &quot;molecular vaccine&quot; and
                    alleviating the full impact of the disease. Surgeons are important clinician
                    scientists who can carry this discipline forward and develop its full potential
                    in the clinics and in the community. Advances in molecular biology, genetics,
                    and other technologies have permitted seminal understanding of the carcinogenic
                    pathways and identification of targets and intermediate end points in neoplasia.
                    In this review, we will see that we have the means of preventing significant
                    numbers of colorectal carcinomas (CRC).</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    221CH&#xD;Times Cited: 0&#xD;Cited Reference Count: 164&#xD;Cited References:
                    &#xD; *TRIAL EARL BREAST, 2001, COCHRANE DB SYST REV, P1&#xD; ALBANES D, 2000,
                    CANCER CAUSE CONTROL, V11, P197&#xD; ALBERTS DS, 2000, NEW ENGL J MED, V342,
                    P1156&#xD; ARBER N, 2006, NEW ENGL J MED, V355, P885&#xD; BABBAR N, 2003,
                    BIOCHEM SOC T 2, V31, P388&#xD; BAILEY LB, 2003, J NUTR, V133, P3748&#xD; BARON
                    JA, 1999, NEW ENGL J MED, V340, P101&#xD; BARON JA, 2003, J NATL CANCER I, V95,
                    P717&#xD; BARON JA, 2003, NEW ENGL J MED, V348, P891&#xD; BARRETT JH, 2003,
                    CARCINOGENESIS, V24, P275&#xD; BERLIN NI, 1979, PERSEPCT BIOL MED, V22,
                    P500&#xD; BERTAGNOLLI MM, 2006, NEW ENGL J MED, V355, P873&#xD; BERTARIO L,
                    2003, J CLIN ONCOL, V21, P1698&#xD; BINGHAM SA, 2003, LANCET, V361, P1496&#xD;
                    BOLAND CR, 1998, CANCER RES, V58, P5248&#xD; BOLAND R, 2007, J CLIN ONCOL, V25,
                    P754&#xD; BONITHONKOPP C, 2000, LANCET, V356, P1300&#xD; BOYLE P, 2002, BRIT MED
                    BULL, V64, P1&#xD; BRAAKHUIS BJM, 2003, CANCER RES, V63, P1727&#xD; BRINK M,
                    2003, CARCINOGENESIS, V24, P703&#xD; BYERS T, 2002, CA-CANCER J CLIN, V52,
                    P92&#xD; CALVERT PM, 2002, ANN INTERN MED, V137, P603&#xD; CAPPEL WHDN, 2004,
                    INT J CANCER, V109, P468&#xD; CHAN AOO, 2002, AM J PATHOL, V160, P1823&#xD; CHAN
                    AT, 2004, ANN INTERN MED, V140, P157&#xD; CHLEBOWSKI RT, 2004, NEW ENGL J MED,
                    V350, P991&#xD; CHO KR, 1992, CANCER, V70, P1727&#xD; CHU D, 2006, SYOOKENEBTAK
                    CALCIUM, P714&#xD; CHU DZJ, 1986, CANCER, V57, P445&#xD; CHUNG DC, 2003, ANN
                    INTERN MED, V138, P560&#xD; CHURCH RD, 2003, BRIT J SURG, V90, P1055&#xD;
                    COLANGELO LA, 2004, CANCER, V100, P288&#xD; COLBERT LH, 2002, CANCER CAUSE
                    CONTROL, V13, P445&#xD; COLE BF, 2007, JAMA-J AM MED ASSOC, V297, P2351&#xD;
                    CRABTREE MD, 2002, GUT, V51, P306&#xD; DEJONG MM, 2002, CANCER EPIDEM BIOMAR,
                    V11, P1332&#xD; DELENG WWJ, 2003, CLIN CANCER RES, V9, P3065&#xD; DONALDSON MS,
                    2004, NUTR J, V3, P1&#xD; DRIVER JA, 2007, AM J MED, V120, P257&#xD;
                    DUFFIELDLILLICO AJ, 2002, CANCER EPIDEM BIOMAR, V11, P630&#xD; EYRE H, 2004,
                    STROKE, V35, P1999&#xD; FISHEL R, 1993, CELL, V75, P1027&#xD; FLOOD DM, 2000,
                    CANCER CAUSE CONTROL, V11, P403&#xD; FREDERIKSEN CM, 2003, J CANCER RES CLIN,
                    V129, P263&#xD; FRIEDENREICH CM, 2002, J NUTR, V132, P3456&#xD; FURUKAWA T,
                    2002, GENE CHROMOSOME CANC, V35, P1&#xD; GIARDIELLO FM, 2001, GASTROENTEROLOGY,
                    V121, P198&#xD; GILMAN A, 1946, SCIENCE, V103, P409&#xD; GIOVANNUCCI E, 1996, J
                    NATL CANCER I, V88, P1717&#xD; GOEL A, 2003, CANCER RES, V63, P1608&#xD; GOODMAN
                    JE, 2006, INT J CANCER, V8, P1790&#xD; GOSS KH, 2000, J CLIN ONCOL, V18,
                    P1967&#xD; GRADY WM, 2003, GASTROENTEROLOGY, V124, P1574&#xD; GRADY WM, 2004,
                    CANCER METAST REV, V23, P11&#xD; GRAU MV, 2003, J NATL CANCER I, V95, P1765&#xD;
                    GREENBERG ER, 1996, IARC SCI PUBLICATION, V139&#xD; GREENWALD P, 2001, EUR J
                    CANCER, V37, P948&#xD; GUO ZM, 2001, CLIN CANCER RES, V7, P1963&#xD; HEMMINKI K,
                    2004, INT J CANCER, V108, P109&#xD; HENDRIKS Y, 2003, AM J PATHOL, V12, P50&#xD;
                    HOFF G, 1996, SCAND J GASTROENTERO, V31, P1006&#xD; HUERTA S, 2003, INT J ONCOL,
                    V22, P663&#xD; HURSTING SD, 2003, ANNU REV MED, V54, P131&#xD; IIZAKA M, 2002,
                    BIOCHEM BIOPH RES CO, V292, P498&#xD; IMPERIALE TF, 2003, NEW ENGL J MED, V348,
                    P879&#xD; ITZKOWITZ SH, 2004, AM J PHYSIOL-GASTR L, V287, G7&#xD; JACOBY RF,
                    2000, CANCER RES, V60, P1864&#xD; JASS JR, 2002, GASTROENTEROLOGY, V123,
                    P862&#xD; JEMAL A, 2007, CA-CANCER J CLIN, V57, P43&#xD; JENNE DE, 1998, NAT
                    GENET, V18, P38&#xD; JORGENSEN OD, 2002, GUT, V50, P29&#xD; JOTHY S, 1996, TUMOR
                    BIOL, V17, P58&#xD; JUBB AM, 2001, J PATHOL, V195, P11&#xD; KELLOFF GJ, 1999,
                    EUR J CANCER, V35, P1755&#xD; KEY TJ, 2002, LANCET, V360, P861&#xD; KIM KP,
                    2004, ANTICANCER RES, V24, P1805&#xD; KOPELOVICH L, 2003, J NATL CANCER I, V95,
                    P1747&#xD; KRESSNER U, 1999, J CLIN ONCOL, V17, P593&#xD; KUSHI L, 2002, AM J
                    MED, V113, S63&#xD; LAWSON KR, 2000, CANCER EPIDEM BIOMAR, V9, P1155&#xD;
                    LECHNER S, 2003, GUT, V52, P1148&#xD; LEVIN B, 2002, CANCER, V95, P1618&#xD;
                    LIEBERMAN DA, 2003, JAMA-J AM MED ASSOC, V290, P2959&#xD; LIM W, 2003, BRIT J
                    CANCER, V89, P308&#xD; LIN YM, 2002, ONCOGENE, V21, P4120&#xD; LINDOR NM, 2006,
                    JAMA-J AM MED ASSOC, V296, P1507&#xD; LIPKIN M, 1999, ANN NY ACAD SCI, V889,
                    P120&#xD; LOEVE F, 2004, INT J CANCER, V111, P147&#xD; LOVIG T, 2002, SCAND J
                    GASTROENTERO, V37, P1184&#xD; LU SC, 2001, P NATL ACAD SCI USA, V98, P5560&#xD;
                    LYNCH HT, 1966, ARCH INTERN MED, V117, P206&#xD; LYNCH HT, 1988, GASTROENTEROL
                    CLIN N, V17, P679&#xD; LYNCH HT, 1996, DIS COLON RECTUM, V39, P109&#xD; LYNCH
                    HT, 2003, NEW ENGL J MED, V348, P919&#xD; MACLENNAN R, 1995, J NATL CANCER I,
                    V87, P1760&#xD; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491&#xD; MARIADASON
                    JM, 2002, CANCER RES, V62, P4791&#xD; MARTINEZ ME, 1998, CANCER EPIDEM BIOMAR,
                    V7, P163&#xD; MARTINEZ ME, 2003, P NATL ACAD SCI USA, V100, P7859&#xD; MATTAR M,
                    2005, CLIN COLORECTAL CANC, V5, P274&#xD; MCCULLOUGH ML, 2004, ONCOGENE, V23,
                    P6349&#xD; MEYSKENS FL, 1999, CLIN CANCER RES, V5, P945&#xD; MOSLEIN G, 2003,
                    LANGENBECK ARCH SURG, V388, P9&#xD; OKUTSU J, 2002, MOL CANCER THER, V1,
                    P1035&#xD; OLSON JS, 1989, HIST CANC ANNOTATED, P41&#xD; OSHAUGHNESSY JA, 2002,
                    CLIN CANCER RES, V8, P314&#xD; PARSONS R, 1995, CANCER RES, V55, P548&#xD; PEEL
                    DJ, 2000, J NATL CANCER I, V92, P1517&#xD; PEGG AE, 1995, J CELL BIOCH S, V22,
                    P132&#xD; PELTOMAKI P, 2003, J CLIN ONCOL, V21, P1174&#xD; PIGNONE M, 2002, ANN
                    INTERN MED, V137, P132&#xD; POTTER JD, 1995, J NATL CANCER I, V87, P1039&#xD;
                    POTTER JD, 1999, J NATL CANCER I, V91, P916&#xD; RENKONENSINISALO L, 2000,
                    CANCER DETECT PREV, V24, P137&#xD; RIBIC CM, 2003, NEW ENGL J MED, V349,
                    P247&#xD; RODRIGUEZBIGAS MA, 1997, ANN SURG, V225, P202&#xD; ROTH S, 1999, GENE
                    CHROMOSOME CANC, V26, P54&#xD; SABICHI AL, 2003, CANCER RES, V63, P5649&#xD;
                    SALAHSHOR S, 1999, GENE CHROMOSOME CANC, V26, P247&#xD; SANDLER RS, 2000, CANCER
                    EPIDEM BIOMAR, V9, P653&#xD; SANDLER RS, 2003, NEW ENGL J MED, V348, P883&#xD;
                    SAYED MG, 2002, ANN SURG ONCOL, V9, P901&#xD; SCHATZKIN A, 2000, NEW ENGL J MED,
                    V342, P1149&#xD; SCHWARTZ LM, 2004, JAMA-J AM MED ASSOC, V291, P71&#xD; SEIFRIED
                    HE, 2003, CANCER RES, V63, P4295&#xD; SHAHEEN NJ, 2002, CANCER, V94, P950&#xD;
                    SHARMA S, 2002, ANN ONCOL, V13, P1067&#xD; SIEBER OM, 2003, NEW ENGL J MED,
                    V348, P791&#xD; SLATTERY ML, 2001, CANCER RES, V61, P126&#xD; SLAUGHTER DP,
                    1953, CANCER, V6, P963&#xD; SPORN MB, 1993, LANCET, V342, P1211&#xD; SPORN MB,
                    2002, NAT REV CANCER, V2, P537&#xD; STEINBACH G, 2000, NEW ENGL J MED, V342,
                    P1946&#xD; SU LK, 2002, HUM GENET, V111, P88&#xD; TERRY P, 2001, INT J CANCER,
                    V91, P585&#xD; THUN MJ, 2002, J NATL CANCER I, V94, P252&#xD; TOYOTA M, 1999, P
                    NATL ACAD SCI USA, V96, P8681&#xD; TSAO AS, 2004, CA-CANCER J CLIN, V54,
                    P150&#xD; TURECI O, 2003, FASEB J, V17, P376&#xD; UEDA E, 2002, J EXP CLIN CANC
                    RES, V21, P149&#xD; UMAR A, 2002, INT J CLIN ONCOL, V7, P2&#xD; UMAR A, 2004, J
                    NATL CANCER I, V96, P261&#xD; VAINIO H, 2003, ACTA ONCOL, V42, P809&#xD;
                    VANSTOLK RU, 2002, GASTROINTEST ENDOSC, V12, P111&#xD; VASEN HFA, 1991, DIS
                    COLON RECTUM, V34, P424&#xD; VASEN HFA, 1999, GASTROENTEROLOGY, V116, P1453&#xD;
                    VILLA E, 1996, GASTROENTEROLOGY, V110, P1346&#xD; VINCENT F, 1996, BIOCHEM BIOPH
                    RES CO, V223, P561&#xD; VOGELSTEIN B, 2004, NAT MED, V10, P789&#xD;
                    WACTAWSKIWENDE J, 2006, NEW ENGL J MED, V354, P687&#xD; WADDELL WR, 1983, J SURG
                    ONCOL, V24, P83&#xD; WALSH JME, 2003, JAMA-J AM MED ASSOC, V289, P1288&#xD;
                    WARNER TD, 2004, FASEB J, V18, P790&#xD; WHANGER PD, 2004, BRIT J NUTR, V91,
                    P11&#xD; WILLIAMS NS, 2003, CLIN CANCER RES, V9, P931&#xD; WINAWER SJ, 1993, NEW
                    ENGL J MED, V329, P1977&#xD; WINGO PA, 1998, CANCER, V82, P1197&#xD; WOGAN GN,
                    2004, SEMIN CANCER BIOL, V14, P473&#xD; WOLFF J, 1907, SCI CANCEROUS DIS EA,
                    V1&#xD; YIU HY, 2004, INT J CANCER, V109, P777&#xD; YOU YN, 2007, WORLD J SURG,
                    V31, P450&#xD; YOUNG J, 2001, AM J PATHOL, V159, P2107&#xD; YUEN ST, 2002,
                    ONCOGENE, V21, P7585&#xD; ZOU TT, 2002, ONCOGENE, V21, P4855</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250204500007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>559</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">559</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1892</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Singh, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Hematopoietic Stem
                    Cell and Leukemia Research, Division of Hematology and Hematopoietic Cell
                    Transplantation, City of Hope National Medical Center, 1500 East Duarte Road,
                    Duarte, CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">BCR-tyrosine 177 plays an
                        essential role in Ras and Akt activation and in human hematopoietic
                        progenitor transformation in chronic myelogenous leukemia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">7045-53</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">14</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens,
                        CD34/biosynthesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Adhesion</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Proliferation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Transformation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fusion Proteins, bcr-abl/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Green Fluorescent
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cells/
                        cytology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukemia, Myeloid, Chronic/
                        blood/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Piperazines/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-akt/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proto-Oncogene Proteins c-bcr/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retroviridae/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tyrosine/ chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ras Proteins/ metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17638918</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Chronic myelogenous leukemia (CML)
                    results from the transformation of a primitive hematopoietic cell by the BCR/ABL
                    gene. BCR/ABL signaling has been studied in cell lines and murine models, but
                    the transforming effects of BCR/ABL are highly dependent on cellular context,
                    and mechanisms responsible for the transformation of primitive human
                    hematopoietic cells remain poorly understood. Current targeted therapies fail to
                    eliminate malignant CML progenitors, and improved understanding of crucial
                    molecular mechanisms of progenitor transformation may facilitate the development
                    of improved therapeutic approaches. We investigated the role of BCR/ABL tyrosine
                    177 (BCR/ABL-Y177) in CML progenitor transformation by comparing the effects of
                    expression of Y177-mutated BCR/ABL, wild-type BCR/ABL, or green fluorescent
                    protein alone on normal CD34(+) cells. We show that BCR/ABL-Y177 plays a
                    critical role in CML progenitor expansion, proliferation, and survival. BCR/ABL
                    expression results in enhanced Ras and Akt activity but reduced
                    mitogen-activated protein kinase activity in human hematopoietic cells, which is
                    reversed by BCR/ABL-Y177 mutation. Blocking BCR/ABL-Y177-mediated signaling
                    enhances targeting of CML progenitors by imatinib mesylate. Our studies indicate
                    that BCR/ABL-Y177 plays an essential role in Ras and Akt activation and in human
                    hematopoietic progenitor transformation in CML.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>590</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">590</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1466</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Clavijo, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reyland, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Dept Mol Pharmacol
                    &amp; Toxicol, Los Angeles, CA 90089 USA. Univ So Calif, Dept Med, Los Angeles,
                    CA 90089 USA. Univ So Calif, Will Rogers Inst Pulm, Res Ctr, Los Angeles, CA
                    90089 USA. City Hope Natl Med Ctr, Dept Clin &amp; Mol Pharmacol, Duarte, CA
                    91010 USA. Univ Colorado, Dept Craniofacial Biol Cell &amp; Dev Biol, Aurora, CO
                    USA. Hlth Sci Ctr, Aurora, CO USA. Univ Nacl Colombia, Dept Biol, Bogota,
                    Colombia.&#xD;Ann, DK, City Hope Natl Med Ctr, Dept Clin &amp; Mol Pharmacol,
                    1500 E Duarte Rd,KCRB Rm 1004, Duarte, CA 91010 USA.&#xD;dann@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Protein kinase C delta-dependent
                        and -independent signaling in genotoxic response to treatment of
                        desferroxamine, a hypoxia-mimetic agent</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Physiology-Cell Physiology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Am. J. Physiol.-Cell
                        Physiol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Physiology-Cell Physiology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Physiol. Cell
                        Physiol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Physiol Cell
                        Physiol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">C2150-C2160</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">292</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">caspase-3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Akt</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SALIVARY
                        EPITHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCED DNA-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEOLYTIC ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PKC-DELTA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCED APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OXIDATIVE-STRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IRON CHELATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TYROSINE PHOSPHORYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATAXIA-TELANGIECTASIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMOOTH-MUSCLE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0363-6143</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247936600016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Protein kinase C (PKC) plays a
                    critical role in diseases such as cancer, stroke, and cardiac ischemia and
                    participates in a variety of signal transduction pathways including apoptosis,
                    cell proliferation, and tumor suppression. Here, we demonstrate that PKC delta
                    is proteolytically cleaved and translocated to the nucleus in a time-dependent
                    manner on treatment of desferroxamine (DFO), a hypoxia-mimetic agent. Specific
                    knockdown of the endogenous PKC delta by RNAi (sh-PKC delta) or expression of
                    the kinase-dead (Lys376Arg) mutant of PKC delta (PKC delta KD) conferred
                    modulation on the cellular adaptive responses to DFO treatment. Notably, the
                    time-dependent accumulation of DFO-induced phosphorylation of Ser-139-H2AX
                    (gamma-H2AX), a hallmark for DNA damage, was altered by sh-PKC delta, and sh-PKC
                    delta completely abrogated the activation of caspase-3 in DFO-treated cells.
                    Expression of Lys376Arg-mutated PKC delta-enhanced green fluorescent protein
                    (EGFP) appears to abrogate DFO/hypoxia-induced activation of endogenous PKC
                    delta and caspase-3, suggesting that PKC delta KD-EGFP serves a
                    dominant-negative function. Additionally, DFO treatment also led to the
                    activation of Chk1, p53, and Akt, where DFO-induced activation of p53, Chk1, and
                    Akt occurred in both PKC delta-dependent and -independent manners. In summary,
                    these findings suggest that the activation of a PKC delta-mediated signaling
                    network is one of the critical contributing factors involved in fine-tuning of
                    the DNA damage response to DFO treatment.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    188RI&#xD;Times Cited: 0&#xD;Cited Reference Count: 56</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247936600016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>680</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">680</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1461</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Coons, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chongpison, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wendel, C. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Arizona, Coll Pharm, Dept Pharm
                    Pract &amp; Sci, Tucson, AZ 85721 USA. Univ Arizona, Coll Pharm, Dept Pharm
                    Pract &amp; Sci, Tucson, AZ 85721 USA. Univ Arizona, Coll Publ Hlth, Div Hlth
                    Promot Sci, Tucson, AZ USA. So Arizona Vet Affairs Hlth Care Syst, Res Serv,
                    Tucson, AZ USA. So Arizona Vet Affairs Hlth Care Syst, Surg Care Line, Tucson,
                    AZ USA. City Hope Natl Med Ctr, Beckman Res Inst, Dept Nursing Res &amp; Educ,
                    Duarte, CA 91010 USA. Univ Arizona, Coll Med, Dept Surg, Tucson, AZ
                    USA.&#xD;Coons, SJ, Univ Arizona, POB 210202, Tucson, AZ 85721
                    USA.&#xD;coons@pharmacy.arizona.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Overall quality of life and
                        difficulty paying for ostomy supplies in the veterans affairs ostomy
                        health-related quality of life study - An exploratory analysis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Medical Care</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Medical Care</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Med. Care</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Med Care</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">891-895</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">45</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ostomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">out-of-pocket costs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">US Department of
                        Veterans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Affairs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">financial strain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QOL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0025-7079</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249415800011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To explore whether there
                    was a significant relationship between difficulty paying for ostomy supplies and
                    overall quality of life among a sample of ostomates receiving care from the
                    Veterans Health Administration (VHA). Methods: The data were collected as part
                    of the Veterans Affairs (VA) Ostomy Health-Related Quality of Life Study, in
                    which 511 respondents (239 cases, 272 controls) completed a survey instrument
                    that included the modified City of Hope Quality of Life (mCOH-QOL) Ostomy
                    questionnaire, SF-36V, and sociodemographic items. Responses from the 239 cases
                    (ie, patients with intestinal stomas) were used in this analysis. The modified
                    City of Hope Quality of Life Ostomy questionnaire item, &quot;How good is your
                    overall quality of life?,&quot; was the dependent variable for this analysis.
                    The primary independent variable was the response (yes/no) to the item, &quot;If
                    you pay for any of the (ostomy) costs, is it difficult for you?&quot; A
                    hierarchical regression model was used to examine whether difficulty paying was
                    significantly related to overall quality of life after adjusting for age,
                    income, race/ethnicity, and physical health. Results: After accounting for the
                    proportion of variance explained by age, income, race/ethnicity, and physical
                    health, the additional proportion of variance explained by difficulty paying was
                    statistically significant. Individuals reporting difficulty paying had a roughly
                    1 point lower (ie, beta-coefficient = - 1.052; SE = 0.481) overall quality of
                    life score on the 11-point scale. Conclusions: We found a significant
                    association between difficulty paying for ostomy supplies and overall quality of
                    life. Although the cross-sectional study design does not allow causal inference,
                    the results suggest a relationship that merits further examination.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    209VJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 30&#xD;Cited References:
                    &#xD; *DEP VET, 2002, 2002049 VHA&#xD; *NAT SEC ARCH, 2006, VA TAK 9 MONTHS
                    LOC&#xD; ANDREWS FM, 1984, PUBLIC OPIN QUART, V48, P409&#xD; AROZULLAH AM, 2004,
                    J SUPPORT ONCOL, V2, P271&#xD; BERKMAN BJ, 1993, CANCER, V72, P2846&#xD; DEBOER
                    AGEM, 2004, QUAL LIFE RES, V13, P311&#xD; DEMAVASWALT C, 2005, INCOME POVERTY
                    HLTH&#xD; DIENER E, 1994, SOC INDIC RES, V31, P103&#xD; FRYBACK DG, 2004, J NATL
                    CANC I MONOGR, V33, P134&#xD; GRANT M, 2004, QUAL LIFE RES, V13, P1445&#xD;
                    HEISLER M, 2004, AM J MED, V116, P753&#xD; HEISLER M, 2004, MED CARE, V42,
                    P626&#xD; KAZIS LE, 1998, ARCH INTERN MED, V158, P626&#xD; KAZIS LE, 2000, MED
                    OUTCOMES TRUST M, V5, P1&#xD; KAZIS LE, 2000, MED OUTCOMES TRUST M, V5, P13&#xD;
                    KIM SP, 1999, ONCOLOGY-NY, V13, P823&#xD; KROUSE RS, 2006, CURR MED RES OPIN,
                    V22, P781&#xD; LONG JA, 2005, AM J PUBLIC HEALTH, V95, P2246&#xD; NORMAN GR,
                    2003, MED CARE, V41, P582&#xD; ODDONE EZ, 2002, MED CARE S1, V40, P13&#xD; OHARA
                    B, 2004, J HEALTH CARE POOR U, V15, P63&#xD; PAVOT W, 1993, PSYCHOL ASSESSMENT,
                    V5, P164&#xD; PIETTE JD, 2005, ARCH INTERN MED, V165, P1749&#xD; ROHRER JE,
                    2004, BMC PUBLIC HEALTH, V4&#xD; SCHOEN C, 2005, HLTH AFF MILWOOD&#xD; SHANE S,
                    2006, DATA SUGGESTS VAST C&#xD; SHARKEY JR, 2005, J AM GERIATR SOC, V53,
                    P666&#xD; SHORT PF, 2006, MED CARE, V44, P16&#xD; SIRGY MJ, 2006, SOC INDIC RES,
                    V76, P343&#xD; SLOAN JA, 1998, J CLIN ONCOL, V16, P3662</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249415800011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>655</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">655</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1460</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Coyne, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paice, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Malloy, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Virani, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fennimore, L. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Virginia Commonwealth Univ, Hlth
                    Care Syst, Richmond, VA 23284 USA. Northwestern Univ, Canc Pain Program,
                    Feinberg Sch Med, Chicago, IL 60611 USA. City Hope Natl Med Ctr, Duarte, CA USA.
                    Amer Assoc Coll Nursing, Washington, DC USA. Univ Pittsburgh, Med Ctr
                    Presbyterian Hosp, Pittsburgh, PA 15260 USA.&#xD;Paice, JA, Virginia
                    Commonwealth Univ, Hlth Care Syst, Richmond, VA 23284
                    USA.&#xD;j-paice@northwestern.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Oncology End-of-Life Nursing
                        Education Consortium training program: Improving palliative care in
                        cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncol Nurs Forum</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncol Nurs Forum</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">801-807</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NURSES KNOWLEDGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MANAGEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SYMPTOMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDREN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0190-535X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248010400009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose/Objectives: To describe an
                    evaluation of the oncology version of the End-of-Life Nursing Education
                    Consortium (ELNEC-Oncology) training program, which is designed to provide
                    oncology nurses with the knowledge and materials necessary to disseminate
                    palliative care information to their colleagues in local chapters of the
                    Oncology Nursing Society (ONS). Data Sources: Participant reports. Data
                    Synthesis: 124 nurses representing 74 DNS chapters attended the first two
                    courses. Dyads of DNS members from local chapters applied to attend ELNEC and
                    completed surveys regarding their goals and expectations for implementing
                    end-of-life (EOL) education and training after completion of the program.
                    Participants educated more than 26,000 nurses after attending the program,
                    including 7,593 nurses within their DNS chapters and 18,517 colleagues within
                    their workplaces. Barriers to implementation included a lack of funding and time
                    constraints. Participants sought additional palliative care learning
                    opportunities, including attending other workshops, subscribing to palliative
                    care journals, and becoming involved in committees focused on palliative care.
                    Conclusion: The ELNEC-Oncology program is a national collaboration with DNS that
                    provides oncology nurses with the tools and expertise to effectively disseminate
                    palliative care content to colleagues within their local chapters and work
                    settings. Implications for Nursing: EOL care information remains critical to the
                    science of oncology nursing, and ELNEC-Oncology provides an effective strategy
                    for disseminating the information.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    189TC&#xD;Times Cited: 0&#xD;Cited Reference Count: 29</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248010400009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>197</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">197</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1458</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Danks, M. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yoon, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bush, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Remack, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wierdl, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsurkan, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garcia, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Metz, M. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Najbauer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Potter, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">St Jude Childrens Hosp, Dept Mol
                    Pharmacol, Memphis, TN 38105 USA. Univ British Columbia Hosp, Dept Med,
                    Vancouver, BC, Canada. City Hope Natl Med Ctr, Div Hematol Hematopoiet Cell
                    Transplantat, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Neurosci,
                    Duarte, CA 91010 USA.&#xD;Danks, MK, St Jude Childrens Hosp, Dept Mol Pharmacol,
                    332 N Lauderdale, Memphis, TN 38105 USA.&#xD;mary.danks@stjude.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Tumor-targeted enzyme/prodrug
                        therapy mediates long-term disease-free survival of mice bearing
                        disseminated neuroblastoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">22-25</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NEURAL STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELIVERY VEHICLES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IRINOTECAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBOXYLESTERASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDREN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CPT-11</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RABBIT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243320000005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Neural stem cells and progenitor
                    cells migrate selectively to tumor loci in vivo. We exploited the tumor-tropic
                    properties of HB1.F3.C1 cells, an immortalized cell line derived from human
                    fetal telencephalon, to deliver the cDNA encoding a secreted form of rabbit
                    carboxylesterase (rCE) to disseminated neuroblastoma tumors in mice. This enzyme
                    activates the prodrug CPT-11 more efficiently than do human enzymes. Mice
                    bearing multiple tumors were treated with rCE-expressing HB1.F3.C1 cells and
                    schedules of administration of CPT-11 that produced levels of active drug
                    (SN-38) tolerated by patients. Both HB1.F3.C1 cells and CPT-11 were given i.v.
                    None of the untreated mice and 30% of mice that received only CPT-11 survived
                    long term. In contrast, 90% of mice treated with rCE-expressing HB1.F3.C1 cells
                    and 15 mg/kg CPT-11 survived for 1 year without detectable tumors. Plasma
                    carboxylesterase activity and SN-38 levels in mice receiving both rCE-expressing
                    HB1.F3.C1 cells (HB1.F3.C1/AdCMVrCE) and CPT-11 were comparable with those in
                    mice receiving CPT-11 only. These data support the hypothesis that the antitumor
                    effect of the described neural stem/progenitor cell-directed enzyme prodrug
                    therapy (NDEPT) is mediated by production of high concentrations of active drug
                    selectively at tumor sites, thereby maximizing the antitumor effect of CPT-11.
                    NDEPT approaches merit further investigation as effective, targeted therapy for
                    metastatic tumors. We propose that the described approach may have greatest use
                    for eradicating minimum residual disease.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123TX&#xD;Times Cited: 0&#xD;Cited Reference Count: 18&#xD;Cited References:
                    &#xD; ABOODY KS, 2000, P NATL ACAD SCI 07/01 USA, V97, P12846&#xD; ABOODY KS,
                    2006, NEURO-ONCOLOGY, V8, P119&#xD; ABOODY KS, 2006, PLOS ONE, V1, E23&#xD;
                    BROWN AB, 2003, HUM GENE THER, V14, P1777&#xD; DANKS MK, 1999, CLIN CANCER RES,
                    V5, P917&#xD; DICKSON PV, 2007, IN PRESS J PED SURG&#xD; FLAX JD, 1998, NAT
                    BIOTECHNOL, V16, P1033&#xD; FURMAN WL, 1999, J CLIN ONCOL, V17, P1815&#xD;
                    FURMAN WL, 2006, J CLIN ONCOL, V24, P563&#xD; KABOS P, 2003, EXPERT OPIN BIOL
                    TH, V3, P759&#xD; KHANNA R, 2000, CANCER RES, V60, P4725&#xD; KIM SU, 2002, METH
                    MOL B, V198, P55&#xD; MA MK, 2000, CLIN CANCER RES, V6, P813&#xD; MORTON CL,
                    2005, CANCER CHEMOTH PHARM, V56, P629&#xD; POTTER PM, 1998, CYTOMETRY, V32,
                    P223&#xD; STUDENY M, 2004, J NATL CANCER I, V96, P1593&#xD; THOMPSON J, 2001,
                    CANCER CHEMOTH PHARM, V47, P211&#xD; WAGNER LM, 2002, CANCER RES, V62,
                    P5001</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243320000005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>224</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">224</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1453</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Dickson, P. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamner, J. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burger, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garcia, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ouma, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ng, C. Y. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gray, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Danks, M. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davidoff, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">St Jude Childrens Hosp, Dept Surg,
                    Memphis, TN 38105 USA. Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN
                    38163 USA. St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA.
                    Univ British Columbia, UBC Hosp, Div Neurol, Vancouver, BC V6T 2B5, Canada. St
                    Jude Childrens Hosp, Dept Expt Hematol, Memphis, TN 38105 USA. City Hope Natl
                    Med Ctr, Div Hematol &amp; Hematopoiet Cell Transplantat, Duarte, CA 91010 USA.
                    City Hope Natl Med Ctr, Div Neurosci, Duarte, CA 91010 USA. City Hope Natl Med
                    Ctr, Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Davidoff, AM, St Jude Childrens
                    Hosp, Dept Surg, 332 N Lauderdale, Memphis, TN 38105
                    USA.&#xD;andrew.davidoff@stjude.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Intravascular administration of
                        tumor tropic neural progenitor cells permits targeted delivery of
                        interferon-beta and restricts tumor growth in a murine model of disseminated
                        neuroblastoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Pediatric
                        Surgery</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Pediatr. Surg.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Pediatric
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Pediatr. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pediatr Surg</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Pediatric
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Pediatr. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pediatr Surg</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">48-53</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">42</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">interferon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neural progenitor cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neuroblastoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDIATED SYSTEMIC
                        DELIVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESPOND</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALPHA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-3468</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243707100008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Interferon-beta
                    (IFN-beta) has potent antitumor activity; however, systemic toxicity has limited
                    its clinical use. We investigated the potential of targeted delivery using
                    tumor-tropic neural progenitor cells (NPCs) transduced to express human IFN-beta
                    (hIFN-beta). Methods: Disseminated neuroblastoma was established in SCID mice by
                    tail vein injection of tumor cells. Fourteen days after tumor cell inoculation,
                    systemic disease was confirmed with bioluminescence imaging (BLI). Mice were
                    then treated by intravenous injection of human F3.C1 NPCs that had been
                    transduced with a replication deficient adenovirus to overexpress hIFN-beta
                    (F3-IFN-beta). Two injections were given: the first at 14 days and the second at
                    28 days following tumor cell injection. Control mice received NPCs transduced
                    with empty vector adenovirus at the same time points. Progression of disease was
                    monitored using BLI. At sacrifice, organ weights and histology further evaluated
                    tumor burden. Results: After initiation of therapy, BLI demonstrated a
                    significant decrease in the rate of disease progression in mice receiving
                    F3-IFN-beta. At necropsy, control mice had bulky tumor replacing the liver and
                    kidneys, as well as extensive retroperitoneal and mediastinal adenopathy.
                    Impressively, these sites within mice receiving F3-IFN-beta therapy appeared
                    grossly normal with the exception of small nodules within the kidneys of some of
                    the F3-IFN-beta-treated mice. The accumulation of F3.C1 cells within sites of
                    tumor growth was confirmed by fluorescence imaging. Importantly, systemic levels
                    of hIFN-beta in the treated mice remained below detectable levels. Conclusions:
                    These data indicate that in this model of disseminated neuroblastoma, the
                    tumor-tropic property of F3.C1 NPCs was exploited to target delivery of IFN-beta
                    to disseminated tissue foci, resulting in significant tumor growth delay. The
                    described novel approach for effective IFN-beta therapy may circumvent
                    limitations associated with the systemic toxicity of IFN-beta. (c) 2007 Elsevier
                    Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    129CX&#xD;Times Cited: 0&#xD;Cited Reference Count: 18</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243707100008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>810</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">810</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">985</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">DiGiusto, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cooper, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Hematol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Div Pediat,
                    Houston, TX 77030 USA.&#xD;DiGiusto, D, Univ Texas MD Anderson Canc Ctr, Unit
                    907,Holcombe Blvd, Houston, TX 77030 USA.&#xD;ddigiusto@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Preparing clinical grade
                        Ag-specific T cells for adoptive immunotherapy trials</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cytotherapy</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">613-629</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">t-cell manufacturing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">good manufacturing
                        practice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EX-VIVO EXPANSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALDEHYDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEHYDROGENASE-ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENHANCED
                        ANTITUMOR-ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIGEN-PRESENTING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SERUM-FREE CONDITIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUICIDE GENE-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UMBILICAL-CORD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOOD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1465-3249</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251087200002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The production of clinical-grade T
                    cells for adoptive immunotherapy has evolved from the ex vivo numerical
                    expansion of tumor-infiltrating lymphocytes to sophisticated bioengineering
                    processes often requiring cell selection, genetic modification and other
                    extensive tissue culture manipulations, to produce desired cells with improved
                    therapeutic potential. Advancements in understanding the biology of lymphocyte
                    signaling, activation, homing and sustained in vivo proliferative potential have
                    redefined the strategies used to produce T cells suitable for clinical
                    investigation. When combined with new technical methods in cell processing and
                    culturing, the therapeutic potential of T cells manufactured in academic centers
                    has improved dramatically. Paralleling these technical achievements in cell
                    manufacturing is the development of broadly applied regulatory standards that
                    define the requirements for the clinical implementation of cell products with
                    ever-increasing complexity. In concert with academic facilities operating in
                    compliance with current good manufacturing practice, the prescribing physician
                    can now infuse T cells with a highly selected or endowed phenotype that has been
                    uniformly manufactured according to standard operating procedures and that meets
                    federal guidelines for quality of investigational cell products. In this review
                    we address salient issues related to the technical, immunologic, practical and
                    regulatory aspects of manufacturing these advanced T-cell products for clinical
                    use.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    233JM&#xD;Times Cited: 0&#xD;Cited Reference Count: 128&#xD;Cited References:
                    &#xD; ADAMSON L, 2004, CYTOTHERAPY, V6, P363&#xD; AHMAD M, 2004, CANCER IMMUNOL
                    IMMUN, V53, P844&#xD; ALTVATER B, 2006, CLIN EXP IMMUNOL, V144, P447&#xD; ATKINS
                    MB, 2000, CANCER J SCI AM S1, V6, S11&#xD; ATKINS MB, 2006, CLIN CANCER RES S 2,
                    V12, S2353&#xD; BERGER C, 2006, BLOOD, P108&#xD; BERGER C, 2006, BLOOD, V107,
                    P2294&#xD; BERNSTEIN WB, 2004, CLIN IMMUNOL, V111, P262&#xD; BONINI C, 2007, MOL
                    THER, V15, P1248&#xD; BULFONEPAUS S, 1999, FASEB J, V13, P1575&#xD; CARLENS S,
                    2000, EXP HEMATOL, V28, P1137&#xD; CICERI F, 2007, BLOOD, V109, P4698&#xD;
                    COBBOLD M, 2005, J EXP MED, V202, P379&#xD; COHEN CJ, 2006, CANCER RES, V66,
                    P8878&#xD; COHEN CJ, 2007, CANCER RES, V67, P3898&#xD; COMOLI P, 2002, BLOOD,
                    V99, P2592&#xD; COOPER LJ, 2005, CANC CHEMOTHER BIOL, V22, P293&#xD; COOPER LJN,
                    2000, J VIROL, V74, P8207&#xD; COOPER LJN, 2003, BLOOD, V101, P1637&#xD; COOPER
                    LJN, 2006, CYTOTHERAPY, V8, P105&#xD; DUDLEY ME, 2001, J IMMUNOTHER, V24,
                    P363&#xD; DUDLEY ME, 2002, SCIENCE, V298, P850&#xD; DUDLEY ME, 2005, J CLIN
                    ONCOL, V23, P2346&#xD; ELIAS M, 2005, J CLIN APHERESIS, V20, P197&#xD; ESHHAR Z,
                    1993, P NATL ACAD SCI USA, V90, P720&#xD; FROMMOLT R, 2006, FUTURE ONCOL, V2,
                    P345&#xD; GARLIE NK, 1999, J IMMUNOTHER, V22, P336&#xD; GENTRY T, 2007,
                    CYTOTHERAPY, V9, P259&#xD; GEURTS AM, 2006, NUCLEIC ACIDS RES, V34, P2803&#xD;
                    GOTTSCHALK S, 2005, LEUKEMIA LYMPHOMA, V46, P1&#xD; HACEINBEYABINA S, 2003,
                    SCIENCE, V302, P415&#xD; HACKETT PB, 2007, MOL THER, V15, P10&#xD; HAMI LS,
                    2004, CYTOTHERAPY, V6, P554&#xD; HESS DA, 2006, BLOOD, V107, P2162&#xD; HUANG X,
                    2006, BLOOD, V107, P483&#xD; HUNTENBURG CC, 1998, J HEMATOTHER, V7, P175&#xD;
                    IMAI C, 2004, LEUKEMIA, V18, P676&#xD; IVICS Z, 1997, CELL, V91, P501&#xD;
                    JAYASINGHE SM, 2006, CYTOM PART B-CLIN B, V70, P344&#xD; JENSEN MC, 2003,
                    CYTOTHERAPY, V5, P131&#xD; JENSEN MC, 2007, MOL THER, V15, S142&#xD; KAHLON KS,
                    2004, CANCER RES, V64, P9160&#xD; KERSHAW MH, 2006, CLIN CANCER RES 1, V12,
                    P6106&#xD; KLEBANOFF CA, 2005, P NATL ACAD SCI USA, V102, P9571&#xD; KLINGEMANN
                    HG, 2004, CYTOTHERAPY, V6, P15&#xD; KORNBLAU SM, 2007, EXP HEMATOL, V35,
                    P842&#xD; KOWOLIK CM, 2006, CANCER RES, V66, P10995&#xD; KUBALL J, 2007, BLOOD,
                    V109, P2331&#xD; LAMERS CH, 2006, J CLIN ONCOL, V24, E20&#xD; LAMERS CH, 2007,
                    CANC IMMUNOL IMMUNOT&#xD; LAPORT GG, 2003, BLOOD, V102, P2004&#xD; LEEN AM,
                    2006, NAT MED, V12, P1160&#xD; LEMARIE C, 2005, TRANSFUSION, V45, P737&#xD;
                    LEMARIE C, 2007, J IMMUNOL METHODS, V318, P30&#xD; LENNARTZ K, 2005, CYTOM PART
                    A A, V66, P119&#xD; LEVINE BL, 1998, J HEMATOTHER, V7, P437&#xD; LIU Z, 2005,
                    CYTOTHERAPY, V7, P353&#xD; LOSKOG A, 2006, LEUKEMIA, V20, P1819&#xD; MACKENSEN
                    A, 2006, J CLIN ONCOL, V24, P5060&#xD; MAHER J, 2002, NAT BIOTECHNOL, V20,
                    P70&#xD; MAUS MV, 2002, NAT BIOTECHNOL, V20, P143&#xD; MAUS MV, 2003, CLIN
                    IMMUNOL, V106, P16&#xD; MCNIECE IK, 1998, J HEMATOTHER, V7, P457&#xD; MICHIELS
                    A, 2006, GENE THER, V13, P1027&#xD; MILLER JS, 2005, BLOOD, V105, P3051&#xD;
                    MITSUYASU RT, 2000, BLOOD, V96, P785&#xD; MORGAN RA, 2006, SCIENCE, V314,
                    P126&#xD; MUELLER YM, 2003, BLOOD, V101, P1024&#xD; MUELLER YM, 2003, INT
                    IMMUNOL, V15, P49&#xD; NAGANO M, 2007, BLOOD, V110, P151&#xD; NUMBENJAPON T,
                    2006, LEUKEMIA, V20, P1889&#xD; OBERYSZYN AS, 2001, CYTOMETRY, V43, P217&#xD;
                    OELKE M, 2003, NAT MED, V9, P619&#xD; ORCHARD PJ, 2002, HUM GENE THER, V13,
                    P979&#xD; PARK JR, 2007, MOL THER, V15, P825&#xD; PEGGS KS, 2003, LANCET, V362,
                    P1375&#xD; PEGGS KS, 2005, BRIT J HAEMATOL, V130, P809&#xD; PENG JC, 2005, J
                    IMMUNOTHER, V28, P599&#xD; PERFETTO SP, 2004, METHOD MOL BIOL, V263, P419&#xD;
                    PERRUCCIO K, 2005, BLOOD, V106, P4397&#xD; PORTER DL, 2006, BLOOD, V107,
                    P1325&#xD; POWELL DJ, 2005, BLOOD, V105, P241&#xD; POWELL DJ, 2006, J IMMUNOL,
                    V177, P6527&#xD; RAPOPORT AP, 2005, NAT MED, V11, P1230&#xD; RAUSER G, 2004,
                    BLOOD, V103, P3565&#xD; RIDDELL SR, 1992, SCIENCE, V257, P238&#xD; RIZZUTO GA,
                    2005, CYTOTHERAPY, V7, P391&#xD; ROBINSON KL, 2002, EXP HEMATOL, V30, P245&#xD;
                    ROONEY CM, 1998, BLOOD, V92, P1549&#xD; ROSENBERG SA, 2004, P NATL ACAD SCI U
                    S2, V101, P14639&#xD; ROSSIG C, 2002, BLOOD, V99, P2009&#xD; ROSZKOWSKI JJ,
                    2005, CANCER RES, V65, P1570&#xD; SANTEGOETS SJAM, 2006, CANCER IMMUNOL IMMUN,
                    V55, P1480&#xD; SATO T, 2007, MOL THER, V15, P962&#xD; SCHOLTEN KBJ, 2005, CLIN
                    IMMUNOL, V114, P119&#xD; SCHRODER ARW, 2002, CELL, V110, P521&#xD; SINGH H,
                    2007, CANCER RES, V67, P2872&#xD; SOMBROEK CC, 2002, J IMMUNOL, V168, P4333&#xD;
                    SORG RV, 2003, J IMMUNOTHER, V26, P374&#xD; STORMS RW, 2005, BLOOD, V106,
                    P95&#xD; STRAATHOF KC, 2005, BLOOD, V105, P4247&#xD; STRAATHOF KCM, 2005, BLOOD,
                    V105, P1898&#xD; TAM YK, 2003, CYTOTHERAPY, V5, P259&#xD; TEAGUE RM, 2006, NAT
                    MED, V12, P335&#xD; TEY SK, 2007, MOL THER, V15, P666&#xD; THOMAS AK, 2002, CLIN
                    IMMUNOL, V105, P259&#xD; THURNER B, 1999, J IMMUNOL METHODS, V223, P1&#xD;
                    TRAVERSARI C, 2007, BLOOD, V109, P4708&#xD; TRICKETT AE, 2002, J IMMUNOL
                    METHODS, V262, P71&#xD; TRIVEDI D, 2005, BLOOD, V105, P2793&#xD; UPHAM JW, 1995,
                    CLIN EXP ALLERGY, V25, P634&#xD; VANDERVEKEN LT, 2005, GENE THER, V12,
                    P1686&#xD; WALDMANN TA, 2001, IMMUNITY, V14, P105&#xD; WALKER RE, 2000, BLOOD,
                    V96, P467&#xD; WALTER EA, 1995, NEW ENGL J MED, V333, P1038&#xD; WARNCKE M,
                    2006, J IMMUNOL METHODS, V310, P1&#xD; WATTS MJ, 2002, BRIT J HAEMATOL, V118,
                    P117&#xD; WESTWOOD JA, 2005, P NATL ACAD SCI USA, V102, P19051&#xD; WHERRY EJ,
                    2003, NAT IMMUNOL, V4, P225&#xD; WILLEMSEN RA, 2000, GENE THER, V7, P1369&#xD;
                    WILLIAMS SF, 1996, BLOOD, V87, P1687&#xD; WU JY, 2006, CYTOTHERAPY, V8,
                    P141&#xD; WU XL, 2003, SCIENCE, V300, P1749&#xD; YEE C, 2002, P NATL ACAD SCI
                    USA, V99, P16168&#xD; ZHANG Y, 2005, J IMMUNOL, V174, P3051&#xD; ZHANG Y, 2005,
                    NAT MED, V11, P1299&#xD; ZHOU JH, 2004, J IMMUNOL, V173, P7622&#xD; ZHOU JH,
                    2005, J IMMUNOTHER, V28, P53</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251087200002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>811</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">811</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1444</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ebbinghaus, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hussain, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tannir, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gordon, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Desai, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Knight, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Humerickhouse, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gordon, G. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Arizona Canc Ctr, Tucson, AZ USA.
                    Univ Michigan, Med Ctr, Ann Arbor, MI USA. Univ Texas MD Anderson Canc Ctr,
                    Houston, TX USA. Premiere Oncol Arizona, Scottsdale, AZ USA. Univ Chicago, Med
                    Ctr, Chicago, IL 60637 USA. Abbott Labs, Abbott Pk, IL 60064 USA. City Hope
                    Comprehens Canc Ctr, Duarte, CA USA.&#xD;Ebbinghaus, S, Merck Res Labs, UG4D 72
                    PO Box 1000, N Wales, PA 19454 USA.&#xD;Scot_Ebbinghaus@merck.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase 2 study of ABT-510 in
                        patients with previously untreated advanced renal cell carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">6689-6695</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">22</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ANGIOGENESIS INHIBITOR
                        ABT-510</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THROMBOSPONDIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMBINATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BEVACIZUMAB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUNITINIB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251207100020</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: Angiogenesis is a
                    characteristic of renal cell carcinoma. ABT-510 is an angiogenesis inhibitor
                    that mimics the antiangiogenic properties of thrombospondin-1. This study was
                    clesigned to assess the safety and efficacy of ABT-510 in patients with advanced
                    renal cell carcinoma. Experimental Design: Patients with previously untreated
                    metastatic or unresectable renal cell carcinoma were randomized to treatment
                    with one of two doses of ABT-510, self-administered s.c. twice daily in 28-day
                    treatment periods without intervening rest periods. End points were
                    progression-free survival (PFS), objective response rate, overall survival, and
                    toxicity. Results: The objective response-rate was 4% in the 10 mg twice daily
                    group, and there were two unconfirmed PRs in the 100 mg twice daily group.
                    Respective median PFS was 4.2 and 3.3 months, with a 6-month PFS of 39% and 32%.
                    Median overall survival was 27.8 months (10 mg twice daily) and 26.1 months (100
                    mg twice daily). The most frequent adverse events were injection site reactions
                    (84%), fatigue (50%), headache (20%), and nausea (19%). The incidence of
                    treatment-related, grade 3/4 adverse events was low and included three bleeding
                    episodes (gastrointestinal hemorrhage, intracranial hemorrhage, and hemoptysis)
                    and one thrombotic event (deep vein thrombosis). No deaths were attributed to
                    ABT-510. Conclusions: There was little evidence of clinical activity for
                    ABT-510, and further evaluation as a single agent for treating advanced renal
                    cell carcinoma is not warranted. The evidence of a favorable safety profile may
                    justify further evaluation in combination therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    235AY&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; ATKINS MB, 2004, J CLIN ONCOL, V22, P909&#xD; BAKER LH, 2005, J CLIN ONCOL
                    S 1, V23, S819&#xD; CARR R, 2002, EUR J CANCER S7, V38, S79&#xD; DAMERON KM,
                    1994, SCIENCE, V265, P1582&#xD; ESCUDIER B, 2007, NEW ENGL J MED, V356,
                    P125&#xD; GORDON MS, 2003, P AN M AM SOC CLIN, V22, P195&#xD; HAINSWORTH JD,
                    2005, J CLIN ONCOL, V23, P7889&#xD; HOEKSTRA R, 2005, J CLIN ONCOL, V23,
                    P5188&#xD; HOEKSTRA R, 2006, EUR J CANCER, V42, P467&#xD; HUDES G, 2007, NEW
                    ENGL J MED, V356, P2271&#xD; JEMAL A, 2007, CA-CANCER J CLIN, V57, P43&#xD;
                    KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457&#xD; LAWLER J, 1986, BLOOD, V67,
                    P1197&#xD; LINEHAN WM, 2001, CANC PRINCIPLES PRAC, P1362&#xD; MCKEEGAN EM, 2006,
                    1 AACR INT C MOL DIA&#xD; MOTZER RJ, 2002, J CLIN ONCOL, V20, P289&#xD; MOTZER
                    RJ, 2006, J CLIN ONCOL, V24, P16&#xD; MOTZER RJ, 2006, JAMA-J AM MED ASSOC,
                    V295, P2516&#xD; MOTZER RJ, 2007, NEW ENGL J MED, V356, P115&#xD; PATEL PH,
                    2006, BRIT J CANCER, V94, P614&#xD; RATAIN MJ, 2006, J CLIN ONCOL, V24,
                    P2505&#xD; SCHOFFSKI P, 2006, ANN ONCOL, V17, P1185&#xD; THERASSE P, 2000, J
                    NATL CANCER I, V92, P205&#xD; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217,
                    P326&#xD; YANG JC, 2003, NEW ENGL J MED, V349, P427&#xD;Part 1</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251207100020 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>682</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">682</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1443</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Eddy, S. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kane, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sonenshein, G. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Boston Univ, Sch Med, Dept Biochem,
                    Boston, MA 02118 USA. Boston Univ, Sch Med, Womens Hlth Interdisciplinary Res
                    Ctr, Boston, MA 02118 USA. Beckman Res Inst City Hope, Div Mol Med, Duarte, CA
                    USA.&#xD;Sonenshein, GE, Boston Univ, Sch Med, Dept Biochem, 715 Albany St,
                    Boston, MA 02118 USA.&#xD;gsonensh@bu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Trastuzumab-resistant
                        HER2-Driven breast cancer cells are sensitive to epigallocatechin-3
                        gallate</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">9018-9023</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">19</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTATIC BREAST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TEA POLYPHENOL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIBODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249955500009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Overexpression of the epidermal
                    growth factor receptor family member HER2 is found in similar to 30% of breast
                    cancers and is a target for immunotherapy. Trastuzumab, a humanized monoclonal
                    antibody against HER2, is cytostatic when added alone and highly successful in
                    clinical settings when used in combination with other chemotherapeutic agents.
                    Unfortunately, HER2 tumors in patients develop resistance to trastuzumab or
                    metastasize to the brain, which is inaccessible to antibody therapy. Previously,
                    we showed that the green tea polyphenol epigallocatechin-3 gallate (EGCG)
                    inhibits growth and transformed phenotype of Her-2/neu-driven mouse mammary
                    tumor cells. The different modes of action of EGCG and trastuzumab led us to
                    hypothesize that EGCG will inhibit HER2-driven breast cancer cells resistant to
                    trastuzumab. We studied trastuzumab-resistant BT474 human breast cancer cells,
                    isolated by chronic trastuzumab exposure, and JIMT-1 breast cancer cells,
                    derived from a pleural effusion in a patient who displayed clinical resistance
                    to trastuzumab therapy. EGCG treatment caused a dose-dependent decrease in
                    growth and cellular ATP production, and apoptosis at high concentrations. Akt
                    activity was suppressed by EGCG leading to the induction of FOX03a and target
                    cyclin-dependent kinase inhibitor P27(KiP1) levels. Thus, EGCG in combination
                    with trastuzumab may provide a novel strategy for treatment of
                    HER2-overexpressing breast cancers, given that EGCG can cross the blood-brain
                    barrier.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    217NV&#xD;Times Cited: 0&#xD;Cited Reference Count: 20</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249955500009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>595</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">595</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1441</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Elting, L. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, Y. C. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stiff, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bensinger, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cantor, S. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cooksley, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spielberger, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Emmanoulides, C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas, MD Anderson Canc Ctr,
                    Dept Biostat, Hlth Serv Res, Houston, TX 77030 USA. Loyola Univ, Cardinal
                    Bernardin Canc Ctr, Maywood, IL 60153 USA. Fred Hutchinson Canc Res Ctr,
                    Seattle, WA 98104 USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Interbalkan
                    Hosp, Thessaloniki, Greece.&#xD;Elting, LS, Univ Texas, MD Anderson Canc Ctr,
                    Dept Biostat, Hlth Serv Res, 1515 Holcombe Blvd,Unit 447, Houston, TX 77030
                    USA.&#xD;lelting@mdanderson.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Economic impact of palifermin on
                        the costs of hospitalization for autologous hematopoietic stem-cell
                        transplant: Analysis of phase 3 trial results</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">806-813</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">palifermin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stem cell transplant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">economic analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cost of illness</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORAL MUCOSITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUCOSAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INJURY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OUTCOMES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247861200007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A double-blind, randomized trial
                    showed that, compared with placebo, palifermin (recombinant human keratinocyte
                    growth factor) reduced the frequency and duration of oral mucositis in patients
                    with hematologic malignancies undergoing high-dose chemotherapy and total-body
                    irradiation with autologous stem-cell support. This previously published study
                    also showed a significant reduction in the incidence of adverse subsequent
                    outcomes. The objective of this study was to estimate the impact of palifermin
                    prophylaxis on hospital costs of trarrsplantation in the trial. This was a
                    retrospective, economic analysis of estimated costs for a previously published
                    clinical trial. Costs were not collected during the trial. Therefore, we
                    estimated the direct medical costs of hospitalization using hospital charges
                    from similar patients&apos; hospitalization charges selected from the National
                    Inpatient Sample, a population-based, nationally representative sample of
                    hospital claims. Costs were estimated from charges using Medicare&apos;s
                    state-specific cost-to-charge ratios. These cost estimates were applied to the
                    outcome data (incidence of febrile neutropenia, bacteremia/fungemia, or
                    pneumonia, and use of total parenteral nutrition) from the clinical trial.
                    Patients were those with hematologic malignancies who received high-dose
                    chemotherapy and total-body irradiation with autologous stem cell transplant. We
                    compared the estimated total hospital costs (in 2005 United States dollars)
                    incurred by patients who received palifermin in the clinical trial with those
                    incurred by patients who received placebo. Costs were analyzed from the
                    provider&apos;s perspective. The mean cost of a hospital day in this population
                    varied between $2,834, when no adverse outcomes occurred, and $4,663, when all 4
                    outcomes occurred. Reductions in adverse outcomes and their associated hospital
                    stay offset the acquisition price of palifermin. A nonsignificant mean savings
                    of $3,595 per patient (95% confidence interval: $2,09045,103) was observed. In
                    sensitivity analyses, this observation was robust to all plausible values of per
                    them hospital costs and hypothetic per them outpatient costs. In addition to its
                    previously demonstrated clinical benefit, palifermin prophylaxis offers a
                    favorable economic profile among patients with hematologic malignancies who
                    receive total body irradiation and autologous stem cell support. (c) 2007
                    American Society for Blood and Marrow Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    187PV&#xD;Times Cited: 0&#xD;Cited Reference Count: 21</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247861200007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>420</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">420</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">984</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Extermann, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ S Florida, H Lee Moffitt Canc
                    Ctr, Tampa, FL 33612 USA. City Hope Natl Med Ctr, Duarte, CA USA.&#xD;Extermann,
                    M, Univ S Florida, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33612
                    USA.&#xD;extermann@moffitt.usf.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Comprehensive geriatric
                        assessment for older patients with cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1824-1831</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">14</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COGNITIVE FUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL STATUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ELDERLY-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADJUVANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC-FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHYSICAL FUNCTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246675500002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose During the last decade,
                    oncologists and geriatricians have begun to work together to integrate the
                    principles of geriatrics into oncology care. The increasing use of a
                    comprehensive geriatric assessment (CGA) is one example of this effort. A CGA
                    includes an evaluation of an older individual&apos;s functional status, comorbid
                    medical conditions, cognition, nutritional status, psychological state, and
                    social support; and a review of the patient&apos;s medications. This article
                    discusses recent advances on the use of a CGA in older patients with cancer.
                    Methods In this article, we provide an update on the studies that address the
                    domains of a geriatric assessment applied to the oncology patient, review the
                    results of the first studies evaluating the use of a CGA in developing
                    interventions to improve the care of older adults with cancer, and discuss
                    future research directions. Results The evidence from recent studies
                    demonstrates that a CGA can predict morbidity and mortality in older patients
                    with cancer. Accumulating data show the benefits of incorporating a CGA in the
                    evaluation of older patients with cancer. Prospective trials evaluating the
                    utility of a CGA to guide interventions to improve the quality of cancer care in
                    older adults are justified. Conclusion Growing evidence demonstrates that the
                    variables examined in a CGA can predict morbidity and mortality in older
                    patients with cancer, and uncover problems relevant to cancer care that would
                    otherwise go unrecognized.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    170PI&#xD;Times Cited: 1&#xD;Cited Reference Count: 79&#xD;Cited References:
                    &#xD; AUDISIO RA, 2005, ONCOLOGIST, V10, P262&#xD; BALDUCCI L, 2007, CANC
                    CONTROL, V14, P7&#xD; BIRIM O, 2006, EJSO, V32, P12&#xD; BOUCHARDY C, 2003, J
                    CLIN ONCOL, V21, P3580&#xD; CALLEN LJ, 2004, J CLIN ONCOL, V2, P745&#xD; CHEN
                    HB, 2003, CANCER, V97, P1107&#xD; CORCORAN ME, 1997, CANC CONTROL, V4, P419&#xD;
                    DEMARKWAHNEFRIED W, 2006, J CLIN ONCOL, V24, P3465&#xD; DEWYS WD, 1980, AM J
                    MED, V69, P491&#xD; DIFIORE F, 2006, WORLD J GASTROENTERO, V12, P4185&#xD;
                    EBERHARDT B, 2006, SUPPORT CARE CANCER, V14, P216&#xD; EXTERMANN M, 1998, J CLIN
                    ONCOL, V16, P1582&#xD; EXTERMANN M, 2000, J CLIN ONCOL, V18, P1709&#xD;
                    EXTERMANN M, 2002, EUR J CANCER, V38, P1466&#xD; EXTERMANN M, 2003, CANC
                    CONTROL, V10, P463&#xD; EXTERMANN M, 2004, CRIT REV ONCOL HEMAT, V49, P69&#xD;
                    EXTERMANN M, 2005, CMP HEALTHCARE MEDIA, P1&#xD; EXTERMANN M, 2007, CANC
                    CONTROL, V14, P13&#xD; FIRAT S, 2002, INT J RADIAT ONCOL, V52, P1047&#xD; FLOOD
                    KL, 2006, J CLIN ONCOL, V24, P2298&#xD; FRASCI G, 2000, J CLIN ONCOL, V18,
                    P2536&#xD; FREYER G, 2005, ANN ONCOL, V16, P1795&#xD; FRIED LP, 2005, SCI AGING
                    KNOWLEDGE, PE24&#xD; FRIED TR, 2002, NEW ENGL J MED, V346, P1061&#xD;
                    FRIEDENTHAL H, 1902, Z ALLG PHYSL, V1, P56&#xD; GOODWIN JS, 2003, J AM GERIATR
                    SOC, V51, P1252&#xD; GOODWIN JS, 2004, J AM GERIATR SOC, V52, P106&#xD; GOODWIN
                    PJ, 2002, J CLIN ONCOL, V20, P42&#xD; GORIN SS, 2005, J AM GERIATR SOC, V53,
                    P1897&#xD; GUPTA SK, 2004, J AM GERIATR SOC, V52, P1681&#xD; HALEY WE, 2003, J
                    SUPPORT ONCOL, V1, P25&#xD; HAMMARSTEN J, 2005, EUR J CANCER, V41, P2887&#xD;
                    HOUTERMAN S, 2006, PROSTATE CANCER P D, V9, P179&#xD; HURRIA A, 2005, CANCER,
                    V104, P1998&#xD; HURRIA A, 2006, BREAST CANCER RES TR, V98, P343&#xD; HURRIA A,
                    2006, J AM GERIATR SOC, V54, P925&#xD; INGRAM SS, 2002, J CLIN ONCOL, V20,
                    P770&#xD; JOHNSON D, 2006, 5 SPRING C EUR ONC N&#xD; JOLY F, 2006, J UROLOGY 1,
                    V176, P2443&#xD; KASTRITIS E, 2006, GYNECOL ONCOL, V104, P372&#xD; KEATING NL,
                    2005, J AM GERIATR SOC, V53, P2145&#xD; KORNBLITH AB, 2003, CANCER, V98,
                    P679&#xD; KORNBLITH AB, 2006, CANCER, V107, P2706&#xD; KOROUKIAN SM, 2006, J
                    CLIN ONCOL, V24, P2304&#xD; KROENKE CH, 2006, J CLIN ONCOL, V24, P1105&#xD;
                    LANDI F, 2000, ARCH INTERN MED, V160, P2641&#xD; LANGA KM, 2004, AM J PSYCHIAT,
                    V161, P857&#xD; LIDOUREN G, 2006, CRIT REV ONCOL HEMAT, V60, P531&#xD; MAIONE P,
                    2005, J CLIN ONCOL, V23, P6865&#xD; MCCORKLE R, 2000, J AM GERIATR SOC, V48,
                    P1707&#xD; MCCUSKER J, 1999, J AM GERIATR SOC, V47, P1229&#xD; MEYERKARDT JA,
                    2003, J CLIN ONCOL, V21, P433&#xD; MION LC, 2001, J AM GERIATR SOC, V49,
                    P1379&#xD; MOERTEL CG, 1995, ANN INTERN MED, V122, P321&#xD; MOHILE SG, 2007,
                    CANCER, V109, P802&#xD; NEWMAN AB, 2001, J AM GERIATR SOC, V49, P1309&#xD;
                    OVERCASH JA, 2005, CRIT REV ONCOL HEMAT, V54, P129&#xD; OVERCASH JA, 2006, CRIT
                    REV ONCOL HEMAT, V59, P205&#xD; PAVELKA JC, 2006, CANCER, V107, P1520&#xD;
                    PENNINX BWJH, 1998, JAMA-J AM MED ASSOC, V279, P1720&#xD; PICCIRILLO JF, 2004,
                    JAMA-J AM MED ASSOC, V291, P2441&#xD; RAMESH H, 2006, CRIT REV ONCOL HEM S,
                    V21&#xD; RAO AV, 2005, J GERONTOL A-BIOL, V60, P798&#xD; REPETTO L, 2002, J CLIN
                    ONCOL, V20, P494&#xD; RETORNAZ F, 2006, CAN J AGING S, V25, P269&#xD; REUBEN DB,
                    1992, AM J MED, V93, P663&#xD; REYNOLDS MW, 1999, J AM GERIATR SOC, V47,
                    P1409&#xD; ROEHRIG B, 2006, CRIT REV ONCOL 1211&#xD; SALIBA D, 2000, J GERONTOL,
                    V55, P750&#xD; SATARIANO WA, 1994, ANN INTERN MED, V120, P104&#xD; SEEMAN TE,
                    1993, ANN EPIDEMIOL, V3, P325&#xD; SOEJONO C, 2006, CRIT REV ONCOL HEMAT, V60,
                    S20&#xD; SOUBEYRAN P, 2006, CRIT REV ONCOL HE S1, V60, S23&#xD; STAFFORD RS,
                    1997, CANCER, V80, P1973&#xD; STEYERBERG EW, 2006, J CLIN ONCOL, V24, P4277&#xD;
                    TOLIUSIENE J, 2004, SUPPORT CARE CANCER, V12, P716&#xD; WALLACE JI, 1995, J AM
                    GERIATR SOC, V43, P329&#xD; WALLACE K, 2005, 41 ANN M AM SOC CLIN&#xD;
                    WAXLERMORRISON N, 1991, SOC SCI MED, V33, P177</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246675500002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>875</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">875</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1440</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Falabella, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore-Jeffries, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sullivan, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lew, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div
                    Anesthesiol, Dept Anesthesiol, Duarte, CA 91010 USA.&#xD;Falabella, A, City Hope
                    Natl Med Ctr, Div Anesthesiol, Dept Anesthesiol, 1500 E Duarte Rd, Duarte, CA
                    91010 USA.&#xD;Afalabella@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cardiac function during steep
                        Trendelenburg position and CO2 pneumoperitoneum for robotic-assisted
                        prostatectomy: a trans-oesophageal Doppler probe study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of Medical
                        Robotics and Computer Assisted Surgery</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">312-315</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">3</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cardiac function</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Trendelenburg position</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pneumoperitoneum</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">robotic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LAPAROSCOPIC
                        CHOLECYSTECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PERSPECTIVE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1478-5951</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252867300006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background Haemodynamic changes
                    associated with pneumoperitoneum and steep Trendelenburg position were
                    investigated in non-obese, ASA I-II males, using general anaesthesia
                    (sevoflurane in air/O-2, 40%) undergoing robotic-assisted laparoscopic
                    prostatectomy. Methods A trans-oesophageal echo-Doppler probe (Arrow
                    International) measured cardiovascular changes in heart rate (HR), mean arterial
                    pressure (MAP), cardiac output (C 0), systemic vascular resistance (SVR), stroke
                    volume (SV) and aortic diameter (AoD) in 35 of 37 males. Assessments were
                    conducted after induction of general anaesthesia in: the supine position; at 45
                    degrees Trendelenburg; Trendelenburg + pnuemoperitoneurn (intra-abdominal 15
                    mmHg); and at the end of surgery in the supine position. Results The
                    Trendelenburg position increased stroke volume. Trendelenburg position +
                    pneumoperitoneum increased MAP and SVR and decreased AoD. Conclusions
                    Pneumoperitoneum and steep Trendelenburg position significantly increase MAP and
                    SVR. Trendelenburg position increased stroke volume. Pneumoperitoneum decreases
                    aortic diameter. No significant changes in cardiac output or stroke volume were
                    noted. Copyright (c) 2008 John Wiley &amp; Sons, Ltd.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    258KR&#xD;Times Cited: 0&#xD;Cited Reference Count: 12&#xD;Cited References:
                    &#xD; ALFONSI P, 2006, ANESTH ANALG, V102, P1304&#xD; CHUI PT, 1993, ANAESTH
                    INTENS CARE, V21, P163&#xD; CUNNINGHAM AJ, 1993, ANESTH ANALG, V76, P1120&#xD;
                    CUSCHIEN J, 1998, CRIT CARE MED S, V26, A82&#xD; JORIS JL, 1993, ANESTH ANALG
                    CURR RE, V76, P1067&#xD; KELMAN GR, 1972, BRIT J ANAESTH, V44, P1155&#xD;
                    KOLIOPANOS A, 2005, SURG LAPARO ENDO PER, V15, P332&#xD; LANFRANCO AR, 2004, ANN
                    SURG, V239, P14&#xD; OMALLLEY C, 2001, ANESTHESIOL CLIN N A, V1, P1&#xD; SATAVA
                    RM, 2002, SURG LAPARO ENDO PER, V12, P6&#xD; SHARMA KC, 1996, CHEST, V110,
                    P810&#xD; WAHBA RWM, 1995, CAN J ANAESTH, V42, P51</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252867300006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>780</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">780</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1878</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Nursing Research and Education, City
                    of Hope National Medical Center, Duarte, California 91010, USA.
                    bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">On finding a balance</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">309-12</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Career Choice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Career Mobility</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Empathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nursing Research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oncologic Nursing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/
                        standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Social Values</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Terminal Care/ standards</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1096-6218 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17472501</style>
            </accession-num>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/12/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>577</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">577</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1875</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Connor, S. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cordes, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dahlin, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fine, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hutton, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leenay, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lentz, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Person, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meier, D. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zuroski, K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research &amp;
                    Education, City of Hope Medical Center, Duarte, California 91010-3000, USA.
                    bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The national agenda for quality
                        palliative care: the National Consensus Project and the National Quality
                        Forum</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of pain and symptom
                        management</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">737-44</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">33</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Outcome and Process Assessment
                        (Health Care)/organization &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Palliative Care/ organization
                        &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Practice Guidelines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0885-3924 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17531914</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The release in 2007 of the National
                    Quality Forum (NQF) preferred practices is a significant advance in the field of
                    palliative care. These NQF preferred practices build on the clinical practice
                    guidelines for palliative care developed by the National Consensus Project
                    (NCP). The NQF is dedicated to improving the quality of American health care,
                    and their focus on palliative care recognizes its growing place within the
                    broader scope of health care. This article reviews the work of both the NCP and
                    NQF and presents the domains and preferred practices that should guide quality
                    improvement efforts in hospice and palliative care.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">National Consensus Project for
                    Quality Palliative Care Task Force Members</style>
            </notes>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/09/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>375</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">375</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1435</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Figarola, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shanmugam, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rahbar, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Diabet
                    Endocrinol &amp; Metab, Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Rahbar, S,
                    City Hope Natl Med Ctr, Dept Diabet Endocrinol &amp; Metab, Beckman Res Inst,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;srahbar@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Anti-inflammatory effects of the
                        advanced glycation end product inhibitor LR-90 in human monocytes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Diabetes</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Diabetes</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Diabetes</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Diabetes</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">647-655</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">56</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-ADHESION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING-PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFLAMMATORY DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NADPH OXIDASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECEPTOR RAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANIMAL-MODELS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATHEROSCLEROSIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0012-1797</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244827500011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Ligation of advanced glycation end
                    products (AGEs) with their receptor (RAGE) plays an important role in the
                    development of various diabetes complications, including atherosclerosis.
                    Monocyte activation, adhesion, and migration are key events in the pathogenesis
                    of atherosclerosis. Previous studies showed that AGEs and S100b, a specific RAGE
                    ligand, could augment monocyte inflammatory responses via RAGE. In this study,
                    we examined whether LR-90, a compound belonging to a new class of AGE inhibitor,
                    could inhibit inflammatory responses in human monocytes. Human THP-1 cells were
                    pretreated with LR-90 and then stimulated with S100b. LR-90 significantly
                    inhibited S100b-induced expression of RAGE and other proinflammatory genes
                    including monocyte chemoattractant protein-1, interferon-gamma-inducible
                    protein-10, and cyclooxygenase-2 in a dose-dependent manner. These inhibitory
                    effects may be exerted via inhibition of nuclear factor-kappa B (NF-kappa B)
                    activation, as LR-90 suppressed both S100b- and tumor necrosis
                    factor-alpha-induced I kappa B-alpha degradation as well as NF-kappa B promoter
                    transcriptional activity. LR-90 also prevented oxidative stress in activated
                    monocytes, as demonstrated by its inhibitory effects on S100b-induced expression
                    of NADPH oxidase and intracellular superoxide production. In addition, LR-90
                    blocked S100b-induced monocyte adhesion to human umbilical vein endothelial
                    cell. These new data show that, in addition to its AGE inhibitory effects, LR-90
                    has novel anti-inflammatory properties and might therefore have additional
                    protective effects against diabetic vascular complications.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    144WQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; ANRATHER J, 2006, J BIOL CHEM, V281, P5657&#xD; BASTA G, 2004, CARDIOVASC
                    RES, V63, P582&#xD; BECKMAN JA, 2002, JAMA-J AM MED ASSOC, V287, P2570&#xD;
                    BIERHAUS A, 2005, J MOL MED-JMM, V83, P876&#xD; BOTELLA LM, 2000, J IMMUNOL,
                    V164, P1372&#xD; BRETT J, 1993, AM J PATHOL, V143, P1699&#xD; BUCCIARELLI LG,
                    2001, CIRCULATION, V106, P2827&#xD; CATHCART MK, 2004, ARTERIOSCL THROM VAS,
                    V24, P23&#xD; CAVE AC, 2006, ANTIOXID REDOX SIGN, V8, P691&#xD; CHAVAKIS T,
                    2003, J EXP MED, V198, P1507&#xD; DEGROOT J, 2004, CURR OPIN PHARMACOL, V4,
                    P301&#xD; DEWINTHER MPJ, 2005, ARTERIOSCL THROM VAS, V25, P904&#xD; DING Y,
                    2007, J LEUKOCYTE BIOL, V81&#xD; FIGAROLA JL, DIABETOLOGIA, V46, P1140&#xD;
                    GERRITY RG, 1981, AM J PATHOL, V103, P181&#xD; GILMORE TD, REL NF KAPPAB
                    TRANSC&#xD; HAYDEN MS, 2004, GENE DEV, V18, P2195&#xD; HUDSON BI, 2003, ARCH
                    BIOCHEM BIOPHYS, V419, P80&#xD; KIM W, 2005, ANN NY ACAD SCI, V1043, P553&#xD;
                    LI NX, 1999, FASEB J, V13, P1137&#xD; LIBBY P, 2002, NATURE, V42, P868&#xD; MARX
                    N, 2004, DIABETES, V53, P2662&#xD; NAKA Y, 2004, ARTERIOSCL THROM VAS, V24,
                    P1342&#xD; NAWROTH P, 2005, CURR DIAB REP, V5, P11&#xD; OSTERUD B, 2003, PHYSIOL
                    REV, V83, P1069&#xD; PARK L, 1998, NAT MED, V4, P1025&#xD; PIERCE JW, 1997, J
                    BIOL CHEM, V272, P21096&#xD; RAHBAR S, 2003, ARCH BIOCHEM BIOPHYS, V419,
                    P63&#xD; RENARD C, 2006, DIABETES METAB, V32, P15&#xD; ROLLINS BJ, 1996, MOL MED
                    TODAY, V2, P198&#xD; ROSS R, 1999, NEW ENGL J MED, V340, P115&#xD; SCHMIDT AM,
                    1993, J CLIN INVEST, V91, P2155&#xD; SCHMIDT AM, 1995, J CLIN INVEST, V96,
                    P1395&#xD; SCHMIDT AM, 2000, BBA-MOL CELL RES, V1498, P99&#xD; SHANMUGAM N,
                    2003, DIABETES, V52, P1256&#xD; SHANMUGAM N, 2003, J BIOL CHEM, V278,
                    P34834&#xD; SHANMUGAM N, 2006, J BIOL CHEM, V281, P31212&#xD; SINGH R, 2001,
                    DIABETOLOGIA, V44, P129&#xD; SORESCU D, 2002, CIRCULATION, V105, P1429&#xD;
                    SOULIS T, 1997, DIABETOLOGIA, V40, P619&#xD; SUMIMOTO H, 2004, JPN J INFECT DIS,
                    V57, S24&#xD; TANJI N, 2000, J AM SOC NEPHROL, V11, P1656&#xD; TAUB DD, 1993, J
                    EXP MED, V177, P1809&#xD; WASSMANN S, 2004, HYPERTENSION, V44, P381&#xD; WAUTIER
                    MP, 2001, AM J PHYSIOL-ENDOC M, V280, P685&#xD; WENDT T, 2002, CURR ATHEROSCLER
                    REP, V4, P228&#xD; XIONG SG, 2003, J BIOL CHEM, V278, P17646&#xD; YAMAGISHI S,
                    2004, DRUG EXP CLIN RES, V30, P169&#xD; YAN SD, 1994, J BIOL CHEM, V269,
                    P9889</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244827500011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>643</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">643</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1431</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Fineberg, I. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aziz, N. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Payne, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kagawa-Singer, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dunn, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kinzbrunner, B. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palos, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shinagawa, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Nursing
                    Res &amp; Educ, Duarte, CA 91010 USA. Univ Lancaster, Inst Hlth Res, Int Observ
                    End Life Care, Lancaster LA1 4YQ, England. NCI, Off Canc Survivorship, Bethesda,
                    MD 20892 USA. NCI, Div Canc Control &amp; Populat Sci, Bethesda, MD 20892 USA.
                    Duke Univ, Divin Sch, Duke Inst Care End Life, Durham, England. Univ Calif Los
                    Angeles, Sch Publ Hlth, Asian Amer Studies Dept, Community Hlth Sci Dept, Los
                    Angeles, CA 90024 USA. Univ Calif Los Angeles, Ctr Hlth Disparities, Los
                    Angeles, CA 90024 USA. Amer Coll Surgeons, Surg Palliat Care Task Force, Erie,
                    PA USA. VITAS Healthcare Corp, Miami, FL USA. Univ Texas, MD Anderson Canc Ctr,
                    Div Anesthesiol &amp; Crit Care, Houston, TX 77025 USA. Univ Texas, MD Anderson
                    Canc Ctr, Dept Sympton Res, Houston, TX 77025 USA. Asian Amer Network Canc
                    Awareness Res &amp; Training, Spring Valley, CA USA. So Arizona Vet Affairs Hlth
                    Care Syst, Tucson, AZ USA. Univ Arizona, Coll Med, Tucson, AZ 85721
                    USA.&#xD;Grant, M, City Hope Natl Med Ctr, Dept Nursing Res &amp; Educ, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;mgrant@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Prospective integration of
                        cultural consideration in biomedical research for patients with advanced
                        cancer: Recommendations from an International Conference on Malignant Bowel
                        Obstruction in palliative care</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Pain and Symptom
                        Management</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Pain Symptom Manage.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of pain and symptom
                        management</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Pain and Symptom
                        Management</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Pain Symptom Manage.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-2>
                <abbr-3>
                    <style face="normal" font="default" size="100%">Journal of Pain &amp; Symptom
                        Management</style>
                </abbr-3>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">S28-S39</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">culture</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">palliative care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">research methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">multidisciplinary
                        research</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mixed method</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">approaches</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">END</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STROKE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0885-3924</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248055200004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In the setting of an international
                    conference on malignant bowel obstruction as a model for randomized controlled
                    trials (RCTs) in palliative care, we discuss the importance of incorporating
                    prospective cultural considerations into research design. The approach commonly
                    used in biomedical research has traditionally valued the RCT as the ultimate
                    &quot;way of knowing&quot; about how to best treat a medical condition. The
                    foremost limitation of this approach is the lack of recognition of the impact of
                    cultural viewpoints on research outcomes. We propose that interest relevant to
                    cultural viewpoints should be emphasized in conceptualizing and interpreting
                    research questions, designs, and results. In addition to recognizing our
                    cultural biases as individuals and researchers, we recommend two major shifts in
                    designing and implementing RCTs: 1) inclusion of a multidisciplinary team of
                    researchers to inform the diversity of perspectives and expertise brought to the
                    research, and 2) use of mixed methods of inquiry, reflecting both deductive and
                    inductive modes of inference.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    190JN&#xD;Times Cited: 0&#xD;Cited Reference Count: 37&#xD;Suppl. S</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248055200004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>393</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">393</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1429</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Flodby, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Minoo, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Crandall, E. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Borok, Z.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Keck Sch Med, Dept
                    Med, Will Rogers Inst Pulm Res Ctr,Div Pulm &amp; Crit Car, Los Angeles, CA
                    90033 USA. City Hope Natl Med Ctr, Dept Clin &amp; Mol Pharmacol, Duarte, CA
                    91010 USA. Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033
                    USA.&#xD;Flodby, P, Univ So Calif, Keck Sch Med, Dept Med, Will Rogers Inst Pulm
                    Res Ctr,Div Pulm &amp; Crit Car, IRD 620,2020 Zonal Ave, Los Angeles, CA 90033
                    USA.&#xD;flodby@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Conserved elements within first
                        intron of aquaporin-5 (Aqp5) function as transcriptional enhancers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Biophys Res
                        Commun</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">26-31</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">356</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">transcriptional
                        regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transient transfections</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell lines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aquaporin water channels</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEAVY-CHAIN GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPITHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LACRIMAL GLANDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WATER CHANNELS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOUSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUNG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SALIVARY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOLOCALIZATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-291X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245419300005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A 4.3 kb rat aquaporin-5 (Aqp5)
                    promoter that directs lung and salivary cell-specific expression in vitro
                    directs low level expression of a GFP reporter in lungs of transgenic mice.
                    Alignment of rat, mouse, and human AQP5 genomic sequences identified a highly
                    conserved region in the 3&apos; portion of intron 1, here termed cil. To
                    investigate the role of cil in Aqp5 expression, transient transfections were
                    undertaken in AQP5-expressing mouse lung epithelial (MLE-15) and rat salivary
                    (Pa-4) cells and AQP5-non-expressing NIH/3T3 cells. A 536 bp cil fragment
                    enhanced transcriptional activity of the rat Aqp5 minimal promoter specifically
                    in MLE-15 cells in an orientation-independent manner. Enhancer activity was Aqp5
                    promoter-specific, since no increase in activity was detected with the TK
                    promoter. These results suggest that expression of transgenes in mouse lungs
                    under direction of the 4.3 kb rat Aqp5 promoter may be augmented by inclusion of
                    cil in transgenic constructs. (c) 2007 Elsevier Inc. All rights
                    reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    153GE&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; BANERJI J, 1983, CELL, V33, P729&#xD; BORGNIA M, 1999, ANNU REV BIOCHEM,
                    V68, P425&#xD; BOROK Z, 1998, AM J RESP CELL MOL, V18, P554&#xD; BOROK Z, 2000,
                    J BIOL CHEM, V275, P26507&#xD; BOROK Z, 2002, J APPL PHYSIOL, V93, P2199&#xD;
                    DUBCHAK I, 2006, METH MOL B, V338, P69&#xD; FRAZER KA, 2004, NUCLEIC ACIDS RES,
                    V32, P273&#xD; FUNAKI H, 1998, AM J PHYSIOL-CELL PH, V275, C1151&#xD; GILLIES
                    SD, 1983, CELL, V33, P717&#xD; ISHIDA N, 1997, BIOCHEM BIOPH RES CO, V238,
                    P891&#xD; JAINCHILL JL, 1969, J VIROL, V4, P549&#xD; KING LS, 2004, NAT REV MOL
                    CELL BIO, V5, P687&#xD; MA TH, 1997, GENOMICS, V43, P387&#xD; MATSUZAKI T, 1999,
                    CELL TISSUE RES, V295, P513&#xD; NEJSUM LN, 2002, P NATL ACAD SCI USA, V99,
                    P511&#xD; NEUBERGER MS, 1983, EMBO J, V2, P1373&#xD; NIELSEN S, 1997, AM J
                    PHYSIOL, V273, P1549&#xD; NOMURA J, 2006, BIOCHEM BIOPH RES CO, V351, P1048&#xD;
                    PERL AKT, 2002, P NATL ACAD SCI USA, V99, P10482&#xD; PERL AKT, 2002, TRANSGENIC
                    RES, V11, P21&#xD; QUISSELL DO, 1998, IN VITRO CELL DEV-AN, V34, P58&#xD; RAINA
                    S, 1995, J BIOL CHEM, V270, P1908&#xD; ROWNTREE RK, 2001, HUM MOL GENET, V10,
                    P1455&#xD; STEMMLER MP, 2005, DEVELOPMENT, V132, P965&#xD; WIKENHEISER KA, 1993,
                    P NATL ACAD SCI USA, V90, P11029&#xD; YANG HH, 2002, DEVELOPMENT, V129,
                    P2233&#xD; ZARDOYA R, 2001, J MOL EVOL, V52, P391&#xD; ZHOU B, 2003, AM J RESP
                    CRIT CARE, V167, A809</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245419300005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>560</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">560</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1869</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Frankel, P. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reid, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marshall, J. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Biostatistics, City of
                    Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010-3000, United
                    States. pfrankel@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A permutation test for a
                        weighted Kaplan-Meier estimator with application to the nutritional
                        prevention of cancer trial</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Contemp Clin Trials</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">343-7</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Area Under Curve</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bias (Epidemiology)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Colorectal
                        Neoplasms/diagnosis/mortality/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Dietary Supplements</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Follow-Up Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Kaplan-Meiers Estimate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lung
                        Neoplasms/diagnosis/mortality/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/diagnosis/mortality/
                        prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Proportional Hazards
                        Models</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatic
                        Neoplasms/diagnosis/mortality/prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Randomized Controlled Trials/
                        statistics &amp; numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Selenium/ administration &amp;
                        dosage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Failure</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Yeast, Dried/ administration
                        &amp; dosage</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1551-7144 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17150413</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The phenomenon of losing statistical
                    significance with increasing follow-up can arise when a proportional hazard
                    model is applied in a clinical trial where the impact of the intervention
                    results in delaying a negative event such as cancer diagnosis, progression or
                    death. Often parametric methods can be employed in such a setting, however, in
                    studies where only a small percentage of subjects have an event, these methods
                    are often inappropriate. We present an alternative method based on a weighted
                    Kaplan-Meier estimator and a permutation test, and demonstrate its utility in
                    the setting of the Nutritional Prevention of Cancer study where increasing
                    follow-up resulted in loss of statistical significance for the ability of
                    selenized yeast to prevent lung cancer.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>838</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">838</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1424</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Friebel, T. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Domchek, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Neuhausen, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagner, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Evans, D. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Isaacs, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garber, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daly, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Eeles, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Matloff, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tomlinson, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, H. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tung, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blum, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rubinstein, W. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ganz, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Couch, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rebbeck, T. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Penn, Sch Med, Dept Biostat
                    &amp; Epidemiol, Ctr Clin Epidemiol &amp; Biostat, Philadelphia, PA 19104 USA.
                    Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Penn,
                    Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Calif Irvine, Irvine, CA
                    92717 USA. Univ Vienna, A-1010 Vienna, Austria. St Marys Hosp, Manchester M13
                    0JH, Lancs, England. Georgetown Univ, Vincent T Lombardi Canc Res Ctr,
                    Washington, DC 20057 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Fox Chase
                    Canc Ctr, Philadelphia, PA 19111 USA. Royal Marsden Hosp, NHS Trust, Sutton,
                    Surrey, England. Yale Univ, New Haven, CT 06520 USA. Creighton Univ, Omaha, NE
                    68178 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Baylor Univ, Med
                    Ctr, Dallas, TX USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Evanston NW
                    Hlthcare Ctr Med Genet, Evanston, IL USA. Univ Calif Los Angeles, Jonsson
                    Comprehens Canc Ctr, Los Angeles, CA 90024 USA. Mayo Clin, Coll Med, Rochester,
                    MN USA.&#xD;Friebel, TM, Univ Penn, Sch Med, Dept Biostat &amp; Epidemiol, Ctr
                    Clin Epidemiol &amp; Biostat, 909 Blockley Hall,423 Guardian Dr, Philadelphia,
                    PA 19104 USA.&#xD;tfriebel@mail.med.upenn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Bilateral prophylactic
                        oophorectomy and bilateral prophylactic mastectomy in a prospective cohort
                        of unaffected BRCA1 and BRCA2 mutation carriers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Breast Cancer</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">875-882</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic testing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hereditary breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER RISK</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SALPINGO-OOPHORECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREVENTIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEASURES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE MUTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POPULATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1526-8209</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252098700008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Women with BRCA1 or
                    BRCA2 (BRCA1/2) mutations can reduce cancer incidence and mortality by using
                    bilateral prophylactic oophorectomy (BPO) or bilateral prophylactic mastectomy
                    (BPM). The availability of these risk-reduction strategies is an important
                    consideration in the decision to undergo genetic testing. Patients and Methods:
                    We evaluated the use of BPO and BPM in a prospective sample of 537 female
                    BRCA1/2 mutation carriers from 17 centers in North America and Europe. These
                    women were aged &gt; 30 years, had no BPM, BPO, breast cancer, or ovarian cancer
                    before the disclosure of their genetic test results and were followed for &gt; 6
                    months. Results: Bilateral prophylactic oophorectomy is used significantly more
                    frequently than BPM (55% vs. 21%; P &lt; .001). Bilateral prophylactic
                    oophorectomy was more common among women age &gt;= 40 years compared with women
                    aged &lt; 40 years (68% vs. 43%; P &lt; .001) and among porous women compared
                    with nulliparous women (60% vs. 39%; P &lt; .001). There was no difference in
                    BPM (P = .83) or BPO (P = .09) in BRCA1 versus BRCA2 carriers. Multivariate
                    models identified age and parity as a predictor of BPO in BRCA1 carriers; age
                    and ovarian cancer family history in BRCA2 carriers; parity and ovarian cancer
                    family history as a predictor of BPM in BRCA1 carriers; and smoking and ovarian
                    cancer family history in BRCA2 carriers. Conclusion: Bilateral prophylactic
                    oophorectomy is more commonly used than BPM in unaffected BRCA1/2 mutation
                    carriers. Parity, age, and family history can also influence BPO and BPM uptake.
                    Consistent with current recommendations, BPO is used by the majority of porous
                    women aged &gt; 40 years.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    247RX&#xD;Times Cited: 0&#xD;Cited Reference Count: 26&#xD;Cited References:
                    &#xD; NATL COMPREHENSIVE C&#xD; ANDERSON K, 2006, ANN INTERN MED, V144,
                    P397&#xD; DOMCHEK SM, 2006, LANCET ONCOL, V7, P223&#xD; DOMCHEK SM, 2007, CURR
                    OPIN OBSTET GYN, V19, P27&#xD; EISEN A, 2005, J CLIN ONCOL, V23, P7491&#xD;
                    FINCH A, 2006, JAMA-J AM MED ASSOC, V296, P185&#xD; GRONWALD J, 2007, CLIN
                    GENET, V71, P153&#xD; HARTMANN LC, 2001, J NATL CANCER I, V93, P1633&#xD; HOGG
                    R, 2004, J CLIN ONCOL, V22, P1315&#xD; KAUFF ND, 2002, NEW ENGL J MED, V346,
                    P1609&#xD; LEACH MO, 2005, LANCET, V365, P1769&#xD; MADALINSKA JB, 2005, J CLIN
                    ONCOL, V23, P6890&#xD; MADALINSKA JB, 2007, J CLIN ONCOL, V25, P301&#xD;
                    MEIJERSHEIJBOER EJ, 2000, LANCET, V355, P2015&#xD; MEIJERSHEIJBOER H, 2001, NEW
                    ENGL J MED, V345, P159&#xD; METCALFE KA, 2005, FAM CANCER, V4, P97&#xD; PHILLIPS
                    KA, 2006, CLIN GENET, V70, P198&#xD; REBBECK TR, 1999, J NATL CANCER I, V91,
                    P1475&#xD; REBBECK TR, 2002, NEW ENGL J MED, V346, P1616&#xD; REBBECK TR, 2004,
                    J CLIN ONCOL, V22, P1055&#xD; RUTTER JL, 2003, J NATL CANCER I, V95, P1072&#xD;
                    SCHEUER L, 2002, J CLIN ONCOL, V20, P1260&#xD; SCHMELER KM, 2006, OBSTET GYNECOL
                    1, V108, P515&#xD; SCHWARTZ MD, 2003, J CLIN ONCOL, V21, P4034&#xD; UYEI A,
                    2006, CANCER, V107, P2745&#xD; WAINBERG S, 2004, CANCER EPIDEM BIOMAR, V13,
                    P1989</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252098700008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>225</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">225</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1868</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Fukui, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Immunology, Beckman
                    Research Institute of the City of Hope, 1450 East Duarte Road, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">NvMap: automated analysis of NMR
                        chemical shift perturbation data</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bioinformatics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Bioinformatics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Bioinformatics</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Bioinformatics</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">378-80</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">23</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Algorithms</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Biopolymers/ analysis/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Magnetic Resonance Spectroscopy/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Interaction Mapping/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Software</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">User-Computer Interface</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1460-2059 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17118956</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">NMR chemical shift perturbation
                    experiments are widely used to define binding sites in biomolecular complexes.
                    Especially in the case of high throughput screening of ligands, rapid analysis
                    of NMR spectra is essential. NvMap extends NMRViewJ and provides a means for
                    rapid assignments and book-keeping of NMR titration spectra. Our module offers
                    options to analyze multiple titration spectra both separately and sequentially,
                    where the sequential spectra are analyzed either two at a time or all
                    simultaneously. The first option is suitable for slow or intermediate exchange
                    rates between free and bound proteins. The latter option is particularly useful
                    for fast exchange situations and can compensate for the lack of indicators for
                    overlapped peaks. Our module also provides a simple user interface to automate
                    the analysis process from dataset to peak list. We demonstrate the effectiveness
                    of our program using NMR spectra of SUMO in complexes with three different
                    peptides. Availability: NvMap is available on the web at
                    http://www.cityofhope.org/Researchers/ChenYuan/NvMap/ Supplemental information:
                    Manual pages and test spectra will be available on the web at the above
                    site.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 07/02; </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>421</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">421</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1422</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Fung, H. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stiff, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schriber, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Toor, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rodriguez, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Molina, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ivers, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kogut, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Popplewell, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rodriguez, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr,
                    Duarte, CA 91010 USA.&#xD;Nademanee, A, City Hope Comprehens Canc Ctr, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;anademanee@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Tandem autologous stem cell
                        transplantation for patients with primary refractory or poor risk recurrent
                        Hodgkin lymphoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">594-600</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Hodgkin lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tandem transplant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW
                        TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOSE SEQUENTIAL
                        CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMBINATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FIRST RELAPSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLOPHOSPHAMIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARMUSTINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ETOPOSIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOOD</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246252600011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Although autologous stem cell
                    transplantation (ASCT) for patients with relapsed/refractory Hodgkin lymphoma
                    (HL) appears to offer a survival advantage over conventional therapy, only
                    approximately 25% to 35% of patients with primary progressive or poor-risk
                    recurrent HL can achieve durable remission after ASCT, with disease progressive
                    after transplant accounting for most of the treatment failures. We conducted a
                    pilot study to evaluate the toxicities and efficacy of a tandem transplant
                    approach in this subgroup of patients. Between April 1998 and March 2000, 46
                    patients were enrolled in the study. Eligibility criteria: primary progressive
                    (n = 28) or recurrent HL (n = 18) with at least I of the following poor
                    prognostic factors: first complete remission (CR) &lt; 12 months (n = 15) or
                    extra-nodal disease (n = 4) or B symptoms at relapse (n = 4). The first cycle
                    consisted of melphalan (150 mg/m(2)) alone. The second cycle consisted of
                    fractionated total body irradiation (FTBI) 1200 cGy or BCNU (450 mg/m(2)) in
                    combination with etoposide (60 mg/kg) and cyclophosphamide (100 mg/kg). Of the
                    46 patients, 5 (11%) did not receive the planned tandem transplants because of
                    inadequate stem cell collection for 2 ASCT. After a median of 64 days (25-105),
                    41 patients received the second ASCT. With a median follow-up of 5.3 years
                    (1.6-8.1), the 5-year estimate of overall survival, progression-free survival,
                    and freedom from progression were 54% (95% confidence interval [CI] 40%-69%),
                    49% (95% CI, 34%-63%),and 55% (95%CI, 40%-70%), respectively. Our mature results
                    from this study suggest that in patients with primary progressive or poor risk
                    recurrent HL, this tandem ASCT program is effective and well tolerated and
                    compares favorably with the conventional single transplant. (c) 2007 American
                    Society for Blood and Marrow Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    164RV&#xD;Times Cited: 0&#xD;Cited Reference Count: 17&#xD;Cited References:
                    &#xD; AHMED T, 1997, BONE MARROW TRANSPL, V19, P449&#xD; AISENBERG AC, 1999,
                    BLOOD, V93, P761&#xD; BONFANTE V, 1997, J CLIN ONCOL, V15, P528&#xD; BRICE P,
                    1999, ANN ONCOL, V10, P1485&#xD; BRICE P, 2001, LEUK LYMPHOMA S2, V42, P72&#xD;
                    HORNING SJ, 1997, BLOOD, V89, P801&#xD; JONES RJ, 1990, J CLIN ONCOL, V8,
                    P527&#xD; JOSTING A, 2005, ANN ONCOL, V16, P116&#xD; LAZARUS HM, 2001, BONE
                    MARROW TRANSPL, V27, P387&#xD; LONGO DL, 1992, J CLIN ONCOL, V10, P210&#xD;
                    NADEMANEE A, 1995, BLOOD, V85, P1381&#xD; REECE DE, 1994, BLOOD, V83, P1193&#xD;
                    REECE DE, 1999, BONE MARROW TRANSPL, V23, P1131&#xD; RUSSELL JA, 1989, BONE
                    MARROW TRANSPL, V4, P425&#xD; STIFF PJ, 2003, BIOL BLOOD MARROW TR, V9,
                    P529&#xD; TARELLA C, 2003, CANCER, V97, P2748&#xD; WHEELER C, 1990, J CLIN
                    ONCOL, V8, P648</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246252600011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>956</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">956</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1858</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Economou, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Nursing Research and
                    Education, City of Hope National Medical Center, 1500 East Duarte Road, Duarte,
                    CA 91010-3000, USA. mgrant@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Preparing professional staff to
                        care for cancer survivors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Cancer Surviv</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">J Cancer Surviv</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">98-106</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">1</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">California</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cancer Care
                        Facilities/organization &amp; administration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Curriculum</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Medical Oncology/
                        education</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/
                        mortality/psychology/therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oncologic Nursing/
                        education</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Patient Education as
                        Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Program Evaluation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survivors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Terminal Care/ organization
                        &amp; administration</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1932-2267 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18648949</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">INTRODUCTION: Oncology health care
                    professionals frequently lack the background to implement needed survivorship
                    activities and follow-up care. The purpose of this project is to assist
                    providers in the clarification and initiation of potentially durable changes in
                    survivorship care by developing a health professional curriculum, recruiting
                    participants, implementing the course, conducting course evaluation and
                    following participants&apos; defined goals over time. MATERIALS AND METHODS: The
                    curriculum was developed based on recommendations from the Institute of Medicine
                    Report-From Cancer Patient to Cancer Survivor--Lost in Transition. Three
                    concepts were used to structure the course: cancer survivorship quality of life,
                    changing practice via performance improvement, and principles of adult
                    education. Expert faculty designed and implemented the curriculum and teaching
                    methods using adult learning principles and an interactive approach.
                    Competitively-selected, two-person interdisciplinary teams for the first course
                    (July 12-15, 2006, Pasadena, California) were selected based on stated
                    interests, three projected goals, and letters of commitment from administrators.
                    RESULTS: Participants represented 52 cancer care settings from 28 states. Teams
                    included Nurses (48.1%), Social Workers (20.7%), Physicians (18.8%),
                    Directors/Administrators (6.6%), Psychologists (2.8%), and others (3%). The
                    institutional barriers identified by teams were lack of survivorship knowledge
                    (94 %), financial constraints (61%), lack of administrative support (6%), and
                    staff philosophy that excluded survivorship (15%). Evaluation of content from
                    the first course was consistently positive. CONCLUSIONS: Dissemination of
                    survivorship education for health care professionals stimulates participants to
                    define and begin to implement goals for improving survivors&apos; care.
                    IMPLICATIONS FOR CANCER SURVIVORS: A training program such as the one described
                    provides professional knowledge regarding survivorship that has the potential to
                    facilitate change in the health care that cancer survivors receive thus ideally
                    improving long term health and well being.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2008/09/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>812</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">812</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1856</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hanson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mullan, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spolum, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical
                    Center/Beckman Research Institute, Duarte, CA 91010, USA. mgrant@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Disseminating end-of-life
                        education to cancer centers: overview of program and of evaluation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Cancer Educ</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Cancer
                        Education</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Cancer Educ.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Cancer Educ</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">140-8</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cancer Care Facilities</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Congresses as Topic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Curriculum</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Information Dissemination/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Program Evaluation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Terminally Ill</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">United States</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep&#xD;</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0885-8195 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17760518</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Systematic provision of
                    compassionate end-of-life (EOL) care requires strategic training of health
                    professionals. Disseminating EOL Education to Cancer Centers (DELEtCC) targeted
                    education of interdisciplinary institutional teams. METHODS:
                    Competitively-selected two-person teams participated in a national three-day EOL
                    conference. Nationally recognized faculty created and presented the curriculum.
                    Project faculty supported teams over 18 months as they implemented EOL goals.
                    Conference evaluations were very positive. RESULTS: Independent participant and
                    administrative evaluations reported successful implementation of goals aimed an
                    improving EOL care. CONCLUSIONS: DELEtCC disseminated education representing
                    best EOL practices, and participants used this knowledge to create and implement
                    goals aimed at improving EOL care.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>684</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">684</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1407</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Guha, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xu, Z. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tung, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lanting, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Kalypsys Inc, Dept Pharmacol, San
                    Diego, CA 92121 USA. Beckman Inst City Hope, Dept Diabet, Duarte, CA USA. Pfizer
                    Inc, St Louis, MO USA.&#xD;Guha, M, Kalypsys Inc, Dept Pharmacol, 10420
                    Wateridge Circle, San Diego, CA 92121 USA.&#xD;mguha@kalypsys.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Specific down-regulation of
                        connective tissue growth factor attenuates progression of nephropathy in
                        mouse models of type 1 and type 2 diabetes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Faseb Journal</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Faseb J.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">FASEB Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">FASEB J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">FASEB J</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">FASEB Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">FASEB J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">FASEB J</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">3355-3368</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">diabetic nephropathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CTGF</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">glomerular mesangial
                        cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antisense</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oligonucleotide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN MESANGIAL CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIGH GLUCOSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TGF-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTRACELLULAR-MATRIX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AUTOCRINE ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR CTGF</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CCN FAMILY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0892-6638</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249781600036</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Diabetic nephropathy ( DN) remains a
                    major complication in both type 1 and type 2 diabetes. Systemic administration
                    of antitransforming growth factor-beta ( TGF-beta) antibody has shown some
                    promise in mouse models of DN. However, chronic blockade of the multifunctional
                    TGB-beta could be problematic. Several downstream effects of TGF-beta are
                    mediated by connective tissue growth factor ( CTGF), which is up-regulated in
                    several renal cells and secreted in the urine in the diabetic state. Using
                    murine models of DN ( type 1 and type 2) and a CTGF antisense oligonucleotide (
                    ASO) of novel chimeric chemistry, we evaluated the specific role of this target
                    in DN. In the type 1 model of DN, C57BL6 mice were made diabetic using
                    streptozotocin injections and hyperglycemic animals were treated with CTGF ASOs
                    ( 20 mg/kg/2 qw) for 4 months. ASO, but not mismatch control oligonucleotide,
                    -treated animals showed significant reduction in target CTGF expression in the
                    kidney with a concomitant decrease in proteinuria and albuminuria. Treatment
                    with the CTGF ASO for 8 wk reduced serum creatinine and attenuated urinary
                    albuminuria and proteinuria in diabetic db/db mice, a model of type 2 DN. The
                    ASO also reduced expression of genes involved in matrix expansion such as
                    fibronectin and collagen ( I and IV) and an inhibitor of matrix degradation,
                    PAI-1, in the renal cortex, contributing to significant reversal of mesangial
                    expansion in both models of DN. Pathway analyses demonstrated that
                    diabetes-induced phosphorylation of p38 MAPK and its downstream target CREB was
                    also inhibited by the ASO. Our results strongly suggest that blocking CTGF using
                    a chimeric ASO holds substantial promise for the treatment of DN. - Guha, M.,
                    Xu, Z-G., Tung, D., Lanting, L., Natarajan, R. Specific down-regulation of
                    connective tissue growth factor attenuates progression of nephropathy in mouse
                    models of type 1 and type 2 diabetes.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    215BE&#xD;Times Cited: 0&#xD;Cited Reference Count: 41</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249781600036 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>422</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">422</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1406</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gunning, P. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Katt, W. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Glenn, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Siddique, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sebti, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Turkson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamilton, A. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Yale Univ, Dept Chem, New Haven, CT
                    06520 USA. Univ Cent Florida, Dept Mol Biol &amp; Microbiol, Burnett Coll Biomed
                    Sci, Orlando, FL 32816 USA. City Hope Natl Med Ctr, Duarte, CA USA. H Lee
                    Moffitt Canc Ctr &amp; Res Inst, Drug Discovery Program, Tampa, FL
                    USA.&#xD;Hamilton, AD, Yale Univ, Dept Chem, New Haven, CT 06520 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Isoform selective inhibition of
                        STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural
                        recognition of STAT SH2 domains</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bioorganic &amp; Medicinal
                        Chemistry Letters</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Bioorganic &amp; Medicinal
                        Chemistry Letters</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Bioorg. Med. Chem. Lett.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Bioorg Med Chem Lett</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1875-1878</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">STAT1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STAT3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">peptidomimetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anti-cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SH2 domain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">recognition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNAL TRANSDUCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULAR TARGETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0960-894X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245827900008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The identification of constitutively
                    activated STAT (Signal Transducers and Activators of Transcription) proteins in
                    aberrant cell signaling pathways has led to investigations targeting the
                    selective disruption of specific STAT isoforms directly associated with
                    oncogenisis. We have identified, through the design of a library of
                    peptidomimetic inhibitors, agents that selectively disrupt STAT1 or STAT3
                    homo-dimerization at low micromolar concentrations. ISS840 has 20-fold higher
                    inhibition of STAT1 homo-dimerization (IC50 value of 31 mu M) relative to STAT3
                    (IC50 value of 560 mu M). (c) 2007 Published by Elsevier Ltd.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    158XE&#xD;Times Cited: 0&#xD;Cited Reference Count: 19&#xD;Cited References:
                    &#xD; *ACC, QSAR MOD CER VERS 4&#xD; BECKER S, 1998, NATURE, V394, P145&#xD;
                    BOWMAN T, 2000, ONCOGENE, V19, P2489&#xD; BROMBERG J, 2000, ONCOGENE, V19,
                    P2468&#xD; BUETTNER R, 2002, CLIN CANCER RES, V8, P945&#xD; CHEN XM, 1998, CELL,
                    V93, P827&#xD; COLEMAN DR, 2005, J MED CHEM, V48, P6661&#xD; DARNELL JE, 1997,
                    SCIENCE, V277, P1630&#xD; HEIM MH, 1995, SCIENCE, V267, P1347&#xD; JIN N, 2005,
                    ANTI-CANCER DRUG, V16, P601&#xD; JONES G, 1997, J MOL BIOL, V267, P727&#xD;
                    MERAZ MA, 1996, CELL, V84, P431&#xD; MOA X, 2005, J MOL CELL, V17, P761&#xD;
                    SHAO H, 2003, CANCER RES, V63, P3923&#xD; SHUAI K, 1993, SCIENCE, V261,
                    P1744&#xD; TURKSON J, 2000, ONCOGENE, V19, P6613&#xD; TURKSON J, 2001, J BIOL
                    CHEM, V276, P45443&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P261&#xD;
                    WIEDERKEHRADAM M, 2003, J BIOL CHEM, V278, P16117</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245827900008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>423</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">423</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1405</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Guo, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tommasi, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yee, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dammann, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Biol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst,
                    Div Virol, Duarte, CA 91010 USA. Univ Halle Wittenberg, Fac Med, D-06097 Halle,
                    Germany.&#xD;Pfeifer, GP, City Hope Natl Med Ctr, Beckman Res Inst, Div Biol,
                    Duarte, CA 91010 USA.&#xD;gpfeifer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">RASSF1A is part of a complex
                        similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor
                        network</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Current Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Current Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Curr. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Curr Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">700-705</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-CYCLE EXIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTES APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATION ARREST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN HOMOLOG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LATS1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIPPO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0960-9822</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245864000026</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The Ras Association Domain Family 1A
                    (RASSF1A) gene is one of the most frequently silenced genes in human cancer.
                    RASSF1A has been shown to interact with the proapoptotic kinase MST1. Recent
                    work in Drosophila has led to the discovery of a new tumor-suppressor pathway
                    involving the Drosophila MST1 and MST2 ortholog, Hippo, as well as the
                    Lats/Warts serine/threonine kinase and a protein named Salvador (Sav). Little is
                    known about this pathway in mammalian cells. We report that complexes consisting
                    of RASSF1 A, MST2, WW45 (the human ortholog of Sav), and LATS1 exist in human
                    cells. MST2 enhances the RASSF1A-WW45 interaction, which requires the C-terminal
                    SARAH domain of both proteins. Components of this complex are localized at
                    centrosomes and spindle poles from interphase to telophase and at the midbody
                    during cytokinesis. Both RASSF1 A and WW45 activate MST2 by promoting MST2
                    autophosphorylation and LATS1 phosphorylation. Mitosis is delayed in Rassfla-/-
                    mouse embryo fibroblasts and frequently results in cytokinesis failure, similar
                    to what has been observed for LATS1-deficlent cells. RASSF1A, MST2, or WW45 can
                    rescue this defect. The complex of RASSF1A, MST2, WW45, and LATS1 consists of
                    several tumor suppressors, is conserved in mammalian cells, and appears to be
                    involved in controlling mitotic exit.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    159KG&#xD;Times Cited: 0&#xD;Cited Reference Count: 26&#xD;Cited References:
                    &#xD; AGATHANGGELOU A, 2005, CANCER RES, V65, P3497&#xD; AVRUCH J, 2005, METHOD
                    ENZYMOL, V407, P290&#xD; BOTHOS J, 2005, CANCER RES, V65, P6568&#xD; CHAN EH,
                    2005, ONCOGENE, V24, P2076&#xD; DAMMANN R, 2000, NAT GENET, V25, P315&#xD;
                    HARVEY KF, 2003, CELL, V114, P457&#xD; HERGOVICH A, 2006, NAT REV MOL CELL BIO,
                    V7, P253&#xD; IIDA S, 2004, ONCOGENE, V23, P5266&#xD; KANGOSINGH M, 2002,
                    DEVELOPMENT, V129, P5719&#xD; KHOKHLATCHEV A, 2002, CURR BIOL, V12, P253&#xD;
                    KUNINAKA S, 2005, ONCOGENE, V24, P5287&#xD; NISHIYAMA Y, 1999, FEBS LETT, V459,
                    P159&#xD; OH HJ, 2006, CANCER RES, V66, P2562&#xD; PANTALACCI S, 2003, NAT CELL
                    BIOL, V5, P921&#xD; POLESELLO C, 2006, CURR BIOL, V16, P2459&#xD; PRASKOVA M,
                    2004, BIOCHEM J 2, V381, P453&#xD; SCHEEL H, 2003, CURR BIOL, V13, R899&#xD;
                    STJOHN MAR, 1999, NAT GENET, V21, P182&#xD; STORCHOVA Z, 2004, NAT REV MOL CELL
                    BIO, V5, P45&#xD; TAKAHASHI Y, 2005, CLIN CANCER RES, V11, P1380&#xD; TAPON N,
                    2002, CELL, V110, P467&#xD; TOMMASI S, 2005, CANCER RES, V65, P92&#xD; UDAN RS,
                    2003, NAT CELL BIOL, V5, P914&#xD; WU S, 2003, CELL, V114, P445&#xD; YANG XL,
                    2001, ONCOGENE, V20, P6516&#xD; YANG XL, 2004, NAT CELL BIOL, V6, P609</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245864000026 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>781</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">781</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1403</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Gurney, J. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tersak, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ness, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Landier, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Matthay, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmidt, M. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Michigan, Dept Pediat, Child
                    Evalut &amp; Res Unit, Ann Arbor, MI 48109 USA. Univ Pittsburgh, Dept Pediat,
                    Div Hematol Oncol, Pittsburgh, PA 15260 USA. St Jude Childrens Hosp, Dept
                    Epidemiol &amp; Canc Control, Memphis, TN 38105 USA. City Hope Natl Med Ctr, Div
                    Populat Sci, Duarte, CA 91010 USA. Univ Calif San Francisco, Dept Pediat, Pediat
                    Hematol Oncol, San Francisco, CA 94143 USA. Univ Illinois, Dept Pediat, Div
                    Pediat Hematol Oncol, Chicago, IL USA.&#xD;Gurney, JG, Univ Michigan, Dept
                    Pediat, Child Evalut &amp; Res Unit, 300 N Ingalls St,ROom 6L02, Ann Arbor, MI
                    48109 USA.&#xD;jamegum@umich.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Hearing loss, quality of life,
                        and academic problems in long-term neuroblastoma survivors: Report from the
                        Children&apos;s Oncology Group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pediatrics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatrics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatrics</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatrics</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">E1229-E1236</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">120</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cisplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">education</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">psychosocial problems</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment late effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ototoxicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENERIC CORE SCALES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OTOTOXICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RELIABILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VALIDITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBOPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PERFORMANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CISPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LANGUAGE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0031-4005</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250618900057</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVES. Among a cohort of
                    long-term neuroblastoma survivors, our aims were to (1) assess the association
                    between treatment intensity and parent-reported hearing loss in the child, (2)
                    evaluate the strength of the association between hearing loss and
                    parent-reported academic and psychosocial difficulties in the child, and (3)
                    examine the association between parent-reported academic and psychosocial
                    difficulties in the child and the child&apos;s self-reported quality of life.
                    PATIENTS AND METHODS. Through a mailed survey that included the Pediatric
                    Quality of Life Inventory 4.0 and an outcomes questionnaire for parents, we
                    evaluated 137 children (aged 8-17 years) who were previously enrolled in 1 of 2
                    Children&apos;s Cancer Group neuroblastoma clinical studies. RESULTS. Childhood
                    survivors of neuroblastoma who had prevalent hearing loss, as reported by their
                    parents, had at least twice the risk of an identified problem with reading
                    skills, math skills, and/or attention and a similarly higher risk of a general
                    learning disability and/or special educational needs than did neuroblastoma
                    survivors without hearing loss. Consistent with this finding, hearing loss was
                    associated with a 10-point-lower mean score in the school-functioning scale of
                    the Pediatric Quality of Life Inventory 4.0. We also observed a clear pattern of
                    poorer self-reported quality-of-life scores among children with parent-reported
                    academic and psychosocial problems compared with those without such problems,
                    particularly with school functioning, even after controlling for reported
                    hearing loss. CONCLUSIONS. We found evidence that long-term neuroblastoma
                    survivors, especially those with hearing loss, are at elevated risk for academic
                    learning problems and psychosocial difficulties. We also found strong
                    concordance between parent-reported learning problems in the child and
                    indications of distress in the child&apos;s self-reported quality of
                    life.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    226WJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 32&#xD;Cited References:
                    &#xD; BARR RD, 2000, J CLIN ONCOL, V18, P3280&#xD; BERG AL, 1999, LARYNGOSCOPE,
                    V109, P1806&#xD; BERGERON C, 2005, PEDIATR BLOOD CANCER, V45, P32&#xD; BERTOLINI
                    P, 2004, J PEDIAT HEMATOL ONC, V26, P649&#xD; BESS FH, 1998, EAR HEARING, V19,
                    P339&#xD; BHAT SR, 2005, J CLIN ONCOL, V23, P5493&#xD; BROCK PR, 1992, BR J CANC
                    S, V18, S36&#xD; BRODEUR GM, 2006, PRINCIPLES PRACTICE, P895&#xD; DAVIS JM,
                    1986, J SPEECH HEAR DISORD, V51, P53&#xD; DUTTON SC, 1996, INT J RADIAT ONCOL,
                    V36, P167&#xD; GILMERKNIGHT KR, 2005, J CLIN ONCOL, V23, P8588&#xD; GOODMAN MT,
                    1999, CANC INCIDENCE SURVI, P65&#xD; GURNEY JG, 1996, CANCER, V78, P532&#xD;
                    GURNEY JG, 1997, J PEDIAT HEMATOL ONC, V19, P428&#xD; HORWITZ AR, 2002, J ACOUST
                    SOC AM 1, V111, P409&#xD; KUSHNER BH, 2006, CANCER, V107, P417&#xD;
                    LANVERSKAMINSKY C, 2006, PEDIATR BLOOD CANCER, V47, P183&#xD; LAVERDIERE C,
                    2005, NEUROBLASTOMA, P277&#xD; LAVERDIERE C, 2005, PEDIATR BLOOD CANCER, V45,
                    P324&#xD; MATTHAY KK, 1999, NEW ENGL J MED, V341, P1165&#xD; NESS KK, 2005, ANN
                    INTERN MED, V143, P639&#xD; NICKERSON HJ, 2000, J CLIN ONCOL, V18, P477&#xD;
                    NORMAN GR, 2000, PATH ANAL STRUCTURAL, P178&#xD; PARSONS SK, 1998, BONE MARROW
                    TRANSPL, V22, P669&#xD; ROLAND JT, 1998, OTOLARYNGOLOGY HEAD, V4, P3186&#xD;
                    ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P147&#xD; SAVITZ DA, 1995, AM J
                    EPIDEMIOL, V142, P904&#xD; SCHMIDT ML, 2000, J CLIN ONCOL, V18, P1260&#xD;
                    STELMACHOWICZ PG, 2004, ARCH OTOLARYNGOL, V130, P556&#xD; VARNI JW, 2001, MED
                    CARE, V39, P800&#xD; VARNI JW, 2002, CANCER, V94, P2090&#xD; VARNI JW, 2006,
                    QUAL LIFE RES, V15, P203</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250618900057 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>199</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">199</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">979</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hadjistavropoulos,
                            T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Herr, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Turk, D. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fine, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dworkin, R. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Helme, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jackson, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parmelee, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rudy, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Beattie, B. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chibnall, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Craig, K. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fillingim, R. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gagliese, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gallagher, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gibson, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Harrison, E. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Katz, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Keefe, F. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lieber, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lussier, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmader, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tait, R. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiner, D. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Regina, Dept Psychol, Regina,
                    SK S4S 0A2, Canada. Univ Regina, Ctr Aging &amp; Hlth, Regina, SK S4S 0A2,
                    Canada. Univ Saskatchewan, Sch Phys Therapy, Saskatoon, SK, Canada. Univ British
                    Columbia, Dept Psychol, Vancouver, BC, Canada. Univ British Columbia, Vancouver,
                    BC V5Z 1M9, Canada. Univ British Columbia, Div Palliat Care, Vancouver, BC V5Z
                    1M9, Canada. York Univ, Sch Kinesiol &amp; Hlth Studies, Toronto, ON M3J 2R7,
                    Canada. Univ Hlth Network, Toronto, ON, Canada. McGill Univ, Div Geriatr Med,
                    Montreal, PQ, Canada. McGill Univ, Pain Ctr, Montreal, PQ, Canada. Univ Iowa,
                    Coll Nursing, Iowa City, IA 52242 USA. Univ Washington, Dept Anaesthesiol,
                    Seattle, WA 98195 USA. Univ Utah, Pain Res Ctr, Salt Lake City, UT USA. Univ
                    Utah, Dept Pharmacotherapy, Salt Lake City, UT USA. Univ Rochester, Sch Med
                    &amp; Dent, Rochester, NY USA. Univ Melbourne, Dept Med, Melbourne, Vic,
                    Australia. Natl Ageing Res Inst, Melbourne, Vic, Australia. St Vincents Hlth,
                    Melbourne, Vic, Australia. Emory Univ, Sch Med, Dept Psychiat &amp; Behav SCI
                    07/01, Atlanta, GA USA. Univ Pittsburgh, Dept Anaesthesiol, Pittsburgh, PA USA.
                    Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA USA. St Louis Univ, Sch Med, St
                    Louis, MO USA. City Hope Natl Med Ctr, Los Angeles, CA USA. Univ Calif Los
                    Angeles, David Geffen Sch Med, Los Angeles, CA USA. Univ Florida, Coll Dent,
                    Gainesville, FL USA. Duke Univ, Med Ctr, Dept Psychiat &amp; Behav SCI 07/01,
                    Durham, NC USA. Duke Univ, Div Geriatr, Durham, NC USA. Durham VA Med Ctr,
                    Durham, NC USA.&#xD;Hadjistavropoulos, T, Univ Regina, Dept Psychol, Regina, SK
                    S4S 0A2, Canada.&#xD;hadjistt@uregina.ca</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An interdisciplinary expert
                        consensus statement on assessment of pain in older persons</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Journal of Pain</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Journal of Pain</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. J. Pain</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin J Pain</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">S1-S43</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">23</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">Supp 1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">older adults</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">elderly</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dementia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LOW-BACK-PAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NURSING-HOME RESIDENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMPACT MEASUREMENT
                        SCALES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMMUNITY-DWELLING
                        ELDERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNIVERSITIES
                        OSTEOARTHRITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH-ASSESSMENT
                        QUESTIONNAIRE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RHEUMATOID-ARTHRITIS
                        PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >WESTERN-ONTARIO-UNIVERSITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PASSIVE COPING
                        STRATEGIES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0749-8047</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243329900001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">This paper represents an
                    expert-based consensus statement on pain assessment among older adults. It is
                    intended to provide recommendations that will be useful for both researchers and
                    clinicians. Contributors were identified based on literature prominence and with
                    the aim of achieving a broad representation of disciplines. Recommendations are
                    provided regarding the physical examination and the assessment of pain using
                    self-report and observational methods (suitable for seniors with dementia). In
                    addition, recommendations are provided regarding the assessment of the physical
                    and emotional functioning of older adults experiencing pain. The literature
                    underlying the consensus recommendations is reviewed. Multiple revisions led to
                    final reviews of 2 complete drafts before consensus was reached.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123XI&#xD;Times Cited: 0&#xD;Cited Reference Count: 412&#xD;Cited References:
                    &#xD; *AM GER SOC PAN PE, 2002, J AM GERIATR SOC, V50, S205&#xD; *AM MED DIR
                    ASS, 2003, PAIN MAN LONG TERM C&#xD; *AM PAIN SOC, 2003, PRINC AN US TREATM
                    A&#xD; *AM PSYCH ASS, 2000, DIAGN STAT MAN MENT&#xD; *AM SOC HLTH SYST, 1996, AM
                    J HEALTH-SYST PH, V53, P1713&#xD; *AUSTR PAIN SOC, 2005, PAIN RES AG CAR
                    FAC&#xD; *WHO, 1997, J AGING PHYS ACTIV, V5, P2&#xD; *WHO, 2001, INT
                    CLASSIFICATION F&#xD; ABBEY J, 2004, INT J PALLIAT NURS, V10, P6&#xD; ACHAT H,
                    2000, ANN BEHAV MED, V22, P127&#xD; AFFLECK G, 1991, HEALTH PSYCHOL, V10,
                    P419&#xD; AGUEROTORRES H, 1998, INT J GERIATR PSYCH, V13, P755&#xD; ANDERSEN G,
                    1995, PAIN, V61, P187&#xD; ASMUNDSON GJG, 2004, PAIN PSYCHOL PERSPEC, P35&#xD;
                    ATTAL N, 1999, ACTA NEUROL SCAND S, V173, P12&#xD; BACKONJA MM, 1998, NEUROL
                    CLIN, V16, P775&#xD; BACKONJA MM, 2003, CLIN J PAIN, V19, P315&#xD; BAKER FM,
                    2001, COMMUNITY MENT HLT J, V37, P31&#xD; BANDURA A, 1997, SELF EFFICACY
                    EXERCI&#xD; BARON R, 1993, BRAIN, V116, P1477&#xD; BARON R, 1999, NEUROLOGY,
                    V53, P548&#xD; BARON R, 2000, CLIN J PAIN S, V16, S12&#xD; BEAN B, 1993, HERPES
                    ZOSTER POSTHE, P27&#xD; BEATON DE, 2001, J CLIN EPIDEMIOL, V54, P1204&#xD; BECK
                    AT, 1978, DEPRESSION INVENTORY&#xD; BECK AT, 1988, J CONSULT CLIN PSYCH, V56,
                    P893&#xD; BECK JG, 2003, PSYCHOL ASSESSMENT, V15, P184&#xD; BELLAMY N, 1988, J
                    RHEUMATOL, V15, P1833&#xD; BELLAMY N, 1989, SEMIN ARTHRITIS RHEU, V18, P14&#xD;
                    BENESH LR, 1997, HOME HEALTHCARE NURS, V15, P207&#xD; BENNETT D, 2005, PHARMACOL
                    THERAPEUT, V30, P296&#xD; BENNETT GJ, 1998, HOSP PRACT, V33, P101&#xD; BENNETT
                    GJ, 1998, HOSP PRACT, V33, P107&#xD; BENNETT GJ, 1998, HOSP PRACT, V33, P95&#xD;
                    BENNETT M, 2001, PAIN, V92, P147&#xD; BENNETT MI, 2005, J PAIN, V6, P149&#xD;
                    BERGER A, 2002, PRINCIPLES PRACTICE, P53&#xD; BERGH I, 2000, AGING-CLIN EXP RES,
                    V12, P380&#xD; BERGH I, 2001, AGING-CLIN EXP RES, V13, P355&#xD; BERIC A, 1998,
                    NEUROL CLIN, V16, P899&#xD; BERKMAN LF, 1993, J CLIN EPIDEMIOL, V46, P1129&#xD;
                    BESSON JM, 1999, LANCET, V353, P1610&#xD; BIERI D, 1990, PAIN, V41, P139&#xD;
                    BLALOCK SJ, 1995, ANN BEHAV MED, V17, P107&#xD; BOHANNON RW, 1997, AGE AGEING,
                    V26, P15&#xD; BOIVIE J, 1989, PAIN, V37, P173&#xD; BOIVIE J, 1992, HYPERALGESIA
                    ALLODYN, P363&#xD; BOMBARDIER C, 1995, MED CARE, V33, P131&#xD; BOOTHBY JL,
                    2004, PAIN, V109, P500&#xD; BOUHASSIRA D, 2004, PAIN, V108, P248&#xD; BOUHASSIRA
                    D, 2005, PAIN, V114, P29&#xD; BRADBURN NM, 1969, STRUCTURE PSYCHOL WE&#xD;
                    BRENES GA, 2002, J BEHAV MED, V25, P219&#xD; BRODERICK JE, 2004, PAIN, V109,
                    P94&#xD; BROOK RH, 2000, INT J QUAL HEALTH C, V12, P281&#xD; BROWN GK, 1987,
                    PAIN, V31, P53&#xD; BRUCE B, 2004, ARTHRIT RHEUM-ARTHR, V51, P730&#xD; BUCKELEW
                    SP, 1990, PAIN, V42, P287&#xD; BUFFUM MD, 2004, J AM GERIATR SOC, V52,
                    P1093&#xD; CAMPBELL LC, 2003, BIOL PSYCHIAT, V54, P399&#xD; CANHAO H, 2001, CLIN
                    RHEUMATOL, V20, P119&#xD; CASTEN RJ, 1995, PAIN, V61, P271&#xD; CHANDLER JM,
                    1998, ARCH PHYS MED REHAB, V79, P24&#xD; CHIBNALL JT, 1994, ARCH PHYS MED REHAB,
                    V75, P1082&#xD; CHIBNALL JT, 2001, PAIN, V92, P173&#xD; CHIBNALL JT, 2005, J AM
                    GERIATR SOC, V53, P1921&#xD; CLEELAND CS, 1994, ANN ACAD MED SINGAP, V23,
                    P129&#xD; CLOSS SJ, 2002, INT J NURS STUD, V39, P563&#xD; CLOSS SJ, 2004, J PAIN
                    SYMPTOM MANAG, V27, P196&#xD; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99&#xD;
                    COOK AJ, 2001, PAIN RES MANAGE, V6, P142&#xD; COPLAN PM, 2004, J PAIN, V5,
                    P344&#xD; CORRAN TM, 1994, P 7 WORLD C PAIN SEA, P895&#xD; CORRAN TM, 1997, CLIN
                    J PAIN, V13, P207&#xD; COSTA P, 1992, REVISED NEO PERSONAL&#xD; COSTA PT, 1986,
                    PSYCHOL AGING, V1, P144&#xD; COVIC T, 2000, RHEUMATOLOGY, V39, P1027&#xD; CRAIG
                    KD, 1992, APS J, V1, P153&#xD; CREAMER P, 1999, ARTHRIT CARE RES, V12, P3&#xD;
                    CREAMER P, 1999, J RHEUMATOL, V26, P1785&#xD; CRUCCU G, 2004, EUR J NEUROL, V11,
                    P153&#xD; CUTRONA CE, 1987, ADV PERSONAL RELATIO, V1, P37&#xD; DALTROY LH, 1995,
                    AM J PUBLIC HEALTH, V85, P558&#xD; DAVIES GM, 1999, ARTHRIT CARE RES, V12,
                    P172&#xD; DECKER SA, 2003, PAIN MANAGE NURS, V4, P77&#xD; DEFILIPPIS LG, 2004,
                    INT J CLIN PHARM RES, V24, P103&#xD; DEKKER J, 1993, BEHAV RES THER, V31,
                    P203&#xD; DESAI AK, 2004, CNS DRUGS, V18, P853&#xD; DIENER E, 1985, J PERS
                    ASSESS, V49, P71&#xD; DODGE HH, 2003, ARCH NEUROL-CHICAGO, V60, P253&#xD; DODGE
                    HH, 2005, GERONTOLOGIST, V45, P222&#xD; DOHERTY M, 1988, RHEUM DIS CLIN N AM,
                    V14, P395&#xD; DOUZJIAN M, 1998, ANN LONG TERM CARE, V6, P174&#xD; DUNCAN PW,
                    1990, J GERONTOL, V45, P192&#xD; DUONG BD, 2005, J AM GERIATR SOC, V53,
                    P687&#xD; DWORKIN RH, 2001, HDB PAIN ASSESSMENT, P519&#xD; DWORKIN RH, 2003,
                    ARCH NEUROL-CHICAGO, V60, P1524&#xD; DWORKIN RH, 2005, PAIN, V113, P9&#xD;
                    EARLEY CJ, 2000, J NEUROSCI RES, V62, P623&#xD; ECCLESTON C, 1997, PAIN, V72,
                    P209&#xD; EKMAN P, 1978, INVESTIGATORS GUIDE&#xD; EKMAN P, 2002, NEW VERSION
                    FACIAL A&#xD; ELL K, 2005, HOME HEALTH CARE SER, V24, P1&#xD; ERSEK M, 2003,
                    CLIN J PAIN, V19, P156&#xD; ERSEK M, 2004, BMC GERIATR, V4, P7&#xD; EVERS AWM,
                    2003, BEHAV RES THER, V41, P1295&#xD; FAIRBANK JCT, 1980, PHYSIOTHERAPY, V66,
                    P271&#xD; FALCONER J, 1991, J AM GERIATR SOC, V39, P695&#xD; FAM AG, 1981, CAN
                    MED ASSOC J, V124, P545&#xD; FARRELL MJ, 1996, CLIN J PAIN, V12, P6&#xD; FAUCHER
                    M, 2004, JOINT BONE SPINE, V71, P121&#xD; FELDT KS, 1998, J AM GERIATR SOC, V46,
                    P1079&#xD; FELDT KS, 2000, PAIN MANAGEMENT NURS, V1, P13&#xD; FELSON DT, 1987,
                    ARTHRITIS RHEUM, V30, P914&#xD; FELSON DT, 1989, J RHEUMATOL, V16, P1241&#xD;
                    FELTON BJ, 1984, J CONSULT CLIN PSYCH, V52, P343&#xD; FERRELL BA, 1990, J AM
                    GERIATR SOC, V38, P409&#xD; FERRELL BA, 1995, J PAIN SYMPTOM MANAG, V10,
                    P591&#xD; FERRELL BA, 1998, J AM GERIATR SOC, V46, P635&#xD; FERRELL BA, 2000, J
                    AM GERIATR SOC, V48, P1669&#xD; FERRELL BR, 2001, J PAIN, V2, P171&#xD;
                    FILLENBAUM GG, 1988, MULTIDIMENSIONAL FUN&#xD; FISHER SE, 2006, GERONTOLOGIST,
                    V46, P81&#xD; FOLKMAN S, 1985, J PERS SOC PSYCHOL, V48, P150&#xD; FOLKMAN S,
                    2004, ANNU REV PSYCHOL, V55, P745&#xD; FOLLICK MJ, 1984, PAIN, V19, P373&#xD;
                    FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189&#xD; FORBES WF, 1991, CAN J PUBLIC
                    HEALTH, V82, P240&#xD; FRAZIER LD, 1999, AGING MENT HEALTH, V3, P213&#xD;
                    FUCHSLACELLE S, 2004, PAIN MANAG NURS, V5, P37&#xD; FUCHSLACELLE S, 2005, 11
                    WORLD C PAIN SEAT, P84&#xD; GAGLIESE L, 1997, PAIN, V70, P3&#xD; GAGLIESE L,
                    2000, PAIN RES MANAGEMENT, V5, P251&#xD; GAGLIESE L, 2001, HDB PAIN ASSESSMENT,
                    P119&#xD; GAGLIESE L, 2003, PAIN, V103, P11&#xD; GAGLIESE L, 2003, PAIN, V104,
                    P597&#xD; GAGLIESE L, 2005, PAIN, V117, P412&#xD; GALER BS, 1997, NEUROLOGY,
                    V48, P332&#xD; GALLO JJ, 1998, J GERONTOL B-PSYCHOL, V53, P277&#xD; GALLOWAY S,
                    1999, J GERONTOL NURS, V25, P34&#xD; GAMBLE GE, 2002, EUR J PAIN-LONDON, V6,
                    P467&#xD; GENDREAU M, 2003, BEST PRACT RES CL RH, V17, P575&#xD; GERWIN RD,
                    2001, CURR PAIN HEADACHE R, V5, P412&#xD; GIBSON SJ, 1994, DISABIL REHABIL, V16,
                    P127&#xD; GIBSON SJ, 2000, PAIN, V85, P375&#xD; GIBSON SJ, 2001, PAIN RES MANAG,
                    V6, P126&#xD; GIBSON SJ, 2005, PAIN ELDERLY, P87&#xD; GIL KM, 1990, BEHAV THER,
                    V21, P349&#xD; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304&#xD; GLOTH FM,
                    2001, J AM MED DIR ASS, V2, P110&#xD; GOUBERT L, 2004, PAIN, V107, P234&#xD;
                    GRAFFRADFORD SB, 2004, CURR PAIN HEADACHE R, V8, P463&#xD; GRAFTON KV, 2005,
                    CLIN J PAIN, V21, P73&#xD; GREEN S, 2006, PAIN RES MANAGE, V11, P112&#xD;
                    GUARNERA S, 1987, J GERONTOL, V42, P594&#xD; GUILLEMIN F, 1997, ARTHRITIS RHEUM,
                    V40, P1267&#xD; GUNNARSDOTTIR S, 2002, PAIN, V99, P385&#xD; GURALNIK JM, 1994, J
                    GERONTOL, V49, M85&#xD; HAAVARDSHOLM EA, 2000, J RHEUMATOL, V27, P2810&#xD;
                    HADJISTAVROPOUL.T, 1998, PAIN RES MANAGE, V3, P145&#xD; HADJISTAVROPOUL.T, 2005,
                    PAIN ELDERLY, P135&#xD; HADJISTAVROPOULOS T, 1997, PAIN CLINIC, V10, P71&#xD;
                    HADJISTAVROPOULOS T, 2000, CLIN J PAIN, V16, P54&#xD; HADJISTAVROPOULOS T, 2002,
                    BEHAV RES THER, V40, P551&#xD; HADJISTAVROPOULOS T, 2002, EUR J PAIN-LONDON, V6,
                    P179&#xD; HAN SC, 1997, REGION ANESTH, V22, P89&#xD; HANKS GW, 1998, OXFORD TXB
                    PALLIATIV, P257&#xD; HARRISON AL, 2004, PHYS THER, V84, P822&#xD; HARTIKAINEN
                    SA, 2005, ANN PHARMACOTHER, V39, P11&#xD; HASSETT AL, 2000, ARTHRITIS RHEUM,
                    V43, P2493&#xD; HAWK C, 2000, J AM GERIATR SOC, V48, P534&#xD; HELME RD, 1996,
                    CLIN GERIATR MED, V12, P563&#xD; HELME RD, 1998, AUST J AGEING, V17, P5&#xD;
                    HERR K, 2004, PAIN MANAG NURS S1, V5, P9&#xD; HERR K, 2005, PAIN OLDER ADULTS,
                    P111&#xD; HERR K, 2006, J PAIN SYMPTOM MANAG, V31, P170&#xD; HERR KA, 1993, APPL
                    NURS RES, V6, P39&#xD; HERR KA, 1998, CLIN J PAIN, V14, P29&#xD; HERR KA, 2001,
                    CLIN GERIATR MED, V17, P457&#xD; HERR KA, 2004, CLIN J PAIN, V20, P207&#xD;
                    HICKS CL, 2001, PAIN, V93, P173&#xD; HOLM MB, 1998, ARTHRIT CARE RES, V11,
                    P346&#xD; HOPMANROCK M, 1996, J RHEUMATOL, V23, P1037&#xD; HOPMANROCK M, 1998,
                    ARTHRIT CARE RES, V11, P243&#xD; HOYL MT, 1999, J AM GERIATR SOC, V47, P873&#xD;
                    HUGHES SL, 1991, ARTHRITIS RHEUM, V34, P856&#xD; HURLEY AC, 1992, RES NURS
                    HEALTH, V15, P369&#xD; JAKOBSSON U, 2005, EUR J PAIN&#xD; JARVIK JJ, 2001,
                    SPINE, V26, P1158&#xD; JENSEN MP, 1989, ANN M SOC BEH MED SA&#xD; JENSEN MP,
                    1995, PAIN, V60, P203&#xD; JENSEN MP, 2001, J CONSULT CLIN PSYCH, V69, P655&#xD;
                    JENSEN MP, 2005, J PAIN, V6, P98&#xD; JENSEN TS, 2003, PAIN, V102, P1&#xD; JETTE
                    AM, 1987, J RHEUMATOL, V14, P15&#xD; JOKL P, 1990, RHEUM DIS CLIN N AM, V16,
                    P837&#xD; JONES GT, 2005, PAIN OLDER PERSONS, P3&#xD; KAASALAINEN S, 2003, CAN J
                    NURS RES, V35, P58&#xD; KAASALAINEN S, 2004, CLIN NURSING RES, V13, P199&#xD;
                    KEEFE FJ, 1982, BEHAV THER, V13, P363&#xD; KEEFE FJ, 1987, J CONSULT CLIN PSYCH,
                    V55, P208&#xD; KEEFE FJ, 1992, J CONSULT CLIN PSYCH, V60, P528&#xD; KEEFE FJ,
                    2004, PAIN, V110, P539&#xD; KELLER S, 2004, CLIN J PAIN, V20, P309&#xD; KELLNER
                    R, 1986, ILLNESS ATTITUDE SCA, P319&#xD; KEMP B, 1999, REHABIL PSYCHOL, V44,
                    P235&#xD; KEMP CA, 2005, BMC GERIATR, V5, P12&#xD; KENNEY RA, 1982, PHYSL AGING
                    SYNOPSIS&#xD; KERNS RD, 1985, PAIN, V23, P345&#xD; KERNS RD, 2002, ANN BEHAV
                    MED, V24, P100&#xD; KING L, 2005, PAIN OLDER PERSONS, P403&#xD; KING MB, 2000,
                    PHYS THER, V80, P8&#xD; KIRKWOOD TBL, 1998, BROCKLEHURSTS TXB GE, P45&#xD;
                    KOBASA SC, 1979, J PERS SOC PSYCHOL, V37, P1&#xD; KOENIG HG, 1988, J AM GERIATR
                    SOC, V36, P699&#xD; KOVACH CR, 1999, J PAIN SYMPTOM MANAG, V18, P412&#xD; KRAUSE
                    SJ, 2003, CLIN J PAIN, V19, P306&#xD; KROENKE K, 2001, J GEN INTERN MED, V16,
                    P606&#xD; KRULEWITCH H, 2000, J AM GERIATR SOC, V48, P1607&#xD; LACHAPELLE DL,
                    2005, CAN J BEHAV SCI 07/01, V37, P123&#xD; LACHMAN ME, 1998, J GERONTOL
                    B-PSYCHOL, V53, P43&#xD; LAPSLEY HM, 2001, ARTHRIT RHEUM-ARTHR, V45, P301&#xD;
                    LAWTON MP, 1975, J GERONTOL, V30, P85&#xD; LAWTON MP, 1993, PSYCHOL AGING, V8,
                    P165&#xD; LAWTON MP, 2001, J AGING HEALTH, V13, P3&#xD; LECHNER DE, 1993, PHYS
                    WORK PERFORMANC&#xD; LEFEBVRE JC, 2002, CLIN J PAIN, V18, P56&#xD; LEFEBVRE MF,
                    1981, J CONSULT CLIN PSYCH, V49, P517&#xD; LERESCHE L, 2001, OROFACIAL PAIN
                    BASIC, P15&#xD; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37&#xD; LUGGEN AS, 1998, J
                    GERONTOL NURS, V24, P48&#xD; LYNCH ME, 2003, PAIN, V103, P111&#xD; LYNESS JM,
                    1995, J AM GERIATR SOC, V43, P216&#xD; MAIN CJ, 1991, PAIN, V46, P287&#xD;
                    MANCINI JA, 1992, J GERONTOL, V47, P14&#xD; MANFREDI PL, 2003, INT J GERIATR
                    PSYCH, V18, P700&#xD; MANZ BD, 2000, PAIN MANAG NURS, V1, P106&#xD; MARKS R,
                    1994, ARTHRIT CARE RES, V7, P50&#xD; MARTIN MY, 1996, PAIN, V68, P45&#xD; MARTIN
                    R, 2005, CAN J NURS RES, V37, P142&#xD; MARTIN RR, 2005, PAIN RES MANAGE, V10,
                    P211&#xD; MARTIRE LM, 2003, AGING MENT HEALTH, V7, P53&#xD; MASON JH, 1988,
                    ARTHRITIS RHEUM, V31, P714&#xD; MCALINDON TE, 1993, ANN RHEUM DIS, V52,
                    P258&#xD; MCCAHON S, 2005, CLIN J PAIN, V21, P223&#xD; MCCONNELL S, 2001,
                    ARTHRIT RHEUM-ARTHR, V45, P453&#xD; MCCRACKEN LM, 1992, PAIN, V50, P67&#xD;
                    MCDONALD DD, 2004, WESTERN J NURS RES, V26, P836&#xD; MCGLYNN EA, 1998, AM J
                    PREV MED S, V14, P14&#xD; MCGRATH P, 1996, PAIN, V64, P435&#xD; MCHORNEY CA,
                    1995, QUAL LIFE RES, V4, P293&#xD; MCKENDRICK MW, 1999, J INFECTION, V39,
                    P209&#xD; MEENAN RF, 1980, ARTHRITIS RHEUM, V23, P146&#xD; MEENAN RF, 1992,
                    ARTHRITIS RHEUM, V35, P1&#xD; MELZACK R, 1975, PAIN, V1, P277&#xD; MELZACK R,
                    1987, PAIN, V30, P191&#xD; MELZACK R, 1988, CHALLENGE PAIN&#xD; MENDOZA TR,
                    2004, CLIN J PAIN, V20, P357&#xD; MERCADANTE S, 2002, CANCER, V94, P832&#xD;
                    MERCADO AC, 2000, HEALTH PSYCHOL, V19, P333&#xD; MERSKEY H, 1994, CLASSIFICATION
                    CHRON&#xD; MESSIER SP, 2002, ARTHRIT RHEUM-ARTHR, V47, P141&#xD; MIRO J, 2005, J
                    PAIN, V6, P727&#xD; MOBILY PR, 1994, J AGING HEALTH, V6, P139&#xD; MORIN CM,
                    1999, J CLIN GEROPSYCHOLOG, V5, P19&#xD; MORRISON RS, 1998, J PAIN SYMPTOM
                    MANAG, V15, P91&#xD; MORRISON RS, 2003, J GERONTOL A-BIOL, V58, P76&#xD; MUNIN
                    MC, 1998, JAMA-J AM MED ASSOC, V279, P847&#xD; MYERS AM, 1996, J GERONTOL
                    A-BIOL, V51, M37&#xD; NESSELROADE JR, 1984, RES AGING, V6, P3&#xD; NEWTONJOHN
                    TRO, 2002, RAIN REV, V9, P7&#xD; NICASSIO PM, 1985, J RHEUMATOL, V12, P462&#xD;
                    OAKLANDER AL, 1998, ANN NEUROL, V44, P789&#xD; ORMEL J, 2001, AM J PSYCHIAT,
                    V158, P885&#xD; OWENS KMB, 2000, AGING MENT HEALTH, V4, P309&#xD; OXMAN MN,
                    2005, NEW ENGL J MED, V352, P2271&#xD; PARMELEE PA, 1989, PSYCHOL ASSESSMENT J,
                    V1, P331&#xD; PARMELEE PA, 1991, J GERONTOL, V46, P15&#xD; PARMELEE PA, 1993, J
                    AM GERIATR SOC, V41, P517&#xD; PARMELEE PA, 1995, ANN M GER SOC AM LOS&#xD;
                    PARMELEE PA, 1996, CLIN GERIATR MED, V12, P473&#xD; PARMELEE PA, 2005, PAIN
                    ELDERLY, P175&#xD; PASERO C, 1999, PAIN CLIN MANUAL, P674&#xD; PAUTEX S, 2005, J
                    GERONTOL A-BIOL, V60, P524&#xD; PAVOT W, 1993, PSYCHOL ASSESSMENT, V5, P164&#xD;
                    PAYNE R, 1998, ASSESSMENT TREATMENT&#xD; PEARLIN LI, 1978, J HEALTH SOC BEHAV,
                    V19, P2&#xD; PETERSEN KL, 2000, PAIN, V88, P125&#xD; PODSIADLO D, 1991, J AM
                    GERIATR SOC, V39, P142&#xD; PORTENOY RK, 2006, J PAIN, V7, P583&#xD; POWELL LE,
                    1995, J GERONTOL A-BIOL, V50, P28&#xD; PROCTOR WR, 2001, PAIN RES MANAG, V6,
                    P119&#xD; RADLOFF LS, 1977, APPL PSYCH MEAS, V3, P385&#xD; RADLOFF LS, 1986,
                    CLIN GERONTOLOGIST, V5, P119&#xD; RAMIREZMAESTRE C, 2004, J BEHAV MED, V27,
                    P147&#xD; RASMUSSEN PV, 2004, PAIN, V110, P461&#xD; REESOR KA, 1988, PAIN, V32,
                    P35&#xD; REICH JW, 1990, J GERONTOL B-PSYCHOL, V45, P46&#xD; REID MC, 2005, J
                    GERONTOL A-BIOL, V60, P793&#xD; REJESKI WJ, 2001, J GERONTOL B-PSYCHOL, V56,
                    S261&#xD; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105&#xD; REUBEN DB, 1990, J
                    AM GERIATR SOC, V38, P855&#xD; RIKLI RE, 1999, J AGING PHYS ACTIV, V7, P162&#xD;
                    ROLAND M, 1983, SPINE, V8, P141&#xD; ROLKE R, 2006, EUR J PAIN, V10, P77&#xD;
                    ROOS EM, 1999, SCAND J RHEUMATOL, V28, P210&#xD; ROSENSTIEL AK, 1983, PAIN, V17,
                    P33&#xD; ROWBOTHAM MC, 1996, NEUROBIOL DIS, V3, P205&#xD; ROWBOTHAM MC, 1998,
                    PAIN FORUM, V7, P231&#xD; RUDY TE, 2005, PAIN OLDER ADULTS, P153&#xD; RUSSELL
                    IJ, 2001, BONICAS MANAGEMENT P, P543&#xD; RYFF CD, 1989, J PERS SOC PSYCHOL,
                    V57, P1069&#xD; SALAFFI F, 2003, OSTEOARTHR CARTILAGE, V11, P551&#xD; SALAFFI F,
                    2005, CLIN RHEUMATOL, V24, P29&#xD; SAUVAGET C, 2002, GERONTOLOGY, V48,
                    P226&#xD; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063&#xD; SCHERDER EJA,
                    2000, GERONTOLOGY, V46, P47&#xD; SCHULZ R, 2003, PERSONAL CONTROL SOC, P233&#xD;
                    SCHUMACHER KL, 2002, ONCOL NURS FORUM, V29, P1304&#xD; SCUDDS RJ, 2000, J
                    GERONTOL A-BIOL, V55, P393&#xD; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41,
                    P541&#xD; SHERBOURNE CD, 1991, SOC SCI 07/01 MED, V32, P705&#xD; SHERMAN SE,
                    1998, J GEN INTERN MED, V13, P817&#xD; SHIMP LA, 1998, PHARMACOTHERAPY, V18,
                    P1313&#xD; SHORR RI, 1992, J GERONTOL, V47, M111&#xD; SHULMAN KI, 2000, INT J
                    GERIATR PSYCH, V15, P548&#xD; SIMMONS SF, 2002, CLIN J PAIN, V18, P380&#xD;
                    SIMONS DG, 1999, TRAVELL SIMONS MYOFA, V1, P11&#xD; SIMONS W, 1995, J ADV NURS,
                    V22, P663&#xD; SMITH JA, 2002, ANN BEHAV MED, V24, P326&#xD; SMITH SJA, 2004,
                    PAIN, V112, P183&#xD; SMITH TW, 1994, HEALTH PSYCHOL, V13, P213&#xD; SNOW AL,
                    2004, DEMENT GERIATR COGN, V17, P240&#xD; SNOWTUREK AL, 1996, PAIN, V64,
                    P455&#xD; SORKIN BA, 1990, J GERONTOL, V45, P64&#xD; SPIELBERGER CD, 1983,
                    MANUAL STATE TRAIT A&#xD; SPIERA R, 2004, GERIATRICS, V59, P25&#xD; SPINHOVEN P,
                    1997, PSYCHOL MED, V27, P363&#xD; STEIN MJ, 1988, J RHEUMATOL, V15, P427&#xD;
                    STEIN WM, 2001, CLIN GERIATR MED, V17, P575&#xD; STOLEE P, 2005, J AM GERIATR
                    SOC, V53, P319&#xD; STROUD MW, 2000, PAIN, V84, P347&#xD; STUPPY DJ, 1998, APPL
                    NURS RES, V11, P84&#xD; SULLIVAN MJL, 2001, PAIN, V91, P147&#xD; SUURMEIJER
                    TPBM, 1994, AM J PUBLIC HEALTH, V84, P1270&#xD; SVENDSEN KB, 2005, EUR J PAIN,
                    V9, P195&#xD; SZEBENYI B, 2006, ARTHRITIS RHEUM, V54, P230&#xD; TAAL E, 2004,
                    ANN RHEUM DIS, V63, P1655&#xD; TACCARI E, 1998, REV RHUM, V65, P751&#xD; TAIT
                    RC, 1990, PAIN, V40, P171&#xD; TAM VC, 2005, CAN MED ASSOC J, V173, P510&#xD;
                    TAYLOR LJ, 2003, PAIN MANAGEMENT NURS, V4, P87&#xD; TAYLOR LJ, 2005, REHABIL
                    NURS, V30, P55&#xD; THEILER R, 2002, SWISS MED WKLY, V132, P566&#xD; THOMAS E,
                    2004, PAIN, V110, P361&#xD; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119&#xD;
                    TINETTI ME, 1990, J GERONTOL, V45, P239&#xD; TITTLE MB, 2003, ONCOL NURS FORUM,
                    V30, P325&#xD; TREEDE RD, 2003, NEUROPHYSIOL CLIN, V33, P303&#xD; TRENTINI CM,
                    2005, REV BRAS PSIQUIATR, V27, P119&#xD; TSAI PF, 2006, J NURS MANAGE, V14,
                    P90&#xD; TUOKKO H, 1995, CLOCK TEST ADM SCORI&#xD; TUOKKO H, 1998, ASSESSMENT
                    GUDIE GER&#xD; TURK DC, 2003, PAIN, V106, P337&#xD; UCHINO BN, 2001, J BEHAV
                    MED, V24, P361&#xD; VILLANUEVA MR, 2003, J AM MED DIR ASS, V4, P1&#xD; VITALIANO
                    PP, 1985, MULTIVAR BEHAV RES, V20, P3&#xD; VONKORFF M, 1991, PSYCHOSOM MED, V53,
                    P61&#xD; WADDELL G, 1998, BACK PAIN REVOLUTION&#xD; WALLSTON KA, 1978, HLTH ED
                    MONOGRAPHS, V6, P160&#xD; WARDEN V, 2003, J AM MED DIR ASSOC, V4, P9&#xD; WARY
                    B, 1999, SOINS GERONTOLOGIE, V19, P25&#xD; WASHBURN RA, 1993, J CLIN EPIDEMIOL,
                    V46, P153&#xD; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063&#xD; WEEKS SK,
                    2003, J NURS SCHOLARSHIP, V35, P133&#xD; WEINER D, 1996, PAIN, V67, P461&#xD;
                    WEINER D, 1999, CLIN J PAIN, V15, P92&#xD; WEINER D, 1999, PAIN, V80, P577&#xD;
                    WEINER DK, 1992, J AM GERIATR SOC, V40, P203&#xD; WEINER DK, 1993, ARCH PHYS MED
                    REHAB, V74, P796&#xD; WEINER DK, 1994, J AM GERIATR SOC, V42, P257&#xD; WEINER
                    DK, 1998, AGING-CLIN EXP RES, V10, P411&#xD; WEINER DK, 1998, GERONTOLOGY, V44,
                    P217&#xD; WEINER DK, 1999, ANALGESIA, V4, P377&#xD; WEINER DK, 2001, DRUG AGING,
                    V18, P13&#xD; WEINER DK, 2002, COMPREHENSIVE INTERD&#xD; WEINER DK, 2003, J AM
                    GERIATR SOC, V51, P599&#xD; WEINER DK, 2005, PAIN OLDER PERSONS, P329&#xD;
                    WEINER DK, 2006, J AM GERIATR SOC, V54, P11&#xD; WHEELER AH, 1999, SPINE, V24,
                    P1290&#xD; WILLIAMS CS, 2005, GERONTOLOGIST, V45, P68&#xD; WILLIAMS DA, 1989,
                    PAIN, V36, P351&#xD; WILLIAMS ME, 1990, J AM GERIATR SOC, V38, P1120&#xD;
                    WILLIAMS VSL, 2006, J PAIN SYMPTOM MANAG, V31, P48&#xD; WILLIAMSON GM, 1995,
                    PSYCHOL AGING, V10, P369&#xD; WITTINK H, 2004, CLIN J PAIN, V20, P133&#xD; WOLFE
                    F, 1990, ARTHRITIS RHEUM, V33, P160&#xD; WOLFE F, 1995, ARTHRITIS RHEUM, V38,
                    P19&#xD; WOLFE GI, 1999, ARCH NEUROL-CHICAGO, V56, P540&#xD; WONG D, 1988,
                    PEDIATR NURS, V14, P9&#xD; WYNNE CF, 2000, GERIATR NURS, V21, P20&#xD; YESAVAGE
                    JA, 1983, ASSESSMENT GERIATRIC, P153&#xD; YESAVAGE JA, 1983, J PSYCHIAT RES,
                    V17, P37&#xD; YILMAZ B, 2004, JOINT BONE SPINE, V71, P563&#xD; YONG HH, 2001, J
                    GERONTOL B-PSYCHOL, V56, P279&#xD; ZALON ML, 1999, J NURS MEAS, V7, P135&#xD;
                    ZASLANSKY R, 1998, J NEUROL SCI 07/01, V153, P215&#xD; ZAUTRA A, 2001, J CONSULT
                    CLIN PSYCH, V69, P786&#xD; ZAUTRA AJ, 1992, ANN BEHAVIORAL MED, V14, P31&#xD;
                    ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361&#xD; ZWAKHALEN SM, IN PRESS
                    PAIN&#xD; ZWAKHALEN SM, 2006, BMC GERIATR, V6, P3&#xD;Suppl. S</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243329900001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>951</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">951</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1844</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hakim, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, P. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilczynski, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nguyen, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynes, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wakabayashi, M. T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Gynecologic Oncology,
                    City of Hope, 1500 East Duarte Road, Duarte, CA 91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Indications and efficacy of the
                        human papillomavirus vaccine</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Curr Treat Options Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Curr Treat Options Oncol</style>
                </full-title>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">393-401</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">8</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Alphapapillomavirus/ drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human papillomavirus 11/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human papillomavirus 16/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human papillomavirus 18/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Human papillomavirus 6/drug
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Papillomavirus
                        Infections/complications/ drug therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Papillomavirus Vaccines/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Uterine Cervical Neoplasms/
                        prevention &amp; control/ virology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1534-6277 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18172770</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In the United States, there are
                    11,150 cases and 3670 deaths projected due to invasive cervical cancer for 2007.
                    Approximately 500,000 new cases and 274,000 deaths will occur in women
                    throughout the world. Human papillomavirus (HPV) has been designated by the
                    World Health Organization (WHO) as a &quot;necessary cause&quot; of cervical
                    cancer. There are 6.2 million new cases of HPV diagnosed each year. In addition
                    to cervical cancer, the virus has also been implicated in vaginal, vulvar,
                    penile, anal, and head and neck cancers. Current methods for prevention of
                    cervical cancer include Pap smears, HPV testing, ablative procedures, cervical
                    conization, and hysterectomy. These are costly as well as invasive. The HPV
                    vaccine is the most recent breakthrough for the prevention of cervical cancer.
                    The quadrivalent HPV vaccine (Gardasil) covers types 6, 11, 16, &amp; 18. The
                    bivalent vaccine (Cervarix) covers types 16 &amp; 18, and is expected to come
                    out in the early part of 2007. Approximately 70% of cervical cancer is caused by
                    HPV types 16 &amp; 18. HPV types 6 &amp;11 are responsible for 90% of anogenital
                    warts. Females of ages 11-12 and those prior to their sexual debut should be
                    vaccinated, with all females in the age range of 9-26 also eligible. This
                    vaccination strategy can prevent the above HPV infections, cervical dysplasia,
                    and possibly cervical cancer.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2008/07/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>584</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">584</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1400</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hall, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, K. H. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Felt, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gridley, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yee, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baylink, D. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Loma Linda Univ, Jerry L Pettis Mem
                    VA Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA. Loma Linda Univ,
                    Dept Med &amp; Biochem, Loma Linda, CA 92357 USA. Loma Linda Univ, Dept Radiat
                    Med, Radiobiol Program, Loma Linda, CA 92357 USA. City Hope Natl Med Ctr,
                    Duarte, CA USA.&#xD;Lau, KHW, Loma Linda Univ, Jerry L Pettis Mem VA Med Ctr,
                    Musculoskeletal Dis Ctr, Loma Linda, CA 92357
                    USA.&#xD;William.Lau@med.va.gov</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An improved mouse Sca-1+
                        cell-based bone marrow transplantation model for use in gene- and cell-based
                        therapeutic studies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Acta Haematologica</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Acta Haematol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Acta Haematologica</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Acta Haematol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Acta Haematol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Acta Haematologica</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Acta Haematol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Acta Haematol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">24-33</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">117</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">bone marrow
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cell therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">engraftment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic progenitor
                        cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MURINE MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENGRAFTMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNODEFICIENCY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECONSTITUTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IRRADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECIPIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEFECTS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0001-5792</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000242164900005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">This study sought to develop a
                    murine bone marrow transplantation strategy that would yield consistently high
                    levels of long-term engraftment without significant morbidity and mortality.
                    Hematopoietic stem cell (HSC)-enriched Sca-1+ cells were used for
                    transplantation because of their propensity of homing to bone marrow. Green
                    fluorescent protein (GFP)-expressing transgenic mice were used as donors. Murine
                    Sca-1+ cells were enriched 13-fold from whole bone marrow with immunomagnetic
                    column chromatography. Retroorbital injections yielded highly reproducible and
                    higher levels of engraftment compared with tail vein injections. The combination
                    of W-41/W-41 recipient mice and sublethal irradiation preconditioning produced
                    long-term engraftment with minimal morbidity and mortality. A 24-hour delay
                    between the sublethal irradiation and transplantation did not affect the
                    efficiency and level of engraftment, but provided flexibility with respect to
                    the timing of transplantation. Based on these findings, a mouse Sca-1+
                    cell-based strategy, involving the retroorbital injection of Sca-1+ cells into
                    sublethally irradiated, myelosuppressed W-41/W-41 recipient mice within 24 h
                    after irradiation, was developed. Transplantation of lentiviral
                    vector-transduced wild-type Sca-1+ cells expressing GFP by this strategy led to
                    consistently high levels of long-term engraftment. In summary, this murine
                    Sca-1+ cell-based strategy could be used in studies of HSC-based gene or cell
                    therapies. Copyright (c) 2007 S. Karger AG, Basel.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    107IR&#xD;Times Cited: 0&#xD;Cited Reference Count: 36</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000242164900005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>291</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">291</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1399</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Han, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J. Y. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Radiat
                    Phys, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Radiat Oncol, Duarte, CA
                    91010 USA.&#xD;Han, CH, City Hope Natl Med Ctr, Dept Radiat Phys, 1500 E Duarte
                    Rd, Duarte, CA 91010 USA.&#xD;chan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Dosimetric study and in-vivo
                        dose verification for conformal avoidance treatment of anal adenocarcinoma
                        using helical tomotherapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Medical Dosimetry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Medical Dosimetry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Med. Dosim.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Med Dosim</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">33-37</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">helical tomotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">conformal avoidance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">intensity-modulated</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IRRADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Spr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0958-3947</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244796100006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">This study evaluated the efficacy of
                    using helical tomotherapy for conformal avoidance treatment of anal
                    adenocarcinoma. We retrospectively generated step-and-shoot intensity-modulated
                    radiotherapy (sIMRT) plans and helical tomotherapy plans for two anal cancer
                    patients, one male and one female, who were treated by the sIMRT technique. Dose
                    parameters for the planning target volume (PTV) and the organs-at-risk (OARs)
                    were compared between the sIMRT and the helical tomotherapy plans. The helical
                    tomotherapy plans showed better dose homogeneity in the PTV, better dose
                    conformity around the PTV, and, therefore, better sparing of nearby OARs
                    compared with the sIMRT plans. In-vivo skin dose measurements were performed
                    during conformal avoidance helical tomotherapy treatment of an anal cancer
                    patient to verify adequate delivery of skin dose and sparing of OARs. (C) 2007
                    American Association of Medical Dosimetrists.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    144KY&#xD;Times Cited: 0&#xD;Cited Reference Count: 13&#xD;Cited References:
                    &#xD; ABLE CM, 1991, INT J RADIAT ONCOL, V21, P1063&#xD; AKAZAWA C, 1989, MED
                    DOSIM, V14, P129&#xD; CHAO KSC, 1998, PRINCIPLES PRACTICE, P1724&#xD; CHEN YJ,
                    2005, INT J RADIAT ONCOL, V63, P274&#xD; ESCHWEGE F, 1985, RADIOTHER ONCOL, V3,
                    P145&#xD; HUNT MA, 1995, INT J RADIAT ONCOL, V32, P227&#xD; JAMES SW, 2002, TECH
                    CANC RES TREAT, V4, P311&#xD; MACKIE TR, 1999, SEMIN RADIAT ONCOL, V9, P108&#xD;
                    MARTENSON JA, 1993, CANCER, V71, P1736&#xD; MEEKS SL, 2005, MED PHYS, V32,
                    P2673&#xD; ORTON N, 2005, MED DOSIM, V30, P162&#xD; VALICENTI RK, 1994, INT J
                    RADIAT ONCOL, V30, P431&#xD; WIELAND P, 2004, INT J RADIAT ONCOL, V59,
                    P1236</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244796100006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>688</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">688</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1398</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Harris, T. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grosso, J. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, H. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xin, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kortylewski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Albesiano, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hipkiss, E. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Getnet, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goldberg, M. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maris, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Housseau, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pardoll, B. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Drake, C. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Johns Hopkins Sidney Kimmel
                    Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA. City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Canc Immunotherapeut &amp; Tumor Immunol, Duarte, CA
                    91019 USA.&#xD;Drake, CG, Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept
                    Oncol, Bunting Blaustein Canc Res Bldg 1 Room 452,1650 O, Baltimore, MD 21231
                    USA.&#xD;drakech@jhmi.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An in vivo requirement for STAT3
                        signaling in T(H)17 development and T(H)17-dependent autoimmunity(1)</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">4313-4317</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">179</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TGF-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOKINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFLAMMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENCEPHALOMYELITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIFFERENTIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-17</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAYS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249752100004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">STAT3 activation has been observed
                    in several autoimmune diseases, suggesting that STAT3-mediated pathways promote
                    pathologic immune responses. We provide in vivo evidence that the fundamental
                    role of STAT3 signaling in autoimmunity relates to its absolute requirement for
                    generating T(H)17 T cell responses. We show that STAT3 is a master regulator of
                    this pathogenic T cell subtype, acting at multiple levels in vivo, including
                    T(H)17 T cell differentiation and cytokine production, as well as induction of
                    ROR gamma t and the IL-23R. Neither naturally occurring T(H)17 cells nor
                    T,T(H)17-dependent autoimmunity occurs when STAT3 is ablated in CD4 cells.
                    Furthermore, ablation of STAT3 signaling in CD4 cells results in increased T(H)1
                    responses, indicating that STAT3 signaling skews T-H responses away from the TO
                    pathway and toward the T(H)17 pathway. Thus, STAT3 is a candidate target for
                    T(H)17-dependent autoimmune disease immunotherapy that could selectively inhibit
                    pathogenic immune pathways.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    214QB&#xD;Times Cited: 0&#xD;Cited Reference Count: 20</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249752100004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>750</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">750</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1395</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">He, H. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cheng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Pathol,
                    Div Pathol, Duarte, CA 91010 USA. Beijing Univ, Hlth Sci Ctr, Dept Pathol,
                    Beijing 100871, Peoples R China. Indiana Univ, Sch Med, Dept Pathol,
                    Indianapolis, IN 46202 USA.&#xD;Chu, PG, City Hope Natl Med Ctr, Dept Pathol,
                    Div Pathol, 1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;pchu@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Clinical outcome of incidental
                        pelvic node malignant B-cell lymphomas discovered at the time of radical
                        prostatectomy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Leukemia &amp; Lymphoma</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Leukemia &amp; Lymphoma</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Leuk. Lymphoma</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Leuk Lymphoma</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1976-1980</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">pelvic lymph node</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">B-cell lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMALL LYMPHOCYTIC
                        LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NON-HODGKINS-LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1042-8194</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249872600015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Incidental pelvic node malignant
                    B-cell lymphomas diagnosed at the time of radical prostatectomy are rare. Their
                    clinical outcome has not been studied. We studied thirteen such cases with
                    long-term clinical follow-up. Patients were followed between 9 and 94 months
                    after surgery. Of 13 cases, 9 were chronic lymphocytic leukemia/small
                    lymphocytic lymphoma ( CLL/SLL), 3 marginal zone B-cell lymphoma ( MZL) and 1
                    mantle cell lymphoma ( MCL). All 13 patients did not receive radiation or
                    chemotherapy; and five of 13 cases showed hematologic evidence of lymphoma
                    progression between 1 and 5 months after radical prostatectomy. After
                    progression, the mantle cell lymphoma patient received aggressive chemotherapy
                    and had systemic dissemination. Two of 13 cases had recurrent prostate
                    carcinoma. None of 13 patients had died from lymphoma or prostate carcinoma at
                    the last follow-up. In conclusion, most incidental pelvic node lymphomas ( 8/13)
                    showed no evidence of systemic dissemination to peripheral blood or bone marrow
                    after a mean 42.8 weeks of follow-up despite the fact that no additional
                    treatment was given. Strong consideration should be given to withholding further
                    treatment in patients diagnosed with pelvic low-grade B-cell lymphoma at the
                    time of radical prostatectomy until disease progression occurs.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    216IV&#xD;Times Cited: 0&#xD;Cited Reference Count: 10&#xD;Cited References:
                    &#xD; BENEZRA J, 1989, BLOOD, V73, P579&#xD; BERGER F, 1994, BLOOD, V83,
                    P2829&#xD; CHU PGG, 2005, AM J SURG PATHOL, V29, P693&#xD; DRINIS S, 2001, UROL
                    INT, V66, P105&#xD; EISENBERGER CF, 1999, UROLOGY, V53, P175&#xD; HORNING SJ,
                    1984, NEW ENGL J MED, V311, P1471&#xD; MORRISON WH, 1989, J CLIN ONCOL, V7,
                    P598&#xD; TERRIS MK, 1997, J UROLOGY, V158, P1457&#xD; WEIR EG, 2003, ARCH
                    PATHOL LAB MED, V127, P567&#xD; WINSTANLEY AM, 2002, J CLIN PATHOL, V55,
                    P623</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249872600015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>374</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">374</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1391</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Heidel, J. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, J. Y. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heale, B. S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bartlett, D. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davis, M. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Calando Pharmaceut Inc, Pasadena, CA
                    91107 USA. CALTECH, Pasadena, CA 91125 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA.&#xD;Heidel, JD, Calando Pharmaceut Inc, 2585 Nina
                    St, Pasadena, CA 91107 USA.&#xD;jheidel@calandopharma.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Potent siRNA inhibitors of
                        ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and
                        in vivo</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2207-2215</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ADVANCED SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA INTERFERENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">M2 SUBUNIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GTI-2040</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245660800034</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: Ribonucleotide reductase
                    (RR) is a therapeutic target for DNA replication - dependent diseases such as
                    cancer. Here, a potent small interfering RNA (siRNA) duplex against the M2
                    subunit of RR (RRM2) is developed and shown to reduce the growth potential of
                    cancer cells both in vitro and in vivo. Experimental Design: Three anti-RRM2
                    siRNAs were identified via computational methods, and the potency of these and
                    additional &quot;tiling&quot; duplexes was analyzed in cultured cells via
                    cotransfections using a RRM2-luciferase fusion construct. Knockdown of RRM2 by
                    the best duplex candidates was confirmed directly by Western blotting. The
                    effect of potent duplexes on cell growth was investigated by a real-time cell
                    electronic sensing assay. Finally, duplex performance was tested in vivo in
                    luciferase-expressing cells via whole animal bioluminescence imaging. Results:
                    Moderate anti-RRM2 effects are observed from the three duplexes identified by
                    computational methods. However, the tiling experiments yielded an extremely
                    potent duplex (siR2B+5). This duplex achieves significant knockdown of RRM2
                    protein in cultured cells and has pronounced antiproliferative activity. S.c.
                    tumors of cells that had been transfected with siR2B+5 preinjection grew slower
                    than those of control cells. Conclusions: An anti-RRM2 siRNA duplex is
                    identified that exhibits significant anti proliferative activity in cancer cells
                    of varying human type and species (mouse, rat, monkey); these findings suggest
                    that this duplex is a promising candidate for therapeutic development.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    156PG&#xD;Times Cited: 0&#xD;Cited Reference Count: 22&#xD;Cited References:
                    &#xD; CERQUEIRA NMFSA, 2005, CURR MED CHEM, V12, P1283&#xD; CHEN SY, 2000,
                    ANTISENSE NUCLEIC A, V10, P111&#xD; DESAI AA, 2004, EJC SUPPL, V2, P136&#xD;
                    DESAI AA, 2005, ANN ONCOL, V16, P958&#xD; DU Q, 2005, NUCLEIC ACIDS RES, V33,
                    P1671&#xD; DUXBURY MS, 2004, ONCOGENE, V23, P1539&#xD; DUXBURY MS, 2004,
                    SURGERY, V136, P261&#xD; ELBASHIR SM, 2001, NATURE, V411, P494&#xD; ENGSTROM Y,
                    1985, J BIOL CHEM, V260, P9114&#xD; HEALE BSE, 2005, NUCLEIC ACIDS RES, V33&#xD;
                    HULIESKOVAN S, 2005, CANCER RES, V65, P8984&#xD; JENSEN RA, 1994, P NATL ACAD
                    SCI USA, V91, P9257&#xD; LEE Y, 2003, CANCER RES, V63, P2802&#xD; LIN ZP, 2004,
                    J BIOL CHEM, V279, P27030&#xD; MIAO CH, 2000, MOL THER, V1, P522&#xD; MURREN J,
                    2003, CLIN CANCER RES, V9, P4092&#xD; ORR RM, 2001, CURR OPIN INVESTIG D, V2,
                    P1462&#xD; ORR RM, 2005, METH MOLEC MED, V106, P85&#xD; PEREIRA S, 2006, EUR
                    BIOPHYS J BIOPHY, V35, P125&#xD; SOLLY K, 2004, ASSAY DRUG DEV TECHN, V2,
                    P363&#xD; TAKESHITA F, 2006, CANCER SCI, V97, P689&#xD; ZHOU BS, 2003, CANCER
                    RES, V63, P6583</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245660800034 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>463</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">463</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1390</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Held, D. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kissel, J. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Thacker, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Michalowski, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saran, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ji, J. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hardy, R. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burke, D. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Missouri, Sch Med, Dept Mol
                    Microbiol &amp; Immunol, Columbia, MO 65211 USA. Univ Missouri, Sch Med, Dept
                    Biochem, Columbia, MO 65211 USA. Indiana Univ, Dept Biochem, Bloomington, IN
                    47405 USA. Indiana Univ, Dept Chem, Bloomington, IN 47405 USA. Cedars Sinai Med
                    Ctr, Div Cardiol, Los Angeles, CA 90048 USA. City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA.&#xD;Burke, DH,
                    Univ Missouri, Sch Med, Life Sci Ctr 471H, 1201 E Rollins St, Columbia, MO 65211
                    USA.&#xD;burkedh@missouri.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cross-clade inhibition of
                        recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian
                        immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot
                        aptamers</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Virology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Virology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Virol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Virol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5375-5384</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">81</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIPLE SEQUENCE
                        ALIGNMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RIBONUCLEASE-H ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG-RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBTYPE-C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NONNUCLEOSIDE INHIBITORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIRETROVIRAL THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">V106M</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPLICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IDENTIFICATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-538X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246464200045</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Reverse transcriptase (RT) remains a
                    primary target in therapies directed at human immunodeficiency virus type I
                    (HIV-1). RNA aptamers that bind RT from HIV-1 subtype B have been shown to
                    protect human cells from infection and to reduce viral infectivity, but little
                    is known about the sensitivity of the inhibition to amino sequence variations of
                    the RT target. Therefore, we assembled a panel of 10 recombinant RTs from
                    phylogenetically diverse lentiviral isolates (including strains of HIV-1, simian
                    immunodeficiency virus SIVcpz, and HIV-2). After validating the panel by
                    measuring enzymatic activities and inhibition by small-molecule drugs,
                    dose-response curves for each enzyme were established for four pseudoknot RNA
                    aptamers representing two structural subfamilies. All four aptamers potently
                    inhibited RTs from multiple HIV-1 subtypes. For aptamers carrying family 1
                    pseudoknots, natural resistance was essentially all-or-none and correlated with
                    the identity of the amino acid at position 277. In contrast, natural resistance
                    to aptamers carrying the family 2 pseudoknots was much more heterogeneous, both
                    in degree (gradation of 50% inhibitory concentrations) and in distribution
                    across clades. Site-directed and subunit-specific mutagenesis identified a
                    common R/K polymorphism within the p66 subunit as a primary determinant of
                    resistance to family 1, but not family 2, pseudoknot aptamers. RNA structural
                    diversity therefore translates into a nonoverlapping spectrum of mutations that
                    confer resistance, likely due to differences in atomic-level contacts with
                    RT.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    167PS&#xD;Times Cited: 0&#xD;Cited Reference Count: 67&#xD;Cited References:
                    &#xD; AMADO RG, 2004, HUM GENE THER, V15, P251&#xD; BOBKOV A, 1994, AIDS, V8,
                    P1649&#xD; BOYER PL, 2006, PLOS PATHOG, V2, P101&#xD; BRENNER B, 2003, AIDS,
                    V17, F1&#xD; BURKE DH, 1996, J MOL BIOL, V264, P650&#xD; CHALOIN L, 2002,
                    NUCLEIC ACIDS RES, V30, P4001&#xD; CHEN LM, 2004, J VIROL, V78, P3722&#xD;
                    COLLINS JA, 2004, J VIROL, V78, P603&#xD; CORNELISSEN M, 1997, J VIROL, V71,
                    P6348&#xD; DAMOND F, 2004, AIDS RES HUM RETROV, V20, P666&#xD; DESCAMPS D, 1997,
                    J VIROL, V71, P8893&#xD; DING JP, 1998, J MOL BIOL, V284, P1095&#xD; ERON JJ,
                    1993, ANTIMICROB AGENTS CH, V37, P1480&#xD; FAN NS, 1996, BIOCHEMISTRY-US, V35,
                    P1911&#xD; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368&#xD; FISHER TS, 2002, J
                    VIROL, V76, P4068&#xD; FROST SDW, 2000, J VIROL, V74, P6262&#xD; GAO F, 1999,
                    NATURE, V397, P385&#xD; GILBERT PB, 2003, STAT MED, V22, P573&#xD; GILL SC,
                    1989, ANAL BIOCHEM, V182, P319&#xD; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168,
                    P30&#xD; GREEN L, 1995, J MOL BIOL, V247, P60&#xD; GROSSMAN Z, 2004, AIDS, V18,
                    P909&#xD; GUPTA RK, 2005, AIDS, V19, P1916&#xD; HELD DM, 2006, FRONT BIOSCI,
                    V11, P89&#xD; HELD K, 2006, J BIOL CHEM, V281, P25712&#xD; HIZI A, 1991, J BIOL
                    CHEM, V266, P6230&#xD; HUANG HF, 1998, SCIENCE, V282, P1669&#xD; ISAKA Y, 2001,
                    ARCH VIROL, V146, P743&#xD; ISEL C, 2001, J BIOL CHEM, V276, P48725&#xD; JAEGER
                    J, 1998, EMBO J, V17, P4535&#xD; JOBB G, 2004, BMC EVOL BIOL, V4&#xD; JOSHI P,
                    2002, J VIROL, V76, P6545&#xD; JOSHI PJ, 2003, CURR DRUG TARGETS IN, V3,
                    P383&#xD; JOSHI PJ, 2005, MOL THER, V11, P677&#xD; KEELE BF, 2006, SCIENCE,
                    V313, P523&#xD; KENSCH O, 2000, J BIOL CHEM, V275, P18271&#xD; KISSEL JD, IN
                    PRESS AIDS RES HU&#xD; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652&#xD;
                    LEVINE BL, 2006, P NATL ACAD SCI USA, V103, P17372&#xD; LITTLE SJ, 2002, NEW
                    ENGL J MED, V347, P385&#xD; LOEMBA H, 2002, ANTIMICROB AGENTS CH, V46,
                    P2087&#xD; MACPHERSON JL, 2005, J GENE MED, V7, P552&#xD; MANSKY LM, 2002, J
                    VIROL, V76, P9253&#xD; MARLINK R, 1994, SCIENCE, V265, P1587&#xD; MEYER PR,
                    1999, MOL CELL, V4, P35&#xD; MORGENSTERN B, 1999, BIOINFORMATICS, V15, P211&#xD;
                    MORRIS L, 2003, AIDS, V17, P1698&#xD; OSMANOV S, 2002, J ACQ IMMUN DEF SYND,
                    V29, P184&#xD; POST K, 2003, J VIROL, V77, P7623&#xD; QUAN YD, 2003, AIDS RES
                    HUM RETROV, V19, P743&#xD; QUINONESMATEU ME, 1997, VIROLOGY, V236, P364&#xD; REN
                    J, 2001, J MOL BIOL, V312, P795&#xD; RODES B, 2000, J CLIN MICROBIOL, V38,
                    P1370&#xD; SARAFIANOS SG, 2001, EMBO J, V20, P1449&#xD; SEVILYA Z, 2001, J MOL
                    BIOL, V311, P957&#xD; SEVILYA Z, 2003, NUCLEIC ACIDS RES, V31, P1481&#xD; SHARP
                    PM, 1999, BIOL BULL, V196, P338&#xD; SHIMODAIRA H, 1999, MOL BIOL EVOL, V16,
                    P1114&#xD; SPENCE RA, 1995, SCIENCE, V267, P988&#xD; TEMESGEN Z, 2006, EXPERT
                    OPIN PHARMACO, V7, P1541&#xD; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22,
                    P4673&#xD; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988&#xD; TUSKE S, 2004,
                    NAT STRUCT MOL BIOL, V11, P469&#xD; VANHEUVERSWYN F, 2006, NATURE, V444,
                    P164&#xD; WITVROUW M, 1999, AIDS, V13, P1477&#xD; WOHRL BM, 1999, J MOL BIOL,
                    V292, P333</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246464200045 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>751</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">751</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1389</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hellan, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anderson, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paz, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pigazzi, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Gen
                    &amp; Oncol Surg, Duarte, CA 91010 USA.&#xD;Pigazzi, A, City Hope Natl Med Ctr,
                    Dept Gen &amp; Oncol Surg, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;apigazzi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Short-term outcomes after
                        robotic-assisted total mesorectal excision for rectal cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Surg Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3168-3173</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">total mesorectal
                        excision</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">minimally invasive
                        surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">robotic-assisted</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rectal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LAPAROSCOPIC RADICAL
                        PROSTATECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SPHINCTER PRESERVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLON-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OPEN SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPERIENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1068-9265</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250204500020</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Laparoscopic total
                    mesorectal excision for rectal cancer remains a difficult procedure with high
                    conversion rates. We have sought to improve on some of the pitfalls of
                    laparoscopy by using the DaVinci robotic system. Here we report our two-year
                    experience with robotic-assisted laparoscopic surgery for primary rectal cancer.
                    Methods: A prospectively maintained database of all rectal cancer cases starting
                    in November 2004 was created. A series of 39 consecutive unselected patients
                    with primary rectal cancer was analyzed. Clinical and pathologic outcomes were
                    reviewed retrospectively. Results: 22 patients had low anterior, 11
                    intersphincteric and six abdominoperineal resections. Postoperative mortality
                    and morbidity were % and 12.8%, respectively. The median operative time was 285
                    minutes (range 180-540 mins). The conversion rate was 2.6%. A total mesorectal
                    excision with negative circumferential and distal margins was accomplished in
                    all patients, and a median of 13 (range 7-28) lymph nodes was removed. The
                    anastomotic leak rate was 12.1%. The median hospital stay was 4 days. There have
                    been no local recurrences at a median follow-up of 13 months. Conclusions:
                    Robotic-assisted surgery for rectal cancer can be carried out safely and
                    according to oncological principles. This approach shows promising short-term
                    outcomes and may facilitate the adoption of minimally invasive rectal
                    surgery.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    221CH&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; AHLERING TE, 2003, J UROLOGY, V170, P1738&#xD; AZIZ O, 2006, ANN SURG
                    ONCOL, V13, P413&#xD; BALLANTYNE GH, 2003, SURG CLIN N AM, V83, P1293&#xD;
                    BARLEHNER E, 2005, SURG ENDOSC, V19, P757&#xD; BRETAGNOL F, 2005, SURG ENDOSC,
                    V19, P892&#xD; CARLSEN E, 1998, BRIT J SURG, V85, P526&#xD; DANNIBALE A, 2004,
                    DIS COLON RECTUM, V47, P2162&#xD; GIULIANOTTI PC, 2003, ARCH SURG-CHICAGO, V138,
                    P777&#xD; GUILLOU PJ, 2005, LANCET, V365, P1718&#xD; HARTLEY JE, 2001, DIS COLON
                    RECTUM, V44, P315&#xD; HEALD RJ, 1998, ARCH SURG-CHICAGO, V133, P894&#xD;
                    LANFRANCO AR, 2004, ANN SURG, V239, P14&#xD; LEROY J, 2004, SURG ENDOSC, V18,
                    P281&#xD; LEUNG KL, 2004, LANCET, V363, P1187&#xD; MOLOO H, 2004, SURG ENDOSC,
                    V18, P732&#xD; MORGAN BJ, 2001, COLORECTAL DIS, V3, P135&#xD; MORINO M, 2003,
                    ANN SURG, V237, P335&#xD; MORINO M, 2005, SURG ENDOSC, V19, P1460&#xD; MUNZ Y,
                    2004, AM J SURG, V187, P88&#xD; NELSON H, 2004, NEW ENGL J MED, V350, P2050&#xD;
                    PATEL VR, 2007, INT J CLIN PRACT, V61, P309&#xD; PIGAZZI A, 2006, SURG ENDOSC,
                    V20, P1521&#xD; RAWLINGS AL, 2006, SURG ENDOSC, V20, P1713&#xD; ROCKALL TA,
                    2003, SURG CLIN N AM, V83, P1463&#xD; STYLOPOULOS N, 2003, SURG CLIN N AM, V83,
                    P1321&#xD; TSANG WW, 2006, ANN SURG, V243, P35&#xD; VELDKAMP R, 2004, SURG
                    ENDOSC, V18, P1163&#xD; ZHOU ZG, 2004, SURG ENDOSC, V18, P1211</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250204500020 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>607</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">607</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1388</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Heo, J. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Han, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vaidehi, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wendel, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kekenes-Huskey, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goddard, W. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">CALTECH, Div Chem &amp; Chem Engn,
                    Mat &amp; Proc Simulat Ctr 139 74, Pasadena, CA 91125 USA. CALTECH, Div Biol 147
                    75, Pasadena, CA 91125 USA. Beckman Res Inst, Div Immunol, City Hope Grad Sch
                    Biol Sci, Duarte, CA 91010 USA.&#xD;Goddard, WA, CALTECH, Div Chem &amp; Chem
                    Engn, Mat &amp; Proc Simulat Ctr 139 74, Pasadena, CA 91125
                    USA.&#xD;wag@wag.caltech.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Prediction of the 3D structure
                        of FMRF-amide neuropeptides bound to the mouse MrgC11 GPCR and experimental
                        validation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Chembiochem</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">ChemBioChem</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1527-1539</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">8</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">13</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">FMRFamide neuropeptide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G protein-coupled
                        receptors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">molecular</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">modeling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mrg receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mutagenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN-COUPLED
                        RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING-SITE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BETA-2-ADRENERGIC
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RHODOPSIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOCKING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IDENTIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIMULATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTAGONISTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALGORITHM</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1439-4227</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249366500011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We report the 3D structure predicted
                    for the mouse MrgC11 (mMrgC11) receptor by using the MembStruk computational
                    protocol, and the predicted binding site for the F-M-R-F-NH2 neuro-peptide
                    together with four singly chirally modified ligands. We predicted that the
                    R-F-NH2 part of the tetrapeptide sticks down into the protein between the
                    transmembrane (TM) domains 3, 4, 5, and 6. The Phe (F-NH2) interacted favorably
                    with Tyr110 (TM3) while the Arg makes salt bridges to Asp161 (TM4) and Asp179
                    (TMS). We predicted that the Met extends from the binding site, but the terminal
                    Phe residue sticks back into an aromatic/hydrophobic site flanked by Tyr237,
                    Leu238, Leu240, and Tyr256 (TM6), and Trp162 (TM4). We carried out subsequent
                    mutagenesis experiments followed by intracellular calcium-release assays that
                    demonstrated the dramatic decrease in activity for the Tyr110Als, Asp161Ala, and
                    Asp179Ala substitutions, which was predicted by our model. These experiments
                    provide strong evidence that our predicted G protein-coupled receptor (GPCR)
                    structure is sufficiently accurate to identify binding sites for selective
                    ligands. Similar studies were made with the mMrg-A1 receptor, which did not bind
                    the R-F-NH2 dipeptide, we explain this to be due to the increased hydrophobic
                    character of the binding pocket in mMrgA1.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    209CR&#xD;Times Cited: 0&#xD;Cited Reference Count: 36</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249366500011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>658</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">658</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1387</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hernandez, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chapman, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chua, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baldwin, W. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas, El Paso, TX 79968 USA.
                    City Hope Natl Med Ctr, Duarte, CA 91010 USA. Baylor Coll Med, Houston, TX 77030
                    USA.&#xD;Baldwin, WS, Univ Texas, 500 W Univ Ave, El Paso, TX 79968
                    USA.&#xD;wbaldwin@utep.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The environmental estrogen,
                        nonylphenol, activates the constitutive androstane receptor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Toxicological Sciences</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Toxicol. Sci.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Toxicological Sciences</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Toxicol. Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Toxicol Sci</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Toxicological Sciences</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Toxicol. Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Toxicol Sci</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">416-426</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">98</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">nonylphenol</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CAR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PXR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyp2b10</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p450</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREGNANE-X-RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORPHAN NUCLEAR RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL DETERMINANTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALKYLPHENOLIC COMPOUNDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISTINCT CLASSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG-METABOLISM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN-KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BISPHENOL-A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYP2B GENE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1096-6080</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248375000010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Nonylphenol (NP) and its parent
                    compounds, the nonylphenol ethoxylates are some of the most prevalent chemicals
                    found in U.S. waterways. NP is also resistant to biodegradation and is a known
                    environmental estrogen, which makes NP a chemical of concern. Our data show that
                    NP also activates the constitutive androstane receptor (CAR), an orphan nuclear
                    receptor important in the induction of detoxification enzymes, including the
                    P450s. Transactivation assays demonstrate that NP increases murine CAR (mCAR)
                    transcriptional activity, and NP treatment can overcome the inhibitory effects
                    of the inverse agonist, androstanol, on mCAR activation. Treatment of wild-type
                    (CAR +/+) mice with NP at 50 or 75 mg/kg/day increases Cyp2b protein expression
                    in a dose-dependent manner as demonstrated by Western blotting, and was
                    confirmed by quantitative reverse transcription-PCR of Cyp2b10 transcript
                    levels. CAR-null (CAR -/-) mice show no increased expression of Cyp2b following
                    NP treatment, indicating that CAR is required for NP-mediated Cyp2b induction.
                    In addition, NP increases the translocation of CAR into the nucleus, which is
                    the key step in the commencement of CAR&apos;s transcriptional activity. NP also
                    induced CYP2B6 in primary human hepatocytes, and increased Cyp2b10 messenger RNA
                    and protein expression in humanized CAR mice, indicating that NP is an activator
                    of human CAR as well. In conclusion, NP is a CAR activator, and this was
                    demonstrated in vitro with transactivation assays and in vivo with transgenic
                    CAR mouse models.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    194WR&#xD;Times Cited: 0&#xD;Cited Reference Count: 67</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248375000010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>603</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">603</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1383</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Holtz, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Hematol
                    &amp; Bone Marrow Transplantat, Dept Hematopoiet Stem Cell &amp; Leukemia Res,
                    Duarte, CA 91010 USA.&#xD;Bhatia, R, City Hope Natl Med Ctr, Div Hematol &amp;
                    Bone Marrow Transplantat, Dept Hematopoiet Stem Cell &amp; Leukemia Res, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;rbhatia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Growth factor stimulation
                        reduces residual quiescent chronic myelogenous leukemia progenitors
                        remaining after imatinib treatment</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1113-1120</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLETE CYTOGENETIC
                        REMISSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ABL TYROSINE KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SELF-RENEWAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIT-LIGAND</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-KIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G-CSF</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244137300036</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The BCR/ABL tyrosine kinase
                    inhibitor imatinib mesylate is highly effective in the treatment of chronic
                    myelogenous leukemia (CML) but fails to eliminate all leukemia cells. Residual
                    leukemia stem and progenitor cells persist in imatinib-responsive patients and
                    may be a potential source of relapse. previous studies indicate that imatinib
                    preferentially targets dividing cells, and nondividing progenitor cells are
                    resistant to imatinib-mediated apoptosis. We investigated whether growth factor
                    stimulation of progenitor proliferation could reduce the number of residual
                    nondividing cells remaining after imatinib treatment. CML and normal CD34(+)
                    cells were labeled with 5-(and 6-)-carboxyfluorescein diacetate succinimidyl
                    ester (CFSE) to track cell division and cultured in low or high concentrations
                    of growth factor to determine effects of growth factor stimulation on
                    nondividing cells. High growth factor concentrations significantly enhanced CML
                    proliferation with or without imatinib treatment and significantly reduced the
                    number of viable, nondividing USE bright cells remaining after imatinib
                    exposure. Stimulation with high growth factor before imatinib treatment further
                    reduced the number of residual nondividing CML CD34(+) cells. Importantly,
                    clinically achievable concentrations of granulocyte macrophage
                    colony-stimulating factor alone or in combination with granulocyte
                    colony-stimulating factor also significantly reduced nondividing CML CD34(+)
                    cells. These results support the potential efficacy of growth factor stimulation
                    in reducing the residual leukemia progenitor population in imatinib-treated
                    patients.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    135EQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 36</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244137300036 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>226</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">226</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1380</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, Y. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, S. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst, Dept Surg Res,
                    Duarte, CA 91010 USA. Beckman Res Inst, Div Informat Sci, Duarte, CA 91010
                    USA.&#xD;Chen, SA, Beckman Res Inst, Dept Surg Res, Duarte, CA 91010
                    USA.&#xD;schen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Molecular basis for the
                        aromatization reaction and exemestane-mediated irreversible inhibition of
                        human aromatase</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Endocrinology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Mol. Endocrinol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Endocrinology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Endocrinol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Endocrinol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Endocrinology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Endocrinol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Endocrinol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">401-414</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN PLACENTAL
                        AROMATASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SITE-DIRECTED
                        MUTAGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRYSTAL-STRUCTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING CHARACTERISTICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESTROGEN BIOSYNTHESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">3-DIMENSIONAL MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESCHERICHIA-COLI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOCHROME-P450</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0888-8809</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243791000007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Aromatase converts androgens to
                    aromatic estrogens. Aromatase inhibitors have been used as first-line drugs in
                    the treatment of hormone-dependent breast cancer. Structural basis of the
                    aromatization reaction and drug recognition by aromatase has remained elusive
                    because of its unknown three-dimensional structure. In this study, recombinant
                    human aromatase was expressed and purified from Escherichia coli. Using this
                    purified and active preparation, the three-dimensional folding of aromatase was
                    revealed by proteomic analysis. Combined with site-directed mutagenesis, several
                    critical residues involved in enzyme catalysis and suicide inhibition by
                    exemestane were evaluated. Based on our results, a new clamping mechanism of
                    substrate/ exemestane binding to the active site is proposed. These
                    structure-function studies of aromatase would provide useful information to
                    design more effective aromatase inhibitors for the prevention and the treatment
                    of hormone-dependent breast cancer.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast; </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    130HP&#xD;Times Cited: 0&#xD;Cited Reference Count: 48</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243791000007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>814</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">814</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">978</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, D. T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, Sch Dent,
                    Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Dent Res Inst, Los
                    Angeles, CA 90095 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch
                    Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Sch Med, Div Otolaryngol
                    Head &amp; Neck Surg, Los Angeles, CA 90095 USA. City Hope Natl Med Ctr, Duarte,
                    CA 91010 USA.&#xD;Wong, DT, Univ Calif Los Angeles, Sch Dent, Los Angeles, CA
                    90095 USA.&#xD;dtww@ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Implications of salivary
                        proteomics in drug discovery and development: a focus on cancer drug
                        discovery</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Drug Discovery Today</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Drug Discovery Today</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Drug Discov. Today</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Drug Discov Today</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">911-916</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">12</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">21-22</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SQUAMOUS-CELL CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORAL LICHEN-PLANUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2-DIMENSIONAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GEL-ELECTROPHORESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TANDEM MASS-SPECTROMETRY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIQUID-CHROMATOGRAPHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULAR-MARKER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-MARKERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WHOLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SALIVA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1359-6446</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251490600004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Human saliva proteomics has proven
                    to be a novel approach in the search for protein biomarkers for non-invasive
                    detection of human cancers. This approach may also have implications within the
                    process of anti-cancer drug discovery. Information from saliva proteomic
                    measurements may contribute to the target discovery and validation, assessment
                    of efficacy and toxicity of candidate drugs, identification of disease
                    subgroups, and prediction of responses of individual patients. In this article,
                    we aim to give a brief overview on human saliva proteome analysis, as well as
                    its applications to cancer biomarker discovery. Potential applications of saliva
                    proteomics in anticancer drug discovery and development will also be
                    discussed.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    239AS&#xD;Times Cited: 0&#xD;Cited Reference Count: 61&#xD;Cited References:
                    &#xD; AEBERSOLD R, 2003, NATURE, V422, P198&#xD; BIGLER LR, 2002, J ORAL PATHOL
                    MED, V31, P421&#xD; BOGAERTS J, 2006, NAT CLIN PRACT ONCOL, V3, P540&#xD; BRAILO
                    V, 2006, ORAL ONCOL, V42, P370&#xD; BUTLER GS, 2007, CURR PHARM DESIGN, V13,
                    P263&#xD; CASTAGNOLA M, 2004, J BIOL CHEM, V279, P41436&#xD; COLBURN WA, 2003, J
                    CLIN PHARMACOL, V43, P329&#xD; DAWES C, 1974, ARCH ORAL BIOL, V19, P887&#xD;
                    DRAKE RR, 2005, EXPERT REV MOL DIAGN, V5, P93&#xD; FINGLETON B, 2004, CLIN
                    CANCER RES, V10, P7865&#xD; FLOYD E, 2004, TOXICOL PATHOL S1, V32, P106&#xD;
                    FRANZMANN EJ, 2003, INT J CANCER, V106, P438&#xD; FRANZMANN EJ, 2005, CANCER
                    EPIDEM BIOMAR, V14, P735&#xD; GUO T, 2006, J PROTEOME RES, V5, P1469&#xD; HARDT
                    M, 2005, ANAL CHEM, V77, P4947&#xD; HIRTZ C, 2005, PROTEOMICS, V5, P4597&#xD; HU
                    J, 2005, BRIEF FUNCT GENOMIC, V3, P322&#xD; HU S, IN PRESS ARTHRITIS R&#xD; HU
                    S, 2005, PROTEOMICS, V5, P1714&#xD; HU S, 2006, PROTEOMICS, V6, P6326&#xD; HU S,
                    2007, AM ASS CANC RES ANN&#xD; HU S, 2007, ANN NY ACAD SCI, V1098, P323&#xD;
                    INZITARI R, 2005, PROTEOMICS, V5, P805&#xD; INZITARI R, 2006, PROTEOMICS, V6,
                    P6370&#xD; KELLOFF GJ, 2005, EUR J CANCER, V41, P491&#xD; LESKO LJ, 2001, ANNU
                    REV PHARMACOL, V41, P347&#xD; LUPI A, 2003, PROTEOMICS, V3, P461&#xD; LYONS AJ,
                    2000, J ORAL PATHOL MED, V29, P267&#xD; MA Y, 2006, CLIN CANCER RES, V12,
                    P4583&#xD; MANDEL ID, 1987, J DENT RES, V66, P623&#xD; MANDEL ID, 1990, J ORAL
                    PATHOL, V19, P119&#xD; MCCLELLAND CM, 2003, BIOCHEM SOC T 6, V31, P1488&#xD;
                    MESSANA I, 2004, J PROTEOME RES, V3, P792&#xD; MIZUKAWA N, 1999, ORAL DIS, V5,
                    P139&#xD; NAGLER R, 2006, CLIN CANCER RES, V12, P3979&#xD; PEPE MS, 2001, J NATL
                    CANCER I, V93, P1054&#xD; PETRICOIN EF, 2004, TOXICOL PATHOL, V32, P1&#xD;
                    RAMACHANDRAN P, 2006, J PROTEOME RES, V5, P1493&#xD; RANSOHOFF DF, 2005, NAT REV
                    CANCER, V5, P142&#xD; RHODUS NL, 2005, CANC DETECT PREV, V29, P42&#xD; RHODUS
                    NL, 2005, CLIN IMMUNOL, V114, P278&#xD; RHODUS NL, 2005, MOL CARCINOGEN, V44,
                    P77&#xD; RHODUS NL, 2006, ORAL DIS, V12, P112&#xD; RYU OH, 2006, RHEUMATOLOGY,
                    V45, P1077&#xD; SHAK S, 1999, SEMIN ONCOL S12, V26, P71&#xD; SPARANO JA, 2006,
                    CLIN BREAST CANCER, V7, P347&#xD; STJOHN MAR, 2004, ARCH OTOLARYNGOL, V130,
                    P929&#xD; STOUGHTON RB, 2005, NAT REV DRUG DISCOV, V4, P345&#xD; STRECKFUS C,
                    2000, CANCER INVEST, V18, P101&#xD; STRECKFUS C, 2000, CLIN CANCER RES, V6,
                    P2363&#xD; SUNG FL, 2006, J PROTEOME RES, V5, P3260&#xD; TABAK LA, 2001, J DENT
                    EDUC, V65, P1335&#xD; TAO XO, 2007, ORAL SURG ORAL MED O, V103, P661&#xD; WALZ
                    A, 2006, PROTEOMICS, V6, P1631&#xD; WARNAKULASURIYA S, 2000, J PATHOL, V192,
                    P52&#xD; WILMARTH PA, 2004, J PROTEOME RES, V3, P1017&#xD; WONG DT, 2006, J AM
                    DENT ASSOC, V137, P313&#xD; WULFKUHLE JD, 2006, NAT CLIN PRACT ONCOL, V3,
                    P256&#xD; XIE HW, 2005, MOL CELL PROTEOMICS, V4, P1826&#xD; YATES JR, 2006, ANAL
                    CHEM, V78, P493&#xD; ZHONG LP, 2005, INT J ORAL MAX SURG, V34, P566</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251490600004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>815</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">815</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1378</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hu, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raynard, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sehorn, M. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lu, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bussen, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zheng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stark, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barnes, E. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chi, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Janscak, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jasin, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vogel, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sung, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Luo, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Case Western Reserve Univ, Univ Hosp
                    Cleveland, Case Comprehens Canc Ctr, Dept Genet, Cleveland, OH 44106 USA. Yale
                    Univ, Sch Med, Dept Mol Biophys &amp; Biochem, New Haven, CT 06520 USA. Univ
                    Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland. City Hope Natl Med Ctr,
                    Beckman Res Inst, Dept Radiat Biol, Duarte, CA 91010 USA. Mem Sloan Kettering
                    Canc Ctr, Dev Biol Program, New York, NY 10021 USA. Stanford Univ, Med Ctr, Dept
                    Pathol, Stanford, CA 94305 USA.&#xD;Sung, P, Case Western Reserve Univ, Univ
                    Hosp Cleveland, Case Comprehens Canc Ctr, Dept Genet, Cleveland, OH 44106
                    USA.&#xD;Patrick.Sung@yale.edu guangbin.luo@case.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">RECQL5/Recql5 helicase regulates
                        homologous recombination and suppresses tumor formation via disruption of
                        Rad51 presynaptic filaments</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Genes &amp; Development</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Genes &amp; Development</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Genes Dev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Genes Dev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3073-3084</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">23</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Recq15 helicase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">homologous recombination</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">suppressor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rad51 recombinase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRAND BREAK REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAMAGED REPLICATION
                        FORKS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOOMS-SYNDROME GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BOX DNA HELICASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SACCHAROMYCES-CEREVISIAE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN RECQ5-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREDISPOSITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOPOISOMERASE-III</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECQ HELICASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">YEAST RAD51</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0890-9369</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251512400006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Members of the RecQ helicase family
                    play critical roles in genome maintenance. There are five RecQ homologs in
                    mammals, and defects in three of these (BLM, WRN, and RECQL4) give rise to
                    cancer predisposition syndromes in humans. RECQL and RECQL5 have not been
                    associated with a human disease. Here we show that deletion of Recql5 in mice
                    results in cancer susceptibility. Recql5-deficient cells exhibit elevated
                    frequencies of spontaneous DNA double-strand breaks and homologous recombination
                    (HR) as scored using a reporter that harbors a direct repeat, and are prone to
                    gross chromosomal rearrangements in response to replication stress. To
                    understand how RECQL5 regulates HR, we use purified proteins to demonstrate that
                    human RECQL5 binds the Rad51 recombinase and inhibits Rad51-mediated D-loop
                    formation. By biochemical means and electron microscopy, we show that RECQL5
                    displaces Rad51 from single-stranded DNA (ssDNA) in a reaction that requires ATP
                    hydrolysis and RPA. Together, our results identify RECQL5 as an important tumor
                    suppressor that may act by preventing inappropriate HR events via Rad51
                    presynaptic filament disruption.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    239IQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 47&#xD;Cited References:
                    &#xD; AGUILERA A, 1988, GENETICS, V119, P779&#xD; BENNETT RJ, 2000, J BIOL CHEM,
                    V275, P26898&#xD; BUGREEV DV, 2007, GENES DEV&#xD; CHANG M, 2005, EMBO J, V24,
                    P2024&#xD; CHI P, 2006, DNA REPAIR, V5, P381&#xD; ELLIS NA, 1995, CELL, V83,
                    P655&#xD; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391&#xD; GARCIA PL, 2004, EMBO
                    J, V23, P2882&#xD; GERMAN J, 1993, MEDICINE, V72, P393&#xD; GOSS KH, 2002,
                    SCIENCE, V297, P2051&#xD; HICKSON ID, 2003, NAT REV CANCER, V3, P169&#xD; HU YD,
                    2005, MOL CELL BIOL, V25, P3431&#xD; IRA G, 2003, CELL, V115, P401&#xD; JOHNSON
                    RD, 1999, NATURE, V401, P397&#xD; KANAGARAJ R, 2006, NUCLEIC ACIDS RES, V34,
                    P5217&#xD; KOHZAKI M, 2007, MOL CELL BIOL, V27, P2812&#xD; KREJCI L, 2003,
                    NATURE, V423, P305&#xD; LIBERI G, 2005, GENE DEV, V19, P339&#xD; LUO GB, 2000,
                    NAT GENET, V26, P424&#xD; MANN MB, 2005, HUM MOL GENET, V14, P813&#xD; MAZIN AV,
                    2000, EMBO J, V19, P1148&#xD; MORISHITA T, 2005, MOL CELL BIOL, V25, P8074&#xD;
                    MULLEN JR, 2005, MOL CELL BIOL, V25, P4476&#xD; OGAWA T, 1993, SCIENCE, V259,
                    P1896&#xD; ONODA F, 2000, MUTAT RES-DNA REPAIR, V459, P203&#xD; OSMAN F, 2005,
                    MOL CELL BIOL, V25, P8084&#xD; OTTERLEI M, 2006, J CELL SCI, V119, P5137&#xD;
                    PAPOULI E, 2005, MOL CELL, V19, P123&#xD; PAQUES F, 1999, MICROBIOL MOL BIOL R,
                    V63, P349&#xD; PARRINELLO S, 2003, NAT CELL BIOL, V5, P741&#xD; PAULL TT, 2000,
                    CURR BIOL, V10, P886&#xD; PETUKHOVA G, 1998, NATURE, V393, P91&#xD; PETUKHOVA
                    GV, 2005, NAT STRUCT MOL BIOL, V12, P449&#xD; PFANDER B, 2005, NATURE, V436,
                    P428&#xD; POMMIER Y, 2003, MUTAT RES-FUND MOL M, V532, P173&#xD; RAYNARD S,
                    2006, J BIOL CHEM, V281, P13861&#xD; ROTHKAMM K, 2003, MOL CELL BIOL, V23,
                    P5706&#xD; SHIMAMOTO A, 2000, NUCLEIC ACIDS RES, V28, P1647&#xD; STARK JM, 2003,
                    MOL CELL BIOL, V23, P733&#xD; SUNG P, 1995, CELL, V82, P453&#xD; SUNG P, 2006,
                    NAT REV MOL CELL BIO, V7, P739&#xD; SYMINGTON LS, 2002, MICROBIOL MOL BIOL R,
                    V66, P630&#xD; THOMPSON LH, 2002, MUTAT RES-FUND MOL M, V509, P49&#xD; VEAUTE X,
                    2003, NATURE, V423, P309&#xD; WU L, 2003, NATURE, V426, P870&#xD; WU L, 2006,
                    ANNU REV GENET, V40, P279&#xD; WU L, 2006, P NATL ACAD SCI USA, V103,
                    P4068</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251512400006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>617</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">617</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1377</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, C. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tang, Z. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tucker, P. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas, Mol Genet Sect, Austin,
                    TX 78712 USA. Univ Texas, Inst Mol &amp; Cellular Biol, Austin, TX 78712 USA.
                    City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010
                    USA.&#xD;Tucker, PW, Univ Texas, Mol Genet Sect, 1 Univ Stn,A5000, Austin, TX
                    78712 USA.&#xD;philtucker@mail.utexas.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phosphorylation by SR kinases
                        regulates the binding of PTB-associated splicing factor (PSF) to the
                        pre-mRNA polypyrimidine tract</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Febs Letters</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">FEBS Lett.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">FEBS Letters</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">FEBS Lett.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">FEBS Lett</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">FEBS Letters</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">FEBS Lett.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">FEBS Lett</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">223-232</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">581</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">phosphorylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">snRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">spliceosome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ribonucleoprotein</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">U4/U6-CENTER-DOT-U5
                        TRI-SNRNP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN-SPECIFIC KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR IMPORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOMAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SPLICEOSOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P54(NRB)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEPHOSPHORYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DROSOPHILA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0014-5793</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244188700009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PSF (PTB-associated splicing factor)
                    is a multi-functional protein that participates in transcription and RNA
                    processing. While phosphorylation of PSF has been shown to be important for some
                    functions, the sites and the kinases involved are not well understood. Although
                    PSF does not contain a typical RS domain, we report here that PSF is
                    phosphorylated in vivo to generate an epitope(s) that can be recognized by a
                    monoclonal antibody specific for phosphorylated RS motifs within SR proteins.
                    PSF can be phosphorylated by human and yeast SR kinases in vivo and in vitro at
                    an isolated RS motif within its N terminus. A functional consequence of SR
                    phosphorylation of PSF is to inhibit its binding to the 3&apos; polypyrimidine
                    tract of pre-mRNA. These results indicate that PSF is a substrate of SR kinases
                    whose phosphorylation regulates its RNA binding capacity and ultimate biological
                    function. (c) 2006 Federation of European Biochemical Societies. Published by
                    Elsevier B.V. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    135YB&#xD;Times Cited: 1&#xD;Cited Reference Count: 56</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244188700009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>611</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">611</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1376</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, L. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hua, X. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lu, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gao, G. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tian, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hua, Y. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Zhejiang Univ, Inst Nucl Agr Sci,
                    Hangzhou 310029, Peoples R China. Yangzhou Univ, Jiangsu Prov Key Lab Crop Genet
                    &amp; Physiol, Jiangsu 225009, Peoples R China. City Hope Natl Med Ctr, Dept
                    Radiat Biol, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA 91010
                    USA.&#xD;Hua, YJ, Zhejiang Univ, Inst Nucl Agr Sci, Hangzhou 310029, Peoples R
                    China.&#xD;yjhua@zju.edu.cn</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Three tandem HRDC domains have
                        synergistic effect on the RecQ functions in Deinococcus radiodurans</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">167-176</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Deinococcus radiodurans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RecQ</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">helicase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HRDC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-BINDING-PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SINGLE-STRANDED-DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBSTRATE-SPECIFIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESCHERICHIA-COLI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IONIZING-RADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WERNER-SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOOMS-SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOLLIDAY JUNCTIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HELICASE ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SYNDROME GENE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1568-7864</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244024400003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The RecQ family of DNA helicases
                    performs essential functions in the maintenance of genomic stability in all
                    organisms. in Deinococcus radiodurans, DR1289 is a special member of RecQ family
                    with unique arrangement of three tandem HRDC domains in the C-terminus. A dr1289
                    mutant is hypersensitive to gamma-irradiation, UV, H2O2 and mitomycin C. By
                    complementing the dr1289 mutant with various domains of Dr1289 in vivo, we have
                    determined that the helicase and all three HRDC domains are indispensable for
                    complete DNA damage resistance. Using a continuous fluorescent dye-displacement
                    assay, we investigated the optimal conditions for Dr1289 unwinding function at
                    various concentrations of ATP and metal ions to show that the helicase activity
                    is comparable to what observed in Escherichia coli RecQ. We also found that the
                    helicase domain is necessary for the unwinding and ATPase activity and that the
                    three tandem HRDC domains increase the efficiency of these activities. Based on
                    these data, we propose that the C-terminus of Dr1289 has evolved in D.
                    radiodurans to confront the types and amounts of DNA damage. (c) 2006 Elsevier
                    B.V. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    133PI&#xD;Times Cited: 0&#xD;Cited Reference Count: 53</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244024400003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>783</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">783</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1826</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Su, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ai, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fan, C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Pathology, City of Hope
                    National Medical Center, Duarte, CA 91010, USA. qhang@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Promoter hypermethylation of
                        multiple genes in primary gastric lymphoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Leuk Lymphoma</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Leukemia &amp; Lymphoma</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Leuk. Lymphoma</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Leuk Lymphoma</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1988-96</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression
                        Profiling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression Regulation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphoma/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Promoter Regions
                        (Genetics)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stomach Neoplasms/
                        genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1042-8194 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17852707</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Aberrant hypermethylation of CpG
                    islands in the promoter region of tumor suppressor and other important genes in
                    neoplastic cells of lymphoma has been demonstrated to be one of the mechanisms
                    for epigenetic loss of gene function. In this study, we analyzed promoter
                    hypermethylation of the following genes in 49 cases of primary gastric lymphoma
                    (PGL): ATM, p16INK4a(CDKN2A), hMLH1, MGMT, DAPK, and CDH1(ECAD). The PGL cases
                    studied included 26 (53%) cases of diffuse large B-cell lymphoma (DLBCL), 12
                    (25%) cases of extranodal marginal zone lymphoma (MZL), 7 (14%) cases of MZL
                    with large cell transformation (MZL/DLBCL), 1 (2%) case of follicular lymphoma
                    (FL), one (2%) case of Burkitt-like lymphoma (BL), one case (2%) of
                    lymphoplasmacytic lymphoma (LPL) and one case (2%) of peripheral T-cell
                    lymphoma. Available pathologic data regarding to extragastric involvement at the
                    time of resection of the PGLs were reviewed and correlated. Promoter
                    hypermethylation was detected in 6 of 49 (12.2%) cases for ATM; 13 of 49 (26.5%)
                    for p16INK4a, 19 of 49 (38.8%) for hMLH1; 22 of 49 (44.9%) for MGMT; 27 of 49
                    (55.1%) for DAPK and 16 of 49 (32.7%) for CDH1. A total of 85% of the PGLs had
                    promoter hypermethylation in at least one of these genes. With different
                    histologic subtypes, promoter hypermethylation of DAPK, hMLH1, and CDH1 genes
                    occurred in 70%, 42%, and 42% respectively for DLBCL, which appeared to be
                    higher than combined MZL and MZL/DLBCL subgroup. Approximately 81% PGLs
                    demonstrated H. pylori infection by immunohistochemistry. H. pylori status did
                    not appear to be statistically correlated with promoter hypermethylation of the
                    genes. Of 37 PGL cases, 19 cases had extragastric involvement at the time of
                    resection, indicating relatively higher stage disease. The frequencies of
                    promoter methylation in those cases were 58% for DAPK, 42% for hMLH1, 37% for
                    CDH1, 26% for p16INK4a and 11% for ATM respectively. The promoter methylation at
                    MGMT gene was significantly higher in the PGLs without extragastric involvement
                    (61%) as compared to those with extragastric involvement (26%).</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/12/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>690</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">690</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1374</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, Y. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snyder, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaal, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palmer, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Pathol,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Hematopoiet Stem Cell
                    Transplantat, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Biostat, Duarte,
                    CA 91010 USA.&#xD;Huang, Q, City Hope Natl Med Ctr, Div Pathol, 1500 E Duarte
                    Rd, Duarte, CA 91010 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Clinical and Pathologic analysis
                        of 16 cases of relapsed chronic myeloid leukemia after stem cell
                        transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of Clinical
                        Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Clinical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Clin. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Clin Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">565-570</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">128</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">chronic myeloid leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic stem cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">relapse</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytogenetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOGENOUS
                        LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ABL TYROSINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPERIENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MECHANISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CML</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-9173</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249589900004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Chronic myeloid leukemia (CML) is a
                    myeloproliferative disease that originates in an abnormal pluripotent bone
                    marrow stem cell and is characteristically associated with the Philadelphia
                    chromosome and/or the bcr/abl fusion gene. Despite the exciting success of the
                    bcr/abl tyrosine kinase-specific inhibitor imatinib for CML treatment,
                    hematopoietic stem cell (bone marrow or peripheral blood stem cell)
                    transplantation (HCT) remains the only &quot;curative&quot; approach for the
                    majority of patients. Although HCT outcomes for patients with CML have improved
                    considerably during the past 2 decades, relapse after HCT may occur We analyzed
                    the clinical and pathologic features of 16 cases of hematologically relapsed CML
                    after HCT during a 5-year period at City of Hope National Medical Center,
                    Duarte, CA. The results of our analysis showed that relapsed CML after HCT
                    frequently manifested with advanced disease with a more aggressive clinical
                    course and was often refractory to therapy. The frequency of acute leukemic
                    transformation at time of relapse was largely associated with pre-HCT disease
                    status and acquired secondary cytogenetic abnormalities. Disease mortality in
                    patients with relapsed CML after HCT was closely associated with advanced
                    disease and HCT-related complications.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    212IM&#xD;Times Cited: 0&#xD;Cited Reference Count: 21&#xD;Cited References:
                    &#xD; CLIFT RA, 1996, BONE MARROW TRANS S3, V17, S1&#xD; CULLIS JO, 1992, BRIT J
                    HAEMATOL, V81, P378&#xD; DEININGER MWN, 2000, CANCER RES, V60, P2049&#xD; DRUKER
                    BJ, 2001, NEW ENGL J MED, V344, P1031&#xD; FOUCAR K, 2001, BONE MARROW PATHOLOG,
                    P175&#xD; GOLDMAN JM, 2001, BLOOD, V98, P2039&#xD; GOLDMAN JM, 2003, NEW ENGL J
                    MED, V349, P1451&#xD; GRATWOHL A, 1998, LANCET, V352, P1087&#xD; HANSEN JA,
                    1998, NEW ENGL J MED, V338, P962&#xD; HOROWITZ MM, 1996, BONE MARROW TRANS S3,
                    V17, S5&#xD; HUANG Q, 2004, AM J SURG PATHOL, V28, P693&#xD; ILARIA RL, 2005,
                    HEMATOL AM SOC HEMAT, P188&#xD; MCGLAVE PB, 2000, BLOOD, V95, P2219&#xD; MELO
                    JV, 1993, BLOOD, V81, P158&#xD; MELO JV, 2003, HEMATOLOGY AM SOC HE, P132&#xD;
                    MITELMAN F, 1995, ISCN 1995 INT SYSTEM&#xD; RADICH J, 2002, HEMATOLOGY AM SOC
                    HE, P124&#xD; SHET AS, 2002, LEUKEMIA, V16, P1402&#xD; SOKAL JE, 1984, BLOOD,
                    V63, P789&#xD; THOMAS ED, 1986, ANN INTERN MED, V104, P155&#xD; VASDIMAN JW,
                    2001, PATHOLOGY GENETICS T, P20</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249589900004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>616</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">616</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">977</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, Z. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xie, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, R. Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, Z. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst, Div Immunol,
                    Duarte, CA 91010 USA.&#xD;Sun, ZM, Beckman Res Inst, Div Immunol, Duarte, CA
                    91010 USA.&#xD;zuoming@uic.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Retinoid-related orphan receptor
                        gamma t is a potential therapeutic target for controlling inflammatory
                        autoimmunity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Expert Opinion on Therapeutic
                        Targets</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Expert Opin. Ther.
                        Targets</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Expert Opinion on Therapeutic
                        Targets</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Expert Opin. Ther.
                        Targets</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Expert Opin Ther Targets</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Expert Opinion on Therapeutic
                        Targets</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Expert Opin. Ther.
                        Targets</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Expert Opin Ther Targets</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">737-743</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">11</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">autoimmunity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bcl-x(L)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IL-17</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inflammation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ROR gamma t</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T(H)17</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ROR-GAMMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TGF-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEUTROPHIL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECRUITMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IL-17-DEFICIENT MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOKINE PRODUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIPLE-SCLEROSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THYMOCYTE SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CUTTING EDGE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1472-8222</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247105600003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Retinoid-related orphan receptor
                    gamma t (ROR gamma t) is a member of the nuclear receptor family that is
                    specifically expressed in T cell compartments. ROR gamma t regulates the
                    development of T cells in the thymus and the differentiation of effector T cells
                    in the periphery. During T cell development, ROR gamma t enhances CD4(+)CD8(+)
                    double positive thymocyte survival by upregulating Bcl-x(L). In the periphery,
                    ROR gamma t regulates IL-17 production and dictates the differentiation of
                    pro-inflammatory T helper 17 (T(H)17) cells that play a critical role in
                    inflammatory conditions and autoimmunity. ROR gamma t-deficient T cells fail to
                    differentiate into T(H)17 cells, whereas forced expression of ROR gamma t is
                    sufficient to induce naive T cells to produce IL-17. T(H)17 cells are believed
                    to be the major inflammatory cells in autoimmune diseases. Therefore, inhibition
                    of ROR gamma t activity could potentially alleviate the symptoms associated with
                    the T(H)17-dependent inflammatory autoimmune diseases. ROR gamma t is thus
                    potentially an excellent therapeutic target for the intervention of inflammatory
                    autoimmunity.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    176SQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 64</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247105600003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>691</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">691</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1372</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hui, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, H. L. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baergen, R. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sklar, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, X. M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Soslow, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Yale Univ, Sch Med, Dept Pathol,
                    Programs Mol Diagnost, New Haven, CT 06520 USA. Washington Univ, Dept Pathol, St
                    Louis, MO 63130 USA. City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA.
                    Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA. Univ Rochester, Dept
                    Pathol, Rochester, NY 14627 USA. Cornell Univ, Weil Med Coll, Dept Pathol, New
                    York, NY USA. Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021
                    USA.&#xD;Hui, P, Yale Univ, Sch Med, Dept Pathol, Programs Mol Diagnost, 310
                    Cedar St, New Haven, CT 06520 USA.&#xD;pei.hui@yale.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Absence of Y chromosome in human
                        placental site trophoblastic tumor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Modern Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Modern Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mod. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mod Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1055-1060</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">20</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">trophoblastic tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">sex chromosome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genomic imprinting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPARATIVE GENOMIC
                        HYBRIDIZATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATERNAL X-CHROMOSOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTRAEMBRYONIC TISSUES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOMEOBOX GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMELOGENIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ORIGIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0893-3952</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249583000006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Placental site trophoblastic tumor
                    is a neoplasm of extravillous intermediate trophoblast at the implantation site,
                    preceded in the majority of cases by a female gestational event. Our pilot
                    investigation suggested that the development of this tumor might require a
                    paternally derived X chromosome and the absence of a Y chromosome. Twenty cases
                    of placental site trophoblastic tumor were included in this study. Genotyping at
                    15 polymorphic loci and one sex determination locus was performed by multiplex
                    PCR followed by capillary electrophoresis. X chromosome polymorphisms were
                    determined by PCR amplification of exon 1 of the human androgen receptor gene
                    using primers flanking the polymorphic CAG repeats within this region.
                    Genotyping at 15 polymorphic loci was informative and paternal alleles were
                    present in all tumors, confirming the trophoblastic origin of the tumors. The
                    presence of an X chromosome and the absence of a Y chromosome were observed in
                    all tumors. Among 13 cases in which analysis of the X chromosome polymorphism
                    was informative, all but one demonstrated at least two X alleles and seven cases
                    showed one identifiable paternal X allele. These results confirm a unique
                    pathogenetic mechanism in placental site trophoblastic tumor, involving an
                    exclusion of the Y chromosome from the genome and, therefore, a tumor arising
                    from the trophectoderm of a female conceptus. As epigenetic regulations of
                    imprinting during X chromosome inactivation are of significant biological
                    implications, placental site trophoblastic tumor may provide an important model
                    for studying the sex chromosome biology and the proliferative advantage
                    conferred by the paternal X chromosome.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    212GT&#xD;Times Cited: 0&#xD;Cited Reference Count: 34&#xD;Cited References:
                    &#xD; ABUAMERO S, 2006, CYTOGENET GENOME RES, V113, P262&#xD; AJITHKUMAR TV,
                    2003, OBSTET GYNECOL SURV, V58, P484&#xD; AKANE A, 1998, METH MOL B, V98,
                    P245&#xD; BAERGEN RN, 2006, GYNECOL ONCOL, V100, P511&#xD; BARLOW DP, 1995,
                    SCIENCE, V270, P1610&#xD; COLLINS PJ, 2004, J FORENSIC SCI, V49, P1265&#xD;
                    CONSTANCIA M, 2004, NATURE, V432, P53&#xD; COOPER DW, 1971, NATURE-NEW BIOL,
                    V230, P155&#xD; FUKUNAGA M, 1993, HUM PATHOL, V24, P1098&#xD; GOTO T, 1997, MOL
                    HUM REPROD, V3, P77&#xD; GRAVES JAM, 1996, ANNU REV GENET, V30, P233&#xD; HAIG
                    D, 2006, NAT GENET, V38, P271&#xD; HASSADIA A, 2005, GYNECOL ONCOL, V99,
                    P603&#xD; HOW J, 1995, INT J GYNECOL CANCER, V5, P241&#xD; HUI P, 2000, LAB
                    INVEST, V80, P965&#xD; HUI P, 2004, MODERN PATHOL, V17, P248&#xD; HUYNH KD,
                    2003, NATURE, V426, P857&#xD; KAJII T, 1977, NATURE, V268, P633&#xD; KHAN S,
                    2006, BJOG-INT J OBSTET GY, V113, P344&#xD; KOBEL M, 2005, AM J PATHOL, V167,
                    P879&#xD; KOTYLO PK, 1992, INT J GYNECOL PATHOL, V11, P245&#xD; LEE JT, 2003,
                    CURR BIOL, V13, R242&#xD; LI YH, 1997, DEV BIOL, V188, P85&#xD; LIN TP, 1994,
                    DEV BIOL, V166, P170&#xD; LOOIJENGA LHJ, 1999, AM J HUM GENET, V64, P1445&#xD;
                    MIGEON BR, 2002, AM J HUM GENET, V71, P286&#xD; OLDT RJ, 2002, AM J PATHOL,
                    V161, P1033&#xD; SADO T, 2005, HUM MOL GENET, V14, R59&#xD; SALIDO EC, 1992, NAT
                    GENET, V2, P196&#xD; SHIH IM, 2001, INT J GYNECOL PATHOL, V20, P31&#xD; SOLTER
                    D, 1998, INT J DEV BIOL, V42, P951&#xD; SZULMAN AE, 1984, J REPROD MED, V29,
                    P788&#xD; TILGHMAN SM, 1999, CELL, V96, P185&#xD; XUE WC, 2002, CANCER, V94,
                    P2288</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249583000006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>692</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">692</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1825</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Cancer and Aging Research Program,
                    City of Hope Cancer Center, Duarte, California 91010, USA.
                    ahuria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Clinical trials in older adults
                        with cancer: past and future</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology (Williston
                        Park)</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">351-8; discussion 363-4, 367</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged, 80 and over</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Forecasting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/ drug therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Randomized Controlled
                        Trials/trends</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0890-9091 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17447438</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The risk of cancer increases with
                    age, and as the U.S. population rapidly ages, the number of older adults seeking
                    treatment for cancer is also increasing dramatically. However, this growing
                    population of older adults has been underrepresented in clinical trials that set
                    the standards for oncology care. In addition, most clinical trials conducted to
                    date have not addressed the problems that accompany aging, including reduced
                    physiologic reserve, changes in drug pharmacokinetics, and the impact of
                    comorbid medical conditions and polypharmacy on treatment tolerance. As a
                    result, there are variations in treatment patterns between older and younger
                    adults and few evidence-based guidelines accounting for the changes in
                    physiology or pharmacokinetics that occur with aging. This article examines the
                    demographics of cancer and aging, the barriers to enrollment of older adults on
                    clinical trials, and approaches for future trials to address the needs of the
                    older patient.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/10/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>563</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">563</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1823</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lachs, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, CA 91010, USA.
                    ahurria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Is cognitive dysfunction a
                        complication of adjuvant chemotherapy in the older patient with breast
                        cancer?</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Research and
                        Treatment</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Breast Cancer Res.
                        Treat.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">259-68</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">103</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ complications/
                        drug therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chemotherapy, Adjuvant/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cognition/drug effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cognition Disorders/
                        complications</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Geriatrics/methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neuropsychological Tests</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-6806 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17429718</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">For a number of years, patients have
                    anecdotally reported changes in memory and concentration problems after
                    receiving chemotherapy for breast cancer. Neuropsychological studies have been
                    performed to seek objective evidence as to the existence and extent of this
                    phenomenon; however, these studies were primarily performed in younger women and
                    there is sparse data regarding the impact of adjuvant chemotherapy on an older
                    woman&apos;s cognition. The objective of this paper was to evaluate the current
                    literature in order to propose ways to overcome methodological limitations of
                    studies to consider whether chemotherapy-associated cognitive dysfunction exists
                    in older patients and if so, who is at risk. A systematic review of relevant
                    literature was performed including study design, mean age of participants,
                    treatment received, neuropsychological tests employed, timing of assessments,
                    definition of cognitive impairment, and results. The literature primarily
                    consists of small studies, which lack a prospective longitudinal design, vary in
                    design measures, and exclude older patients who are at greatest risk for
                    cognitive impairment. Since aging is the number one risk factor for breast
                    cancer, future studies of the neuropsychological impact of chemotherapy should
                    include older patients.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>693</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">693</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1369</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lichtman, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gardes, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Limaye, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Patil, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zuckerman, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tew, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamlin, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Abou-Alfa, G. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lachs, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kelly, E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Med
                    Oncol &amp; Therapeut Res, Canc &amp; Aging Res Program, Duarte, CA 91010 USA.
                    Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. Mem Sloan
                    Kettering Canc Ctr, Dept Epidemiol &amp; Biostat, New York, NY 10021 USA. Mem
                    Sloan Kettering Canc Ctr, Dept Psychiat &amp; Behav Sci, New York, NY 10021 USA.
                    Mem Sloan Kettering Canc Ctr, Dept Nursing, New York, NY 10021 USA. Cornell
                    Univ, Weill Med Coll, Dept Med, New York, NY USA. Long Isl Jewish Med Ctr, Dept
                    Med, New Hyde Pk, NY USA.&#xD;Hurria, A, City Hope Natl Med Ctr, Div Med Oncol
                    &amp; Therapeut Res, Canc &amp; Aging Res Program, 1500 E Duarte Rd, Duarte, CA
                    91010 USA.&#xD;ahurria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Identifying vulnerable older
                        adults with cancer: Integrating geriatric assessment into oncology
                        practice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the American
                        Geriatrics Society</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Am. Geriatr. Soc.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the American
                        Geriatrics Society</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Am. Geriatr. Soc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Am Geriatr Soc</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the American
                        Geriatrics Society</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Am. Geriatr. Soc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Am Geriatr Soc</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1604-1608</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">55</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">geriatric assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">self-administered</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">older cancer patient</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">questionnaire</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL STATUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ELDERLY-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATIENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FEASIBILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORTALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-8614</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249825500015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVES: To integrate the
                    principles of geriatric assessment into the care of older patients with cancer
                    in order to identify vulnerable older adults and develop interventions to
                    optimize cancer treatment. DESIGN: A brief, comprehensive, self-administered
                    questionnaire and intervention algorithm were developed consisting of measures
                    of geriatric assessment that are brief, reliable, validated, and predictive of
                    mortality and morbidity in older patients. SETTING: Academic tertiary care
                    cancer center and community-based satellite practice. PARTICIPANTS: Patients
                    aged 65 and older with cancer. MEASUREMENTS: The questionnaire solicits
                    information about the patient&apos;s functional status, comorbidity,
                    psychological status, nutritional status, and social support. A scoring
                    algorithm for referral to a multidisciplinary team was developed. RESULTS: Two
                    hundred forty-five of 250 patients completed the questionnaire (mean age 76,
                    range 65-95). The majority of patients were women (71%), white (95%), married
                    (52%), and retired (90%), with a variety of tumor types and stages. Most
                    patients (78%) completed the questionnaire on their own and reported acceptance
                    of questionnaire length (91%), no difficult questions (94%), no upsetting
                    questions (96%), and no missing questions (89%). The mean time to completion was
                    15 minutes, with a median of 12.5 (standard deviation 10, range 2-60).
                    Information from this questionnaire helped identify physical and psychological
                    impairments, poor nutrition, lack of social support, and untreated
                    comorbidities. Appropriate referrals to a multidisciplinary team were made.
                    CONCLUSION: This brief, comprehensive, self-administered questionnaire is
                    feasible for use in the outpatient oncology setting and helped identify the
                    needs of geriatric oncology patients. Prospective trials are needed to determine
                    the effectiveness of the interventions offered.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    215RA&#xD;Times Cited: 0&#xD;Cited Reference Count: 28</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249825500015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>754</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">754</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1820</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hurria, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ahles, T.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope, Duarte, CA 91010, USA.
                    ahurria@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Renaming
                        &quot;chemobrain&quot;</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Invest</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Investigation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Invest.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Invest</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">373-7</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Brain/ drug effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Breast Neoplasms/ drug
                        therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cognition Disorders/ chemically
                        induced</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0735-7907 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17882646</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">A subset of breast cancer survivors
                    are reporting cognitive impairment after cancer treatment, which has commonly
                    been attributed to the receipt of chemotherapy and colloquially termed
                    &quot;chemobrain.&quot; For some, a fear of this side effect enters into their
                    decision regarding therapy. Our review of the literature reveals that so-called
                    &quot;chemobrain&quot; is complex and that factors other than chemotherapy may
                    affect cognitive function, including the impact of surgery and anesthesia,
                    hormonal therapy, menopause, anxiety, depression, fatigue, supportive care
                    medications, genetic predisposition, comorbid medical conditions, or possibly
                    paraneoplastic phenomenon. Studies to date have differed in their assessment and
                    definition of cognitive impairment, thus, making comparisons between studies
                    difficult. In addition, most studies have been limited by a small sample size,
                    and there has been a general lack of focus on older patients despite their high
                    concentration within the cancer population. Large, multicenter studies are
                    needed to better understand the magnitude and mechanism of cognitive changes in
                    cancer survivors and to assess the impact of cognitive changes on the
                    patient&apos;s daily lives. We propose that the phenomenon commonly referred to
                    as &quot;chemobrain&quot; would be more accurately labeled &quot;cancer- or
                    cancer-therapy-associated cognitive change.&quot;</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/</style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/11/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>755</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">755</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1367</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hutson, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Baylor Sammons Canc Ctr,
                    Genitourinary Oncol Program, Texas Oncol, PA, Dallas, TX USA. US Oncol Res
                    Network, Dallas, TX USA. City Hope Natl Med Ctr, Div Med Oncol &amp; Expt
                    Therapeut, Duarte, CA 91010 USA.&#xD;Figlin, RA, City Hope Natl Med Ctr, Div Med
                    Oncol, Associate Director Clin Res, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rfiglin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Renal cell cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Journal</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer J</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">282-286</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">REFRACTORY SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAYS ON/7 DAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RAF</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BAY-43-9006</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHARMACOKINETICS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep-Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1528-9117</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250027500003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Metastatic renal cell cancer has
                    traditionally been treated with interferon and interleukin-2. An improved
                    understanding of the biology of renal cancer has engendered novel targeted
                    therapeutic agents that have altered the natural history of this disease. The
                    vascular endothelial growth factor and its related receptor and the mammalian
                    target of rapamycin signal transduction pathway in particular have been utilized
                    as therapeutic targets. Sunitinib malate, sorafenib tosylate, temsirolimus, and
                    bevacizumab/interferon alfa have improved clinical outcomes in randomized
                    trials. Other antiangiogenic agents have also demonstrated activity in early
                    studies. Given the availability of multiple treatment options, several questions
                    emerge as to how to integrate these new therapies into the management of
                    metastatic renal cell cancer. Recently reported and planned clinical trials will
                    help clarify the role of these agents. The future of therapy for renal cancer
                    appears promising owing to the efficacy of these novel agents.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    218PN&#xD;Times Cited: 0&#xD;Cited Reference Count: 34&#xD;Cited References:
                    &#xD; AMATO RJ, 2007, J CLIN ONCOL S, V25, P5026&#xD; AWADA A, 2005, BRIT J
                    CANCER, V92, P1855&#xD; BUKOWSKI RM, 2006, J CLIN ONCOL, V24, P4523&#xD;
                    BUKOWSKI RM, 2007, J CLIN ONCOL S18, V25, P5023&#xD; CLARK JW, 2005, CLIN CANCER
                    RES, V11, P5472&#xD; DHAM A, 2007, J CLIN ONCOL S, V25, P5106&#xD; EISEN T,
                    2006, J CLIN ONCOL S, V24, P4524&#xD; ESCUDIER B, 2007, J CLIN ONCOL, V25,
                    P3&#xD; ESCUDIER B, 2007, NEW ENGL J MED, V356, P125&#xD; GIBBONS JJ, 1999, P AM
                    ASSOC CANC RES, V40, P301&#xD; GORE ME, 2007, J CLIN ONCOL ASCO AN, V25,
                    P5010&#xD; HAINSWORTH JD, 2005, J CLIN ONCOL, V23, P7889&#xD; HUDES G, 2007, NEW
                    ENGL J MED, V356, P2271&#xD; HUDSON CC, 2002, MOL CELL BIOL, V22, P7004&#xD;
                    HUTSON TE, 2005, CLIN GENITOURIN CANC, V4, P181&#xD; HUTSON TE, 2007, J CLIN
                    ONCOL S, V25, P5031&#xD; HUTSON TE, 2007, PRINCIPLES PRACTICE, V21&#xD; JEMAL A,
                    2007, CA-CANCER J CLIN, V57, P43&#xD; MCDERMOTT DF, 2004, EXPERT OPIN BIOL TH,
                    V4, P455&#xD; MITA MM, 2003, CANCER BIOL THER S1, V2, S169&#xD; MOORE M, 2005,
                    ANN ONCOL, V16, P1688&#xD; MOTZER RJ, 2006, J CLIN ONCOL, V24, P16&#xD; MOTZER
                    RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516&#xD; MOTZER RJ, 2007, J CLIN ONCOL
                    S18, V25, P5024&#xD; MOTZER RJ, 2007, NEW ENGL J MED, V356, P115&#xD; PICKLE LW,
                    2007, CA-CANCER J CLIN, V57, P30&#xD; RINI B, 2005, J CLIN ONCOL, V23,
                    P4509&#xD; RINI BI, 2007, J CLIN ONCOL S, V25, P5032&#xD; SABLIN MP, 2007, J
                    CLIN ONCOL S, V25, P5038&#xD; STADLER WM, 2007, J CLIN ONCOL, V25, P5036&#xD;
                    STRUMBERG D, 2005, J CLIN ONCOL, V23, P965&#xD; SZCZYLIK C, 2007, J CLIN ONCOL,
                    V25, P5025&#xD; WILHELM SM, 2004, CANCER RES, V64, P7099&#xD; YANG JC, 2003, NEW
                    ENGL J MED, V349, P427</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250027500003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>912</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">912</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1366</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Hutson, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr, Div
                    Med Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Med Oncol &amp;
                    Expt Therapeut, Duarte, CA USA. PA Baylor Sammons Canc Ctr, Genitourinary Oncol
                    Program, Dallas, TX USA. US Oncol Res Network, Dallas, TX USA.&#xD;Figlin, RA,
                    City Hope Comprehens Canc Ctr, Div Med Oncol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rfiglin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Evolving role of novel targeted
                        agents in renal cell carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology-New York</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">1180</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">REFRACTORY SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAYS ON/7 DAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RAF</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC-FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTITUMOR-ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITOR</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0890-9091</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000253738400001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The treatment of metastatic renal
                    cell carcinoma (RCC) has changed dramatically over the past few years. An
                    improved understanding of the biology of RCC has resulted in the development of
                    novel targeted therapeutic agents that have altered the natural history of this
                    disease. In particular, the hypoxia-inducible factor (HIF)/vascular endothelial
                    growth factor (VEGF) path way and the mammalian target of rapamycin (mTOR)
                    signal transduction pathway have been exploited. Sunitinib malate (Sutent),
                    sorafenib tosylate (Nexavar), bevacizumab (Avastin)/interferon alfa, and
                    temsirolimus (Torisel) have improved clinical outcomes in randomized trials by
                    inhibiting these tumorigenic pathways. Combinations and sequences of these
                    agents are being evaluated. Other novel multitargeted tyrosine kinase inhibitors
                    (pazopanib and axitinib) and m TOR inhibitors (everolimus) are in clinical
                    development. Recently reported and ongoing clinical trials will help further
                    define the role of these agents as therapy for metastatic RCC.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    270RR&#xD;Times Cited: 0&#xD;Cited Reference Count: 37&#xD;Cited References:
                    &#xD; AMATO RJ, 2007, J CLIN ONCOL, V25, S241&#xD; AWADA A, 2005, BRIT J CANCER,
                    V92, P1855&#xD; BOULAY A, 2004, CANCER RES, V64, P252&#xD; BUKOWSKI RM, 2006, J
                    CLIN ONCOL S 1, V24, S222&#xD; BUKOWSKI RM, 2007, J CLIN ONCOL, V25, S240&#xD;
                    CLARK JW, 2005, CLIN CANCER RES, V11, P5472&#xD; DICOSIMO S, 2004, P AN M AM SOC
                    CLIN, V23, P213&#xD; EISEN T, 2006, J CLIN ONCOL, V24, S223&#xD; ESCUDIER B,
                    2007, J CLIN ONCOL, V25, S2&#xD; ESCUDIER B, 2007, NEW ENGL J MED, V356,
                    P125&#xD; GIBBONS JJ, 1999, P AM ASSOC CANC RES, V40, P301&#xD; HAINSWORTH JD,
                    2005, J CLIN ONCOL, V23, P7889&#xD; HUDES G, 2007, NEW ENGL J MED, V356,
                    P2271&#xD; HUDSON CC, 2002, MOL CELL BIOL, V22, P7004&#xD; HUTSON TE, 2005, CLIN
                    GENITOURIN CANC, V4, P181&#xD; HUTSON TE, 2007, J CLIN ONCOL, V25, S242&#xD;
                    HUTSON TE, 2007, PRINCIPLES PRACTICE, V21, P1&#xD; JEMAL A, 2007, CA-CANCER J
                    CLIN, V57, P43&#xD; MCDERMOTT DF, 2004, EXPERT OPIN BIOL TH, V4, P455&#xD;
                    MEKHAIL TM, 2005, J CLIN ONCOL, V23, P832&#xD; MITA MM, 2003, CANCER BIOL THER
                    S1, V2, S169&#xD; MOORE M, 2005, ANN ONCOL, V16, P1688&#xD; MOTZER RJ, 1997,
                    PRINCIPLES PRACTICE, P885&#xD; MOTZER RJ, 1999, J CLIN ONCOL, V17, P2530&#xD;
                    MOTZER RJ, 2004, J CLIN ONCOL, V22, P454&#xD; MOTZER RJ, 2006, J CLIN ONCOL,
                    V24, P16&#xD; MOTZER RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516&#xD; MOTZER RJ,
                    2007, J CLIN ONCOL S, V25, S241&#xD; MOTZER RJ, 2007, NEW ENGL J MED, V356,
                    P115&#xD; PICKLE LW, 2007, CA-CANCER J CLIN, V57, P30&#xD; RINI B, 2005, J CLIN
                    ONCOL S 1, V23, S380&#xD; RINI BI, 2007, J CLIN ONCOL, V25, S242&#xD; STRUMBERG
                    D, 2005, J CLIN ONCOL, V23, P965&#xD; SZCZYLIK C, 2007, J CLIN ONCOL, V25,
                    S241&#xD; WILHELM SM, 2004, CANCER RES, V64, P7099&#xD; YAGODA A, 1995, SEMIN
                    ONCOL, V22, P42&#xD; YANG JC, 2003, NEW ENGL J MED, V349, P427</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000253738400001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/04/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>958</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">958</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1365</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Idell, C. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kirk, C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">[Idell, Cynthia Smith; Grant,
                    Marcia; Kirk, Christina] City Hope Natl Med Ctr, Duarte, CA 91010
                    USA.&#xD;Idell, CS, City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;cidell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Alignment of Pain Reassessment
                        Practices and National Comprehensive Cancer Network Guidelines</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncol Nurs Forum</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">661-671</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ORGANIZATIONAL-CHANGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MANAGEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0190-535X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000261316400012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose/Objectives: To improve
                    nursing pain reassessment practices using a research utilization model and
                    advanced practice nurses (APNs). Design: A pre- and postintervention one-group
                    design. Setting: A cancer hospital located in the western United States. Sample:
                    42 oncology RNs from the inpatient staff of medical or surgical oncology units
                    working at least 24 hours per week. Methods: National Comprehensive Cancer
                    Network clinical practice guidelines were adopted. Interventions included
                    one-on-one feedback regarding reassessment practices and nursing pain rounds.
                    Instruments used were Nurses&apos; Knowledge and Attitudes Survey Regarding Pain
                    (NKASRP), Pain Reassessment Data Tool, and Pain Competency Evaluation (PCE).
                    Main Research Variables: Independent variables were pain rounds and one-on-one
                    feedback. Dependent variables were PCE scores, percentage of pain reassessment
                    documentation, and NKASRP test scores. Findings: Changing staff pain practices
                    requires more than education. Barriers may be overcome through careful planning,
                    using a systematic change process such as a research utilization approach.
                    NKASRP and PCE scores and a percentage of reassessment documentation reached
                    statistically significant increases postintervention. Conclusions: Adapting
                    research recommendations allowed staff to create unit-specific solutions,
                    evaluate practice changes, establish research partnerships, and use research in
                    bedside care. Staff increased their proficiency in pain reassessment practices
                    after the intervention. Implications for Nursing: Research utilization models
                    bring about desired practice changes under APN leadership. Aligning pain
                    reassessment practices with clinical pain guideline recommendations promotes
                    improved pain management through better reassessment documentation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    378JG&#xD;Times Cited: 0&#xD;Cited Reference Count: 38&#xD;Cited References:
                    &#xD; *AG HLTH CAR POL R, 1994, MAN CANC PAIN CLIN P&#xD; *AM PAIN SOC, 2003,
                    PRINC AN US TREATM A&#xD; *CIT HOP, 2006, PERF ASS TOOLS POS S&#xD; *COCHR COLL,
                    2006, PAIN PALL SUPP CAR&#xD; *JOINT COMM ACCR H, 2000, PAIN ASS MAN ORG
                    APP&#xD; *NAT COMPR CANC NE, 2004, CANC PAIN CLIN PRACT&#xD; *WHO, 1990, TECHN
                    REP SER WHO, V804&#xD; AIKEN LH, 1997, MED CARE S, V35, NS6&#xD; ASSELIN ME,
                    2001, J NURSES STAFF DEV, V17, P115&#xD; BALTIC TE, 2002, CANCER PRACT S1, V10,
                    S39&#xD; BUCKNALL T, 2001, INT J NURSING PRACTI, V7, P266&#xD; CAMERON G, 1998,
                    J NURS ADMIN, V28, P3&#xD; COHEN MZ, 2003, J PAIN SYMPTOM MANAG, V25, P519,
                    DOI&#xD; 10.1016/S0885-3924(03)00068-X&#xD; DOOKS P, 2001, CANCER NURS, V24,
                    P99&#xD; DUFAULT MA, 1995, J ADV NURS, V21, P634&#xD; DUNCAN K, 2001, OUTCOMES
                    MANAG NURS, V5, P57&#xD; FERRELL BR, 1993, J PROF NURS, V9, P79&#xD; FRANCKE AL,
                    1997, J PAIN SYMPTOM MANAG, V13, P90&#xD; GELINAS C, 2004, AM J CRIT CARE, V13,
                    P126&#xD; GIVEN B, 2004, NURSING SENSITIVE PA&#xD; GORDON DB, 2005, ARCH INTERN
                    MED, V165, P1574&#xD; HAMBLETON RK, 1983, J EDUC MEAS, V20, P355&#xD; HERR K,
                    2004, CLIN J PAIN, V20, P331&#xD; HORSLEY JA, 1978, J NURS ADMIN, V8, P4&#xD;
                    IDELL CS, 2004, ONCOLOGY SUPPORTIVE, V3, P30&#xD; JANKEN JK, 2002, ONLINE J
                    KNOWL SYN N, V9, ARTN 2C&#xD; JASSAK PF, 2001, ONCOL NUS FORUM, V28, P3&#xD;
                    MCCAUGHAN D, 2002, J ADV NURS, V39, P46&#xD; MELNICHENKO TN, 2002, GLASS PHYS
                    CHEM+, V28, P25&#xD; MERCADANTE S, 2005, ANN ONCOL S4, V16, P132, DOI
                    10.1093/annonc/mdi922&#xD; ROGERS EM, 1995, DIFFUSION INNOVATION&#xD; ROUSSEAU
                    DM, 1999, J APPL PSYCHOL, V84, P514&#xD; RUTLEDGE D, 1995, ONCOLGOY NURSING UPD,
                    P1&#xD; RUTLEDGE DN, 1998, ONLINE J CLIN INNOVA, V1, P1&#xD; RUTLEDGE DN, 2002,
                    SEMINARS ONCOLOGY NU, V18, P3&#xD; THOMPSON CJ, 1997, THESIS TEXAS WOMANS&#xD;
                    VALLERAND AH, 1997, SEMIN ONCOL NURS, V13, P16&#xD; WILLSON H, 2000, J ADV NURS,
                    V31, P1145</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000261316400012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI</style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">10.1188/07.onf.661-671</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>200</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">200</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1361</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Itakura, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Asari, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ito, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, C. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sasaki, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mullen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Dept Diabet Endocrinol &amp; Metab, So Calif Islet Cell Resource Ctr,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol,
                    Duarte, CA 91010 USA. Univ Tokyo, Lab Vet Surg, Tokyo, Japan.&#xD;Itakura, S,
                    City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet Endocrinol &amp; Metab, So
                    Calif Islet Cell Resource Ctr, Duarte, CA 91010
                    USA.&#xD;sitakura@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mesenchymal stem cells
                        facilitate the induction of mixed hematopoietic chimerism and islet
                        allograft tolerance without GVHD in the rat</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Transplantation</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Transplantation</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">336-346</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">GVHD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immune tolerance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">islet transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mesenchymal stem cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mixed chimerism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW STROMAL CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UMBILICAL-CORD BLOOD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CULTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REVERSAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1600-6135</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243440100010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Induction of hematopoietic chimerism
                    and subsequent donor-specific immune tolerance via bone marrow transplantation
                    is an ideal approach for islet transplantation to treat type-1 diabetes. We
                    examined the potential of mesenchymal stem cells (MSCs) in the induction of
                    chimerism and islet allograft tolerance without the incidence of
                    graft-versus-host disease (GVHD). Streptozotocin-diabetic rats received a
                    conditioning regimen consisting of antilymphocyte serum and 5 Gy total body
                    irradiation, followed by an intraportal co-infusion of allogeneic MSCs, bone
                    marrow cells (BMCs) and islets. Although all the recipients rejected the islets
                    initially, half of them developed stable mixed chimerism and donor-specific
                    immune tolerance, shown by the engraftment of donor skin and second-set islet
                    transplants and acute rejection of a third-party skin. The engraftment of the
                    primary islet allografts with stable chimerism was achieved by the addition of a
                    2-week peritransplant administration of 15-deoxyspergualin (DSG). Without MSCs,
                    none of the recipients treated with DSG developed chimerism or reversal of
                    diabetes. GVHD was not observed in any of the recipients infused with MSCs
                    (0/15), whereas it occurred in 4/11 recipients without MSCs. These results
                    indicate a potential use of MSCs for induction of hematopoietic chimerism and
                    subsequent immune tolerance in clinical islet transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    125KF&#xD;Times Cited: 0&#xD;Cited Reference Count: 38&#xD;Cited References:
                    &#xD; BARTHOLOMEW A, 2002, EXP HEMATOL, V30, P42&#xD; BENSIDHOUM M, 2004, BLOOD,
                    V103, P3313&#xD; CALLERY MP, 1989, TRANSPLANTATION, V47, P1092&#xD; CORCIONE A,
                    2005, BLOOD, V107, P367&#xD; DINICOLA M, 2002, BLOOD, V99, P3838&#xD; DORSHKIND
                    K, 1990, ANNU REV IMMUNOL, V8, P111&#xD; FRIEDENSTEIN AJ, 1968, TRANSPLANTATION,
                    V6, P230&#xD; GLENNIE S, 2005, BLOOD, V105, P2821&#xD; IKEBUKURO K, 2002,
                    TRANSPLANTATION, V73, P512&#xD; JAKSCH M, 2005, SCAND J IMMUNOL, V61, P398&#xD;
                    JIANG XX, 2005, BLOOD, V105, P4120&#xD; JIANG YH, 2002, NATURE, V418, P41&#xD;
                    KAMADA N, 1981, NATURE, V292, P840&#xD; KAUFMAN DB, 1994, DIABETES, V43,
                    P778&#xD; KENMOCHI T, 1996, CELL TRANSPLANT, V5, P41&#xD; KOC ON, 2000, J CLIN
                    ONCOL, V18, P307&#xD; KRAMPERA M, 2003, BLOOD, V101, P3722&#xD; LAZARUS HM,
                    2005, BIOL BLOOD MARROW TR, V11, P389&#xD; LEBLANC K, 2004, LANCET, V363,
                    P1439&#xD; LEE OK, 2004, BLOOD, V103, P1669&#xD; LEE ST, 2002, BRIT J HAEMATOL,
                    V118, P1128&#xD; MATSUURA A, 2000, J IMMUNOL, V164, P3140&#xD; MEISEL R, 2004,
                    BLOOD, V103, P4619&#xD; MUGURUMA Y, 2005, BLOOD, V107, P1878&#xD; MUSINA RA,
                    2005, B EXP BIOL MED+, V139, P504&#xD; NIKOLIC B, 2004, DIABETES, V53, P376&#xD;
                    NOORT WA, 2002, EXP HEMATOL, V30, P870&#xD; PROCKOP DJ, 1997, SCIENCE, V276,
                    P71&#xD; ROMBOUTS WJC, 2003, LEUKEMIA, V17, P160&#xD; ROSSINI AA, 2001,
                    TRANSPLANTATION S, V72, S43&#xD; SOTIROPOULOU PA, 2005, STEM CELLS&#xD;
                    SPAGGIARI GM, 2005, BLOOD&#xD; SYKES M, 1988, IMMUNOL TODAY, V9, P23&#xD; THOMAS
                    JM, 2001, DIABETES, V50, P1227&#xD; TOYOFUKU A, 2006, DIABETES, V55, P34&#xD;
                    TSE WT, 2003, TRANSPLANTATION, V75, P389&#xD; WANG L, 2002, EXP HEMATOL, V30,
                    P831&#xD; ZAPPIA E, 2005, BLOOD, V106, P1755</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243440100010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>817</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">817</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1360</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jain, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McGory, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ko, C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sverdlik, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tomlinson, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wendel, C. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Coons, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawl, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmidt, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McCorkle, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mohler, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baldwin, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Dept Surg, Ctr Surg Outcomes &amp; Qual, Los Angeles, CA 90095 USA.
                    Greater W Los Angeles VA Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA.
                    So Arizona Vet Affairs Hlth Care Syst, Res Serv Line, Tucson, AZ 85723 USA. Univ
                    Arizona, Coll Publ Hlth, Tucson, AZ 85721 USA. Univ Arizona, Coll Pharm, Tucson,
                    AZ 85721 USA. Indiana Univ, Sch Nursing, Ctr Nursing Res, Indianapolis, IN 46202
                    USA. Indiana Univ, Sch Med, Richard L Roudebush VA Med Ctr, Dept Surg &amp;
                    Biochem Mol Biol,Canc Res Inst R4, Indianapolis, IN 46202 USA. City Hope Natl
                    Med Ctr, Beckman Res Inst, Dept Nursing Res &amp; Educ, Duarte, CA 91010 USA.
                    Yale Univ, Sch Nursing, New Haven, CT 06536 USA. Univ Arizona, Coll Med, Hlth
                    Serv Res Ctr Surg Care Line, Tucson, AZ 85723 USA. Arizona State Univ, Coll
                    Nursing &amp; Heathcare Innovat SW Borderlands, Phoenix, AZ 85004 USA.&#xD;Jain,
                    S, Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ctr Surg Outcomes
                    &amp; Qual, 72-215 CHS,10833 Le Conte Ave, Los Angeles, CA 90095
                    USA.&#xD;sjain@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Comorbidities play a larger role
                        in predicting health-related quality of life compared to having an
                        ostomy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">774-779</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">194</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">comorbidites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ostomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">health-related quality of
                        life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECTAL-CANCER PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VETERANS-HEALTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STOMA PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMMUNITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLOSTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMPACT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-9610</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251276000014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Previous research
                    suggests an ostomy worsens health-related quality of life (HR-QOL), but
                    comorbidities also can affect HR-QOL. Methods: Eligible patients had abdominal
                    operation with ostomy (cases) or similar procedure without ostomy (controls).
                    Patients were recruited for this case-control study from 3 Veterans Affairs
                    hospital medical and pharmacy records. Comorbidities were assessed with
                    Charlson-Deyo Comorbidity Index. Multinomial logistic regression evaluated the
                    impact of comorbidities and having an ostomy on HR-QOL, measured using the
                    Medical Outcomes Study Short Form 36 for Veterans. Results: A total of 237
                    ostomates (cases) and 268 controls were studied. Average age was 69 years;.64%
                    of cases had colostomy, 36% ileostomy. Twenty-nine percent of patients had a
                    high level of comorbidifies. Cases and controls were similar except for reasons
                    for undergoing surgery. High comorbidity was a significant predictor of low
                    HR-QOL in 6 domains of the Short Form 36 for Veterans; having an ostomy was a
                    significant predictor in 4. Conclusions: High comorbidity significantly
                    influences low HR-QOL and impacted more domains than having an ostomy. (c) 2007
                    Excerpta Medica Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    236AS&#xD;Times Cited: 0&#xD;Cited Reference Count: 22&#xD;Cited References:
                    &#xD; *CIT HOP, BECKM RES I PAIN RES&#xD; DEYO RA, 1992, J CLIN EPIDEMIOL, V45,
                    P613&#xD; ENGEL J, 2003, ANN SURG, V238, P203&#xD; KARADAG AE, 2003, INT J
                    COLORECTAL DIS, V18, P234&#xD; KAZIS LE, 1998, ARCH INTERN MED, V158, P626&#xD;
                    KAZIS LE, 1999, AM J MED QUAL, V14, P28&#xD; KAZIS LE, 2004, J AMBUL CARE
                    MANAGE, V27, P263&#xD; KROUSE RS, 2006, CURR MED RES OPIN, V22, P781&#xD;
                    LAMONICA G, 1985, DIS COLON RECTUM, V28, P937&#xD; MACDONALD LD, 1984, J
                    EPIDEMIOL COMMUN H, V38, P284&#xD; MACDONALD LD, 1985, EUR J SURG ONCOL, V11,
                    P235&#xD; MANGIONE CM, 1997, J GEN INTERN MED, V12, P686&#xD; MARQUIS P, 2003,
                    OSTOMY WOUND MANAG, V49, P48&#xD; NUGENT KP, 1999, DIS COLON RECTUM, V42,
                    P1569&#xD; SILVA MA, 2003, WORLD J SURG, V27, P421&#xD; SINGH B, 1998, HEAD
                    NECK-J SCI SPEC, V20, P1&#xD; SPRANGERS MAG, 1995, DIS COLON RECTUM, V38,
                    P361&#xD; STOJANOVIC M, 2007, ARTIF ORGANS, V31, P53&#xD; TUMBULL GB, 2003,
                    OSTOMY WOUND MANAG, V49, P22&#xD; WARE JE, 1992, MED CARE, V30, P473&#xD;
                    WILLIAMS NS, 1983, BRIT J SURG, V70, P460&#xD; WIRSCHING M, 1975, PSYCHOTHER
                    PSYCHOSOM, V26, P245</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251276000014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>878</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">878</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1357</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div Canc
                    Immunotherapeut &amp; Tumor Immunol, Duarte, CA USA.&#xD;Jensen, MC, Beckman Res
                    Inst City Hope, Div Canc Immunotherapeut &amp; Tumor Immunol, Duarte, CA
                    USA.&#xD;mjensen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Engineering GVL through T cell
                        gene transfer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5-5</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252333500004</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    250XB&#xD;Times Cited: 0&#xD;Cited Reference Count: 0&#xD;Suppl. 1</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252333500004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/03/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>842</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">842</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1356</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Jiang, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fan, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heung, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xue, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kirschbaum, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Clin
                    &amp; Mol Pharmacol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Bone
                    Marrow Transplantat &amp; Hematol, Duarte, CA 91010 USA.&#xD;Yen, Y, City Hope
                    Natl Med Ctr, Dept Clin &amp; Mol Pharmacol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;yyen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A sequential treatment of
                        depsipeptide followed by 5-azacytidine enhances Gadd45 beta expression in
                        hepatocellular carcinoma cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Anticancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Anticancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Anticancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Anticancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3783-3789</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">27</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6B</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">depsipeptide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">5-azacytidine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gadd45 beta</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HCC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">synergistic effect</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HISTONE DEACETYLASE
                        INHIBITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA METHYLTRANSFERASE
                        INHIBITORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYELOID-LEUKEMIA CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN CANCER-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPRESS TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACETYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYD118</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov-Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0250-7005</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251901700002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: DNA methylation can
                    influence histone modification and gene expression. The growth-arrest DNA damage
                    inducible gene 45 beta (Gadd45 beta) has been reported as a potential diagnostic
                    marker for aggressive hepatocellular carcinoma. In this study, the synergistic
                    effect of the histone deacetylase inhibitor depsipeptide and the DNA
                    methyltransferase inhibitor 5-azacytidine on the Gadd45 beta gene expression in
                    human liver cells was examined. Materials and Methods: The effects of
                    depsipeptide and 5-azacytidine in CL-48, HepG2 and Hep3B cells were examined by
                    PCR, cell viability test, Western blot and chromatin immunoprecipitation assay.
                    Results: Two mu M depsipeptide reactivated Gadd45 beta gene expression
                    considerably within 4 h in HepG2 cells, but not in CL-48 or Hep3B cells. Up to
                    10 mu M 5-azacytidine had no reactivation effect on Gadd45 beta. A sequential
                    treatment of depsipeptide+5-azacytidine (but not 5-azacytidine+depsipeptide)
                    exhibited a synergistic effect on Gadd45 beta gene reactivation in the HepG2
                    cells. Conclusion: The results show for the first time that histone acetylation
                    in sequence with hypermethylation can override transcriptional repression. Our
                    results provide a novel insight into the epigenetics-based strategy for treating
                    human liver cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    244YP&#xD;Times Cited: 0&#xD;Cited Reference Count: 35&#xD;Cited References:
                    &#xD; ABDOLLAHI A, 1991, ONCOGENE, V6, P165&#xD; CAMERON EE, 1999, NAT GENET,
                    V21, P103&#xD; CHEUNG YW, 1984, AM J HOSP PHARM, V41, P1156&#xD; DENHARTIGH J,
                    1989, AM J HOSP PHARM, V46, P2500&#xD; ESTELLER M, 2002, J PATHOL, V196, P1&#xD;
                    GORE SD, 2006, CANCER RES, V66, P6361&#xD; GROTH A, 2007, CELL, V128, P721&#xD;
                    HE J, 2005, J VIROL, V79, P13497&#xD; JONES PA, 2002, NAT REV GENET, V3,
                    P415&#xD; JONES PL, 1998, NAT GENET, V19, P187&#xD; KASS SU, 1997, TRENDS GENET,
                    V13, P444&#xD; KIM IA, 2006, CLIN CANCER RES 1, V12, P940&#xD; KLISOVIC MI,
                    2003, LEUKEMIA, V17, P350&#xD; LEE MG, 2006, MOL CELL BIOL, V26, P6395&#xD; LI
                    E, 1992, CELL, V69, P915&#xD; MAJOR MB, 2004, J BIOL CHEM, V279, P5278&#xD;
                    MARKS PA, 2000, J NATL CANCER I, V92, P1210&#xD; NAN XS, 1998, NATURE, V393,
                    P386&#xD; PEART MJ, 2003, CANCER RES, V63, P4460&#xD; PEART MJ, 2005, P NATL
                    ACAD SCI USA, V102, P3697&#xD; QIU WH, 2003, AM J PATHOL, V162, P1961&#xD; QIU
                    WH, 2004, AM J PATHOL, V165, P1689&#xD; RICHON VM, 2000, P NATL ACAD SCI USA,
                    V97, P10014&#xD; ROBERTSON KD, 2000, NAT GENET, V25, P338&#xD; SAMBUCETTI LC,
                    1999, J BIOL CHEM, V274, P34940&#xD; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14,
                    P2352&#xD; SILVERMAN LR, 2004, BEST PRACT RES CL HA, V17, P585&#xD; SINGAL R,
                    1999, BLOOD, V93, P4059&#xD; STEINER FA, 2005, ONCOGENE, V24, P2386&#xD; THYSS
                    R, 2005, EMBO J, V24, P128&#xD; VAIRAPANDI M, 2000, J BIOL CHEM, V275,
                    P16810&#xD; VAIRAPANDI M, 2002, J CELL PHYSIOL, V192, P327&#xD; WADE PA, 2001,
                    HUM MOL GENET, V10, P693&#xD; WEISBERG E, 2004, LEUKEMIA, V18, P1951&#xD;
                    WISCHNEWSKI F, 2006, MOL CANCER RES, V4, P339</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251901700002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>818</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">818</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1348</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kantarjian, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Giles, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gattermann, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhalla, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Alimena, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palandri, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ossenkoppele, G. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nicolini, F. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Brien, S. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Litzow, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cervantes, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haque, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shou, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Resta, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzman, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hochhaus, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">le Coutre, P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">MD Anderson Canc Ctr, Houston, TX
                    77030 USA. Univ Klinikum Duesseldorf, Dusseldorf, Germany. H Lee Moffitt Canc
                    Ctr &amp; Res Inst, Tampa, FL USA. Univ Roma La Sapienza, Azienda Policlin
                    Umberto, Rome, Italy. Univ Bologna, S Orsola Malpighi Univ Hosp, Bologna, Italy.
                    Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. Hop Edouard Herriot,
                    Lyon, France. Royal Victoria Infirm, Newcastle Upon Tyne, Tyne &amp; Wear,
                    England. Mayo Clin, Sch Med, Rochester, MN USA. City Hope Natl Med Ctr, Duarte,
                    CA USA. Hosp Clin Barcelona, Barcelona, Spain. Nova Pharmaceut, Florham Pk, NJ
                    USA. Univ Heidelberg, Med Fak Mannhein, Med Klin 3, Mannheim, Germany. Humboldt
                    Univ, Camp Virchow Klin, Berlin, Germany.&#xD;Kantarjian, HM, MD Anderson Canc
                    Ctr, Houston, TX 77030 USA.&#xD;hkantarj@mdanderson.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nilotinib (formerly AMN107), a
                        highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients
                        with Philadelphia chromosome-positive chronic myelogenous leukemia in
                        chronic phase following imatinib resistance and intolerance</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3540-3546</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">110</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOGENETIC RESPONSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLAST CRISIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DASATINIB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESYLATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIOLOGY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CML</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250946300016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Nilotinib, an orally bioavailable,
                    selective Ber-Abl tyrosine kinase inhibitor, is 30-fold more potent than
                    imatinib in preclinical models, and overcomes most imatinib resistant BCR-ABL
                    mutations. In this phase 2 open-label study, 400 mg nilotinib was administered
                    orally twice daily to 280 patients with Philadelphia chromosome-positive (Ph+)
                    chronic myeloid leukemia in chronic phase (CML-CP) after imatinib failure or
                    intolerance. Patients had at least 6 months of followup and were evaluated for
                    hematologic and cytogenetic responses, as well as for safety and overall
                    survival. At 6 months, the rate of major cytogenetic response (Ph &lt;= 35%) was
                    48%: complete (Ph = 0%) in 31%, and partial (Ph = 1%-35%) in 16%. The estimated
                    survival at 12 months was 95%. Nilotinib was effective in patients harboring
                    BCR-ABL mutations associated with imatinib resistance (except T315I), and also
                    in patients with a resistance mechanism independent of BCR-ABL mutations.
                    Adverse events were mostly mild to moderate, and there was minimal
                    cross-intolerance with imatinib. Grades 3 to 4 neutropenia and thrombocytopenia
                    were observed in 29% of patients; pleural or pericardial effusions were observed
                    in 1% (none were severe). In summary, nilotinib is highly active and safe in
                    patients with CML-CP after imatinib failure or intolerance. This clinical trial
                    is registered at http://clinicaltrials.gov as ID no. NCT00109707.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    231KS&#xD;Times Cited: 0&#xD;Cited Reference Count: 23&#xD;Cited References:
                    &#xD; COWANJACOB SW, 2007, ACTA CRYSTALLOGR D 1, V63, P80&#xD; DRUKER BJ, 2006,
                    NEW ENGL J MED, V355, P2408&#xD; FADERL S, 1999, NEW ENGL J MED, V341, P164&#xD;
                    GOLEMOVIC M, 2005, CLIN CANCER RES, V11, P4941&#xD; GORRE ME, 2001, SCIENCE,
                    V293, P876&#xD; HOCHHAUS A, 2004, LEUKEMIA, V18, P1321&#xD; HOCHHAUS A, 2007,
                    BLOOD, V109, P2303&#xD; KANTARJIAN H, 2002, NEW ENGL J MED, V346, P645&#xD;
                    KANTARJIAN H, 2004, BLOOD, V103, P2873&#xD; KANTARJIAN H, 2006, NEW ENGL J MED,
                    V354, P2542&#xD; KANTARJIAN HM, 1987, AM J MED, V83, P445&#xD; KANTARJIAN HM,
                    1988, CANCER, V61, P1441&#xD; MANLEY PW, 2006, BLOOD 1, V108, A224&#xD; MANLEY
                    PW, 2007, P AM ASS CANC RES, V48&#xD; OBRIEN SG, 2003, NEW ENGL J MED, V348,
                    P994&#xD; OHARE T, 2005, CANCER RES, V65, P4500&#xD; QUINTASCARDAMA A, 2006,
                    BLOOD, V108&#xD; SAWYERS CL, 1999, NEW ENGL J MED, V340, P1330&#xD; SHAH NP,
                    2004, SCIENCE, V305, P399&#xD; SILVER RT, 2004, BLOOD 1, V104, A11&#xD; TALPAZ
                    M, 2006, NEW ENGL J MED, V354, P2531&#xD; WEISBERG E, 2005, CANCER CELL, V7,
                    P129&#xD; WEISBERG E, 2006, BRIT J CANCER, V94, P1765</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250946300016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>632</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">632</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1347</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kaplan, F. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Glaser, D. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shore, E. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pignolo, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xu, M. Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Senitzer, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Emerson, S. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Penn, Sch Med, Dept Orthopaed
                    Surg, Ctr Res Fibrodyplasia Ossificans Progress &amp; Relat, Philadelphia, PA
                    19104 USA. City Hope Natl Med Ctr, Div Hematol &amp; Hematopoiet Cell
                    Transplantat, Duarte, CA 91010 USA.&#xD;Kaplan, FS, Univ Penn, Sch Med, Dept
                    Orthopaed Surg, Ctr Res Fibrodyplasia Ossificans Progress &amp; Relat, 424
                    Stemmler Hall,36th &amp; Hamilton Walk, Philadelphia, PA 19104
                    USA.&#xD;frederick.kaplan@uphs.upenn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Hematopoietic stem-cell
                        contribution to ectopic skeletogenesis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Bone and Joint
                        Surgery-American Volume</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Bone Joint Surg.-Am.
                        Vol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Bone and Joint
                        Surgery-American Volume</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Bone Joint Surg. Am.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Bone Joint Surg Am</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">347-357</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">89A</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">FIBRODYSPLASIA OSSIFICANS
                        PROGRESSIVA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESENCHYMAL PROGENITOR
                        CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HETEROTOPIC OSSIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OSTEOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMPERFECTA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STROMAL CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NONHEMATOPOIETIC TISSUES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNALING PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NATURAL-HISTORY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSGENIC MICE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9355</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244121800017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Fibrodysplasia
                    ossificans progressiva is a rare genetic disorder of ectopic skeletogenesis
                    associated with dysregulation of bone morphogenetic protein (BMP) signaling.
                    Hematopoietic cells have been implicated in the ectopic skeletogenesis of
                    fibrodysplasia ossificans progressiva, and their replacement has been postulated
                    as a possible cure. However, the definitive contribution of hematopoietic cells
                    to the pathogenesis of ectopic skeletogenesis remains obscure. Methods: We
                    employed both careful clinical observation and in vivo murine transplantation
                    studies to more precisely determine the contribution of hematopoietic cells to
                    ectopic skeletogenesis. We identified a patient with fibrodysplasia ossificans
                    progressiva who had undergone bone marrow transplantation for the treatment of
                    intercurrent aplastic anemia twenty-five years earlier and investigated whether
                    the clinical course of the fibrodysplasia ossificans progressiva had been
                    influenced by bone marrow replacement or immunosuppression, or both. In
                    complementary studies, we transplanted hematopoietic stem cells from
                    constitutively expressing LacZ transgenic mice to identify the contribution of
                    hematopoietic cells to BMP4-induced heterotopic ossification, a histopathologic
                    model of fibrodysplasia ossificans progressiva. Results: We found that
                    replacement of hematopoietic cells was not sufficient to prevent ectopic
                    skeletogenesis in the patient with fibrodysplasia ossificans progressiva but
                    pharmacologic suppression of the apparently normal donor immune system following
                    transplantation in the new host modulated the activity of the fibrodysplasia
                    ossificans progressiva and diminished the expression of skeletal ectopia. In
                    complementary murine transplantation studies, we found that cells of
                    hematopoietic origin contributed to the early inflammatory and late
                    marrow-repopulating stages of BMP4-induced heterotopic ossification but were not
                    represented in the fibroproliferative, chondrogenic, or osteogenic stages of
                    heterotopic ossification. Interestingly, both recombinant human BMP4 induction
                    in an animal model and the dysregulated BMP signaling pathway in a patient with
                    fibrodysplasia ossificans progressiva were sufficient to recruit at least two
                    populations of cells, one of hematopoietic origin and at least one of
                    non-hematopoietic origin, that contribute to the formation of an ectopic
                    skeleton. Conclusions: Taken together, these findings demonstrate that bone
                    marrow transplantation did not cure fibrodysplasia ossificans progressiva in the
                    patient in this study, most likely because the hematopoietic cell population is
                    not the site, or at least not the dominant site, of the intrinsic dysregulation
                    of the BMP signaling pathway in fibrodysplasia ossificans progressiva. However,
                    following transplantation of bone marrow from a presumably normal donor,
                    immunosuppression of the immune system appeared to ameliorate activation of
                    ectopic skeletogenesis in a genetically susceptible host. Thus, cells of
                    hematopoietic origin may contribute to the formation of an ectopic skeleton,
                    although they are not sufficient to initiate the process alone. Clinical
                    Relevance: Therapeutic regulation of hematopoietic and osteogenic cell
                    populations involved in fibrodysplasia ossificans progressiva lesions holds
                    promise for treatment of fibrodysplasia ossificans progressiva and possibly
                    other disorders of heterotopic ossification.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    134YX&#xD;Times Cited: 0&#xD;Cited Reference Count: 75</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244121800017 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>696</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">696</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1344</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kateb, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van Handel, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, L. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bronikowski, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Manohara, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Badie, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Comprehens Canc Ctr,
                    Dept Neurosurg, Brain Tumor Program, Duarte, CA 91010 USA. CALTECH, Jet Prop
                    Lab, Pasadena, CA 91109 USA.&#xD;Kateb, B, City Hope Natl Comprehens Canc Ctr,
                    Dept Neurosurg, Brain Tumor Program, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;Bkateb@IBMISPS.Org Bbadie@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Internalization of MWCNTs by
                        microglia: Possible application in immunotherapy of brain tumors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Neuroimage</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">NeuroImage</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">NeuroImage</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">NeuroImage</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">S9-S17</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">37</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">multi-walled carbon
                        nanotubes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nanotechnology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nanomedicine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">brain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nanoparticles</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microglia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONALIZED CARBON
                        NANOTUBES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG-DELIVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE DELIVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BUNDLE ARRAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PLASMID DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPORTERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FLUORESCENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1053-8119</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249434100001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">There is a pressing need for new
                    therapeutic, diagnostic, and drug delivery approaches for treating brain
                    cancers. Nanotechnology offers a new method for targeted brain cancer therapy
                    and could play a major role in gene and drug delivery. The goals of our study
                    were to visualize in vitro ingestion, cytotoxicity, and loading capacity of
                    Multi-Walled Carbon Nanotubes (MWCNTs) in microglia. Furthermore, we
                    investigated internalization differences between microglia and glioma cells. BV2
                    microglia and GL261 glioma cells were incubated with MWCNTs, which were
                    synthesized through catalytic chemical vapor deposition technique. Real-time
                    RT-PCR, cell proliferation analysis, siRNA and DNA loading, electron microscopy,
                    and flow cytometry were performed. We demonstrated that MWCNTs do not result in
                    proliferative or cytokine changes in vitro, are capable of carrying DNA and
                    siRNA and are internalized at higher levels in phagocytic cells as compared to
                    tumor cells. This study suggests MWCNTs could be used as a novel, non-toxic, and
                    biodegradable nano-vehicles for targeted therapy in brain cancers. Further
                    studies are needed to demonstrate the full capacity of MWCNTs as nanovectors.
                    (c) 2007 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    210CK&#xD;Times Cited: 0&#xD;Cited Reference Count: 36&#xD;Cited References:
                    &#xD; BIANCO A, 2004, EXPERT OPIN DRUG DEL, V1, P57&#xD; BIANCO A, 2005, CURR
                    DRUG DELIV, V2, P253&#xD; BIANCO A, 2005, CURR OPIN CHEM BIOL, V9, P674&#xD;
                    BIANCO A, 2005, J AM CHEM SOC, V127, P58&#xD; BLOCK ML, 2007, NAT REV NEUROSCI,
                    V8, P57&#xD; BRONIKOWSKI MJ, 2006, CARBON, V44, P2822&#xD; BRONIKOWSKI MJ, 2006,
                    J VAC SCI TECHNOL A, V24, P1318&#xD; CAI D, 2005, NAT METHODS, V2, P449&#xD;
                    CHERUKURI P, 2004, J AM CHEM SOC, V126, P15638&#xD; DOBSON J, 2006, GENE THER,
                    V13, P283&#xD; DUGGAL R, 2006, PHYS REV LETT, V96&#xD; FIORITO S, 2006,
                    NANOTECHNOLOGY, V6, P591&#xD; IIJIMA S, 1991, NATURE, V354, P56&#xD; KAM NWS,
                    2004, J AM CHEM SOC, V126, P6850&#xD; KAM NWS, 2005, J AM CHEM SOC, V127,
                    P12492&#xD; KAM NWS, 2005, J AM CHEM SOC, V127, P6025&#xD; KAM NWS, 2005, P NATL
                    ACAD SCI USA, V102, P11600&#xD; KLUMPP C, 2003, BIOCHIM BIOPHYS ACTA, V1758,
                    P404&#xD; LI X, 2006, NUCLEIC ACIDS RES, V34, P3670&#xD; MANOHARA HM, 2005, J
                    VAC SCI TECHNOL B, V23, P157&#xD; OCONNELL MJ, 2002, SCIENCE, V297, P593&#xD;
                    PANHUIS MIH, 2003, CHEM BIOL, V10, P897&#xD; PANTAROTTO D, 2003, CHEM BIOL, V10,
                    P961&#xD; PANTAROTTO D, 2004, ANGEW CHEM INT EDIT, V43, P5242&#xD; PASTORIN G,
                    2006, CHEM COMMUN, P1182&#xD; POLIZU S, 2006, J NANOSCI NANOTECHNO, V6,
                    P1883&#xD; PORTNEY GN, 2006, ANAL BIOANAL CHEM, V384, P620&#xD; RADOMSKI A,
                    2005, BRIT J PHARMACOL, V146, P882&#xD; SALVADORMORALES C, 2006, MOL IMMUNOL,
                    V43, P193&#xD; SATO Y, 2005, MOL BIOSYST, V1, P176&#xD; SHVEDOVA AA, 2005, AM J
                    PHYSIOL-LUNG C, V289, P608&#xD; SINGH R, 2005, J AM CHEM SOC, V127, P4388&#xD;
                    VENKATESAN N, 2005, BIOMATERIALS, V26, P7154&#xD; WATTERS JJ, 2005, J NEUROSCI
                    RES, V81, P447&#xD; XIAO H, 2007, ANAL BIOANAL CHEM, V387, P119&#xD; YINGHUAI Z,
                    2005, J AM CHEM SOC, V127, P9875&#xD;Suppl. 1</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249434100001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>314</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">314</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1343</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kato, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lanting, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Gonda Diabet Ctr, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman
                    Res Inst, Div Mol Biol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman
                    Res Inst, Grad Sch Biol Sci, Duarte, CA 91010 USA.&#xD;Natarajan, R, City Hope
                    Natl Med Ctr, Beckman Res Inst, Gonda Diabet Ctr, 1500 E Duarte Rd, Duarte, CA
                    91010 USA.&#xD;rnatarajan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">MicroRNA-192 in diabetic kidney
                        glomeruli and its function in TGF-beta-induced collagen expression via
                        inhibition of E-box repressors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3432-3437</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">diabetic nephropathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mesangial cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small noncoding RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transforming growth factor beta
                        1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR-BETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHORT-INTERFERING RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESANGIAL CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTRACELLULAR-MATRIX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNALING PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELTA-EF1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMAD PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244661400073</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Key features of diabetic nephropathy
                    (DN) include the accumulation of extracellular matrix proteins such as collagen
                    1-alpha 1 and -2 (Col1a1 and -2). Transforming growth factor beta 1 (TGF-beta),
                    a key regulator of these extracellular matrix genes, is increased in mesangial
                    cells (MC) in DN. By microarray profiling, we noted that TGF-beta increased
                    Col1a2 mRNA in mouse MC (MMC) but also decreased mRNA levels of an E-box
                    repressor, delta EF1. TGF-beta treatment or short hairpin RNAs targeting delta
                    EF1 increased enhancer activity of upstream E-box elements in the Col1a2 gene.
                    TGF-beta also decreased the expression of Smad-interacting protein 1 (SIP1),
                    another E-box repressor similar to delta EF1. Interestingly, we noted that SIN
                    is a target of microRNA-192 (miR-192), a key miR highly expressed in the kidney.
                    miR-192 levels also were increased by TGF-beta in MMC. TGF-beta treatment or
                    transfection with miR-192 decreased endogenous SIP1 expression as well as
                    reporter activity of a SIP1 3&apos; UTIR-containing luciferase construct in MMC.
                    Conversely, a miR-192 inhibitor enhanced the luciferase activity, confirming
                    SIP1 to be a miR-192 target. Furthermore, miR-192 synergized with delta EF1
                    short hairpin RNAs to increase Col1a2 E-box-luc activity. Importantly, the in
                    vivo relevance was noted by the observation that miR-192 levels were enhanced
                    significantly in glomeruli isolated from streptozotocin-injected diabetic mice
                    as well as diabetic db/db mice relative to corresponding nondiabetic controls,
                    in parallel with increased TGF-beta and Col1a2 levels. These results uncover a
                    role for miRs in the kidney and DN in controlling TGF-beta-induced Col1a2
                    expression by down-regulating E-box repressors.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    142PG&#xD;Times Cited: 0&#xD;Cited Reference Count: 33&#xD;Cited References:
                    &#xD; AMBROS V, 2004, NATURE, V431, P350&#xD; BAGGA S, 2005, CELL, V122,
                    P553&#xD; CHIN BY, 2001, AM J PHYSIOL-RENAL, V280, F495&#xD; EGER A, 2005,
                    ONCOGENE, V24, P2375&#xD; ESQUELAKERSCHER A, 2006, NAT REV CANCER, V6, P259&#xD;
                    FURUSAWA T, 1999, MOL CELL BIOL, V19, P8581&#xD; HAYASHIDA T, 1999, KIDNEY INT,
                    V56, P1710&#xD; HE L, 2004, NAT REV GENET, V5, P522&#xD; KATO M, 2006, J AM SOC
                    NEPHROL, V17, P3325&#xD; KIM YS, 2005, J AM SOC NEPHROL, V16, P352&#xD;
                    KRUTZFELDT J, 2005, NATURE, V438, P685&#xD; LI SL, 2005, J LIPID RES, V46,
                    P220&#xD; LIU SY, 2005, CELL PHYSIOL BIOCHEM, V16, P207&#xD; MIAO F, 2004, J
                    BIOL CHEM, V279, P18091&#xD; MURRAY D, 2000, J BIOL CHEM, V275, P3610&#xD;
                    PASQUINELLI AE, 2006, DEV CELL, V10, P419&#xD; PONCELET AC, 2001, J BIOL CHEM,
                    V276, P6983&#xD; PONTICOS M, 2004, MOL CELL BIOL, V24, P6151&#xD; POSTIGO AA,
                    2003, EMBO J, V22, P2443&#xD; RAYMOND CK, 2005, RNA, V11, P1737&#xD; RAZZAQUE
                    MS, 2001, NEPHRON, V89, P1&#xD; REEVES WB, 2000, P NATL ACAD SCI USA, V97,
                    P7667&#xD; ROBERTS AB, 1992, KIDNEY INT, V41, P557&#xD; ROSSI JJ, 2005, NAT CELL
                    BIOL, V7, P643&#xD; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692&#xD; SHARMA K,
                    1995, DIABETES, V44, P1139&#xD; SUN YQ, 2004, NUCLEIC ACIDS RES, V32&#xD;
                    TSUCHIDA K, 2003, KIDNEY INT, V63, P2000&#xD; VERSCHUEREN K, 1999, J BIOL CHEM,
                    V274, P20489&#xD; WU LG, 2006, P NATL ACAD SCI USA, V103, P4034&#xD; YANG YC,
                    2003, P NATL ACAD SCI USA, V100, P10269&#xD; YEKTA S, 2004, SCIENCE, V304,
                    P594&#xD; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244661400073 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>843</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">843</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1342</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kaur, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Feldhahn, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Trageser, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muschen, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pertz, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Groffen, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heisterkamp, N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Childrens Hosp, Saban
                    Res Inst, Div Hematol Oncol,Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA.
                    Univ So Calif, Keck Sch Med, Los Angeles, CA USA. City Hope Natl Med Ctr, Div
                    Hematol &amp; Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. Univ So
                    Calif, Childrens Hosp, Saban Res Inst, Div Hematol Oncol,Sect Leukemia Genet
                    &amp; Cell Biol, Los Angeles, CA 90027 USA.&#xD;Heisterkamp, N, Univ So Calif,
                    Childrens Hosp, Saban Res Inst, Div Hematol Oncol,Sect Mol Carcinogenesis, Los
                    Angeles, CA 90027 USA.&#xD;pavinder@gmail.com niklas@feldhahn.de BZhang@coh.org
                    DTrageser@chla.usc.edu MMuschen@chla.usc.edu veerlepertz@hotmail.com
                    jgroffen@chla.usc.edu heisterk@hsc.usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nilotinib treatment in mouse
                        models of P190 Bcr/Abl lymphoblastic leukemia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer</style>
                </secondary-title>
            </titles>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOGENOUS
                        LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ABL-KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOMAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMATINIB STI571
                        RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BCR-ABL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHILADELPHIA-CHROMOSOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TYROSINE KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FARNESYLTRANSFERASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMINOPYRIMIDINE
                        INHIBITOR</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1476-4598</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252277000001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Ph-positive leukemias
                    are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a
                    selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely
                    used to treat chronic myelogenous leukemia. Because Ph-positive acute
                    lymphoblastic leukemia only responds transiently to imatinib therapy, we have
                    used mouse models to test the efficacy of nilotinib against lymphoblastic
                    leukemia caused by the P190 form of Bcr/Abl. Results: After transplant of 10,000
                    highly malignant leukemic cells into compatible recipients, untreated mice
                    succumbed to leukemia within 21 days, whereas mice treated with 75 mg/kg
                    nilotinib survived significantly longer. We examined cells from mice that
                    developed leukemia while under treatment for Bcr/Abl kinase domain point
                    mutations but these were not detected. In addition, culture of such cells ex
                    vivo showed that they were as sensitive as the parental cell line to nilotinib
                    but that the presence of stromal support allowed resistant cells to grow out.
                    Nilotinib also exhibited impressive anti-leukemia activity in P190 Bcr/Abl
                    transgenic mice that had developed overt leukemia/lymphoma masses and that
                    otherwise would have been expected to die within 7 days. Visible lymphoma masses
                    disappeared within six days of treatment and leukemic cell numbers in peripheral
                    blood were significantly reduced. Treated mice survived more than 30 days.
                    Conclusion: These results show that nilotinib has very impressive anti-leukemia
                    activity but that lymphoblastic leukemia cells can become unresponsive to it
                    both in vitro and in vivo through mechanisms that appear to be Bcr/Abl
                    independent.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    250CG&#xD;Times Cited: 0&#xD;Cited Reference Count: 52&#xD;Cited References:
                    &#xD; BRADEEN HA, 2006, BLOOD, V108, P2332&#xD; COWANJACOB SW, 2004, MINI-REV
                    MED CHEM, V4, P285&#xD; DALEY GQ, 1990, SCIENCE, V247, P824&#xD; DEININGER M,
                    2005, BLOOD, V105, P2640&#xD; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1031&#xD;
                    DRUKER BJ, 2001, NEW ENGL J MED, V344, P1038&#xD; DRUKER BJ, 2002, HEMATOLOGY AM
                    SOC HE, P111&#xD; DRUKER BJ, 2006, NEW ENGL J MED, V355, P2408&#xD; FADERL S,
                    2003, CANCER, V98, P1337&#xD; GOLEMOVIC M, 2005, CLIN CANCER RES, V11,
                    P4941&#xD; GORRE ME, 2001, SCIENCE, V293, P876&#xD; GRUBER FX, 2006, LEUKEMIA,
                    V20, P2057&#xD; HARDY RR, 2000, IMMUNOL REV, V175, P23&#xD; HEISTERKAMP N, 1990,
                    NATURE, V344, P251&#xD; HOCHHAUS A, 2002, LEUKEMIA, V16, P2190&#xD; HOCHHAUS A,
                    2003, SEMIN HEMATOL S2, V40, P69&#xD; HOFMANN WK, 2002, BLOOD, V99, P1860&#xD;
                    IHLE JN, 2007, CURR OPIN GENET DEV, V17, P8&#xD; KANTARJIAN H, 2006, NEW ENGL J
                    MED, V354, P2542&#xD; KURZROCK R, 2003, ANN INTERN MED, V138, P819&#xD; LAURENT
                    E, 2001, CANCER RES, V61, P2343&#xD; LECOUTRE P, 2000, BLOOD, V95, P1758&#xD;
                    LUGO TG, 1990, SCIENCE, V247, P1079&#xD; MISHRA S, 2003, ONCOGENE, V22,
                    P8255&#xD; MISHRA S, 2004, LEUKEMIA, V18, P23&#xD; MISHRA S, 2006, CANCER RES,
                    V66, P5387&#xD; MISHRA S, 2007, LEUKEMIA, V21, P178&#xD; MURRAY PJ, 2007, J
                    IMMUNOL, V178, P2623&#xD; OHARE T, 2005, CANCER RES, V65, P4500&#xD; OTTMANN OG,
                    2002, BLOOD, V100, P1965&#xD; PFEIFER H, 2007, IN PRESS BLOOD&#xD; RANE SG,
                    2002, ONCOGENE, V21, P3334&#xD; RAY A, 2007, IN PRESS BLOOD&#xD; REN R, 2005,
                    NAT REV CANCER, V5, P172&#xD; RICCI C, 2002, CANCER RES, V62, P5995&#xD;
                    ROCHELESTIENNE C, 2002, BLOOD, V100, P1014&#xD; SACHA T, 2003, LEUKEMIA RES,
                    V27, P1163&#xD; SAMANTA AK, 2006, CANCER RES, V66, P668&#xD; SCAPPINI B, 2004,
                    CANCER, V100, P1459&#xD; STEELMAN LS, 2004, LEUKEMIA, V18, P189&#xD; VERSTOVSEK
                    S, 2005, CANCER, V104, P1230&#xD; VONBUBNOFF N, 2006, BLOOD, V108, P1328&#xD;
                    VONCKEN JW, 1992, CANCER RES, V52, P4534&#xD; WANG Y, 2007, BLOOD, V109,
                    P2147&#xD; WEISBERG E, 2005, CANCER CELL, V7, P129&#xD; WEISBERG E, 2006, BRIT J
                    CANCER, V94, P1765&#xD; WILLIAMS RT, 2006, P NATL ACAD SCI USA, V103, P6688&#xD;
                    XIE SH, 2001, ONCOGENE, V20, P6188&#xD; XIE SH, 2002, ONCOGENE, V21, P7137&#xD;
                    ZHANG B, 2005, BLOOD, V106, P1355&#xD; ZHANG B, 2007, LEUKEMIA, V21, P1189&#xD;
                    ZHANG XF, 2001, BLOOD, V97, P3342</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252277000001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <electronic-resource-num>
                <style face="normal" font="default" size="100%">67&#xD;Artn 67</style>
            </electronic-resource-num>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>227</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">227</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1341</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kenanova, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olafsen, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, L. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ruel, N. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Longmate, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yazaki, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Colcher, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Dept Mol &amp; Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA
                    90095 USA. City Hope Natl Med Ctr, Dept Radioimmunotherapy, Duarte, CA 91010
                    USA. City Hope Natl Med Ctr, Div Radiol, Duarte, CA 91010 USA. City Hope Natl
                    Med Ctr, Dept Biostat, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Mol Biol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA.&#xD;Wu, AM, Univ Calif Los Angeles,
                    David Geffen Sch Med, Dept Mol &amp; Med Pharmacol, Crump Inst Mol Imaging, 700
                    Westwood Plaza, Los Angeles, CA 90095 USA.&#xD;awu@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Radioiodinated versus
                        radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody
                        fragments: Optimal pharmacokinetics for therapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">718-726</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECOMBINANT ANTIBODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRYSTAL-STRUCTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUDE-MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">XENOGRAFTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IGG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIABODIES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243683000037</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Antibody fragments with optimized
                    pharmacokinetic profiles hold potential for detection and therapy of tumor
                    malignancies. We studied the behavior of three anti-carcinoembryonic antigen
                    (CEA) single-chain Fv-Fc (scFv-Fc) variants (I253A, H310A, and H310A/H435Q,
                    Kabat numbering system) that exhibited differential serum persistence.
                    Biodistribution studies done on CEA-positive tumor xenografted mice revealed
                    that the In-111-labeled I253A fragment with the slowest clearance kinetics
                    (T-1/2 beta, 27.7 h) achieved the highest tumor uptake (44.6% ID/g at 24 h),
                    whereas the radiometal-labeled H310A/H435Q fragment with the most rapid
                    elimination (T-1/2 beta, 7.05 h) reached a maximum of 28.0% ID/g at 12 h
                    postinjection. The H310A protein was characterized by both intermediate serum
                    half-life and tumor uptake. The In-111-based biodistribution studies showed that
                    all three fragments were eliminated primarily through the liver, and hepatic
                    radiometal activity correlated with the rate of fragment clearance. The
                    In-111-labeled H310A/H435Q protein exhibited the highest liver uptake (23.5%
                    ID/g at 24 h). Metabolism of the I-125-labeled scFv-Fc proteins resulted in low
                    normal organ activity. Finally, the I-125/In-111 biodistribution data allowed
                    for dose estimations, which suggest the I-131-labeled scFv-Fc H310A/H435Q as a
                    promising candidate for radioimmunotherapy.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">TopTier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    128TZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 42</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243683000037 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>578</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">578</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1800</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Thoracic Surgery, Lung
                    Cancer and Thoracic Oncology Program, City of Hope Medical Center, 1500 E Duarte
                    Rd, Warsaw MOB, Duarte, CA 91010-3000, USA. kkernstine@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Invited commentary</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Ann Thorac Surg</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Thoracic
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Thorac. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Thorac Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">971-2</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">84</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Bronchi/ surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Bronchial Fistula/prevention
                        &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Diabetes Complications/
                        prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pleural Diseases/prevention
                        &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pneumonectomy/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Postoperative Complications/
                        prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Surgical Flaps</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1552-6259 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17720410</style>
            </accession-num>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/09/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>784</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">784</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1340</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">DeArmond, D. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shamoun, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Campos, J. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Thorac
                    Surg, Duarte, CA 91010 USA. Univ Iowa, Dept Surg, Div Cardiothorac Surg, Iowa
                    City, IA 52242 USA. Univ Iowa, Dept Internal Med, Div Gastroenterol, Iowa City,
                    IA 52242 USA. Univ Iowa, Dept Anesthesiol, Iowa City, IA 52242
                    USA.&#xD;Kernstine, KH, City Hope Natl Med Ctr, Dept Thorac Surg, 1500 E Duarte
                    Rd,Suite 2001G, Duarte, CA 91010 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The first series of completely
                        robotic esophagectomies with three-field lymphadenectomy: initial
                        experience</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Surgical Endoscopy and Other
                        Interventional Techniques</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Surgical Endoscopy and Other
                        Interventional Techniques</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Surg. Endosc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Surg Endosc</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2285-2292</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">esophageal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">esophagectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">minimally invasive
                        surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">robotics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINIMALLY INVASIVE
                        ESOPHAGECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODE DISSECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGICAL-TREATMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SQUAMOUS-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESOPHAGUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADENOCARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0930-2794</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250923200035</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: This study investigated
                    the use of robotics to perform extended esophageal resection in a series of
                    patients. Methods: A total of 14 patients with a median age of 64 years
                    underwent esophagectomy using the da Vinci robot. At presentation, there were 12
                    cases of cancer, staged at T2N1 (n = 2), T3N0 (n = 2), T3N1 (n = 6), T4N1 (n =
                    1), and M1a (n = 1); 2 cases of high-grade dysplasia; 8 cases of adenocarcinoma;
                    and 4 cases of squamous cell cancer; as well as 2 middle third, 9 lower third,
                    and one gastroesophageal junction tumor. Nine patients had undergone
                    preoperative chemoradiotherapy, and six had undergone prior abdominal surgery.
                    The patients were categorized into three chronological groups according to the
                    procedure performed. Group 1 consisted of the first three patients in the
                    series, whose surgery was thoracic only (robotically assisted esophagectomy).
                    Group 2, the next three patients, had robotically assisted thoracic
                    esophagectomy plus thoracic duct ligation using a laparoscopic gastric conduit.
                    Group 3, the last eight patients, underwent completely robotic esophagectomy.
                    Results: For Group 3, the total operating room time was 11.1 +/- 0.8 h (range,
                    11.3-13.2 h), with a console time of 5.0 +/- 0.5 h (range, 4.8-5.8 h). The
                    estimated blood loss was 400 +/- 300 ml (range, 200-950 ml). One patient in
                    group 1 had a thoracic duct leak. In groups 2 and 3, thoracic duct ligation
                    resulted in no further leaks. Other postoperative complications included severe
                    pneumonia (1 case), atrial fibrillation (5 cases), cervical anastomotic leak (2
                    cases), wound infection (1 case), and bilateral vocal cord paresis requiring
                    tracheostomy (1 case). In seven of the cases, no intensive care unit time was
                    required. There was one death from pneumonia 72 days after the procedure. The
                    rate of disease-free survival was 87%. Conclusion: The robotic approach
                    facilitates an extended three-field esophagolymphadenectomy even after induction
                    therapy and abdominal surgery. Larger scale trials are needed to define the role
                    of this technique.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    231CD&#xD;Times Cited: 0&#xD;Cited Reference Count: 26&#xD;Cited References:
                    &#xD; ALTORKI N, 2002, ANN SURG, V236, P177&#xD; ALTORKI NK, 2000, CHEST SURG
                    CLIN N AM, V10, P553&#xD; ANDO N, 2000, ANN SURG, V232, P225&#xD; ANDO N, 2003,
                    J CLIN ONCOL, V21, P4592&#xD; BLOT WJ, 1987, AM J PUBLIC HEALTH, V77, P296&#xD;
                    COLLARD JM, 1991, CURRENT PRACTICE SUR, P183&#xD; COLLARD JM, 2001, ANN SURG,
                    V234, P25&#xD; COOPER JS, 1999, JAMA-J AM MED ASSOC, V281, P1623&#xD; HORGAN S,
                    2003, AM SURGEON, V69, P624&#xD; HULSCHER JBF, 2001, ANN THORAC SURG, V72,
                    P306&#xD; HULSCHER JBF, 2001, BRIT J SURG, V88, P715&#xD; KATLIC MR, 1990, J
                    THORAC CARDIOV SUR, V99, P929&#xD; KERNSTINE KH, 2004, AM J SURG S, V188,
                    S89&#xD; KERNSTINE KH, 2004, J THORAC CARDIOV SUR, V127, P1847&#xD; LERUT T,
                    2004, ANN SURG, V240, P962&#xD; LERUT TE, 2004, BEST PRACT RES CL GA, V18,
                    P901&#xD; LUKETICH JD, 2003, ANN SURG, V238, P486&#xD; MCKEOWN KC, 1985, J R
                    COLL SURG EDINB, V30, P1&#xD; NGUYEN NT, 2000, SURGERY, V127, P284&#xD; NGUYEN
                    NT, 2003, J AM COLL SURGEONS, V197, P902&#xD; ORRINGER MB, 1978, J THORAC
                    CARDIOVASC, V76, P643&#xD; SINGH D, 2001, ANN THORAC SURG, V71, P419&#xD;
                    SWANSON SJ, 2001, ANN THORAC SURG, V72, P1918&#xD; SWANSTROM LL, 1997, ARCH
                    SURG-CHICAGO, V132, P943&#xD; TSURUMARU M, 2001, ANN THORAC CARDIOVAS, V7,
                    P325&#xD; WANG PY, 1983, ANN THORAC SURG, V35, P143</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250923200035 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>844</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">844</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1339</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Khalsa, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Karim, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mack, W. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Minkoff, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cohen, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Young, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anastos, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tien, P. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Seaberg, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Levine, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Los Angeles, CA 90089
                    USA. New York State Univ, Brooklyn, NY USA. CORE Ctr, Cook Cty Hosp, Chicago, IL
                    USA. Georgetown Univ, Washington, DC USA. Montefiore Med Ctr, Bronx, NY 10467
                    USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco Vet
                    Aff Med Ctr, San Francisco, CA USA. Johns Hopkins Univ, WDMAC Data Coordinat
                    Ctr, Baltimore, MD USA. City Hope Med Ctr, Duarte, CA USA.&#xD;Khalsa, A, Univ
                    So Calif, Los Angeles, CA 90089 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Correlates of prevalent
                        hypertension in a large cohort of HIV-infected women: Women&apos;s
                        Interagency HIV Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Aids</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">AIDS</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">AIDS</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">AIDS</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2539-2541</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">21</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">18</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVE ANTIRETROVIRAL
                        THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ELEVATED BLOOD-PRESSURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NAIVE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0269-9370</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251636400023</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Correlates of hypertension were
                    assessed in 1266 HIV-positive and 368 HIV-negative women in the Women&apos;s
                    Interagency HIV Study. Hypertension prevalence was similar in HIV-positive and
                    HIV-negative women (26 versus 28%, P = 0.38). Factors associated with
                    hypertension included increasing age (P &lt; 0.0001), African-American race (P
                    &lt; 0.0001), and body mass index greater than 30 kg/m(2) (P &lt; 0.0001),
                    whereas current pregnancy was protective (P &lt; 0.04). HIV infection, CD4 cell
                    count, HIV-1 viral load, and antiretroviral therapy were not associated with
                    hypertension.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    241DF&#xD;Times Cited: 0&#xD;Cited Reference Count: 11&#xD;Cited References:
                    &#xD; BERGERSEN BM, 2003, EUR J CLIN MICROBIOL, V22, P731&#xD; CHOW DC, 2003,
                    HIV CLIN TRIALS, V4, P411&#xD; CRANE HM, 2006, AIDS, V20, P1019&#xD; DIGGLE PJ,
                    1994, ANAL LONGITUDINAL DA&#xD; HESSOL NA, 2000, AIDS RES HUM RETROV, V16,
                    P1105&#xD; JERICO C, 2005, AM J HYPERTENS, V18, P1396&#xD; PALACIOS R, 2006, HIV
                    MED, V7, P10&#xD; PALELLA FJ, 1998, NEW ENGL J MED, V338, P853&#xD; SATTLER FR,
                    2001, AIDS, V15, P2001&#xD; SEABERG EC, 2005, AIDS, V19, P953&#xD; THIEBAUT R,
                    2004, 11 C RETR OPP INF SA</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251636400023 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>297</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">297</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">974</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Grad Sch Biol Sci, Div Mol Biol, Duarte, CA 91010 USA.&#xD;Rossi, JJ, City
                    Hope Natl Med Ctr, Beckman Res Inst, Grad Sch Biol Sci, Div Mol Biol, 1450 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;jrossi@bricoh.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Strategies for silencing human
                        disease using RNA interference</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nature Reviews Genetics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nature Reviews Genetics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nat. Rev. Genet.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nat Rev Genet</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">173-184</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">8</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DOUBLE-STRANDED-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHORT HAIRPIN RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STABLE EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRUCTURAL BASIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-1 INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODIFIED SIRNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR EXPORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOUSE MODEL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1471-0056</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244274400011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Since the first description of RNA
                    interference (RNAi) in animals less than a decade ago, there has been rapid
                    progress towards its use as a therapeutic modality against human diseases.
                    Advances in our understanding of the mechanisms of RNAi and studies of RNAi in
                    vivo indicate that RNAi-based therapies might soon provide a powerful new
                    arsenal against pathogens and diseases for which treatment options are currently
                    limited. Recent findings have highlighted both promise and challenges in using
                    RNAi for therapeutic applications. Design and delivery strategies for RNAi
                    effector molecules must be carefully considered to address safety concerns and
                    to ensure effective, successful treatment of human diseases.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    137DY&#xD;Times Cited: 0&#xD;Cited Reference Count: 93&#xD;Cited References:
                    &#xD; AMARZGUIOUI M, 2005, FEBS LETT, V579, P5974&#xD; AN DS, 2006, MOL THER,
                    V14, P494&#xD; BARTEL DP, 2004, NAT REV GENET, V5, P396&#xD; BEHLKE MA, 2006,
                    MOL THER, V13, P644&#xD; BERNSTEIN E, 2001, NATURE, V409, P363&#xD; BIRMINGHAM
                    A, 2006, NAT METHODS, V3, P199&#xD; BITKO V, 2005, NAT MED, V11, P50&#xD;
                    BORCHERT GM, 2006, NAT STRUCT MOL BIOL, V13, P1097&#xD; BRUMMELKAMP TR, 2002,
                    SCIENCE, V296, P550&#xD; CHECK E, 2005, NAT MED, V11, P243&#xD; CHENDRIMADA TP,
                    2005, NATURE, V436, P740&#xD; CHIU YL, 2003, RNA, V9, P1034&#xD; CHU TC, 2006,
                    NUCLEIC ACIDS RES, V34&#xD; COBURN GA, 2002, J VIROL, V76, P9225&#xD; CZAUDERNA
                    F, 2003, NUCLEIC ACIDS RES, V31, P2705&#xD; DEVEER MJ, 2005, IMMUNOL CELL BIOL,
                    V83, P224&#xD; DYKXHOORN DM, 2006, CELL, V126, P231&#xD; DYKXHOORN DM, 2006,
                    PLOS MED, V3, P1000&#xD; ELBASHIR SM, 2001, GENE DEV, V15, P188&#xD; ELBASHIR
                    SM, 2001, NATURE, V411, P494&#xD; FIRE A, 1998, NATURE, V391, P806&#xD; GREGORY
                    RI, 2004, NATURE, V432, P235&#xD; GRIMM D, 2006, GENE THER, V13, P563&#xD; GRIMM
                    D, 2006, NATURE, V441, P537&#xD; HANNON GJ, 2004, NATURE, V431, P371&#xD;
                    HORNUNG V, 2005, NAT MED, V11, P263&#xD; HUANG YX, 1996, NAT MED, V2, P1240&#xD;
                    HULIESKOVAN S, 2005, CANCER RES, V65, P8984&#xD; HUTVAGNER G, 2002, SCIENCE,
                    V297, P2056&#xD; JACKSON AL, 2006, RNA, V12, P1179&#xD; JACQUE JM, 2002, NATURE,
                    V418, P435&#xD; JANOWSKI BA, 2006, NAT STRUCT MOL BIOL, V13, P787&#xD; JUDGE AD,
                    2005, NAT BIOTECHNOL, V23, P457&#xD; KIM DH, 2004, NAT BIOTECHNOL, V22,
                    P321&#xD; KIM DH, 2005, NAT BIOTECHNOL, V23, P222&#xD; KIM DH, 2006, NAT STRUCT
                    MOL BIOL, V13, P793&#xD; LANDEN CN, 2005, CANCER RES, V65, P6910&#xD; LEE NS,
                    2002, NAT BIOTECHNOL, V20, P500&#xD; LEE RC, 1993, CELL, V75, P843&#xD; LEE Y,
                    2003, NATURE, V425, P415&#xD; LEE Y, 2004, EMBO J, V23, P4051&#xD; LEE Y, 2006,
                    EMBO J, V25, P522&#xD; LEWIS BP, 2005, CELL, V120, P15&#xD; LI MJ, 2005, MOL
                    THER, V12, P900&#xD; LIU JD, 2004, SCIENCE, V305, P1437&#xD; LIU JD, 2005, NAT
                    CELL BIOL, V7, P719&#xD; LUND E, 2004, SCIENCE, V303, P95&#xD; MA JB, 2004,
                    NATURE, V429, P318&#xD; MANCHE L, 1992, MOL CELL BIOL, V12, P5238&#xD; MARQUES
                    JT, 2006, NAT BIOTECHNOL, V24, P559&#xD; MARTINEZ J, 2002, CELL, V110, P563&#xD;
                    MARTINEZ J, 2004, GENE DEV, V18, P975&#xD; MATRANGA C, 2005, CELL, V123,
                    P607&#xD; MATZKE MA, 2005, NAT REV GENET, V6, P24&#xD; MCFARLAND TJ, 2004,
                    EXPERT OPIN BIOL TH, V4, P1053&#xD; MCNAMARA JO, 2006, NAT BIOTECHNOL, V24,
                    P1005&#xD; MEISTER G, 2004, NATURE, V431, P343&#xD; MORRIS KV, 2004, SCIENCE,
                    V305, P1289&#xD; MORRIS KV, 2006, GENE THER, V13, P553&#xD; MORRISSEY DV, 2005,
                    HEPATOLOGY, V41, P1349&#xD; MORRISSEY DV, 2005, NAT BIOTECHNOL, V23, P1002&#xD;
                    NOVINA CD, 2002, NAT MED, V8, P681&#xD; ORBAN TI, 2005, RNA, V11, P459&#xD;
                    PADDISON PJ, 2002, GENE DEV, V16, P948&#xD; PAI SI, 2006, GENE THER, V13,
                    P464&#xD; PAI SI, 2006, GENE THER, V13, P464&#xD; PALLISER D, 2006, NATURE,
                    V439, P89&#xD; PARKER JS, 2005, NATURE, V434, P663&#xD; PREALL JB, 2005, CELL,
                    V123, P543&#xD; RALPH GS, 2005, NAT MED, V11, P429&#xD; RAND TA, 2005, CELL,
                    V123, P621&#xD; RAOUL C, 2005, NAT MED, V11, P423&#xD; RAOUL C, 2006, GENE THER,
                    V13, P487&#xD; ROBBINS MA, 2006, NAT BIOTECHNOL, V24, P566&#xD; ROSSL JJ, 2006,
                    BIOTECHNIQUES, V40, S25&#xD; SARNOW P, 2006, NAT REV MICROBIOL, V4, P651&#xD;
                    SETH RB, 2006, CELL RES, V16, P141&#xD; SILVA JM, 2005, NAT GENET, V37,
                    P1281&#xD; SIOLAS D, 2005, NAT BIOTECHNOL, V23, P227&#xD; SONG EW, 2005, NAT
                    BIOTECHNOL, V23, P709&#xD; SOUTSCHEK J, 2004, NATURE, V432, P173&#xD; TING AH,
                    2005, NAT GENET, V37, P906&#xD; VASTENHOUW NL, 2006, NATURE, V442, P882&#xD;
                    WASSENEGGER M, 2005, CELL, V122, P13&#xD; WEINBERG MS, 2006, RNA, V12, P256&#xD;
                    WIGHTMAN B, 1993, CELL, V75, P855&#xD; XIA HB, 2004, NAT MED, V10, P816&#xD;
                    YEKTA S, 2004, SCIENCE, V304, P594&#xD; YI R, 2003, GENE DEV, V17, P3011&#xD;
                    ZAMORE PD, 2000, CELL, V101, P25&#xD; ZENG Y, 2002, MOL CELL, V9, P1327&#xD;
                    ZHANG WD, 2005, NAT MED, V11, P56&#xD; ZIMMERMANN TS, 2006, NATURE, V441,
                    P111</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244274400011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>426</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">426</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1335</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Biol, Duarte, CA 91010 USA.&#xD;Besaratinia, A, City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Biol, 1450 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;ania@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mutagenicity of ultraviolet A
                        radiation in the lacI transgene in Big Blue mouse embryonic
                        fibroblasts</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mutation Research-Fundamental
                        and Molecular Mechanisms of Mutagenesis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Mutation Research-Fundamental
                        and Molecular Mechanisms of Mutagenesis</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mutat. Res.-Fundam. Mol. Mech.
                        Mutag.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mutat Res-Fundam Mol Mech
                        Mutag</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">71-78</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">617</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1-2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">lacI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mutations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transgene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ultraviolet A radition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLOBUTANE PYRIMIDINE
                        DIMERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLAR UV-RADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TO-T TRANSVERSIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN SKIN CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIPYRIMIDINE
                        PHOTOPRODUCTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WAVELENGTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEPENDENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCED MUTAGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATION SPECTRUM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VISIBLE RADIATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-5107</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245901000008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Sunlight ultraviolet A (UVA)
                    irradiation has been implicated in the etiology of human skin cancer. A
                    genotoxic mode of action for UVA radiation has been suggested that involves
                    photosensitization reactions giving rise to promutagenic DNA lesions. We
                    investigated the mutagenicity of UVA in the lacI transgene in Big Blue mouse
                    embryonic fibroblasts. UVA irradiation of these cells at a physiologically
                    relevant dose of 18 J/cm(2) caused a 2.8-fold increase in the lacI mutant
                    frequency relative to control, i.e., 12.12 +/- 1.84 versus 4.39 +/- 1.99 x
                    10(-5) (mean +/- S.D.). DNA sequencing analysis showed that of 100 UVA-induced
                    mutant plaques and 54 spontaneously arisen control plaques, 97 and 5 1,
                    respectively, contained a minimum of one mutation along the lacI transgene. The
                    vast majority of both induced- and spontaneous mutations were single base
                    substitutions, although less frequently, there were also single and multiple
                    base deletions and insertions, and tandem base substitutions. Detailed mutation
                    spectrometry analysis revealed that G:C -&gt; T:A transversions, the signature
                    mutations of oxidative DNA damage, were significantly induced by UVA irradiation
                    (P &lt; 0.003). The absolute frequency of this type of mutations was 7.4-fold
                    increased consequent to UVA irradiation as compared to control (3.38 versus
                    0.454 x 10(-5); P &lt; 0.00001). These findings are in complete agreement with
                    those previously observed in the cII transgene of the same model system, and
                    reaffirm the notion that intracellular photosensitization reactions causing
                    promutagenic oxidative DNA damage are involved in UVA genotoxicity. (c) 2007
                    Elsevier B.V. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    159XK&#xD;Times Cited: 0&#xD;Cited Reference Count: 43&#xD;Cited References:
                    &#xD; ADAMS WT, 1987, J MOL BIOL, V194, P391&#xD; AGAR NS, 2004, P NATL ACAD SCI
                    USA, V101, P4954&#xD; BESARATINIA A, 2004, BIOCHEMISTRY-US, V43, P15557&#xD;
                    BESARATINIA A, 2004, BIOCHEMISTRY-US, V43, P8169&#xD; BESARATINIA A, 2005,
                    CARCINOGENESIS, V27, P1526&#xD; BESARATINIA A, 2005, P NATL ACAD SCI USA, V102,
                    P10058&#xD; CADET J, 1997, BIOL CHEM, V378, P1275&#xD; CADET J, 2005, MUTAT
                    RES-FUND MOL M, V571, P3&#xD; DEGRUIJL FR, 1993, CANCER RES, V53, P53&#xD;
                    DEGRUIJL FR, 1999, EUR J CANCER, V35, P2003&#xD; DEGRUIJL FR, 2002, SKIN
                    PHARMACOL APPL, V15, P316&#xD; DENISSENKO MF, 1998, ONCOGENE, V16, P1241&#xD;
                    DOUKI T, 1999, PHOTOCHEM PHOTOBIOL, V70, P184&#xD; DOUKI T, 2003,
                    BIOCHEMISTRY-US, V42, P9221&#xD; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92,
                    P2350&#xD; IKEHATA H, 2003, MUTAGENESIS, V18, P511&#xD; IKEHATA H, 2004, MUTAT
                    RES-FUND MOL M, V556, P11&#xD; IZUMIZAWA Y, 2000, NUCL ACIDS S SER, P73&#xD;
                    JAKUBCZAK JL, 1996, P NATL ACAD SCI USA, V93, P9073&#xD; JHAPPAN C, 2003,
                    ONCOGENE, V22, P3099&#xD; KAPPES UP, 2005, RADIAT RES 1, V164, P440&#xD; KAPPES
                    UP, 2006, J INVEST DERMATOL, V126, P667&#xD; KIELBASSA C, 1997, CARCINOGENESIS,
                    V18, P811&#xD; KOHLER SW, 1990, NUCLEIC ACIDS RES, V18, P3007&#xD; KOZMIN S,
                    2005, P NATL ACAD SCI USA, V102, P13538&#xD; KVAM E, 1997, CARCINOGENESIS, V18,
                    P2379&#xD; LAMBERT LB, 2005, MUTAT RES-REV MUTAT, V590, P1&#xD; MELLON I, 1987,
                    CELL, V51, P241&#xD; PALMER CM, 1997, PHOTOCHEM PHOTOBIOL, V65, P543&#xD; PERDIZ
                    D, 2000, J BIOL CHEM, V275, P26732&#xD; PFEIFER GP, 1999, METHOD ENZYMOL, V304,
                    P548&#xD; PFEIFER GP, 2005, MUTAT RES-FUND MOL M, V571, P19&#xD; PONKA P, 1999,
                    AM J MED SCI, V318, P241&#xD; ROBERT C, 1996, J INVEST DERMATOL, V106, P721&#xD;
                    ROCHETTE PJ, 2003, NUCLEIC ACIDS RES, V31, P2786&#xD; SAGE E, 1996, P NATL ACAD
                    SCI USA, V93, P176&#xD; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363&#xD;
                    VANKRANEN HJ, 1997, CANCER RES, V57, P1238&#xD; WANG SQ, 2001, J AM ACAD
                    DERMATOL, V44, P837&#xD; WOODHEAD AD, 1999, J EPIDEMIOL S, V9, P102&#xD;
                    WOOLLONS A, 1999, BRIT J DERMATOL, V140, P1023&#xD; YOU YH, 1999, J MOL BIOL,
                    V293, P493&#xD; ZHANG XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245901000008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>819</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">819</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1792</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Besaratinia, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Biology, Beckman
                    Research Institute of the City of Hope National Medical Center, Duarte,
                    California 91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Lack of mutagenicity of
                        acrolein-induced DNA adducts in mouse and human cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">11640-7</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">24</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Acrolein/ pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Adducts/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenicity Tests</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagens/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ultraviolet Rays</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1538-7445 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">18089793</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Acrolein is an endogenous metabolite
                    and a ubiquitous environmental pollutant. Recently, it has been suggested that
                    acrolein is a major etiologic agent for tobacco smoking-related lung cancer.
                    Despite the known DNA-damaging effects of acrolein, its mutagenicity to
                    mammalian cells remains uncertain. We have investigated acrolein-induced DNA
                    damage in relation to mutagenesis, with special focus on DNA repair, in mouse
                    and human cells. We mapped the formation of acrolein-induced DNA adducts and the
                    kinetics of repair of the induced lesions in the cII transgene, the mutational
                    target, in acrolein-treated transgenic mouse fibroblasts. Acrolein-DNA adducts
                    were formed preferentially at specific nucleotide positions, mainly at G:C base
                    pairs, along the cII transgene. The induced acrolein-DNA adducts were moderately
                    resistant to DNA repair. Quantification of cII mutant frequency in
                    acrolein-treated cells, however, revealed that acrolein was not mutagenic to
                    these cells at doses sufficient to produce DNA adducts. Determination of supF
                    mutant frequency in DNA repair-proficient and DNA repair-deficient human
                    fibroblasts transfected with acrolein-treated plasmids confirmed a lack of
                    acrolein mutagenicity. Because CpG methylation may intensify acrolein-DNA
                    adduction, we examined whether the extent of CpG methylation in the supF gene
                    can determine acrolein-induced mutagenesis in human cells. Enhancement of
                    acrolein-DNA adduction by methylating CpGs in the supF sequence did not elicit a
                    mutagenic response in human fibroblasts, however. We conclude that acrolein is
                    not mutagenic to mouse and human fibroblasts, regardless of DNA repair capacity
                    or methylation status of CpGs, possibly because of a highly accurate replication
                    bypass of the induced lesions.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>820</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">820</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1334</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pullarkat, V.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Hematol
                    &amp; Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. City Hope Natl Med
                    Ctr, Div Pathol, Duarte, CA 91010 USA.&#xD;Pullarkat, V, City Hope Natl Med Ctr,
                    Div Hematol &amp; Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA
                    91010 USA.&#xD;vpullarkat@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Distinct clonal origins of
                        systemic mastocytosis and associated B-cell lymphoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Leukemia Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Leukemia Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Leukemia Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Leukemia Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1749-1754</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">31</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">systemic mastocytosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematologic malignancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIT mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphoproliferative
                        disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Non-Hodgkin&apos;s
                        lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAST-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEUKEMIC CLONE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-KIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HODGKINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0145-2126</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251573900019</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Systemic rnastocytosis (SM) may
                    rarely be associated with lymphoproliferative disorders. In such cases, the
                    relationship between the neoplastic mast cells and the malignant lymphocytes
                    remains unclear. We describe a patient with indolent SM whose bone marrow showed
                    evidence of low-grade B-cell lymphoma. By detecting the activating KIT mutation
                    D816V in the microdissected bone marrow mast cells, but not in the neoplastic
                    B-lymphocytes, we demonstrate the distinct clonal origins of the mastocytosis
                    and lymphoma when these two entities coexist. We also highlight the clinical and
                    pathologic differences between SM associated with lymphoid as opposed to myeloid
                    neoplasms and discuss their pathogenesis. (C) 2007 Elsevier Ltd. All rights
                    reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    240FZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 15&#xD;Cited References:
                    &#xD; AKIN C, 2000, EXP HEMATOL, V28, P140&#xD; HORNY HP, 1988, BRIT J HAEMATOL,
                    V69, P449&#xD; HORNY HP, 2003, J CLIN PATHOL, V56, P575&#xD; HORNY HP, 2006, J
                    CLIN PATHOL, V59, P264&#xD; KING PHM, 1991, BRIT J HAEMATOL, V77, P436&#xD;
                    MOLIN D, 2001, BRIT J HAEMATOL, V114, P616&#xD; PULLARKAT V, 2007, LEUKEMIA RES,
                    V31, P261&#xD; PULLARKAT VA, 2003, AM J HEMATOL, V73, P12&#xD; SALETTI P, 1999,
                    ANN HEMATOL, V78, P97&#xD; SPERR WR, 2005, CLIN CANCER RES 1, V11, P6787&#xD;
                    STELLMACHER F, 2004, LEUKEMIA LYMPHOMA, V45, P801&#xD; TAYLOR ML, 2004, J MOL
                    DIAGN, V6, P335&#xD; TOURNILHAC O, 2006, ANN ONCOL, V17, P1275&#xD; TRAVIS WD,
                    1988, MEDICINE, V67, P345&#xD; VALENT P, 2001, TUMORS HAEMATOPOETIC,
                    P104</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251573900019 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI? reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>592</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">592</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1333</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kirn, J. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, Y. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zern, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Davis, Med Ctr,
                    Transplant Res Program, Dept Internal Med, Sacramento, CA 95817 USA. Seoul Natl
                    Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea. City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA.&#xD;Wu, J, Univ Calif
                    Davis, Med Ctr, Transplant Res Program, Dept Internal Med, Sacramento, CA 95817
                    USA.&#xD;jdwu@ucdavis.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Short hairpin RNA causes the
                        methylation of transforming growth factor-beta receptor II promoter and
                        silencing of the target gene in rat hepatic stellate cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Biophys Res
                        Commun</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Biophys Res
                        Commun</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">292-297</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">359</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">promoter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">small interfering RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">short hairpin RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transcriptional gene
                        silencing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transforming growth factor-beta
                        receptor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIRECTED DNA METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOUBLE-STRANDED-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HISTONE METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PCR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CASSETTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELIVERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SITES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-291X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247494400017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Small interfering RNA (siRNA)
                    induces transcriptional gene silencing (TGS) in plant and animal cells. RNA
                    dependent DNA methylation (RdDM) accounts for TGS in plants, but it is unclear
                    whether siRNA induces RdDM in mammalian cells. To determine whether stable
                    expression of short hairpin siRNA (shRNA) induces DNA methylation in mammalian
                    cells, we transduced rat hepatic stellate SBC10 cells with lentiviral vectors
                    which encode an U6 promoter-driven shRNA expression cassette homologous to the
                    transforming growth factor-beta receptor (TGF beta RII) promoter region.
                    Sequencing analysis of bisulfite-modified genomic DNA showed the methylation of
                    cytosine residues both in CpG dinucleotides and non-CpG sites around the target
                    region of the TGF beta RII promoter in SBC10 cells transduced with the
                    promoter-targeting lentiviral vector. In these cells, real-time RT-PCR showed a
                    decrease in TGF beta RII mRNA levels which were reversed by treatment with
                    5-aza-2-deoxycytidine. Our results demonstrate that recombinant
                    lentivirus-mediated shRNA delivery resulted in the methylation of the homologous
                    promoter area in mammalian cells, and this approach may be used as a tool for
                    transcriptional gene silencing by epigenetic modification of mammalian cell
                    promoters. (c) 2007 Published by Elsevier Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    182GZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 30</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247494400017 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>785</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">785</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1331</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Knobf, M. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Juarez, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, S. Y. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haozous, E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Yale Univ, Sch Nursing, Adult Adv
                    Practice Program, New Haven, CT 06536 USA. City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Natl Taipei Coll, Taipei, Taiwan. Univ Calif Los Angeles, Los
                    Angeles, CA USA. SUNY Hlth Sci Ctr, New York, NY USA.&#xD;Knobf, MT, Yale Univ,
                    Sch Nursing, Adult Adv Practice Program, New Haven, CT 06536
                    USA.&#xD;tish.knobf@yale.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Challenges and strategies in
                        recruitment of ethnically diverse Populations for cancer nursing
                        research</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncology Nursing Forum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncol. Nurs. Forum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncol Nurs Forum</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1187-1194</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">AFRICAN-AMERICAN WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLINICAL-TRIALS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINORITY WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH DISPARITIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CERVICAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLACK-WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BARRIERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPERIENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RETENTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0190-535X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250862600011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose/Objectives: To describe
                    common barriers, identify challenges for researchers, and provide strategies for
                    recruitment and retention of ethnic minority groups for cancer nursing research.
                    Data Sources: Computerized search of databases, published articles, abstracts,
                    master&apos;s theses, and doctoral dissertations. Data Synthesis: Social,
                    economic, and cultural factors present challenges to recruitment of minorities
                    into research. Knowing the culture of the target population, developing trust,
                    engaging the community, and using tailored materials are strategies for
                    recruitment and retention of minorities. Conclusions: Knowledge of potential
                    barriers and challenges to research with diverse populations provides the
                    foundation for the development of strategies for successful recruitment of
                    minorities in cancer nursing research. Implications for Nursing: Increasing
                    ethnic minorities in research will generate knowledge that will contribute to
                    culturally competent cancer care.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    230FW&#xD;Times Cited: 0&#xD;Cited Reference Count: 76&#xD;Cited References:
                    &#xD; *AG HEALTHC RES QU, 2005, NAT HEALTHC DISP REP&#xD; *ONC NURS SOC, 2000,
                    MULT OUTC GUID CULT&#xD; *ONC NURS SOC, 2000, MULT TOOLK 2&#xD; *US BUR CENS,
                    2004, US CENS 2004&#xD; ADAMSCAMPBELL LL, 2004, J CLIN ONCOL, V22, P730&#xD;
                    ALEXANDER GA, 2000, ANN EPIDEMIOL S, V10, S61&#xD; ALVIDREZ J, 2002, ETHICS
                    BEHAV, V12, P103&#xD; ANDREWS JO, 2004, J NURS SCHOLARSHIP, V36, P358&#xD;
                    ASHINGGIWA K, 1997, J PSYCHOSOC ONCOL, V15, P19&#xD; ASHINGGIWA K, 1999, J NATL
                    MED ASSOC, V91, P255&#xD; ASHINGGIWA KT, 2004, CANCER, V101, P450&#xD;
                    ASHINGGIWA KT, 2004, PSYCHO-ONCOL, V13, P408&#xD; ASHINGGIWA KT, 2004,
                    PSYCHO-ONCOL, V13, P709&#xD; AZIZ NM, 2002, ONCOL NURS FORUM, V29, P789&#xD;
                    BAKER EA, 1999, AM J PREV MED S, V16, P86&#xD; BANKSWALLACE J, 2004, ADV NURS
                    SCI, V27, P102&#xD; BLACK MEA, 2006, ONCOL NURS FORUM, V33, P873&#xD; BRANT JM,
                    1999, ONCOL NURS FORUM, V26, P731&#xD; BROWN BA, 2000, WOMEN HEALTH, V31,
                    P153&#xD; BROWN DR, 2000, ANN EPIDEMIOL S, V10, S13&#xD; BURHANSSTIPANOV L,
                    2001, SEMIN ONCOL NURS, V17, P206&#xD; CABRAL DN, 2003, AM J EPIDEMIOL, V158,
                    P272&#xD; CARRESE JA, 1995, JAMA-J AM MED ASSOC, V274, P826&#xD; CLANTON M,
                    2006, CANCER S, V107, P1931&#xD; COHEN M, 2001, SEMINARS ONCOLOGY NU, V17,
                    P190&#xD; CULVER JL, 2002, PSYCHO-ONCOL, V11, P495&#xD; DANCY BL, 2004, NURS
                    OUTLOOK, V52, P234&#xD; DAUNT DJ, 2003, APPL NURS RES, V16, P189&#xD; DAVIS SM,
                    1999, AM J CLIN NUTR S, V69, S755&#xD; DIRKSEN ST, 2002, ONCOLOGY NURSING FOR,
                    V29, P820&#xD; ENG E, 1993, CANCER, V72, P1071&#xD; FLASKERUD JH, 2002, NURS
                    RES, V51, P74&#xD; GALASSO P, 2005, DIABETES EDUCATOR, V31, P719&#xD; GIBSON LM,
                    2003, CANC CONTROL S, V10, P52&#xD; GILLISS CL, 2001, J WOMEN HEALTH GEN-B, V10,
                    P77&#xD; GUIDRY JJ, 2003, CANCER, V97, P318&#xD; GUILIANO AR, 2000, ANN
                    EPIDEMIOL, V10, S22&#xD; HAOZOUS E, 2003, CANC PAIN PLAINS NAT&#xD; HEINEY SP,
                    2006, CANCER NURS, V29, P291&#xD; HENDERSON PD, 2003, ONCOL NURS FORUM, V30,
                    P641&#xD; HODGE FS, 2000, ANN EPIDEMIOL S, V10, S41&#xD; HOWE HL, 2006, CANCER,
                    V107, P1711&#xD; JEMAL A, 2005, CA-CANCER J CLIN, V55, P10&#xD; JULION W, 2000,
                    NURS OUTLOOK, V48, P230&#xD; KNOBF MT, 2003, P E NURSING RES SOC, P70&#xD; KNOBF
                    MT, 2005, AM CANC SOC C ATL GA&#xD; KOLB B, 2006, ONCOLOGY, V20, P1256&#xD; LEE
                    SC, 2002, P DEP DEF BREAST CAN, V3&#xD; LEE SC, 2003, THESIS YALE SCH NURS&#xD;
                    LEEMAN J, 2003, NURS OUTLOOK, V51, P20&#xD; LILLINGTON L, 2000, MED AM&#xD;
                    MANDELBLATT J, 2005, PREV MED, V40, P611&#xD; MORGAN PD, 2005, ONCOL NURS FORUM,
                    V32, P979&#xD; NARANJO LE, 1998, PUBLIC HEALTH NURS, V15, P25&#xD; NEWLIN K,
                    2002, ADV NURS SCI, V25, P57&#xD; NORTHOUSE LL, 1999, RES NURS HEALTH, V22,
                    P449&#xD; PARRAN L, 2004, ONS NEWS, V19, P4&#xD; PASKETT ED, 2004, CANCER, V101,
                    P2650&#xD; PHILLIPS J, 2002, ONCOLOGY NURSING FOR, V29, P807&#xD; PLETSCH PK,
                    1995, IMAGE, V27, P211&#xD; POLITE BN, 2006, J CLIN ONCOL, V24, P2179&#xD;
                    PORTER CP, 1993, NURS OUTLOOK, V41, P59&#xD; PORTILLO CJ, 2001, NURS OUTLOOK,
                    V49, P263&#xD; POWELL DL, 2003, J NATL BLACK NURSES, V14, P34&#xD; SHEPPARD VB,
                    2005, J GEN INTERN MED, V20, P444&#xD; STARK N, 2002, J NATL MED ASSOC, V94,
                    P31&#xD; STRUTHERS R, 2004, COMPLEMENTARY THERAP, V10, P141&#xD; SUDORE RL,
                    2006, J GEN INTERN MED, V21, P867&#xD; SUN V, 2002, THESIS YALE U SCH NU&#xD;
                    SUN Y, 2006, THESIS YALE U SCH NU&#xD; UNDERWOOD SM, 2000, ANN EPIDEMIOL S, V10,
                    S3&#xD; WARD E, 2004, CA-CANCER J CLIN, V54, P78&#xD; WILLIAMS DR, 2005, HEALTH
                    AFFAIR, V24, P325&#xD; WILMOTH MC, 2001, ONCOL NURS FORUM, V28, P875&#xD; YANCEY
                    AK, 2006, ANNU REV PUBL HEALTH, V27, P1&#xD; ZIMMERMAN SM, 1997, ONCOL NURS
                    FORUM, V24, P499</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250862600011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>286</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">286</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">971</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kortylewski, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Civ Canc Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010
                    USA.&#xD;Yu, H, City Hope Natl Med Ctr, Beckman Res Inst, Civ Canc
                    Immunotherapeut &amp; Tumor Immunol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;hyu@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Stat3 as a potential target for
                        cancer immunotherapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunother</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">131-139</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">30</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">stat3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC
                        CELL-DIFFERENTIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTITUMOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE-RESPONSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLONY-STIMULATING
                        FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMATURE MYELOID CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTATIC MELANOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNAL TRANSDUCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSTITUTIVE ACTIVATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb-Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1524-9557</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244551400001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The abilities of tumor cells to
                    proliferate uncontrollably, resist apoptosis, induce vasculature formation, and
                    invade distant organs are well-recognized hallmarks of cancer. More recently,
                    the capability of tumors to evade immune Surveillance and avoid destruction by
                    the immune system has also gained significant acceptance in the cancer research
                    field. However, the initial explanation for the lack of antitumor immune
                    responses was ascribed to mutations affecting tumor-associated antigen
                    expression, antigen processing, and presentation, Although these mutations
                    undoubtedly facilitate tumor immune evasion, they cannot account for how tumors
                    remain undetected before the occurrence of these genetic alterations. Moreover,
                    the tumor microenvironment, whose pivotal role in immune paralysis is gaining
                    appreciation, does not seem to directly cause these mutations. In addition, many
                    tumors retain intact genes encoding major histocompatibility complex,
                    costimulatory molecules and tumor antigens, but with reduced expression levels
                    in the presence of tumor-secreted factors. Discoveries from several recent
                    studies support the hypothesis that oncogenesis itself, Lis a result of
                    overactivity of growth factor receptors, cytokine receptors, or oncoproteins,
                    coordinates immune evasion. In particular, signal transducer and transcription
                    activator 3 (Stat3), which is a point of convergence for many oncogenic
                    pathways, has emerged as a critical mediator of tumor immune evasion at multiple
                    levels. As a result, molecules involved in the oncogenic signaling pathways,
                    particularly Stat3, provide targets for cancer immunotherapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    141BN&#xD;Times Cited: 0&#xD;Cited Reference Count: 105&#xD;Cited References:
                    &#xD; ALMAND B, 2001, J IMMUNOL, V166, P678&#xD; ALONZI T, 2004, CYTOKINE, V26,
                    P45&#xD; ATTIA P, 2005, J CLIN ONCOL, V23, P6043&#xD; BLANKENSTEIN T, 2005, CURR
                    OPIN IMMUNOL, V17, P180&#xD; BLANSFIELD JA, 2005, J IMMUNOTHER, V28, P593&#xD;
                    BLATTMAN JN, 2004, SCIENCE, V305, P200&#xD; BOWMAN T, 2000, ONCOGENE, V19,
                    P2474&#xD; BROMBERG J, 2000, ONCOGENE, V19, P2468&#xD; BROMBERG JF, 1999, CELL,
                    V98, P295&#xD; BUETTNER R, 2002, CLIN CANCER RES, V8, P945&#xD; BURDELYA L,
                    2005, J IMMUNOL, V174, P3925&#xD; CATLETTFALCONE R, 1999, IMMUNITY, V10,
                    P105&#xD; CHENG FD, 2003, IMMUNITY, V19, P425&#xD; COLONNA M, 2004, NAT IMMUNOL,
                    V5, P1219&#xD; CORINTI S, 2001, J IMMUNOL, V166, P4312&#xD; COSTAPEREIRA AP,
                    2002, P NATL ACAD SCI USA, V99, P8043&#xD; DARNELL JE, 1994, SCIENCE, V264,
                    P1415&#xD; DARNELL JE, 2002, NAT REV CANCER, V2, P740&#xD; DAUER DJ, 2005,
                    ONCOGENE, V24, P3397&#xD; DIAZ N, 2006, CLIN CANCER RES, V12, P20&#xD; DRANOFF
                    G, 2004, NAT REV CANCER, V4, P11&#xD; DUNN GP, 2002, NAT IMMUNOL, V3, P991&#xD;
                    EPLINGBURNETTE PK, 2001, J CLIN INVEST, V107, P351&#xD; FERRONE S, 1995, IMMUNOL
                    TODAY, V16, P487&#xD; FUCHS EJ, 1996, SEMIN IMMUNOL, V8, P271&#xD; GABRILOVICH
                    D, 2004, NAT REV IMMUNOL, V4, P941&#xD; GABRILOVICH DI, 1996, NAT MED, V2,
                    P1096&#xD; GALM O, 2003, BLOOD, V101, P2784&#xD; GRANDIS JR, 2000, P NATL ACAD
                    SCI USA, V97, P4227&#xD; GRITSKO T, 2006, CLIN CANCER RES, V12, P11&#xD; HANAHAN
                    D, 2000, CELL, V100, P57&#xD; HE B, 2003, P NATL ACAD SCI USA, V100, P14133&#xD;
                    HEINRICH PC, 2003, BIOCHEM J 1, V374, P1&#xD; HODI FS, 2003, P NATL ACAD SCI
                    USA, V100, P4712&#xD; HOENTJEN F, 2005, BLOOD, V105, P689&#xD; JACKSON SH, 2004,
                    J IMMUNOL, V172, P2307&#xD; KANO A, 2003, J EXP MED, V198, P1517&#xD; KIRKWOOD
                    JM, 2001, J CLIN ONCOL, V19, P2370&#xD; KITAMURA H, 2005, IMMUNITY, V23,
                    P491&#xD; KIUCHI N, 1999, J EXP MED, V189, P63&#xD; KOBAYASHI M, 2003, J CLIN
                    INVEST, V111, P1297&#xD; KOMAZAKI T, 2004, JPN J CLIN ONCOL, V34, P191&#xD;
                    KORTYLEWSKI M, 2003, J BIOL CHEM, V278, P5242&#xD; KORTYLEWSKI M, 2005, CANCER
                    METAST REV, V24, P315&#xD; KORTYLEWSKI M, 2005, NAT MED, V11, P1314&#xD;
                    KUSMARTSEV S, 2004, J IMMUNOL, V172, P989&#xD; LEE CK, 2000, J IMMUNOL, V165,
                    P3571&#xD; LEE H, 2003, J ENDOUROL, V17, P63&#xD; LOTZE MT, 1986, JAMA-J AM MED
                    ASSOC, V256, P3117&#xD; MASUDA M, 2002, CANCER RES, V62, P3351&#xD;
                    MENETRIERCAUX C, 1998, BLOOD, V92, P4778&#xD; NABARRO S, 2005, J EXP MED, V202,
                    P1399&#xD; NAGAI H, 2003, J HUM GENET, V48, P65&#xD; NEFEDOVA Y, 2004, J
                    IMMUNOL, V172, P464&#xD; NEFEDOVA Y, 2005, CANCER RES, V65, P9525&#xD; NISHIKAWA
                    H, 2005, J IMMUNOL, V175, P4433&#xD; NIU G, 2002, ONCOGENE, V21, P7001&#xD; NIU
                    GL, 1999, CANCER RES, V59, P5059&#xD; NIU GL, 2001, CANCER RES, V61, P3276&#xD;
                    NIU GL, 2002, ONCOGENE, V21, P2000&#xD; NIU GL, 2005, MOL CELL BIOL, V25,
                    P7432&#xD; PARDOLL D, 2003, ANNU REV IMMUNOL, V21, P807&#xD; PARDOLL DM, 2002,
                    NAT REV IMMUNOL, V2, P227&#xD; PARK SJ, 2004, J IMMUNOL, V173, P3844&#xD;
                    PAWELEC G, 1997, CRIT REV ONCOGENESIS, V8, P111&#xD; PEGUETNAVARRO J, 2003, J
                    IMMUNOL, V170, P3488&#xD; PHAN GQ, 2003, P NATL ACAD SCI USA, V100, P8372&#xD;
                    RATTA M, 2002, BLOOD, V100, P230&#xD; REAL PJ, 2002, ONCOGENE, V21, P7611&#xD;
                    ROBINSON MR, 2004, J IMMUNOTHER, V27, P478&#xD; ROSENBERG SA, 1985, NEW ENGL J
                    MED, V313, P1485&#xD; ROSENBERG SA, 1989, J CLIN ONCOL, V7, P1863&#xD; ROSENBERG
                    SA, 2004, NAT MED, V10, P909&#xD; SANO S, 1999, EMBO J, V18, P4657&#xD; SANO S,
                    2005, NAT MED, V11, P43&#xD; SCHULER G, 2003, CURR OPIN IMMUNOL, V15, P138&#xD;
                    SHEN YH, 2001, P NATL ACAD SCI USA, V98, P1543&#xD; SHIROGANE T, 1999, IMMUNITY,
                    V11, P709&#xD; SINIBALDI D, 2000, ONCOGENE, V19, P5419&#xD; SOMBROEK CC, 2002, J
                    IMMUNOL, V168, P4333&#xD; STEINBRINK K, 1997, J IMMUNOL, V159, P4772&#xD;
                    STEINMAN RM, 2003, ANN NY ACAD SCI, V987, P15&#xD; SUTMULLER RPM, 2001, J EXP
                    MED, V194, P823&#xD; TAKEDA K, 1999, IMMUNITY, V10, P39&#xD; TURKSON J, 2001, J
                    BIOL CHEM, V276, P45443&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P1533&#xD;
                    TURKSON J, 2004, MOL CANCER THER, V3, P261&#xD; VANELSAS A, 1999, J EXP MED,
                    V190, P355&#xD; VICARI AP, 2002, SEMIN CANCER BIOL, V12, P33&#xD; WANG TH, 2004,
                    NAT MED, V10, P48&#xD; WEI DY, 2003, ONCOGENE, V22, P319&#xD; WEI LH, 2003,
                    ONCOGENE, V22, P1517&#xD; WELTE T, 2003, P NATL ACAD SCI USA, V100, P1879&#xD;
                    WILLIAMS L, 2004, J IMMUNOL, V172, P567&#xD; XIE J, 2003, BLOOD, V101,
                    P4005&#xD; XIE TX, 2004, ONCOGENE, V23, P3550&#xD; XU Q, 2005, ONCOGENE, V24,
                    P5552&#xD; YAHATA Y, 2003, J BIOL CHEM, V278, P40026&#xD; YANG AS, 2003, CANCER
                    RES, V63, P2150&#xD; YOSHIKAWA H, 2001, NAT GENET, V28, P29&#xD; YU H, 2004, NAT
                    REV CANCER, V4, P97&#xD; YU P, 2005, J EXP MED, V201, P779&#xD; YU ZY, 2002,
                    BIOCHEM J 1, V367, P97&#xD; ZHOU P, 1998, BLOOD, V92, P3226&#xD; ZOU WP, 2005,
                    NAT REV CANCER, V5, P263</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244551400001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>384</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">384</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1321</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dean, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Nursing Res
                    &amp; Educ Dept, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Biostat,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Gen &amp; Oncol Dept Surg, Duarte,
                    CA 91010 USA.&#xD;Grant, M, City Hope Natl Med Ctr, Nursing Res &amp; Educ Dept,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;mgrant@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Quality of life outcomes in 599
                        cancer and non-cancer patients with colostomies</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Surgical
                        Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Surgical
                        Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Surg. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Surg Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">79-87</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">138</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">colostomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">non-cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFLAMMATORY
                        BOWEL-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ULCERATIVE-COLITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEXUAL FUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CROHNS-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DYSFUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESECTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-4804</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244841900013</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background. A colostomy is known to
                    impact negatively on a patient&apos;s quality of life (QOL). Concerns include
                    incontinence, rectal discharge, gas, difficulties in returning to work,
                    decreased sexual activity, and travel and leisure challenges. Reports have
                    described QOL outcomes in cancer patients with colostomies and inflammatory
                    bowel syndrome with colostomies, but little has been written regarding a
                    comparison of cancer and non-cancer populations. The purpose of this study was
                    to describe QOL issues of colostomy patients and compare these issues in cancer
                    and non-cancer participants. Materials and methods. A QOL-ostomy questionnaire
                    was mailed to 2455 California members of the United Ostomy Association. Results.
                    Of the 1457 respondents (59%), 599 had a colostomy. Most were results from
                    cancer (517/599), with colorectal cancer being the most common diagnosis. The
                    most common benign diagnoses were inflammatory bowel disease and diverticulitis.
                    Demographics were similar, except for more females in the non-cancer group
                    (76%), and increased length of time with colostomy from the cancer group (mean
                    135.9 versus 106.4 months, P = 0.03). Common QOL problems included sexual
                    problems, gas, constipation, travel difficulties, and dissatisfaction with
                    appearance. Overall, cancer patients had less difficulty adjusting to their
                    colostomies. Conclusions. Results confirmed the negative impact of a colostomy
                    on QOL. While patients with cancer had a better overall QOL than those with
                    benign processes, concerns were common to all colostomy patients. These results
                    provide health care practitioners with information useful in discussing QOL
                    concerns during pre-operation treatment decisions and post operative teaching
                    and follow-up care. (c) 2007 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    145CC&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; *CANC FACTS FIG, 2005, CAN J CLIN, V55, P10&#xD; BARTHA I, 1995, ORVOSI
                    HETILAP, V136&#xD; CAMILLERIBRENNAN J, 1998, BRIT J SURG, V85, P1036&#xD; COHEN
                    AM, 1997, CANC PRINCIPLES PRAC, P1163&#xD; DECOSSE JJ, 1997, J SURG ONCOL, V65,
                    P321&#xD; DROSSMAN DA, 1991, PSYCHOSOM MED, V53, P701&#xD; DUKES CE, 1947,
                    LANCET, V2, P12&#xD; FAZIO VW, 1980, WORLD J SURG, V4, P149&#xD; FERRELL B,
                    1991, HOSPICE J, V7, P9&#xD; FERRELL B, 1992, CANCER NURS, V15, P247&#xD;
                    FERRELL BR, 1995, QUAL LIFE RES, V4, P523&#xD; FERRELL BR, 1997, PSYCHO-ONCOL,
                    V6, P13&#xD; GRANT M, 1990, SEMIN ONCOL NURS, V6, P260&#xD; GRANT M, 1992, QUAL
                    LIFE RES, V1, P375&#xD; GRANT M, 1999, HEMATOPOIETIC CELL T, P407&#xD; GRANT M,
                    2004, QUAL LIFE RES, V13, P1445&#xD; GRANT MM, 1984, P 4 NAT C CANC NURS&#xD;
                    GRANT MM, 1999, DEV SUPPORT CANC CAR, V3, P4&#xD; GRUMANN MM, 2001, EDITORIAL
                    ANN SURG, V223, P149&#xD; GRUNBERG K, 1986, J ENTEROSTOMAL THERA, V13, P148&#xD;
                    HJORTSWANG H, 1998, AM J GASTROENTEROL, V93, P2203&#xD; HOLLENDER J, 1979, ARCH
                    PHYSICAL MED RE, V60, P45&#xD; IRVINE EJ, 1997, AM J GASTROENTEROL S, V92,
                    S18&#xD; JENKS JM, 1997, APPL NURS RES, V10, P174&#xD; KEYES K, 1987,
                    GERONTOLOGIST, V27, P182&#xD; KOUKOURAS D, 1991, EUR J SURG ONCOL, V17,
                    P285&#xD; KURTZMAN S, 1988, AM J SURG, V155, P791&#xD; LAMONICA G, 1985, DIS
                    COLON RECTUM, V28, P937&#xD; LASK B, 1987, GUT, V28, P1257&#xD; MACDONALD LD,
                    1984, J EPIDEMIOL COMMUN H, V38, P284&#xD; MOSER G, 1995, EUR J GASTROEN HEPAT,
                    V7, P853&#xD; OFMAN US, 1992, CURR OPIN ONCOL, V4, P605&#xD; ORBACH CE, 1965,
                    ARCH GEN PSYCHIAT, V12, P126&#xD; OSOBA D, 1994, J CLIN ONCOL, V12, P609&#xD;
                    PADILLA GV, 1985, ADV NURS SCI, V8, P45&#xD; PADILLA GV, 1990, CANCER NURS, V13,
                    P108&#xD; SAHAY TB, 2000, CANCER PRACT, V8, P38&#xD; SANTANGELO ML, 1987, AM J
                    SURG, V154, P502&#xD; SCHWARTZ RA, 1982, INT J PSYCHIAT MED, V12, P67&#xD;
                    SERLIN RC, 1995, PAIN, V61, P277&#xD; SPILKER B, 1996, QUALITY LIFE PHARMAC,
                    P1&#xD; SPRANGERS MAG, 1995, DIS COLON RECTUM, V38, P361&#xD; STAHLGREN LH,
                    1959, ARCHS SURG CHICAGO, V78, P604&#xD; SUTHERLAND AM, 1952, CANCER, V5,
                    P857&#xD; WATSON PG, 1983, CANC NURS, V3, P21&#xD; WEBER TK, 1998, ONCOLOGY-NY,
                    V12, P933&#xD; WILLIAMS NS, 1983, BRIT J SURG, V70, P460&#xD; WIRSCHING M, 1975,
                    PSYCHOTHER PSYCHOSOM, V26, P245&#xD; YAZDANPANAH Y, 1997, AM J GASTROENTEROL,
                    V92, P1897</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244841900013 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>848</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">848</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1319</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wendel, C. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mohler, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawl, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baldwin, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Coons, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McCorkle, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ko, C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmidt, C. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Arizona, Coll Med, So Arizona
                    VA Hlth Care Syst, Tucson, AZ 85723 USA. City Hope Natl Med Ctr, Dept Nursing
                    Res &amp; Educ, Duarte, CA 91010 USA. Univ Arizona, Coll Publ Hlth, Tucson, AZ
                    USA. Indiana Univ, Sch Nursing, Ctr Nursing Res, Indianapolis, IN 46204 USA.
                    Arizona State Univ, Coll Nursing, Phoenix, AZ USA. Univ Arizona, Coll Pharm, Div
                    Social &amp; Adm Sci, Tucson, AZ 85721 USA. Yale Univ, Sch Nursing, New Haven,
                    CT 06536 USA. Univ Calif Los Angeles, Ctr Hlth Sci, VA Greater Los Angeles
                    Healthcare Syst, Los Angeles, CA 90024 USA. Indiana Univ, Sch Med, Dept Surg,
                    Richard L Roudebush VA Med Ctr, Indianapolis, IN 46204 USA.&#xD;Krouse, RS, Univ
                    Arizona, Coll Med, So Arizona VA Hlth Care Syst, 2-112,3601 S 6th Ave, Tucson,
                    AZ 85723 USA.&#xD;robert.krouse@va.gov</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A mixed-methods evaluation of
                        health-related quality of life for male veterans with and without intestinal
                        stomas</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Diseases of the Colon &amp;
                        Rectum</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Diseases of the Colon &amp;
                        Rectum</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Dis. Colon Rectum</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Dis Colon Rectum</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2054-2066</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">50</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Ostomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">focus groups</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stomas</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSYCHOSOCIAL MORBIDITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLOSTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DYSFUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADJUSTMENT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0012-3706</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251641700007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: Intestinal stomas have a
                    major impact on Cases&apos; lives. It is essential to better understand the
                    areas in which interventions may help to minimize the negative consequences.
                    METHODS: This was a case-control survey study using validated instruments (City
                    of Hope Quality of Life-Ostomy and Short Form 36 for Veterans). Cases were
                    accrued from Veterans Affairs Medical Centers in Tucson, Indianapolis, and Los
                    Angeles. Eligibility included a major intra-abdominal surgical procedure that
                    led to an ostomy (cases), or a similar procedure that did not mandate a stoma
                    (controls). Analysis included quantitative and qualitative responses. RESULTS:
                    The response rate was 48 percent (511/1063). Cases and controls had relatively
                    similar demographic characteristics. Because of low numbers of female
                    respondents (13 cases and 11 controls), only results for males are reported.
                    Based on both the City of Hope Quality of Life-Ostomy and Short Form 36 for
                    Veterans, cases reported significantly poorer scores on scales/domains
                    reflecting psychologic and social functioning and well being. Additionally,
                    cases reported poorer scores on Short Form 36 for Veterans scales reflecting
                    physical functioning and significantly lower scores on multiple Life-Ostomy
                    compared with controls. Two-thirds of cases replied to an open-ended question on
                    their &quot;greatest challenge&quot; related to their ostomy, which led to
                    further clarification of major issues. CONCLUSIONS: Multiple health-related
                    quality of life problems were reported by male veterans with intestinal stomas.
                    The greatest differences between cases and controls were observed in the social
                    and psychologic domains/scales. Findings from this study provide a greater
                    understanding of the challenges faced by ostomates and will inform the
                    development and evaluation of urgently needed intervention strategies.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    241FG&#xD;Times Cited: 0&#xD;Cited Reference Count: 44&#xD;Cited References:
                    &#xD; *UN OST ASS AM, PHOEN OST CHAPT&#xD; BORWELL B, 1997, PROFESSIONAL NURSE,
                    V12, P250&#xD; DECOSSE JJ, 1997, J SURG ONCOL, V65, P231&#xD; DEYO RA, 1992, J
                    CLIN EPIDEMIOL, V45, P613&#xD; DUKES CE, 1947, LANCET, V2, P12&#xD; EWING MR,
                    1950, POSTGRAD MED J, V26, P584&#xD; FAZIO VW, 1980, WORLD J SURG, V4, P149&#xD;
                    GRANDIN HM, 2003, ORG ELECTRON, V4, P9&#xD; GRANT M, 1990, SEMIN ONCOL NURS, V6,
                    P260&#xD; GRANT M, 1998, QUAL LIFE RES, V7, P599&#xD; GRANT M, 2004, QUAL LIFE
                    RES, V13, P1445&#xD; GRUNBERG K, 1986, J ENTEROSTOMAL THERA, V13, P148&#xD; HOJO
                    K, 1991, DIS COLON RECTUM, V34, P532&#xD; HURNY C, 1985, CANCER, V36, P170&#xD;
                    ITO N, 2005, J WOUND OSTOMY CONT, V32, P178&#xD; JENKS JM, 1997, APPL NURS RES,
                    V10, P174&#xD; KARADAG A, 2005, J CLIN NURS, V14, P479&#xD; KAZIS LE, 1998, ARCH
                    INTERN MED, V158, P626&#xD; KAZIS LE, 1999, AM J MED QUAL, V14, P28&#xD; KEYES
                    K, 1987, GERONTOLOGIST, V27, P182&#xD; KLOPP AL, 1990, J ENTEROSTOMAL THER, V17,
                    P98&#xD; KRIPPENDOFF K, 1980, CONTENT ANAL&#xD; KROUSE R, 1999, P AN M AM SOC
                    CLIN, V18, A599&#xD; KROUSE R, 2007, J SURG RES, V138, P79&#xD; KROUSE RS, 2006,
                    CURR MED RES OPIN, V22, P781&#xD; KUCHENHOFF J, 1981, PSYCHOTHER PSYCHOSOM, V36,
                    P98&#xD; MCKENZIE F, 2006, BR J NURS, V15, P308&#xD; MILES MB, 1994, QUALITATIVE
                    DATA ANA&#xD; MORSE JM, 1995, QUALITATIVE RES METH&#xD; NUGENT KP, 1999, DIS
                    COLON RECTUM, V42, P1569&#xD; OFMAN US, 1992, CURR OPIN ONCOL, V4, P605&#xD;
                    OSOBA D, 1994, J CLIN ONCOL, V12, P609&#xD; SIDERIS L, 2005, DIS COLON RECTUM,
                    V48, P2180&#xD; SLOAN J, 2003, DRUG INF J, V37, P23&#xD; SPILKER B, 1996,
                    QUALITY LIFE PHARMAC, P1&#xD; SPRANGERS MAG, 1995, DIS COLON RECTUM, V38,
                    P361&#xD; SUTHERLAND AM, 1952, CANCER, V5, P857&#xD; THOMAS C, 1984, J PSYCHOSOM
                    RES, V28, P251&#xD; THOMAS C, 1987, J PSYCHOSOM RES, V31, P311&#xD; WALKER CS,
                    1987, QUALITY LIFE ASSESSM&#xD; WARE JE, 1992, MED CARE, V31, P247&#xD; WHITE
                    CA, 1997, ANN ROY COLL SURG, V79, P3&#xD; WIRSCHING M, 1975, PSYCHOTHER
                    PSYCHOSOM, V26, P245&#xD; YEAGER ES, 1980, ANN SURG, V191, P169</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251641700007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>427</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">427</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1316</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Kuptsova, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kopecky, K. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Godwin, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anderson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hoque, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Willman, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ambrosone, C. B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Roswell Pk Canc Inst, Dept Canc
                    Prevent &amp; Control, Buffalo, NY 14263 USA. Fred Hutchinson Canc Res Ctr, SW
                    Oncol Grp, Ctr Stat, Seattle, WA 98104 USA. So Illinois Univ, Sch Med,
                    Springfield, IL USA. Katmai Oncol Grp, Anchorage, AK USA. Univ Texas, MD
                    Anderson Canc Ctr, Houston, TX 77030 USA. Univ New Mexico, Albuquerque, NM 87131
                    USA. City Hope Natl Med Ctr, Dept Cytogenet, Duarte, CA 91010
                    USA.&#xD;Ambrosone, CB, Roswell Pk Canc Inst, Dept Canc Prevent &amp; Control,
                    Elm &amp; Carlton St, Buffalo, NY 14263
                    USA.&#xD;christine.ambrosone@roswellpark.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Polymorphisms in DNA repair
                        genes and therapeutic outcomes of AML patients from SWOG clinical
                        trials</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3936-3944</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOUTHWEST-ONCOLOGY-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SINGLE-STRAND BREAKS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC
                        LYMPHOCYTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PLATINUM-BASED</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BASE EXCISION-REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMBINATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEOTIDE POLYMORPHISMS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246091400051</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Repair of damage to DNA resulting
                    from chemotherapy may influence drug toxicity and survival in response to
                    treatment. We evaluated the role of polymorphisms in DNA repair genes APE1,
                    XRCC1, ERCC1, XPD, and XRCC3 in predicting therapeutic outcomes of older adults
                    with acute myeloid leukemia (AML) from 2 Southwest Oncology Group (SWOG)
                    clinical trials. All patients received standard chemotherapy induction regimens.
                    Using logistic and proportional hazards regression models, relationships between
                    genotypes, haplotypes, and toxicities, response to induction therapy, and
                    overall survival were evaluated. Patients with XPD Gln751C/Asp312G
                    (&apos;D&apos;) haplotype were more likely to have complete response (OR = 3.06;
                    95% Cl, 1.44-6.70) and less likely to have resistant disease (OR = 0.32; 95%Cl,
                    0.14-0.72) than patients with other haplotypes. ERCC1 polymorphisms were
                    significantly associated with lung (P =.037) and metabolic (P =.041) toxicities,
                    and patients with the XRCC3241 Met variant had reduced risk of liver toxicity
                    (OR = 0.32; 95%Cl, 0.110.95). Significant associations with other toxicities
                    were also found for variant XPD genotypes/haplotypes. These data from clinical
                    trials of older patients treated for AML indicate that variants in DNA repair
                    pathways may have an impact on both outcomes of patients and toxicities
                    associated with treatments. With validation of results in larger samples, these
                    findings could lead to optimizing individual chemotherapy options.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    162MJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 50&#xD;Cited References:
                    &#xD; ALLAN JM, 2004, BLOOD, V104, P3872&#xD; ANDERSON JE, 2002, BLOOD, V100,
                    P3869&#xD; AU WW, 2003, ENVIRON HEALTH PERSP, V111, P1843&#xD; BERWICK M, 2004,
                    J CLIN ONCOL, V22, P3997&#xD; CHANEY SG, 1996, J NATL CANCER I, V88, P1346&#xD;
                    CHANGCLAUDE J, 2005, CLIN CANCER RES, V11, P4802&#xD; CHRISTODOULOPOULOS G,
                    1998, CANCER RES, V58, P1789&#xD; CISTULLI C, 2004, DNA REPAIR, V3, P581&#xD;
                    CROOK TR, 1986, CANCER RES, V46, P5029&#xD; EVANS RA, 2003, IEEE T RELIAB, V52,
                    P2&#xD; EVANS WE, 2003, NEW ENGL J MED, V348, P538&#xD; EVANS WE, 2004, NATURE,
                    V429, P464&#xD; FRAM RJ, 1982, CANCER RES, V42, P4050&#xD; GODWIN JE, 1998,
                    BLOOD, V91, P3607&#xD; GOODE EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513&#xD;
                    GREEN S, 1992, INVEST NEW DRUG, V10, P239&#xD; GURUBHAGAVATULA S, 2004, J CLIN
                    ONCOL, V22, P2594&#xD; HAN JL, 2004, CANCER RES, V64, P3009&#xD; HU JJ, 2001,
                    CARCINOGENESIS, V22, P917&#xD; ISLA D, 2004, ANN ONCOL, V15, P1194&#xD; KELLNER
                    U, 2000, ONKOLOGIE, V23, P424&#xD; KRAJINOVIC M, 2002, CLIN CANCER RES, V8,
                    P802&#xD; LEITH CP, 1997, BLOOD, V89, P3323&#xD; LENTZ F, 2005, AM J
                    PHARMACOGENOMIC, V5, P21&#xD; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65&#xD;
                    MATULLO G, 2001, CARCINOGENESIS, V22, P1437&#xD; MATULLO G, 2006,
                    CARCINOGENESIS, V27, P997&#xD; MEHTA PA, 2006, BLOOD, V107, P39&#xD; MOULLAN N,
                    2003, CANCER EPIDEM BIOMAR, V12, P1168&#xD; MULLER C, 1998, BLOOD, V92,
                    P2213&#xD; PARK DJ, 2001, CANCER RES, V61, P8654&#xD; PARK DJ, 2003, CLIN ADV
                    HEMATOL ONC, V1, P162&#xD; RATHNASABAPATHY R, 2003, CANC CONTROL, V10, P469&#xD;
                    ROSELL R, 2003, DRUGS TODAY, V39, P775&#xD; RYU JS, 2004, LUNG CANCER-J IASLC,
                    V44, P311&#xD; SAMPATH D, 2003, ONCOGENE, V22, P9063&#xD; SEEDHOUSE C, 2002,
                    BLOOD, V100, P3761&#xD; SEEDHOUSE C, 2004, CLIN CANCER RES, V10, P2675&#xD; SHEN
                    M, 2003, CANCER EPIDEM BIOMAR, V12, P1234&#xD; SMITH TR, 2003, CANCER EPIDEM
                    BIOMAR, V12, P1200&#xD; SOSSOU M, 2005, NUCLEIC ACIDS RES, V33, P298&#xD;
                    STOEHLMACHER J, 2001, ANTICANCER RES, V21, P3075&#xD; STOEHLMACHER J, 2004, BRIT
                    J CANCER, V91, P344&#xD; SUK R, 2005, CLIN CANCER RES, V11, P1534&#xD; VODICKA
                    P, 2004, CARCINOGENESIS, V25, P757&#xD; WANG ZM, 2001, J NATL CANCER I, V93,
                    P1473&#xD; YAMAYOSHI Y, 2005, INT J CLIN ONCOL, V10, P5&#xD; YIN JY, 2002,
                    CANCER EPIDEM BIOMAR, V11, P1449&#xD; YOON SM, 2005, INT J RADIAT ONCOL, V63,
                    P885&#xD; ZHOU W, 2004, CLIN CANCER RES, V10, P4939</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246091400051 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>379</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">379</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1776</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">La Rosa, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Limaye, A. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krishnan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Longmate, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Laboratory of Vaccine Research,
                    Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
                    ddiamond@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Longitudinal assessment of
                        cytomegalovirus (CMV)-specific immune responses in liver transplant
                        recipients at high risk for late CMV disease</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Infect Dis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Infectious
                        Disease</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Infect. Dis.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Infect Dis</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">633-44</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">195</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antiviral Agents/therapeutic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD4-Positive
                        T-Lymphocytes/cytology/immunology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Cytomegalovirus/physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cytomegalovirus Infections/drug
                        therapy/ immunology/prevention &amp;</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">control/virology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ganciclovir/analogs &amp;
                        derivatives/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immediate-Early
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interferon Type
                        II/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Liver
                        Transplantation/immunology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Longitudinal Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphocyte Count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >Phosphoproteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk Factors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral Matrix
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viral
                        Proteins/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Viremia</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1899 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17262704</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Cytomegalovirus (CMV)-seronegative
                    recipients (R(-)) of a liver transplant from CMV-positive donors (D(+)) are at
                    high risk for developing late CMV disease after discontinuation of antiviral
                    prophylaxis. Levels of viremia and CMV-specific interferon (IFN)- gamma
                    -producing CD4(+) and IFN- gamma -producing CD8(+) T cell responses were
                    prospectively measured from discontinuation of antiviral prophylaxis until 1
                    year after transplantation in 17 consecutive D(+)/R(-) patients. CMV loads of
                    &gt;1000 copies/mL were strongly associated with CMV disease in the 6
                    symptomatic patients. Despite immunosuppression, broadly diverse T cells
                    specific for CMV lysate or peptide libraries spanning pp65 and immediate early
                    (IE) 1 immunodominant CMV antigens developed in all patients. A vigorous CD8(+)
                    T cell response to pp65 and IE1 antigens characterized the D(+)/R(-) cohort.
                    Unexpectedly, none of these responses were predictive of CMV disease or viremia.
                    No significant lymphopenia or functional impairment of CMV-specific T cells was
                    detected in the symptomatic patients, whose morbidity was resolved after
                    antiviral treatment while measurable CMV immunity was maintained during the
                    1-year observation period.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 07/04</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>618</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">618</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">969</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lacey, S. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Lab Vaccine Res, Duarte, CA 91010 USA.&#xD;Lacey, SF, City Hope Natl Med
                    Ctr, Beckman Res Inst, Lab Vaccine Res, Fox S Bld,Rm 1001C, Duarte, CA 91010
                    USA.&#xD;slacey@cob.org wzhou@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Immune responses to BK and JC
                        viruses in immunocompromised patients</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Future Virology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Future Virol.</style>
                </alt-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">255-266</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">2</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BK virus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cidofovir</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytotoxic T-lymphocyte</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hemorrhagic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cystitis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">JC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">virus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">natalizumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nephropathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">progressive multifocal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">leukoencephalopathy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">polyomaviruses</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">rituxumab</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSIVE MULTIFOCAL
                        LEUKOENCEPHALOPATHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RENAL-TRANSPLANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECIPIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOTOXIC T-LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYOMAVIRUS TYPE BK</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIRETROVIRAL THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RELAPSING
                        MULTIPLE-SCLEROSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PLACEBO-CONTROLLED TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOPROLIFERATIVE
                        DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIDNEY-TRANSPLANTATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1746-0794</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249427000011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BK virus (BKV) and JC virus (JCV)
                    are ubiquitous human polyomaviruses that establish persistent asymptomatic
                    infections in immunocompetent individuals, but in a minority of
                    immunocompromised patients, reactivate and cause clinical disease. BKV is
                    associated with BKV nephropathy (BKVN) in kidney transplant recipients and JCV
                    is the etiologic agent of progressive multifocal leukoencephalopathy (PML) in
                    AIDS patients. Humoral responses do not appear adequate to protect against
                    reactivation or disease, and both BKVN and PML appear to be due to a failure of
                    cellular immune responses to control the virus. Among the goals of current
                    research is the identification of the functional correlates of cellular immune
                    protection against these viruses in immunocompetent individuals. Such insights
                    may help identify the small subset of patients at risk of BKV and JCV
                    reactivation, aid clinical management and permit the development of
                    immunotherapeutic approaches.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    209ZR&#xD;Times Cited: 0&#xD;Cited Reference Count: 80</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249427000011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>608</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">608</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1314</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lam, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pantuck, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Belldegrun, A. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Dept Urol, Div Urol Oncol,Kidney Canc Program, Los Angeles, CA USA.
                    Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los
                    Angeles, CA USA.&#xD;Figlin, RA, City Hope Natl Med Ctr, Div Med Oncol &amp;
                    Therapeut Res, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rfiglin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Protein expression profiles in
                        renal cell carcinoma: Staging, prognosis, and patient selection for clinical
                        trials</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">703S-708S</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBONIC-ANHYDRASE-IX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TISSUE MICROARRAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TECHNOLOGY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDEPENDENT PREDICTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P21 WAF1/CIP1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNALING PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HODGKINS LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-MARKERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIDNEY CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244043600007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Attempts to predict survival in
                    patients with renal cell carcinoma (RCC) have traditionally relied on standard
                    clinical variables, such as tumor-node-metastasis stage, histologic grade, and
                    performance status. An accurate method for predicting patient survival is useful
                    for patient counseling, planning follow-up, and selecting patients most likely
                    to benefit from novel and established therapies. Furthermore, an improved
                    prognostic system will allow for more accurate comparisons of clinical trials
                    based on varying inclusion criteria. A large number of potential prognostic
                    markers have recently been identified from methods based on gene arrays, which
                    screen for differential expression of thousands of genes. The accepted method of
                    clinical validation of novel markers is on formalin-fixed and paraffin-embedded
                    specimens using immunohistochemistry. The development of tissue microarrays as a
                    high-throughput technique has allowed for thousands of different cores of
                    pathologic tissue to be assessed simultaneously in a timely and cost-efficient
                    manner. This technology has enabled the analysis of protein expression profiles
                    on specimens to determine their potential clinical significance and role in RCC
                    biology. This article reviews the protein expression profiles in RCC and their
                    association with pathobiology, prognosis, and response to treatment as well as
                    their role in serving as potential molecular targets for therapy of RCC.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    133WC&#xD;Times Cited: 1&#xD;Cited Reference Count: 61&#xD;Part 2 Suppl.
                    S</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244043600007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>644</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">644</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1313</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Laneader, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Angelos, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kolker, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miner, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Padilla, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Swaney, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Casarett, D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Penn, Res Compliance &amp; Qual
                    Improvement, Philadelphia, PA 19104 USA. Univ Chicago, MacLean Ctr Clin Med Eth,
                    Med Ctr, Chicago, IL 60637 USA. City Hope Natl Med Ctr, Dept Nursing Res &amp;
                    Educ, Duarte, CA 91010 USA. Ovarian Canc Natl Alliance, Washington, DC USA.
                    Brown Univ, Sch Med, Dept Surg, Providence, RI 02912 USA. Univ Calif San
                    Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. Univ
                    Arizona, Coll Med, Dept Surg, Tucson, AZ 85721 USA. Arizona Vet Affairs Hlth
                    Care, Tucson, AZ USA. Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104
                    USA. Univ Penn, Ctr Hlth Equ Res &amp; Promot, Philadelphia, PA 19104
                    USA.&#xD;Casarett, D, Univ Penn, Res Compliance &amp; Qual Improvement, 3615
                    Chestnut St, Philadelphia, PA 19104 USA.&#xD;Casarett@mail.med.upenn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ethical issues in research to
                        improve the management of malignant bowel obstruction: Challenges and
                        recommendations</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Pain and Symptom
                        Management</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Pain Symptom Manage.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of pain and symptom
                        management</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Pain and Symptom
                        Management</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Pain Symptom Manage.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-2>
                <abbr-3>
                    <style face="normal" font="default" size="100%">Journal of Pain &amp; Symptom
                        Management</style>
                </abbr-3>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">S20-S27</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">end of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ethics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">research ethics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">palliative care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PALLIATIVE CARE RESEARCH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLINICAL RESEARCH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFORMED CONSENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DECISION-MAKING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADVANCED CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GUIDELINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELIRIUM</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0885-3924</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248055200003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Research to improve the care of
                    patients with malignant bowel obstruction (MBO) is urgently needed. In
                    particular, there is an urgent need for high-quality descriptive research,
                    including prospective cohort studies, as well as randomized controlled trials to
                    define optimal management strategies. However, investigators and clinicians face
                    numerous barriers in conducting high-quality research in this patient
                    population. These barriers include lack of funding, difficulties in identifying
                    eligible patients, and a variety of practical and methodological challenges of
                    designing these studies. In addition, there are a variety of ethical challenges
                    that arise in the design and conduct of studies of MBO and particularly in the
                    conduct of clinical trials. In this article, we address four categories of
                    ethical issues: study design, recruitment, informed consent, and Institutional
                    Review Board review. For each, we outline salient issues and suggest
                    recommendations for enhancing the ethics of MBO studies, including
                    interventional trials.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    190JN&#xD;Times Cited: 0&#xD;Cited Reference Count: 33&#xD;Suppl. S</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248055200003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>565</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">565</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1769</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lacey, S. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, W. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pathology, Beckman
                    Research Institute, City of Hope National Medical Center, Duarte, California
                    91010, USA. SLau@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Low frequency of BK virus in
                        prostatic adenocarcinomas</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Apmis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">APMIS</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">APMIS</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">APMIS</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">743-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">115</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenocarcinoma/virology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens, Viral, Tumor/
                        analysis/biosynthesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BK Virus/genetics/ isolation
                        &amp; purification/pathogenicity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA, Viral/ analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prostatic Neoplasms/
                        virology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Markers,
                        Biological</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0903-4641 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17550383</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BK virus (BKV) exhibits many
                    oncogenic properties and has been associated with a variety of tumors in humans.
                    BKV has not been well studied in the context of prostate neoplasia; however, an
                    association of BKV with prostatic adenocarcinoma has been suggested based on the
                    detection of viral DNA sequences and expression of viral proteins in clinical
                    samples. To further investigate the reported association of BKV with prostatic
                    adenocarcinoma and the potential role of the virus in prostate tumorigenesis, 30
                    cases of adenocarcinoma of the prostate were analyzed for evidence of BKV
                    infection by in situ hybridization and immunohistochemistry. In situ
                    hybridization analysis detected BKV DNA in 2 of 30 (7%) prostatic
                    adenocarcinomas, with positive signals focally identified in less than 1% of the
                    neoplastic cells in both cases. However, none of the tumors evaluated
                    demonstrated evidence of BKV large tumor antigen expression by
                    immunohistochemistry. Among prostatic adenocarcinomas that showed no evidence of
                    BKV infection, BKV DNA was focally observed in the adjacent non-neoplastic
                    prostate tissue in four cases by in situ hybridization in the absence of BKV
                    large tumor antigen immunoreactivity. The findings of the present study indicate
                    rare cases of prostatic adenocarcinoma may be associated with BKV infection.
                    However, lack of localization of BKV to a large population of the neoplastic
                    cells and absence of BKV large tumor antigen expression suggest that the virus
                    does not play a role in the pathogenesis of prostate cancer.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>400</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">400</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1308</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Pathol,
                    Duarte, CA 91010 USA.&#xD;Lau, SK, City Hope Natl Med Ctr, Dept Pathol, Duarte,
                    CA 91010 USA.&#xD;slau@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Calcifying fibrous tumor of the
                        adrenal gland</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">656-659</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">38</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">calcifying fibrous tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">adrenal gland</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">factor XIIIa</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFLAMMATORY MYOFIBROBLASTIC
                        TUMOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSEUDOTUMOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0046-8177</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245319800018</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Calcifying fibrous tumor is an
                    uncommon entity with distinctive pathologic features. Most calcifying fibrous
                    tumors involve the peripheral soft tissues or serosal surfaces, with reports of
                    visceral examples of this lesion being extremely limited. We report the clinical
                    and pathologic features of an unusual case of calcifying fibrous tumor occurring
                    in the adrenal gland of a 32-year-old woman. Microscopically, the lesion was
                    well circumscribed and composed of dense, poorly cellular collagenous tissue,
                    scattered spindle cells, an inflammatory infiltrate consisting of plasma cells
                    and lymphocytes, and dystrophic calcifications. The morphologic diagnosis of
                    calcifying fibrous tumor was supported by diffuse positive immumoreactivity for
                    factor XIIIa and absence of reactivity for muscle specific actin, smooth muscle
                    actin, and anaplastic lymphoma kinase. Although rare, awareness that calcifying
                    fibrous tumor may occur at this particular site is important so as not to
                    confuse this lesion with other mesenchymal neoplasms of the adrenal gland. (c)
                    2007 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    151VV&#xD;Times Cited: 0&#xD;Cited Reference Count: 15&#xD;Cited References:
                    &#xD; ARBER DA, 1995, HUM PATHOL, V26, P1093&#xD; CARNEY JA, 1987, HUM PATHOL,
                    V18, P980&#xD; CHAN JKC, 2001, AM J SURG PATHOL, V25, P761&#xD; COFFIN CM, 1995,
                    AM J SURG PATHOL, V19, P859&#xD; DARGENT JL, 1999, J CLIN PATHOL, V52, P547&#xD;
                    EFTEKHARI F, 2001, BRIT J RADIOL, V74, P452&#xD; FETSCH JF, 1993, AM J SURG
                    PATHOL, V17, P502&#xD; HILL KA, 2001, MODERN PATHOL, V14, P784&#xD; LAWRENCE B,
                    2000, AM J PATHOL, V157, P377&#xD; MONTGOMERY E, 2002, PATHOLOGY GENETICS T,
                    P77&#xD; NASCIMENTO AF, 2002, INT J SURG PATHOL, V10, P189&#xD; ROSENTHAL NS,
                    1988, ARCH PATHOL LAB MED, V112, P798&#xD; SIGEL JE, 2001, ANN DIAGN PATHOL, V5,
                    P10&#xD; VANDORPE J, 1999, AM J SURG PATHOL, V23, P329&#xD; ZAMECNIK M, 2000,
                    HISTOPATHOLOGY, V36, P183</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245319800018 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>295</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">295</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1307</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Pathol,
                    Duarte, CA 91010 USA.&#xD;Lau, SK, City Hope Natl Med Ctr, Dept Pathol, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;SLau@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">D2-40 immunohistochemistry in
                        the differential diagnosis of seminoma and embryonal carcinoma: a
                        comparative immunohistochemical study with KIT (CD117) and CD30</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Modern Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Modern Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mod. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mod Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">320-325</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">20</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CD30</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">D2-40</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">embryonal carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">seminoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GERM-CELL TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-KIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALKALINE-PHOSPHATASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TESTICULAR-TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TESTIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOKERATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">M2A</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0893-3952</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244748800003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The distinction between seminoma and
                    embryonal carcinoma based on morphology alone can sometimes be problematic,
                    requiring the use of immunohistochemistry to facilitate diagnosis. D2-40 is a
                    monoclonal antibody that reacts with an oncofetal antigen expressed by fetal
                    germ cells and testicular germ cell tumors. The diagnostic value of D2-40
                    immunohistochemistry in distinguishing seminoma from embryonal carcinoma has not
                    been determined. D2-40 immunoreactivity was evaluated in a series of testicular
                    germ cell tumors and compared with that of KIT (CD117) and CD30, to assess the
                    relative utility of this marker in discriminating between seminoma and embryonal
                    carcinoma. Forty testicular germ cell neoplasms were examined, which included 19
                    seminomas, three embryonal carcinomas, three teratomas, one yolk sac tumor, and
                    14 mixed germ cell tumors. The 14 cases of mixed germ cell tumors contained
                    components of seminoma (n = 7), embryonal carcinoma (n = 11), teratoma (n = 10),
                    yolk sac tumor (n = 2), and choriocarcinoma (n 1). All cases of pure seminoma
                    and the seminomatous components of mixed germ cell tumors exhibited positive
                    immunoreactivity for D2-40. Focal positivity for D2-40 was also observed in 29%
                    of the embryonal carcinoma samples. D2-40 immunoreactivity in seminomas was
                    characterized by diffuse membrane staining, whereas for embryonal carcinomas,
                    staining was focal and distributed along the apical surfaces of the neoplastic
                    cells. Immunohistochemical staining for KIT was observed in 92% of the seminoma
                    samples and in none of the embryonal carcinomas. Conversely, CD30 expression was
                    identified in 93% of the embryonal carcinoma samples and in none of the
                    seminomas. Other germ cell components showed no immunoreactivity for D2-40, KIT,
                    or CD30. KIT and CD30 are effective immunohistochemical markers in separating
                    seminoma from embryonal carcinoma. Although a highly sensitive marker for
                    seminomas, D2-40 positivity was also observed in a subset of embryonal
                    carcinomas, thus limiting the utility of this antibody for discriminating
                    between these two malignancies.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    143TU&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; BAILEY D, 1986, P NATL ACAD SCI USA, V83, P5291&#xD; BAILEY D, 1991,
                    MODERN PATHOL, V4, P167&#xD; BATTIFORA H, 1984, CANCER, V54, P843&#xD; BIERMANN
                    K, 2006, HISTOPATHOLOGY, V49, P290&#xD; CHEVILLE JC, 2000, AM J CLIN PATHOL,
                    V113, P583&#xD; DELANEY RJ, 2005, HISTOPATHOLOGY, V47, P166&#xD; DURKOP H, 2000,
                    J PATHOL, V190, P613&#xD; EBLE JN, 2004, WHO CLASSIFICATION T&#xD; FERREIRO JA,
                    1994, HUM PATHOL, V25, P522&#xD; GIWERCMAN A, 1988, APMIS, V96, P667&#xD;
                    GIWERCMAN A, 1991, APMIS, V99, P586&#xD; HITTMAIR A, 1996, HUM PATHOL, V27,
                    P1166&#xD; IZQUIERDO MA, 1995, J PATHOL, V177, P253&#xD; LEE AHS, 1999, BJU INT,
                    V84, P75&#xD; LEROY X, 2002, J HISTOCHEM CYTOCHEM, V50, P283&#xD; MARKS A, 1999,
                    BRIT J CANCER, V80, P569&#xD; NAKAGAWA Y, 1988, J PATHOL, V156, P67&#xD;
                    PALLESEN G, 1988, AM J PATHOL, V133, P446&#xD; PARKINSON MC, 2001,
                    HISTOPATHOLOGY, V38, P183&#xD; RAMAEKERS F, 1985, VIRCHOWS ARCH A, V408,
                    P127&#xD; SEGELOV E, 1993, BRIT J UROL, V71, P736&#xD; SONNE SB, 2006, VIRCHOWS
                    ARCH, V449, P200&#xD; STROHMEYER T, 1995, J UROLOGY, V153, P511&#xD; SUSTER S,
                    1998, HUM PATHOL, V29, P737&#xD; TIAN QS, 1999, AM J PATHOL, V154, P1643&#xD;
                    TICKOO SK, 2002, INT J SURG PATHOL, V10, P23&#xD; TSUURA Y, 1994, VIRCHOWS ARCH,
                    V424, P135&#xD; ULBRIGHT TM, 2005, MODERN PATHOL S2, V18, S61</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244748800003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>566</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">566</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1767</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Pathology, City of
                    Hope National Medical Center, Duarte, CA 91010, USA. SLau@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Association of intratubular
                        seminoma and intratubular embryonal carcinoma with invasive testicular germ
                        cell tumors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Surgical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Surg. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Surg Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1045-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">31</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Embryonal/chemistry/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Germ Cells/chemistry/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms, Multiple Primary/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Seminiferous Tubules/chemistry/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Seminoma/chemistry/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Testicular Neoplasms/chemistry/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Markers,
                        Biological/analysis</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0147-5185 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17592271</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The classification of intratubular
                    germ cell neoplasia of the testis includes an unclassified type (IGCNU), in
                    addition to various other intratubular lesions that show specific forms of
                    differentiation, such as intratubular seminoma and intratubular embryonal
                    carcinoma. Although IGCNU is recognized as a precursor lesion for testicular
                    germ cell tumors, the relationship between differentiated types of intratubular
                    germ cell neoplasia and invasive germ cell tumors of the testis is not well
                    established. The aim of the present study was to examine the association between
                    invasive testicular germ cell tumors and intratubular neoplastic lesions, with
                    particular emphasis on differentiated types of intratubular germ cell neoplasia.
                    The seminiferous tubules adjacent to 42 testicular germ cell tumors were
                    evaluated for the presence of various forms of intratubular germ cell neoplasia.
                    IGCNU was observed in 37 (88%) of 42 cases, whereas intratubular seminoma and
                    intratubular embryonal carcinoma were seen in 19% and 7% of the cases,
                    respectively. Intratubular seminoma was associated primarily with seminomas or
                    mixed germ cell tumors with a seminomatous component, but was also present in a
                    case of a nonseminomatous germ cell tumor. Intratubular embryonal carcinoma was
                    associated exclusively with nonseminomatous germ cell tumors. All cases of
                    intratubular embryonal carcinoma were identified morphologically and exhibited
                    histologic features corresponding to traditional definitions of this lesion. No
                    examples of intratubular embryonal carcinoma as defined by CD30 expression alone
                    in the absence of an intratubular proliferation were observed. The presence of
                    intratubular seminoma in a nonseminomatous germ cell tumor suggests that it is a
                    true preinvasive lesion rather than a manifestation of intratubular spread of an
                    established invasive seminoma. The low incidence of intratubular embryonal
                    carcinoma supports the theory that most nonseminomatous germ cell tumors evolve
                    initially as seminomas, rather than directly from a differentiated intratubular
                    neoplastic lesion.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>202</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">202</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1303</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Biol, Duarte, CA 91010 USA.&#xD;Pfeifer, GP, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;gpfeifer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Mutagenesis induced by the
                        nitric oxide donor sodium nitroprusside in mouse cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">63-67</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">22</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DOUBLE-EDGED ROLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REACTIVE OXYGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATION ASSAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEROXYNITRITE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTAGENICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENOTOXICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2&apos;-DEOXYXANTHOSINE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0267-8357</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243327000008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Nitric oxide (NO) is an important
                    bioactive molecule derived from endogenous or exogenous sources. NO can exhibit
                    genotoxicity through the formation of reactive nitrogen species. Nitric oxide
                    releasing compounds, such as sodium nitroprusside, are widely used for the
                    therapy of hypertension and other disorders. Here we have characterized the
                    mutagenicity of sodium nitroprusside in mouse embryo fibroblasts carrying the
                    cII mutation reporter gene. Sodium nitroprusside dose-dependently increased the
                    cII mutant frequency to levels similar to 5-fold above background. The
                    mutational spectrum induced by sodium nitroprusside was characterized by an
                    increase in the fraction of G -&gt; T transversion mutations (P &lt; 0.003) but
                    the proportion of transition mutations was not increased. We discuss the
                    potential origin of the G -&gt; T mutations induced by this compound in
                    mammalian cells.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123WN&#xD;Times Cited: 0&#xD;Cited Reference Count: 46&#xD;Cited References:
                    &#xD; ANDREASSI MG, 2001, MUTAGENESIS, V16, P517&#xD; ARROYO PL, 1992, MUTAT
                    RES, V281, P193&#xD; ASAKA M, 1997, GASTROENTEROLOGY S, V113, S56&#xD; BECKMAN
                    JS, 1991, J DEV PHYSIOL, V15, P53&#xD; BESARATINIA A, 2002, CANCER RES, V62,
                    P4331&#xD; BESARATINIA A, 2004, J NATL CANCER I, V96, P1023&#xD; BESARATINIA A,
                    2005, BIOCHEMISTRY-US, V44, P8418&#xD; BIRNBOIM HC, 2000, NITRIC OXIDE-BIOL CH,
                    V4, P496&#xD; BURNEY S, 1999, CHEM RES TOXICOL, V12, P513&#xD; DAVIDSON C, 1999,
                    AM HERITAGE, V50, P30&#xD; DEDON PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12&#xD;
                    DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473&#xD; DONG M, 2003, CHEM RES
                    TOXICOL, V16, P1044&#xD; DONG M, 2006, CHEM RES TOXICOL, V19, P50&#xD; ERITJA R,
                    1986, NUCLEIC ACIDS RES, V14, P8135&#xD; FARRELL RJ, 2002, LANCET, V359,
                    P331&#xD; GREEN LC, 1982, ANAL BIOCHEM, V126, P131&#xD; HARBACH PR, 1999,
                    ENVIRON MOL MUTAGEN, V33, P132&#xD; HERSKOWITZ I, 1980, ANNU REV GENET, V14,
                    P399&#xD; HUSSAIN SP, 2003, NAT REV CANCER, V3, P276&#xD; IGNARRO LJ, 1993, P
                    NATL ACAD SCI 07/01 USA, V90, P8103&#xD; JAKUBCZAK JL, 1996, P NATL ACAD SCI
                    07/01 USA, V93, P9073&#xD; JEONG JK, 1998, CHEM RES TOXICOL, V11, P550&#xD;
                    JUEDES MJ, 1996, MUTAT RES-FUND MOL M, V349, P51&#xD; KAMIYA H, 1992, NUCLEOS
                    NUCLEOT NUCL, V11, P247&#xD; KERWIN JF, 1995, J MED CHEM, V38, P4343&#xD; LIN
                    WC, 1998, MUTAT RES-GEN TOX EN, V413, P121&#xD; LIN WC, 2000, MUTAT RES-GEN TOX
                    EN, V466, P187&#xD; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73&#xD; MARAGOS
                    CM, 1993, MUTAT RES, V298, P187&#xD; MONCADA S, 1991, PHARMACOL REV, V43,
                    P109&#xD; NAKANO T, 2005, MUTAGENESIS, V20, P209&#xD; NATHAN C, 1992, FASEB J,
                    V6, P3051&#xD; NGUYEN T, 1992, P NATL ACAD SCI 07/01 USA, V89, P3030&#xD; NILES
                    JC, 2006, NITRIC OXIDE-BIOL CH, V14, P109&#xD; RAO DNR, 1996, BBA-GEN SUBJECTS,
                    V1289, P195&#xD; ROUTLEDGE MN, 1994, CHEM RES TOXICOL, V7, P628&#xD; ROUTLEDGE
                    MN, 1994, MUTAT RES-GEN TOX EN, V322, P341&#xD; ROUTLEDGE MN, 2000, MUTAT
                    RES-FUND MOL M, V450, P95&#xD; SANDHU JK, 1997, MUTAT RES-FUND MOL M, V379,
                    P241&#xD; SCHMIDT HHHW, 1992, LANCET, V339, P986&#xD; SUZUKI T, 2000, NUCLEIC
                    ACIDS RES, V28, P544&#xD; VONGCHAMPA V, 2003, NUCLEIC ACIDS RES, V31, P1045&#xD;
                    WINK DA, 1991, SCIENCE, V254, P1001&#xD; WINK DA, 1998, CARCINOGENESIS, V19,
                    P711&#xD; WUENSCHELL GE, 2003, BIOCHEMISTRY-US, V42, P3608</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243327000008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>567</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">567</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1761</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, H. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hong, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baker, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Connor, T. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Biology, Beckman
                    Research Institute, City of Hope National Medical Center, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Monitoring repair of DNA damage
                        in cell lines and human peripheral blood mononuclear cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Anal Biochem</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Analytical Biochemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Anal. Biochem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Anal Biochem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">246-59</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">365</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Damage/drug effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Repair/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, p53/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Leukocytes, Mononuclear/drug
                        effects/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Plasmids/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0003-2697 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17449003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We introduce a method to follow DNA
                    repair that is suitable for both clinical and laboratory samples. An episomal
                    construct with a unique 8-oxoguanine (8-oxoG) base at a defined position was
                    prepared in vitro using single-stranded phage harboring a 678-bp tract from
                    exons 5 to 9 of the human P53 gene. Mixing curve experiments showed that the
                    real-time PCR method has a linear response to damage, suggesting that it is
                    useful for DNA repair studies. The episomal construct with a unique 8-oxoG base
                    was introduced into AD293 cells or human peripheral blood mononuclear cells, and
                    plasmids were recovered as a function of time. The quantitative real-time PCR
                    assay demonstrated that repair of the 8-oxoG was 80% complete in less than 48 h
                    in AD293 cells. Transfection of small interfering RNAs down-regulated OGG1
                    expression in AD293 cells and reduced the repair of 8-oxoG to 30%. Transfection
                    of the episome into unstimulated white blood cells showed that 8-oxoG repair had
                    a half-life of 2 to 5h. This method is a rapid, reproducible, and robust way to
                    monitor repair of specific adducts in virtually any cell type.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>851</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">851</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1299</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, M. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, W. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Van, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Contag, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, C. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Immunol, Duarte, CA 91010 USA. Stanford Univ, Sch Med, Dept Pediat,
                    MIPS, Stanford, CA USA. Stanford Univ, Sch Med, Dept Radiol, MIPS, Stanford, CA
                    USA. Stanford Univ, Sch Med, Dept Microbiol &amp; Immunol, MIPS, Stanford, CA
                    USA.&#xD;Liu, CP, City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, City
                    Hope,1450 E Duarte Rd, Duarte, CA 91010 USA.&#xD;cliu@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Image-guided analyses reveal
                        that non-CD4 splenocytes contribute to CD4(+) T cell-mediated inflammation
                        leading to islet destruction by altering their local function and not
                        systemic trafficking patterns</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Imaging</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Imaging</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Imaging</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Imaging</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">369-383</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NONOBESE DIABETIC MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NOD MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADOPTIVE TRANSFER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOUSE MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD4+</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MELLITUS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov-Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1535-3508</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251569400001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Recruitment of CD4(+) T cells into
                    islets is a critical component of islet inflammation (insulitis) leading to type
                    1 diabetes; therefore, determining if conditions used to treat diabetes change
                    their trafficking patterns is relevant to the outcome. Cotransfer of
                    CD4(+)BDC2.5 (BDC) cells with non-CD4 splenocytes obtained from newly diabetic
                    NOD mice, but not when they are transferred alone, induces accelerated diabetes.
                    It is unclear whether these splenocytes affect diabetes development by altering
                    the systemic and/or local trafficking and proliferation patterns of BDC cells in
                    target and nontarget tissues. To address these questions, we developed an animal
                    model to visualize BDC cell trafficking and proliferation using whole-body in
                    vivo bioluminescence imaging and used the images to direct tissue sampling for
                    further analyses of the cell distribution within tissues. The whole-body, or
                    macroscopic, trafficking patterns were not dramatically altered in both groups
                    of recipient mice. However, the local patterns of cell distribution were
                    distinct, which led to invasive insulitis only in cotransferred mice with an
                    increased number of islet-infiltrating CD11b(+) and CD11c(+) cells. Taken
                    together, the non-CD4 splenocytes act locally by promoting invasive insulitis
                    without altering the systemic trafficking patterns or proliferation of BDC cells
                    and thus contributing to diabetes by altering the localization within the
                    tissue.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    240EG&#xD;Times Cited: 0&#xD;Cited Reference Count: 36&#xD;Cited References:
                    &#xD; ATKINSON MA, 1999, NAT MED, V5, P601&#xD; BACH JF, 1994, ENDOCR REV, V15,
                    P516&#xD; BEDOSSA P, 1989, EUR J IMMUNOL, V19, P1947&#xD; BENDELAC A, 1987, J
                    EXP MED, V166, P823&#xD; CALDERON B, 2006, AM J PATHOL, V169, P2137&#xD; CAO YA,
                    2004, P NATL ACAD SCI USA, V101, P221&#xD; CAO YA, 2005, TRANSPLANTATION, V80,
                    P134&#xD; CHEN C, 2003, J IMMUNOL, V171, P733&#xD; CHEN C, 2006, J IMMUNOL,
                    V176, P3449&#xD; CHRISTIANSON SW, 1993, DIABETES, V42, P44&#xD; CONTAG CH, 2002,
                    J MAGN RESON IMAGING, V16, P378&#xD; CONTAG PR, 1998, NAT MED, V4, P245&#xD;
                    COSTA GL, 2001, J IMMUNOL, V167, P2379&#xD; DENIS MC, 2004, P NATL ACAD SCI USA,
                    V101, P12634&#xD; HANAFUSA T, 1988, DIABETES, V37, P204&#xD; HARDY J, 2001, EXP
                    HEMATOL, V29, P1353&#xD; HASKINS K, 1989, P NATL ACAD SCI USA, V86, P8000&#xD;
                    HASKINS K, 1990, SCIENCE, V249, P1433&#xD; KATZ JD, 1993, CELL, V74, P1089&#xD;
                    KATZ JD, 1995, SCIENCE, V268, P1185&#xD; LIU CP, 2000, P NATL ACAD SCI USA, V97,
                    P14596&#xD; MATHIS D, 2001, NATURE, V414, P792&#xD; MCDEVITT H, 2001, ADV EXP
                    MED BIOL, V490, P59&#xD; MILLER BJ, 1988, J IMMUNOL, V140, P52&#xD; MOORE A,
                    2004, DIABETES, V53, P1459&#xD; NAKAJIMA A, 2001, J CLIN INVEST, V107,
                    P1293&#xD; NEPOM GT, 1998, DIABETES, V47, P1177&#xD; PETERLIN B, 2004, GENET
                    TEST, V8, P45&#xD; PETERSON JD, 1998, CELL IMMUNOL, V189, P92&#xD; QUINN A,
                    2001, CURR DIRECT AUTOIMMU, V4, P171&#xD; THIVOLET C, 1991, J IMMUNOL, V146,
                    P85&#xD; VAREY AM, 1991, BIOCHEM SOC T, V19, P187&#xD; VIROSTKO J, 2004, MOL
                    IMAGING, V3, P333&#xD; WANG Y, 1991, P NATL ACAD SCI USA, V88, P527&#xD;
                    WETTERWALD A, 2002, AM J PATHOL, V160, P1143&#xD; YOU S, 2003, J IMMUNOL, V170,
                    P4011</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251569400001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>203</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">203</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1297</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, Y. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Thomas, S. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Clin
                    &amp; Mol Pharmacol, Duarte, CA 91010 USA. Univ So Calif, Norris Canc Ctr, Los
                    Angeles, CA 90033 USA. Univ So Calif, Dept Mol Pharmacol &amp; Toxicol, Los
                    Angeles, CA 90033 USA. Univ So Calif, Dept Pharmaceut SCI 07/01, Los Angeles, CA
                    90033 USA. Univ So Calif, Dept Med, Los Angeles, CA 90033 USA. Univ Maryland,
                    Greenebaum Canc Ctr, Dept Anat &amp; Neurobiol, Baltimore, MD 21201
                    USA.&#xD;Ann, DK, City Hope Natl Med Ctr, Dept Clin &amp; Mol Pharmacol, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;dann@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Doxorubicin down-regulates
                        Kruppel-associated box domain-associated protein 1 sumoylation that relieves
                        its transcription repression on p21(WAF1/CIP1) in breast cancer MCF-7
                        cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1595-1606</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ZINC-FINGER PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HETEROGENEOUS NUCLEAR
                        RIBONUCLEOPROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUMO-BINDING MOTIF</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KAP-1 COREPRESSOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METHYLTRANSFERASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IDENTIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERACTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243451300011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The role of post-translational
                    modification, such as sumoylation, in modulating the efficacy of doxorubicin
                    (Dox) treatment remains unclear. Transcriptional cofactor KRAB domain-associated
                    protein 1 (KAP1) has been shown to complex with the KRAB zinc finger protein,
                    ZBRK1, to repress the transcription of target genes. Through a combination of
                    proteomic screening and site-directed mutagenesis approaches, we have identified
                    lysines 554, 779, and 804 as the major sumoylation sites in KAP1. We then
                    present evidence that Dox-mediated induction of cell cycle regulator p21
                    expression is differentially regulated by KAP1 sumoylation status. Moreover, the
                    KAP1 sumoylation level was transiently decreased upon Dox exposure, and
                    transfection with the KAP1 sumoylation mimetic, SUMO-1-KAP1, desensitizes breast
                    cancer MCF-7 cells to Dox-elicited cell death. The sumoylation-dependent
                    stimulation of KAP1 function is achieved by enhancing the methylation of H3-K9
                    and attenuating the acetylation of H3-K9 and H3-K14 at the p21 core promoter. We
                    also show that occupancy of ZBRK1 response elements located at the p21 promoter
                    by ZBRK1 center dot KAP1 is independent of KAP1 sumoylation. Hence, sumoylation
                    of KAP1 represses p21 transcription via a chromatin silencing process without
                    affecting interaction between KAP1 center dot ZBRK1 and DNA, thus providing a
                    novel mechanistic basis for the understanding of Dox-induced de-repression of
                    p21 transcription. Taken together, our results suggest that Dox-induced decrease
                    in KAP1 sumoylation is essential for Dox to induce p21 expression and subsequent
                    cell growth inhibition in MCF-7 cells.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast; Top Tier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    125OK&#xD;Times Cited: 0&#xD;Cited Reference Count: 42&#xD;Cited References:
                    &#xD; BAYER P, 1998, J MOL BIOL, V280, P275&#xD; COOPER HJ, 2005, ANAL CHEM,
                    V77, P6310&#xD; ELDEIRY WS, 1993, CELL, V75, P817&#xD; FRIEDMAN JR, 1996, GENE
                    DEV, V10, P2067&#xD; FURUTA S, 2006, CANCER CELL, V10, P13&#xD; GILL G, 2004,
                    GENE DEV, V18, P2046&#xD; GIRDWOOD D, 2003, MOL CELL, V11, P1043&#xD; HUANG DT,
                    2004, ONCOGENE, V23, P1958&#xD; HUANG WC, 2004, EUR J BIOCHEM, V271, P4114&#xD;
                    JACKSON PK, 2001, GENE DEV, V15, P3053&#xD; JENUWEIN T, 2001, SCIENCE, V293,
                    P1074&#xD; JOHNSON ES, 2004, ANNU REV BIOCHEM, V73, P355&#xD; KIM DH, 2005, NAT
                    BIOTECHNOL, V23, P222&#xD; KIM SS, 1996, P NATL ACAD SCI 07/01 USA, V93,
                    P15299&#xD; LECHNER MS, 2000, MOL CELL BIOL, V20, P6449&#xD; LI HW, 2006, J BIOL
                    CHEM, V281, P19489&#xD; LI TW, 2004, P NATL ACAD SCI 07/01 USA, V101, P8551&#xD;
                    LIAO GL, 2005, J VIROL, V79, P245&#xD; MOOSMANN P, 1996, NUCLEIC ACIDS RES, V24,
                    P4859&#xD; MULLER S, 2001, NAT REV MOL CELL BIO, V2, P202&#xD; NIELSEN AL, 1999,
                    EMBO J, V18, P6385&#xD; PENG HZ, 2000, J MOL BIOL, V295, P1139&#xD; ROTH SY,
                    2001, ANNU REV BIOCHEM, V70, P81&#xD; RYAN RF, 1999, MOL CELL BIOL, V19,
                    P4366&#xD; SCHULTZ DC, 2001, GENE DEV, V15, P428&#xD; SCHULTZ DC, 2002, GENE
                    DEV, V16, P919&#xD; SEELER JS, 2003, NAT REV MOL CELL BIO, V4, P690&#xD; SHIIO
                    Y, 2003, P NATL ACAD SCI 07/01 USA, V100, P13225&#xD; SHILATIFARD A, 2006, ANNU
                    REV BIOCHEM, V75, P243&#xD; SONG J, 2004, P NATL ACAD SCI 07/01 USA, V101,
                    P14373&#xD; SONG J, 2005, J BIOL CHEM, V280, P40122&#xD; TAKAHASHI H, 2005, J
                    BIOL CHEM, V280, P5611&#xD; URRUTIA R, 2003, GENOME BIOL, V4&#xD; VASSILEVA MT,
                    2004, MOL CELL BIOL, V24, P3623&#xD; VERTEGAAL ACO, 2004, J BIOL CHEM, V279,
                    P33791&#xD; WANG CG, 2005, EMBO J, V24, P3279&#xD; YANG L, 2003, BIOCHEM J 3,
                    V369, P651&#xD; YANG SH, 2003, MOL CELL, V12, P63&#xD; YANG SH, 2004, MOL CELL,
                    V13, P611&#xD; YUN JH, 2003, MOL CELL BIOL, V23, P7305&#xD; ZHAO YM, 2004, J
                    BIOL CHEM, V279, P20999&#xD; ZHENG L, 2000, MOL CELL, V6, P757</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243451300011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>786</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">786</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1291</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Li, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qin, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, X. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, C. X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, D. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ma, W. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, Y. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, S. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, S. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Chinese Acad Med Sci, Inst Canc,
                    Peking Union Med Coll, Dept Immunol, Beijing 100021, Peoples R China. Chinese
                    Acad Sci, Inst Biophys, Ctr Infect &amp; Immun, Natl Lab Biomacromol, Beijing
                    100101, Peoples R China. Chinese Acad Med Sci, Inst Canc, Peking Union Med Coll,
                    State Key Lab Mol Oncol, Beijing 100021, Peoples R China. City Hope Natl Med
                    Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.&#xD;Wang, SD, Chinese
                    Acad Med Sci, Inst Canc, Peking Union Med Coll, Dept Immunol, Beijing 100021,
                    Peoples R China.&#xD;sdwang@moon.ibp.ac.cn biotherapy@caca.sina.net</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Synergistic antitumor effect of
                        chemotactic-pro state tumor-associated antigen gene-modified tumor cell
                        vaccine and anti-CTLA-4 mAb in murine tumor model</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Immunology Letters</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Immunology Letters</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Immunol. Lett.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Immunol Lett</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">90-98</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">113</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">prostate cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PAP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor cell vaccine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">anti-CTLA-4</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATED T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FC-GAMMA-RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA VACCINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE-RESPONSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOKINE SLC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CTLA-4</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AUTOIMMUNITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0165-2478</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250852500005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In this study, we demonstrate that
                    an effective immune response against prostate tumors in mouse tumor model can be
                    elicited using a strategy that combines CTLA-4 blockade and pSLC-3P-Fc-modified
                    tumor cell vaccine (named B 16F10-SLC-3P-Fc). Treatment of B16F10-3P-bearing
                    mice resulted in a significant reduction in tumor incidence as assessed 2 months
                    after treatment. In vivo Ab depletion confirmed that the antitumor effect was
                    primarily CD8(+) T cells and CD4(+) T lymphocytes were required for the
                    induction of CD8(+) CTL response in B 16F10-SLC-3P-Fc + anti-CTLA-4
                    mAb-immunized mice. Moreover, mice that were cured of an established tumor were
                    protected against a rechallenge with the same tumor for at least 4 months,
                    suggesting the generation of memory responses. Adoptive transfer experiments
                    further indicate that antitumor reactivity can be transferred to naive mice by
                    splenocytes. These findings demonstrate that this combinatorial treatment can
                    elicit a potent anti-tumor immune response and suggest potential of this
                    approach for treatment of prostate cancer. (C) 2007 Elsevier B.V. All rights
                    reserved.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    230CF&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; ALBERT ML, 1998, NATURE, V392, P86&#xD; BANCHEREAU J, 1998, NATURE, V392,
                    P245&#xD; BERGES RR, 1995, CLIN CANCER RES, V1, P473&#xD; BOWNE WB, 1999, J EXP
                    MED, V190, P1717&#xD; BRUNET JF, 1987, NATURE, V328, P267&#xD; CYSTER JG, 1999,
                    J EXP MED, V189, P447&#xD; DAVIS SJ, 2003, NAT IMMUNOL, V4, P217&#xD; DESILVA
                    HD, 1998, IMMUNOLOGY, V93, P405&#xD; DUNN IS, 1987, NUCLEIC ACIDS RES, V15,
                    P2677&#xD; EGEN JG, 2002, NAT IMMUNOL, V3, P611&#xD; FERRONE S, 2000, IMMUNOL
                    TODAY, V21, P70&#xD; GAJEWSKI TF, 2001, J IMMUNOL, V166, P3900&#xD; GILBOA E,
                    1998, CANCER IMMUNOL IMMUN, V46, P82&#xD; GILBOA E, 1999, IMMUNITY, V11,
                    P263&#xD; GUNN MD, 1998, P NATL ACAD SCI USA, V95, P258&#xD; GURUNATHAN S, 2000,
                    ANNU REV IMMUNOL, V18, P927&#xD; HAEFFNERCAVAILL.N, 1979, J IMMUNOL, V123,
                    P1905&#xD; HART DNJ, 1997, BLOOD, V90, P3245&#xD; HEISER A, 2000, J IMMUNOL,
                    V164, P5508&#xD; HILLMAN GG, 1999, CANCER DETECT PREV, V23, P333&#xD; HORTON HM,
                    1999, P NATL ACAD SCI USA, V96, P1553&#xD; HOUGHTON AN, 2001, CURR OPIN IMMUNOL,
                    V13, P134&#xD; IKEDA H, 1997, IMMUNITY, V6, P199&#xD; JEMAL A, 2006, CA-CANCER J
                    CLIN, V56, P106&#xD; KEARNEY ER, 1995, J IMMUNOL, V155, P1032&#xD; KIM CH, 1999,
                    CELL IMMUNOL, V193, P226&#xD; KUMAR V, 1996, J EXP MED, V184, P1609&#xD; MURRAY
                    JS, 1998, IMMUNOL TODAY, V19, P157&#xD; NAGIRA M, 1998, EUR J IMMUNOL, V28,
                    P1516&#xD; OHASHI PS, 1996, CURR OPIN IMMUNOL, V8, P808&#xD; QIN HJ, 2005,
                    IMMUNOL LETT, V99, P85&#xD; QIN HJ, 2006, IMMUNOLOGY, V117, P419&#xD; RAVETCH
                    JV, 1994, CELL, V78, P553&#xD; REGNAULT A, 1999, J EXP MED, V189, P371&#xD; TJOA
                    B, 1996, PROSTATE, V28, P65&#xD; VELDERS MP, 2001, J IMMUNOL, V166, P5366&#xD;
                    WALUNAS TL, 1994, IMMUNITY, V1, P405&#xD; WANG Y, 2005, J IMMUNOTHER, V28,
                    P535&#xD; WILLIMANN K, 1998, EUR J IMMUNOL, V28, P2025&#xD; YANG SC, 2004, CLIN
                    CANCER RES, V10, P2891</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250852500005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>228</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">228</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1289</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Li, N. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forbes, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vignali, K. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heale, B. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saftig, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hartmann, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Black, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blobel, C. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dempsey, P. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Workman, C. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vignali, D. A. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">St Jude Childrens Hosp, Dept
                    Immunol, Memphis, TN 38105 USA. Beckman Inst, Grad Sch Biol Sci, Duarte, CA USA.
                    Univ Kiel, Inst Biochem, D-2300 Kiel, Germany. Katholieke Univ Leuven, Dept
                    Human Genet, Louvain, Belgium. Univ Ghent VIB, Inst Biotechnol, Louvain,
                    Belgium. Amgen Inc, Dept Inflammat, Seattle, WA USA. Cornell Univ, Weill Med
                    Coll, Arthrit &amp; Tissue Degenerat Program, New York, NY 10021 USA. Pacific NW
                    Res Inst, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195
                    USA.&#xD;Vignali, DAA, St Jude Childrens Hosp, Dept Immunol, 332 N Lauderdale,
                    Memphis, TN 38105 USA.&#xD;dario.vignali@stjude.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Metalloproteases regulate T-cell
                        proliferation and effector function via LAG-3</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">EMBO Journal</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Embo J.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">EMBO Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">EMBO J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">EMBO J</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">EMBO Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">EMBO J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">EMBO J</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">494-504</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ADAM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LAG-3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metalloproteases</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">shedding</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-cell function</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTE-ACTIVATION
                        GENE-3</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE-C-THETA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NECROSIS-FACTOR-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMYLOID PRECURSOR
                        PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >DISINTEGRIN-METALLOPROTEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AUTOINFLAMMATORY
                        SYNDROMES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MATRIX
                        METALLOPROTEINASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONVERTING-ENZYME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLEAVAGE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0261-4189</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243730700020</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Tight control of T-cell
                    proliferation and effector function is essential to ensure an effective but
                    appropriate immune response. Here, we reveal that this is controlled by the
                    metalloprotease-mediated cleavage of LAG-3, a negative regulatory protein
                    expressed by all activated T cells. We show that LAG-3 cleavage is mediated by
                    two transmembrane metalloproteases, ADAM10 and ADAM17, with the activity of both
                    modulated by two distinct T-cell receptor (TCR) signaling-dependent mechanisms.
                    ADAM10 mediates constitutive LAG-3 cleavage but increases similar to 12-fold
                    following T-cell activation, whereas LAG-3 shedding by ADAM17 is induced by TCR
                    signaling in a PKC theta-dependent manner. LAG-3 must be cleaved from the cell
                    surface to allow for normal T-cell activation as noncleavable LAG-3 mutants
                    prevented proliferation and cytokine production. Lastly, ADAM10 knockdown
                    reduced wild-type but not LAG-3(-/-) T-cell proliferation. These data
                    demonstrate that LAG-3 must be cleaved to allow efficient T-cell proliferation
                    and cytokine production and establish a novel paradigm in which T-cell expansion
                    and function are regulated by metalloprotease cleavage with LAG-3 as its sole
                    molecular target.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">TopTier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    129LJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 51</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243730700020 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>822</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">822</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1288</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Li, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, Y. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jeng, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schultz, D. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, H. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dep Clin
                    &amp; Mol Pharmacol, Duarte, CA 91010 USA. Univ So Calif, Dept Pharmacol &amp;
                    Pharmaceut Sci, Los Angeles, CA 90033 USA. Acad Sinica, Inst Biomed Sci, Taipei
                    11529, Taiwan. Wistar Inst Anat &amp; Biol, Philadelphia, PA 19104 USA.&#xD;Ann,
                    DK, City Hope Natl Med Ctr, Dep Clin &amp; Mol Pharmacol, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;dann@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Role for KAP1 serine 824
                        phosphorylation and sumoylation/desumoylation switch in regulating
                        KAP1-mediated transcriptional repression</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">36177-36189</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">50</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ZINC-FINGER PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-DAMAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEPENDENT TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUMO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MDM2 INTERACTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G(2) CHECKPOINT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-JUN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251458300007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">As a multifunctional protein, KRAB
                    domain-associated protein 1 (KAP1) is reportedly subjected to multiple protein
                    post-translational modifications, including phosphorylation and sumoylation.
                    However, gaps exist in our knowledge of how KAP1 phosphorylation cross-talks
                    with KAP1 sumoylation and what the biological consequence is. Here, we show that
                    doxorubicin (Dox) treatment induces KAP1 phosphorylation at Ser-824 via an
                    ataxia telangiectasia mutated (ATM)-dependent manner, correlating with the
                    transcriptional de-repression of p21(WAF1/CIP1) and Gadd45 alpha. A S824A
                    substitution of KAP1, which ablates the ATM-induced phosphorylation, results in
                    an increase of KAP1 sumoylation and repression of p21 transcription in
                    Dox-treated cells. By contrast, a S824D mutation of KAP1, which mimics
                    constitutive phosphorylation of KAP1, leads to a decrease of KAP1 sumoylation
                    and stimulation of p21 transcription before the exposure of Dox. We further
                    provide evidence that SENP1 deSUMOylase is involved in activating basal, but not
                    Dox-induced, KAP1 Ser-824 phosphorylation, rendering a stimulation of p21 and
                    Gadd45 alpha transcription. Moreover, KAP1 and differential sumoylation of KAP1
                    were also demonstrated to fine-tune the transcription of three additional
                    KAP1-targeted genes, including Bax, Puma, and Noxa. Taken together, our results
                    suggest a novel role for ATM that selectively stimulates KAP1 Ser-824
                    phosphorylation to repress its sumoylation, leading to the de-repression of
                    expression of a subset of genes involved in promoting cell cycle control and
                    apoptosis in response to genotoxic stresses.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    238OY&#xD;Times Cited: 0&#xD;Cited Reference Count: 45&#xD;Cited References:
                    &#xD; BOSSIS G, 2005, MOL CELL BIOL, V25, P6964&#xD; BOSSIS G, 2006, CELL DIV,
                    V1, P13&#xD; BROUDE EV, 2007, ONCOGENE, V26, P6954&#xD; CHENG JK, 2004, MOL CELL
                    BIOL, V24, P6021&#xD; CHENG JK, 2005, J BIOL CHEM, V280, P14492&#xD; ELDEIRY WS,
                    1993, CELL, V75, P817&#xD; GREGOIRE S, 2006, J BIOL CHEM, V281, P4423&#xD; HAY
                    RT, 2005, MOL CELL, V18, P1&#xD; HIETAKANGAS V, 2003, MOL CELL BIOL, V23,
                    P2953&#xD; HIETAKANGAS V, 2006, P NATL ACAD SCI USA, V103, P45&#xD; JOHNSON ES,
                    2004, ANNU REV BIOCHEM, V73, P355&#xD; KASTAN MB, 2004, NATURE, V432, P316&#xD;
                    LECHNER MS, 2000, MOL CELL BIOL, V20, P6449&#xD; LEE YK, 2007, J BIOL CHEM,
                    V282, P1595&#xD; LEVINE AJ, 1997, CELL, V88, P323&#xD; LIN JY, 2004, FEBS LETT,
                    V573, P15&#xD; MANNING G, 2002, SCIENCE, V298, P1912&#xD; MULLER S, 2000, J BIOL
                    CHEM, V275, P13321&#xD; NEFKENS I, 2003, J CELL SCI, V116, P513&#xD; NGHIEM P,
                    2001, P NATL ACAD SCI USA, V98, P9092&#xD; OGEEN H, 2007, PLOS GENET, V3,
                    P916&#xD; OKAMOTO K, 2006, BIOCHEM BIOPH RES CO, V351, P216&#xD; OREN M, 2003,
                    CELL DEATH DIFFER, V10, P431&#xD; PASSALARIS TM, 1999, MOL CELL BIOL, V19,
                    P5872&#xD; RIBALLO E, 2004, MOL CELL, V16, P715&#xD; SANCAR A, 2004, ANNU REV
                    BIOCHEM, V73, P39&#xD; SCHULTZ DC, 2001, GENE DEV, V15, P428&#xD; SCHULTZ DC,
                    2002, GENE DEV, V16, P919&#xD; SHILOH Y, 1997, ANNU REV GENET, V31, P635&#xD;
                    SHILOH Y, 2006, TRENDS BIOCHEM SCI, V31, P402&#xD; SRIPATHY SP, 2006, MOL CELL
                    BIOL, V26, P8623&#xD; TAYLOR WR, 2001, ONCOGENE, V20, P1803&#xD; UNDERHILL C,
                    2000, J BIOL CHEM, V275, P40463&#xD; URRUTIA R, 2003, GENOME BIOL, V4&#xD;
                    VANDEWETERING M, 2003, EMBO REP, V4, P609&#xD; VOGELSTEIN B, 2000, NATURE, V408,
                    P307&#xD; VOUSDEN KH, 2002, NAT REV CANCER, V2, P594&#xD; WANG CG, 2005, EMBO J,
                    V24, P3279&#xD; WANG QZ, 1996, J NATL CANCER I, V88, P956&#xD; WHITE DE, 2006,
                    CANCER RES, V66, P11594&#xD; YUN JH, 2003, MOL CELL BIOL, V23, P7305&#xD; ZHAO
                    LY, 2003, J VIROL, V77, P11809&#xD; ZHENG L, 2000, MOL CELL, V6, P757&#xD; ZIV
                    Y, 1997, ONCOGENE, V15, P159&#xD; ZIV Y, 2006, NAT CELL BIOL, V8, P870</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251458300007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>647</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">647</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1286</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Li, Y. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhu, F. Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vaidehi, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goddard, W. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sheinerman, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reiling, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Morize, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mu, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Harris, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ardati, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Laoui, A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">CALTECH, Mat &amp; Proc Simulat Ctr,
                    Pasadena, CA 91125 USA. Sanofi Aventis Pharma, Bridgewater, NJ 08807
                    USA.&#xD;Vaidehi, N, City Hope Natl Med Ctr, Beckman Res Inst, 1500 Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;NVaidehi@coh.org wag@wag.caltech.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Prediction of the 3D structure
                        and dynamics of human DP G-protein coupled receptor bound to an agonist and
                        an antagonist</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of the American Chemical
                        Society</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Am. Chem. Soc.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the American Chemical
                        Society</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Am. Chem. Soc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Am Chem Soc</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of the American Chemical
                        Society</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Am. Chem. Soc.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Am Chem Soc</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">10720-10731</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">129</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">35</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SITE-DIRECTED
                        MUTAGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THROMBOXANE A(2)
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2ND EXTRACELLULAR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LOOP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN PROSTACYCLIN
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTAGLANDIN EP3
                        RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIGAND-BINDING
                        SPECIFICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSFER-RNA SYNTHETASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMINO-ACID-RESIDUES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTANOID RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OLFACTORY RECEPTORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-7863</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249208300037</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Prostanoids play important
                    physiological roles in the cardiovascular and immune systems and in pain
                    sensation in peripheral systems through their interactions with eight G-protein
                    coupled receptors. These receptors are important drug targets, but development
                    of subtype specific agonists and antagonists has been hampered by the lack of 3D
                    structures for these receptors. We report here the 3D structure for the human DP
                    G-protein coupled receptor (GPCR) predicted by the MembStruk computational
                    method. To validate this structure, we use the HierDock computational method to
                    predict the binding mode for the endogenous agonist (PGD2) to DP. Based on our
                    structure, we predicted the binding of different antagonists and optimized them.
                    We find that PGD2 binds vertically to DP in the TM1237 region with the a chain
                    toward the extracellular (EC) region and the omega chain toward the middle of
                    the membrane. This structure explains the selectivity of the DID receptor and
                    the residues involved in the predicted binding site correlate very well with
                    available mutation experiments on DP, IP, TP, FP, and EP subtypes. We report
                    molecular dynamics of DP in explicit lipid and water and find that the binding
                    of the PGD2 agonist leads to correlated rotations of helices of TM3 and TM7,
                    whereas binding of antagonist leads to no such rotations. Thus, these motions
                    may be related to the mechanism of activation.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    206UL&#xD;Times Cited: 0&#xD;Cited Reference Count: 49</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249208300037 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>703</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">703</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1285</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Najbauer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Salvaterra, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mamelak, A. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barish, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garcia, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Metz, M. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kendall, S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bowers, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kateb, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Johnson, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aboody, K. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Hematol &amp; Hematopoiet Cell Transplant, Duarte, CA 91010 USA. City
                    Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA.
                    Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA. City Hope Natl Med Ctr,
                    Beckman Res Inst, Dept Neurosurg, Duarte, CA 91010 USA. City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA. Ajou Univ, Dept Med, Suwon,
                    South Korea. Univ British Columbia, Dept Med, Vancouver, BC, Canada. Yale Univ,
                    Sch Med, Ctr Child Study, New Haven, CT 06511 USA. Cedars Sinai Med Ctr, Maxine
                    Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA.&#xD;Aboody, KS, City Hope Natl
                    Med Ctr, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;kaboody@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Novel method for visualizing and
                        modeling the spatial distribution of neural stem cells within intracranial
                        glioma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Neuroimage</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">NeuroImage</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">NeuroImage</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">NeuroImage</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">S18-S26</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">37</style>
            </volume>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">brain tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">confocal imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene delivery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">glioma therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">neural</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">stem cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor targeting</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">three-dimensional
                        modeling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-TUMOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SINGLE CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MIGRATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRECURSORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1053-8119</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249434100002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Neural stem cells (NSCs) hold great
                    promise for glioma therapy due to their inherent tumor-tropic properties,
                    enabling them to deliver therapeutic agents directly to invasive tumor sites. In
                    the present study, we visualized and quantitatively analyzed the spatial
                    distribution of tumor-tropic NSCs in a mouse model of orthotopic glioma in order
                    to predict the therapeutic efficacy of a representative NSC-based glioma
                    therapy. U251.eGFP human glioma was established in the brain of athymic mice,
                    followed by stereotactic injection of CM-DiI-labeled human NSCs
                    posterior-lateral to the tumor site. Confocal microscopy, three-dimensional
                    modeling and mathematical algorithms were used to visualize and characterize the
                    spatial distribution of NSCs throughout the tumor. The pattern of NSC
                    distribution showed a gradient with higher densities toward the centroid of the
                    tumor mass. We estimate that NSC-mediated therapy would eradicate 70-90% of the
                    primary tumor mass and the majority of invasive tumor foci. Our method may serve
                    as a model for optimizing the efficacy of NSC-based glioma therapy. Published by
                    Elsevier Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    210CK&#xD;Times Cited: 0&#xD;Cited Reference Count: 33&#xD;Cited References:
                    &#xD; ABOODY KS, 2000, P NATL ACAD SCI USA, V97, P12846&#xD; ANDERSON SA, 2005,
                    BLOOD, V105, P420&#xD; ARBAB AS, 2006, STEM CELLS, V24, P671&#xD; BENEDETTI S,
                    2000, NAT MED, V6, P447&#xD; DUNN JCY, 2006, TISSUE ENG, V12, P705&#xD; EHTESHAM
                    M, 2002, CANCER RES, V62, P5657&#xD; EHTESHAM M, 2002, CANCER RES, V62,
                    P7170&#xD; EHTESHAM M, 2004, NEOPLASIA, V6, P287&#xD; EHTESHAM M, 2005,
                    NEUROSURG FOCUS, V19, E5&#xD; ERLANDSSON A, 2004, EXP CELL RES, V301, P201&#xD;
                    FRIEBOES HB, 2006, CANCER RES, V66, P1597&#xD; HEESE O, 2005, NEURO-ONCOLOGY,
                    V7, P476&#xD; HEYN C, 2006, MAGNET RESON MED, V55, P23&#xD; HINDS KA, 2003,
                    BLOOD, V102, P867&#xD; HUBER BE, 1994, P NATL ACAD SCI USA, V91, P8302&#xD;
                    JUBELIRER SJ, 1996, W V MED J, V92, P186&#xD; KIM SK, 2005, CLIN CANCER RES,
                    V11, P5965&#xD; KIM SK, 2006, CLIN CANCER RES, V12, P5550&#xD; KIM SU, 2004,
                    NEUROPATHOLOGY, V24, P159&#xD; KUSTERMANN E, 2005, NMR BIOMED, V18, P362&#xD;
                    LEE J, 2003, CANCER RES, V63, P8877&#xD; LEPORE AC, 2006, EXP NEUROL, V201,
                    P49&#xD; LESNIAK MS, 2006, NEUROTHERAPEUTICS, V6, P1&#xD; RIETZE RL, 2001,
                    NATURE, V412, P736&#xD; SCHMIDT NO, 2005, NEOPLASIA, V7, P623&#xD; SEMENZA GL,
                    2003, NAT REV CANCER, V3, P721&#xD; SHAH K, 2005, ANN NEUROL, V57, P34&#xD; SUN
                    LX, 2004, J CLIN INVEST, V113, P1364&#xD; SURAWICZ TS, 1998, J NEURO-ONCOL, V40,
                    P151&#xD; TALLHEDEN T, 2006, LIFE SCI, V79, P999&#xD; UHL M, 2005, BIOCHEM BIOPH
                    RES CO, V328, P125&#xD; WEISSLEDER R, 2002, NAT REV CANCER, V2, P11&#xD; ZHANG
                    ZG, 2004, NEUROIMAGE, V23, P281&#xD;Suppl. 1</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249434100002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>612</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">612</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1284</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, H. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xiong, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ho, Y. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nguyen, H. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Deng, H. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Borok, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ann, D. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Clin
                    &amp; Mol Pharmacol, Duarte, CA 91010 USA. Univ So Calif, Dept Mol Pharmacol
                    &amp; Toxicol, Los Angeles, CA USA. Univ So Calif, Dept Med, Los Angeles, CA
                    USA. Univ So Calif, Norris Canc Ctr, Los Angeles, CA USA. Univ So Calif, Will
                    Rogers Inst, Pulm Res Ctr, Los Angeles, CA USA. Wayne State Univ, Inst Environm
                    Hlth Sci, Detroit, MI USA.&#xD;Ann, DK, City Hope Natl Med Ctr, Dept Clin &amp;
                    Mol Pharmacol, KCRB 1022,1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;dann@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Transcriptional regulation by
                        targeted expression of architectural transcription factor high mobility
                        group A2 in salivary glands of transgenic mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">European Journal of Oral
                        Sciences</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Eur. J. Oral Sci.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">European Journal of Oral
                        Sciences</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Eur. J. Oral Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Eur J Oral Sci</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">European Journal of Oral
                        Sciences</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Eur. J. Oral Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Eur J Oral Sci</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">30-39</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">115</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">gene expression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HMGA2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microarrays</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">salivary glands</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transgenic mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NATURAL-KILLER-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HMGI-C GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPITHELIAL-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROUP-PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMOSOMAL-PROTEINS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PITUITARY-ADENOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN LIPOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISRUPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0909-8836</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244227900005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">High mobility group A2 (HMGA2)
                    protein is a non-histone architectural transcription factor. Numerous studies
                    have demonstrated that HMGA2 is exclusively expressed in the nucleus of
                    embryonic, but not of terminally differentiated, cells, and aberrant expression
                    of HMGA2 is associated with various benign tumors, including pleomorphic
                    salivary adenoma. Herein, we report the use of a 4.5-kb enhancer/promoter region
                    of the aquaporin-5 (AQP-5) gene to target HMGA2 transgene expression in the
                    mouse salivary acinar cells as a model to investigate the biochemical and
                    biological role of ectopic HMGA2 expression. The expression pattern was analyzed
                    by microarray analyses to pro. le HMGA2-dependent salivary gene regulation. By
                    using quantitative reverse transcription-polymerase chain reaction (RT-PCR)
                    assays, the expression of a cluster of genes involved in cytokine signaling,
                    including Il7r, Il2rg, and Ptprc, was verified to be up-regulated in the
                    salivary glands of AQP-5/HMGA2 mice. In concert, the expression of a cluster of
                    genes, namely Ppara, Phyh, and Cidea, governing fatty acid and lipid metabolism,
                    was confirmed to be down-regulated by HMGA2. Additionally, squamous
                    carcinoma-like salivary tumors were observed in the AQP-5/HMGA2 transgenic mice,
                    albeit at a low incidence. Our findings indicate that the AQP-5
                    promoter/enhancer-containing region is sufficient to target salivary-specific
                    transgene expression and suggest novel roles for HMGA2 in salivary epithelial
                    cells.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    136MM&#xD;Times Cited: 0&#xD;Cited Reference Count: 48</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244227900005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>652</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">652</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1281</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, M. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kochounian, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, T. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rao, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fong, H. K. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Doheny Eye Inst, Los Angeles, CA
                    90033 USA. Univ So Calif, Keck Sch Med, Dept Mol Microbiol &amp; Immunol, Los
                    Angeles, CA USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte,
                    CA 91010 USA. Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA
                    90089 USA.&#xD;Fong, HKW, Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA
                    90033 USA.&#xD;hfong@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Deposition of exon-skipping
                        splice isoform of human retinal G protein-coupled receptor from retinal
                        pigment epithelium into Bruch&apos;s membrane</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Vision</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Mol. Vis.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Vision</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Vis.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Vis</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Vision</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Vis.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Vis</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1203-1214</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">131-33</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN GENOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OPSIN HOMOLOG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RGR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LIGHT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1090-0535</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248645900001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE: Human retina and retinal
                    pigment epithelium (RPE) express a relatively abundant mRNA that encodes an
                    extraneous splice isoform of the RPE retinal G protein-coupled receptor (RGR)
                    opsin. In this study, we investigate this exon-skipping RGR splice isoform
                    (RGR-d) in separated neural retina and RPE cells of human donors of various
                    ages. METHODS: We used mass spectrometry, sensitive western blot assay,
                    immunohistochemical localization and real-time RT-PCR to analyze RGR-d. RESULTS:
                    Western blot assay detected the RGR-d protein in the neural retina of all donors
                    analyzed. Mass spectrometric analysis of the immunoreactive proteins
                    independently confirmed the presence of RGR-d. In contrast, RGR-d protein in the
                    RPE of most donors was barely detectable by western blot assay, even though
                    expression of RGR-d mRNA was confirmed by amplification of RGR-d transcripts in
                    both the RPE and neural retina. Quantitative real-time RT-PCR assays showed that
                    RGR-d/RGR mRNA transcript ratios were about 0.17 and about 0.33 in the RPE and
                    neural retina, respectively. Immunohistochemical localization studies revealed
                    that the RGR-d epitope was present near the basal boundary of RPE cells and
                    primarily in the extracellular areas of Bruch&apos;s membrane, adjacent
                    choriocapillaris, and intercapillary region of both young and older donors.
                    Positive immunostaining was seen in the drusen of older individuals.
                    CONCLUSIONS: The RGR-d protein is a common mutant form of human RGR that can be
                    identified in donor eyes by mass spectrometry. These results indicate that after
                    RGR-d is synthesized, the RGR-d epitope is released at the basal surface of the
                    RPE and deposited into Bruch&apos;s membrane in human eyes throughout adult
                    life.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    198RT&#xD;Times Cited: 0&#xD;Cited Reference Count: 31</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248645900001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>467</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">467</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1744</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mi, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xue, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chau, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Un, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical &amp;
                    Molecular Pharmacology, City of Hope National Medical Center, 1500 E. Duarte
                    Road, Duarte, CA 91010-3000, United States.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An increase of cytochrome C
                        oxidase mediated disruption of gemcitabine incorporation into DNA in a
                        resistant KB clone</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochem Pharmacol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical Pharmacology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Pharmacol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Pharmacol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1927-38</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">73</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenosine
                        Triphosphate/analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antimetabolites, Antineoplastic/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Blotting, Western</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Clone Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA/genetics/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Deoxycytidine/ analogs &amp;
                        derivatives/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Resistance,
                        Neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Electron Transport Complex
                        IV/antagonists &amp;</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inhibitors/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Enzyme
                        Inhibitors/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression Regulation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KB Cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Oligonucleotide Array Sequence
                        Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Polymerase Chain
                        Reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA,
                        Messenger/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sodium
                        Azide/pharmacology</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-2952 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17428446</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Mechanistic aberrations leading to
                    Gemcitabine (2&apos;,2&apos;-dFdCyd,2,2-difluorodeoxycytidine, Gem) resistance
                    may include alteration in its transport, metabolism and incorporation into DNA.
                    To explore the mechanism of Gem resistance, the restriction fragment
                    differential display PCR (RFDD-PCR) was employed to compare the mRNA expression
                    patterns of KBGem (Gem resistant), KBHURs (hydroxyurea resistant) and KBwt
                    (parental KB cell). Nine gene fragments were overexpressed specifically in the
                    KBGem clone. Sequencing and BLAST results showed that three fragments represent
                    cytochrome C oxidase (CCOX, respiration complex IV) subunit III (CCOX3). The
                    cDNA microarray confirmed that the mRNAs of CCOX and ATP synthase subunits were
                    upregulated in KBGem as compared to KBwt and KBHURs. The increase in CCOX1
                    protein and activity led to the increase of free ATP concentration, which is
                    consistent with the gene expression profile of KBGem. Furthermore, the
                    sensitivity to Gem could be reversed by sodium azide, a CCOX inhibitor.
                    Following the treatment of sodium azide, the cellular accumulation of [3H]-Gem
                    increased in a dose (of azide)-dependent manner, which is associated with
                    increase of [3H]-Gem incorporation into DNA in KBGem. In summary, an increase of
                    CCOX activity and free ATP level may reduce the transport, metabolism and DNA
                    incorporation of Gem, resulting in Gem resistance.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 07/07/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>373</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">373</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1743</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xue, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Un, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Clinical &amp; Molecular
                    Pharmacology Department, City of Hope National Medical Center, Duarte, CA
                    91010-3000, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Ribonucleotide reductase
                        subunits M2 and p53R2 are potential biomarkers for metastasis of colon
                        cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clin Colorectal Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Colorectal
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Colorectal Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Colorectal Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">374-81</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adult</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Cycle Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Movement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Colonic
                        Neoplasms/genetics/metabolism/ physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunohistochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-Binding Proteins</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ribonucleoside Diphosphate
                        Reductase/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ribonucleotide Reductases/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Risk</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Markers,
                        Biological</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Suppressor Protein
                        p53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Suppressor
                        Proteins</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1533-0028 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17311703</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Ribonucleoside
                    diphosphate reductase plays a key role in converting ribonucleoside diphosphate
                    to 2&apos;-deoxyribonucleoside diphosphate, which is necessary for DNA repair
                    and replication. To determine if human ribonucleotide reductase small subunit M2
                    (hRRM2) and p53-dependent human ribonucleotide reductase small subunit R2
                    (p53R2) play roles on invasion ability of cancer cells, the gene transferring
                    technique was used to construct stable hRRM2 and p53R2 overexpression
                    transfectants. Increase of hRRM2 dramatically enhanced the cell migration in KB
                    and PC-3 cells, but p53R2 overexpression reduced cellular invasion potential to
                    50% and 40% in KB and PC-3 cells, respectively. Furthermore, hRRM2 enhanced
                    cancer cells to induce the cell migration of Human Umbilical Vein Endothelial
                    Cells, but p53R2 reduced this ability in transfectants. PATIENTS AND METHODS: To
                    further determine the role of human ribonucleotide reductase subunits on cancer
                    metastasis, a tissue array, including 59 primary and 49 metastatic colon
                    adenocarcinoma samples, was used. Immunohistochemistry was used to evaluate the
                    relationship between human ribonucleotide reductase subunits and metastasis.
                    RESULTS: Univariate and multivariate analysis revealed that p53R2 is negatively
                    related to the metastasis of colon adenocarcinoma samples (odds ratio, 0.23; P
                    &lt; 0.05); hRRM2 increases the risk of metastasis in colon cancer, but did not
                    show significantly. Thus, opposing regulation of hRRM2 and p53R2 in invasion
                    potential might play a critical role in determining the invasion and metastasis
                    phenotype in cancer cells. CONCLUSION: The expression level of ribonucleotide
                    reductase small subunits could serve as biomarkers to predict the malignancy
                    potential of human cancers in the future.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 07/04</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>757</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">757</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1273</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lo, H. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yam, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Marcovecchio, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zaia, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yee, J. K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Virol, Duarte, CA 91010 USA.&#xD;Yee, JK, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Virol, Room 110, Duarte, CA 91010
                    USA.&#xD;jyee@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Inhibition of HIV-1 replication
                        with designed miRNAs expressed from RNA polymerase II promoters</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1503-1512</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">21</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">siRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">microRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">promoter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >HUMAN-IMMUNODEFICIENCY-VIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMALL INTERFERING RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LENTIVIRAL VECTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-ELEGANS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DELIVERY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0969-7128</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250226400001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Small interfering RNA (siRNA)
                    mediates sequence-specific RNA cleavage and represents a potential approach to
                    treat the infection of human immunodeficiency virus (HIV). Expression of a
                    single siRNA species frequently led to the emergence of HIV escape variants.
                    Thus, multiple siRNAs targeted to different regions in the HIV-1 genome may be
                    required. However, overexpression of different anti-HIV siRNA genes from
                    multiple pol III promoters can induce cell toxicity, thus may not be a viable
                    option in the setting of human gene therapy trials. In the current study, we
                    evaluated the strategy of using pol II promoters to drive the expression of
                    siRNAs against HIV-1. We replaced the stem sequence in the stem-loop structure
                    of the well- characterized miR-30a with siRNA sequences and showed that designed
                    microRNA (miRNA) could be expressed from pol II promoters. We demonstrated
                    efficient inhibition of HIV-1 replication with such designed miRNA, but the
                    efficacy was directly correlated with the expression level. Both the vector copy
                    number and the promoter strength directly affected the ability of the siRNA to
                    inhibit HIV-1 replication. We also showed that a combination of pol II and pol
                    III promoters to express two different siRNAs increased the efficacy against
                    HIV-1 replication without comprising cell viability.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    221KO&#xD;Times Cited: 0&#xD;Cited Reference Count: 37&#xD;Cited References:
                    &#xD; AN DS, 2006, MOL THER, V14, P494&#xD; ANDERSON J, 2005, RETROVIROLOGY,
                    V2&#xD; BARTEL DP, 2004, CELL, V116, P281&#xD; BAUM C, 2003, ACTA
                    HAEMATOL-BASEL, V110, P107&#xD; BAUM C, 2004, MOL THER, V9, P5&#xD; BERNSTEIN E,
                    2001, NATURE, V409, P363&#xD; BODEN D, 2003, J VIROL, V77, P11531&#xD; DAS AT,
                    2004, J VIROL, V78, P2601&#xD; ELBASHIR SM, 2001, NATURE, V411, P494&#xD; FIRE
                    A, 1998, NATURE, V391, P806&#xD; GASMI M, 1999, J VIROL, V73, P1828&#xD; GRAHAM
                    FL, 1973, VIROLOGY, V52, P456&#xD; GRIMM D, 2006, NATURE, V441, P537&#xD;
                    GRISHOK A, 2001, CELL, V106, P23&#xD; HANNON GJ, 2002, NATURE, V418, P244&#xD;
                    HUTVAGNER G, 2001, SCIENCE, V293, P834&#xD; JACKSON AL, 2004, TRENDS GENET, V20,
                    P521&#xD; JACQUE JM, 2002, NATURE, V418, P435&#xD; KETTING RF, 2001, GENE DEV,
                    V15, P2654&#xD; KIMPTON J, 1992, J VIROL, V66, P2232&#xD; KNIGHT SW, 2001,
                    SCIENCE, V293, P2269&#xD; LI MJ, 2003, MOL THER, V8, P196&#xD; LI MJ, 2005, MOL
                    THER, V12, P900&#xD; NOVINA CD, 2002, NAT MED, V8, P681&#xD; OTT M, 1997,
                    SCIENCE, V275, P1481&#xD; QIN XF, 2003, P NATL ACAD SCI USA, V100, P183&#xD;
                    REYNOLDS A, 2004, NAT BIOTECHNOL, V22, P326&#xD; SCHRODER O, 2003, P NATL ACAD
                    SCI USA, V100, P934&#xD; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263,
                    P181&#xD; SONG EW, 2003, J VIROL, V77, P7174&#xD; STEGMEIER F, 2005, P NATL ACAD
                    SCI USA, V102, P13212&#xD; TAZI J, 1993, MOL CELL BIOL, V13, P1641&#xD; TERBRAKE
                    O, 2006, MOL THER, V14, P883&#xD; YAM P, 2006, MOL THER, V14, P236&#xD; YAM PY,
                    2002, MOL THER, V5, P479&#xD; YI R, 2005, RNA, V11, P220&#xD; ZENG Y, 2002, MOL
                    CELL, V9, P1327</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250226400001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>758</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">758</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">965</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lowe, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr, Div
                    Med Oncol &amp; Therapeut Res, Duarte, CA 91010 USA.&#xD;Lowe, T, City Hope
                    Comprehens Canc Ctr, Div Med Oncol &amp; Therapeut Res, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;tlowe@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Second malignancies after
                        allogeneic hematopoietic cell transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1121-1134</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">allogeneic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transplant</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">second malignancy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PTLD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPSTEIN-BARR-VIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTTRANSPLANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOPROLIFERATIVE
                        DISORDER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NON-HODGKINS-LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOTOXIC T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TREATMENT-RELATED
                        MYELODYSPLASIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLID-ORGAN
                        TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYELOGENOUS LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEVERE APLASTIC-ANEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SECONDARY MALIGNANCIES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250103400001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Allogencic hematopoietic cell
                    transplantation (allo-HCT) may prolong life and cure patients suffering from
                    otherwise fatal diseases. However, the growing population of long-term survivors
                    has led to the realization of multiple long-term complications, including the
                    risk of second malignancies. Compared to the autologous setting, allo-HCT
                    carries a much higher risk of posttransplant lymphoproliferative disorder
                    (PTLD), which usually occurs within the first year after allo-HCT and is
                    strongly associated with the Epstein-Barr virus (EBV). Treatment-related
                    myelodysplastic syndromes (tMDS) and second leukemias are extremely rare. Both
                    autologous and allo-HCT carry increased risks for second solid malignancies
                    (SSM). The cumulative incidence of SSM continues to increase in each of the
                    largest studies with as much as 20 years of follow-up, likely related to the
                    long latency of radiation-related SSM. Systematic, prospective monitoring,
                    vigilant screening processes, and well-maintained survivorship clinics and
                    databases are absolute necessities, and should be included in the infrastructure
                    of individual transplant centers and networks, with mandatory periodic reporting
                    of second malignancy incidences. Primary care and transplant physicians alike
                    must be aware of the risk of second malignancies after allo-HCT. Most
                    importantly, guidelines should be developed in regard to screening and
                    prevention of second malignancies, so that physicians can provide
                    state-of-the-art counsel and care for the benefit of our patients. (C) 2007
                    American Society for Blood and Marrow Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    219RX&#xD;Times Cited: 0&#xD;Cited Reference Count: 117&#xD;Cited References:
                    &#xD; 2004, AM J TRANSPLANT, V10, P59&#xD; 2004, LANCET, V364, P2153&#xD;
                    *CHILDR ONC GROUP, 2006, LONG TERM FOLL UP GU&#xD; *UNSCEAR, 2000, SOURC EFF ION
                    RAD, V2&#xD; AISENBERG AC, 1997, CANCER, V79, P1203&#xD; ANDREOME P, 2003, ARCH
                    INTERN MED, V163, P1997&#xD; ARIS RM, 1996, AM J RESP CRIT CARE, V154,
                    P1712&#xD; ARMITAGE JO, 2003, J CLIN ONCOL, V21, P897&#xD; ATLAS LD, 2006,
                    TRANSFUSION, V46, P1080&#xD; AU WY, 2005, GASTROENTEROLOGY, V129, P2058&#xD;
                    BAKER KS, 2003, J CLIN ONCOL, V21, P1352&#xD; BARKER JN, 2001, BIOL BLOOD MARROW
                    TR, V7, P395&#xD; BHATIA S, 1996, BLOOD, V87, P3633&#xD; BHATIA S, 1996, NEW
                    ENGL J MED, V334, P745&#xD; BHATIA S, 2001, J CLIN ONCOL, V19, P464&#xD; BLAES
                    AH, 2005, CANCER, V104, P1661&#xD; BLAZAR B, 1980, J EXP MED, V151, P614&#xD;
                    BODO I, 1999, NEW ENGL J MED, V341, P807&#xD; BOIVIN JF, 1995, J NATL CANCER I,
                    V87, P732&#xD; BROWN SA, 1995, EUR J HAEMATOL, V54, P198&#xD; BRUNSTEIN CG,
                    2006, BLOOD, V108, P2874&#xD; COCKFIELD SM, 2001, TRANSPL INFECT DIS, V3,
                    P70&#xD; CODELUPPI M, 2005, TRANSPLANT P, V37, P2634&#xD; COHEN JI, 1991,
                    MEDICINE, V70, P137&#xD; COMOLI P, 2002, BLOOD, V99, P2592&#xD; CORNELIUS EA,
                    1972, J EXP MED, V136, P1533&#xD; CORNELIUS EA, 1972, SCIENCE, V177, P524&#xD;
                    CURTIS RE, 1997, NEW ENGL J MED, V336, P897&#xD; CURTIS RE, 1999, BLOOD, V94,
                    P2208&#xD; DARENKOV IA, 1997, TRANSPLANTATION, V64, P848&#xD; DARRINGTON DL,
                    1994, J CLIN ONCOL, V12, P2527&#xD; DAVIS CL, 1995, CLIN TRANSPLANT, V9,
                    P53&#xD; DEEG HJ, 1984, EXP HEMATOL, V12, P660&#xD; DEEG HJ, 1993, HEMATOL ONCOL
                    CLIN N, V7, P417&#xD; DEEG HJ, 1996, BLOOD, V87, P386&#xD; DEEG HJ, 1998, BLOOD,
                    V91, P1833&#xD; DURANDY A, 2001, TRANSPLANT INFECT DI, V3, P104&#xD; ELSTROM RL,
                    2006, AM J TRANSPLANT, V6, P569&#xD; FIALKOW PJ, 1971, LANCET, V1, P251&#xD;
                    FRIZZERA G, 1981, CANCER RES, V41, P4262&#xD; FUNCH DP, 2005, AM J TRANSPLANT,
                    V5, P2894&#xD; GALLAGHER G, 2007, CANCER, V109, P84&#xD; GARWICZ S, 2000, INT J
                    CANCER, V88, P672&#xD; GLEICHMANN E, 1978, RECENT RESULTS CANC, V64, P292&#xD;
                    GONG JZ, 2006, AM J SURG PATHOL, V300, P328&#xD; GROSS TG, 1999, BONE MARROW
                    TRANSPL, V23, P251&#xD; GUSTAFSSON A, 2000, BLOOD, V95, P807&#xD; HADDAD E,
                    2001, BLOOD, V97, P1590&#xD; HANCOCK SL, 1993, J NATL CANCER I, V85, P25&#xD;
                    HANTO DW, 1985, TRANSPLANTATION, V39, P461&#xD; HAQUE T, 2002, LANCET, V360,
                    P436&#xD; HARRIS NL, 1997, SEMIN DIAGN PATHOL, V14, P8&#xD; HASEGAWA W, 2005,
                    BONE MARROW TRANSPL, V35, P51&#xD; HAWKINS MM, 1987, BRIT J CANCER, V56,
                    P339&#xD; HEBNER CM, 2006, REV MED VIROL, V16, P83&#xD; HENLE G, 1979,
                    EPSTEINBARR VIRUS, P297&#xD; HOOVER RN, 1992, CANCER RES, V52, P5477&#xD; INSKIP
                    PD, 1999, MULTIPLE PRIMARY CAN, P91&#xD; JAFFE ES, 2001, WHO CLASSIFICATION T,
                    V3, P264&#xD; JAIN AB, 2005, TRANSPLANTATION, V80, P1692&#xD; KATZ F, 1993, BRIT
                    J HAEMATOL, V85, P326&#xD; KEAY S, 1998, CLIN INFECT DIS, V26, P596&#xD; KNOWLES
                    DM, 1995, BLOOD, V85, P552&#xD; KOLB HJ, 1992, BONE MARROW TRANS S1, V10,
                    P135&#xD; KOLB HJ, 1999, ANN INTERN MED, V131, P738&#xD; KRISHNAN A, 2000,
                    BLOOD, V95, P1588&#xD; KUO PC, 1995, TRANSPLANTATION, V59, P135&#xD; LEBLOND V,
                    1998, J CLIN ONCOL, V16, P2052&#xD; LEISENRING W, 2006, J CLIN ONCOL, V24,
                    P1119&#xD; LIEBOWITZ D, 1998, NEW ENGL J MED, V338, P1413&#xD; LIN JC, 1984, J
                    VIROL, V50, P50&#xD; LISHNER M, 1990, CANCER, V65, P473&#xD; LOWSKY R, 1994, J
                    CLIN ONCOL, V12, P2187&#xD; MATHUR A, 1994, TRANSPLANTATION, V57, P1042&#xD;
                    MCKHANN CF, 1969, TRANSPLANTATION, V8, P209&#xD; MICALLEF INM, 2000, J CLIN
                    ONCOL, V18, P947&#xD; MILLIGAN DW, 1999, BRIT J HAEMATOL, V106, P1020&#xD;
                    MOURAD WA, 2006, ARCH PATHOL LAB MED, V130, P1649&#xD; NALESNIK MA, 1988, AM J
                    PATHOL, V133, P173&#xD; NALESNIK MA, 1988, CURR PROB SURG, V25, P367&#xD; NEGLIA
                    JP, 2001, J NATL CANCER I, V93, P618&#xD; NEUGUT AL, 1999, MULTIPLE PRIMARY CAN,
                    P1&#xD; NIEDERWIESER DW, 1990, NEW ENGL J MED, V322, P1794&#xD; OERTEL SHK,
                    2005, AM J TRANSPLANT, V5, P2901&#xD; ORAZI A, 1997, AM J CLIN PATHOL, V107,
                    P419&#xD; PAKAKASAMA S, 2004, TRANSPLANTATION, V78, P755&#xD; PEARSON GR, 1986,
                    J NATL CANCER I, V56, P485&#xD; PEDERSENBJERGAA.J, 1988, NEW ENGL J MED, V318,
                    P1028&#xD; PENN I, 1969, TRANSPLANT P, V1, P106&#xD; PIERGA JY, 1994, RADIOTHER
                    ONCOL, V30, P55&#xD; PITMAN SD, 2006, AM J SURG PATHOL, V30, P470&#xD;
                    PREIKSAITIS JK, 2004, CLIN INFECT DIS, V39, P1016&#xD; PRESTON DL, 2003, RADIAT
                    RES, V160, P381&#xD; QU LR, 2005, TRANSFUSION, V45, P591&#xD; RIES LAG, 2006,
                    SEER CANC STAT REV&#xD; ROONEY CM, 1998, BLOOD, V92, P1549&#xD; ROWLAND J, 2004,
                    MMWR-MORBID MORTAL W, V53, P526&#xD; SCHWARTZ RS, 1972, LANCET, V1, P1266&#xD;
                    SHAPIRO RS, 1988, BLOOD, V71, P1234&#xD; SNYDER MJ, 2004, AM J SURG PATHOL, V28,
                    P794&#xD; SOCIE G, 1991, BLOOD, V78, P277&#xD; SOCIE G, 2000, J CLIN ONCOL, V18,
                    P348&#xD; STONE RM, 1994, J CLIN ONCOL, V12, P2535&#xD; TAM CS, 2006,
                    HAEMATOL-HEMATOL J, V91, P1546&#xD; THOMAS ED, 1972, LANCET, V1, P1310&#xD;
                    TRAVIS LB, 1995, J NATL CANCER I, V87, P524&#xD; TUCKER MA, 1987, NEW ENGL J
                    MED, V317, P588&#xD; VANESSER JWJ, 2002, BLOOD, V99, P4364&#xD; VANLEEUWEN FE,
                    2000, J CLIN ONCOL, V18, P487&#xD; VANLEEUWEN FE, 2003, J NATL CANCER I, V95,
                    P971&#xD; VEGASTROMBERG T, 2003, J INFUS NURS, V26, P353&#xD; WALLACE LE, 1982,
                    NATURE, V297, P413&#xD; WEINSTOCK DM, 2006, BONE MARROW TRANSPL, V37, P539&#xD;
                    WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784&#xD; WITHERSPOON RP, 1992,
                    BLOOD, V79, P289&#xD; WITHERSPOON RP, 1994, TRANSPLANTATION, V57, P1413&#xD; ZHU
                    K, 2005, HEMATOLOGY, V10, P365</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250103400001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>788</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">788</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">964</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lowe, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr, Div
                    Med Oncol &amp; Therapeut Res, Duarte, CA 91010 USA.&#xD;Lowe, TE, City Hope
                    Comprehens Canc Ctr, Div Med Oncol &amp; Therapeut Res, Duarte, CA 91010
                    USA.&#xD;tlowe@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Increased abdominal girth in a
                        29-year-old breast cancer patient with extensive liver metastasis and
                        presumed chemotherapy induced amenorrhea. A case report and review of the
                        literature</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Research and
                        Treatment</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Breast Cancer Research and
                        Treatment</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Breast Cancer Res.
                        Treat.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Breast Cancer Res Treat</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">305-306</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">106</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">AROMATASE INHIBITORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-6806</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250579800001</style>
            </accession-num>
            <label>
                <style face="normal" font="default" size="100%">Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    226HJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 5&#xD;Cited References:
                    &#xD; BURSTEIN HJ, 2006, CLIN BREAST CANCER, V7, P158&#xD; FORNIER MN, 2005,
                    CANCER, V104, P1575&#xD; JEMAL A, 2004, CA-CANCER J CLIN, V54, P8&#xD; PETREK
                    JA, 2006, J CLIN ONCOL, V24, P1045&#xD; SMITH IE, 2006, J CLIN ONCOL, V24,
                    P2444</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250579800001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI? reported to Irene Tomeck
                    01/28/2009</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>629</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">629</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1266</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lundberg, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Openshaw, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, M. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yang, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cantin, E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Virol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst,
                    Dept Immunol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst,
                    Dept Neurol, Duarte, CA 91010 USA.&#xD;Cantin, E, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Virol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;ecantin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Effects of CXCR3 signaling on
                        development of fatal encephalitis and corneal and periocular skin disease in
                        HSV-infected mice are mouse-strain dependent</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Investigative Ophthalmology
                        &amp; Visual Science</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Invest. Ophthalmol. Vis.
                        Sci.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Investigative Ophthalmology
                        &amp; Visual Science</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Invest. Ophthalmol. Vis.
                        Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Invest Ophthalmol Vis
                        Sci</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Investigative Ophthalmology
                        &amp; Visual Science</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Invest. Ophthalmol. Vis.
                        Sci.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Invest Ophthalmol Vis
                        Sci</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">4162-4170</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HERPES-SIMPLEX-VIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CENTRAL-NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STROMAL KERATITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOKINE PRODUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LETHAL ENCEPHALITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROGLIAL CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VIRAL-INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CUTTING EDGE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0146-0404</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249061900037</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">PURPOSE. The host inflammatory
                    response to ocular infection with herpes simplex virus (HSV) can be either
                    protective, with disease-free survival, or it can promote diseases such as HSV
                    corneal disease ( or herpes stromal keratitis [HSK] in humans) and encephalitis
                    (HSE), depending on mouse strain. The role of CXCR3 chemokine signaling in
                    HSV-induced central nervous system (CNS) inflammation and corneal disease was
                    evaluated, and responses in genetically susceptible and resistant strains of
                    mice were contrasted. METHODS. Resistant C57BL/6J (B6) and susceptible 129S6 (
                    129) mice were given monoclonal antibodies (mAbs) to neutralize the CXCR3
                    ligands monokine induced by interferon-gamma ( MIG, CXCL9) and interferon
                    inducible protein-10 (IP-10, CXCL10) during HSV infection. In addition, the
                    development of HSV disease was monitored in CXCR3-null mutant mice derived from
                    resistant ( B6) and susceptible (BALB/c) strains. Inflammatory cells
                    infiltrating the cornea and brain stem were isolated and stained for flow
                    cytometric analysis. RESULTS. MIG and IP-10 were induced in nervous system
                    tissue after HSV inoculation by the corneal route. HSV-infected 129 mice treated
                    with MIG- or IP-10-neutralizing mAbs showed significantly enhanced survival
                    compared with mice treated with control isotype antibody, whereas survival of
                    the B6 mice was unaltered. Similarly, greater survival was observed for BALB.
                    CXCR3 (-/-) mice compared with control BALB/ c mice. Reduced CNS inflammation
                    was documented that extended to the cornea, such that HSV corneal disease
                    severity was reduced in susceptible BALB. CXCR3 (-/-) . In contrast, although
                    survival of B6 and B6. CXCR3 (-/-) mice was indistinguishable, B6. CXCR3 (-/-)
                    mice developed more severe corneal and periocular skin disease. CONCLUSIONS. The
                    effects of CXCR3 signaling in HSV infection are strongly dependent on mouse
                    strain.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    204RO&#xD;Times Cited: 0&#xD;Cited Reference Count: 45</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249061900037 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>229</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">229</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1265</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Lundberg, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Welander, P. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Edwards, C. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">van Rooijen, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cantin, E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. Beckman Res Inst, Dept Virol, Duarte, CA 91010 USA. Beckman Res Inst,
                    Dept Immunol, Duarte, CA 91010 USA. Beckman Res Inst, Dept Neurol, Duarte, CA
                    91010 USA. Vrije Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, NL-1081 HV
                    Amsterdam, Netherlands.&#xD;Cantin, E, City Hope Natl Med Ctr, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;ecantin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Tumor necrosis factor (TNF)
                        protects resistant C57BL/6 mice against herpes simplex virus-induced
                        encephalitis independently of signaling via TNF receptor 1 or 2</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Virology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Virol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Virology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Virol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Virol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Virology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Virol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Virol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1451-1460</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">81</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">NITRIC-OXIDE SYNTHASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GAMMA-INTERFERON</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIGEMINAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GANGLION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TYPE-1 INFECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IFN-GAMMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOKINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRODUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTIVIRAL ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STROMAL KERATITIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-538X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243766800039</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Tumor necrosis factor (TNF) is a
                    multifunctional cytokine that has a role in induction and regulation of host
                    innate and adaptive immune responses. The importance of TNF antiviral mechanisms
                    is reflected by the diverse strategies adopted by different viruses,
                    particularly members of the herpesvirus family, to block TNF responses. TNF
                    binds and signals through two receptors, Tnfrsf1a (TNF receptor 1 [TNFR1], or
                    p55) and Tnfrsf1b (TNFR2, or p75). We report here that herpes simplex virus 1
                    (HSV-1) infection of TNF-/- mice on the resistant C57BL/6 genetic background
                    results in significantly increased susceptibility (P &lt; 0.0001, log rank test)
                    to fatal HSV encephalitis (HSE) and prolonged persistence of elevated levels of
                    virus in neural tissues. In contrast, although virus titers in neural tissues of
                    p55(-/-)N13 mice were elevated to levels comparable to what was found for the
                    TNF-/- mice, the p55(-/-)N13 mice were as resistant as control C57BL/6 mice (P
                    &gt; 0.05). The incidence of fatal HSE was significantly increased by in vivo
                    neutralization of TNF using soluble TNFR1 (sTNFR1) or depletion of macrophages
                    in C57BL/6 mice (P = 0.0038 and P = 0.0071, respectively). Strikingly, in vivo
                    neutralization of TNF in HSV-1-infected p55(-/-) p75(-/-) mice by use of three
                    independent approaches (treatment with soluble p55 receptor, anti-TNF monoclonal
                    antibody, or in vivo small interfering RNA against TNF) resulted in
                    significantly increased mortality rates (P = 0.005), comparable in magnitude to
                    those for C57BL/6 mice treated with sTNFR1 (P = 0.0018). Overall, these results
                    indicate that while TNF is required for resistance to fatal HSE, both p55 and
                    p75 receptors are dispensable. Precisely how TNF mediates protection against
                    HSV-1 mortality in p55(-/-) p75(-/-) mice remains to be determined.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">TopTier</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    129YU&#xD;Times Cited: 0&#xD;Cited Reference Count: 73</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243766800039 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>430</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">430</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1262</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ma, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Durrin, L. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lv, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhu, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Han, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Nanjing Med Univ, Coll Basic Med,
                    Key Lab Human Funct Genom &amp; Jiangsu Province, Nanjing 210029, Peoples R
                    China. Nanjing Med Univ, Dept Cell Biol &amp; Med Genet, Nanjing 210029, Peoples
                    R China. Nanjing Med Univ, Sch Pharm, Nanjing 210029, Peoples R China. City Hope
                    Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA.&#xD;Sun, Y, Nanjing Med Univ,
                    Coll Basic Med, Key Lab Human Funct Genom &amp; Jiangsu Province, Hangzhong Rd
                    140, Nanjing 210029, Peoples R China.&#xD;hanxiao@njmu.edu.cn
                    yujiesun@njmu.edu.cn</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The BCL2 major breakpoint region
                        (mbr) regulates gene expression</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2649-2657</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">18</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BCL2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">mbr</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">t(14</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">18)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">homologous recombination</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gene regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T(14/18) LYMPHOMA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAR-BINDING PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AU-RICH ELEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CODING SEQUENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOWN-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SATB1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SITE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0950-9232</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245831200012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BCL2 expression is finely tuned by a
                    variety of environmental and endogenous stimuli and regulated at both
                    transcriptional and post-transcriptional levels. Our previous investigations
                    demonstrated that the BCL2 major breakpoint region (mbr) in the 30-UTR
                    upregulates reporter gene expression, which implies that this region possessed
                    intrinsic regulatory function. However, the effect of the mbr on BCL2
                    expression, and the underlying regulatory mechanisms, remain to be elucidated.
                    To assess the direct effect of the mbr on the transcriptional activity of the
                    BCL2 gene, we employed targeted homologous recombination to establish a mbr(+) /
                    mbr(-) heterozygous Nalm-6 cell line and then compared the transcriptional
                    activity and apoptotic effect on transcription between the wild type and
                    targeted alleles. We found that deletion of the mbr significantly decreased the
                    transcriptional activity of the corresponding allele in the mbr(+)/mbr(-) cell.
                    The BCL2 allele deleted of the mbr had a slower response to apoptotic stimuli
                    than did the wild type allele. The regulatory function of the mbr was mediated
                    through SATB1. Overexpression of SATB1 increased BCL2 expression, while
                    knockdown of SATB1 with RNAi decreased BCL2 expression. Our results clearly
                    indicated that the mbr could positively regulate BCL2 gene expression and this
                    regulatory function was closely related to SATB1.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    158YI&#xD;Times Cited: 0&#xD;Cited Reference Count: 36&#xD;Cited References:
                    &#xD; ADAMS JM, 1999, COLD SPRING HARB SYM, V64, P351&#xD; ALVAREZ JD, 2000,
                    GENE DEV, V14, P521&#xD; CHEN DF, 1997, NATURE, V385, P434&#xD; CHEN HM, 1995,
                    MOL CELL BIOL, V15, P3840&#xD; CHEN M, 1995, CANCER RES, V55, P991&#xD; DELIC J,
                    1991, BIOCHEM BIOPH RES CO, V181, P818&#xD; DICKINSON LA, 1992, CELL, V70,
                    P631&#xD; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137&#xD; DONNINI M,
                    2004, J BIOL CHEM, V279, P20154&#xD; GRAWUNDER U, 1998, MOL CELL, V2, P477&#xD;
                    GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389&#xD; HECKMAN CA, 2000, J BIOL CHEM,
                    V275, P6499&#xD; HECKMAN CA, 2002, ONCOGENE, V21, P3898&#xD; HOCKENBERY D, 1990,
                    NATURE, V348, P334&#xD; KATO M, 1992, J BIOCHEM, V112, P492&#xD; KOHWI Y, 1991,
                    GENE DEV, V5, P2547&#xD; LANG G, 2005, IMMUNOLOGY, V114, P25&#xD; MIYASHITA T,
                    1994, CANCER RES, V54, P3131&#xD; NARLA RK, 2001, LEUKEMIA LYMPHOMA, V41,
                    P625&#xD; PATRONE G, 2000, BIOTECHNIQUES, V29, P1012&#xD; PERILLO B, 2000, MOL
                    CELL BIOL, V20, P2890&#xD; RAGHAVAN SC, 2005, J BIOL CHEM, V280, P22749&#xD;
                    RAMAKRISHNAN M, 2000, MOL CELL BIOL, V20, P868&#xD; SATO N, 1994, J NEUROBIOL,
                    V25, P1227&#xD; SCHIAVONE N, 2000, FASEB J, V14, P174&#xD; SUN YJ, 2006, CELL
                    BIOL INT, V30, P244&#xD; SUZUKI A, 1996, ONCOGENE, V13, P31&#xD; TONG X, 2005, J
                    BIOL CHEM, V280, P15503&#xD; TSURUSAWA M, 1997, INT J HEMATOL, V66, P79&#xD;
                    VANHOLDE K, 1994, BIOESSAYS, V16, P59&#xD; WILSON BE, 1996, MOL CELL BIOL, V16,
                    P5546&#xD; WU YL, 2001, ONCOGENE, V20, P240&#xD; YASUI D, 2002, NATURE, V419,
                    P641&#xD; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686&#xD; ZHANG JJ, 2006, GENE,
                    V379, P127&#xD; ZHANG MX, 2005, P NATL ACAD SCI USA, V102, P16967</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245831200012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>469</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">469</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1259</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">MacDonald, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sarna, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">van Servellen, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bastani, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Giger, J. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Clin Canc
                    Genet Dept, City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA. Univ Calif Los
                    Angeles, Sch Nursing, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch
                    Publ Hlth, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024
                    USA.&#xD;MacDonald, DJ, City Hope Natl Med Ctr, Clin Canc Genet Dept, City Hope
                    Comprehens Canc Ctr, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;dmacdonald@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Selection of family members for
                        communication of cancer risk and barriers to this communication before and
                        after genetic cancer risk assessment</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Genetics in Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Genetics in Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Genet. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Genet Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">275-282</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">family communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer risk
                        communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">communication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">barriers</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetic counseling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RELATIVES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUSCEPTIBILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFORMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISCLOSURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATTITUDES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDREN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1098-3600</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246631400003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: The impact of genetic
                    cancer risk assessment on communication of cancer risk information within
                    families is not fully known. We compared women&apos;s selection of family
                    members for cancer risk communication and perceived barriers to this
                    communication before genetic cancer risk assessment and 6 months afterward.
                    Methods: Mailed surveys were used to collect prospective data from consenting
                    women undergoing genetic cancer risk assessment because of a personal and/or
                    family history of breast or ovarian cancers. Analysis included descriptive
                    statistics, chi-square and McNemar tests, and paired t tests. Results: A total
                    of 122 women met the study criteria. Although risk communications increased with
                    first-degree relatives (84%-90% for females; 53%-62% for males) and decreased
                    with non-first-degree relatives (21%-9%) before and after genetic cancer risk
                    assessment, the degree of change was nonsignificant. The most commonly cited
                    communication barrier was loss of contact (30%). Demographics, personal or
                    family cancer history, and BRCA status did not significantly influence findings.
                    Conclusions: There was a high degree of cancer risk communications with female
                    first-degree relatives, but less so with male first-degree relatives, both
                    before and after genetic cancer risk assessment. For the majority of women,
                    interpersonal barriers did not preclude risk discussions. Further research is
                    needed to identify how best to facilitate risk communication.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    169ZU&#xD;Times Cited: 0&#xD;Cited Reference Count: 49&#xD;Cited References:
                    &#xD; *INT SOC NURS GEN, 1998, STAT SCOP STAND GEN&#xD; BALMANA J, 2004, J MED
                    GENET, V41&#xD; BASTANI R, 1999, PREV MED, V29, P355&#xD; BONADONA V, 2002,
                    CANCER EPIDEM BIOMAR, V11, P97&#xD; BRUINOOGE SS, 2003, J CLIN ONCOL, V21,
                    P2397&#xD; CLAES E, 2003, AM J MED GENET A A, V116, P11&#xD; CLAUS EB, 1994,
                    CANCER, V73, P643&#xD; COSTALAS JW, 2003, AM J MED GENET C C, V119, P11&#xD;
                    DALY MB, 2006, J NATL COMPR CANC NE, V4, P156&#xD; FORD D, 1998, AM J HUM GENET,
                    V62, P676&#xD; FORREST K, 2003, CLIN GENET, V64, P317&#xD; GIGER J, 2004,
                    TRANSCULTURAL NURSIN&#xD; GRECO KE, 2003, INTERNET J ADV NURSI, V5&#xD; GREEN J,
                    1997, J GENET COUNSEL, V6, P45&#xD; HUGHES C, 1999, CANC RES THERAPY CON, V8,
                    P51&#xD; HUGHES C, 2002, AM J MED GENET, V107, P143&#xD; JEMAL A, 2006,
                    CA-CANCER J CLIN, V56, P106&#xD; JULIANREYNIER C, 1996, J MED GENET, V33,
                    P731&#xD; KEELING SL, 2004, J LAW MED, V12, P235&#xD; KENEN R, 2004,
                    PSYCHO-ONCOL, V13, P335&#xD; KNOPPERS BM, 1998, AM J HUM GENET, V62, P474&#xD;
                    LERMAN C, 1994, J CLIN ONCOL, V12, P843&#xD; LERMAN C, 1995, AM J MED GENET,
                    V57, P385&#xD; LERMAN C, 1996, ONCOLOGY, V10, P191&#xD; LERMAN C, 2002, J
                    CONSULT CLIN PSYCH, V70, P784&#xD; LOVELANDCHERRY CJ, 2004, PROMOTING HLTH
                    FAMIL, V3, P61&#xD; MACDONALD DJ, IN PRESS SEMIN BREAS&#xD; MACDONALD DJ, 1997,
                    QUALITY LIFE NURSING, V6, P8&#xD; MACDONALD DJ, 1998, HOLIST NURS PRACT, V12,
                    P9&#xD; MACDONALD DJ, 2002, J MED GENET, V39, P526&#xD; MACDONALD DJ, 2002,
                    MEDSURG NURSING, V11, P183&#xD; MACDONALD DJ, 2005, CANCER NURS, V28, P372&#xD;
                    MACDONALD DJ, 2006, ONCOL NURS FORUM, V33, E27&#xD; MANNE S, 2004, ANN BEHAV
                    MED, V28, P211&#xD; MCGIVERN B, 2004, GENET MED, V6, P503&#xD; METCALFE K, 2004,
                    J CLIN ONCOL, V22, P2328&#xD; METCALFE KA, 2005, GYNECOL ONCOL, V96, P222&#xD;
                    MIESFELDT S, 2003, AM J MED GENET C C, V119, P45&#xD; NAROD SA, 2003, LANCET,
                    V361, P179&#xD; OFFIT K, 2004, JAMA-J AM MED ASSOC, V292, P1469&#xD; PATENAUDE
                    AF, 2006, J CLIN ONCOL, V24, P700&#xD; SARNA L, 2001, CANCER PRACT, V9,
                    P134&#xD; SELTZER V, 1995, JAMA-J AM MED ASSOC, V273, P491&#xD; SERMIJN E, 2004,
                    J MED GENET, V41&#xD; SMITH KR, 2002, GENET TEST, V6, P89&#xD; STRUEWING JP,
                    1997, NEW ENGL J MED, V336, P1401&#xD; TERCYAK KP, 2001, PATIENT EDUC COUNS,
                    V42, P213&#xD; TERCYAK KP, 2002, PATIENT EDUC COUNS, V47, P145&#xD; ZIOGAS A,
                    2000, CANCER EPIDEM BIOMAR, V9, P103</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246631400003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>370</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">370</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1256</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Mai, P. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sullivan-Halley, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ursin, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stram, D. O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Deapen, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Villaluna, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Horn-Ross, P. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Clarke, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reynolds, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ross, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">West, D. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anton-Culver, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ziogas, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Norris Comprehens
                    Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA. City Hope Natl Med Ctr,
                    Clin Canc Genet Dept, Duarte, CA 91010 USA. Univ So Calif, Keck Sch Med, Dept
                    Prevent Med, Los Angeles, CA 90089 USA. No Calif Canc Ctr, Fremont, CA USA. Univ
                    Calif Irvine, Sch Med, Irvine, CA 92717 USA.&#xD;Bernstein, L, Univ So Calif,
                    Norris Comprehens Canc Ctr, Dept Prevent Med, Room 4449,1441 Eastlake Ave, Los
                    Angeles, CA 90033 USA.&#xD;lbern@usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Physical activity and colon
                        cancer risk among women in the california teachers study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">517-525</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">16</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HORMONE REPLACEMENT
                        THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LARGE-BOWEL CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESTROGEN PLUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGESTIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNITED-STATES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTMENOPAUSAL WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSPECTIVE COHORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INCIDENCE RATES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREVENTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPIDEMIOLOGY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1055-9965</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245093900027</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Existing data suggest
                    that physical activity reduces colon cancer risk, but the association is not
                    consistently observed in women. One potential explanation for this inconsistency
                    is that hormone therapy, which is associated with lower colon cancer risk, acts
                    as a modifier of the physical activity/colon cancer relationship. Methods:
                    Participants in the California Teachers Study (N = 120,147), a prospective
                    cohort of female teachers and administrators residing in California, ages 22 to
                    84 years at baseline and with no prior history of colon cancer were eligible for
                    study. Between 1996 and 2002, 395 patients were diagnosed with invasive colon
                    cancer. The relative risks (RR) associated with lifetime (high school through
                    age 54 years or current age) and recent (past 3 years) strenuous and moderate
                    recreational physical activity were estimated using Cox proportional hazards
                    regression models. Results: Combined lifetime moderate and strenuous
                    recreational physical activity was only mode [&gt;= 4 versus &lt;= 0.5 h/wk/y:
                    RR, 0.75; 95% confidence interval, 0.57-1.00; P-trend = 0.23]. Lifetime physical
                    activity reduced colon cancer risk among postmenopausal women who had never
                    taken hormone therapy (&gt;= 4 versus &lt;= 0.5 h/wk/y: RR, 0.51; 95% confidence
                    interval, 0.31-0.85; P-trend = 0.02). Postmenopausal women with histories of
                    hormone therapy use had lower colon cancer risk, but their risk was not
                    associated with physical activity. The likelihood ratio test for interaction
                    between hormone use and lifetime moderate plus strenuous physical activity was
                    of borderline statistical significance (P = 0.05). We observed no effect
                    modification by age, body mass index, smoking status, menopausal status, or
                    folate intake. Conclusions: Lifetime recreational physical activity may protect
                    against colon cancer among postmenopausal women who have never used hormone
                    therapy. Among hormone therapy users, who have lower risk of colon cancer,
                    recreational physical activity does not seem to provide any additional benefit.
                    With declining rates of hormone therapy use, physical activity offers one
                    possible means for reducing women&apos;s colon cancer risk.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    148SC&#xD;Times Cited: 0&#xD;Cited Reference Count: 58&#xD;Cited References:
                    &#xD; *CDC, 2004, BEH RISK FACT SURV S&#xD; *IARC, 2002, IARC HDB CANC PREV, V6,
                    P134&#xD; *UK COL CANC SCREE, 2004, BRIT MED J, V3029, P133&#xD; ANDERSON GL,
                    2004, JAMA-J AM MED ASSOC, V291, P1701&#xD; BALLARDBARBASH R, 1990, CANCER RES,
                    V50, P3610&#xD; BARTRAM HP, 1989, AM J GASTROENTEROL, V84, P109&#xD; BERNSTEIN
                    L, 2002, CANCER CAUSE CONTROL, V13, P625&#xD; BOYLE P, 2002, BRIT MED BULL, V64,
                    P1&#xD; BUIST DSM, 2004, OBSTET GYNECOL 1, V104, P1042&#xD; BURT RW, 2000,
                    GASTROENTEROLOGY, V119, P837&#xD; CALLE EE, 1995, J NATL CANCER I, V87,
                    P517&#xD; CALTON BA, 2006, INT J CANCER, V119, P385&#xD; CAMPAGNOLI C, 2003,
                    MATURITAS, V46, P39&#xD; CHAO A, 2004, CANCER EPIDEM BIOMAR, V13, P2187&#xD;
                    CHLEBOWSKI RT, 2004, NEW ENGL J MED, V350, P991&#xD; COLBERT LH, 2001, CANCER
                    EPIDEM BIOMAR, V10, P265&#xD; COLDITZ GA, 1997, CANCER CAUSE CONTROL, V8,
                    P649&#xD; COX DR, 1972, J ROY STAT SOC B MET, V34, P187&#xD; EVERSON GT, 1991, J
                    CLIN INVEST, V87, P237&#xD; FRIEDENREICH CM, 2001, CANCER EPIDEM BIOMAR, V10,
                    P287&#xD; FRIEDENREICH CM, 2002, J NUTR, V132, P3456&#xD; GARABRANT DH, 1984, AM
                    J EPIDEMIOL, V119, P1005&#xD; GIOVANNUCCI E, 2001, J NUTR, V131, P3109&#xD;
                    GRODSTEIN F, 1998, ANN INTERN MED, V128, P705&#xD; GRODSTEIN F, 1999, AM J MED,
                    V106, P574&#xD; HEALD A, 2005, GYNECOL ENDOCRINOL, V20, P176&#xD; HEBERTCROTEAU
                    N, 1998, CANCER EPIDEM BIOMAR, V7, P653&#xD; HERSH AL, 2004, JAMA-J AM MED
                    ASSOC, V291, P47&#xD; HOFVIND S, 2006, INT J CANCER, V118, P3112&#xD; HORNROSS
                    PL, 2002, CANCER CAUSE CONTROL, V13, P407&#xD; JANNE PA, 2000, NEW ENGL J MED,
                    V342, P1960&#xD; KAMPMAN E, 1997, CANCER CAUSE CONTROL, V8, P146&#xD; KIM N,
                    2005, J GEN INTERN MED, V20, P1026&#xD; KWONG S, 2001, CANC CALIFORNIA 1988&#xD;
                    MARTINEZ ME, 1997, J NATL CANCER I, V89, P948&#xD; NILSEN TIL, 2001, BRIT J
                    CANCER, V84, P417&#xD; PRIHARTONO N, 2000, CANCER EPIDEM BIOMAR, V9, P443&#xD;
                    REDDY BS, 1977, CANCER, V39, P2533&#xD; ROSS RK, 2000, J NATL CANCER I, V92,
                    P328&#xD; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY&#xD; SCHAIRER C, 2000, JAMA-J AM
                    MED ASSOC, V283, P485&#xD; SLATTERY ML, 2002, MED SCI SPORT EXER, V34, P913&#xD;
                    SLATTERY ML, 2003, CANCER CAUSE CONTROL, V14, P75&#xD; STRUL H, 2006, AM J
                    GASTROENTEROL, V101, P255&#xD; TANG RP, 1999, INT J CANCER, V82, P484&#xD;
                    THERNEAU TM, 1996, EXTENDING COX MODEL&#xD; THOMAS ML, 1993, ENDOCRINOLOGY,
                    V132, P426&#xD; THUNE I, 1996, BRIT J CANCER, V73, P1134&#xD; TOMEO CA, 1999,
                    CANCER CAUSE CONTROL, V10, P167&#xD; WEISSFELD JL, 2005, J NATL CANCER I, V97,
                    P989&#xD; WINAWER SJ, 1997, GASTROENTEROLOGY, V112, P594&#xD; WINAWER SJ, 2005,
                    SURG ONCOL CLIN N AM, V14, P699&#xD; WITTE D, 2001, HUM PATHOL, V32, P940&#xD;
                    WU AH, 1987, BRIT J CANCER, V55, P687&#xD; WU XC, 2006, CANCER S, V107,
                    P1121&#xD; YOUNG JL, 2000, PU BNIH&#xD; YU H, 2000, J NATL CANCER I, V92,
                    P1472&#xD; ZARIDZE DG, 1983, J NATL CANCER I, V70, P389</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245093900027 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>759</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">759</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1254</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Majhail, N. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ness, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burns, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Francisco, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baker, K. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Minnesota, Div Hematol Oncol
                    &amp; Transplantat, Blood &amp; Marrow Tranplant Program, Dept Med, Minneapolis,
                    MN 55455 USA. Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA. St Jude
                    Childrens Hosp, Dept Epidemiol &amp; Canc Control, Memphis, TN 38105 USA. City
                    Hope Natl Med Ctr, Div Populat Sci, Duarte, CA 91010 USA. City Hope Natl Med
                    Ctr, Div Hematol &amp; Hematopoiet Cell Transplantat, Duarte, CA 91010
                    USA.&#xD;Majhail, NS, Univ Minnesota, Div Hematol Oncol &amp; Transplantat,
                    Blood &amp; Marrow Tranplant Program, Dept Med, 420 Delware St SE,MMC 480,
                    Minneapolis, MN 55455 USA.&#xD;majha001@dmn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Late effects in survivors of
                        Hodgkin and non-hodgkin lymphoma treated with autologous hematopoietic cell
                        transplantation: A report from the bone marrow transplant survivor
                        study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1153-1159</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">autologous hematopoietic cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hodgkin lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">non-Hodgkin lymphoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">late complications</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINERAL DENSITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RISK-FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FOLLOW-UP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLICATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORTALITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250103400004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We determined the prevalence of
                    self-reported late-effects in survivors of autologous hematopoictic cell
                    transplantation (HCT) for Hodgkin lymphoma (HL, n = 92) and non-Hodgkin lymphoma
                    (NHL, n = 184) using a 255-item questionnaire and compared them to 319 sibling
                    controls in the Bone Marrow Transplant Survivor Study. Median age at HCT was 39
                    years (range: 13-69) and median posttransplant follow-up was 6 years (range:
                    2-17). Median age at survey was 46 years (range: 21-73) for survivors and 44
                    years (range: 19-79) for siblings. Compared to siblings, HCT survivors reported
                    a significantly higher frequency of cataracts, dry mouth, hypothyroidism, bone
                    impairments (osteoporosis and avascular necrosis), congestive heart failure,
                    exercise-induced shortness of breath, neurosensory impairments, inability to
                    attend work or school, and poor overall health. Compared to those receiving no
                    total-body irradiation (TBI), patients treated with TBI-based conditioning had
                    higher risks of cataracts (odds-ratio [OR] 4.9, 95% confidence interval [CI]
                    1.5-15.5) and dry mouth (OR 3.4,95% CI 1.1-10.4). Females had a greater
                    likelihood of reporting osteoporosis (OR 8.7,95% CI: 1.8-41.7), congestive heart
                    failure (OR 4.3, 95% CI 1.1-17.2), and abnormal balance, tremor, or weakness (OR
                    2.4, 95% CI 1.0-5.5). HL and NHL survivors of autologous HCT have a high
                    prevalence of long-term health-related complications and require continued
                    monitoring for late effects of transplantation. (C) 2007 American Society for
                    Blood and Marrow Transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    219RX&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; ALEMAN BMP, 2003, J CLIN ONCOL, V21, P3431&#xD; ALEMAN BMP, 2007, BLOOD,
                    V109, P1878&#xD; ANDRYKOWSKI MAA, 2005, J CLIN ONCOL, V23, P599&#xD; BAKER KS,
                    2004, BLOOD, V104, P1898&#xD; BHATIA S, 2005, BLOOD, V105, P4215&#xD;
                    BRUSAMOLINO E, 2006, CLIN CANCER RES, V12, P6487&#xD; GANDHI MK, 2003, BRIT J
                    HAEMATOL, V121, P462&#xD; HANCOCK SL, 1993, J CLIN ONCOL, V11, P1208&#xD; HULL
                    MC, 2003, JAMA-J AM MED ASSOC, V290, P2831&#xD; JOSTING A, 2003, J CLIN ONCOL,
                    V21, P3440&#xD; KOONTZ BF, 2006, J CLIN ONCOL, V24, P605&#xD; KRISHNAN A, 2000,
                    BLOOD, V95, P1588&#xD; LAVOIE JC, 2005, BLOOD, V106, P1473&#xD; LEE SJ, 2001, J
                    CLIN ONCOL, V19, P242&#xD; LENZ G, 2004, J CLIN ONCOL, V22, P4926&#xD; LIKERT
                    RA, 1932, ARCH PSYCHOL, V140, P55&#xD; LOUIE AD, 2000, BONE MARROW TRANSPL, V25,
                    P1191&#xD; METAYER C, 2003, BLOOD, V101, P2015&#xD; MOSER EC, 2005, CLIN
                    LYMPHOMA MYELOM, V6, P122&#xD; MOSER EC, 2006, BLOOD, V107, P2912&#xD; NG AK,
                    2002, BLOOD, V100, P1989&#xD; NG AK, 2002, J CLIN ONCOL, V20, P2101&#xD; RIZZO
                    JD, 2006, BIOL BLOOD MARROW TR, V12, P138&#xD; ROBISON LL, 2002, MED PEDIATR
                    ONCOL, V38, P229&#xD; RUIZSOTO R, 2005, CANCER, V104, P2735&#xD; SCHIMMER AD,
                    2001, BONE MARROW TRANSPL, V28, P387&#xD; SYRJALA KL, 2004, JAMA-J AM MED ASSOC,
                    V291, P2335&#xD; ZEGER SL, 1986, BIOMETRICS, V42, P121</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250103400004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>705</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">705</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1252</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Malloy, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sumner, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Virani, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">AACN, Washington, DC USA. Elisabeth
                    Hosp, Escondido, CA USA. City Hope Natl Med Ctr, ELNEC, Duarte, CA 91010
                    USA.&#xD;Malloy, P, AACN, Washington, DC USA.&#xD;pmalloy@aacn.nche.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">End-of-life nursing education
                        consortium for pediatric palliative care (ELNEC-PPC)</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Mcn-the American Journal of
                        Maternal-Child Nursing</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">298-302</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">32</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">nursing</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pediatric</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">palliative care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">education</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep-Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0361-929X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249318600007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Pediatric nurses must often care for
                    children with life-threatening illness. Although the child may be a neonate with
                    multiple organ failure, a young adolescent diagnosed with HIV, or a 7-year-old
                    child involved in a serious bicycle accident, pediatric nurses are an essential
                    part of the interdisciplinary team that plans, organizes, implements and manages
                    the care of these children and their families. To date, more than 600 pediatric
                    nurses have attended a national End-of-Life Nursing Education
                    Consortium-Pediatric Palliative Care (ELNEC-PPC) training program. Many of these
                    nurses have returned to their institutions dedicated to making a difference in
                    the palliative care provided to children and their families. Because pediatric
                    palliative care education is so important, many trainers have incorporated
                    ELNEC-PPC into their nursing orientation, annual competencies, and undergraduate
                    and graduate nursing education. They are developing standards of care and serve
                    on key hospital/hospice committees such as police education, clinical care, and
                    ethics committees. This article showcases various activities of ELNEC-PPC
                    trainers and demonstrates their commitment to improve pediatric palliative care
                    not only in their institutions but also on local, state, national, and
                    international levels.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    208KQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 9&#xD;Cited References:
                    &#xD; *AACN, 1997, PEAC DEATH REC COMP&#xD; *ELNEC PPC, 2005, CURR PROV GRANT
                    AETN&#xD; DABBS D, 2007, MCN-AM J MATERN-CHIL, V32, P311&#xD; FERRELL B, 1999,
                    ONCOLOGY NURSING FOR, V26, P869&#xD; FERRELL BR, 1999, NURS OUTLOOK, V47,
                    P252&#xD; FERRELL BR, 2006, TXB PALLIATIVE NURSI&#xD; FIELD MJ, 2003, CHILDREN
                    DIE IMPROVI&#xD; GOLDMAN A, 1999, CARE DYING CHILD&#xD; HIMELSTEIN BP, 2006, J
                    PALLIAT MED, V9, P163</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249318600007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>633</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">633</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1249</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Margolin, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lara, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frankel, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lacey, S. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Quinn, D. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baratta, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dutcher, J. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xi, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gandara, D. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Med
                    Oncol, Duarte, CA 91010 USA. Univ Calif Davis, Davis, CA 95616 USA. City Hope
                    Natl Med Ctr, Div Informat Sci, Duarte, CA 91010 USA. City Hope Natl Med Ctr,
                    Lab Vaccine Res, Duarte, CA 91010 USA. USC, Norris Comprehens Canc Ctr, Los
                    Angeles, CA USA. Our Lady Mercy Med Ctr, Bronx, NY USA.&#xD;Margolin, K, City
                    Hope Natl Med Ctr, Div Med Oncol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;cabrown@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Oblimersen and alpha-interferon
                        in metastatic renal cancer: a phase II study of the California Cancer
                        Consortium</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Cancer Research and
                        Clinical Oncology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Cancer Res. Clin.
                        Oncol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Cancer Research and
                        Clinical Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Cancer Res. Clin.
                        Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Cancer Res Clin Oncol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Cancer Research and
                        Clinical Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Cancer Res. Clin.
                        Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Cancer Res Clin Oncol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">705-711</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">133</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">oblimersen</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G3139</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">alpha-Interferon</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">renal cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BCL-2 ANTISENSE
                        OLIGONUCLEOTIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REFRACTORY
                        PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-PRODUCT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SODIUM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G3139</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEUKEMIA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0171-5216</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249008700004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose Oblimersen is an 18-base
                    oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic
                    protein that is upregulated in renal and other cancers. This study was designed
                    to evaluate the combination of oblimersen with alpha-Interferon in advanced
                    renal cancer. Trial endpoints were antitumor efficacy and toxicity,
                    pharmacokinetics, and evidence of apoptosis in peripheral blood mononuclear
                    cells. Methods Patients with measurable advanced renal cancer and 0-1 prior
                    therapy were eligible. Treatment consisted of oblimersen, 7 mg/kg/day, as a
                    continuous intravenous infusion 7 days of every 14 day cycle, plus alpha-IFN, 5
                    million units/m(2)supercript stop subcutaneously, days 4 and 6 of the first
                    oblimersen infusion, then thrice weekly. Blood for laboratory correlates was
                    collected before treatment, during oblimersen, and during therapy with both
                    agents. Results Twenty-three patients were enrolled, five of whom had prior
                    systemic therapy (three with prior high-dose interleukin-2). The median number
                    of treatment cycles was 4 (range 1-12). One patient had a partial response
                    lasting 2.5 months. The Grade 3-4 toxicities were fatigue, fever,
                    myelosuppression, hepatic enzyme and metabolic abnormalities. Laboratory
                    analyses of CD3+ lymphocyte apoptotic markers demonstrated no change between
                    pre-treatment and on-treatment levels of bcl-2 or Annexin/PI positivity by flow
                    cytometry. Mean oblimersen steady-state plasma concentration and clearance was
                    2.3 +/- 0.9 mu g/ml and 0.15 +/- 0.07 l/h/kg, respectively. Conclusions
                    Oblimersen given in this dose and schedule with alpha-IFN does not appear
                    sufficiently active to warrant further study in advanced renal cancer.
                    Combinations with newer targeted agents may show greater promise.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    203YA&#xD;Times Cited: 0&#xD;Cited Reference Count: 33</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249008700004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>707</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">707</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1248</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Marsh, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frankel, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">King, C. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shannon, W. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McLeod, H. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Washington Univ, Sch Med, St Louis,
                    MO 63110 USA. Siteman Canc Ctr, St Louis, MO USA. City Hope Comprehensive Canc
                    Ctr, Dept Med Oncol &amp; Therapeut Res, Duarte, CA USA. City Hope Comprehensive
                    Canc Ctr, Div Informat Sci, Duarte, CA USA.&#xD;Marsh, S, Washington Univ, Sch
                    Med, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110
                    USA.&#xD;smarsh@im.wustl.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Pharmacogenetic analysis of
                        paclitaxel transport and metabolism genes in breast cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pharmacogenomics Journal</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Pharmacogenomics J.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pharmacogenomics Journal</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pharmacogenom. J.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pharmacogenom J</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">362-365</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pharmacogenetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">paclitaxel</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">polymorphism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYP1B1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN LIVER-MICROSOMES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN CYP1B1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOCHROME-P450</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYP1B1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTER VARIANT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P-GLYCOPROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYMORPHISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1470-269X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249866600011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Paclitaxel is commonly used in the
                    treatment of breast cancer. Variability in paclitaxel clearance may contribute
                    to the unpredictability of clinical outcomes. We assessed genomic DNA from the
                    plasma of 93 patients with high-risk primary or stage IV breast cancer, who
                    received dose-intense paclitaxel, doxorubicin and cyclophosphamide. Eight
                    polymorphisms in six genes associated with metabolism and transport of
                    paclitaxel were analyzed using Pyrosequencing. We found no association between
                    ABCB1, ABCG2, CYP1B1, CYP3A4, CYP3A5 and CYP2C8 genotypes and paclitaxel
                    clearance. However, patients homozygous for the CYP1B1*3 allele had a
                    significantly longer progression-free survival than patients with at least one
                    Valine allele (P = 0.037). This finding could reflect altered paclitaxel
                    metabolism, however, the finding was independent of paclitaxel clearance.
                    Alternatively, the role of CYP1B1 in estrogen metabolism may influence the risk
                    of invasive or paclitaxel resistant breast cancer in patients carrying the
                    CYP1B1*3 allele.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    216GN&#xD;Times Cited: 0&#xD;Cited Reference Count: 44</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249866600011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>825</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">825</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1244</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">McCaffery, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pasero, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Duarte, CA
                    91010 USA.&#xD;McCaffery, M, City Hope Natl Med Ctr, Duarte, CA 91010
                    USA.&#xD;margopain@aol.com cpasero@aol.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Nurses&apos; decisions about
                        opioid dose</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Nursing</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">35-39</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">107</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE PAIN MANAGEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ATTITUDES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KNOWLEDGE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-936X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251303800025</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    236LF&#xD;Times Cited: 0&#xD;Cited Reference Count: 12&#xD;Cited References:
                    &#xD; *AM PAIN SOC, 2003, PRINC AN US TREATM A&#xD; *AM PAIN SOC, 2005, GUID MAN
                    CANC PAIN A&#xD; APFELBAUM JL, 2003, ANESTH ANALG, V97, P534&#xD; GORDON DB,
                    2002, PAIN MANAG NURS, V3, P116&#xD; KATSMA DL, 2000, PAIN MANAGEMENT NURS, V1,
                    P88&#xD; LABUS JS, 2003, PAIN, V102, P109&#xD; MARKS RM, 1973, ANN INTERN MED,
                    V78, P173&#xD; MCCAFFERY M, 1997, J PAIN SYMPTOM MANAG, V14, P175&#xD; MCCAFFERY
                    M, 2000, PAIN MANAG NURS, V1, P79&#xD; PASERO C, 2007, AM J NURS, V107, P52&#xD;
                    PLAISANCE L, 2006, PAIN MANAG NURS, V7, P167&#xD; WARFIELD CA, 1995,
                    ANESTHESIOLOGY, V83, P1090</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251303800025 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>399</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">399</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1239</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Meyer, D. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bailis, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div Mol
                    Biol, Duarte, CA 91010 USA. City Hope Grad Sch Biol Sci, Duarte, CA 91010
                    USA.&#xD;Bailis, AM, Beckman Res Inst City Hope, Div Mol Biol, 1450 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;abailis@bricoh.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Telomere dysfunction drives
                        increased mutation by error-prone polymerases rev1 and zeta in Saccharomyces
                        cerevisiae</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1533-1537</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">175</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">GROSS CHROMOSOMAL
                        REARRANGEMENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSLESION SYNTHESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-POLYMERASES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPLICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RECOMBINATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INSTABILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FIDELITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTANTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ROLES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">YEAST</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0016-6731</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245590600045</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Using a model system, we have shown
                    that replicative senescence is accompanied by a 16-fold increase in base
                    substitution and frameshift mutations near a chromosome end. The increase was
                    dependent on error-prone polymerases required for the mutagenic response to DNA
                    lesions that block the replication fork.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    155PO&#xD;Times Cited: 0&#xD;Cited Reference Count: 22&#xD;Cited References:
                    &#xD; CHEN C, 1999, NAT GENET, V23, P81&#xD; COUNTER CM, 1997, P NATL ACAD SCI
                    USA, V94, P9202&#xD; DUBOIS ML, 2002, GENETICS, V161, P995&#xD; GOODMAN MF,
                    2002, ANNU REV BIOCHEM, V71, P17&#xD; HACKETT JA, 2001, CELL, V106, P275&#xD;
                    HACKETT JA, 2003, MOL CELL BIOL, V23, P8450&#xD; HARACSKA L, 2000, NAT GENET,
                    V25, P458&#xD; JOHNSON RE, 1999, SCIENCE, V285, P263&#xD; JOHNSON RE, 2000, J
                    BIOL CHEM, V275, P7447&#xD; LEA DE, 1949, J GENET, V49, P264&#xD; LEHMANN AR,
                    2005, FEBS LETT, V579, P873&#xD; LENDVAY TS, 1996, GENETICS, V144, P1399&#xD;
                    LENGAUER C, 1998, NATURE, V396, P643&#xD; LURIA SE, 1943, GENETICS, V28,
                    P491&#xD; MINESINGER BK, 2005, GENETICS, V169, P1939&#xD; MOTEGI A, 2006, MOL
                    CELL BIOL, V26, P1424&#xD; MYUNG K, 2001, NATURE, V411, P1073&#xD; PENNANEACH V,
                    2004, NAT GENET, V36, P612&#xD; PLOSKY BS, 2004, CURR OPIN GENET DEV, V14,
                    P113&#xD; PRAKASH S, 2005, ANNU REV BIOCHEM, V74, P317&#xD; QUAH SK, 1980,
                    GENETICS, V96, P819&#xD; RATTRAY AJ, 2002, GENETICS, V162, P1063</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245590600045 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>433</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">433</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1236</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Miao, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, X. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, L. X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, Y. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Dept
                    Diabet, Duarte, CA 91010 USA. Beckman Res Inst City Hope, Dept Biomed Informat,
                    Duarte, CA 91010 USA. Beckman Res Inst City Hope, Dept Biol, Duarte, CA 91010
                    USA.&#xD;Natarajan, R, Beckman Res Inst City Hope, Dept Diabet, 1500 E Duarte
                    Rd, Duarte, CA 91010 USA.&#xD;RNatarajan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Genome-wide analysis of histone
                        lysine methylation variations caused by diabetic conditions in human
                        monocytes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">13854-13863</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">18</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CPG ISLANDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CODING REGIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVE GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">END-PRODUCTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">H3 LYSINE-9</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATTERNS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLICATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMATIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246060300075</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Aberrant histone lysine methylation
                    patterns that change chromatin structure can promote dysregulated gene
                    transcription and disease progression. Diabetic conditions such as high glucose
                    (HG) are known to alter key pathologic pathways. However, their impact on
                    cellular histone lysine methylation is unknown. We hypothesized that chronic HG
                    can induce aberrant changes in histone H3 lysine 4 and lysine 9 dimethylation
                    (H3K4me2 and H3K9me2) within target cells. Chromatin immunoprecipitation linked
                    to microarrays (ChIP-on-chip) is currently a widely used approach for acquiring
                    genome-wide information on histone modifications. We adopted this approach to
                    profile and compare the variations in H3K4me2 and H3K9me2 in human gene coding
                    and CpG island regions in THP-1 monocytes cultured in normal glucose and HG.
                    Subsequently, we identified key relevant candidate genes displaying differential
                    changes in H3K4me2 and H3K9me2 in HG versus normal glucose and also validated
                    them with follow-up conventional ChIPs. Relevance to human diabetes was
                    demonstrated by noting that H3K9me2 at the coding and promoter regions of two
                    candidate genes was significantly greater in blood monocytes of diabetic
                    patients relative to normal controls similar to the THP-1 data. In addition,
                    regular mRNA profiling with cDNA arrays revealed correlations between mRNA and
                    H3K9me2 levels. These novel results show histone methylation variations, for the
                    first time, under diabetic conditions at a genome-wide level.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    162BC&#xD;Times Cited: 0&#xD;Cited Reference Count: 43&#xD;Cited References:
                    &#xD; BAYNES JW, 1991, DIABETES, V40, P405&#xD; BERNSTEIN BE, 2002, P NATL ACAD
                    SCI USA, V99, P8695&#xD; BERNSTEIN BE, 2005, CELL, V120, P169&#xD; BROWNLEE M,
                    1988, NEW ENGL J MED, V318, P1315&#xD; BROWNLEE M, 2001, NATURE, V414, P813&#xD;
                    CROSS SH, 1994, NAT GENET, V6, P236&#xD; FRAGA MF, 2005, NAT GENET, V37,
                    P391&#xD; GENTLEMAN RC, 2004, GENOME BIOL, V5&#xD; HARBISON CT, 2004, NATURE,
                    V431, P99&#xD; HEISLER LE, 2005, NUCLEIC ACIDS RES, V33, P2952&#xD; HUANG THM,
                    1999, HUM MOL GENET, V8, P459&#xD; ISHII H, 1998, J MOL MED-JMM, V76, P21&#xD;
                    KLIPPERAURBACH Y, 1995, MED HYPOTHESES, V45, P486&#xD; KLOSE RJ, 2006, NATURE,
                    V442, P312&#xD; KURDISTANI SK, 2004, CELL, V117, P721&#xD; LIEB JD, 2001, NAT
                    GENET, V28, P327&#xD; LITT MD, 2001, SCIENCE, V293, P2453&#xD; MIAO F, 2004, J
                    BIOL CHEM, V279, P18091&#xD; MIAO F, 2005, MOL CELL BIOL, V25, P4650&#xD; MILLAR
                    CB, 2006, NAT REV MOL CELL BIO, V7, P657&#xD; NISHIKAWA T, 2000, NATURE, V404,
                    P787&#xD; NOMA K, 2001, SCIENCE, V293, P1150&#xD; PENA PV, 2006, NATURE, V442,
                    P100&#xD; POLLACK JR, 1999, NAT GENET, V23, P41&#xD; REN B, 2000, SCIENCE, V290,
                    P2306&#xD; RUDERMAN NB, 1992, FASEB J, V6, P2905&#xD; SCHENA M, 1995, SCIENCE,
                    V270, P467&#xD; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521&#xD; SCHNEIDER
                    R, 2004, NAT CELL BIOL, V6, P73&#xD; SCHUBELER D, 2004, GENE DEV, V18,
                    P1263&#xD; SHANMUGAM N, 2003, DIABETES, V52, P1256&#xD; SHI XB, 2006, NATURE,
                    V442, P96&#xD; SIMS RJ, 2003, TRENDS GENET, V19, P629&#xD; SIMS RJ, 2006, GENE
                    DEV, V20, P2779&#xD; SMYTH GK, 2004, STAT APPL GENET MOL, V3&#xD; STEFFES MW,
                    2003, JAMA-J AM MED ASSOC, V290, P2159&#xD; STRAHL BD, 2000, NATURE, V403,
                    P41&#xD; TAMARU H, 2001, NATURE, V414, P277&#xD; VAKOC CR, 2005, MOL CELL, V19,
                    P381&#xD; VANSTEENSEL B, 2005, NAT GENET S, V37, S18&#xD; WERMAN A, 2004, P NATL
                    ACAD SCI USA, V101, P2434&#xD; WHETSTINE JR, 2006, CELL, V125, P467&#xD; ZHANG
                    Y, 2001, GENE DEV, V15, P2343</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246060300075 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>761</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">761</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1234</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Mitchell, K. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawl, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schmidt, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ko, C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baldwin, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wendel, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krouse, R. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Purdue Univ, Indiana Univ, Sch
                    Nursing, Indianapolis, IN USA. St Francis Med Ctr, Coll Nursing, Peoria, IL USA.
                    Ctr Nursing Res, Indianapolis, IN USA. Richard L Roudebush Vet Affairs Med Ctr,
                    Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Biochem &amp; Mol Biol,
                    Indianapolis, IN 46204 USA. City Hope Natl Med Ctr, Dept Nursing Res &amp; Educ,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010
                    USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los
                    Angeles, Los Angeles, CA USA. Arizona State Univ, SW Borderlands, Coll Nursing,
                    Phoenix, AZ USA. So Arizona VA Hlth Care Syst, Tucson, AZ USA. Univ Arizona,
                    Tucson, AZ USA.&#xD;Krouse, RS, 511 NE Greenleaf, Peoria, IL 61603
                    USA.&#xD;kamitch@insightbb.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Demographic, clinical, and
                        quality of life variables related to embarrassment in veterans living with
                        an intestinal stoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Wound Ostomy and
                        Continence Nursing</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">524-532</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RECTAL-CANCER PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGERY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ILEOSTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLOSTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BODY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep-Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1071-5754</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249844100014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVE: The study aims were to
                    identify demographic, clinical, and quality of life variables related to
                    embarrassment for people living with ostomies and to determine the experiences
                    and/or feelings of veterans who were embarrassed by their ostomy. DESIGN: This
                    was a cross-sectional, correlational study. SETTING AND SUBJECTS: A convenience
                    sample of veterans (n = 239) living with ostomies from 3 VA medical centers was
                    studied. The veterans were primarily Caucasian (84%), male (92%), and older (M =
                    69). INSTRUMENTS: The modified City of Hope Quality of Life-Ostomy questionnaire
                    was used. Additionally, an open-ended question related to living with an ostomy
                    was asked. METHODS: The questionnaire packets were mailed to participants and
                    self-administered. RESULTS: Approximately half of the participants (48%) rated
                    their embarrassment as low, but 26% reported high embarrassment. Participants
                    with high embarrassment were compared to those with low embarrassment on
                    demographic, clinical, and quality of life variables. High embarrassment was
                    associated with poorer total quality of life (P &lt; .001) and poorer quality of
                    life on the physical (P &lt; .001), psychological (P &lt; .001), social (P &lt;
                    .001), and spiritual (P &lt; .001) subscales. Younger (P &lt; .001) and
                    unpartnered veterans (P &lt; .001) were more likely to be highly embarrassed.
                    Veterans with high embarrassment had higher anxiety (P &lt; .001) and depression
                    (P &lt; .001), more difficulty with intimacy (P &lt; .001), and felt more
                    isolated (P &lt; .001). Spiritual domain variables like hopefulness were
                    associated with low embarrassment (P &lt; .001). Sources of embarrassment
                    included leakage, odor, and noise. CONCLUSIONS: Embarrassment may negatively
                    impact a person&apos;s quality of life; therefore, the variables associated with
                    high embarrassment should be recognized and addressed.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    215YE&#xD;Times Cited: 0&#xD;Cited Reference Count: 26&#xD;Cited References:
                    &#xD; *AM CANC SOC, 2005, CANC FACTS FIG 2005, P12&#xD; *CROHNS COL FDN AM, ANN
                    REP 2004 PAT ED&#xD; *UN OST ASS AM, OST INF&#xD; *US DEP VET AFF, 2003, 2001
                    NAT SURV VET&#xD; BERNDTSSON I, 2005, J WOUND OSTOMY CONT, V32, P321&#xD;
                    CARLSSON E, 2003, SCAND J GASTROENTERO, V38, P978&#xD; DEVILLIS RF, 2006, SCALE
                    DEV THEORY APP, P95&#xD; GRANT M, 2004, QUAL LIFE RES, V13, P1445&#xD; HAMASHIMA
                    C, 2002, J GASTROEN HEPATOL, V17, P571&#xD; HENDREN SK, 2005, ANN SURG, V242,
                    P212&#xD; HOLZER B, 2005, DIS COLON RECTUM, V48, P2209&#xD; JESS P, 2002, SCAND
                    J GASTROENTERO, V37, P1201&#xD; KELLY M, 1992, SOCIOLOGY HLTH ILLNE, V14,
                    P390&#xD; KROUSE RS, 2006, CURR MED RES OPIN, V22, P781&#xD; MANDERSON L, 2005,
                    SOC SCI MED, V61, P405&#xD; MCVEY J, 2001, BRIT J CLIN PSYCHO 4, V40, P337&#xD;
                    MODIGLIANI A, 1968, SOCIOMETRY, V31, P313&#xD; NORTON C, 2005, DIS COLON RECTUM,
                    V48, P1062&#xD; NUGENT KP, 1999, DIS COLON RECTUM, V42, P1569&#xD; PADILLA GV,
                    1990, CANCER NURS, V13, P108&#xD; PERSSON E, 2002, J WOUND OSTOMY CONTI, V29,
                    P103&#xD; PIWONKA MA, 1999, J WOUND OSTOMY CONT, V26, P298&#xD; ROZMOVITS L,
                    2004, QUAL HEALTH RES, V14, P187&#xD; SALTER MJ, 1992, J ADV NURS, V17,
                    P841&#xD; SERLIN RC, 1995, PAIN, V61, P227&#xD; SPILKER B, 1996, QUALITY LIFE
                    ASSESSM</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249844100014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>323</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">323</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1233</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Mobley, P. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barry, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waring, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gordon, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Calif State Polytech Univ Pomona,
                    Dept Chem, Pomona, CA 91768 USA. Univ Calif Los Angeles, Dept Med, Los Angeles,
                    CA 90095 USA. Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Inst
                    Harbor, Torrance, CA 90502 USA. City Hope Natl Med Ctr, Dept Biomed Informat,
                    Duarte, CA 91010 USA.&#xD;Mobley, PW, Calif State Polytech Univ Pomona, Dept
                    Chem, 3801 W Temple Ave, Pomona, CA 91768
                    USA.&#xD;pwmobley@csupomona.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Membrane perturbing actions of
                        HIV type 1 glycoprotein 41 domains are inhibited by helical
                        C-peptides</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Aids Research and Human
                        Retroviruses</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">AIDS Research and Human
                        Retroviruses</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">AIDS Res. Hum.
                        Retroviruses</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">AIDS Res Hum
                        Retroviruses</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">224-242</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">23</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >HUMAN-IMMUNODEFICIENCY-VIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMINO-TERMINAL PEPTIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODY 2F5</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSFORM
                        INFRARED-SPECTROSCOPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUSION-ACTIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONFORMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSMEMBRANE PROTEIN
                        GP41</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRYPTOPHAN-RICH REGION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENV-MEDIATED FUSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-CELL FUSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENVELOPE GLYCOPROTEIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0889-2229</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245030500006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">To study the membrane actions of
                    various domains of HIV-1 glycoprotein 41,000 (gp41), synthetic peptides were
                    prepared corresponding to the N-terminal fusion region ( FP; gp41 residues 519 -
                    541), the nearby N-leucine zipper domain (N-peptides; DP-107; gp41 residues 560
                    - 597), the C-leucine zipper domain (C-peptides; DP-178; gp41 residues 645 -
                    680), and the viral envelope adjacent domain that partially overlaps DP-178
                    (PreTM; gp41 residues 671 - 690). With erythrocytes, FP, DP-107, and Pre-TM
                    induced hemolysis and cell aggregation; the order for hemolytic activity was
                    Pre-TM &gt; FP &gt; DP-107, but each was equally effective in aggregating cells
                    at the highest peptide concentrations tested. DP- 178 produced neither hemolysis
                    nor aggregation, but efficiently reduced FP-, DP-107-, and Pre-TM-induced
                    membrane actions. Fourier transform infrared spectroscopy indicated that the
                    membrane perturbations of Pre-TM, as well as the ability of DP- 178 to block
                    membrane activities of other gp41 domains, are dependent on Pre-TM and DP-178
                    each maintaining helical conformations and tryptophans at residues 673, 677, and
                    679. These results suggest that the corresponding N-terminal fusion, N-leucine
                    zipper, and viral membrane-adjacent regions of HIV-1 gp41 may similarly promote
                    key membrane perturbations underlying the merging of the viral envelope with the
                    cell surface. Further, the antiviral mechanism of exogenous DP- 178 ( clinically
                    approved enfuvirtide) may be partially explained by its coordinate inhibition of
                    the fusogenic actions of the FP, DP- 107, and Pre-TM regions of gp41.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    147VJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 99&#xD;Cited References:
                    &#xD; ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900&#xD; ALOIA RC, 1993, P NATL
                    ACAD SCI USA, V90, P5181&#xD; ARRONDO JLR, 1999, PROG BIOPHYS MOL BIO, V72,
                    P367&#xD; BARBATO G, 2003, J MOL BIOL, V330, P1101&#xD; BIRON Z, 2002,
                    BIOCHEMISTRY-US, V41, P12687&#xD; BIRON Z, 2005, BIOCHEMISTRY-US, V44,
                    P13611&#xD; BRASSEUR R, 1988, AIDS RES HUM RETROV, V4, P83&#xD; BULLOUGH PA,
                    1994, NATURE, V371, P37&#xD; BYLER DM, 1986, BIOPOLYMERS, V25, P469&#xD; CAO J,
                    1993, J VIROL, V67, P2747&#xD; CARR CM, 1993, CELL, V73, P823&#xD; CHAN DC,
                    1997, CELL, V89, P263&#xD; CHAN DC, 1998, CELL, V93, P681&#xD; CHANG DK, 1997, J
                    VIROL, V71, P6593&#xD; CHANG DK, 1999, J BIOL CHEM, V274, P5299&#xD; CHANG DK,
                    1999, J STRUCT BIOL, V128, P270&#xD; CHANG DK, 2001, J PEPT RES, V57, P234&#xD;
                    CHEN SSL, 1993, J VIROL, V67, P3615&#xD; CHEN SSL, 1994, J VIROL, V68,
                    P2002&#xD; CONSONNI R, 1996, BIOPOLYMERS, V38, P423&#xD; DIMITROV AS, 2001, J
                    BIOL CHEM, V276, P30335&#xD; DIMITROV AS, 2003, BIOCHEMISTRY-US, V42,
                    P14150&#xD; DUBAY JW, 1992, J VIROL, V66, P4748&#xD; EGELHOFER M, 2004, J VIROL,
                    V78, P568&#xD; EISENBERG D, 1990, BIOPOLYMERS, V29, P171&#xD; EPAND RF, 2005,
                    BIOCHEMISTRY-US, V44, P5525&#xD; FERNANDEZ A, 2003, P NATL ACAD SCI USA, V100,
                    P2391&#xD; FUJII G, 1992, PROTEIN SCI, V1, P1454&#xD; FURUTA RA, 1998, NAT
                    STRUCT BIOL, V5, P276&#xD; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431&#xD;
                    GALLO SA, 2003, BBA-BIOMEMBRANES, V1614, P36&#xD; GORDON LM, 1988, BIOCHIM
                    BIOPHYS ACTA, V943, P331&#xD; GORDON LM, 1992, BIOCHIM BIOPHYS ACTA, V1139,
                    P257&#xD; GORDON LM, 1993, AIDS RES HUM RETROV, V9, P1145&#xD; GORDON LM, 1995,
                    AIDS RES HUM RETROV, V11, P677&#xD; GORDON LM, 2002, BBA-BIOMEMBRANES, V1559,
                    P96&#xD; GORDON LM, 2004, PROTEIN SCI, V13, P1012&#xD; HEIL ML, 2004, J VIROL,
                    V78, P7582&#xD; HILDINGER M, 2001, J VIROL, V75, P3038&#xD; JIANG SB, 1993,
                    BIOCHEM BIOPH RES CO, V195, P533&#xD; JIANG SB, 1993, NATURE, V365, P113&#xD;
                    JIANG SB, 2002, CURR PHARM DESIGN, V8, P563&#xD; JOHNSON WC, 1990,
                    PROTEIN-STRUCT FUNCT, V7, P214&#xD; JOYCE JG, 2002, J BIOL CHEM, V277,
                    P45811&#xD; KANYALKAR M, 2004, J PEPT SCI, V10, P363&#xD; KAZMIERSKI WM, 1996, J
                    MED CHEM, V39, P2681&#xD; KILBY JM, 1998, NAT MED, V4, P1302&#xD; KLIGER Y,
                    1997, J BIOL CHEM, V272, P13496&#xD; KLIGER Y, 2000, J MOL BIOL, V295, P163&#xD;
                    KLIGER Y, 2001, J BIOL CHEM, V276, P1391&#xD; KOENIG S, 1989, P NATL ACAD SCI
                    USA, V86, P2443&#xD; LAWLESS MK, 1996, BIOCHEMISTRY-US, V35, P13697&#xD; LIU SW,
                    2005, J BIOL CHEM, V280, P11259&#xD; LU M, 1995, NAT STRUCT BIOL, V2, P1075&#xD;
                    MARTIN I, 1996, J VIROL, V70, P298&#xD; MOBLEY PW, 1992, BIOCHIM BIOPHYS ACTA,
                    V1139, P251&#xD; MOBLEY PW, 1995, BBA-MOL BASIS DIS, V1271, P304&#xD; MOBLEY PW,
                    1999, BBA-BIOMEMBRANES, V1418, P1&#xD; MOBLEY PW, 2001, AIDS RES HUM RETROV,
                    V17, P311&#xD; MORENO MR, 2004, BBA-BIOMEMBRANES, V1661, P97&#xD; MORRIS KF,
                    2004, BBA-BIOMEMBRANES, V1667, P67&#xD; MUNOZBARROSO I, 1998, J CELL BIOL, V140,
                    P315&#xD; MUNOZBARROSO I, 1999, J VIROL, V73, P6089&#xD; MUSTER T, 1993, J
                    VIROL, V67, P6642&#xD; MYERS G, 1991, HUMAN RETROVIRUSES A, II81&#xD; NEURATH
                    AR, 1995, AIDS RES HUM RETROV, V11, P189&#xD; NEURATH AR, 1995, AIDS RES HUM
                    RETROV, V11, P687&#xD; OFEK G, 2004, J VIROL, V78, P10724&#xD; PARKER CE, 2001,
                    J VIROL, V75, P10906&#xD; PEISAJOVICH SG, 2003, J BIOL CHEM, V278, P21012&#xD;
                    PEREIRA FB, 1995, FEBS LETT, V362, P243&#xD; PEREIRA FB, 1997, AIDS RES HUM
                    RETROV, V13, P1203&#xD; PEREIRA FB, 1997, BIOPHYS J, V73, P1977&#xD;
                    PEREZALVAREZ L, 2006, J MED VIROL, V78, P141&#xD; QIAO ZS, 2005, J BIOL CHEM,
                    V280, P23138&#xD; RABENSTEIN M, 1995, BIOCHEMISTRY-US, V34, P13390&#xD;
                    RABENSTEIN MD, 1996, BIOCHEMISTRY-US, V35, P13922&#xD; RIMSKY LT, 1998, J VIROL,
                    V72, P986&#xD; SACKETT K, 2003, J MOL BIOL, V333, P47&#xD; SAEZCIRION A, 2002,
                    BBA-BIOMEMBRANES, V1564, P57&#xD; SAEZCIRION A, 2002, J BIOL CHEM, V277,
                    P21776&#xD; SAEZCIRION A, 2003, BIOPHYS J, V85, P3780&#xD; SALZWEDEL K, 1999, J
                    VIROL, V73, P2469&#xD; SANTOS NC, 1998, BIOCHEMISTRY-US, V37, P8674&#xD; SCHIBLI
                    DJ, 2001, BIOCHEMISTRY-US, V40, P9570&#xD; SHNAPER S, 2004, J BIOL CHEM, V279,
                    P18526&#xD; SHU W, 2000, BIOCHEMISTRY-US, V39, P1634&#xD; SHU W, 2000, J BIOL
                    CHEM, V275, P1839&#xD; SREERAMA N, 2000, ANAL BIOCHEM, V287, P252&#xD; SUAREZ T,
                    2000, FEBS LETT, V477, P145&#xD; SUAREZ T, 2000, J VIROL, V74, P8038&#xD; VEIGA
                    S, 2004, BIOCHEM J 1, V377, P107&#xD; VINCENT N, 2003, BIOCHIM BIOPHYS ACTA,
                    V1567, P157&#xD; WEISSENHORN W, 1997, NATURE, V387, P426&#xD; WILD C, 1992, P
                    NATL ACAD SCI USA, V89, P10537&#xD; WILD C, 1993, AIDS RES HUM RETROV, V9,
                    P1051&#xD; WILD C, 1995, AIDS RES HUM RETROV, V11, P323&#xD; WOODY RW, 1994, EUR
                    BIOPHYS J, V23, P253&#xD; YANG J, 2001, BIOCHEMISTRY-US, V40, P8126</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245030500006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>579</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">579</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1716</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Modi, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McDonald, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yee, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Hematopoietic Stem
                    Cell and Leukemia Research, Division of Hematology and Hematopoietic Cell
                    Transplantation (HCT), City of Hope National Medical Center, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Role of BCR/ABL gene-expression
                        levels in determining the phenotype and imatinib sensitivity of transformed
                        human hematopoietic cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5411-21</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line, Transformed</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Proliferation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Resistance,
                        Neoplasm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fusion Proteins, bcr-abl/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression Regulation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hematopoietic Stem Cells/
                        pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Phenotype</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Piperazines/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pyrimidines/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transduction, Genetic</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun 15</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17347407</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Increased levels of Bcr-Abl
                    expression in chronic myelogenous leukemia (CML) cells are associated with
                    disease progression and imatinib (IM) resistance. However, it is not clear if
                    these associations are a direct result of elevated Bcr-Abl expression. We used a
                    human transduction model of CML to directly investigate the role of varying
                    Bcr-Abl expression levels in determining the phenotype and IM sensitivity of
                    hematopoietic cells. CD34(+) cells were transduced with vectors coexpressing
                    Bcr-Abl and GFP, and cells expressing low and high levels of GFP and Bcr-Abl
                    (BA(lo) and BA(hi)) were selected. BA(hi) cells demonstrated enhanced activation
                    of downstream proliferative and antiapoptotic signaling and enhanced
                    proliferation and survival compared to BA(lo) cells. Freshly isolated BA(hi)
                    CD34(+) cells and cell lines demonstrated increased IM-mediated growth
                    inhibition likely reflecting Bcr-Abl dependence for growth and survival. CD34(+)
                    cells expressing BCR/ABL kinase-mutant genes demonstrated resistance to
                    IM-mediated inhibition of proliferation and viability, which was not enhanced by
                    increased expression of BCR/ABL kinase-mutant genes. We conclude that Bcr-Abl
                    overexpression results in increased proliferation and antiapoptotic signaling in
                    CD34(+) cells, but may not play a direct role in IM resistance in progenitor
                    cells expressing either wild-type or mutant BCR/ABL genes.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/09/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>381</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">381</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1231</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Mojica, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D. I.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Surg,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Informat Sci, Duarte, CA 91010
                    USA.&#xD;Ellenhorn, JDI, City Hope Natl Med Ctr, Div Surg, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;jellenhorn@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Adjuvant radiation therapy is
                        associated with improved survival in Merkel cell carcinoma of the
                        skin</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1043-1047</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SENTINEL LYMPH-NODE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRABECULAR CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MANAGEMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISSECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIOPSY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245348600007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose Merkel cell carcinoma (MCC)
                    is a rare cutaneous malignancy. Because of the absence of randomized studies,
                    the real benefit of adjuvant radiation therapy in MCC is unclear. The aim of
                    this study was to better define the role of adjuvant radiation therapy in the
                    management of MCC. Methods The Surveillance, Epidemiology, and End Results
                    (SEER) survey from the National Cancer Institute was queried from 1973 through
                    2002. Retrospective analysis was performed. The end point of the study was
                    overall survival. Results There were 1,665 cases of MCC in the SEER registry.
                    Presentation by stage were 55% stage I, 31% stage II, and 6% stage III. Eight
                    percent of the cases could not be staged because of incomplete data. Surgical
                    intervention was a component of therapy in 89% of the cases (n = 1,487). The
                    median survival for the entire cohort was 49 months, and median follow-up was 40
                    months. Adjuvant radiation was a component of therapy in 40% of the surgical
                    cases. The median survival for those patients receiving adjuvant radiation
                    therapy was 63 months compared with 45 months for those treated without adjuvant
                    radiation. The use of radiation was associated with an improved survival for
                    patients with all sizes of tumors, but the improvement with radiation use was
                    particularly prominent when analyzing those patients with primary lesions larger
                    than 2 cm. Conclusion The use of adjuvant radiation therapy is associated with
                    improved survival in patients with MCC. Prospective evaluation of adjuvant
                    radiation therapy in this setting is warranted.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    152GD&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; ALGHAZAL SK, 1996, BRIT J PLAST SURG, V49, P491&#xD; ALLEN PJ, 2005, J
                    CLIN ONCOL, V23, P2300&#xD; AMES SE, 1998, J SURG ONCOL, V67, P251&#xD; BOURNE
                    RG, 1988, AUST NZ J SURG, V58, P971&#xD; COIT DG, 2001, ANN SURG ONCOL, V8,
                    P99&#xD; EICH HT, 2002, AM J CLIN ONCOL-CANC, V25, P50&#xD; ENG TY, 2004, AM J
                    CLIN ONCOL-CANC, V27, P510&#xD; FRITZ A, 2004, INT CLASSIFICATION D&#xD;
                    GOESSLING W, 2002, J CLIN ONCOL, V20, P588&#xD; HERBST A, 2002, J AM ACAD
                    DERMATOL, V46, P640&#xD; HILL ADK, 1999, BRIT J SURG, V86, P518&#xD; HITCHCOCK
                    CL, 1988, ANN SURG, V207, P201&#xD; HODGSON NC, 2005, J SURG ONCOL, V89, P1&#xD;
                    KOLJONEN VS, 2006, WORLD J SURG ONCOL, V4, P7&#xD; LAWENDA BD, 2001, AM J CLIN
                    ONCOL-CANC, V24, P35&#xD; LEONARD JH, 1995, INT J RADIAT ONCOL, V32, P1401&#xD;
                    MARENDA SA, 1993, OTOLARYNG CLIN N AM, V26, P87&#xD; MEEUWISSEN JA, 1995, INT J
                    RADIAT ONCOL, V31, P325&#xD; MENDENHALL WM, 2004, LARYNGOSCOPE, V114, P906&#xD;
                    MESSINA JL, 1997, ANN SURG ONCOL, V4, P389&#xD; MORRISON WH, 1990, INT J RADIAT
                    ONCOL, V19, P583&#xD; OCONNOR WJ, 1996, DERMATOL SURG, V22, P262&#xD; OTT MJ,
                    1999, ARCH SURG-CHICAGO, V134, P388&#xD; QUEIROLO P, 1997, ANTICANCER RES, V17,
                    P673&#xD; RYWLIN AM, 1982, AM J DERMATOPATH, V4, P513&#xD; SIAN KU, 1999, ANN
                    PLAS SURG, V42, P679&#xD; SMITH DE, 1995, AM J CLIN ONCOL-CANC, V18, P199&#xD;
                    TOKER C, 1972, ARCH DERMATOL, V105, P107&#xD; VICTOR NS, 1996, AM SURGEON, V62,
                    P879&#xD; WASSERBERG N, 1999, EUR J SURG ONCOL, V25, P444&#xD; YIENGPRUKSAWAN A,
                    1991, ARCH SURG-CHICAGO, V126, P1514</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245348600007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>281</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">281</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1229</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Morgan, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gandara, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muggia, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scudder, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reed, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Margolin, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raschko, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leong, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tetef, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vasilev, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McGonigle, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Longmate, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chow, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carroll, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Doroshow, J. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Med
                    Oncol &amp; Therapeut Res, Duarte, CA 91010 USA. Univ Calif Davis, Dept Med
                    Oncol, Davis, CA 95616 USA. Univ So Calif, Dept Med Oncol, Los Angeles, CA USA.
                    NCI, Med Branch, Bethesda, MD 20892 USA. City Hope Natl Med Ctr, Dept Biostat,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Gynecol Oncol, Duarte, CA
                    91010 USA.&#xD;Morgan, RJ, City Hope Natl Med Ctr, Div Med Oncol &amp; Therapeut
                    Res, 1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;rmorgan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase II trial of carboplatin
                        and infusional cyclosporine with alpha-interferon in recurrent ovarian
                        cancer: a California Cancer Consortium Trial</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Gynecological Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Gynecological Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Gynecol. Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Gynecol Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">373-378</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">17</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">chemomodulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chemotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REFRACTORY GYNECOLOGIC
                        CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIDRUG-RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOLOGY-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WHOLE-BLOOD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG-RESISTANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CISPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASSAY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar-Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1048-891X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244885300009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The purpose of this study was to
                    estimate the response rate of 26-h continuous infusion cyclosporine A (CSA)
                    combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in
                    recurrent ovarian cancer (OC), and to measure their effects on CBDCA
                    pharmacokinetics. OC patients relapsing following platinum-based chemotherapy
                    received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The
                    pharmacokinetics of CSA and CBDCA were determined in a subset of patients.
                    Thirty patients received 84 courses of therapy. Three partial responses were
                    observed. Nine patients were stable for &gt; 4 months. Toxicity was similar to
                    that observed in our previously reported phase I study and consisted of
                    myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA
                    level (high-performance liquid chromatographic assay [HPLC]) was 1109 +/- 291 mu
                    g/mL (mean +/- SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61
                    versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels
                    versus errors in the estimation of CBDCA clearance using measured creatinine
                    clearance. Steady-state levels of &gt; 1 mu g/mL CSA (HPLC assay) are achievable
                    in vivo. Insufficient clinical resistance reversal was observed in this study to
                    warrant further investigation of this combination.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    145SR&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; ATKINSON K, 1987, BONE MARROW TRANSPL, V1, P265&#xD; BEREK JS, 1999,
                    GYNECOL ONCOL, V75, P10&#xD; CHAMBERS SK, 1996, CLIN CANCER RES, V2, P1693&#xD;
                    CHAMBERS SK, 1996, CLIN CANCER RES, V2, P1699&#xD; CHAMBERS SK, 1997, J CLIN
                    ONCOL, V15, P1945&#xD; CHARAK BS, 1992, CANCER RES, V52, P6482&#xD; DARGENIO DZ,
                    1979, COMPUT PROGRAMS BIOM, V9, P115&#xD; GREEN S, 1992, INVEST NEW DRUG, V10,
                    P239&#xD; JOZAN S, 1998, ANTI-CANCER DRUG, V9, P229&#xD; KAPLAN EL, 1958, J AM
                    STAT ASSOC, V53, P457&#xD; KASHANISABET M, 1990, J BIOL CHEM, V265, P11285&#xD;
                    LENSMEYER GL, 1987, CLIN CHEM, V33, P1841&#xD; LI QD, 1999, BIOCHEM PHARMACOL,
                    V57, P347&#xD; LUM BL, 1992, J CLIN ONCOL, V10, P1635&#xD; MANETTA A, 1994,
                    CANCER, V73, P196&#xD; MORGAN RJ, 1995, J CLIN ONCOL, V13, P2238&#xD; PAIETTA E,
                    1995, BLOOD REV, V9, P47&#xD; SCANLON KJ, 1990, CANCER TREAT REV, V17, P27&#xD;
                    SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1&#xD; SONNEVELD P, 1992, LANCET,
                    V340, P255&#xD; TWENTYMAN PR, 1988, BRIT J CANCER, V57, P254&#xD; TWENTYMAN PR,
                    1992, BIOCHEM PHARMACOL, V43, P109&#xD; VOGT W, 1988, CLIN CHEM, V34, P1459&#xD;
                    YAHANDA AM, 1992, J CLIN ONCOL, V10, P1624&#xD; YATSCOFF RW, 1990, CLIN CHEM,
                    V36, P1969</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244885300009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>277</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">277</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1228</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Morgan, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xi, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lim, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Margolin, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schwartz, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leong, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Twardowski, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chow, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tetef, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paz, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koczywas, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagman, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frankel, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stalter, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Doroshow, J. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Med
                    Oncol &amp; Therapeut Res, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept
                    Gen &amp; Oncol Surg, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Gynecol
                    Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Biostat, Duarte, CA
                    91010 USA.&#xD;Morgan, RJ, City Hope Comprehens Canc Ctr, Dept Med Oncol &amp;
                    Therapeut Res, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rmorgan@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase I trial of intraperitoneal
                        gemcitabine in the treatment of advanced malignancies primarily confined to
                        the peritoneal cavity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1232-1237</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >GYNECOLOGIC-ONCOLOGY-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STAGE-III OVARIAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CISPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PACLITAXEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADENOCARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RATIONALE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SCHEDULE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244501100023</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To determine the maximally
                    tolerated dose, toxicity, and pharmacokinetics of i.p. gemcitabine. Experimental
                    Design: Patients had peritoneal carcinomatosis. Gemcitabine (40, 80, 120, or 160
                    mg/m(2)) was administered into the peritoneal cavity in 2 L of warmed saline on
                    days 1, 4, 8, and 12 of a 28-day cycle. Results: Thirty patients received 63
                    (median, 2; range, 0-6) courses. Tumors included ovary (14), uterus (2), colon
                    (6), pancreas (3), and others (5). Dose-limiting toxicity included nausea,
                    vomiting, diarrhea, dyspnea, fatal respiratory failure, and grade 3 elevation of
                    alanine aminotransferase in three patients. Hematologic toxicity and pain were
                    &lt;= grade 2. Three patients had decreased or resolved ascites. Of 19 patients
                    evaluable for response, 10 had stable disease (median, 3.5 courses) and 9 had
                    progressive disease. The median peak peritoneal concentration was 1,116-fold
                    (range, 456-1,886) higher than the peak plasma level. Plasma and peritoneal
                    levels were undetectable within 8 to 12 h. At 120 mg/m(2), the median peritoneal
                    area under the concentration versus time curve (AUC) was 82,612 ng/mL x h
                    (range, 53,296-199,830) and the plasma AUC was 231 ng/mL x h (range,
                    47.6-259.5). The mean peritoneal advantage (AUC(peritoneal)/ AUC(plasma)) was
                    847 (range, 356-1,385). Conclusions: I.p. administration of gemcitabine is
                    tolerated within the tested dosage range. Technical problems with the Porta-Cath
                    device and i.p. therapy per se may have been exacerbated by the enrollment of
                    many patients with a variety of advanced i.p. diseases. Given the significant
                    increase in local dose intensity and the documented activity of this drug, this
                    agent may be an excellent candidate for i.p. therapy in optimally debulked
                    ovarian cancer, either alone or in combination.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    140JO&#xD;Times Cited: 0&#xD;Cited Reference Count: 29&#xD;Cited References:
                    &#xD; *NAT CANC I, 2006, NCI ISS CLIN ANN PRE&#xD; ALBERTS DS, 1996, NEW ENGL J
                    MED, V335, P1950&#xD; ARMSTRONG DK, 2002, P AN M AM SOC CLIN, V21, A201&#xD;
                    ARMSTRONG DK, 2006, NEW ENGL J MED, V354, P34&#xD; BOVEN E, 1993, BRIT J CANCER,
                    V68, P52&#xD; BRAAKHUIS BJM, 1995, SEMIN ONCOL, V22, P42&#xD; DEDRICK RL, 1978,
                    CANCER TREAT REP, V62, P1&#xD; FRANCIS P, 1995, J CLIN ONCOL, V13, P2961&#xD;
                    FREEMAN KB, 1995, J CHROMATOGR B, V665, P171&#xD; FREI E, 1980, AM J MED, V69,
                    P585&#xD; GREEN S, 1992, INVEST NEW DRUG, V10, P239&#xD; HRYNIUK WM, 1988,
                    IMPORTANT ADV ONCOLO, P121&#xD; MARKMAN M, 1988, HEMATOL ONCOL CLIN N, V2,
                    P457&#xD; MARKMAN M, 1992, J CLIN ONCOL, V10, P1485&#xD; MARKMAN M, 1993,
                    CANCER, V71, P1565&#xD; MARKMAN M, 1994, SEMIN SURG ONCOL, V10, P299&#xD;
                    MARKMAN M, 2001, J CLIN ONCOL, V19, P1001&#xD; MCGINN CJ, 2002, CANCER S, V95,
                    P933&#xD; MUGGIA FM, 1996, GYNECOL ONCOL, V61, P395&#xD; PETERS WP, 1991,
                    IMPORTANT ADV ONCOLO, P135&#xD; PIVER MS, 1988, J CLIN ONCOL, V6, P1679&#xD;
                    RUIZVANHAPEREN VW, 1994, BIOCHEM PHARMACOL, V48, P1327&#xD; SABBATINI P, 2004,
                    CLIN CANCER RES, V10, P2962&#xD; SPEYER JL, 1985, SEMIN ONCOL, V12, P23&#xD;
                    TEMPERO M, 2003, J CLIN ONCOL, V21, P3402&#xD; VANPUTTEN JWG, 2001, CANCER RES,
                    V61, P1585&#xD; VERWAAL VJ, 2003, J CLIN ONCOL, V21, P3737&#xD; WALKER JL, 2006,
                    GYNECOL ONCOL, V100, P27&#xD; YILMAZ B, 2004, ANAL BIOCHEM, V332, P234</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244501100023 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>471</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">471</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1227</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Morris, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynch, J. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Nebraska, Med Ctr, Dept Prevent
                    &amp; Societal Med, Omaha, NE 68198 USA. City Hope Natl Med Ctr, Dept Nursing
                    Res &amp; Educ, Duarte, CA 91010 USA.&#xD;Morris, ME, Univ Nebraska, Med Ctr,
                    Dept Prevent &amp; Societal Med, 984350 Nebraska Med Ctr, Omaha, NE 68198
                    USA.&#xD;memorris@unmc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Patient-reported family distress
                        among long-term cancer survivors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Nursing</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Nursing</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Nurs.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Nurs</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1-8</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">30</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">long-term survivorship</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient and family
                        survivors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">patient-reported</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">family distress</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW TRANSPLANT
                        SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INSTRUMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMPACT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan-Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0162-220X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247112700001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Two quality of life studies at the
                    University of Nebraska Medical Center and 3 similar studies in the nursing
                    literature were compared regarding family distress to illness scores as reported
                    by long-term cancer survivors. All studies were cross-sectional mail surveys and
                    used City of, Hope National Medical Center questionnaires. Participants
                    represented a broad range of survivorship in terms of diagnosis and length of
                    survival (range of means 3-8 years). Single-item scores were compared among
                    participants regarding the item &quot;How distressing has your illness been for
                    your family?&quot; Significant levels of patient-reported family distress to
                    illness were reported in all 5 studies. Patient survivors may have been able to
                    recall past levels of significant family distress despite prolonged survival or
                    they may have reported significant ongoing family distress as a result of their
                    disease and treatment. Longitudinal assessment of patients&apos; and
                    families&apos; quality of life is essential throughout survivorship. Future
                    studies should identify and compare the types distress experienced by patient
                    survivors and families over time and also measure the intensity of their
                    distress. Interventions designed to meet their individual and collective needs,
                    thereby decreasing their distress, are needed to improve quality of life for
                    survivors and families.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    176VJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 43&#xD;Cited References:
                    &#xD; AARONSON NK, 1993, J NATL CANCER I, V85, P365&#xD; BAKER F, 1999, CANCER
                    PRACT, V7, P190&#xD; BELEC RH, 1992, ONCOL NURS FORUM, V19, P31&#xD; BYAR KL,
                    2005, CANCER NURS, V28, P148&#xD; CELLA D, 1997, FACT BMT QUESTIONNAI&#xD; CELLA
                    D, 1997, FUNCTIONAL ASSESSMEN&#xD; CELLA DF, 1993, J CLIN ONCOL, V11, P570&#xD;
                    CHOCHINOV HM, 1997, AM J PSYCHIAT, V154, P674&#xD; DIBBLE SL, 1998, ONCOL NURS
                    FORUM, V25, P577&#xD; DOW KH, 1999, ONCOL NURS FORUM, V26, P519&#xD; EILERS JG,
                    1997, BLOOD MARROW STEM CE, P442&#xD; ERSEK M, 1997, WESTERN J NURS RES, V19,
                    P334&#xD; FERRANS CE, 1990, ONCOL NURS FORUM S, V17, P15&#xD; FERRELL B, 1992,
                    CANCER NURS, V15, P153&#xD; FERRELL B, 1992, CANCER NURS, V15, P247&#xD; FERRELL
                    BR, 1995, ONCOL NURS FORUM, V22, P915&#xD; FERRELL BR, 1995, QUAL LIFE RES, V4,
                    P523&#xD; FERRELL BR, 1997, INSTRUMENTS CLIN HLT, P319&#xD; FERRELL BR, 1997,
                    ONCOLOGY, V11, P565&#xD; FERRELL BR, 2003, CITY HOPE NATL MED C&#xD; GERMINO B,
                    1991, CANC NURSING COMPREH, P38&#xD; GIVEN BA, 2001, CA-CANCER J CLIN, V51,
                    P213&#xD; GOTAY CC, 1997, ONCOLOGY WILLISTON P, V11, P576&#xD; GRANT M, CITY
                    HOPE NATL MED C&#xD; GRANT M, 1996, CANC NURSING, P1312&#xD; GRANT M, 1999, CITY
                    HOPE NATL MED C&#xD; JASSAK PF, 1992, ONCOL NURS FORUM, V19, P871&#xD; LEWIS FM,
                    1986, PATIENT EDUC COUNS, V8, P269&#xD; LYNCH JC, 2003, ANN C INT SOC QUAL
                    L&#xD; MATTHEWS NS, 2003, VET ANAESTH ANALG, V30, P3&#xD; MEADOWS AT, 1998,
                    CANCER EPIDEM BIOMAR, V7, P1145&#xD; MELLON S, 2001, RES NURS HEALTH, V24,
                    P446&#xD; MELLON S, 2002, ONCOL NURS FORUM, V29, P1117&#xD; MORRIS ME, 2002,
                    BLOOD MARR STEM CELL&#xD; PADILLA GV, 1983, RES NURS HEALTH, V6, P117&#xD; PEDRO
                    LW, 2001, CANCER NURS, V24, P1&#xD; PERSSON L, 1998, CANCER NURS, V21, P97&#xD;
                    SALES BC, 2001, RECENT TRENDS THERMO, V2, P1&#xD; SCHACHTER S, 1992, J
                    PALLIATIVE CARE, V8, P61&#xD; SCHAG CAC, 1991, CANCER, V68, P1406&#xD; STETZ K,
                    1998, QUALITY LIFE NURSING, P157&#xD; WARE JE, 1993, SF 36 HLTH SURVEY MA&#xD;
                    WHEDON M, 1995, ONCOL NURS FORUM, V22, P1527</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247112700001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>204</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">204</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1221</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Motzer, R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hutson, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tomczak, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Michaelson, M. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bukowski, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rixe, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Oudard, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Negrier, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Szczylik, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, S. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bycott, P. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baum, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Mem Sloan Kettering Canc Ctr, New
                    York, NY 10021 USA. Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA. Klin
                    Onkol Oddzial Chemioterapii, Poznan, Poland. Massachusetts Gen Hosp, Ctr Canc,
                    Boston, MA USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. Hop La Pitie
                    Salpetriere, Paris, France. Hop Europeen Georges Pompidou, Paris, France. Ctr
                    Leon Berard, F-69373 Lyon, France. Mil Inst Med, Warsaw, Poland. Pfizer Global
                    Res &amp; Dev, La Jolla, CA USA. City Hope Comprehens Canc Ctr, Los Angeles, CA
                    USA.&#xD;Motzer, RJ, Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY
                    10021 USA.&#xD;motzerr@mskcc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Sunitinib versus interferon alfa
                        in metastatic renal-cell carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">New England Journal of
                        Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">New England Journal of
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">New Engl. J. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">New Engl J Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">115-124</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">356</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ENDOTHELIAL
                        GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOSE RECOMBINANT
                        INTERLEUKIN-2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TYROSINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KINASE INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-SUPPRESSOR GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-III TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLINICAL-TRIALS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0028-4793</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243373700004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: Since sunitinib malate
                    has shown activity in two uncontrolled studies in patients with metastatic
                    renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3
                    trial is warranted. METHODS: We enrolled 750 patients with previously untreated,
                    metastatic renal-cell carcinoma in a multicenter, randomized, phase 3 trial to
                    receive either repeated 6-week cycles of sunitinib (at a dose of 50 mg given
                    orally once daily for 4 weeks, followed by 2 weeks without treatment) or
                    interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). The
                    primary end point was progression-free survival. Secondary end points included
                    the objective response rate, overall survival, patient-reported outcomes, and
                    safety. RESULTS: The median progression-free survival was significantly longer
                    in the sunitinib group (11 months) than in the interferon alfa group (5 months),
                    corresponding to a hazard ratio of 0.42 (95% confidence interval, 0.32 to 0.54;
                    P&lt;0.001). Sunitinib was also associated with a higher objective response rate
                    than was interferon alfa (31% vs. 6%, P&lt;0.001). The proportion of patients
                    with grade 3 or 4 treatment-related fatigue was significantly higher in the
                    group treated with interferon alfa, whereas diarrhea was more frequent in the
                    sunitinib group (P&lt;0.05). Patients in the sunitinib group reported a
                    significantly better quality of life than did patients in the interferon alfa
                    group (P&lt;0.001). CONCLUSIONS: Progression-free survival was longer and
                    response rates were higher in patients with metastatic renal-cell cancer who
                    received sunitinib than in those receiving interferon alfa.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    124NE&#xD;Times Cited: 2&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; ABRAMS TJ, 2003, MOL CANCER THER, V2, P471&#xD; BRUCKER PS, 2005, EVAL
                    HEALTH PROF, V28, P192&#xD; BRUCKER PS, 2005, EVAL HEALTH PROF, V28, P370&#xD;
                    CELLA D, 2006, J SUPPORT ONCOL, V4, P191&#xD; CELLA DF, 1993, J CLIN ONCOL, V11,
                    P570&#xD; COPPIN C, 2005, COCHRANE DB SYST REV, V1&#xD; COX DR, 1990, ANAL
                    SURVIVAL DATA&#xD; ESCUDIER B, 2005, P AN M AM SOC CLIN, V24, S380&#xD; FISHER
                    RI, 2000, CANCER J SCI 07/01 AM S1, V6, S55&#xD; FITZMAURICE GM, 2004, APPL
                    LONGITUDINAL AN, P187&#xD; FYFE GA, 1996, J CLIN ONCOL, V14, P2410&#xD; GNARRA
                    JR, 1994, NAT GENET, V7, P85&#xD; ILIOPOULOS O, 1996, P NATL ACAD SCI 07/01 USA,
                    V93, P10595&#xD; JANZEN NK, 2003, UROL CLIN N AM, V30, P843&#xD; KAMMULA US,
                    1998, CANCER, V83, P797&#xD; LAM JS, 2005, WORLD J UROL, V23, P202&#xD; LAN KKG,
                    1983, BIOMETRIKA, V70, P659&#xD; MANTEL N, 1966, CANCER CHEMOTHERAPY, V50,
                    P163&#xD; MAXWELL PH, 1999, NATURE, V399, P271&#xD; MCDERMOTT DF, 2005, J CLIN
                    ONCOL, V23, P133&#xD; MCDERMOTT DF, 2005, J CLIN ONCOL, V23, P2877&#xD; MEKHAIL
                    TM, 2005, J CLIN ONCOL, V23, P832&#xD; MENDEL DB, 2003, CLIN CANCER RES, V9,
                    P327&#xD; MOTZER RJ, 1996, NEW ENGL J MED, V335, P865&#xD; MOTZER RJ, 2000, J
                    CLIN ONCOL, V18, P2972&#xD; MOTZER RJ, 2000, J UROLOGY, V163, P408&#xD; MOTZER
                    RJ, 2002, J CLIN ONCOL, V20, P289&#xD; MOTZER RJ, 2006, J CLIN ONCOL, V24,
                    P16&#xD; MOTZER RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516&#xD; NA X, 2003, J
                    UROLOGY 1, V170, P588&#xD; NEGRIER S, 1998, NEW ENGL J MED, V338, P1272&#xD;
                    NEGRIER S, 2005, P AN M AM SOC CLIN, V23, S380&#xD; OFARRELL AM, 2003, BLOOD,
                    V101, P3597&#xD; PARKIN DM, 2005, CA-CANCER J CLIN, V55, P74&#xD; PYRHONEN S,
                    1999, J CLIN ONCOL, V17, P2859&#xD; RITCHIE A, 1999, LANCET, V353, P14&#xD;
                    SINGER JD, 2003, APPL LONGITUDINAL DA, P75&#xD; THERASSE P, 2000, J NATL CANCER
                    I, V92, P205&#xD; YANG JC, 2003, J CLIN ONCOL, V21, P3127&#xD; YANG JC, 2003,
                    NEW ENGL J MED, V349, P427</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243373700004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>709</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">709</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">961</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Mularski, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dy, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shugarman, L. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilkinson, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lynn, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shekelle, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Morton, S. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, V. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hughes, R. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hilton, L. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maglione, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rhodes, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rolon, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lorenz, K. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Oregon Hlth &amp; Sci Univ, Kaiser
                    Permanente NW, Ctr Hlth Res, Portland, OR 97227 USA. Johns Hopkins Bloomberg Sch
                    Publ Hlth, Baltimore, MD USA. Sch Med, Baltimore, MD USA. RAND Hlth, So Calif
                    Evidence Based Practice Ctr, Santa Monica, CA USA. RAND Corp, Arlington, VA USA.
                    RTI Int, Res Triangle Pk, NC USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA.
                    Agcy Healthcare Res &amp; Qual, Ctr Primary Care Prevent &amp; Clin
                    Partnerships, Rockville, MD USA.&#xD;Mularski, RA, Oregon Hlth &amp; Sci Univ,
                    Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate,WIN 1060, Portland, OR
                    97227 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A systematic review of measures
                        of end-of-life care and its outcomes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Health Services Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Health Services Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Health Serv. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Health Serv Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1848-1870</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">42</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of health care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">outcome and process assessment
                        (health care)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">end-of-life care</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">measures</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">dying</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-SYMPTOM-SCALE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL
                        ASSESSMENT-TOOL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PALLIATIVE CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILY-MEMBERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TERMINALLY-ILL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ONCOLOGY PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INCURABLE CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEEDS-ASSESSMENT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEART-FAILURE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0017-9124</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249429000005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective To identify
                    psychometrically sound measures of outcomes in end-of-life care and to
                    characterize their use in intervention studies. Data Sources English language
                    articles from 1990 to November 2005 describing measures with published
                    psychometric data and intervention studies of end-of-life care. Study Design
                    Systematic review of end-of-life care literature. Extraction Methods Two
                    reviewers organized identified measures into 10 major domains. Eight reviewers
                    extracted and characterized measures from intervention studies. Principal
                    Findings Of 24,423 citations, we extracted 200 articles that described 261
                    measures, accepting 99 measures. In addition to 35 measures recommended in a
                    prior systematic review, we identified an additional 64 measures of the
                    end-of-life experience. The most robust measures were in the areas of symptoms,
                    quality of life, and satisfaction; significant gaps existed in continuity of
                    care, advance care planning, spirituality, and caregiver well-being. We also
                    reviewed 84 intervention studies in which 135 patient-centered outcomes were
                    assessed by 97 separate measures. Of these, 80 were used only once and only
                    eight measures were used in more than two studies. Conclusions In general, most
                    measures have not undergone rigorous development and testing. Measure
                    development in end-of-life care should focus on areas with identified gaps, and
                    testing should be done to facilitate comparability across the care settings,
                    populations, and clinical conditions. Intervention research should use robust
                    measures that adhere to these standards.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    210AL&#xD;Times Cited: 0&#xD;Cited Reference Count: 88&#xD;Cited References:
                    &#xD; *I FUT, 2003, HLTH HEALTHC 2010 FO&#xD; *I MED, 1997, APPR DEATH IMPR
                    CAR&#xD; *NAT CONS PROJ, 2004, CLIN PRACT GUID PALL&#xD; ABRATT R, 1995, S AFR
                    MED J, V85, P896&#xD; BAUSEWEIN C, 2005, J PAIN SYMPTOM MANAG, V30, P51&#xD;
                    BURNETT P, 1997, PSYCHOL MED, V27, P49&#xD; CARSON MG, 2000, PALLIATIVE MED,
                    V14, P25&#xD; CHANG VT, 1998, CANCER, V83, P173&#xD; CHANG VT, 2000, CANCER,
                    V88, P2164&#xD; CHOCHINOV HM, 1997, AM J PSYCHIAT, V154, P674&#xD; CHOW E, 2001,
                    J PAIN SYMPTOM MANAG, V22, P649&#xD; CURTIS JR, 1999, AIDS, V13, P1123&#xD;
                    CURTIS JR, 2002, J PAIN SYMPTOM MANAG, V24, P17&#xD; DOBRATZ MC, 1990, HOSPICE
                    J, V6, P1&#xD; EWING G, 2004, J PAIN SYMPTOM MANAG, V27, P287&#xD; FAINSINGER
                    RL, 2005, J PAIN SYMPTOM MANAG, V29, P224&#xD; FELDSTEIN MA, 1995, CANCER NURS,
                    V18, P228&#xD; FRIED TR, 2002, J GERONTOL B-PSYCHOL, V57, S348&#xD; GATES MF,
                    1995, CANCER PRACT, V3, P201&#xD; GATES MF, 1995, CANCER PRACT, V3, P226&#xD;
                    GERETY MB, 1993, J GERONTOL, V48, M33&#xD; GIORGI F, 1996, AM J CLIN ONCOL-CANC,
                    V19, P394&#xD; GLOTH FM, 1995, AM J PHYS MED REHAB, V74, P45&#xD; GREEN CP,
                    2000, J AM COLL CARDIOL, V35, P1245&#xD; GUO H, 2001, J PAIN SYMPTOM MANAG, V22,
                    P637&#xD; HANSON LC, 1997, J AM GERIATR SOC, V45, P1339&#xD; HEARN J, 1999, QUAL
                    HEALTH CARE, V8, P219&#xD; HENOCH I, 2003, INT J PALLIAT NURS, V9, P474&#xD;
                    HERNDON JE, 1997, CONTROL CLIN TRIALS, V18, P286&#xD; HODDE NM, 2004, CRIT CARE
                    MED, V32, P1648&#xD; HOEKSTRA J, 2004, J PAIN SYMPTOM MANAG, V27, P24&#xD; HOGAN
                    C, 2000, MEDICARE BENEFICIARI&#xD; HOGAN NS, 2001, DEATH STUD, V25, P1&#xD;
                    HOLLEN PJ, 1993, EJC SUPPL, V29, P51&#xD; HOLLEN PJ, 1994, CANCER, V73,
                    P2087&#xD; HOLLEN PJ, 1999, SUPPORT CARE CANCER, V7, P140&#xD; HOLLEN PJ, 2004,
                    CANCER, V101, P587&#xD; HOPWOOD P, 1991, BRIT J CANCER, V64, P353&#xD; JACOBY A,
                    1999, PALLIATIVE MED, V13, P285&#xD; JORDAN JR, 2005, DEATH STUD, V29, P301&#xD;
                    KAASA T, 2000, PALLIATIVE MED, V14, P509&#xD; KAASA T, 2001, J PALLIATIVE CARE,
                    V17, P5&#xD; KIRSCHLING J, 1990, HOSPICE J, V6, P75&#xD; KISSANE DW, 1997, AUST
                    NZ J PSYCHIAT, V31, P370&#xD; KISSANE DW, 2004, J PALLIATIVE CARE, V20,
                    P269&#xD; KOEDOOT N, 2001, PATIENT EDUC COUNS, V45, P187&#xD; KRISTJANSON LJ,
                    1997, J PALLIATIVE CARE, V13, P4&#xD; KRISZTIN T, 2001, J DYNAM DIFFERENTIAL,
                    V13, P1&#xD; KURLOWICZ LH, 2002, AM J GERIAT PSYCHIAT, V10, P600&#xD; LLOBERA J,
                    2003, SUPPORT CARE CANCER, V11, P294&#xD; LLOYDWILLIAMS M, 2004, GEN HOSP
                    PSYCHIAT, V26, P384&#xD; LORENZ KA, 2004, AHRQ PUBLICATION&#xD; LORENZ KA, 2005,
                    J PALLIAT MED S1, V8, S4&#xD; LUNNEY JR, 2003, JAMA-J AM MED ASSOC, V289,
                    P2387&#xD; LYNN J, 1997, ANN INTERN MED, V126, P97&#xD; MORITA T, 2001,
                    PALLIATIVE MED, V15, P197&#xD; MULARSKI R, 2004, J PAIN SYMPTOM MANAG, V28,
                    P306&#xD; MYSTAKIDOU K, 2002, BMC PALLIAT CARE, V1, P3&#xD; MYSTAKIDOU K, 2004,
                    HEALTH QUAL LIFE OUT, V2, P8&#xD; MYSTAKIDOU K, 2005, PSYCHO-ONCOL, V14,
                    P16&#xD; OSSE BHP, 2004, J PAIN SYMPTOM MANAG, V28, P329&#xD; PARSHALL MB, 2001,
                    HEART LUNG, V30, P57&#xD; PATRICK DL, 2001, J PAIN SYMPTOM MANAG, V22, P717&#xD;
                    PATRICK DL, 2003, ANN INTERN MED S 2, V139, P410&#xD; RAINBIRD KJ, 2005,
                    PSYCHO-ONCOL, V14, P297&#xD; ROBINSON LA, 1995, J PALLIATIVE CARE, V11, P5&#xD;
                    SALMON JR, 2005, AM J HOSP PALLIAT CA, V22, P188&#xD; SALMON P, 1996, EUR J
                    CANCER A, V32, P755&#xD; SARNA L, 1997, HEART LUNG, V26, P23&#xD; SCHWARTZ CE,
                    2003, J PALLIAT MED, V6, P575&#xD; SCHWARTZ CE, 2004, J PALLIAT MED, V7,
                    P233&#xD; SHERMAN AC, 2001, PSYCHO-ONCOL, V10, P436&#xD; SINGER PA, 1999,
                    PERSPECTIVES, V281, P163&#xD; STEEL K, 2003, AM J HOSP PALLIAT CA, V20,
                    P211&#xD; STEINHAUSER KE, 2000, JAMA-J AM MED ASSOC, V284, P2476&#xD;
                    STEINHAUSER KE, 2001, J PAIN SYMPTOM MANAG, V22, P727&#xD; STEINHAUSER KE, 2002,
                    J PALLIAT MED, V5, P829&#xD; STERKENBURG CA, 1996, J PALLIATIVE CARE, V12,
                    P18&#xD; SULMASY DP, 2002, J PAIN SYMPTOM MANAG, V23, P458&#xD; TENO J, 2005,
                    TOOLK INSTR MEAS END&#xD; TENO JM, 2004, JAMA-J AM MED ASSOC, V291, P88&#xD;
                    TRANMER JE, 2003, J PAIN SYMPTOM MANAG, V25, P420&#xD; TRAVIS SS, 2003,
                    GERONTOLOGIST, V43, P360&#xD; VOHRA JU, 2004, J PALLIATIVE CARE, V20, P297&#xD;
                    VOLICER L, 2001, ALZ DIS ASSOC DIS, V15, P194&#xD; WARDEN V, 2003, J AM MED DIR
                    ASSOC, V4, P9&#xD; WENRICH MD, 2003, J PAIN SYMPTOM MANAG, V25, P236&#xD; WILSON
                    KG, 2004, CAN J PSYCHIAT, V49, P350</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249429000005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>763</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">763</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1217</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Nakamura, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rodriguez, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Palmer, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stein, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Naing, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tsai, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Spielberger, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kogut, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pullarkat, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kirschbaum, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Donnell, M.
                            R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr, Div
                    Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. City Hope
                    Comprehens Canc Ctr, Dept Biostat, Duarte, CA USA. City Hope Comprehens Canc
                    Ctr, Div Pathol, Duarte, CA USA. City Hope So Calif Kaiser Permanente Bone
                    Marrow, Duarte, CA USA.&#xD;Nakamura, R, City Hope Comprehens Canc Ctr, Div
                    Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rnakamura@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Reduced-intensity conditioning
                        for allogeneic hematopoietic stem cell transplantation with fludarabine and
                        melphalan is associated with durable disease control in myelodysplastic
                        syndrome</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Bone Marrow
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Bone Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Bone Marrow Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Bone Marrow Transplant</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">843-850</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">40</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">myelodysplastic syndromes
                        (MDS)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reduced intensity
                        conditioning</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">fludarabine and
                        melphalan</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">allogeneic hematopoietic stem
                        cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute myelogenous leukemia
                        arising from MDS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAILY INTRAVENOUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BUSULFAN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >POLYMERASE-CHAIN-REACTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOLOGIC MALIGNANCIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGIMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYCLOSPORINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REMISSIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORTALITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0268-3369</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250225700005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We retrospectively evaluated the
                    outcome of reduced-intensity conditioning (RIC) followed by allogeneic
                    hematopoietic stem cell transplantation (HCT) in 43 patients with
                    myelodysplastic syndrome (MDS) or AML arising from MDS. All patients received
                    fludarabine plus melphalan followed by an allogeneic HCT from an HLA-identical
                    sibling(SIB: n = 19) or unrelated donor (MUD: n = 24). Median age was 58 years (
                    range: 30-71). Diagnoses at transplantation were RA ( n 8), RARS (n = 1), RAEB
                    (n = 13), RAEB-T ( n 6), or AML arising from MDS (n = 15). Of 28 patients with
                    MDS, two patients had low, 10 had intermediate-1, nine had intermediate-2 and
                    seven had high-risk MDS by IPSS criteria. All patients initially engrafted with
                    the median neutrophil recovery of 15 days (range: 9-27). The 2-year overall
                    survival, disease-free survival, relapse and transplant-related mortality were
                    53.5% (CI 45.2-61.1), 51.2% (CI 43.3-58.5), 16.3% (CI 7.9-30.7) and 35.2%
                    (26.4-45.7), respectively. Grade II-IV acute graft-versushost disease occurred
                    in 27 (63%) patients. There was no significant survival difference between SIB
                    and MUD-HCT, but the relapse rate was higher among SIB donor recipients when
                    compared to MUD ( 38.5 versus 7%, P = 0.02). RIC with fludarabine plus melphalan
                    was associated with durable disease control and acceptable toxicity in this
                    high-risk cohort.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    221KI&#xD;Times Cited: 0&#xD;Cited Reference Count: 30&#xD;Cited References:
                    &#xD; ANDERSON JE, 1993, BLOOD, V82, P677&#xD; AUL C, 1995, LEUKEMIA LYMPHOMA,
                    V16, P247&#xD; BLUME KG, 1980, HEMATOPOIETIC CELL T&#xD; BRESLOW NE, 1980, IARC
                    SCI PUBL, V32, P5&#xD; CASTROMALASPINA H, 2002, BLOOD, V99, P1943&#xD;
                    CHAKRAVERTY R, 2002, BLOOD, V99, P1071&#xD; CORRADINI P, 2002, BLOOD, V99,
                    P75&#xD; COX DR, 1972, J ROY STAT SOC B MET, V34, P187&#xD; DEEG HJ, 2002,
                    BLOOD, V100, P1201&#xD; DELIMA M, 2004, BLOOD, V104, P857&#xD; DELIMA M, 2004,
                    BLOOD, V104, P865&#xD; FUNG HC, 2003, BIOL BLOOD MARROW TR, V9, P649&#xD; GIRALT
                    S, 1997, BLOOD, V89, P4531&#xD; GREENBERG P, 1997, BLOOD, V89, P2079&#xD; HEANEY
                    ML, 1999, NEW ENGL J MED, V340, P1649&#xD; HO AYL, 2004, BLOOD, V104, P1616&#xD;
                    KAPLAN GL, 1958, J AM STAT ASSOC, V53, P457&#xD; MARTINO R, 2001, BRIT J
                    HAEMATOL, V115, P653&#xD; ODONNELL MR, 1995, J CLIN ONCOL, V13, P2973&#xD;
                    RODRIGUEZ R, 2004, BONE MARROW TRANSPL, V33, P1123&#xD; RUSSELL JA, 2002, BIOL
                    BLOOD MARROW TR, V8, P468&#xD; SCHAFFER M, 2001, TISSUE ANTIGENS, V58, P299&#xD;
                    SCOTT BL, 2005, BIOL BLOOD MARROW TR, V11, P65&#xD; SIERRA J, 2002, BLOOD, V100,
                    P1997&#xD; SLAVIN S, 1998, BLOOD, V91, P756&#xD; SUTTON L, 1991, BONE MARROW
                    TRANS S2, V7, P39&#xD; TAURO S, 2005, J CLIN ONCOL, V23, P9387&#xD; UGOZZOLI L,
                    1991, BLOOD, V77, P1607&#xD; VANBESIEN K, 2005, J CLIN ONCOL, V23, P5728&#xD;
                    ZIKOS P, 1998, BLOOD, V91, P3503</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250225700005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>436</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">436</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1216</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Nam, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Williams, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Vultur, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">List, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Halla, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, F. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA. H Lee Moffitt Canc Ctr &amp; Res Inst, Tampa, FL
                    USA. Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA. Bristol Myers Squibb Co,
                    Pharmaceut Res Inst, Princeton, NJ 08543 USA.&#xD;Jove, R, City Hope Natl Med
                    Ctr, Beckman Res Inst, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;rjove@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Dasatinib (BMS-354825) inhibits
                        Stat5 signaling associated with apoptosis in chronic myelogenous leukemia
                        cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Therapeutics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Cancer
                        Therapeutics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Cancer Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Cancer Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1400-1405</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">6</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ABL KINASE-ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BCR-ABL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSTITUTIVE ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULAR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BCR/ABL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSDUCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMATINIB</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1535-7163</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245939000024</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Dasatinib (BMS-354825) is a novel,
                    oral, potent, multi-targeted kinase inhibitor of Bcr-Abl and Src family kinases
                    (SFK) and is a promising cancer therapeutic agent. Preclinical data indicate
                    that dasatinib is 325-fold more potent than imatinib against cells expressing
                    wild-type Bcr-Abl, and that dasatinib is active against 18 of 19 Bcr-Abl
                    mutations known to cause imatinib resistance. Phase I clinical data show that
                    dasatinib is well tolerated and highly effective for the treatment of
                    imatinib-resistant/imatinib-intolerant chronic myelogenous leukemia (CML) and
                    Philadelphia chromosome-positive acute lymphoblastic leukemia. However, the
                    molecular mechanism of action of dasatinib is not fully understood. In this
                    study, we confirm that dasatinib inhibits tyrosine phosphorylation of SFKs,
                    including Src, Hck, and Lyn, in K562 human CML cells. Significantly, downstream
                    signal transducer and activator of transcription 5 (Stat5) signaling is also
                    blocked by dasatinib as shown by decreases in levels of phosphorylated Stat5 and
                    Stat5 DNA-binding activities. In addition, dasatinib down-regulates expression
                    of Stat5 target genes, including Bcl-x, Mcl-1, and cyclin D1. Consistent with
                    these results, blockade of Stat5 signaling by dasatinib is accompanied by
                    inhibition of cell proliferation and induction of apoptosis. Surprisingly, Stat5
                    DNA-binding activities are enhanced with increasing cell density, which is
                    associated with resistance to apoptosis by dasatinib. Our findings indicate that
                    inhibition of Stat5 signaling downstream of Bcr-Abl/SFKs contributes to the
                    action of dasatinib, and, conversely, that increasing cell density up-regulates
                    Stat5 activation and confers resistance to dasatinib. Moreover, the level of
                    phosphorylated Stat5 in CML cells represents a mechanistically relevant
                    biomarker for monitoring inhibition of Bcr-Abl signaling by dasatinib in CML
                    patients using convenient immunocytochemical assays.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    160KJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 27&#xD;Cited References:
                    &#xD; AICHBERGER KJ, 2005, BLOOD, V105, P3303&#xD; BATTLE TE, 2002, CURR MOL
                    MED, V2, P381&#xD; BROMBERG JF, 1999, CELL, V98, P295&#xD; BUETTNER R, 2002,
                    CLIN CANCER RES, V8, P945&#xD; CARLESSO N, 1996, J EXP MED, V183, P811&#xD;
                    CHIARLE R, 2005, NAT MED, V11, P623&#xD; EPLINGBURNETTE PK, 2001, J CLIN INVEST,
                    V107, P351&#xD; GESBERT F, 2000, BLOOD, V96, P2269&#xD; HORITA M, 2000, J EXP
                    MED, V191, P977&#xD; HUANG M, 2002, ONCOGENE, V21, P8804&#xD; KLEJMAN A, 2002,
                    EMBO J, V21, P5766&#xD; KORTYLEWSKI M, 2005, NAT MED, V11, P1314&#xD; LIONBERGER
                    JM, 2000, J BIOL CHEM, V275, P18581&#xD; LOMBARDO LJ, 2004, J MED CHEM, V47,
                    P6658&#xD; MAGNE S, 2003, MOL CELL BIOL, V23, P8934&#xD; MORIGGL R, 2005, CANCER
                    CELL, V7, P87&#xD; NAM S, 2005, CANCER RES, V65, P9185&#xD; NAM S, 2005, P NATL
                    ACAD SCI USA, V102, P5998&#xD; NIEBOROWSKASKORSKA M, 1999, J EXP MED, V189,
                    P1229&#xD; NIMMANAPALLI R, 2002, CANCER RES, V62, P5761&#xD; OHARE T, 2005,
                    CANCER RES, V65, P4500&#xD; SCHLESSINGER K, 2005, CANCER RES, V65, P5828&#xD;
                    SHAH NP, 2004, SCIENCE, V305, P399&#xD; SPIEKERMANN K, 2001, EUR J HAEMATOL,
                    V67, P63&#xD; VULTUR A, 2004, ONCOGENE, V23, P2600&#xD; WILSON MB, 2002,
                    ONCOGENE, V21, P8075&#xD; YU H, 2004, NAT REV CANCER, V4, P97</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245939000024 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>710</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">710</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1214</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Nathan, P. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Patel, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dilley, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goldsby, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Harvey, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jacobsen, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kadan-Lottick, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McKinley, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Millham, A. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Okcu, M. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Woodman, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brouwers, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Armstrong, F. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Hosp Sick Children, Div Haematol
                    Oncol, Toronto, ON M5G 1X8, Canada. City Hope Natl Med Ctr, Div Pediat, Duarte,
                    CA 91010 USA. Univ Calif San Francisco, Sch Med, Div Pediat Hematol Oncol, San
                    Francisco, CA 94143 USA. Washington Univ, Med Ctr, Dept Pediat Oncol, St Louis,
                    MO USA. Rainbow Babies &amp; Childrens Hosp, Cleveland, OH 44106 USA. Childrens
                    Mem Hosp, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA. Yale Univ Med,
                    New Haven, CT USA. Baylor Coll Med, Childrens Canc Ctr, Houston, TX 77030 USA.
                    Univ Miami, Sch Med, Miami, FL 33152 USA. Childrens Hosp Kings Daughters,
                    Childrens Canc &amp; Blood Disorders Ctr, Norfolk, VA USA. Univ Arizona, Hlth
                    Sci Ctr, Coll Nursing, Tucson, AZ USA. Univ Iowa Hosp &amp; Clin, Dept Psychiat
                    &amp; Family Med, Iowa City, IA 52242 USA. Natl Inst Hlth, NIMH, Div AIDS &amp;
                    Hlth &amp; Behav Res, Rockville, MD USA.&#xD;Nathan, PC, Hosp Sick Children, Div
                    Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8,
                    Canada.&#xD;paul.nathan@sickkids.ca</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Guidelines for identification
                        of, advocacy for, and intervention in neurocognitive problems in survivors
                        of childhood cancer - A report from the children&apos;s oncology
                        group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Archives of Pediatrics &amp;
                        Adolescent Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Archives of Pediatrics &amp;
                        Adolescent Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Arch. Pediatr. Adolesc.
                        Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Arch Pediatr Adolesc Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">798-806</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">161</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CENTRAL-NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOSE CRANIOSPINAL
                        IRRADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRANIAL
                        RADIATION-THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WHOLE-BRAIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTERIOR-FOSSA TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WHITE-MATTER LOSS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COGNITIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEFICITS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1072-4710</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248583000011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">With modern therapies and supportive
                    care, survival of childhood cancer has increased considerably. Patients who have
                    survived cancers involving the central nervous system or who have received
                    therapy toxic to the developing brain are at risk of long-term neurocognitive
                    sequelae. Negative outcomes are observed most frequently in survivors of acute
                    lymphoblastic leukemia and brain tumors. The Children&apos;s Oncology Group
                    Long-term Follow-up Guidelines Task Force on Neurocognitive/Behavioral
                    Complications After Childhood Cancer has generated risk-based, exposure-related
                    guidelines designed to direct the follow-up care of survivors of pediatric
                    malignancies based on a comprehensive literature review and expert opinion. This
                    article expands on these guidelines by reviewing the risk factors for the
                    development of neurocognitive sequelae and describing the expected pattern of
                    these disabilities. We herein present recommendations for the screening and
                    management of neurocognitive late effects and outline important areas of school
                    and legal advocacy for survivors with disabilities. Finally, we list resources
                    that can guide patients, their parents, and their medical caregivers as they
                    face the long-term neurocognitive consequences of cancer therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    197UW&#xD;Times Cited: 0&#xD;Cited Reference Count: 80&#xD;Cited References:
                    &#xD; ARMSTRONG FD, 1999, SCHOOL PSYCHOL REV, V28, P194&#xD; ARMSTRONG FD, 2004,
                    HDB PEDIAT PSYCHOL S, P263&#xD; ATER JL, 1996, J CHILD NEUROL, V11, P462&#xD;
                    BEEBE DW, 2005, J CLIN ONCOL, V23, P5198&#xD; BROUWERS P, 1990, AM J PEDIAT
                    HEMATOL, V12, P174&#xD; BROUWERS P, 2005, J PEDIATR PSYCHOL, V30, P79&#xD; BROWN
                    RT, 1998, J PEDIATR PSYCHOL, V23, P333&#xD; BUTLER R, 1999, J INT NEUROPSYCH
                    SOC, V5, P108&#xD; BUTLER RW, 1994, J CLIN ONCOL, V12, P2621&#xD; BUTLER RW,
                    2002, J INT NEUROPSYCH SOC, V8, P115&#xD; BUTLER RW, 2005, J PEDIATR PSYCHOL,
                    V30, P65&#xD; CHRISTIE D, 1995, ARCH DIS CHILD, V73, P136&#xD; COPELAND DR,
                    1999, J CLIN ONCOL, V17, P3476&#xD; DENNIS M, 1991, NEUROPSYCHOLOGIA, V29,
                    P829&#xD; ELLENBERG L, 1987, NEUROSURGERY, V21, P638&#xD; ESPY KA, 2001, J
                    PEDIATR PSYCHOL, V26, P1&#xD; FARACE E, 2000, J NEUROSURG, V93, P539&#xD;
                    FOULADI M, 2004, J CLIN ONCOL, V22, P4551&#xD; GAY CL, 1995, PEDIATRICS, V96,
                    P1078&#xD; GLAUSER TA, 1991, CHILD NERV SYST, V7, P2&#xD; GRILL J, 1999, INT J
                    RADIAT ONCOL, V45, P137&#xD; HALBERG FE, 1992, INT J RADIAT ONCOL, V22, P13&#xD;
                    HEWITT M, 2003, CHILDHOOD CANC SWURV&#xD; IUVONE L, 2002, CANCER, V95,
                    P2562&#xD; JANKOVIC M, 1994, LANCET, V344, P224&#xD; JOHNSON R, 2004, ARCH DIS
                    CHILD, V89, P374&#xD; KALEITA TA, 1999, CANCER, V85, P1859&#xD; KEENE N, 2003,
                    ED CHILD CANC GUIDE&#xD; KINGMA A, 2001, J PEDIATR, V139, P413&#xD; KINGMA A,
                    2002, J PEDIAT HEMATOL ONC, V24, P106&#xD; KRAMER JH, 1997, BONE MARROW TRANSPL,
                    V19, P607&#xD; KUN L, 1997, PRINCIPLES PRACTICE&#xD; LANDIER W, 2004, J CLIN
                    ONCOL, V22, P4979&#xD; LEUNG W, 2000, J CLIN ONCOL, V18, P3273&#xD; LEVISOHN L,
                    2000, BRAIN 5, V123, P1041&#xD; MABBOTT DJ, 2005, J CLIN ONCOL, V23, P2256&#xD;
                    MARCUS KJ, 2005, INT J RADIAT ONCOL, V61, P374&#xD; MERCHANT TE, 2004, J CLIN
                    ONCOL, V22, P3156&#xD; MOE PJ, 2000, PEDIATR HEMAT ONCOL, V17, P615&#xD; MOLESKI
                    M, 2000, ARCH CLIN NEUROPSYCH, V15, P603&#xD; MULHERN RJ, 1994, PEDIAT
                    PSYCHOONCOLOG&#xD; MULHERN RK, 1992, MED PEDIATR ONCOL, V20, P181&#xD; MULHERN
                    RK, 1998, J CLIN ONCOL, V16, P1723&#xD; MULHERN RK, 1999, ANN NEUROL, V46,
                    P834&#xD; MULHERN RK, 2001, J CLIN ONCOL, V19, P472&#xD; MULHERN RK, 2003, CURR
                    PROB CANCER, V27, P177&#xD; MULHERN RK, 2004, J CLIN ONCOL, V22, P4795&#xD; NAND
                    S, 1986, J CLIN ONCOL, V4, P571&#xD; PACKER RJ, 1987, MED PEDIATR ONCOL, V15,
                    P241&#xD; PACKER RJ, 1989, J NEUROSURG, V70, P707&#xD; PACKER RJ, 2002,
                    NEUROLOGY, V59, P8&#xD; PALMER SL, 2001, J CLIN ONCOL, V19, P2302&#xD; PHIPPS S,
                    2000, J CLIN ONCOL, V18, P1004&#xD; PIZZO PA, 2002, PRINCIPLES PRACTICE&#xD;
                    RADCLIFFE J, 1992, ANN NEUROL, V32, P551&#xD; RADCLIFFE J, 1994, INT J DEV
                    NEUROSCI, V12, P327&#xD; REDDICK WE, 2000, MAGN RESON IMAGING, V18, P787&#xD;
                    REIMERS TS, 2003, MED PEDIATR ONCOL, V40, P26&#xD; RIES LAG, 1999, CANC
                    INCIDENCE SURVI&#xD; RIS MD, 2001, J CLIN ONCOL, V19, P3470&#xD; RIVA D, 2002,
                    NEUROLOGY, V59, P48&#xD; RONNING C, 2005, PEDIATR NEUROSURG, V41, P15&#xD;
                    ROWLAND JH, 1984, J CLIN ONCOL, V2, P1327&#xD; RUBENSTEIN CL, 1990, J DEV BEHAV
                    PEDIATR, V11, P301&#xD; SAID JA, 1989, J CONSULT CLIN PSYCH, V57, P251&#xD;
                    SCHMIDT GM, 1993, TRANSPLANTATION, V55, P551&#xD; SCOTT RB, 2001, DEV MED CHILD
                    NEUROL, V43, P685&#xD; SOLBERG MM, 2001, COGNITIVE REHABILITA&#xD; SPIEGLER BJ,
                    2004, J CLIN ONCOL, V22, P706&#xD; SPIEGLER BJ, 2006, J CLIN ONCOL, V24,
                    P3858&#xD; STEINLIN M, 2003, BRAIN 9, V126, P1998&#xD; THOMPSON SJ, 2001, J CLIN
                    ONCOL, V19, P1802&#xD; VANDERPLOEG RD, 1998, PSYCHOL ASSESSMENT, V10, P277&#xD;
                    VONDERWEID N, 2003, EUR J CANCER, V39, P359&#xD; WABER DP, 1990, DEV MED CHILD
                    NEUROL, V32, P238&#xD; WABER DP, 1992, J CLIN ONCOL, V10, P810&#xD; WABER DP,
                    1995, J CLIN ONCOL, V13, P2490&#xD; WABER DP, 2000, J PEDIAT HEMATOL ONC, V22,
                    P206&#xD; WABER DP, 2001, CANCER, V92, P15&#xD; WABER DP, 2004, J CLIN ONCOL,
                    V22, P2701</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248583000011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>580</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">580</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1711</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Navarro, M. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bi, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bailis, A. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Beckman Research Institute, City of Hope National Medical Center, Duarte,
                    California 91010-0269, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A mutant allele of the
                        transcription factor IIH helicase gene, RAD3, promotes loss of
                        heterozygosity in response to a DNA replication defect in Saccharomyces
                        cerevisiae</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Genetics</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1391-402</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">176</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adenosine Triphosphatases/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Alleles</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Helicases/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA Replication</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA, Fungal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Loss of Heterozygosity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutagenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Mutation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Recombination, Genetic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Saccharomyces cerevisiae/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription Factor TFIIH/
                        genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0016-6731 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17483411</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Increased mitotic recombination
                    enhances the risk for loss of heterozygosity, which contributes to the
                    generation of cancer in humans. Defective DNA replication can result in elevated
                    levels of recombination as well as mutagenesis and chromosome loss. In the yeast
                    Saccharomyces cerevisiae, a null allele of the RAD27 gene, which encodes a
                    structure-specific nuclease involved in Okazaki fragment processing, stimulates
                    mutation and homologous recombination. Similarly, rad3-102, an allele of the
                    gene RAD3, which encodes an essential helicase subunit of the core TFIIH
                    transcription initiation and DNA repairosome complexes confers a
                    hyper-recombinagenic and hypermutagenic phenotype. Combining the rad27 null
                    allele with rad3-102 dramatically stimulated interhomolog recombination and
                    chromosome loss but did not affect unequal sister-chromatid recombination,
                    direct-repeat recombination, or mutation. Interestingly, the percentage of cells
                    with Rad52-YFP foci also increased in the double-mutant haploids, suggesting
                    that rad3-102 may increase lesions that elicit a response by the recombination
                    machinery or, alternatively, stabilize recombinagenic lesions generated by DNA
                    replication failure. This net increase in lesions led to a synthetic growth
                    defect in haploids that is relieved in diploids, consistent with rad3-102
                    stimulating the generation and rescue of collapsed replication forks by
                    recombination between homologs.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/09/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>712</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">712</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1211</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Nicholson, H. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kretschmar, C. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krailo, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bernstein, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kadota, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fort, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Friedman, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Harris, M. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tedeschi-Blok, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mazewski, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sato, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reaman, G. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Oregon Hlth &amp; Sci Univ, Dept
                    Pediat, Portland, OR 97201 USA. Boston Floating Hosp Infants &amp; Children,
                    Dept Pediat Oncol, Boston, MA USA. Univ So Calif, Keck Sch Med, Dept Prevent
                    Med, Los Angeles, CA USA. Hop St Justine, Dept Pediat Hematol Oncol, Montreal,
                    PQ H3T 1C5, Canada. Childrens Hosp, Dept Hematol Oncol, San Diego, CA USA. Univ
                    Virginia, Div Pediat Hematol Oncol, Charlottesville, VA USA. Duke Univ, Div
                    Pediat Neurooncol, Durham, NC USA. Tomorrows Childrens Inst, Dept Pediat Hematol
                    Oncol, Hackensack, NJ USA. Childrens Oncol Grp, Arcadia, CA USA. Childrens
                    Healthcare Atlanta, Dept Hematol Oncol, Atlanta, GA USA. City Hope Natl Med Ctr,
                    Div Pediat, Duarte, CA 91010 USA. Childrens Natl Med Ctr, Dept Hematol Oncol,
                    Washington, DC 20010 USA.&#xD;Nicholson, HS, Childrens Oncol Grp, 440 E
                    Huntington Dr,4th Floor, Arcadia, CA 91006 USA.&#xD;nicholss@ohsu.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Phase 2 study of temozolomide in
                        children and adolescents with recurrent central nervous system tumors - A
                        report from the children&apos;s oncology group</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1542-1550</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">110</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">temozolomide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">childhood cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">central nervous system
                        tumors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">brain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phase 2 trials</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">imidazotetrazine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIGH-GRADE GLIOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MALIGNANT GLIOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">II TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLIOBLASTOMA-MULTIFORME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">O-6-ALKYLGUANINE-DNA
                        ALKYLTRANSFERASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTITUMOR
                        IMIDAZOTETRAZINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA METHYLTRANSFERASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEDIATRIC-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION-THERAPY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249514300017</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. Effective chemotherapy
                    is lacking for most types of central nervous system (CNS) tumors in children.
                    Temozolomide, an agent with activity against adult brain tumors, was
                    investigated in children and adolescents with recurrent CNS tumors. METHODS.
                    Temozolomide was administered orally as monthly 5-day courses at doses of 200
                    mg/m(2)/d (patients with no prior craniospinal irradiation [CSI]) or 180
                    mg/m(2)/d (prior CSI). Patients with a complete (CR) or partial (PR) response or
                    stable disease (SD) could continue temozolomide for up to 12 cycles. RESULTS.
                    The cohort comprised 122 patients, including 113 with CNS tumors. Median age was
                    11 years (range, 1-23 years). Among 104 evaluable patients with CNS tumors, 5
                    PRs and 1 CR were observed. PRs occurred in 1 of 23 evaluable patients with
                    high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with
                    medulloblastoma/primitive neuroectodermal tumor (PNET). The CR occurred in an
                    additional patient with medulloblastoma/PNET. No responses were observed in
                    patients with ependymoma, brain-stem glioma, or other CNS tumors. Notably, 41%
                    of patients with low-grade astrocytoma had SD through 12 courses. The most
                    frequent toxicities were grade 3 or 4 neutropenia (19%) and thrombocytopenia
                    (25%); nonhematologic toxicity was infrequent. CONCLUSIONS. Although overall
                    objective responses were limited, further exploration of temozolomide may be
                    warranted in children with medulloblastoma and other PNETs, or in patients with
                    low-grade astrocytoma, perhaps in a setting of less pretreatment than the
                    patients in the current study, or in the context of multiagent therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    211HG&#xD;Times Cited: 0&#xD;Cited Reference Count: 47&#xD;Cited References:
                    &#xD; AOKI T, 2003, INT J CLIN ONCOL, V8, P301&#xD; ATHANASSIOU H, 2005, J CLIN
                    ONCOL, V23, P2372&#xD; BOWER M, 1997, CANCER CHEMOTH PHARM, V40, P484&#xD; BRADA
                    M, 2001, ANN ONCOL, V12, P259&#xD; BRADA M, 2003, ANN ONCOL, V14, P1715&#xD;
                    BRANDES AA, 2001, ANN ONCOL, V12, P255&#xD; BRANDES AA, 2006, J CLIN ONCOL, V24,
                    P4746&#xD; BROCK CS, 1998, CANCER RES, V58, P4363&#xD; BRONISCER A, 2005,
                    CANCER, V103, P133&#xD; DEANGELIS LM, 2005, NEW ENGL J MED, V352, P1036&#xD;
                    DONSON AM, 2007, PEDIATR BLOOD CANCER, V48, P403&#xD; ESTLIN EJ, 1998, BRIT J
                    CANCER, V78, P652&#xD; FREEMAN CR, 2002, MED PEDIATR ONCOL, V39, P99&#xD;
                    FRIEDMAN HS, 1995, CANCER RES, V55, P2853&#xD; FRIEDMAN HS, 1998, J CLIN ONCOL,
                    V16, P3851&#xD; GILBERT MR, 2002, NEURO-ONCOLOGY, V4, P261&#xD; GURURANGAN S,
                    2007, NEURO-ONCOLOGY, V9, P161&#xD; HEGI ME, 2005, NEW ENGL J MED, V352,
                    P997&#xD; JANSS AJ, 1998, ANTI-CANCER DRUG, V9, P641&#xD; KALIFA C, 2005, J
                    NEURO-ONCOL, V75, P279&#xD; KOKKINAKIS DM, 2001, CLIN CANCER RES, V7, P421&#xD;
                    KREKLAU EL, 1999, J PHARMACOL EXP THER, V291, P1269&#xD; KUO DJ, 2003, J PEDIAT
                    HEMATOL ONC, V25, P372&#xD; LASHFORD LS, 2002, J CLIN ONCOL, V20, P4684&#xD;
                    MARZOLINI C, 1998, CANCER CHEMOTH PHARM, V42, P433&#xD; NEWLANDS ES, 1992, BRIT
                    J CANCER, V65, P287&#xD; NEWLANDS ES, 1996, EUR J CANCER A, V32, P2236&#xD;
                    NEWLANDS ES, 1997, CANCER TREAT REV, V23, P35&#xD; NICHOLSON HS, 1998, J CLIN
                    ONCOL, V16, P3037&#xD; OREILLY SM, 1993, EUR J CANCER, V29, P940&#xD; OSTERMANN
                    S, 2004, CLIN CANCER RES, V10, P3728&#xD; PACKER RJ, 1999, J CLIN ONCOL, V17,
                    P2127&#xD; PATEL M, 2003, J NEURO-ONCOL, V61, P203&#xD; PLOWMAN J, 1994, CANCER
                    RES, V54, P3793&#xD; POLLACK IF, 1994, NEW ENGL J MED, V331, P1500&#xD; QUINN
                    JA, 2003, J CLIN ONCOL, V21, P646&#xD; RIES LG, 1994, NIH PUBLICATION&#xD;
                    SANKAR A, 1999, ANTI-CANCER DRUG, V10, P179&#xD; SPIRO TP, 2001, CLIN CANCER
                    RES, V7, P2309&#xD; STERBA J, 2002, NEOPLASMA, V49, P117&#xD; STEVENS MFG, 1987,
                    CANCER RES, V47, P5846&#xD; STUPP R, 2005, NEW ENGL J MED, V352, P987&#xD;
                    VERSCHUUR AC, 2004, BRIT J CANCER, V91, P425&#xD; WARREN KE, 2005, J CLIN ONCOL,
                    V23, P7646&#xD; WEDGE SR, 1997, ANTI-CANCER DRUG, V8, P92&#xD; YUNG WKA, 1999, J
                    CLIN ONCOL, V17, P2762&#xD; YUNG WKA, 2000, BRIT J CANCER, V83, P588</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249514300017 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>713</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">713</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">960</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Nowak, N. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miecznikowski, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, S. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaile, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bobadilla, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mhawech-Fauceglia,
                            P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reid, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stoler, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Loree, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ritgual, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sullivan, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hicks, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">State University New York Buffalo,
                    New York State Ctr Excellence Bioinformat &amp; Life, Buffalo, NY 14203 USA.
                    State University New York Buffalo, New York State Ctr Excellence Bioinformat
                    &amp; Life, Dept Biochem, Buffalo, NY USA. State University New York Buffalo,
                    New York State Ctr Excellence Bioinformat &amp; Life, Dept Biostat, Buffalo, NY
                    USA. Roswell Pk Canc Inst, Dept Canc Prevent, Buffalo, NY 14263 USA. Roswell Pk
                    Canc Inst, Dept Populat Sci, Buffalo, NY 14263 USA. Roswell Pk Canc Inst, Dept
                    Head &amp; Neck Surg, Buffalo, NY 14263 USA. Roswell Pk Canc Inst, Dept Dent,
                    Buffalo, NY 14263 USA. Roswell Pk Canc Inst, Dept Maxillofacial, Buffalo, NY
                    14263 USA. Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA. City Hope
                    Natl Med Ctr, Div Pathol, Duarte, CA USA. City Hope Natl Med Ctr, Div Informat
                    Sci, Duarte, CA USA. City Hope Natl Med Ctr, Div Surg, Duarte, CA USA. City Hope
                    Natl Med Ctr, Div Hematol, Duarte, CA USA. City Hope Natl Med Ctr, Div
                    Hematopoiet Cell Transplantat, Duarte, CA USA.&#xD;Nowak, NJ, State University
                    New York Buffalo, New York State Ctr Excellence Bioinformat &amp; Life, 701
                    Ellicott St, Buffalo, NY 14203 USA.&#xD;norma.nowak@roswellpark.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Challenges in array comparative
                        genomic hybridization for the analysis of cancer samples</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Genetics in Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Genetics in Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Genet. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Genet Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">585-595</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">9</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">array comparative genomic
                        hybridization</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">whole genome</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">amplification</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">archive tissue</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CGH ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMPLIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ABERRATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROARRAYS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1098-3600</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249640800005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To address some of the
                    challenges facing the incorporation of array comparative genomic hybridization
                    technology as a clinical tool, including archived tumor tissue, tumor
                    heterogeneity, DNA quality and quantity, and array comparative genomic
                    hybridization platform selection and performance. Methods: Experiments were
                    designed to assess the impact of DNA source (e.g., archival material), quantity,
                    and amplification on array comparative genomic hybridization results. Two
                    microdissection methods were used to isolate tumor cells to minimize
                    heterogeneity. These data and other data sets were used in a further performance
                    comparison of two commonly used array comparative genomic hybridization
                    platforms: bacterial artificial chromosome (Roswell Park Cancer Institute) and
                    oligonucleotide (Agilent Technologies, Santa Clara, CA). Results: Array
                    comparative genomic hybridization data from as few as 100 formalin-fixed,
                    paraffin-embedded cells isolated by laser capture microdissection and amplified
                    were remarkably similar to array comparative genomic hybridization copy number
                    alterations detected in the bulk (unamplified) population. Manual
                    microdissection from frozen sections provided a rapid and inexpensive means to
                    isolate tumor from adjacent DNA for amplification and array comparative genomic
                    hybridization. Whole genome amplification introduced no appreciable allele bias
                    on array comparative genomic hybridization. The array comparative genomic
                    hybridization results provided by the bacterial artificial chromosome and
                    Agilent platforms were concordant in general, but bacterial artificial
                    chromosome array comparative genomic hybridization showed far fewer outliers and
                    overall less technical noise, which could adversely affect the statistical
                    interpretation of the data. Conclusions: This study demonstrates that copy
                    number alterations can be robustly and reproducibly detected by array
                    comparative genomic hybridization in DNA isolated from challenging tumor types
                    and sources, including archival materials, low DNA yield, and heterogeneous
                    tissues. Furthermore, bacterial artificial chromosome array comparative genomic
                    hybridization offers the advantage over the Agilent oligonucleotide platform of
                    presenting fewer outliers, which could affect data interpretation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    213BL&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; BOBADILLA D, 2007, BRIT J HAEMATOL, V136, P806&#xD; BREDEL M, 2005, CANCER
                    RES, V65, P4088&#xD; BREDEL M, 2005, J MOL DIAGN, V7, P171&#xD; COE BP, 2007,
                    GENOMICS, P647&#xD; COE BR, 2005, GENE CHROMOSOME CANC, V42, P308&#xD; COWELL
                    JK, 2004, J NEUROPATH EXP NEUR, V63, P151&#xD; DEAN FB, 2002, P NATL ACAD SCI
                    USA, V99, P5261&#xD; DEVRIES S, 2005, J MOL DIAGN, V7, P65&#xD; FENSTERER H,
                    2007, BMC CANCER, V7&#xD; FIEGLER H, 2007, NUCLEIC ACIDS RES, V35&#xD; HESTER S,
                    2007, ABRF ANN M TAMP FL M&#xD; JOHNSON NA, 2006, LAB INVEST, V86, P968&#xD;
                    JOOSSE SA, 2007, BMC CANCER, V7&#xD; KRANZ BR, 2000, LANCET, V356, P1242&#xD;
                    MIECZNIKOWSKI J, 2006, 0607 STAT U NEW YORK, P1&#xD; MILIARAS D, 2007, BIRTH
                    DEFECTS RES A, V79, P236&#xD; MORIARTY AT, 2004, ARCH PATHOL LAB MED, V128,
                    P513&#xD; NIGRO JM, 2005, CANCER RES, V65, P1678&#xD; NOWAK NJ, 2005, CANCER
                    GENET CYTOGEN, V161, P36&#xD; NOWAK NJ, 2005, CURRENT PROTOCOLS HU, P1&#xD;
                    PARIS PL, 2003, AM J PATHOL, V162, P763&#xD; ROSSI MR, 2005, GENE CHROMOSOME
                    CANC, V44, P85&#xD; ROSSI MR, 2006, GENE CHROMOSOME CANC, V45, P290&#xD;
                    SNIJDERS AM, 2001, NAT GENET, V29, P263&#xD; WEISS LM, 1999, HODGKINS DIS,
                    P101</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249640800005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>615</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">615</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1208</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Numbenjapon, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Serrano, L. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cooper, L. J. N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Texas, Childrens Canc Hosp, MD
                    Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA. Beckman Res Inst, Div Mol
                    Med, Duarte, CA USA. Beckman Res Inst, Div Canc Immunotherapeut &amp; Tumor
                    Immunol, Duarte, CA USA. Beckman Res Inst, Div Hematol &amp; Hematopoiet Cell
                    Transplantat, Duarte, CA USA. Beckman Res Inst, Div Pediat Hematol Oncol,
                    Duarte, CA USA. City Hope Natl Med Ctr, Duarte, CA 91010 USA. Phramongkutklao
                    Royal Thai Army Hosp, Dept Med, Div Pediat, Bangkok, Thailand. Coll Med,
                    Bangkok, Thailand.&#xD;Cooper, LJN, Univ Texas, Childrens Canc Hosp, MD Anderson
                    Canc Ctr, Div Pediat, Unit 907,1515 Holcombe Blvd, Houston, TX 77030
                    USA.&#xD;ljncooper@mdanderson.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Antigen-independent and
                        antigen-dependent methods to numerically expand CD19-specific CD8(+) T
                        cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Experimental Hematology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Exp. Hematol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Experimental Hematology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Exp. Hematol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Exp Hematol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Experimental Hematology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Exp. Hematol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Exp Hematol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1083-1090</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">ADOPTIVE IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYELOID-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRESENTING CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOTOXICITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IL-15</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD28</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VIVO</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0301-472X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247801000009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective. Preclinical and clinical
                    trials are investigating the potential of T cells genetically modified to
                    express a first-generation CD19-specific chimeric antigen receptor (CAR),
                    designated CD19R, for adoptive immunotherapy of B-lineage leukemias and
                    lymphomas. Currently, our genetically modified CD19-specific CD8(+)
                    (CD19R(+)CD8(+)) T cells are expanded ex vivo using a rapid expansion protocol
                    (REP) to clinically meaningful numbers after antigen-independent activation with
                    anti-CD3 epsilon and recombinant human interleukin-2 on a double-cell
                    feeder-layer of gamma-irradiated allogeneic peripheral blood mononuclear cells
                    and a lymphoblastoid cell line. We now compare the ability of the REP with
                    CD19-dependent numerical expansion using CD19(+) artificial antigen-presenting
                    cells to propagate CD19R(+)CD8(+) T cells. Materials and Methods. We evaluated
                    long-term (28 days) propagation, CD19R CAR expression, and cytolytic activity of
                    CD19R(+)CD8(+) T cells expanded by either a REP or an antigen expansion protocol
                    (AEP) using K562-derived artificial antigen-presenting cells coexpressing CD19
                    antigen and two T-cell costimulatory molecules (4-1BB ligand and major
                    histocompatibility class I-related chains A) in the presence of exogenous
                    recombinant human interleukin-2 and recombinant human interieukin-15. Results.
                    Populations of CD19R(+)CD8(+) T cells could be numerically expanded on AEP to
                    meet anticipated clinical need. The AEP was superior to REP, as this method
                    selected for an outgrowth of T cells with increased CD19R CAR expression and
                    improved redirected cytolytic activity. Conclusion. Robust propagation of
                    CD19R(+)CD8(+) T cells achieved by AEP supports qualifying this cell line for
                    use in current good manufacturing practices for CAR(+) T cells as an alternative
                    to REP for adoptive immunotherapy clinical trials. (c) 2007 International
                    Society for Experimental Hematology. Published by Elsevier Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    186TL&#xD;Times Cited: 0&#xD;Cited Reference Count: 36</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247801000009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>599</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">599</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1206</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Oehler, V. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gooley, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snyder, D. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Johnston, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lin, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cummings, C. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Negrin, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Appelbaum, F. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Radich, J. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr, Div
                    Clin Res, Seattle, WA 98104 USA. City Hope Natl Med Ctr, Div Hematol Hematopoiet
                    Cell Transplantat, Duarte, CA 91010 USA. Stanford Univ, Div Bone Marrow
                    Transplantat, Stanford, CA 94305 USA.&#xD;Oehler, VG, 1100 Fairview Ave
                    N,D4-100,POB 19024, Seattle, WA 98109 USA.&#xD;voehler@u.washington.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The effects of imatinib mesylate
                        treatment before allogeneic transplantation for chronic myeloid
                        leukemia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Blood</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Blood</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1782-1789</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELL
                        TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC MYELOGENOUS
                        LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TERM-FOLLOW-UP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC-PHASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC GRAFT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-4971</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244219400061</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The impact of imatinib mesylate (IM)
                    treatment for chronic myeloid leukemia (CML) on subsequent allogeneic
                    transplantation is uncertain. To better understand this relationship, we
                    retrospectively compared 145 patients with CIVIL receiving IM for a minimum of 3
                    months before allogeneic hematopoietic cell transplantation (HCT) to 231
                    patients with CIVIL who did not. IM treatment was associated with no increase in
                    early hepatotoxicity or engraftment delay after HCT compared with the historical
                    cohort. In addition, there was no statistically significant difference in the
                    IM-treated cohort compared with the historical cohort with regard to overall
                    survival, disease-free survival, relapse, and nonrelapse mortality. For
                    chronic-phase (CP) patients, IM response prior to HCT was associated with
                    post-HCT outcome. Patients who underwent transplantation in CP with a suboptimal
                    response or a loss of response on IM had a statistically significant higher
                    hazard of mortality when compared with CP patients who achieved a complete
                    cytogenetic response (CCR) or major cytogenetic response (MCR) on IM (HR =
                    5.31,95% confidence interval [CI] 1.13-25.05, P = .03). These data indicate that
                    pre-HCT IM is not associated with increased transplant-related morbidity (TRM)
                    or poorer outcomes. However, patients with a suboptimal or loss of IM response
                    before HCT do worse, suggesting a more aggressive disease course for these
                    patients. (Blood. 2007;109:1782-1789). (c) 2007 by The American Society of
                    Hematology.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    136JW&#xD;Times Cited: 2&#xD;Cited Reference Count: 49</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244219400061 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>474</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">474</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1204</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Olafsen, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gu, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sherman, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leyton, J. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Witkosky, M. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Raubitschek, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Morrison, S. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, A. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reiter, R. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Crump Inst Mol Imaging, Dept Mol &amp; Med Pharmacol, Los Angeles, CA
                    90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles,
                    CA 90095 USA. Beckman Res Inst City Hope, Div Informat Sci, Duarte, CA USA.
                    Beckman Res Inst City Hope, Div Immunizat, Duarte, CA USA. City Hope Natl Med
                    Ctr, Dept Radioimmunotherapy, Duarte, CA USA. Univ Calif Los Angeles, Dept
                    Microbiol Immunol &amp; Mol Genet, Los Angeles, CA 90024 USA. Univ Calif Los
                    Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.&#xD;Olafsen, T, Univ Calif
                    Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Dept Mol &amp; Med
                    Pharmacol, 700 Wetwood Plaza, Los Angeles, CA 90095
                    USA.&#xD;tolafsen@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Targeting, imaging, and therapy
                        using a humanized antiprostate stem cell antigen (PSCA) antibody</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunother</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">396-405</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">30</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">prostate cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PSCA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">antibody therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">I-124</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDEPENDENT
                        PROSTATE-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MONOCLONAL-ANTIBODY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEMBRANE ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CRYSTAL-STRUCTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-GROWTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FRAGMENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">XENOGRAFTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MINIBODY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May-Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1524-9557</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246029600004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The murine 1G8 (mu1GS) monoclonal
                    antibody directed against prostate stem cell antigen (PSCA) prevents prostate
                    tumor establishment, growth, and metastasis in murine models. To further
                    delineate in vivo targeting properties, mu1G8 was radiolabeled with In-III and
                    evaluated in nude mice bearing PC3-PSCA xenografts. Tumor activity ranged from
                    11.8% to 17.1% injected dose per gram (ID/g) at 24 to 96 hours postinjection. To
                    extend the clinical applicability of mu1G8, a chimeric 1G8 antibody was produced
                    that exhibited specific binding to PSCA and significant antitumor effect over
                    mu1G8 in established LAPC-9 prostate cancer xenografts (P = 0.0014). However,
                    low expression yields and instability prompted us to humanize 1GS by grafting
                    the complementary determining regions onto the stable, human Fv framework of
                    anti-p185(HER2) 4D5v8 (trastuzumab). Two humanized 1G8 (hu1G8) versions (A and
                    13) that differed in the number of murine residues present in the C-terminal
                    half of CDR-H2, were produced. Biacore binding studies demonstrated affinities
                    of 1.47 nM for mu 1G8 and 3.74 nM for hu2B3-B, representing a 2.5-fold
                    reduction. Tumor targeting of version B radioiodinated with I-124 was evaluated
                    by serial microPET imaging. Specific tumor targeting of I-124-hu1G8-B to
                    PC3-PSCA [12.7 ( +/- 1.6)% ID/g at 94 h] and LAPC-9 [6.6 ( +/- 0.9)% ID/g at 168
                    h) xenografts was observed. Inhibition of tumor growth by hu1G8-B was
                    demonstrated in mice bearing low-expressing SW-780-PSCA bladder carcinoma
                    xenografts. In this model, the mu1G8 was ineffective, whereas the hu1G8-B
                    exhibited approximately 50% inhibitory effect. These data support further
                    development of hu1G8 anti-PSCA antibody for targeted imaging and therapy for
                    tumors of urogenital origin.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    161QE&#xD;Times Cited: 0&#xD;Cited Reference Count: 47&#xD;Cited References:
                    &#xD; ADAMS GP, 2005, NAT BIOTECHNOL, V23, P1147&#xD; BANDER NH, 2005, J CLIN
                    ONCOL, V23, P4591&#xD; BEBBINGTON CR, 1992, BIO-TECHNOL, V10, P169&#xD; BOEHM
                    MK, 2000, BIOCHEM J 2, V346, P519&#xD; BRECHBIEL MW, 1991, BIOCONJUGATE CHEM,
                    V2, P187&#xD; CHOW PL, 2005, PHYS MED BIOL, V50, P1837&#xD; COBLEIGH MA, 1999, J
                    CLIN ONCOL, V17, P2639&#xD; COLOMA MJ, 1992, J IMMUNOL METHODS, V152, P89&#xD;
                    CRAFT N, 1999, CANCER RES, V59, P5030&#xD; DEFRISE M, 1997, IEEE T MED IMAGING,
                    V16, P145&#xD; EIGENBROT C, 1993, J MOL BIOL, V229, P969&#xD; EWERT S, 2003, J
                    MOL BIOL, V325, P531&#xD; GALFRE G, 1981, METHOD ENZYMOL, V73, P3&#xD; GEISSLER
                    F, 1992, CANCER RES, V52, P2907&#xD; GU Z, 2000, ONCOGENE, V19, P1288&#xD; GU
                    ZN, 2005, CANCER RES, V65, P9495&#xD; HAMILTON A, 1998, P AM ASSOC CANC RES,
                    V39, P440&#xD; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444&#xD; HU SZ,
                    1996, CANCER RES, V56, P3055&#xD; HUBERT RS, 1999, P NATL ACAD SCI USA, V96,
                    P14523&#xD; HWANG WYK, 2005, METHODS, V36, P3&#xD; ISRAELI RS, 1994, CANCER RES,
                    V54, P1807&#xD; JONES PT, 1986, NATURE, V321, P522&#xD; KENANOVA V, 2005, CANCER
                    RES, V65, P622&#xD; KINAHAN PE, 1989, IEEE T NUCL SCI 1, V36, P964&#xD; LOENING
                    AM, 2003, MOL IMAGING, V2, P131&#xD; MACCALLUM RM, 1996, J MOL BIOL, V262,
                    P732&#xD; MILOWSKY MI, 2004, J CLIN ONCOL, V22, P2522&#xD; MORTON TA, 1998,
                    METHOD ENZYMOL, V295, P268&#xD; NANUS DM, 2003, J UROLOGY, V170, P84&#xD;
                    OCONNOR SJ, 1998, PROTEIN ENG, V11, P321&#xD; OLAFSEN T, 2004, PROTEIN ENG DES
                    SEL, V17, P315&#xD; OLAFSEN T, 2005, CANCER RES, V65, P5907&#xD; PADLAN EA,
                    1995, FASEB J, V9, P133&#xD; REITER RE, 1998, P NATL ACAD SCI USA, V95,
                    P1735&#xD; REITER RE, 2000, GENE CHROMOSOME CANC, V27, P95&#xD; SAFFRAN DC,
                    2001, P NATL ACAD SCI USA, V98, P2658&#xD; SMITHJONES PM, 2000, CANCER RES, V60,
                    P5237&#xD; SMITHJONES PM, 2004, Q J NUCL MED MOL IM, V48, P297&#xD; SUNDARESAN
                    G, 2003, J NUCL MED, V44, P1962&#xD; WEINER LM, 2006, J IMMUNOTHER, V29, P1&#xD;
                    WU AM, 2001, PROTEIN ENG, V14, P1025&#xD; WU AM, 2005, NAT BIOTECHNOL, V23,
                    P1137&#xD; XU FJ, 1997, NUCL MED BIOL, V24, P451&#xD; YAZAKI PJ, 2001,
                    BIOCONJUGATE CHEM, V12, P220&#xD; YAZAKI PJ, 2001, J IMMUNOL METHODS, V253,
                    P195&#xD; YAZAKI PJ, 2004, PROTEIN ENG DES SEL, V17, P481</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246029600004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>391</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">391</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1202</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Omori, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Valiente, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Orr, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rawson, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferreri, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Todorov, I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Al-Abdullah, I. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Medicherla, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Potter, A. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schreiner, G. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mullen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, So Calif Islet Cell Resources Ctr, Dept Diabet Endocrinol &amp; Metab,
                    Duarte, CA 91010 USA. Scios Inc, Fremont, CA USA.&#xD;Omori, K, City Hope Natl
                    Med Ctr, Beckman Res Inst, So Calif Islet Cell Resources Ctr, Dept Diabet
                    Endocrinol &amp; Metab, Duarte, CA 91010 USA.&#xD;komori@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Improvement of human islet
                        cryopreservation by a p38 MAPK inhibitor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Transplantation</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Transplantation</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1224-1232</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cryopreservation
                        solution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">human islets</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p38 MAPK inhibitor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATED PROTEIN-KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRO-INFLAMMATORY
                        CYTOKINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEAT-SHOCK</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEIN-27</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-WISCONSIN SOLUTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPERFUSION INJURY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATIC-ISLETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ENVIRONMENTAL-STRESS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INSULIN-SECRETION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIABETES-MELLITUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FOLLOW-UP</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1600-6135</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245937500025</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The activation of p38
                    mitogen-activated protein kinase (MAPK) has been shown to cause
                    ischemia/reperfusion injury of several organs used for transplantation and also
                    to play a significant role in primary islet graft nonfunction. Activation of p38
                    MAPK may also occur during islet cryopreservation and thawing. In this study, a
                    p38 MAPK inhibitor (p38IH) was applied to human islet cryopreservation to
                    improve islet yield and quality after thawing. Under serum-free conditions,
                    human islets were cryopreserved, thawed and cultured using our standard
                    procedures. Three types of solutions were tested: conventional RPMI1640 medium
                    (RPMI), a newly developed islet cryopreservation solution (ICS), and ICS
                    supplemented with a p38IH, SD-282 (ICS-p38IH). Activation or inhibition of p38
                    MAPK was demonstrated by the diminished phosphorylation of HSP27 substrate.
                    Islet recovery on day 2 after thawing was highest with ICS-p38IH and islet
                    viability was not significantly different in the three groups. beta Cell numbers
                    and function were the highest in islets cryopreserved with ICS-p38IH.
                    Glucose-stimulated human C-peptide levels were 86% of that of the nonfrozen
                    islets when measured 4 weeks after transplantation into NODscid mice. This
                    improvement may provide an opportunity to establish islet banks and allow the
                    use of cryopreserved islets for clinical transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    160JU&#xD;Times Cited: 0&#xD;Cited Reference Count: 44&#xD;Cited References:
                    &#xD; ARATA T, 2004, ARTIF ORGANS, V28, P529&#xD; ARITA S, 1999, PANCREAS, V19,
                    P289&#xD; BELZER FO, 1988, TRANSPLANTATION, V45, P673&#xD; COWAN KJ, 2003, J EXP
                    BIOL, V206, P1107&#xD; DUVIVIER V, 1999, CRYOBIOLOGY, V38, P386&#xD; FERANCHAK
                    AP, 2001, J CLIN INVEST, V108, P1495&#xD; FROUD T, 2005, AM J TRANSPLANT, V5,
                    P2037&#xD; GREENWAY SC, 2000, MOL CELL BIOCHEM, V209, P29&#xD; GUAY J, 1997, J
                    CELL SCI 3, V110, P357&#xD; HASHIMOTO N, 2002, TRANSPLANTATION, V74, P320&#xD;
                    HERING BJ, 2005, TRANSPLANTATION, V79, P1296&#xD; HOCHACHKA PW, 1986, INTENS
                    CARE MED, V12, P127&#xD; HOCHACHKA PW, 1986, SCIENCE, V231, P234&#xD; JANJIC D,
                    1996, PANCREAS, V13, P166&#xD; JANSSON L, 2002, DIABETOLOGIA, V45, P749&#xD;
                    KAISER RA, 2004, J BIOL CHEM, V279, P15524&#xD; KEMP JA, 1978, TRANSPLANTATION,
                    V26, P260&#xD; KENMOCHI T, 1998, PANCREAS, V17, P367&#xD; KOBAYASHI M, 2006,
                    HEPATO-GASTROENTEROL, V53, P243&#xD; KOIKE N, 2004, TRANSPLANTATION, V77,
                    P286&#xD; LAKEY JRT, 2001, CELL TRANSPLANT, V10, P583&#xD; LAVOIE JN, 1993, J
                    BIOL CHEM, V268, P24210&#xD; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505&#xD; LI
                    ZH, 2004, J CARDIOVASC PHARM, V44, P486&#xD; LIU K, 2000, TISSUE ENG, V6,
                    P539&#xD; LOOMIS WH, 2003, J BIOL CHEM, V278, P4590&#xD; MATSUDA T, 2005, AM J
                    TRANSPLANT, V5, P484&#xD; MEDICHERLA S, 2006, J PHARMACOL EXP THER, V318,
                    P132&#xD; MENGER MD, 2001, WORLD J SURG, V25, P509&#xD; MIYAMOTO M, 1996,
                    TRANSPLANT P, V28, P1121&#xD; NEMETH ZH, 2002, AM J PATHOL, V161, P987&#xD;
                    PIEMONTI L, 1999, TRANSPLANTATION, V68, P655&#xD; RAINGEAUD J, 1995, J BIOL
                    CHEM, V270, P7420&#xD; RAJOTTE RV, 1977, CRYOBIOLOGY, V14, P116&#xD; RAJOTTE RV,
                    1999, ANN NY ACAD SCI, V875, P200&#xD; ROGER F, 1999, J BIOL CHEM, V274,
                    P34103&#xD; RYAN EA, 2005, DIABETES, V54, P2060&#xD; SHAPIRO AMJ, 2000, NEW ENGL
                    J MED, V343, P230&#xD; SHAPIRO AMJ, 2005, TRANSPLANTATION, V79, P1304&#xD; SMITH
                    L, 1998, EDUC URBAN SOC, V30, P296&#xD; SVENSSON CI, 2003, J NEUROCHEM, V86,
                    P1534&#xD; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89&#xD; WOODS EJ, 2004,
                    TRANSPLANT P, V36, P1139&#xD; YOSHINARI D, 2001, TRANSPLANTATION, V72,
                    P22</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245937500025 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>206</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">206</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1195</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Pameijer, C. R. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Navanjo, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meechoovet, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagner, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aguilar, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wright, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brown, C. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Canc Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010 USA. Stony
                    Brook Univ Hosp, Div Gen &amp; Oncol Surg, Stony Brook, NY USA.&#xD;Jensen, MC,
                    City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Immunotherapeut &amp; Tumor
                    Immunol, 1500 E Duarte Rd,MOB-4, Duarte, CA 91010
                    USA.&#xD;mjensen@coh.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Conversion of a tumor-binding
                        peptide identified by phage display to a functional chimeric T cell antigen
                        receptor</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Gene Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Gene Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">91-97</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">T cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chimeric
                        immuno-receptors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">phage display</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTEGRIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0929-1903</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000242850400011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Adoptive transfer of ex vivo
                    expanded tumor-specific T cells is a promising therapeutic modality for
                    promoting or augmenting antitumor immunity. Several groups, including ours, are
                    developing antigen receptor gene transfer strategies as a means of generating
                    effector cells for adoptive therapy. Chimeric antigen receptors ( CARs) have
                    been described that use single-chain antibodies or cytokine ligands as tumor
                    targeting domains. Here, we describe the capacity of a tumor-binding peptide
                    identified by phage display combinatorial library screening to serve as a CAR
                    targeting domain. A phage library-selected high-affinity 12-mer peptide ( Bpep)
                    specific for alpha( v) beta( 6) integrin ( alpha v beta 6) was chosen for these
                    studies. Primary human T cells were genetically modified to express the Bpep-CAR
                    consisting of an alpha v beta 6-specific peptide and human IgG4 hinge-Fc
                    extracellular domain fused to the cytoplasmic tail of CD3-zeta. T cell
                    expression of the Bpep-CAR was assessed by Western blot analysis, and
                    trafficking of the Bpep-CAR to the cell surface was demonstrated by flow
                    cytometry. Functionally, Bpep-CAR redirected cytotoxic T lymphocytes
                    specifically kill integrin alpha v beta 6(+) ovarian tumor targets, and are
                    activated for interferon gamma secretion. Our data suggest that large new
                    repertoires of tumor-specific T cell antigen receptor transgenes might be
                    available through merging combinatorial peptide libraries with CAR construct
                    design.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    117CN&#xD;Times Cited: 0&#xD;Cited Reference Count: 14&#xD;Cited References:
                    &#xD; AHMED N, 2002, J HISTOCHEM CYTOCHEM, V50, P1371&#xD; ALAMA A, 1996,
                    GYNECOL ONCOL, V62, P82&#xD; BREUSS JM, 1995, J CELL SCI 07/01 6, V108,
                    P2241&#xD; COOPER LJ, 2005, CANC CHEMOTHER BIOL, V22, P293&#xD; COOPER LJN,
                    2003, BLOOD, V101, P1637&#xD; DUDLEY ME, 2002, SCIENCE, V298, P850&#xD; GROSS G,
                    1992, FASEB J, V6, P3370&#xD; JENSEN MC, 2000, MOL THER, V1, P49&#xD; KRAFT S,
                    1999, J BIOL CHEM, V274, P1979&#xD; NIU J, 2001, INT J CANCER, V92, P40&#xD;
                    RENHEIDENREICH L, 2000, HUM GENE THER, V11, P9&#xD; ROSENBERG SA, 1999, CA CANC
                    J CLIN, V49, P65&#xD; ROSENBERG SA, 1999, CA-CANCER J CLIN, V49, P70&#xD; ROSSIG
                    C, 2001, INT J CANCER, V94, P228</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000242850400011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>476</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">476</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1194</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Pantuck, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Seligson, D. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Klatte, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leppert, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moore, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Toole, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gibbons, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Belldegrun, A. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Dept Urol, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen
                    Sch Med, Dept Pathol &amp; Lab Med, Los Angeles, CA USA. Univ Calif Los Angeles,
                    David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Wyeth Ayerst Res,
                    Cambridge, MA USA. Wyeth Res, Pearl River, NY USA.&#xD;Figlin, RA, City Hope
                    Natl Med Ctr, Beckman Res Inst, Div Med Oncol &amp; Expt Therapeut, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;rfiglin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Prognostic relevance of the mTOR
                        pathway in renal cell carcinoma - Implications for molecular patient
                        selection for targeted therapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2257-2267</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">mTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">S6</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Akt</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PTEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p27</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEPENDENT KINASE
                        INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDEPENDENT PREDICTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TISSUE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROARRAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN TARGET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RAPAMYCIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">P27(KIP1)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246679100013</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. The mammalian target of
                    rapamycin (mTOR) pathway is up-regulated in many human cancers, and agents
                    targeting the mTOR pathway are in various stages of clinical development. The
                    goal of the study was to evaluate the potential and limitations of targeting the
                    mTOR pathway in renal cell carcinoma (RCC). METHODS. immunohistochemical
                    analysis using antibodies against pAkt, PTEN, p27, and pS6 was performed on a
                    tissue microarray constructed from paraffin-embedded specimens from 375 patients
                    treated by nephrectomy for RCC. The expression was associated with pathological
                    parameters and survival. RESULTS. The mTOR pathway was more significantly
                    altered in clear-cell RCC, high-grade tumors, and tumors with poor prognostic
                    features. PS6 and PTEN showed the strongest associations with pathological
                    parameters. Survival tree analysis regarding expression of cytoplasmic pAkt,
                    nuclear pAkt, PTEN, cytoplasmic p27, and pS6 identified staining percentages of
                    40%, 10%, 75%, 7%, and 70%, respectively, as ideal cutoff values for
                    stratification, with corresponding P-values of .03, .001,. 02, .005, and
                    &lt;.0001, respectively. Interestingly, high nuclear pAkt expression was
                    associated with a favorable prognosis, whereas high cytoplasmic pAkt expression
                    was associated with a poor prognosis. In multivariate Cox regression analysis,
                    ECOG PS, T classification, N classification, M classification, cytoplasmic Akt,
                    nuclear pAkt, PTEN, and pS6 were independent prognostic factors of DSS,
                    CONCLUSIONS. Components of the mTOR pathway are significantly associated with
                    pathological features and survival. Not all RCC tumor types seem to he equally
                    amenable to mTOR targeted therapy. PTEN, pAkt, p27, and pS6 may serve as
                    surrogate parameters for patient selection and predicting prognosis. Patients
                    with a highly activated mTOR pathway should benefit most from this therapy.
                    External validation of our results is recommended.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    170QN&#xD;Times Cited: 0&#xD;Cited Reference Count: 47&#xD;Cited References:
                    &#xD; ABRAHAM RT, 1998, CURR OPIN IMMUNOL, V10, P330&#xD; ATKINS MB, 2004, J
                    CLIN ONCOL, V22, P909&#xD; BRENNER W, 2002, INT J CANCER, V99, P53&#xD; BUI MHT,
                    2003, CLIN CANCER RES, V9, P802&#xD; CHO D, 2005, P AACR NCI EORTC INT&#xD; CHOE
                    G, 2003, CANCER RES, V63, P2742&#xD; ESCUDIER B, 2007, NEW ENGL J MED, V356,
                    P125&#xD; FRANK I, 2002, J UROLOGY, V168, P2395&#xD; GALANIS E, 2005, J CLIN
                    ONCOL, V23, P5294&#xD; GOFFIN J, 2005, CLIN CANCER RES, V11, P5928&#xD;
                    HAINSWORTH JD, 2005, J CLIN ONCOL, V23, P7889&#xD; HAITEL A, 2001, UROLOGY, V58,
                    P477&#xD; HAY N, 2004, GENE DEV, V18, P1926&#xD; HEDBERG Y, 2003, BRIT J CANCER,
                    V88, P1417&#xD; HOSOI H, 1998, MOL PHARMACOL, V54, P815&#xD; HOSOI H, 1999,
                    CANCER RES, V59, P886&#xD; HUDES G, 2006, J CLIN ONCOL, V24, LBA4&#xD; IHAKA R,
                    1996, J COMPUTATIONAL GRAP, V5, P299&#xD; INOKI K, 2002, NAT CELL BIOL, V4,
                    P648&#xD; JEMAL A, 2006, CA-CANCER J CLIN, V56, P106&#xD; JIANG YH, 2000, P NATL
                    ACAD SCI USA, V97, P10538&#xD; KONONEN J, 1998, NAT MED, V4, P844&#xD; LANGNER
                    C, 2004, VIRCHOWS ARCH, V445, P631&#xD; LIANG J, 2002, NAT MED, V8, P1153&#xD;
                    MIGITA T, 2002, CANCER, V94, P973&#xD; MOTZER RJ, 2006, J CLIN ONCOL, V24,
                    P16&#xD; MOTZER RJ, 2006, JAMA-J AM MED ASSOC, V295, P2516&#xD; MOTZER RJ, 2007,
                    NEW ENGL J MED, V356, P115&#xD; NESHAT MS, 2001, P NATL ACAD SCI USA, V98,
                    P10314&#xD; OREND G, 1998, ONCOGENE, V16, P2575&#xD; PANTUCK AJ, 2003, CLIN
                    CANCER RES, V9, P4641&#xD; PENDE M, 2004, MOL CELL BIOL, V24, P3112&#xD; RATAIN
                    MJ, 2006, J CLIN ONCOL, V24, P2505&#xD; RINI BI, 2006, CURR OPIN ONCOL, V18,
                    P289&#xD; SARBASSOV DD, 2005, CURR OPIN CELL BIOL, V17, P596&#xD; SELIGSON DB,
                    2004, CLIN CANCER RES, V10, P2659&#xD; SHVARTS O, 2005, J UROLOGY, V173,
                    P725&#xD; TOKER A, 2006, CANCER RES, V66, P3963&#xD; VELICKOVIC M, 2002, MODERN
                    PATHOL, V15, P479&#xD; VIGLIETTO G, 2002, CELL CYCLE, V1, P394&#xD; VIGLIETTO G,
                    2002, NAT MED, V8, P1136&#xD; WEISS RH, 2007, J UROLOGY, V177, P63&#xD; WU FY,
                    2006, CANCER RES, V66, P2162&#xD; YANG JC, 2003, NEW ENGL J MED, V349, P427&#xD;
                    ZHANG Y, 2003, NAT CELL BIOL, V5, P578&#xD; ZISMAN A, 2002, J CLIN ONCOL, V20,
                    P1368&#xD; ZISMAN A, 2002, J CLIN ONCOL, V20, P4559</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246679100013 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>235</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">235</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1193</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Papas, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Colton, C. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nelson, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rozak, P. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Avgoustiniatos, E.
                            S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Scott, W. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wildey, G. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pisania, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weir, G. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hering, B. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Minnesota, Dept Surg, Diabet
                    Inst Immunol &amp; Transplantat, Minneapolis, MN 55455 USA. MIT, Dept Chem Engn,
                    Cambridge, MA 02139 USA. City Hope Natl Med Ctr, ABCC, ICR Ctr Consortium,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010
                    USA. Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.&#xD;Papas,
                    KK, Univ Minnesota, Dept Surg, Diabet Inst Immunol &amp; Transplantat, Box 242
                    UMHC, Minneapolis, MN 55455 USA.&#xD;papas006@umn.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Human islet oxygen consumption
                        rate and DNA measurements predict diabetes reversal in nude mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Transplantation</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Transplantation</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Transplantation</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">707-713</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">islet potency</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">oxygen consumption rate</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">nude mice</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality assessment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VIABILITY ASSAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRESERVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREAS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1600-6135</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244715800030</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">There is a need for simple,
                    quantitative and prospective assays for islet quality assessment that are
                    predictive of islet transplantation outcome. The current state-of-the-art
                    athymic nude mouse bioassay is costly, technically challenging and
                    retrospective. In this study, we report on the ability of 2 parameters
                    characterizing human islet quality: (1) oxygen consumption rate (OCR), a measure
                    of viable volume; and (2) OCR/DNA, a measure of fractional viability, to predict
                    diabetes reversal in nude mice. Results demonstrate that the probability for
                    diabetes reversal increases as the graft&apos;s OCR/DNA and total OCR increase.
                    For a given transplanted OCR dose, diabetes reversal is strongly dependent on
                    OCR/DNA. The OCR and OCR/DNA (the &apos;OCR test&apos;) data exhibit 89%
                    sensitivity and 77% specificity in predicting diabetes reversal in nude mice (n
                    = 86). We conclude that the prospective OCR test can effectively replace the
                    retrospective athymic nude mouse bioassay in assessing human islet quality prior
                    to islet transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    143JD&#xD;Times Cited: 0&#xD;Cited Reference Count: 24&#xD;Cited References:
                    &#xD; BARTLETT JE, 2001, INFORMATION TECHNOLO, V19, P43&#xD; COLTON CK, 2006, IN
                    PRESS CELL TRANSP&#xD; ECKHOFF DE, 2003, SURGERY, V134, P169&#xD; FROUD T, 2005,
                    AM J TRANSPLANT, V5, P2037&#xD; HATIPOGLU B, 2005, CURR DIAB REP, V5, P311&#xD;
                    HERING BJ, 2005, JAMA-J AM MED ASSOC, V293, P830&#xD; ICHII H, 2005, AM J
                    TRANSPLANT, V5, P1635&#xD; LONDON NJM, 1989, DIABETES RES CLIN EX, V12,
                    P141&#xD; LONDON NJM, 1990, HORM METAB RES, V25, P82&#xD; MARKMANN JF, 2003, ANN
                    SURG, V237, P741&#xD; PAPAS KK, 1999, BIOTECHNOL BIOENG, V66, P219&#xD; PAPAS
                    KK, 2001, ANN NY ACAD SCI, V944, P96&#xD; PAPAS KK, 2001, CELL TRANSPLANT, V10,
                    P519&#xD; PAPAS KK, 2005, TRANSPLANT P, V37, P3412&#xD; PAPAS KK, 2005,
                    TRANSPLANT P, V37, P3501&#xD; RICORDI C, 2001, TRANSPLANT P, V33, P1709&#xD;
                    SHAPIRO AMJ, 2000, NEW ENGL J MED, V343, P230&#xD; STEINLECHNERMARAN R, 1997,
                    TRANSPLANTATION, V63, P136&#xD; STEURER W, 1999, TRANSPLANT P, V31, P650&#xD;
                    SWEET IR, 2002, DIABETES TECHNOL THE, V4, P661&#xD; WANG RN, 1999, J ENDOCRINOL,
                    V163, P181&#xD; WONNACOTT K, 2005, AM J THER, V12, P600&#xD; YANG H, 2000, J
                    BURN CARE REHABIL, V21, P99&#xD; ZHANG Y, 2000, TRANSPLANT P, V32, P2345</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244715800030 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>387</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">387</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1192</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Park, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">DiGiusto, D. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wright, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Naranjo, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagner, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meechoovet, H. B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bautista, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ostberg, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensens, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Canc Immunotherapeut &amp; Tumor Immunol, Dept Pediat Hematol Oncol,
                    Duarte, CA 91010 USA. Childrens Hosp &amp; Med Ctr, Dept Pediat Hematol Oncol,
                    Seattle, WA 98105 USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Hematol
                    &amp; Hematopoiet Cell Transplant, Duarte, CA 91010 USA. City Hope Natl Med Ctr,
                    Beckman Res Inst, Dept Cytogenet, Duarte, CA 91010 USA. City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA.&#xD;Jensens, MC, City Hope
                    Natl Med Ctr, Beckman Res Inst, Div Canc Immunotherapeut &amp; Tumor Immunol,
                    Dept Pediat Hematol Oncol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;mjensen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Adoptive transfer of chimeric
                        antigen receptor re-directed cytolytic T lymphocyte clones in patients with
                        neuroblastoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">825-833</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-ADHESION MOLECULE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO PERSISTENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTATIC MELANOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN CARCINOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER REGRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-GROWTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">L1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-0016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245215400024</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Metastatic neuroblastoma is a
                    poor-prognosis malignancy arising during childhood that overexpresses the
                    L1-cell adhesion molecule (CD171). We have previously described a tumor L1-cell
                    adhesion molecule-specific, single chain antibody-derived, chimeric antigen
                    receptor designated CE7R for re-directing the antigen-specific effector
                    functioning of cytolytic T lymphocytes. Here, we report on the feasibility of
                    isolating, and the safety of infusing, autologous CD8(+) cytolytic T lymphocyte
                    clones co-expressing CE7R and the selection-suicide expression enzyme HyTK in
                    children with recurrent/ refractory neuroblastoma. The cytolytic T lymphocyte
                    products were derived from peripheral blood mononuclear cells that were
                    subjected to polyclonal activation, plasmid vector electrotransfer, limiting
                    dilution hygromycin selection, and expansion to numbers sufficient for adoptive
                    transfer. In total, 12 infusions (nine at 10(8) cells/m(2), three at 10(9)
                    cells/m(2)) were administered to six patients. No overt toxicities to tissues
                    known to express L1-cell adhesion molecule (e.g., central nervous system,
                    adrenal medulla, and sympathetic ganglia) were observed. The persistence of
                    cytolytic T lymphocyte clones in the circulation, measured by vector-specific
                    quantitative polymerase chain reaction, was short (1-7 days) in patients with
                    bulky disease, but significantly longer (42 days) in a patient with a limited
                    disease burden. This first-in-humans pilot study sets the stage for clinical
                    trials employing adoptive transfer in the context of minimal residual
                    disease.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    150KJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; ALLORY Y, 2005, CLIN CANCER RES, V11, P1190&#xD; ARLT MJE, 2006, CANCER
                    RES, V66, P936&#xD; BERGER C, 2001, J VIROL, V75, P799&#xD; BERGER C, 2006,
                    BLOOD, V107, P2294&#xD; CALVO A, 2002, CANCER RES, V62, P5325&#xD; CLARKE MF,
                    2006, CELL, V124, P1111&#xD; DUDLEY ME, 2005, J CLIN ONCOL, V23, P2346&#xD; EUER
                    NI, 2005, ONCOL REP, V13, P375&#xD; FOGEL M, 2003, LANCET, V362, P869&#xD; GAST
                    D, 2005, INT J CANCER, V115, P658&#xD; GATTINONI L, 2006, NAT REV IMMUNOL, V6,
                    P383&#xD; GAVERT N, 2005, J CELL BIOL, V168, P633&#xD; GONZALEZ S, 2004, J GENE
                    MED, V6, P704&#xD; HIRSCHMANNJAX C, 2004, P NATL ACAD SCI USA, V101, P14228&#xD;
                    HOEFNAGEL CA, 2001, EUR J NUCL MED, V28, P359&#xD; IZUMOTO S, 1996, CANCER RES,
                    V56, P1440&#xD; JENSEN MC, 2000, MOL THER, V1, P49&#xD; KAHLON KS, 2004, CANCER
                    RES, V64, P9160&#xD; MECHTERSHEIMER S, 2001, J CELL BIOL, V155, P661&#xD;
                    METELITSA LS, 2004, J EXP MED, V199, P1213&#xD; MONTGOMERY AMP, 1996, J CELL
                    BIOL, V132, P475&#xD; MORGAN RA, 2006, SCIENCE, V314, P126&#xD; RIDDELL SR,
                    1992, SCIENCE, V257, P238&#xD; ROSENBERG SA, 2004, P NATL ACAD SCI U S2, V101,
                    P14639&#xD; SCHONMANN SM, 1986, INT J CANCER, V37, P255&#xD; SILLETTI S, 2004, J
                    BIOL CHEM, V279, P28880&#xD; THIES A, 2002, EUR J CANCER, V38, P1708&#xD; WANG
                    JJ, 2004, MOL THER, V9, P577</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245215400024 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>207</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">207</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1191</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Parsa, A. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Waldron, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Panner, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Crane, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parney, I. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Barry, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cachola, K. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Murray, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tihan, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mischel, P. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stokoe, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pieper, R. O.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif San Francisco, Dept
                    Neurol Surg, San Francisco, CA 94143 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Canc Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010 USA. Univ
                    Calif Los Angeles, David Geffen Sch Med, Henry E Singleton Brain Canc Res
                    Program, Dept Pathol &amp; Lab Med, Los Angeles, CA 90095 USA.&#xD;Parsa, AT,
                    Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San
                    Francisco, CA 94143 USA.&#xD;parsaa@neurosurg.ucsf.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Loss of tumor suppressor PTEN
                        function increases B7-H1 expression and immunoresistance in glioma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nature Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nature Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nat Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">84-88</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RENAL-CELL CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE EVASION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLIOBLASTOMA-MULTIFORME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POTENTIAL MECHANISM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLOCKADE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PD-L1</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-8956</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243301800040</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Cancer immunoresistance and immune
                    escape(1-3) may play important roles in tumor progression and pose obstacles for
                    immunotherapy. Expression of the immunosuppressive protein B7 homolog 1 (B7-H1),
                    also known as programmed death ligand-1 (PD-L1), is increased in many
                    pathological conditions, including cancer(4-10). Here we show that expression of
                    the gene encoding B7-H1 increases post transcriptionally in human glioma after
                    loss of phosphatase and tensin homolog (PTEN) and activation of the
                    phosphatidylinositol-3-OH kinase (PI(3) K) pathway. Tumor specimens from
                    individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that
                    correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets
                    expressing wild-type PTEN more effectively than those expressing mutant PTEN.
                    These data identify a previously unrecognized mechanism linking loss of the
                    tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123NE&#xD;Times Cited: 0&#xD;Cited Reference Count: 30&#xD;Cited References:
                    &#xD; BLANK C, 2005, CANCER IMMUNOL IMMUN, V54, P307&#xD; BLANK C, 2006, INT J
                    CANCER, V119, P317&#xD; BLUMEJENSEN P, 2001, NATURE, V411, P355&#xD; DONG HD,
                    1999, NAT MED, V5, P1365&#xD; DONG HD, 2002, NAT MED, V8, P793&#xD; DONG HD,
                    2003, J CLIN INVEST, V111, P363&#xD; DONG HD, 2003, J MOL MED-JMM, V81,
                    P281&#xD; DUNN GP, 2002, NAT IMMUNOL, V3, P991&#xD; DUNN GP, 2004, ANNU REV
                    IMMUNOL, V22, P329&#xD; DUNN GP, 2004, IMMUNITY, V21, P137&#xD; HAASKOGAN D,
                    1998, CURR BIOL, V8, P1195&#xD; HIRANO F, 2005, CANCER RES, V65, P1089&#xD; IWAI
                    Y, 2005, INT IMMUNOL, V17, P133&#xD; KAHLON KS, 2004, CANCER RES, V64,
                    P9160&#xD; KAUR S, 2005, J INTERF CYTOK RES, V25, P780&#xD; LATCHMAN YE, 2004, P
                    NATL ACAD SCI 07/01 USA, V101, P10691&#xD; MISCHEL PS, 2003, ONCOGENE, V22,
                    P2361&#xD; MISCHEL PS, 2004, NAT REV NEUROSCI, V5, P782&#xD; OHIGASHI Y, 2005,
                    CLIN CANCER RES, V11, P2947&#xD; PANNER A, 2005, MOL CELL BIOL, V25, P8809&#xD;
                    PARDOLL D, 2004, NAT MED, V10, P887&#xD; RAJASEKHAR VK, 2003, MOL CELL, V12,
                    P889&#xD; RICH JN, 2004, NAT REV DRUG DISCOV, V3, P430&#xD; SAUDEMONT A, 2004,
                    BLOOD, V104, P2124&#xD; SULIS ML, 2003, TRENDS CELL BIOL, V13, P478&#xD;
                    THOMPSON RH, 2004, P NATL ACAD SCI 07/01 USA, V101, P17174&#xD; THOMPSON RH,
                    2005, UROLOGY S, V66, P10&#xD; VIVANCO I, 2002, NAT REV CANCER, V2, P489&#xD;
                    WILMOTTE R, 2005, NEUROREPORT, V16, P1081&#xD; WINTTERLE S, 2003, CANCER RES,
                    V63, P7462</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243301800040 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>408</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">408</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1190</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Parsons, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Preston, B. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Connor, T. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dianov, G. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">MRC, Radiat &amp; Genome Stabil
                    Unit, Harwell, Oxon, England. Univ Washington, Dept Pathol, Seattle, WA 98195
                    USA. City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010
                    USA.&#xD;Dianov, GL, MRC, Radiat &amp; Genome Stabil Unit, Harwell, Oxon,
                    England.&#xD;g.dianov@har.mrc.ac.uk</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">DNA polymerase delta-dependent
                        repair of DNA single strand breaks containing 3 &apos;-end proximal
                        lesions</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1054-1063</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">BASE EXCISION-REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN CELL-EXTRACTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLI ENDONUCLEASE III</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESCHERICHIA-COLI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DAMAGED DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GLYCOSYLASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOMOLOG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESIDUES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLONING</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0305-1048</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245353300011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Base excision repair (BER) is the
                    major pathway for the repair of simple, non-bulky lesions in DNA that is
                    initiated by a damage-specific DNA glycosylase. Several human DNA glycosylases
                    exist that efficiently excise numerous types of lesions, although the close
                    proximity of a single strand break (SSB) to a DNA adduct can have a profound
                    effect on both BER and SSB repair. We recently reported that DNA lesions located
                    as a second nucleotide 5&apos;-upstream to a DNA SSB are resistant to DNA
                    glycosylase activity and this study further examines the processing of these
                    &apos;complex&apos; lesions. We first demonstrated that the damaged base should
                    be excised before SSB repair can occur, since it impaired processing of the SSB
                    by the BER enzymes, DNA ligase III alpha and DNA polymerase beta. Using human
                    whole cell extracts, we next isolated the major activity against DNA lesions
                    located as a second nucleotide 5&apos;-upstream to a DNA SSB and identified it
                    as DNA polymerase delta (Pol delta). Using recombinant protein we confirmed that
                    the 3&apos;-5&apos;-exonuclease activity of Pol delta can efficiently remove
                    these DNA lesions. Furthermore, we demonstrated that mouse embryonic
                    fibroblasts, deficient in the exonuclease activity of Pol delta are partially
                    deficient in the repair of these &apos;complex&apos; lesions, demonstrating the
                    importance of Pol delta during the repair of DNA lesions in close proximity to a
                    DNA SSB, typical of those induced by ionizing radiation.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    152HT&#xD;Times Cited: 0&#xD;Cited Reference Count: 38&#xD;Cited References:
                    &#xD; ALBERTSON TM, 2006, CURR BIOL, V16, P211&#xD; AN Q, 2005, EMBO J, V24,
                    P2205&#xD; BLAISDELL JO, 2001, RADIAT PROT DOSIM, V97, P25&#xD; BUDWORTH H,
                    2005, J MOL BIOL, V351, P1020&#xD; DAVIDCORDONNIER MH, 2001, BIOCHEMISTRY-US,
                    V40, P11811&#xD; DIANOV GL, 1991, MOL GEN GENET, V225, P448&#xD; DIANOV GL,
                    1999, BIOCHEMISTRY-US, V38, P11021&#xD; DIANOV GL, 2001, BIOESSAYS, V23,
                    P745&#xD; DIANOVA II, 2001, BIOCHEMISTRY-US, V40, P12639&#xD; DIZDAROGLU M,
                    1996, NUCLEIC ACIDS RES, V24, P418&#xD; EOTHOULLIER G, 2005, NUCLEIC ACIDS RES,
                    V33, P260&#xD; FROSINA G, 1996, J BIOL CHEM, V271, P9573&#xD; GOLDSBY RE, 2002,
                    P NATL ACAD SCI USA, V99, P15560&#xD; GUZDER SN, 2004, GENE DEV, V18, P2283&#xD;
                    HAZRA TK, 2002, P NATL ACAD SCI USA, V99, P3523&#xD; IKEDA S, 1998, J BIOL CHEM,
                    V273, P21585&#xD; KOW YW, 2002, FREE RADICAL BIO MED, V33, P886&#xD; MACHWE A,
                    2000, NUCLEIC ACIDS RES, V28, P2762&#xD; MANLEY JL, 1983, METHOD ENZYMOL C,
                    V101, P568&#xD; MASAOKA A, 2003, BIOCHEMISTRY-US, V42, P5003&#xD; MATSUMOTO Y,
                    1999, J BIOL CHEM, V274, P33703&#xD; MOE A, 2003, NUCLEIC ACIDS RES, V31,
                    P3893&#xD; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561&#xD; PARSONS JL,
                    2004, NUCLEIC ACIDS RES, V32, P3531&#xD; PARSONS JL, 2005, NUCLEIC ACIDS RES,
                    V33, P2204&#xD; PARSONS JL, 2005, NUCLEIC ACIDS RES, V33, P4849&#xD; PODUST VN,
                    2002, J BIOL CHEM, V277, P3894&#xD; PONNAMPERUMA C, 1961, SCIENCE, V134,
                    P113&#xD; RADICELLA JP, 1997, P NATL ACAD SCI USA, V94, P8010&#xD; ROSENQUIST
                    TA, 1997, P NATL ACAD SCI USA, V94, P7429&#xD; SAPARBAEV M, 1994, P NATL ACAD
                    SCI USA, V91, P5873&#xD; SARKER AH, 1998, J MOL BIOL, V282, P761&#xD; SHEVELEV
                    IV, 2002, NAT REV MOL CELL BIO, V3, P364&#xD; STUCKI M, 1998, ONCOGENE, V17,
                    P835&#xD; TAKAO M, 2002, J BIOL CHEM, V277, P42205&#xD; WARD JF, 1995, RADIAT
                    RES, V142, P362&#xD; WEINFELD M, 2001, RADIAT RES 2, V156, P584&#xD; YANG N,
                    2006, DNA REPAIR, V5, P43</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245353300011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>794</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">794</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1697</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Patel, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lai-Yates, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Anderson, J. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Katz, E. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City of Hope National Medical Center
                    and Beckman Research Institute, Division of Population Sciences &amp;
                    Pediatrics, Duarte, California 91010-3000, USA. supatel@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Attention dysfunction and parent
                        reporting in children with brain tumors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pediatr Blood Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatric Blood &amp;
                        Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatr. Blood Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatr Blood Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">970-4</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">49</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Adolescent</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Attention Deficit Disorder
                        with</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Hyperactivity/classification/
                        diagnosis/ psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Brain Neoplasms/
                        psychology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Child</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neuropsychological Tests</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Psychiatric Status Rating
                        Scales</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retrospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survivors/statistics &amp;
                        numerical data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Time</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1545-5009 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17243136</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND: The IQ declines observed
                    in children treated for brain tumor emerge as &quot;late effects&quot; and are
                    conceptualized as secondary to changes in underlying mental processes, such as
                    attention. Early identification of the underlying changes might help minimize
                    the long-term adverse outcomes. We evaluated the validity of a time-efficient,
                    standardized parent-report measure in identifying attention dysfunction in
                    childhood brain tumor survivors. PROCEDURE: Seventy survivors between ages 6 and
                    16 who met eligibility criteria and who had completed a standard
                    neuropsychological evaluation were classified into an attention dysfunction
                    group and a non-attention dysfunction group, based on their performance on
                    objective measures of attention. Analysis of covariance was used to evaluate
                    group differences on the widely used, parent report Child Behavioral Checklist
                    (CBCL). RESULTS: Survivors in the attention dysfunction group were reported by
                    their parents as having significantly more attention problems relative to the
                    group without attention dysfunction on objective testing. Furthermore, survivors
                    categorized as having attention dysfunction based on their neuropsychological
                    test scores were reported on the CBCL by their parents as having significantly
                    more social problems compared to the non-attention dysfunction group.
                    CONCLUSIONS: Standardized parent reporting of attention problems shows promise
                    as a screening tool to detect attention dysfunction among survivors of childhood
                    brain tumors. Findings include a strong association of decreased social
                    functioning with attention dysfunction in brain tumor survivors. Furthermore,
                    exploratory data suggest that the behavioral presentation of attention
                    dysfunction in this group may be different from other clinical groups.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>623</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">623</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1189</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Paz, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Li, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Santat, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, K. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chatterjee, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Virol,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Hematol &amp; Hematopoiet Cell
                    Transplantat, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA 91010
                    USA.&#xD;Chatterjee, S, City Hope Natl Med Ctr, Div Virol, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;schatterjee@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Quiescent subpopulations of
                        human CD34-positive hematopoietic stem cells are preferred targets for
                        stable recombinant adeno-associated virus type 2 transduction</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Human Gene Therapy</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Hum. Gene Ther.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Gene Ther</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Gene Ther</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">614-626</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">18</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >HUMAN-IMMUNODEFICIENCY-VIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">2-MEDIATED GENE-TRANSFER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE-DEFICIENT MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SKELETAL-MUSCLE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMOPHILIA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AAV VECTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EFFICIENT TRANSDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REVERSE TRANSCRIPTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1043-0342</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248454300004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We have previously demonstrated
                    recombinant adeno-associated viral (rAAV) transduction of human CD34+
                    hematopoietic stem cells (HSCs) capable of serial engraftment in vivo. Here we
                    evaluated the capacity of rAAV2 to mediate gene transfer into nondividing,
                    quiescent, primitive CD34(+) cells subdivided on the basis of metabolic,
                    mitotic, and phenotypic properties. Results revealed that CD34(+)CD38(-) marrow
                    cells are the most quiescent, exist primarily in Go at isolation and are the
                    only population to remain nondividing during the entire exposure to free rAAV.
                    Despite significant differences in the extended clonogenic capacities of CD34(+)
                    subsets in stromal cultures, the frequency of rAAV marking of colonies derived
                    from primitive progenitors was similar in all three populations, suggesting that
                    both primitive and more differentiated progenitors were initially transduced at
                    equal levels. After transduction, episomal and integrated rAAV genomes were
                    detected in all CD34(+) subsets. However, the more quiescent cells displayed
                    higher levels of integrated rAAV than did rapidly dividing cells. Importantly,
                    stable long-term integration was observed only in the most primitive, quiescent
                    CD34(+)CD38(-) subset, indicating that this HSC compartment comprises the
                    preferred substrate for stable rAAV2 transduction. Previously described rate
                    limitations to transgene expression were observed in transduced CD34(+) cells
                    and could be overcome by tyrphostin pretreatment, which resulted in augmented
                    second-strand synthesis. These results represent the first demonstration of
                    rAAV-mediated gene transfer to primitive, quiescent human CD34(+)CD38(-) stem
                    cells and reveal that nondividing CD34(+)CD38(-) HSCs are the optimal CD34(+)
                    targets for rAAV transduction.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    196AR&#xD;Times Cited: 0&#xD;Cited Reference Count: 69</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248454300004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>796</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">796</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">958</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Peebles, K. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mao, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hazra, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reckamp, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krysan, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dohadwala, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heinrich, E. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Walser, T. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cui, X.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baratelli, F. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Garon, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharma, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dubinett, S. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Div Pulm &amp; Crit Care Med, Dept Med,UCLA Lung Canc Res Program, Los
                    Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div
                    Cardiothorac Surg,Jonsson Comprehens Canc Ctr, Dept Surg,UCLA Lung Canc Res
                    Program, Los Angeles, CA 90024 USA. City Hope Natl Med Ctr, Beckman Res Inst,
                    Duarte, CA 91010 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol
                    &amp; Oncol, Dept Med,UCLA Lung Canc Res Program, Los Angeles, CA 90024
                    USA.&#xD;Lee, JM, Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm &amp;
                    Crit Care Med, Dept Med,UCLA Lung Canc Res Program, Los Angeles, CA 90024
                    USA.&#xD;jaymoonlee@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Inflammation and lung
                        carcinogenesis: Applying findings in prevention and treatment</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Expert Review of Anticancer
                        Therapy</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">1405-1421</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">7</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">15-PGDH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cyclooxygenase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epithelial-to-mesenchymal
                        transition</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunosuppression</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inflammation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lung cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">prostaglardin I synthase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STAT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATED-RECEPTOR-GAMMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPIDERMAL-GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPITHELIAL-MESENCHYMAL
                        TRANSITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER CELL-LINES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FACTOR-KAPPA-B</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OBSTRUCTIVE
                        PULMONARY-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MYELOID SUPPRESSOR-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGULATORY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SELECTIVE CYCLOOXYGENASE-2
                        INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE MORPHOGENETIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROTEINS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1473-7140</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250612600014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Lung carcinogenesis is a complex
                    process requiring the acquisition of genetic mutations that confer the malignant
                    phenotype as well as epigenetic alterations that may be manipulated in the
                    course of therapy. Inflammatory signals in the lung cancer microenvironment can
                    promote apoptosis resistance, proliferation, invasion, metastasis, and secretion
                    of proangiogenic and immunosuppressive factors. Here, we discuss several
                    prototypical inflammatory mediators controlling the malignant phenotype in lung
                    cancer. Investigation into the detailed molecular mechanisms underlying the
                    tumor-promoting effects of inflammation in lung cancer has revealed novel
                    potential drug targets. Cytokines, growth factors and small-molecule
                    inflammatory mediators released in the developing tumor microenvironment pave
                    the way for epithelial-mesenchymal transition, the shift from a polarized,
                    epithelial phenotype to a highly motile mesenchymal phenotype that becomes
                    dysregulated during tumor invasion. Inflammatory mediators within the tumor
                    microenvironment are derived from neoplastic cells as well as stromal and
                    inflammatory cells; thus, lung cancer develops in a host environment in which
                    the deregulated inflammatory response promotes tumor progression.
                    Inflammation-related metabolic and catabolic enzymes (prostaglandin E-2
                    synthase, prostaglandin I-2 synthase and 15-hydroxyprostaglandin dehydrogenase),
                    cell-surface receptors (E-type prostaglandin receptors) and transcription
                    factors (ZEB1, SNAIL, PPARs, STATs and NF-kappa B) are differentially expressed
                    in lung cancer cells compared with normal lung epithelial cells and, thus, may
                    contribute to tumor initiation and progression. These newly discovered molecular
                    mechanisms in the pathogenesis of lung cancer provide novel opportunities for
                    targeted therapy and prevention in lung cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    226TY&#xD;Times Cited: 0&#xD;Cited Reference Count: 227&#xD;Cited References:
                    &#xD; 2007, MED LETT DRUGS THER, V49, P57&#xD; ACHIWA H, 1999, CLIN CANCER RES,
                    V5, P1001&#xD; AGGARWAL BB, 2004, CANCER CELL, V6, P203&#xD; ALLEVA DG, 1994, J
                    IMMUNOL, V153, P1674&#xD; ALVAREZ JV, 2006, CANCER RES, V66, P3162&#xD; BALLAZ
                    S, 2003, CLIN LUNG CANCER, V5, P46&#xD; BANCHEREAU J, 1998, NATURE, V392,
                    P245&#xD; BARATELLI F, 2005, J IMMUNOL, V175, P1483&#xD; BATRA RK, 2003, CANCER
                    RES, V63, P642&#xD; BELLUSCI S, 1996, DEVELOPMENT, V122, P1693&#xD; BERGER J,
                    2002, ANNU REV MED, V53, P409&#xD; BHARTI AC, 2002, BIOCHEM PHARMACOL, V64,
                    P883&#xD; BIANCHI R, 1996, J IMMUNOL, V157, P1589&#xD; BRABENDER J, 2002, ANN
                    SURG, V235, P440&#xD; BRENMATTISON Y, 2005, ONCOGENE, V24, P1412&#xD; BREYER RM,
                    2000, ANN NY ACAD SCI, V905, P221&#xD; BRODY JS, 2006, P AM THORAC SOC, V3,
                    P535&#xD; BROMBERG J, 2000, ONCOGENE, V19, P2468&#xD; BROMBERG JF, 1999, CELL,
                    V98, P295&#xD; CAMPA D, 2004, CARCINOGENESIS, V25, P229&#xD; CHA YI, 2006, GENE
                    DEV, V20, P77&#xD; CHANG HC, 2001, ONCOL REP, V8, P1321&#xD; CHANG TH, 2000,
                    CANCER RES, V60, P1129&#xD; CHANG YWE, 2000, MOL CELL BIOL, V20, P8571&#xD;
                    CHARUWORN B, 2006, P AM THOR SOC&#xD; CHAWLA A, 2001, NAT MED, V7, P48&#xD; CHO
                    H, 2002, PROSTAG LEUKOTR ESS, V67, P461&#xD; CLEVERS H, 2004, CELL, V118,
                    P671&#xD; COLOMBO MP, 1996, CANCER RES, V56, P2531&#xD; COUSSENS LM, 2002,
                    NATURE, V420, P860&#xD; CUI X, 2007, ONCOGENE, V26, P4253&#xD; CUI XY, 2006,
                    BIOCHEM BIOPH RES CO, V343, P995&#xD; DALWADI H, 2005, CLIN CANCER RES, V11,
                    P7674&#xD; DANDREA A, 1993, J EXP MED, V178, P1041&#xD; DANNENBERG AJ, 2003,
                    CANCER CELL, V4, P431&#xD; DASARI V, 2006, AM J RESP CELL MOL, V35, P3&#xD;
                    DAVIS DL, 1983, BIOL REPROD, V28, P1114&#xD; DEVISSER KE, 2006, NAT REV CANCER,
                    V6, P24&#xD; DEVITA F, 2000, CHEST, V117, P365&#xD; DEY SK, 1980,
                    PROSTAGLANDINS, V19, P449&#xD; DING YF, 2005, CARCINOGENESIS, V26, P65&#xD;
                    DOHADWALA M, 2001, J BIOL CHEM, V276, P20809&#xD; DOHADWALA M, 2002, J BIOL
                    CHEM, V277, P50828&#xD; DOHADWALA M, 2006, CANCER RES, V66, P5338&#xD; DUBINETT
                    S, 2004, IMMUNOTHERAPY CROSSR, P335&#xD; DUBOIS RN, 1998, FASEB J, V12,
                    P1063&#xD; DUPERRON C, 1997, CARCINOGENESIS, V18, P1001&#xD; DURBIN RJ, 2004,
                    DIABETES OBES METAB, V6, P280&#xD; DWYERNIELD LD, 2005, CARCINOGENESIS, V26,
                    P1196&#xD; ENGELMAN JA, 2007, SCIENCE, V316, P1039&#xD; ERICKSON BA, 1999, J
                    SURG RES, V81, P101&#xD; ERMERT L, 2003, CLIN CANCER RES, V9, P1604&#xD;
                    FITZGERALD G, 2003, NAT REV DRUG DISCOV, V2, P879&#xD; FONTENOT JD, 2005, NAT
                    IMMUNOL, V6, P331&#xD; FUKUMOTO K, 2005, FEBS LETT, V579, P3829&#xD; GADGEEL SM,
                    2007, J THORAC ONCOL, V2, P299&#xD; GALLI A, 2006, EXPERT OPIN INV DRUG, V15,
                    P1039&#xD; GARBER K, 2007, NAT BIOTECHNOL, V25, P17&#xD; GATELY S, 2004, SEMIN
                    ONCOL S7, V31, P2&#xD; GAVIN MA, 2007, NATURE, V445, P771&#xD; GOVINDARAJAN R,
                    2007, J CLIN ONCOL, V25, P1476&#xD; GROSSER T, 2006, J CLIN INVEST, V116,
                    P4&#xD; GUNNING PT, 2007, BIOORG MED CHEM LETT, V17, P1875&#xD; HAGENBAUGH A,
                    1997, J EXP MED, V185, P2101&#xD; HALAK BK, 1999, CANCER RES, V59, P911&#xD; HAN
                    S, 2007, ANTI-CANCER DRUG, V18, P237&#xD; HAN SW, 2003, CLIN CANCER RES, V9,
                    P4627&#xD; HAN SW, 2007, J BIOL CHEM, V282, P7961&#xD; HANAHAN D, 2000, CELL,
                    V100, P57&#xD; HANDELFERNANDEZ ME, 1997, J IMMUNOL, V158, P280&#xD; HARA A,
                    1997, JPN J CANCER RES, V88, P600&#xD; HATANAKA H, 2000, ANN ONCOL, V11,
                    P815&#xD; HATANAKA H, 2001, CLIN CANCER RES, V7, P1287&#xD; HAZRA S, 2007, MOL
                    PHARMACOL, V71, P1715&#xD; HERSCHMAN HR, 1996, BBA-LIPID LIPID MET, V1299,
                    P125&#xD; HEUZEVOURCH N, 2003, CANCER RES, V63, P766&#xD; HIDA T, 1998, CANCER
                    RES, V58, P3761&#xD; HIDA T, 2000, CLIN CANCER RES, V6, P2006&#xD; HOGAN BLM,
                    1996, CURR OPIN GENET DEV, V6, P432&#xD; HONN KV, 1981, SCIENCE, V212,
                    P1270&#xD; HOSOMI Y, 2000, LUNG CANCER-J IASLC, V30, P73&#xD; HSU AL, 2000, J
                    BIOL CHEM, V275, P11397&#xD; HUANG M, 1995, CANCER RES, V55, P3847&#xD; HUANG M,
                    1996, J IMMUNOL, V157, P5512&#xD; HUANG M, 1998, CANCER RES, V58, P1208&#xD;
                    HUARA EB, 2006, CLIN LUNG CANCER, V7, P273&#xD; HUBER MA, 2005, CURR OPIN CELL
                    BIOL, V17, P548&#xD; INOUE H, 2000, J BIOL CHEM, V275, P28028&#xD; JEMAL A,
                    2007, CA-CANCER J CLIN, V57, P43&#xD; JICK SS, 2000, PHARMACOTHERAPY, V20,
                    P741&#xD; JORDAN MS, 2001, NAT IMMUNOL, V2, P301&#xD; KARIN M, 2004, NAT REV
                    DRUG DISCOV, V3, P17&#xD; KARIN M, 2006, NATURE, V441, P431&#xD; KATORI M, 2000,
                    INFLAMM RES, V49, P367&#xD; KEITH RL, 2002, CANCER RES, V62, P734&#xD; KEITH RL,
                    2004, CANCER RES, V64, P5897&#xD; KESHAMOUNI VG, 2005, NEOPLASIA, V7, P294&#xD;
                    KESHAMOUNI VG, 2006, J PROTEOME RES, V5, P1143&#xD; KHURI FR, 2001, CLIN CANCER
                    RES, V7, P861&#xD; KIM HS, 2003, LUNG CANCER-J IASLC, V42, P163&#xD; KIM J,
                    1995, J IMMUNOL, V155, P2240&#xD; KOMAROVA EA, 2005, FASEB J, V19, P1030&#xD;
                    KOPP JB, 2002, KIDNEY INT, V61, P351&#xD; KORTYLEWSKI M, 2005, NAT MED, V11,
                    P1314&#xD; KRYSAN K, 2004, CANCER RES, V64, P6359&#xD; KRYSAN K, 2004, FASEB J,
                    V18, P206&#xD; KRYSAN K, 2005, CANCER RES, V65, P6275&#xD; KRYSAN K, 2006,
                    ANTI-CANCER AGENT ME, V6, P209&#xD; KUMMAR S, 2007, NAT REV CANCER, V7,
                    P131&#xD; LANGENFELD EM, 2005, ANN THORAC SURG, V80, P1028&#xD; LEAHY KM, 2000,
                    CURR MED CHEM, V7, P1163&#xD; LEE JM, 2005, LUNG CANC&#xD; LEE JM, 2006, J CELL
                    BIOL, V172, P973&#xD; LEE JM, 2007, FUTURE ONCOL, V3, P149&#xD; LENG QB, 2006,
                    INT IMMUNOL, V18, P637&#xD; LI M, 2000, MOL CELL BIOL, V20, P4699&#xD; LI MY,
                    2003, WORLD J GASTROENTERO, V9, P1220&#xD; LILENBAUM R, 2006, J CLIN ONCOL, V24,
                    P4825&#xD; LIM HJJ, 2004, ENDOCRINOLOGY, V145, P2886&#xD; LIN MT, 2001, J BIOL
                    CHEM, V276, P48997&#xD; LIN WW, 2007, J CLIN INVEST, V117, P1175&#xD; LIPPMAN
                    SM, 2005, CLIN CANCER RES, V11, P6097&#xD; LIU VC, 2007, J IMMUNOL, V178,
                    P2883&#xD; LIU XH, 1998, CANCER RES, V58, P4245&#xD; LUO JL, 2005, J CLIN
                    INVEST, V115, P2625&#xD; LYNCH TJ, 2006, CLIN CANCER RES S 2, V12, S4365&#xD;
                    MALKINSON AM, 1983, J NATL CANCER I, V70, P931&#xD; MALKINSON AM, 1997, CANCER
                    RES, V57, P2832&#xD; MALKINSON AM, 2005, EXP LUNG RES, V31, P57&#xD; MALKOWSKI
                    MG, 2000, SCIENCE, V289, P1933&#xD; MAO JT, 2004, CLIN CANCER RES, V10,
                    P6872&#xD; MAO JT, 2005, CLIN LUNG CANCER, V7, P30&#xD; MAO JT, 2006, CLIN
                    CANCER RES, V12, P314&#xD; MOLINAHOLGADO E, 2002, NEUROSCI LETT, V324, P237&#xD;
                    MONCADA S, 1981, PHIL T R SOC LOND B, V294, P305&#xD; MOORE KW, 2001, ANNU REV
                    IMMUNOL, V19, P683&#xD; MOYSICH KB, 2002, BMC CANCER, V2&#xD; MURRAY PJ, 2007, J
                    IMMUNOL, V178, P2623&#xD; NARUKE M, 2001, INT J ONCOL, V18, P1213&#xD; NEUNER A,
                    2001, LUNG CANCER-J IAS S2, V34, S79&#xD; NISSEN SE, 2007, NEW ENGL J MED, V356,
                    P2457&#xD; NIU GL, 1999, CANCER RES, V59, P5059&#xD; NIU GL, 2002, ONCOGENE,
                    V21, P2000&#xD; NOMURA T, 2007, NAT IMMUNOL, V8, P333&#xD; NUNES M, 2004, MOL
                    CANCER THER, V3, P21&#xD; OBYRNE KJ, 2007, J CLIN ONCOL, V25, P3266&#xD; ODAJIMA
                    J, 2000, J BIOL CHEM, V275, P24096&#xD; ODONNELL R, 2006, THORAX, V61, P448&#xD;
                    OKADA H, 2005, CLIN EXP NEPHROL, V9, P100&#xD; PAI R, 2002, NAT MED, V8,
                    P289&#xD; PAPIERNIK M, 1998, INT IMMUNOL, V10, P371&#xD; POLD M, 2004, CANCER
                    RES, V64, P1853&#xD; POMINI F, 1999, J CLIN ENDOCR METAB, V84, P4645&#xD;
                    RAMOSNINO ME, 2007, BMC MED, V5&#xD; RAYET B, 1999, ONCOGENE, V18, P6938&#xD;
                    RECKAMP KL, 2006, CLIN CANCER RES 1, V12, P3381&#xD; REDENTE EF, 2007, AM J
                    PATHOL, V170, P693&#xD; RENNARD SI, 2006, P AM THORAC SOC, V3, P276&#xD;
                    REYNOLDS PR, 2006, AM J RESP CELL MOL, V35, P314&#xD; RICOTE M, 1998, NATURE,
                    V391, P79&#xD; RIEDL K, 2004, DRUG RESIST UPDATE, V7, P169&#xD; RIOUX N, 1998,
                    CANCER RES, V58, P5354&#xD; RODRIGUEZ PC, 2005, J EXP MED, V202, P931&#xD; ROSEN
                    CJ, 2007, NEW ENGL J MED, V357, P844&#xD; ROSSI A, 2000, NATURE, V403, P103&#xD;
                    SAKAGUCHI S, 2003, J CLIN INVEST, V112, P1310&#xD; SANCHEZCEJA SG, 2006, LUNG
                    CANCER, V54, P163&#xD; SAWAOKA H, 1998, AM J PHYSIOL, V274, P1061&#xD;
                    SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138&#xD; SEIKE M, 2007, J NATL
                    CANCER I, V99, P1257&#xD; SERAFINI P, 2004, CANCER IMMUNOL IMMUN, V53, P64&#xD;
                    SERAFINI P, 2006, SEMIN CANCER BIOL, V16, P53&#xD; SEVENOAKS MJ, 2006, RESP RES,
                    V7&#xD; SHARMA S, 1999, J IMMUNOL, V163, P5020&#xD; SHARMA S, 2003, CLIN CANCER
                    RES, V9, P961&#xD; SHARMA S, 2005, CANCER RES, V65, P5211&#xD; SHENG HM, 1998,
                    CANCER RES, V58, P362&#xD; SHENG HM, 2001, J BIOL CHEM, V276, P18075&#xD;
                    SHEVACH EM, 2000, ANNU REV IMMUNOL, V18, P423&#xD; SHI W, 2001, AM J
                    PHYSIOL-LUNG C, V280, L1030&#xD; SIDDIQUEE K, 2007, P NATL ACAD SCI USA, V104,
                    P7391&#xD; SIEGFRIED JM, 2007, MOL PHARMACOL, V72, P769&#xD; SMITH CJ, 2006,
                    INHAL TOXICOL, V18, P667&#xD; SOBERMAN RJ, 2006, AM J PHYSIOL-LUNG C, V291,
                    L142&#xD; SOGN JA, 1998, IMMUNITY, V9, P757&#xD; SONG LX, 2003, ONCOGENE, V22,
                    P4150&#xD; SPARMANN A, 2004, CANCER CELL, V6, P447&#xD; SPIRA A, 2007, NAT MED,
                    V13, P361&#xD; STEARMAN RS, 2005, AM J PATHOL, V167, P1763&#xD; STEARMAN RS,
                    2007, MOL CANCER RES, V5, P295&#xD; STOLINA M, 2000, J IMMUNOL, V164, P361&#xD;
                    SU CG, 1999, J CLIN INVEST, V104, P383&#xD; SUBBARAMAIAH K, 2001, J BIOL CHEM,
                    V276, P12440&#xD; SUBBARAMAIAH K, 2002, J BIOL CHEM, V277, P18649&#xD; TAN RJ,
                    2006, AM J RESP CELL MOL, V35, P289&#xD; TANG XM, 2006, CANCER, V107, P2637&#xD;
                    THIERY JP, 2003, CURR OPIN CELL BIOL, V15, P740&#xD; TORCHILIN VP, 2003, DRUG
                    DISCOV TODAY, V8, P259&#xD; TROMBETTA ES, 2005, ANNU REV IMMUNOL, V23, P975&#xD;
                    TSUBOCHI H, 2006, ANN THORAC SURG, V82, P1198&#xD; TSUJII M, 1995, CELL, V83,
                    P493&#xD; TURKSON J, 1998, MOL CELL BIOL, V18, P2545&#xD; TURKSON J, 2001, J
                    BIOL CHEM, V276, P45443&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P1533&#xD;
                    TURKSON J, 2004, MOL CANCER THER, V3, P261&#xD; TURKSON J, 2005, J BIOL CHEM,
                    V280, P32979&#xD; VANE JR, 1995, AM J CARDIOL, V75, P3&#xD; VANE JR, 2002,
                    SCIENCE, V296, P474&#xD; WALKER MR, 2003, J CLIN INVEST, V112, P1437&#xD; WEI
                    DY, 2003, ONCOGENE, V22, P319&#xD; WENG JR, 2006, ENDOCR-RELAT CANCER, V13,
                    P401&#xD; WITTA SE, 2006, CANCER RES, V66, P944&#xD; WOLF I, 2006, CANCER RES,
                    V66, P7818&#xD; WOLFF H, 1998, CANCER RES, V58, P4997&#xD; WU CY, 1993, J
                    IMMUNOL, V151, P1938&#xD; YANAGAWA H, 1995, BRIT J CANCER, V71, P1095&#xD; YANG
                    L, 2003, J CLIN INVEST, V111, P727&#xD; YANG L, 2006, CANCER RES, V66,
                    P9665&#xD; YAO RS, 2000, EXP LUNG RES, V26, P731&#xD; YOSHINO I, 1992, CANCER
                    RES, V52, P775&#xD; YU CL, 1995, SCIENCE, V269, P81&#xD; YU H, 2004, NAT REV
                    CANCER, V4, P97&#xD; YU H, 2007, NAT REV IMMUNOL, V7, P41&#xD; ZEISBERG M, 2003,
                    NAT MED, V9, P964&#xD; ZEISBERG M, 2007, J BIOL CHEM, V282, P23337&#xD; ZHONG Z,
                    1994, SCIENCE, V264, P95&#xD; ZOU W, 2007, CANCER BIOL THER, V6, P99</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250612600014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>477</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">477</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1183</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Pigazzi, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hellan, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ewing, D. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Paz, B. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ballantyne, G. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Canc Ctr, Dept Gen
                    &amp; Oncol Surg, Duarte, CA 91010 USA. Hackensack Univ Med Ctr, Dept Surg,
                    Hackensack, NJ 07601 USA.&#xD;Pigazzi, A, City Hope Natl Canc Ctr, Dept Gen
                    &amp; Oncol Surg, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;apigazzi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Laparoscopic medial-to-lateral
                        colon dissection: How and why</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Gastrointestinal
                        Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Gastrointestinal
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Gastrointest. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Gastrointest Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">778-782</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">11</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">laparoscopic colectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">medial approach</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">technique</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIAL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1091-255X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247242200015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Laparoscopic colectomy is a
                    difficult procedure with a long learning curve. We describe in this study our
                    technique for right- and left-sided laparoscopic medial-to-lateral colectomy.
                    The medial approach involves division of the vascular pedicle first, followed by
                    mobilization of the mesentery toward the abdominal wall, and finally freeing of
                    the colon along the white line of Toldt. This approach allows immediate
                    identification of the plane between the mesocolon and the retroperitoneum and
                    renders the dissection fast and safe. Our series of 50 consecutive laparoscopic
                    colectomies supports this concept. We believe that surgeons familiar with this
                    technique will have an important tool in their armamentarium to circumvent some
                    of the challenges of laparoscopic colectomy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    178TE&#xD;Times Cited: 0&#xD;Cited Reference Count: 9&#xD;Cited References:
                    &#xD; BARNES JP, 1952, SURG GYNECOL OBSTET, V94, P722&#xD; DECANINI C, 1994, DIS
                    COLON RECTUM, V37, P552&#xD; LACY AM, 2002, LANCET, V359, P2224&#xD; LIANG JT,
                    2003, WORLD J SURG, V27, P190&#xD; PAPPAS TN, 2004, NEW ENGL J MED, V350,
                    P2091&#xD; SARTORI CA, 1999, CHIR ITAL, V51, P329&#xD; TURNBULL RB, 1967, ANN
                    SURG, V166, P420&#xD; VELDKAMP R, 2004, SURG ENDOSC, V18, P1163&#xD; WIGGERS T,
                    1988, BRIT J SURG, V75, P409</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247242200015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>645</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">645</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1179</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Podnos, Y. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Borneman, T. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koczywas, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Uman, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Duke Univ, Dept Surg, Raleigh, NC
                    USA. City Hope Natl Med Ctr, Dept Nursing Educ &amp; Res, Duarte, CA 91010 USA.
                    City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA 91010 USA. Vital Res, Dept
                    Biostat, Los Angeles, CA USA.&#xD;Ferrell, BR, Duke Univ, Dept Surg, Raleigh, NC
                    USA.&#xD;bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Symptom concerns and resource
                        utilization in patients with lung cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">899-903</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">QUALITY-OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PALLIATIVE CARE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PAIN</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1096-6218</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249251700020</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective: Lung cancer remains a
                    major source of death in the United States. With the aging of the population,
                    health policy makers are challenged to develop systems of care for the complex
                    needs of these patients. This study sought to determine quality of life and
                    symptom concerns in lung cancer patients. The study also sought to determine how
                    supportive care resources were being used to address these concerns. Methods:
                    One hundred consecutive patients with newly diagnosed lung cancer presenting
                    over a 12-month period were selected from the tumor registry. Charts were
                    reviewed for demographic data, treatment history, treatment received, number and
                    type of practitioner encounters, readmissions, and complications for a 6-month
                    period. Results: Of the 100 charts retrospectively reviewed, 4 patients had
                    small cell and 96 patients had non-small cell lung cancer. The median age was 67
                    years. Fifty-three patients were men. The most common symptoms were pain, cough,
                    dyspnea, and fatigue. A total of 114 referrals in 57 patients were made.
                    Nutrition consultation was the most common. Conclusions: This study serves to
                    guide the institution in the development of more effective support services for
                    patients with lung cancer to address quality of life concerns through
                    collaboration between clinicians and researchers.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    207LD&#xD;Times Cited: 0&#xD;Cited Reference Count: 15</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249251700020 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>230</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">230</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1178</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Podnos, Y. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Juarez, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pameijer, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Choi, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagman, L. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Nursing
                    Res &amp; Educ, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Gen Oncol
                    Surg, Duarte, CA 91010 USA. Vital Res, Los Angeles, CA USA.&#xD;Ferrell, BR,
                    City Hope Natl Med Ctr, Dept Nursing Res &amp; Educ, 1500 E Duarte Rd, Duarte,
                    CA 91010 USA.&#xD;bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Impact of surgical palliation on
                        quality of life in patients with advanced malignancy: Results of the
                        decisions and outcomes in palliative surgery (DOPS) trial</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Surg Oncol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Surg Oncol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">922-928</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">palliation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">surgical palliation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">distress</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">outcomes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COST-EFFECTIVENESS
                        ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STENTS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1068-9265</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243765500087</style>
            </accession-num>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    129YH&#xD;Times Cited: 0&#xD;Cited Reference Count: 12</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243765500087 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>646</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">646</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1177</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Podnos, Y. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Juarez, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pameijer, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Uman, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagman, L. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Duke Univ, Dept Surg, Raleigh, NC
                    USA. City Hope Natl Med Ctr, Dept Nursing Res &amp; Educ, Duarte, CA 91010 USA.
                    City Hope Natl Med Ctr, Dept Gen Oncol Surg, Duarte, CA 91010 USA.&#xD;Ferrell,
                    BR, Duke Univ, Dept Surg, Raleigh, NC USA.&#xD;bferrell@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Surgical palliation of advanced
                        gastrointestinal tumors</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Palliative
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Palliat. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Palliat Med</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">871-876</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">10</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DISTRESS THERMOMETER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1096-6218</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249251700016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Patients with advanced
                    gastrointestinal tumors suffer a spectrum of progressive symptoms that reduce
                    their quality of life (QOL). Operative palliative strategies seeking to improve
                    QOL and decrease symptom burden are poorly studied. This study seeks to measure
                    the effect of operations on symptoms and QOL in patients with advanced
                    gastrointestinal malignancies. Patients undergoing World Health Organization
                    (WHO)-defined palliative operations for gastrointestinal cancers were
                    prospectively followed with monthly QOL and Distress Thermometer surveys until 6
                    months post-operatively. Comparisons were made between preoperative and 3-month
                    postoperative data. Parameters of physical, psychological, social, and spiritual
                    QOL were measured on a scale of 0 (worst) to 5 (best). Frequency of occurrence
                    and degree of distress caused by that specific symptom were scored from 0
                    (rarely/not at all) to 5 (most of the time/severely). Thirty-five patients had
                    gastrointestinal cancer. The median age was 55.3 years. The most common symptoms
                    were pain and obstruction. Thirty-three operations were abdominal. Ultimately,
                    34 patients (97%) were discharged home. When preoperative data were compared to
                    3 months postoperative, the frequency of the primary symptom improved by 2.22 (p
                    = 0.001) and the distress it caused decreased by 1.82 (p = 0.004). Physical QOL
                    decreased by 0.61 (p = 0.009), psychological QOL decreased by 0.50 (p = 0.015),
                    social QOL decreased by 0.48 (p = 0.017), spiritual QOL decreased by 0.42 (p =
                    0.008), and overall QOL decreased by 0.50 (p = 0.012). Because of the
                    unrelenting nature of gastrointestinal tumors, QOL over time will inevitably
                    decrease. Palliative operations effectively improve symptom frequency and
                    distress without greatly affecting the expected decline in QOL and its
                    parameters.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    207LD&#xD;Times Cited: 1&#xD;Cited Reference Count: 11</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249251700016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>569</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">569</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1693</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Podnos, Y. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagman, L. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General Oncologic
                    Surgery, City of Hope National Medical Center, Duarte, California 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Survival in patients with
                        papillary thyroid cancer is not affected by the use of radioactive
                        isotope</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Surg Oncol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Surg Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3-7</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">96</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Papillary/ mortality/
                        radiotherapy/secondary/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Papillary,
                        Follicular/mortality/radiotherapy/secondary/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cohort Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Iodine Radioisotopes/
                        therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymph Nodes/pathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Lymphatic Metastasis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Multivariate Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Prognosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEER Program</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Survival Analysis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Thyroid Neoplasms/
                        mortality/pathology/ radiotherapy/surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Outcome</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul 1</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-4790 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17567872</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">INTRODUCTION: Papillary cancer is
                    the most common neoplasm of the thyroid. The mainstay of treatment is
                    thyroidectomy, but most patients are additionally treated with radioactive
                    iodine (RAI). Its utility is controversial. This study seeks to determine
                    whether RAI use affects patient outcome and to identify specific cohorts of
                    patients that benefit from its use. METHODS: The Surveillance, Epidemiology, and
                    End Results (SEER) database is a large-scale sample of approximately 14% of the
                    US population. It was used to identify patients with papillary carcinoma of the
                    thyroid. Statistical analyses were used to compare prognostic factors such as
                    lymph node status, age, tumor size, and treatment with RAI. RESULTS: A total of
                    14,545 patients were identified in SEER as having papillary cancer of the
                    thyroid. Multivariate analysis showed significantly worse outcome in patients
                    with age&gt;45 years, tumor size &gt;2 cm, lymph node disease, and distant
                    metastases. Multivariate analysis failed to show RAI significantly affecting
                    mortality. Survival between those not treated with RAI was similar to those
                    whose treatment included it (P = 0.9176). Subgroup analysis identified patients
                    older than 45 years with primary tumors &gt;2 cm and disease in the lymph nodes
                    with distant metastatic disease as the only group positively affected by RAI.
                    CONCLUSIONS: Despite its widespread use in the treatment of well-differentiated
                    papillary cancer of the thyroid, RAI only affects a survival advantage in older
                    patients with large primary tumors involving the lymph nodes and with distant
                    spread. Treating other patient groups is costly and offers no improvement in
                    outcome.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>231</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">231</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1172</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Pullarkat, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bedell, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kim, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nakamura, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Senitzer, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept
                    Cytogenet, Div Pathol, Div Hematol &amp; Hematopoiet Cell Transplantat, Duarte,
                    CA 91010 USA.&#xD;Pullarkat, V, City Hope Natl Med Ctr, Dept Cytogenet, Div
                    Pathol, Div Hematol &amp; Hematopoiet Cell Transplantat, 1500 E Duarte Rd,
                    Duarte, CA 91010 USA.&#xD;vpullarkat@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Neoplastic mast cells in
                        systemic mastocytosis associated with t(8;21) acute myeloid leukemia are
                        derived from the leukemic clone</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Leukemia Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Leuk. Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Leukemia Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Leukemia Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Leukemia Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">261-265</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">31</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">systemic mastocytosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">acute myeloid leukemia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytogenetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">translocation(8</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">21)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pathogenesis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIT mutations</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING-FACTOR LEUKEMIAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-KIT MUTATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEUKEMOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AML1-ETO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0145-2126</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243631300022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In systemic mastocytosis with
                    associated clonal, hematological non-mast cell lineage disease (SM-AHNMD), mast
                    cell infiltration of the bone marrow coexists with a hematologic neoplasm,
                    usually of mycloid origin. Activating KIT gene mutations are universally present
                    in these neoplastic mast cells. When SM is associated with AML, the leukemic
                    cells commonly carry the t(8;21)(q22;q22) core binding factor translocation. The
                    precise relationship between neoplastic mast cells and the leukemic clone has
                    remained unclear. By target FISH analysis, we demonstrate t(8:21) in the bone
                    marrow mast cells of a patient with systemic mastocytosis associated with
                    t(8;21) AML, thus, proving the origin of these neoplastic mast cells from the
                    leukemic clone. We also show that after successful allogeneic hematopoietic stem
                    cell transplantation. these neoplastic bone marrow mast cells can persist
                    without adverse consequences and gradually decline with time. (c) 2006 Elsevier
                    Ltd. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    128BQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 14</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243631300022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>478</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">478</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1169</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Pullarkat, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Veliz, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chang, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mohrbacher, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Teotico, A. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Pathol,
                    Duarte, CA 91010 USA. Univ So Calif, Keck Sch Med, Dept Med, Div Haematol, Los
                    Angeles, CA 90033 USA. City Hope Comprehens Canc Ctr, Dept Cytogenet, Duarte, CA
                    USA. City Hope Natl Med Ctr, Div Haematol &amp; Haematopoiet Cell Transplantat,
                    Duarte, CA 91010 USA.&#xD;Pullarkat, V, City Hope Natl Med Ctr, Div Haematol,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;vpullarkat@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Therapy-related, mixed-lineage
                        leukaemia translocation-positive, monoblastic myeloid sarcoma of the
                        uterus</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Pathology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">562-564</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">60</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">FEMALE GENITAL-TRACT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GRANULOCYTIC SARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIAGNOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BLAST</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9746</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246594100022</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Myeloid sarcomas are tumour masses
                    of myeloid leukaemic cells at extramedullary sites. These tumours can, on
                    occasion, occur without concurrent or antecedent leukaemia. Myeloid sarcomas
                    have been described at unusual locations including the female genital tract. An
                    unusual case of therapy-related acute myeloid leukaemia (t-AML) presenting as
                    isolated monoblastic myeloid sarcoma of the uterus in a patient who had received
                    adjuvant chemotherapy for breast cancer is presented. Fluorescence in situ
                    hybridisation analysis performed on paraffin-wax-embedded tumour tissue revealed
                    a mixed-lineage leukaemia (MLL) gene rearrangement, supporting the association
                    of this malignancy with prior chemotherapy. This case illustrates that t-AML can
                    rarely present as isolated extramedullary tumours, and the detection of specific
                    chromosomal abnormalities in these myeloid sarcomas can be useful for risk
                    assessment and guiding definitive therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    169LQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 13&#xD;Cited References:
                    &#xD; AUDOUIN J, 2003, INT J SURG PATHOL, V11, P271&#xD; BRECCIA M, 2004,
                    LEUKEMIA RES, V28, P1165&#xD; CHANG CC, 2000, AM J CLIN PATHOL, V114, P807&#xD;
                    FRIEDMAN HD, 1992, GYNECOL ONCOL, V46, P128&#xD; HERNANDEZ JA, 2002, LEUKEMIA
                    LYMPHOMA, V43, P2151&#xD; JAFFE ES, 2001, TUMORS HAEMATOPOIETI, P104&#xD; LEONE
                    G, 2001, LEUKEMIA LYMPHOMA, V41, P255&#xD; LI ZY, 2005, LEUKEMIA, V19, P183&#xD;
                    OLIVA E, 1997, AM J SURG PATHOL, V21, P1156&#xD; PATERNOSTER SF, 2002, AM J
                    PATHOL, V160, P1967&#xD; QUINTANILLAMARTINEZ L, 1995, AM J CLIN PATHOL, V104,
                    P431&#xD; STEINBOCK GS, 1986, UROLOGY, V3, P268&#xD; SUPER HJG, 1993, BLOOD,
                    V82, P3705</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246594100022 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>722</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">722</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1168</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kaddis, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Niland, J. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Informat
                    Sci &amp; Adm, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Bioinformat
                    Coordinat Ctr Islet Cell Resource Ctr, Duarte, CA 91010 USA.&#xD;Qian, D, City
                    Hope Natl Med Ctr, Div Informat Sci &amp; Adm, 1500 E Duarte Rd, Duarte, CA
                    91010 USA.&#xD;dqian@coh.org jkaddis@coh.org jniland@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A matching algorithm for the
                        distribution of human pancreatic islets</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Computational Statistics &amp;
                        Data Analysis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Computational Statistics &amp;
                        Data Analysis</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Comput. Stat. Data Anal.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Comput Stat Data Anal</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5494-5506</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">51</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">islet distribution</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">matching algorithm</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">exhaustive search</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">space</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">reduction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">importance sampling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM COMPLICATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIABETES-MELLITUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BETA-CELL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGENERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ALLOCATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0167-9473</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249316000005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The success of human pancreatic
                    islet transplantation in a subset of type 1 diabetic patients has led to an
                    increased demand for this tissue in both clinical and basic research, yet the
                    availability of such preparations is limited and the quality highly variable.
                    Under the current process of islet distribution for basic science
                    experimentation nationwide, specialized laboratories attempt to distribute
                    islets to one or more scientists based on a list of known investigators. This
                    local decision making (LDM) process has been found to be ineffective and
                    suboptimal. To alleviate these problems, a computerized Matching Algorithm for
                    Islet Distribution (MAID) was developed to better match the functional,
                    morphological, and quality characteristics of islet preparations to the criteria
                    desired by basic research laboratories, i.e., requesters. The algorithm searches
                    for an optimal combination of requesters using detailed screening, sorting, and
                    search procedures. When applied to a data set of 68 human islet preparations
                    distributed by the Islet Cell Resource (ICR) Center Consortium, MAID reduced the
                    number of requesters that (a) did not receive any islets, and (b) received
                    mis-matched shipments. These results suggest that MAID is an improved more
                    efficient approach to the centralized distribution of human islets within a
                    consortium setting. (C) 2007 Elsevier B.V. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    208JQ&#xD;Times Cited: 0&#xD;Cited Reference Count: 18&#xD;Cited References:
                    &#xD; AHRENS B, 2003, BETA CELL FUNCTION I&#xD; BERNEY T, 2005, TRANSPLANT INT,
                    V18, P763&#xD; GAGLIA JL, 2005, ARCH MED RES, V36, P273&#xD; HARDIKAR AA, 2004,
                    TRENDS ENDOCRIN MET, V15, P198&#xD; KNAZEK RA, 2002, DIABETES TECHNOL THE, V4,
                    P551&#xD; MARTELLO S, 1990, KNAPSACK PROBLEMS AL&#xD; NANJI SA, 2006,
                    METABOLISM, V8, P15&#xD; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676&#xD;
                    NEMHAUSER GL, 1998, INTEGER COMBINATORIA&#xD; PINTO A, 2004, SEMIN VASC MED, V4,
                    P287&#xD; RAMIYA V, 2004, PEDIATR DIABETES S2, V5, P45&#xD; RIDGWAY DM, 2005,
                    TRANSPLANT INT, V18, P828&#xD; SHAMOON H, 1993, NEW ENGL J MED, V329, P977&#xD;
                    SHAPIRO AMJ, 2000, NEW ENGL J MED, V343, P230&#xD; TAYLOR GW, 2004, COMPEND
                    CONTIN ED DE, V25, P179&#xD; TRUCCO M, 2005, J CLIN INVEST, V115, P5&#xD; WEIR
                    GC, 2004, DIABETES S3, V53, S16&#xD; WOODRUFF DL, 2004, COMPUT STAT DATA AN,
                    V47, P237</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249316000005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>570</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">570</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1685</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Qiu, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhou, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Luh, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Clinical and Molecular
                    Pharmacology, City of Hope National Medical Center, Duarte, CA 91010-3000,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The induction of growth arrest
                        DNA damage-inducible gene 45 beta in human hepatoma cell lines by
                        S-adenosylmethionine</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am J Pathol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of
                        Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Pathol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">287-96</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">171</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Antigens,
                        Differentiation/genetics/ metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Binding Sites</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Carcinoma, Hepatocellular/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Electrophoretic Mobility Shift
                        Assay</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression Regulation,
                        Neoplastic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genes, p53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">I-kappa B
                        Kinase/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Liver Neoplasms/
                        genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-kappa B/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Polymerase Chain
                        Reaction</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Promoter Regions
                        (Genetics)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">S-Adenosylmethionine/
                        pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transfection</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Tumor Cells, Cultured</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0002-9440 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17591973</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Down-regulation of GADD45beta, which
                    is known to influence cell growth control, apoptosis, and cellular response to
                    DNA damage, has been verified to be specific in hepatocellular carcinoma and
                    consistent with the degree of malignancy. Here, we identified promoter elements
                    for several transcriptional factors in the proximal promoter of GADD45beta using
                    the luciferase assay. As a methyl donor for biological transmethylation
                    reactions, S-adenosylmethionine (SAMe) could restore GADD45beta expression in
                    HepG2 in Northern blot analyses and quantitative real-time polymerase chain
                    reaction. Activity and binding capacity of nuclear factor (NF)-kappaB were
                    confirmed to be specifically induced by SAMe, as evidenced by electrophoretic
                    mobility shift assay, enzyme-linked immunosorbent assay, and a decrease of
                    IkappaBalpha in Western blot analyses. The most upstream NF-kappaB-binding site
                    was crucial for transcriptional activation. In contrast to NF-kappaB, although
                    there is an E2F-1-binding site adjacent to the NF-kappaB sites, treatment with
                    SAMe could not induce E2F-1-binding activity. Despite showing a similar
                    GADD45beta promoter regulatory pattern as HepG2 (p53 wild type), Hep3B
                    (p53-null) did not exhibit GADD45beta induction by SAMe, and the induction could
                    be partially recovered on reconstituting p53 in Hep3B. Thus, our results suggest
                    that GADD45beta induction by SAMe via NF-kappaB may represent a novel mechanism
                    of SAMe-mediated hepatoprotection, with p53 playing an important role.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>411</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">411</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1163</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Rauch, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Z. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, X. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhong, X. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, X. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kernstine, K. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Riggs, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst, Div Biol, Duarte,
                    CA 91010 USA. Beckman Res Inst, Div Informat Sci, Duarte, CA 91010 USA. Beckman
                    Res Inst, Div Pathol, Duarte, CA 91010 USA. Beckman Res Inst, Div Surg, Duarte,
                    CA 91010 USA. NimbleGen Syst Inc, Madison, WI 53711 USA.&#xD;Riggs, AD, Beckman
                    Res Inst, Div Biol, Duarte, CA 91010 USA.&#xD;ariggs@coh.org
                    gpfeifer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Homeobox gene methylation in
                        lung cancer studied by genome-wide analysis with a microarray-based
                        methylated CpG island recovery assay</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">5527-5532</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">13</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOX genes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">chromatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">polycomb</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ABERRANT PROMOTER
                        METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-SUPPRESSOR GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EMBRYONIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STEM-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROUP PROTEIN EZH2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EPIGENETIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HOX GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DEVELOPMENTAL REGULATORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POLYCOMB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYPERMETHYLATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245331700050</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">human cancer, but the mechanisms of
                    cancer-associated DNA methylation are not known. We have used tiling arrays in
                    combination with the methylated CpG island recovery assay to investigate
                    methylation of CpG islands genome-wide and at high resolution. We find that all
                    four HOX gene clusters on chromosomes 2, 7,12, and 17 are preferential targets
                    for DNA methylation in cancer cell lines and in early-stage lung cancer. CpG
                    islands associated with many other homeobox genes, such as SIX, LHX, PAX, DLX,
                    and Engrailed, were highly methylated as well. Altogether, more than half (104
                    of 192) of all CpG island-associated homeobox genes in the lung cancer cell line
                    A549 were methylated. Analysis of paralogous HOX genes showed that not all
                    paralogues undergo cancer-associated methylation simultaneously. The HOXA
                    cluster was analyzed in greater detail. Comparison with ENCODE-derived data
                    shows that lack of methylation at CpG-rich sequences correlates with presence of
                    the active chromatin mark, histone H3 lysine-4 methylation in the HOXA region.
                    Methylation analysis of HOXA genes in primary squamous cell carcinomas of the
                    lung led to the identification of the HOXA7- and HOXA9-associated CpG islands as
                    frequent methylation targets in stage 1 tumors. Homeobox genes are potentially
                    useful as DNA methylation markers for early diagnosis of the disease. The
                    finding of widespread methylation of homeobox genes lends support to the
                    hypothesis that a substantial fraction of genes methylated in human cancer are
                    targets of the Polycomb complex.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    152AE&#xD;Times Cited: 0&#xD;Cited Reference Count: 58&#xD;Cited References:
                    &#xD; AHRENDT SA, 1999, J NATL CANCER I, V91, P332&#xD; BAYLIN SB, 2006, NAT REV
                    CANCER, V6, P107&#xD; BEARZATTO A, 2002, CLIN CANCER RES, V8, P3782&#xD;
                    BELINSKY SA, 1998, P NATL ACAD SCI USA, V95, P11891&#xD; BELINSKY SA, 2004, NAT
                    REV CANCER, V4, P707&#xD; BOYER LA, 2006, NATURE, V441, P349&#xD; BRACKEN AP,
                    2006, GENE DEV, V20, P1123&#xD; CAO R, 2004, MOL CELL, V15, P57&#xD; CATRON KM,
                    1993, MOL CELL BIOL, V13, P2354&#xD; COSTELLO JF, 2000, NAT GENET, V24,
                    P132&#xD; DAMMANN R, 2000, NAT GENET, V25, P315&#xD; DING L, 2006, CANCER RES,
                    V66, P4095&#xD; EGGER G, 2004, NATURE, V429, P457&#xD; ERHARDT S, 2003,
                    DEVELOPMENT, V130, P4235&#xD; ESTELLER M, 2001, CANCER RES, V61, P3225&#xD;
                    FRIGOLA J, 2006, NAT GENET, V38, P540&#xD; GARCIAFERNANDEZ J, 2005, NAT REV
                    GENET, V6, P881&#xD; GOLPON HA, 2001, AM J PATHOL, V158, P955&#xD; GREER JM,
                    2000, NATURE, V403, P661&#xD; GRIER DG, 2005, J PATHOL, V205, P154&#xD; GROTE
                    HJ, 2005, INT J CANCER, V116, P720&#xD; GUENTHER MG, 2005, P NATL ACAD SCI USA,
                    V102, P8603&#xD; HERNANDEZMUNOZ I, 2005, MOL CELL BIOL, V25, P11047&#xD;
                    HOLLIDAY R, 1975, SCIENCE, V187, P226&#xD; ISSA JP, 2004, NAT REV CANCER, V4,
                    P988&#xD; JIANG CL, 2004, J BIOL CHEM, V279, P52456&#xD; JONES PA, 2002, NAT REV
                    GENET, V3, P415&#xD; KIM SY, 2006, DEVELOPMENT, V133, P4957&#xD; LAIRD PW, 2003,
                    NAT REV CANCER, V3, P253&#xD; LEE TI, 2006, CELL, V125, P301&#xD; LEWIS EB,
                    1978, NATURE, V276, P565&#xD; LIU ZY, 2004, J BIOL CHEM, V279, P11313&#xD; NOVAK
                    P, 2006, CANCER RES, V66, P10664&#xD; OHM JE, 2007, NAT GENET, V39, P237&#xD;
                    OKUDA H, 2006, ONCOGENE, V25, P1733&#xD; PALMISANO WA, 2003, CANCER RES, V63,
                    P4620&#xD; POPOVIC R, 2005, J CELL BIOCHEM, V95, P234&#xD; RAMAN V, 2000,
                    NATURE, V405, P974&#xD; RAUCH T, 2005, LAB INVEST, V85, P1172&#xD; RAUCH T,
                    2006, CANCER RES, V66, P7939&#xD; REYNOLDS PA, 2006, J BIOL CHEM, V281,
                    P24790&#xD; RIGGS AD, 1975, CYTOG C GEN, V14, P9&#xD; SALEH M, 2000, MOL CELL
                    BIOL, V20, P8623&#xD; SAMUEL S, 2005, EUR J CANCER, V41, P2428&#xD; SCHLESINGER
                    Y, 2007, NAT GENET, V39, P232&#xD; SELZER RR, 2005, GENE CHROMOSOME CANC, V44,
                    P305&#xD; SHANMUGAM K, 1999, MOL CELL BIOL, V19, P7577&#xD; SHIRAISHI M, 2002,
                    ONCOGENE, V21, P3659&#xD; SMITH LT, 2006, P NATL ACAD SCI USA, V103, P982&#xD;
                    TERRANOVA R, 2006, P NATL ACAD SCI USA, V103, P6629&#xD; TVRDIK P, 2006, DEV
                    CELL, V11, P239&#xD; USHIJIMA T, 2005, NAT REV CANCER, V5, P223&#xD; VARAMBALLY
                    S, 2002, NATURE, V419, P624&#xD; VIRE E, 2006, NATURE, V439, P871&#xD; WELLIK
                    DM, 2002, GENE DEV, V16, P1423&#xD; WIDSCHWENDTER M, 2007, NAT GENET, V39,
                    P157&#xD; WILLIAMS TM, 2005, DEV BIOL, V277, P457&#xD; XIONG ZG, 1997, NUCLEIC
                    ACIDS RES, V25, P2532</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245331700050 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>480</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">480</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1160</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Reckamp, K. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Figlin, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moldawer, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pantuck, A. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Belldegrun, A. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burdick, M. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Strieter, R. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Med
                    Oncol &amp; Therapeut Res, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA
                    USA. Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22901 USA. Univ Calif
                    Los Angeles, David Geffen Sch Med, Greater Los Angeles Vet Affairs Healthcare
                    Syst, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, David Geffen Sch Med,
                    Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles,
                    David Geffen Sch Med, Dept Urol, Los Angeles, CA 90024 USA.&#xD;Reckamp, KL,
                    City Hope Natl Med Ctr, Div Med Oncol &amp; Therapeut Res, 1500 E Duarte Rd,MOB
                    1001, Duarte, CA 91010 USA.&#xD;kreckamp@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Expression of CXCR3 on
                        mononuclear cells and CXCR3 ligands in patients with metastatic renal cell
                        carcinoma in response to systemic IL-2 therapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunother</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">417-424</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">30</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">chemokines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">renal cell carcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytokine therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-SUPPRESSOR GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-II TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SUBCUTANEOUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHEMOKINE RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOSE INTERLEUKIN-2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIOLOGICAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AXIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RENCA TUMOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BEVACIZUMAB</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May-Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1524-9557</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246029600006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Chemokines play an important role in
                    regulating tumor-mediated immunity, angiogenesis, and tumor cell inetastasis.
                    The chemokine receptor, CXCR3, is expressed in various human tumors, including
                    renal cell carcinoma (RCC). CXCR3 is also associated with antiangiogenic effects
                    in multiple tumors, and we hypothesized that interleukin-2 (IL-2) treatment of
                    patients with metastatic clear cell RCC could augment CXCR3 levels on
                    circulating mononuclear cells and correlate to outcome. The kinetics of CXCR3
                    expression on circulating mononuclear cells and its ligands (CXCL9, CXCL10, and
                    CXCL11) in plasma were evaluated in 20 patients with metastatic clear cell RCC
                    during cycles I and 2 of high dose IL-2 therapy. Subpopulations of peripheral
                    blood mononuclear cells (PBMCs) were studied by dual color flow cytometry.
                    Angiogenic ligands were measured and an &quot;angiogenic ratio&quot; was
                    calculated prehigh and posthigh dose IL-2. CXCR3 expression on PBMC at baseline
                    was similar in patients with metastatic RCC and normal controls. PBMC CXCR3
                    expression increased during treatment, and peaked during cycle 2. Plasma from
                    RCC patients displayed similar baseline levels of CXCR3 ligands to normal
                    controls. however, the angiogenic ratio was significantly increased in patients
                    with metastatic RCC at baseline. Plasma levels of CXCR3 ligands increased during
                    treatment, resulting in a reversal in the angiogenic ratio to favor angiostatic
                    chemokines. The CXCR3/CXCR3 ligand biologic axis and angiogenic ratio may be
                    important biomarkers in clear cell RCC patients who are undergoing high dose
                    IL-2 therapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    161QE&#xD;Times Cited: 0&#xD;Cited Reference Count: 39&#xD;Cited References:
                    &#xD; BELPERIO JA, 2000, J IMMUNOL, V165, P461&#xD; BELPERIO JA, 2000, J
                    LEUKOCYTE BIOL, V68, P1&#xD; BELPERIO JA, 2001, J CLIN INVEST, V108, P547&#xD;
                    BELPERIO JA, 2002, J IMMUNOL, V169, P1037&#xD; COLVIN RA, 2004, J BIOL CHEM,
                    V279, P30219&#xD; COZAR J, 2005, CANCER IMMUNOL IMMUN, V54, P858&#xD;
                    DAGANBERGER M, 2005, IN PRESS BLOOD&#xD; ESCUDIER B, 2005, J CLIN ONCOL, V23,
                    S648&#xD; FIGLIN RA, 1999, J UROLOGY, V161, P381&#xD; FYFE G, 1995, J CLIN
                    ONCOL, V13, P688&#xD; GNARRA JR, 1994, NAT GENET, V7, P85&#xD; HERMAN JG, 1994,
                    P NATL ACAD SCI USA, V91, P9700&#xD; HURWITZ H, 2004, NEW ENGL J MED, V350,
                    P2335&#xD; JEMAL A, 2005, CA-CANCER J CLIN, V55, P10&#xD; JOHNSON DH, 2004, J
                    CLIN ONCOL, V22, P2184&#xD; JOHRER K, 2005, CLIN CANCER RES, V11, P2459&#xD;
                    KEANE MP, 1999, J IMMUNOL, V162, P5511&#xD; LOETSCHER M, 1996, J EXP MED, V184,
                    P963&#xD; LUSTER AD, 1998, NEW ENGL J MED, V338, P436&#xD; MCDERMOTT DF, 2005, J
                    CLIN ONCOL, V23, P133&#xD; MESTAS J, 2005, J IMMUNOL, V175, P5351&#xD; MOSER B,
                    2001, NAT IMMUNOL, V2, P123&#xD; MOTZER RJ, 2005, J CLIN ONCOL, V23, S648&#xD;
                    MULLINS IM, 2004, CANCER RES, V64, P7697&#xD; MUSHA H, 2005, INT J CANCER, V116,
                    P949&#xD; NEGRIER S, 1998, NEW ENGL J MED, V338, P1272&#xD; PAN JD, 2006, J
                    IMMUNOL, V176, P1456&#xD; QIN SX, 1998, J CLIN INVEST, V101, P746&#xD; RABIN RL,
                    1999, J IMMUNOL, V162, P3840&#xD; RAVAUD A, 2003, BRIT J CANCER, V89, P2213&#xD;
                    RINI B, 2005, J CLIN ONCOL, V23, S648&#xD; SHARMA S, 2000, J IMMUNOL, V164,
                    P4558&#xD; SHARMA S, 2003, MOL CANC, V2, P22&#xD; STRIETER RM, 1995, J BIOL
                    CHEM, V270, P27348&#xD; STRIETER RM, 2001, NAT IMMUNOL, V2, P285&#xD; TANNENBAUM
                    CS, 1998, J IMMUNOL, V161, P927&#xD; YANG JC, 2003, J CLIN ONCOL, V21,
                    P3127&#xD; YANG JC, 2003, NEW ENGL J MED, V349, P427&#xD; ZHANG L, 2003, NEW
                    ENGL J MED, V348, P203</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246029600006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>626</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">626</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">955</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Rezk, S. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weiss, L. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Pathol,
                    Duarte, CA 91010 USA.&#xD;Weiss, LM, City Hope Natl Med Ctr, Dept Pathol,
                    Duarte, CA 91010 USA.&#xD;lweiss@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Epstein-Barr virus-associated
                        lymphoproliferative disorders</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Hum. Pathol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Pathol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Human Pathology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Hum. Pathol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Hum Pathol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1293-1304</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">38</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">epstein-Barr virus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">B-cell
                        lymphoproliferative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disorders</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphoproliferative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disorders</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-associated
                        lymphoproliferative</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disorders</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELL LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >POLYMERASE-CHAIN-REACTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REED-STERNBERG-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANGIOCENTRIC IMMUNOPROLIFERATIVE
                        LESIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AIDS-RELATED LYMPHOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHADENOPATHY-LIKE
                        LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRIMARY EFFUSION
                        LYMPHOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CENTRAL-NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NON-HODGKINS-LYMPHOMAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-POSITIVE PATIENTS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0046-8177</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249128100001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Epstein-Barr virus (EBV) is a member
                    of the human herpesvirus family that was initially isolated from a cultured
                    Burkitt lymphoma cell line by Epstein et al in 1964. Subsequent studies have
                    proven that it is the causative agent in most cases of infectious mononucleosis.
                    Primary infection is usually asymptomatic in childhood; but in adulthood, it is
                    associated with a self-limiting infectious mononucleosis syndrome in
                    approximately one third of the cases. EBV has been linked to many human
                    neoplasms including hematopoietic, epithelial, and mesenchymal tumors. In this
                    review, we will only discuss the EBV-associated lymphoproliferative disorders,
                    dividing them into B-cell, T/NK-cell, and HIV-related lymphoproliferative
                    disorders. (c) 2007 Published by Elsevier Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    205PW&#xD;Times Cited: 0&#xD;Cited Reference Count: 133</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249128100001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>409</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">409</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1154</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Ricker, C. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hiyama, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fuentes, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Feldman, N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kumar, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Uman, G. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nedelcu, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blazer, K. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">MacDonald, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weitzel, J. N.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Clin Canc
                    Genet Dept, Duarte, CA 91010 USA. Olive View UCLA Med Ctr, Sylmar, CA 91342 USA.
                    QueensCare Family Clin, Los Angeles, CA 90023 USA. Vital Res LLC, Los Angeles,
                    CA 90048 USA.&#xD;Weitzel, JN, City Hope Natl Med Ctr, Clin Canc Genet Dept,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;jweitzel@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Beliefs and interest in cancer
                        risk in an underserved Latino cohort</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Preventive Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Preventive Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Prev. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Prev Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">241-245</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">44</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">heredity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">disparities</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">underserved minorities</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Latinos</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HISPANICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILIES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRCA1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STATISTICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTATIONS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0091-7435</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245480000011</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective. To measure beliefs about
                    cancer causation, cancer screening behaviors, access to information about and
                    resources for cancer screening, and interest in cancer genetics services in two
                    underserved predominately Latino communities. Methods.. An anonymous survey, in
                    both English and Spanish, was distributed at the registration desk to all
                    attendees of selected general medicine clinics in two underserved healthcare
                    systems. Results. There were a total of 312 respondents, representing 98% of
                    eligible candidates. The reported data focus on 75.3% (n=235) of Latino
                    respondents; mean age 43 years; 78% female; 72% less than high school education.
                    Heredity was perceived as the most frequent cause of cancer, after smoking. Only
                    37% knew of free cancer screening programs. Over 85% expressed interest in
                    obtaining information about personal cancer risk and motivation to participate
                    in cancer genetics services. Conclusions. The results of this survey demonstrate
                    an awareness of heredity as a potential cause of cancer. The observed high level
                    of interest in cancer genetics services suggests the acceptability of cancer
                    genetics services in this predominately underserved Latino population.
                    Furthermore, cancer genetics services would likely augment awareness and
                    utilization of available cancer screening services in the community. (c) 2006
                    Elsevier Inc. All rights reserved.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    154AU&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; *ACS, 2001, CANC FACTS FIG 2001&#xD; AUSTIN LT, 2002, WOMEN HEALTH ISS,
                    V12, P122&#xD; CLAUS EB, 1996, CANCER, V77, P2318&#xD; DIEZ O, 1999, INT J
                    CANCER, V83, P465&#xD; FACIONE NC, 1999, ONCOL NURS FORUM, V26, P689&#xD;
                    FREEMAN HP, 1989, CA-CANCER J CLIN, V39, P266&#xD; HONDA K, 2003, CLIN GENET,
                    V64, P131&#xD; HUERTA EE, 1999, J NATL CANC I MONOGR, V25, P23&#xD; HUERTA EE,
                    2003, CA-CANCER J CLIN, V53, P205&#xD; KELLER CS, 1997, J CARDIOVASCULAR NUR,
                    V11, P15&#xD; KONSTANTOPOULOU I, 2000, HUM MUTAT, V16, P272&#xD; LIEDE A, 2002,
                    HUM MUTAT, V20, P413&#xD; LOCKE D, 1992, INCREASING MULTICULT&#xD; MACDONALD DJ,
                    2002, J MED GENET, V39, P526&#xD; MACLEAN J, 2004, CALIFORNIA BREAST CA, P1&#xD;
                    MARIN G, 1989, PUBLIC HEALTH REP, V104, P411&#xD; MAYO RM, 2003, CANC CONTROL,
                    V10, P60&#xD; MCDONALD CJ, 2001, CANCER, V91, P195&#xD; MCGARVEY EL, 2003,
                    ETHNIC HEALTH, V8, P71&#xD; MONTAGNA M, 2003, HUM MOL GENET, V12, P1055&#xD;
                    OBRIEN K, 2003, CA-CANCER J CLIN, V53, P208&#xD; OLOPADE OI, 2003, CANCER, V97,
                    P236&#xD; ROCHE RA, 1998, J CANCER EDUC, V13, P226&#xD; STRECKER MN, 2002,
                    COMMUNITY GENETICS, V5, P222&#xD; TORTOLEROLUNA G, 1995, J NATL CANC I MONOGR,
                    V49&#xD; TRIANDIS HC, 2001, J PERS, V69, P907&#xD; WEITZEL JN, 1999, CANCER S,
                    V86, P2483&#xD; WEITZEL JN, 2005, CANCER EPIDEM BIOMAR, V14, P1666</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245480000011 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>797</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">797</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1675</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Roberts, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Maghami, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kandeel, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yamauchi, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, H. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of General &amp;
                    Oncologic Surgery, City of Hope National Medical Center, Duarte, California
                    91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The role of positron emission
                        tomography scanning in patients with radioactive iodine scan-negative,
                        recurrent differentiated thyroid cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Am Surg</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Surgeon</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1052-6</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">73</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Differentiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Iodine Radioisotopes/ diagnostic
                        use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasm Recurrence, Local/
                        surgery</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Positron-Emission
                        Tomography</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Recurrence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Retrospective Studies</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Thyroglobulin/blood</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Thyroid
                        Neoplasms/blood/pathology/ radionuclide imaging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Whole Body Imaging</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0003-1348 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17983080</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">An elevated thyroglobulin (Tg) level
                    after total thyroidectomy for differentiated thyroid cancer is often associated
                    with disease recurrence. 131I-whole body scans (131I-WBS) and cross-sectional
                    imaging are commonly used to localize occult metastases in these patients.
                    Localizing disease when 131I-WBS are negative and cross-section imaging is
                    equivocal remains a challenge. The medical records of 12 patients with thyroid
                    cancer undergoing positive positron emission tomography (PET) scans for
                    131I-WBS-negativeTg elevations or the presence of anti-Tg antibodies were
                    identified and charts were reviewed in a retrospective fashion. All had been
                    treated with total thyroidectomy and 131I ablation in the past. Computed
                    tomography, magnetic resonance imaging, or ultrasound studies revealed
                    suspicious lesions in eight patients. All 12 patients underwent resection of the
                    PET-positive lesions. All resections were positive for thyroid cancer in the
                    regions predicted by the positive PET scan. All nine (100%) patients with
                    elevated preoperative Tg levels experienced a reduction in Tg level after
                    resection. PET scans accurately predict the presence of recurrent thyroid cancer
                    when 131I-WBS are negative. PET scans should be considered in the follow up of
                    131I-WBS-negative patients with thyroid cancer who are suspected of having
                    recurrent disease.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>725</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">725</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1149</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Roman, L. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wilczynski, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muderspach, L. I.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bumett, A. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">O&apos;Meara, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brinkman, J. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kast, W. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Facio, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Felix, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aldana, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weber, J. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ So Calif, Keck Sch Med, Dept
                    Obstet &amp; Gynecol, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch Med,
                    Dept Microbiol &amp; Immunol, Los Angeles, CA 90089 USA. Univ So Calif, Keck Sch
                    Med, Dept Med, Los Angeles, CA 90089 USA. City Hope Natl Med Ctr, Dept Pathol,
                    Duarte, CA 91010 USA.&#xD;Roman, LD, Womens &amp; Childrens Hosp, Div Gynecol
                    Oncol, Dept Obstet &amp; Gynecol, Room 1-L-4,1240 N Mission Rd, Los Angeles, CA
                    90033 USA.&#xD;lroman@hsc.usc.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A phase II study of Hsp-7
                        (SGN-00101) in women with high-grade cervical intraepithelial
                        neoplasia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gynecologic Oncology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gynecologic Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gynecol. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gynecol Oncol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">558-566</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">106</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">papillomavirus</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">vaccine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immune response</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">heat-shock</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T cell</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN-PAPILLOMAVIRUS
                        TYPE-16</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RANDOMIZED
                        CONTROLLED-TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHOCK-PROTEIN GP96</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELL RESPONSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOLOGICAL RESPONSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPEUTIC VACCINATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNE-RESPONSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PARTICLE VACCINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEPTIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VACCINE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-PATIENTS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0090-8258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249361100020</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective. Approximately 2 million
                    women worldwide are infected with high-risk human papillonnaviruses (HPV),
                    resulting in a substantial risk for the development of invasive lower genital
                    malignancies. This study was undertaken to determine the effects of vaccination
                    with a protein encoding a bacteria] heat shock protein fused to sequences from
                    the oncogenic E7 protein of HPV-16 in women with high-grade cervical
                    intraepithelial neoplasia. Endpoints included lesion regression, immune
                    response, and viral clearance. Methods. Twenty-one women were prospectively
                    entered into an IRB-approved Phase 11 study. All women had biopsy-proven
                    high-grade cervical intraepithelial neoplasia and persistent post-biopsy lesions
                    visible by colposcopy. Four injections of HPV-16 Hsp E7 fusion protein at a dose
                    of 500 mu g were given 3 weeks apart after which Loop Electrosurgical Excision
                    of the Transformation Zone (LLETZ) was performed. Immune parameters were
                    evaluated pre-vaccine and at the time of LLETZ, and HPV testing was performed at
                    intervals before and after LLETZ. Study subjects were followed for 1 year after
                    LLETZ. Results. Seven of 20 women (35%) evaluable for response had complete
                    regression of their intraepithelial neoplasia at the time of LLETZ, I (5%) had
                    regression to CIN I, II (55%) had stable disease and 1 (5%) had progression due
                    to enlargement of her lesion. Immune responses were seen in 9 of the 17 women
                    tested; 5 of the 7 complete responders had an immune response. Only 5 of 21
                    women had HPV-16 or -18. HPV clearance was not associated with lesion
                    regression. Conclusion. Hsp-7 (SGN-00101), at this dose and schedule induced
                    lesion regression in women with high-grade intraepithelial neoplasia. The fact
                    that regression was correlated with immune response suggests that enhancing the
                    immunogenicity of this vaccine may lead to improvement in the rate of lesion
                    eradication. (c) 2007 Elsevier Inc. All rights reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    209AS&#xD;Times Cited: 0&#xD;Cited Reference Count: 55&#xD;Cited References:
                    &#xD; BALDWIN PJ, 2003, CLIN CANCER RES, V9, P5205&#xD; BELLI F, 2002, J CLIN
                    ONCOL, V20, P4169&#xD; CHU NR, 2000, CLIN EXP IMMUNOL, V121, P216&#xD; CROOK T,
                    1989, EMBO J, V8, P513&#xD; DAVIDSON EJ, 2004, VACCINE, V22, P2722&#xD; DEJONG
                    A, 2004, CANCER RES, V64, P5449&#xD; EINSTTEIN MH, 2005, 36 ANN M SOC GYN
                    ONC&#xD; FAUSCH SC, 2005, J IMMUNOL, V174, P7172&#xD; FRAZER IH, 2004, VACCINE,
                    V23, P172&#xD; GRAVITT PE, 2000, J CLIN MICROBIOL, V38, P357&#xD; GUTIERREZ CMC,
                    2004, HUM GENE THER, V15, P421&#xD; HALLEZ S, 2004, CANCER IMMUNOL IMMUN, V53,
                    P642&#xD; HAMID O, 2007, CLIN CANCER RES, V13, P215&#xD; HARPER DM, 2004,
                    LANCET, V364, P1757&#xD; HERRRERO R, 2005, COSTA RICA JID, V1911, P796&#xD;
                    JANETZKI S, 2000, INT J CANCER, V88, P232&#xD; KADISH AS, 2002, CANCER EPIDEM
                    BIOMAR, V11, P483&#xD; KANODIA S, 2007, CURR CANCER DRUG TAR, V7, P79&#xD;
                    KARLIN S, 2005, P NATL ACAD SCI USA, V102, P7303&#xD; KAUFMANN AM, 2002, CLIN
                    CANCER RES, V8, P3676&#xD; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129&#xD;
                    KLENCKE B, 2002, CLIN CANCER RES, V8, P1028&#xD; KOUTSKY LA, 1992, NEW ENGL J
                    MED, V327, P1272&#xD; KOUTSKY LA, 2002, NEW ENGL J MED, V347, P1645&#xD; MAO C,
                    2006, OBSTET GYNECOL, V107, P18&#xD; MAZZAFERRO V, 2003, CLIN CANCER RES, V9,
                    P3235&#xD; MELNIKOW J, 1998, OBSTET GYNECOL S 2, V92, P727&#xD; MEYER T, 1995,
                    BIOTECHNIQUES, V19, P632&#xD; MONK BJ, 1994, DIAGN MOL PATHOL, V3, P283&#xD;
                    MUDERSPACH L, 2000, CLIN CANCER RES, V6, P3406&#xD; MUNGER K, 1989, EMBO J, V8,
                    P4099&#xD; MUNGER K, 1989, J VIROL, V63, P4417&#xD; MUNOZ N, 2003, NEW ENGL J
                    MED, V348, P518&#xD; NEEFE JR, 2004, DEV BIOL, V116, P193&#xD; PECORELLI S,
                    2002, INT J GYNECOL BSTET, V82, P369&#xD; PINASANCHEZ P, 2006, INT J GYNECOL
                    CANCER, V16, P1041&#xD; SANKARANARAYANAN R, 2001, B WORLD HEALTH ORGAN, V79,
                    P954&#xD; SARKAR AK, 2005, GYNECOL ONCOL, V99, P251&#xD; SCHNEFFNER M, 1990,
                    CELL, V63, P1129&#xD; SHEETS EE, 2003, AM J OBSTET GYNECOL, V188, P916&#xD;
                    SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1&#xD; SMYTH LJC, 2004, CLIN CANCER
                    RES, V10, P2954&#xD; SRIVASTAVA PK, 2006, CURR OPIN IMMUNOL, V18, P2001&#xD;
                    STEELE JC, 2005, BRIT J CANCER, V93, P248&#xD; STELLER MA, 1998, CLIN CANCER
                    RES, V4, P2103&#xD; SUZUE K, 1997, P NATL ACAD SCI USA, V94, P13146&#xD; TAMURA
                    Y, 1997, SCIENCE, V278, P117&#xD; TING Y, 1990, PCR PROTOCOLS GUIDE, P356&#xD;
                    UDONO H, 1993, J EXP MED, V178, P1391&#xD; VANDERBURG SH, 2001, INT J CANCER,
                    V91, P612&#xD; VILLA LL, 2005, LANCET ONCOL, V6, P271&#xD; WARRINO DE, 2004,
                    CLIN CANCER RES, V10, P3301&#xD; WILCZYNSKI SP, 1993, HUM PATHOL, V24, P96&#xD;
                    WONG R, 2004, CLIN CANCER RES, V10, P5004&#xD; WRIGHT TC, 1992, OBSTET GYNECOL,
                    V79, P173</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249361100020 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/10/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>798</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">798</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1674</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Molecular Biology,
                    Graduate School of Biological Sciences, Beckman Research Institute of the City
                    of Hope, Duarte, CA 91010, USA. jrossi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Targeted cleavage: tuneable
                        cis-cleaving ribozymes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">14881-2</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">38</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Allosteric Regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nucleic Acid
                        Conformation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Catalytic/
                        chemistry/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Regulatory Sequences, Nucleic
                        Acid</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep 18</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17855561</style>
            </accession-num>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>827</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">827</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">953</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">June, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kohn, D. B.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Grad Sch
                    Biol Sci, Div Mol Biol, Duarte, CA 91010 USA. Univ Penn, Abramson Family Canc
                    Res Inst, Philadelphia, PA 19104 USA. Univ Penn, Dept Pathol, Philadelphia, PA
                    19104 USA. Univ Penn, Lab Med, Philadelphia, PA 19104 USA. Univ So Calif, Keck
                    Sch Med, Dept Pediat, Childrens Hosp Los Angeles,Div Res Immunol BMT, Los
                    Angeles, CA 90027 USA. Univ So Calif, Keck Sch Med, Dept Mol Microbiol &amp;
                    Immunol, Childrens Hosp Los Angeles,Div Res Immunol BMT, Los Angeles, CA 90027
                    USA.&#xD;Rossi, JJ, Beckman Res Inst City Hope, Grad Sch Biol Sci, Div Mol Biol,
                    Duarte, CA 91010 USA.&#xD;jrossi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Genetic therapies against
                        HIV</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nature Biotechnology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nature Biotechnology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nat. Biotechnol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nat Biotechnol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1444-1454</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNODEFICIENCY-VIRUS
                        TYPE-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC PROGENITOR
                        CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD4(+)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRIMARY
                        HUMAN-LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHORT HAIRPIN RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HU MOUSE MODEL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LENTIVIRAL VECTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFECTED PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADOPTIVE TRANSFER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD34(+) CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1087-0156</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251457800034</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Highly active antiretroviral therapy
                    prolongs the life of HIV-infected individuals, but it requires lifelong
                    treatment and results in cumulative toxicities and viral-escape mutants. Gene
                    therapy offers the promise of preventing progressive HIV infection by sustained
                    interference with viral replication in the absence of chronic chemotherapy.
                    Gene-targeting strategies are being developed with RNA-based agents, such as
                    ribozymes, antisense, RNA aptamers and small interfering RNA, and protein-based
                    agents, such as the mutant HIV Rev protein M10, fusion inhibitors and
                    zinc-finger nucleases. Recent advances in T-cell-based strategies include
                    gene-modified HIV-resistant T cells, lentiviral gene delivery, CD8(+) T cells, T
                    bodies and engineered T-cell receptors. HIV-resistant hematopoietic stem cells
                    have the potential to protect all cell types susceptible to HIV infection. The
                    emergence of viral resistance can be addressed by therapies that use
                    combinations of genetic agents and that inhibit both viral and host targets.
                    Many of these strategies are being tested in ongoing and planned clinical
                    trials.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    238OT&#xD;Times Cited: 0&#xD;Cited Reference Count: 132&#xD;Cited References:
                    &#xD; AIUTI A, 2002, SCIENCE, V296, P2410&#xD; AMADO RG, 1999, HUM GENE THER,
                    V10, P2255&#xD; AMADO RG, 2004, HUM GENE THER, V15, P251&#xD; AN DS, 2006, MOL
                    THER, V14, P494&#xD; AN DS, 2007, P NATL ACAD SCI USA, V104, P13110&#xD;
                    ANDERSON J, 2005, RETROVIROLOGY, V2&#xD; ANDERSON J, 2007, MOL THER, V15,
                    P1182&#xD; ARIEN KK, 2006, VIROLOGY, V347, P65&#xD; BAHNER I, 1996, J VIROL,
                    V70, P4352&#xD; BAHNER I, 2007, MOL THER, V15, P76&#xD; BAI JR, 2002, MOL THER,
                    V6, P770&#xD; BAI JR, 2003, J BIOL CHEM, V278, P1433&#xD; BARBER DL, 2003, J
                    IMMUNOL, V171, P27&#xD; BARRETT ADT, 1986, CURR TOP MICROBIOL, V128, P55&#xD;
                    BAUER G, 1997, BLOOD, V89, P2259&#xD; BERGES BK, 2006, RETROVIROLOGY, V3&#xD;
                    BERKHOUT B, 2006, FEBS LETT, V580, P896&#xD; BEX F, 1994, BLOOD, V84, P3317&#xD;
                    BODEN D, 2003, J VIROL, V77, P11531&#xD; BOUHAMDAN M, 2001, GENE THER, V8,
                    P408&#xD; BOULTER JM, 2003, PROTEIN ENG, V16, P707&#xD; BRAUN SE, 2005, MOL
                    THER, V12, P1157&#xD; BRIZ V, 2006, J ANTIMICROB CHEMOTH, V57, P619&#xD; BRODIE
                    SJ, 2000, J CLIN INVEST, V105, P1407&#xD; CARROLL RG, 1997, SCIENCE, V276,
                    P273&#xD; CAVAZZANACALVO M, 2000, SCIENCE, V288, P669&#xD; CHANG LJ, 2005, GENE
                    THER, V12, P1133&#xD; CHATTERJEE S, 1992, SCIENCE, V258, P1485&#xD; CHECK E,
                    2005, NATURE, V437, P601&#xD; COBURN GA, 2002, J VIROL, V76, P9225&#xD; COOPER
                    LJN, 2000, J VIROL, V74, P8207&#xD; CORDELIER P, 2003, OLIGONUCLEOTIDES, V13,
                    P281&#xD; DAS AT, 2004, J VIROL, V78, P2601&#xD; DAVE UP, 2004, SCIENCE, V303,
                    P333&#xD; DAVIS BR, 1998, HUM GENE THER, V9, P1197&#xD; DEEKS SG, 2002, MOL
                    THER, V5, P788&#xD; DEEKS SG, 2006, BRIT MED J, V332, P1489&#xD; EBERHARDY SR,
                    2006, J VIROL, V80, P2873&#xD; EGELHOFER M, 2004, J VIROL, V78, P568&#xD; FEARON
                    DT, 2001, SCIENCE, V293, P248&#xD; GARRED P, 1997, LANCET, V349, P1884&#xD;
                    GRIMM D, 2006, NATURE, V441, P537&#xD; HACEINBEYABINA S, 2003, SCIENCE, V302,
                    P415&#xD; HANNON GJ, 2004, NATURE, V431, P371&#xD; HELD DM, 2006, FRONT BIOSCI,
                    V11, P89&#xD; HESLOP HE, 1996, NAT MED, V2, P551&#xD; HOLLER PD, 2001, J EXP
                    MED, V194, P1043&#xD; HUANG YX, 1996, NAT MED, V2, P1240&#xD; HUMEAU LM, 2004,
                    MOL THER, V9, P902&#xD; JACQUE JM, 2002, NATURE, V418, P435&#xD; JOSHI PJ, 2003,
                    CURR DRUG TARGETS IN, V3, P383&#xD; JUNE CH, 2007, J CLIN INVEST, V117,
                    P1204&#xD; KAECH SM, 2002, CELL, V111, P837&#xD; KAHN J, 2004, BLOOD, V103,
                    P2942&#xD; KANG EM, 2002, J HEMATOTH STEM CELL, V11, P809&#xD; KIEPIELA P, 2007,
                    NAT MED, V13, P46&#xD; KOHN DB, 1999, BLOOD, V94, P368&#xD; LALEZARI JP, 2003,
                    ANTIVIR THER, V8, P279&#xD; LAPIDOT T, 2001, ANN NY ACAD SCI, V938, P83&#xD;
                    LAPIDOT T, 2002, LEUKEMIA, V16, P1992&#xD; LEAVITT MC, 1994, HUM GENE THER, V5,
                    P1115&#xD; LEE NS, 2002, NAT BIOTECHNOL, V20, P500&#xD; LETVIN NL, 2003, NAT
                    MED, V9, P861&#xD; LEVINE BL, 1996, SCIENCE, V272, P1939&#xD; LEVINE BL, 1997, J
                    IMMUNOL, V159, P5921&#xD; LEVINE BL, 2002, NAT MED, V8, P47&#xD; LEVINE BL,
                    2006, P NATL ACAD SCI USA, V103, P17372&#xD; LI MJ, 2003, MOL THER, V8,
                    P196&#xD; LI MJ, 2005, MOL THER, V12, P900&#xD; LI QJ, 2007, CELL, V129,
                    P147&#xD; LI Y, 2006, J VIROL, V80, P6738&#xD; LOBATO MN, 2004, CURR MOL MED,
                    V4, P519&#xD; LOMBARDO A, 2007, NAT BIOTECHNOL, V25, P1298&#xD; LU XB, 2004, J
                    VIROL, V78, P7079&#xD; LUBAN J, 2007, J VIROL, V81, P1054&#xD; LUIS AJ, 2003,
                    MOL THER, V8, P475&#xD; LUND O, 1997, B MATH BIOL, V59, P725&#xD; MACPHERSON JL,
                    2005, J GENE MED, V7, P552&#xD; MANI M, 2005, BIOCHEM BIOPH RES CO, V335,
                    P447&#xD; MARASCO WA, 1999, J IMMUNOL METHODS, V231, P223&#xD; MARTINEZ MA,
                    2002, TRENDS IMMUNOL, V23, P559&#xD; MASIERO S, 2005, GENE THER, V12, P299&#xD;
                    MAUTINO MR, 2002, GENE THER, V9, P421&#xD; MAZURIER F, 2004, BLOOD, V103,
                    P545&#xD; MICHIENZI A, 2003, ANN NY ACAD SCI, V1002, P63&#xD; MITSUYASU RT,
                    2000, BLOOD, V96, P785&#xD; MORGAN RA, 2005, HUM GENE THER, V16, P1065&#xD;
                    MORGAN RA, 2006, SCIENCE, V314, P216&#xD; MUUL LM, 2003, BLOOD, V101, P2563&#xD;
                    NGOK FK, 2004, METHOD MOL BIOL, V252, P581&#xD; NOVINA CD, 2002, NAT MED, V8,
                    P681&#xD; OTT MG, 2006, NAT MED, V12, P401&#xD; PAYNE KJ, 2007, IMMUNITY, V26,
                    P674&#xD; PEREZ EE, 2005, CLIN IMMUNOL, V115, P26&#xD; PHILLIPS AN, 2007, BRIT
                    MED J, V334, P76&#xD; PODSAKOFF GM, 2005, MOL THER, V12, P77&#xD; POLURI A,
                    2003, EXPERT OPIN BIOL TH, V3, P951&#xD; RANGA U, 1998, P NATL ACAD SCI USA,
                    V95, P1201&#xD; ROBERTS MR, 1994, BLOOD, V84, P2878&#xD; ROSENZWEIG M, 1997,
                    BLOOD, V90, P4822&#xD; ROUX L, 1991, ADV VIRUS RES, V40, P181&#xD; SABARIEGOS R,
                    2006, J VIROL, V80, P571&#xD; SADELAIN M, 2004, GENE THER, V11, P569&#xD; SAMSON
                    M, 1996, NATURE, V382, P722&#xD; SARVER N, 1990, SCIENCE, V247, P1222&#xD;
                    SCHRODER ARW, 2002, CELL, V110, P521&#xD; SCHROERS R, 2002, GENE THER, V9,
                    P889&#xD; SHEPHERD BE, 2007, BLOOD, V110, P1806&#xD; SHULTZ LD, 2007, NAT REV
                    IMMUNOL, V7, P118&#xD; STRAYER DS, 2005, MOL THER, V11, P823&#xD; STREMLAU M,
                    2004, NATURE, V427, P848&#xD; SU LS, 1997, BLOOD, V89, P2283&#xD; SURABHI RM,
                    2002, J VIROL, V76, P12963&#xD; SWAN CH, 2005, J MED PRIMATOL, V35, P236&#xD;
                    SWAN CH, 2006, GENE THER, V13, P1480&#xD; SYMENSMA TL, 1996, J VIROL, V70,
                    P179&#xD; UNWALLA HJ, 2006, J VIROL, V80, P1863&#xD; VANBAARLE D, 2005, IMMUNOL
                    LETT, V97, P19&#xD; VANDENDRIESSCHE T, 1995, J VIROL, V69, P4045&#xD; VANLUNZEN
                    J, 2007, MOL THER, V15, P1024&#xD; VERES G, 1998, J VIROL, V72, P1894&#xD;
                    VONLAER D, 2006, J THEOR BIOL, V238, P60&#xD; WALKER RE, 2000, BLOOD, V96,
                    P467&#xD; WALTER EA, 1995, NEW ENGL J MED, V333, P1038&#xD; WEINBERGER LS, 2003,
                    J VIROL, V77, P10028&#xD; WESTERHOUT EM, 2005, NUCLEIC ACIDS RES, V33, P796&#xD;
                    WODARZ D, 1999, P NATL ACAD SCI USA, V96, P14464&#xD; WOFFENDIN C, 1996, P NATL
                    ACAD SCI USA, V93, P2889&#xD; WONGSTAAL F, 1998, HUM GENE THER, V9, P2407&#xD;
                    YANG AG, 1997, P NATL ACAD SCI USA, V94, P11567&#xD; YANG OO, 1997, P NATL ACAD
                    SCI USA, V94, P11478&#xD; ZAIA JA, 1999, BLOOD S1 1, V94, A642</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251457800034 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>593</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">593</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1144</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sadava, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Whitlock, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kane, S. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Keck Sci Ctr, Claremont, CA 91711
                    USA. City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010
                    USA.&#xD;Sadava, D, Keck Sci Ctr, 925 N Mills Ave, Claremont, CA 91711
                    USA.&#xD;dsadava@jsd.claremont.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">The green tea polyphenol,
                        epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in
                        drug-resistant lung cancer cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Biophys Res
                        Commun</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biochemical and Biophysical
                        Research Communications</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biochem. Biophys. Res.
                        Commun.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biochem Biophys Res
                        Commun</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">233-237</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">360</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">lung cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">drug resistance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">green tea</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EGCG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">telomerase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">apoptosis</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-THE-ART</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROLIFERATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MECHANISMS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LINE</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0006-291X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248137400037</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Epidemiological studies on humans
                    and investigations in animal models suggest that consumption of green tea has
                    anti-cancer effects. Small-cell lung carcinoma (SCLC) has a poor prognosis,
                    particularly due to the development of drug resistance. We investigated the
                    effects of the green tea polyphenol, epigallocatechin-3-gallate (EGCG) on human
                    SCLC cells. EGCG had similar effects (IC50 Of similar to 70 M) on drug-sensitive
                    (H69) and drug-resistant (H69VP) SCLC cells, indicating that it is not part of
                    the drug resistance phenotype expressed in these cells. In both cell lines,
                    incubation in EGCG at 1 X IC50 for 24 h resulted in 50-60% reduced telomerase
                    activity as measured by a PCR-based assay for telomeric repeats. Colorimetric
                    assays of cells treated for 36 h with EGCG demonstrated a reduction in
                    activities of caspases 3 (50%) and 9 (70%) but not caspase 8, indicating
                    initiation of apoptosis. DNA fragmentation as measured by ELISA occurred within
                    cells treated with EGCG and this was confirmed by TUNEL staining.
                    Flow-cytometric analysis of SCLC cells incubated for 36 h in EGCG indicated a
                    cell-cycle block in S phase. These data indicate the potential use of EGCG, and
                    possibly green tea, in treating SCLC. (c) 2007 Elsevier Inc. All rights
                    reserved.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    191NH&#xD;Times Cited: 0&#xD;Cited Reference Count: 29</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248137400037 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>441</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">441</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1142</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Saetrom, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Heale, B. S. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snove, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Aagaard, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Alluin, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Mol Biol, Duarte, CA 91010 USA. Interagon AS, Laboratoriesenteret,
                    NO-7489 Trondheim, Norway. Norwegian Univ Sci &amp; Technol, Dept Comp &amp;
                    Informat Sci, NO-7491 Trondheim, Norway. Norwegian Univ Sci &amp; Technol, Dept
                    Canc Res &amp; Mol Med, NO-7489 Trondheim, Norway.&#xD;Rossi, JJ, City Hope Natl
                    Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010
                    USA.&#xD;jrossi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Distance constraints between
                        microRNA target sites dictate efficacy and cooperativity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2333-2342</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CAENORHABDITIS-ELEGANS/</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BINDING-SITES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN GENOME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LET-7</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IDENTIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLEAVAGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MIRNAS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0305-1048</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246294700030</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">MicroRNAs (miRNAs) have the
                    potential to regulate the expression of thousands of genes, but the mechanisms
                    that determine whether a gene is targeted or not are poorly understood. We
                    studied the genomic distribution of distances between pairs of identical miRNA
                    seeds and found a propensity for moderate distances greater than about 13 nt
                    between seed starts. Experimental data show that optimal down-regulation is
                    obtained when two seed sites are separated by between 13 and 35 nt. By analyzing
                    the distance between seed sites of endogenous miRNAs and transfected small
                    interfering RNAs (siRNAs), we also find that cooperative targeting of sites with
                    a separation in the optimal range can explain some of the siRNA off-target
                    effects that have been reported in the literature.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    165HJ&#xD;Times Cited: 0&#xD;Cited Reference Count: 51&#xD;Cited References:
                    &#xD; AMBROS V, 2004, NATURE, V431, P350&#xD; BAGGA S, 2005, CELL, V122,
                    P553&#xD; BARTEL DP, 2004, CELL, V116, P281&#xD; BASKERVILLE S, 2005, RNA, V11,
                    P241&#xD; BENTWICH I, 2005, NAT GENET, V37, P766&#xD; BIRMINGHAM A, 2006, NAT
                    METHODS, V3, P199&#xD; BRENNECKE J, 2005, PLOS BIOL, V3&#xD; BRUN D, 2005, PLOS
                    COMPUT BIOL, V1, E13&#xD; CHEN K, 2006, NAT GENET, V38, P1452&#xD; DIDIANO D,
                    2006, NAT STRUCT MOL BIOL, V13, P849&#xD; DOENCH JG, 2004, GENE DEV, V18,
                    P504&#xD; DONENCH JG, 2003, GENE DEV, V17, P438&#xD; FEDOROV Y, 2006, RNA, V12,
                    P1188&#xD; GIRALDEZ AJ, 2005, SCIENCE, V308, P833&#xD; GRIFFITHSJONES S, 2006,
                    NUCLEIC ACIDS RES, V34, D140&#xD; HANNON GJ, 2004, NATURE, V431, P371&#xD; HE L,
                    2005, NATURE, V435, P828&#xD; HINRICHS AS, 2006, NUCLEIC ACIDS RES, V34,
                    D590&#xD; JACKSON AL, 2003, NAT BIOTECHNOL, V21, P635&#xD; JACKSON AL, 2006,
                    RNA, V12, P1179&#xD; JACKSON AL, 2006, RNA, V12, P1197&#xD; JOHNSON SM, 2005,
                    CELL, V120, P635&#xD; KADONAGA JT, 2004, CELL, V116, P247&#xD; KLOOSTERMAN WP,
                    2004, NUCLEIC ACIDS RES, V32, P6284&#xD; KREK A, 2005, NAT GENET, V37, P495&#xD;
                    KRUTZFELDT J, 2005, NATURE, V438, P685&#xD; LAGOSQUINTANA M, 2001, SCIENCE,
                    V294, P853&#xD; LAU NC, 2001, SCIENCE, V294, P858&#xD; LEE RC, 2001, SCIENCE,
                    V294, P862&#xD; LEWIS BP, 2003, CELL, V115, P787&#xD; LEWIS BP, 2005, CELL,
                    V120, P15&#xD; LIM LP, 2005, NATURE, V433, P769&#xD; LU J, 2005, NATURE, V435,
                    P834&#xD; MANIATIS T, 2002, NATURE, V418, P236&#xD; MEISTER G, 2004, MOL CELL,
                    V15, P185&#xD; MIRANDA KC, 2006, CELL, V126, P1203&#xD; ODONNELL KA, 2005,
                    NATURE, V435, P839&#xD; OLSEN PH, 1999, DEV BIOL, V216, P671&#xD; RAJEWSKY N,
                    2006, NAT GENET, V38, S8&#xD; REINHART BJ, 2000, NATURE, V403, P901&#xD;
                    RIGOUTSOS I, 2006, P NATL ACAD SCI USA, V103, P6605&#xD; ROSE SD, 2005, NUCLEIC
                    ACIDS RES, V33, P4140&#xD; SETHUPATHY P, 2006, RNA, V12, P192&#xD; VELLA MC,
                    2004, CHEM BIOL, V11, P1619&#xD; VELLA MC, 2004, GENE DEV, V18, P132&#xD;
                    WIGHTMAN B, 1993, CELL, V75, P855&#xD; WU LG, 2006, P NATL ACAD SCI USA, V103,
                    P4034&#xD; WU Q, 2001, GENOME RES, V11, P389&#xD; XIE XH, 2005, NATURE, V434,
                    P338&#xD; YEKTA S, 2004, SCIENCE, V304, P594&#xD; ZAMORE PD, 2000, CELL, V101,
                    P25</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246294700030 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>442</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">442</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">952</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Saetrom, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Snove, O.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div Mol
                    Biol, Duarte, CA 91010 USA. Interagon AS, NO-7006 Trondheim, Norway. Norwegian
                    Univ Sci &amp; Technol, Dept Comp &amp; Informat Sci, NO-7491 Trondheim, Norway.
                    Norwegian Univ Sci &amp; Technol, Dept Canc Res &amp; Mol Med, NO-7006
                    Trondheim, Norway.&#xD;Rossi, JJ, Beckman Res Inst City Hope, Div Mol Biol,
                    Duarte, CA 91010 USA.&#xD;jrossi@bricoh.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Epigenetics and
                        microRNAs</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pediatric Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatric Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatr. Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatr Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">17R-23R</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">61</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SHORT HAIRPIN RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DE-NOVO METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NUCLEAR EXPORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTTRANSCRIPTIONAL
                        REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">C-ELEGANS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CAENORHABDITIS-ELEGANS/</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROPROCESSOR COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN DEVELOPMENT</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0031-3998</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245963300004</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">MicroRNAs (miRNAs) regulate
                    protein-coding genes post transcriptionally in higher eukaryotes. Argonaute
                    proteins are important in miRNA regulation and are also implicated in epigenetic
                    mechanisms such as histone modifications and DNA methylation. Here, we review
                    miRNA regulation and outline its connections to epigenetics.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    160ST&#xD;Times Cited: 0&#xD;Cited Reference Count: 133&#xD;Cited References:
                    &#xD; ALLEN E, 2005, CELL, V121, P207&#xD; ALTUVIA Y, 2005, NUCLEIC ACIDS RES,
                    V33, P2697&#xD; AMARZGUIOUI M, 2003, NUCLEIC ACIDS RES, V31, P589&#xD; AMBROS V,
                    2004, NATURE, V431, P350&#xD; ARAVIN A, 2005, FEBS LETT, V579, P5830&#xD; ARAVIN
                    A, 2006, NATURE, V442, P203&#xD; ASON B, 2006, P NATL ACAD SCI USA, V103,
                    P14385&#xD; BAGGA S, 2005, CELL, V122, P553&#xD; BAO N, 2004, DEV CELL, V7,
                    P653&#xD; BARTEL DP, 2004, CELL, V116, P281&#xD; BASKERVILLE S, 2005, RNA, V11,
                    P241&#xD; BEHLKE MA, 2006, MOL THER, V13, P644&#xD; BENTWICH I, 2005, NAT GENET,
                    V37, P766&#xD; BEREZIKOV E, 2005, CELL, V120, P21&#xD; BEREZIKOV E, 2006, GENOME
                    RES, V16, P1289&#xD; BERNSTEIN E, 2001, NATURE, V409, P363&#xD; BESTOR TH, 1992,
                    EMBO J, V11, P2611&#xD; BIRD A, 2002, GENE DEV, V16, P6&#xD; BIRMINGHAM A, 2006,
                    NAT METHODS, V3, P199&#xD; BOHNSACK MT, 2004, RNA, V10, P185&#xD; BORSANI O,
                    2005, CELL, V123, P1279&#xD; BRENNECKE J, 2005, PLOS BIOL, V3&#xD; BRIDGE AJ,
                    2003, NAT GENET, V34, P263&#xD; CAI XZ, 2004, RNA, V10, P1957&#xD; CALIN GA,
                    2002, P NATL ACAD SCI USA, V99, P15524&#xD; CALIN GA, 2004, P NATL ACAD SCI USA,
                    V101, P2999&#xD; CHANG K, 2006, NAT METHODS, V3, P707&#xD; CHENDRIMADA TP, 2005,
                    NATURE, V436, P740&#xD; DALMAY T, 2000, CELL, V101, P543&#xD; DENLI AM, 2004,
                    NATURE, V432, P231&#xD; DIDIANO D, 2006, NAT STRUCT MOL BIOL, V13, P849&#xD;
                    DOENCH JG, 2003, GENE DEV, V17, P438&#xD; DU Q, 2005, NUCLEIC ACIDS RES, V33,
                    P1671&#xD; DU TT, 2005, DEVELOPMENT, V132, P4645&#xD; EGGER G, 2004, NATURE,
                    V429, P457&#xD; EIS PS, 2005, P NATL ACAD SCI USA, V102, P3627&#xD; ELBAKRI IA,
                    2001, P SOC PHOTO-OPT INS, V2, P1&#xD; ELBASHIR SM, 2001, EMBO J, V20,
                    P6877&#xD; ELBASHIR SM, 2002, METHODS, V26, P199&#xD; ESQUELAKERSCHER A, 2006,
                    NAT REV CANCER, V6, P259&#xD; FEDOROV Y, 2006, RNA, V12, P1188&#xD; GIRALDEZ AJ,
                    2005, SCIENCE, V308, P833&#xD; GIRARD A, 2006, NATURE, V442, P199&#xD; GOLL MG,
                    2006, SCIENCE, V311, P395&#xD; GREGORY RI, 2004, NATURE, V432, P235&#xD; GREGORY
                    RI, 2005, CELL, V123, P631&#xD; GRIFFITHSJONES S, 2006, NUCLEIC ACIDS RES, V34,
                    D140&#xD; GRIMM D, 2006, NATURE, V441, P537&#xD; GRISHOK A, 2000, SCIENCE, V287,
                    P2494&#xD; GRIVNA ST, 2006, GENE DEV, V20, P1709&#xD; HAN J, 2001, DRUG DELIV,
                    V8, P125&#xD; HAN JJ, 2004, GENE DEV, V18, P3016&#xD; HANNON GJ, 2004, NATURE,
                    V431, P371&#xD; HE L, 2005, NATURE, V435, P828&#xD; HUTVAGNER G, 2001, SCIENCE,
                    V293, P834&#xD; JACKSON AL, 2003, NAT BIOTECHNOL, V21, P635&#xD; JACKSON AL,
                    2006, RNA, V12, P1179&#xD; JANOWSKI BA, 2006, NAT STRUCT MOL BIOL, V13,
                    P787&#xD; JENUWEIN T, 2001, SCIENCE, V293, P1074&#xD; KAROLCHIK D, 2003, NUCLEIC
                    ACIDS RES, V31, P51&#xD; KHVOROVA A, 2003, CELL, V115, P209&#xD; KIM DH, 2005,
                    NAT BIOTECHNOL, V23, P222&#xD; KIM DH, 2006, NAT STRUCT MOL BIOL, V13, P793&#xD;
                    KREK A, 2005, NAT GENET, V37, P495&#xD; KURIHARA Y, 2004, P NATL ACAD SCI USA,
                    V101, P12753&#xD; LAGOSQUINTANA M, 2001, SCIENCE, V294, P853&#xD; LAGOSQUINTANA
                    M, 2003, RNA, V9, P175&#xD; LAU NC, 2001, SCIENCE, V294, P858&#xD; LAU NC, 2006,
                    SCIENCE, V313, P363&#xD; LEE RC, 1993, CELL, V75, P843&#xD; LEE RC, 2001,
                    SCIENCE, V294, P862&#xD; LEE Y, 2003, NATURE, V425, P415&#xD; LEE Y, 2004, EMBO
                    J, V23, P4051&#xD; LEWIS BP, 2003, CELL, V115, P757&#xD; LEWIS BP, 2005, CELL,
                    V120, P15&#xD; LI E, 2002, NAT REV GENET, V3, P662&#xD; LIM LP, 2005, NATURE,
                    V433, P769&#xD; LIN XY, 2005, NUCLEIC ACIDS RES, V33, P4527&#xD; LIPPMAN Z,
                    2004, NATURE, V431, P364&#xD; LU J, 2005, NATURE, V435, P834&#xD; LUGER K, 1997,
                    NATURE, V389, P251&#xD; LUND E, 2004, SCIENCE, V303, P95&#xD; MA JB, 2005,
                    NATURE, V434, P666&#xD; MALLORY AC, 2006, NAT GENET, V38, S31&#xD; MARQUES JT,
                    2005, NAT BIOTECHNOL, V23, P1399&#xD; MATRANGA C, 2005, CELL, V123, P607&#xD;
                    MCMANUS MT, 2002, RNA, V8, P842&#xD; MORRIS KV, 2004, SCIENCE, V305, P1289&#xD;
                    OBERNOSTERER G, 2006, RNA, V12, P1161&#xD; ODONNELL KA, 2005, NATURE, V435,
                    P839&#xD; OKANO M, 1999, CELL, V99, P247&#xD; OLSEN PH, 1999, DEV BIOL, V216,
                    P671&#xD; PADDISON PJ, 2002, GENE DEV, V16, P948&#xD; PARKER JS, 2005, NATURE,
                    V434, P663&#xD; PEI Y, 2006, NAT METHODS, V3, P670&#xD; PELISSIER T, 1999,
                    NUCLEIC ACIDS RES, V27, P1625&#xD; RAND TA, 2005, CELL, V123, P621&#xD;
                    RASSOULZADEGAN M, 2006, NATURE, V441, P469&#xD; REINSCHEID RK, 2000, PEPTIDES,
                    V21, P901&#xD; RHOADES MW, 2002, CELL, V110, P513&#xD; RIVAS FV, 2005, NAT
                    STRUCT MOL BIOL, V12, P340&#xD; SAETROM P, 2004, BIOCHEM BIOPH RES CO, V321,
                    P247&#xD; SAETROM P, 2006, OLIGONUCLEOTIDES, V16, P115&#xD; SAITO K, 2006, GENE
                    DEV, V20, P2214&#xD; SCHWARZ DS, 2003, CELL, V115, P199&#xD; SCHWARZ DS, 2006,
                    PLOS GENET, V2, P1307&#xD; SIJEN T, 2001, CELL, V107, P465&#xD; SIOLAS D, 2005,
                    NAT BIOTECHNOL, V23, P227&#xD; SLEDZ CA, 2003, NAT CELL BIOL, V5, P834&#xD;
                    SMALHEISER NR, 2005, TRENDS GENET, V21, P322&#xD; SNOVE O, 2006, GENOME BIOL,
                    V7&#xD; SOUTSCHEK J, 2004, NATURE, V432, P173&#xD; THOMSON JM, 2006, GENE DEV,
                    V20, P2202&#xD; TING AH, 2005, NAT GENET, V37, P906&#xD; TOMARI Y, 2004,
                    SCIENCE, V306, P1377&#xD; VAGIN VV, 2006, SCIENCE, V313, P320&#xD; VELLA MC,
                    2004, CHEM BIOL, V11, P1619&#xD; VELLA MC, 2004, GENE DEV, V18, P132&#xD;
                    VERMEULEN A, 2005, RNA, V11, P674&#xD; WASSENEGGER M, 1994, CELL, V76, P567&#xD;
                    WATANABE T, 2006, GENE DEV, V20, P1732&#xD; WIENHOLDS E, 2005, SCIENCE, V309,
                    P310&#xD; WIGHTMAN B, 1993, CELL, V75, P855&#xD; WU LG, 2006, P NATL ACAD SCI
                    USA, V103, P4034&#xD; XIE XH, 2005, NATURE, V434, P338&#xD; YEKTA S, 2004,
                    SCIENCE, V304, P594&#xD; YI R, 2003, GENE DEV, V17, P3011&#xD; YI R, 2005, RNA,
                    V11, P220&#xD; YU B, 2005, SCIENCE, V307, P932&#xD; ZAMORE PD, 2000, CELL, V101,
                    P25&#xD; ZENG Y, 2004, NUCLEIC ACIDS RES, V32, P4776&#xD; ZENG Y, 2005, EMBO J,
                    V24, P138&#xD; ZIMMERMANN TS, 2006, NATURE, V441, P111&#xD;Part 2</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245963300004 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>483</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">483</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1668</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sahar, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reddy, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Natarajan, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Graduate School of Biological
                    Sciences, Beckman Research Institute of City of Hope, 1500 E. Duarte Rd, Duarte,
                    CA 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cooperation of SRC-1 and p300
                        with NF-kappaB and CREB in angiotensin II-induced IL-6 expression in
                        vascular smooth muscle cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Arterioscler Thromb Vasc
                        Biol</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Arteriosclerosis Thrombosis and
                        Vascular Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Arterioscler. Thromb. Vasc.
                        Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Arterioscler Thromb Vasc
                        Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1528-34</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">27</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Acetylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Angiotensin II/
                        metabolism/pharmacology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CREB-Binding Protein/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cells, Cultured</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">E1A-Associated p300
                        Protein/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression
                        Regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histone Acetyltransferases/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Interleukin-6/genetics/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Models, Animal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Muscle, Smooth, Vascular/
                        enzymology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NF-kappa B/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA,
                        Messenger/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rats</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Rats, Sprague-Dawley</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sensitivity and
                        Specificity</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription Factors/
                        metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1524-4636 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17495236</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">OBJECTIVE: The purpose of this study
                    was to evaluate the role of coactivator histone acetyltransferases (HATs) p300
                    and SRC-1 in angiotensin II (Ang II)-induced interleukin-6 (IL-6) gene
                    expression in vascular smooth muscle cells (VSMCs). METHODS AND RESULTS: Ang II
                    increased IL-6 mRNA expression via NF-kappaB and CREB in an extracellular
                    signal-regulated kinase (ERK)-dependent manner in rat VSMCs. It was also
                    significantly enhanced by the histone deacetylase inhibitor, Trichostatin A.
                    Chromatin immunoprecipitation (ChIP) assays showed that Ang II increased Histone
                    H3 Lysine (K9/14) acetylation on the IL-6 promoter. Ang II-induced IL-6 promoter
                    transactivation was significantly enhanced by p300 and SRC-1, with maximal
                    activation in cells cotransfected with NF-kappaB (p65) and SRC-1. Nucleofection
                    of VSMCs with either an ERK phosphorylation site mutant of SRC-1 or p300/CBP HAT
                    deficient mutants significantly blocked Ang II-induced IL-6 expression. ChIP
                    assays revealed that Ang II enhanced coordinate occupancy of p65, CREB, p300,
                    and SRC-1 at the IL-6 promoter. An ERK pathway inhibitor blocked Ang-induced
                    IL-6 promoter SRC-1 occupancy and histone acetylation. CONCLUSIONS: Ang
                    II-induced IL-6 expression requires NF-kappaB and CREB as well as ERK-dependent
                    histone acetylation mediated by p300 and SRC-1. These results provide new
                    insights into nuclear chromatin mechanisms by which Ang II regulates
                    inflammatory gene expression.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>765</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">765</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1140</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sangiolo, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lesnikova, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nash, R. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nikitine, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kiem, H. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Georges, G. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr, Div
                    Clin Res, Seattle, WA 98109 USA. Univ Turin, Sch Med, Dept Oncol Sci, Turin,
                    Italy. Univ Washington, Dept Med, Seattle, WA USA. City Hope Natl Med Ctr, Div
                    Canc Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010 USA.&#xD;Georges, GE,
                    Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N D1-100, Seattle,
                    WA 98109 USA.&#xD;ggeorges@fhcrc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Lentiviral vector conferring
                        resistance to mycophenolate mofetil and sensitivity to ganciclovir for in
                        vivo T-cell selection</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1549-1554</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">21</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">mycophenolate mofetil</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ganciclovir</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bicistronic lentiviral
                        vector</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD34</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">thymidine kinase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">inosine monophosphate
                        dehydrogenase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDIATED GENE-TRANSFER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THYMIDINE KINASE GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VERSUS-HOST-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RETROVIRAL VECTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMP DEHYDROGENASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSDUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACID</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0969-7128</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250226400007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Several clinical studies of
                    gene-modified T cells have shown limited in vivo function of the cells,
                    immunogenicity of the transgene, and lack of a selective advantage for
                    genemodified T cells. To address these problems, we developed a lentiviral
                    vector (LV) that provides a selectable, proliferative advantage and potentially
                    decreases immunogenicity for transduced T cells. The bicistronic vector
                    expressed two genes linked with an internal ribosomal entry site. One gene is a
                    variant of the inosine monophosphate dehydrogenase 2, inosine monophosphate
                    dehydrogenase (IMPDHIY), conferring resistance to the immunosuppressive drug
                    mycophenolate mofetil (MMF). The other is a suicide gene, herpes simplex virus
                    thymidine kinase (HSV-TK), rendering proliferating cells sensitive to ablation
                    with ganciclovir, fused to the selectable transmembrane marker DCD34 (DCD34/TK).
                    Cells transduced with LV-DCD34/ TK. IMPDHIY were efficiently enriched by
                    immunomagnetic selection for CD34, proliferated in 0.5-5 mu M MMF, and were
                    killed by 0.5 25 mu g ml(-1) ganciclovir. We demonstrate efficient selection and
                    killing of gene- modified cells and suggest LV-DCD34/TK. IMPDHIY-transduced T
                    cells could be used to facilitate allogeneic hematopoietic cell engraftment. The
                    expression of IMPDHIY would allow in vivo selection with MMF, and DCD34/TK
                    expression would allow rapid and safe elimination of transduced T cells if
                    graft-versus-host disease developed.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    221KO&#xD;Times Cited: 0&#xD;Cited Reference Count: 24&#xD;Cited References:
                    &#xD; ALLISON AC, 2000, IMMUNOPHARMACOLOGY, V47, P85&#xD; BERGER C, 2006, BLOOD,
                    V107, P2294&#xD; BONINI C, 1997, SCIENCE, V276, P1719&#xD; DAVIS BM, 1999, HUM
                    GENE THER, V10, P2769&#xD; DAVIS BM, 2000, BLOOD, V95, P3078&#xD; DULL T, 1998,
                    J VIROL, V72, P8463&#xD; GARIN MI, 2001, BLOOD, V97, P122&#xD; GEORGES GE, 1998,
                    TRANSPLANTATION, V66, P540&#xD; GEORGES GE, 2001, BLOOD, V98, P3447&#xD;
                    GIACCONE L, 2005, BLOOD, V106, P4381&#xD; HODGES SD, 1989, J BIOL CHEM, V264,
                    P18137&#xD; HORN PA, 2002, GENE THER, V9, P1464&#xD; LIGHTFOOT T, 1994, BBA-GENE
                    STRUCT EXPR, V1217, P156&#xD; MARTIN PJ, 2004, THOMAS HEMATOPOIETIC, P16&#xD;
                    MAVILIO F, 1994, BLOOD, V83, P1988&#xD; MORRIS JC, 2004, BLOOD, V103, P492&#xD;
                    PLAUTZ G, 1991, NEW BIOL, V3, P709&#xD; RETTIG MP, 2003, MOL THER, V8, P29&#xD;
                    RIDDELL SR, 1996, NAT MED, V2, P216&#xD; SANDRIN V, 2002, BLOOD, V100, P823&#xD;
                    SINTCHAK MD, 1996, CELL, V85, P921&#xD; SPENCER HT, 1996, BLOOD, V87, P2579&#xD;
                    TIBERGHIEN P, 1994, BLOOD, V84, P1333&#xD; YAM P, 2006, MOL THER, V14,
                    P236</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250226400007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>485</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">485</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1138</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Schagdarsurengin, U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dammann, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Halle Wittenberg, Fac Med, Inst
                    Human Genet, AWG Tumour Genet, D-06097 Halle, Germany. City Hope Canc Ctr,
                    Beckman Res Inst, Dept Biol, Duarte, CA USA.&#xD;Dammann, R, Univ Halle
                    Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, Magdeburger Str 2,
                    D-06097 Halle, Germany.&#xD;reinhard.dammann@medizin.uni-halle.de</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Frequent epigenetic inactivation
                        of cystatin M in breast carcinoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Oncogene</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3089-3094</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">26</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">21</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">cystatin M</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumour suppressor gene</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">epigenetic inactivation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">breast cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CST6</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYSTEINE
                        PROTEINASE-INHIBITOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SQUAMOUS-CELL CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-SUPPRESSOR GENE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA METHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTER
                        HYPERMETHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MALIGNANT PHENOTYPE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASSOCIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPRESSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0950-9232</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246395400014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Cystatin M is a potent endogenous
                    inhibitor of lysosomal cysteine proteases. In breast carcinoma, cystatin M
                    expression is frequently downregulated. It has been shown that cystatin M
                    expression suppressed growth and migration of breast cancer cells. We examined
                    the methylation status of the CpG island promoter of cystatin M in four breast
                    cancer cell lines ( MDAMB231, ZR75-1, MCF7 and T47D), in 40 primary breast
                    carcinoma and in corresponding normal tissue probes by combined bisulphite
                    restriction analysis. To investigate the effects of cystatin M expression on the
                    growth of breast carcinoma, cystatin M was transfected in T47D. The cystatin M
                    promoter was highly methylated in all four-breast cancer cell lines. Primary
                    breast tumours were significantly more frequently methylated compared to normal
                    tissue samples ( 60 vs 25%; P = 0.006 Fisher&apos;s exact test). Treatment of
                    breast cancer cells with 5-aza-2&apos;-deoxycytidine ( 5-Aza-CdR), reactivated
                    the transcription of cystatin M. Transfection of breast carcinoma cells with
                    cystatin M caused a 30% decrease in colony formation compared to control
                    transfection ( P = 0.002). Our results show that cystatin M is frequently
                    epigenetically inactivated during breast carcinogenesis and cystatin M
                    expression suppresses the growth of breast carcinoma. These data suggest that
                    cystatin M may encode a novel epigenetically inactivated candidate tumour
                    suppressor gene.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    166QX&#xD;Times Cited: 0&#xD;Cited Reference Count: 31&#xD;Cited References:
                    &#xD; ABRAHAMSON M, 2003, BIOCHEM SOC SYMP, V70, P179&#xD; AHUJA N, 2000, HISTOL
                    HISTOPATHOL, V15, P835&#xD; BURBEE DG, 2001, J NATL CANCER I, V93, P691&#xD;
                    CALKINS CC, 1995, BIOL CHEM H-S, V376, P71&#xD; CHENG T, 2006, J BIOL CHEM,
                    V281, P15893&#xD; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990&#xD; DAMMANN R,
                    2000, NAT GENET, V25, P315&#xD; DAMMANN R, 2001, CANCER RES, V61, P3105&#xD;
                    FROSCH BA, 1999, APMIS, V107, P28&#xD; GUO MZ, 2004, CLIN CANCER RES, V10,
                    P5131&#xD; HAIDER AS, 2006, J INVEST DERMATOL, V126, P869&#xD; HENSKENS YMC,
                    1996, BIOL CHEM H-S, V377, P71&#xD; HERMAN JG, 2003, NEW ENGL J MED, V349,
                    P2042&#xD; JONES PA, 1980, CELL, V20, P85&#xD; JONES PA, 2002, NAT REV GENET,
                    V3, P415&#xD; KREPELA E, 2001, NEOPLASMA, V48, P332&#xD; LAH TT, 1998, BIOL
                    CHEM, V379, P125&#xD; NI J, 1997, J BIOL CHEM, V272, P10853&#xD; NOMURA T, 2005,
                    J MED INVEST, V52, P1&#xD; SHRIDHAR R, 2004, ONCOGENE, V23, P2206&#xD; SONG J,
                    2006, BIOCHEM BIOPH RES CO, V340, P175&#xD; SOTIROPOULOU G, 1997, J BIOL CHEM,
                    V272, P903&#xD; SRIVATSAN ES, 2002, ONCOGENE, V21, P5631&#xD; STENMAN G, 1997,
                    CYTOGENET CELL GENET, V76, P45&#xD; STRUNNIKOVA M, 2005, MOL CELL BIOL, V25,
                    P3923&#xD; VIGNESWARAN N, 2003, ORAL ONCOL, V39, P559&#xD; WAKI T, 2003,
                    ONCOGENE, V22, P4128&#xD; XIONG ZG, 1997, NUCLEIC ACIDS RES, V25, P2532&#xD;
                    ZEEUWEN PLJM, 2002, BRIT J DERMATOL, V147, P87&#xD; ZEEUWEN PLJM, 2004, EUR J
                    CELL BIOL, V83, P761&#xD; ZHANG J, 2004, CANCER RES, V64, P6957</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246395400014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>619</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">619</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">951</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Scherer, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weinberg, M. S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Beckman Res Inst, Div Mol
                    Biol, Duarte, CA 91010 USA. Univ Witwatersrand, Sch Med, Dept Mol Med &amp;
                    Hematol, ZA-2050 Wits, South Africa.&#xD;Rossi, JJ, City Hope Beckman Res Inst,
                    Div Mol Biol, 1450 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;jrossi@bricoh.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Progress and prospects:
                        RNA-based therapies for treatment of HIV infection</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Gene Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Gene Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Gene Ther</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1057-1064</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">14</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNAi</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">siRNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ribozyme</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">aptamer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNODEFICIENCY-VIRUS
                        TYPE-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTERNAL GUIDE SEQUENCES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-HAIRPIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN CYTOMEGALOVIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EFFECTIVE INHIBITION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERING RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGENITOR CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAMMALIAN-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMOSOMAL DNA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0969-7128</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247718200001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The current treatment regimen for
                    HIV-infected individuals combines two or more drugs targeting different viral
                    proteins such as RT and gag. Resistance to conventional drugs can develop
                    quickly, and typically persists. The prospect of longer, continuous
                    antiretroviral therapy brings with it the need for new antiretroviral drugs and
                    approaches. In this context, gene therapies have the potential to prolong life
                    and quality of life as an additional therapeutic class and may serve as an
                    adjuvant to traditional treatments. This review focuses on RNA-based
                    hematopoietic cell gene therapy for treatment of HIV infection. Recent advances
                    in our understanding of RNA interference (RNAi) make this an especially
                    attractive candidate for anti-HIV gene therapy although ribozyme and RNA
                    decoy/aptamer approaches can be combined with RNAi to make a combinatorial
                    therapy akin to highly active anti-retroviral therapy.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    185NR&#xD;Times Cited: 0&#xD;Cited Reference Count: 66</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247718200001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>443</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">443</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1667</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Scherer, L. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frank, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Molecular Biology
                    Beckman Research Institute of the City of Hope, 1450 E. Duarte Road, Duarte,
                    California 91010, USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Optimization and
                        characterization of tRNA-shRNA expression constructs</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Nucleic Acids Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2620-8</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">35</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Base Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Line</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Products,
                        rev/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Products,
                        tat/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Genetic Vectors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HIV-1/ genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Promoter Regions
                        (Genetics)</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA Interference</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Small
                        Interfering/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Transfer, Amino Acyl/
                        chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA, Untranslated/ biosynthesis/
                        chemistry/metabolism</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1362-4962 (Electronic)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17426139</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Expression of short hairpin RNAs via
                    the use of PolIII-based transcription systems has proven to be an effective
                    mechanism for triggering RNAi in mammalian cells. The most popular promoters for
                    this purpose are the U6 and H1 promoters since they are easily manipulated for
                    expression of shRNAs with defined start and stop signals. Multiplexing (the use
                    of siRNAs against multiple targets) is one strategy that is being developed by a
                    number of laboratories for the treatment of HIV infection since it increases the
                    likelihood of suppressing the emergence of resistant virus in applications. In
                    this context, the development of alternative small PolIII promoters other than
                    U6 and H1 would be useful. We describe tRNA(Lys3)-shRNA chimeric expression
                    cassettes which produce siRNAs with comparable efficacy and strand selectivity
                    to U6-expressed shRNAs, and show that their activity is consistent with
                    processing by endogenous 3&apos; tRNAse. In addition, our observations suggest
                    general guidelines for expressing effective tRNA-shRNAs with the potential for
                    graded response, to minimize toxicities associated with competition for
                    components of the endogenous RNAi pathway in cells.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>376</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">376</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1135</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Schultheiss, T. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wong, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Liu, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Olivera, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Radiat
                    Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA
                    91010 USA. Tomotherapy Inc, Madison, WI USA.&#xD;Schultheiss, TE, City Hope Natl
                    Med Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;Schultheiss@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Image-guided total marrow and
                        total lymphatic irradiation using helical tomotherapy</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">International Journal of
                        Radiation Oncology Biology Physics</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Int. J. Radiat. Oncol. Biol.
                        Phys.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Int J Radiat Oncol Biol
                        Phys</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1259-1267</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">total marrow irradiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">total lymphatic
                        irradiation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">image-guided</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">helical tomotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">intensity-modulated
                        radiotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TOTAL-BODY IRRADIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHOTON DOSE CALCULATIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERSTITIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PNEUMONITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONVOLUTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RADIOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RATES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDIA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0360-3016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245021100037</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To develop a treatment
                    technique to spare normal tissue and allow dose escalation in total body
                    irradiation (TBI). We have developed intensity-modulated radiotherapy techniques
                    for the total marrow irradiation (TMI), total lymphatic irradiation, or total
                    bone marrow plus lymphatic irradiation using helical tomotherapy. Methods and
                    Materials: For TBI, we typically use 12 Gy in 10 fractions delivered at an
                    extended source-to-surface distance (SSD). Using helical tomotherapy, it is
                    possible to deliver equally effective doses to the bone marrow and lymphatics
                    while sparing normal organs to a significant degree. In the TMI patients, whole
                    body skeletal bone, including the ribs and sternum, comprise the treatment
                    target. In the total lymphatic irradiation, the target is expanded to include
                    the spleen and major lymph node areas. Sanctuary sites for disease (brain and
                    testes) are included when clinically indicated. Spared organs include the lungs,
                    esophagus, parotid glands, eyes, oral cavity, liver, kidneys, stomach, small and
                    large intestine, bladder, and ovaries. Results: With TBI, all normal organs
                    received the TBI dose; with TMI, total lymphatic irradiation, and total bone
                    marrow plus lymphatic irradiation, the visceral organs are spared. For the first
                    6 patients treated with TMI, the median dose to organs at risk averaged 51%
                    lower than would be achieved with TBI. By putting greater weight on the
                    avoidance of specific organs, greater sparing was possible. Conclusion: Sparing
                    of normal tissues and dose escalation is possible using helical tomotherapy.
                    Late effects such as radiation pneumonitis, veno-occlusive disease, cataracts,
                    neurocognitive effects, and the development of second tumors should be
                    diminished in severity and frequency according to the dose reduction realized
                    for the organs at risk. (c) 2007 Elsevier Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    147RW&#xD;Times Cited: 0&#xD;Cited Reference Count: 16&#xD;Cited References:
                    &#xD; AHNESJO A, 1989, MED PHYS, V16, P577&#xD; ASPRADAKIS MM, 2003, PHYS MED
                    BIOL, V48, P2873&#xD; KIM TH, 1985, INT J RADIAT ONCOL, V11, P1285&#xD; LU C,
                    1984, CANCER TREAT REP, V68, P711&#xD; LU WG, 2005, PHYS MED BIOL, V50,
                    P655&#xD; LYDON JM, 1998, PHYS MED BIOL, V43, P1813&#xD; MACKIE TR, 1985, MED
                    PHYS, V12, P188&#xD; MACKIE TR, 1993, MED PHYS, V20, P1709&#xD; OZSAHIN M, 1994,
                    INT J RADIAT ONCOL, V28, P343&#xD; PETERS LJ, 1979, RADIOLOGY, V131, P243&#xD;
                    SAMPATH S, 2005, INT J RADIAT ONCOL, V63, P876&#xD; SCHULTHEISS TE, 2004, INT J
                    RADIAT ONCOL, V60, S544&#xD; SHANK B, 1981, INT J RADIAT ONCOL, V7, P1109&#xD;
                    SHEPARD DM, 2000, PHYS MED BIOL, V45, P69&#xD; WHELDON TE, 1997, BRIT J RADIOL,
                    V70, P1204&#xD; WONG JYC, 2006, BIOL BLOOD MARROW TR, V12, P306</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245021100037 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>232</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">232</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1134</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Schwarz, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Canc Inst New Jersey, Div Surg
                    Oncol, New Brunswick, NJ 08903 USA. City Hope Canc Ctr, Div Biostat, Duarte, CA
                    91010 USA.&#xD;Schwarz, RE, Univ Med &amp; Dent New Jersey, Robert Wood Johnson
                    Med Sch, Dept Surg, Canc Inst New Jersey, 195 Little Albany St, New Brunswick,
                    NJ 08901 USA.&#xD;r.schwarz@umdnj.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Clinical impact of
                        lymphadenectomy extent in resectable gastric cancer of advanced
                        stage</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Surg Oncol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Annals of Surgical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Ann. Surg. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Ann Surg Oncol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">317-328</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">14</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODE DISSECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-HOSPITAL MORTALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE-SPECIFIC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DATA-BASE REPORT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TNM CLASSIFICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLECTOMY PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC-FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTRECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RESECTION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1068-9265</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243765500008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background: Advanced, but
                    potentially still curable gastric cancer (stages IIIA, IIIB, or stage IV M0) is
                    associated with very high recurrence rates after gastrectomy. The value of an
                    extended lymph node dissection (ELND) remains unclear in this setting. Methods:
                    A resected gastric cancer data set was created through structured queries to the
                    SEER 1973-2000 database. Relationships between the number of lymph nodes (LNs)
                    examined and survival outcomes were analyzed for the stage subgroups
                    characterized by the N categories N2 or N3, and transmural tumor extension (T
                    categories T2b or T3). Results: The study group encompassed 1,377 patients,
                    including T2b/3N2 (n = 1,076) and T2b/3N3 stage subgroups (n = 301). Total LN
                    count (or number of negative LNs examined; P &lt; 0.0001), number of positive
                    LNs (P &lt; 0.0001), age (P &lt; 0.0001), primary site (P = 0.0002), T category
                    (P = 0.0271), race (P = 0.0301) and gender (P = 0.0261) were independent
                    prognostic survival predictors. A cut point analysis yielded the ability to
                    detect significant survival differences for LN numbers up to 30 (N2) or up to 40
                    (N3), always in favor of the higher number of LNs examined. Best long-term
                    survival outcomes were observed with negative LN counts of more than 15 (N2) or
                    more than 20 (N3). Conclusions: Even in transmural or serosa-positive gastric
                    cancer with advanced nodal involvement, more extensive LN dissection and
                    analysis influences survival. Stage-based survival prediction depends on total
                    LN number and number of negative LNs. The mechanism remains uncertain, but is
                    not limited to stage migration. ELND during potentially curative gastrectomy is
                    recommended even for advanced gastric cancer.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    129YH&#xD;Times Cited: 0&#xD;Cited Reference Count: 37</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243765500008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/02; </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>382</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">382</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1133</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Schwarz, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Med &amp; Dent New Jersey,
                    Robert Wood Johnson Med Sch, Dept Surg, Canc Inst New Jersey, New Brunswick, NJ
                    08901 USA. Canc Inst New Jersey, Div Surg Oncol, New Brunswick, NJ 08903 USA.
                    City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA.&#xD;Schwarz, RE, Univ
                    Med &amp; Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Canc Inst New
                    Jersey, 195 Little Albany St, New Brunswick, NJ 08901
                    USA.&#xD;r.schwarz@umdnj.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Lymph node dissection impact on
                        staging and survival of extrahepatic cholangiocarcinomas, based on US
                        population data</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Gastrointestinal
                        Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Gastrointestinal
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Gastrointest. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Gastrointest Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">158-165</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">11</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">extrahepatic
                        cholangiocarcinoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph node count</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gallbladder cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ampullary cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphadenectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTENDED RETROPERITONEAL
                        LYMPHADENECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADVANCED GALLBLADDER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BILE-DUCT CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTRIC-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PERIAMPULLARY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADENOCARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATIC-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PANCREATICODUODENECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTRECTOMY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1091-255X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245170600008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Cholangiocarcinomas (CC) frequently
                    demonstrate lymphatic spread. We investigated lymph node (LN) counts after
                    resection of extrahepatic CC and survival based on the SEER 1973-2004 database.
                    Out of 20,068 CC patients, 1,518 individuals were selected based on M0 stage and
                    at least one LN examined. Primary cancer sites included gallbladder (29%),
                    extrahepatic bile ducts (26%), and intrapancreatic/ampullary bile ducts (45%);
                    42% of patients were LN-positive. The median number of LNs examined was four
                    (range 1-39). Median survival was 37 months for LN-negative and 16 months for
                    LN-positive cancers. Multivariate prognostic variables were the number of
                    positive LNs, primary site, age (all at p &lt; 0.0001), gender (p=0.002), size
                    (p=0.005), T category (p=0.009), and total LN count (or number of negative LNs
                    obtained, p=0.01). The impact of total LN counts was seen in LN-negative (median
                    survival, 1 vs 10 or more LNs examined: 27 vs 51 months, p=0.002) and
                    LN-positive disease (10 vs 22 months, p &lt; 0.0001). Survival prediction of
                    extrahepatic CCs is strongly influenced by total LN counts and numbers of
                    negative LNs obtained. Although the resulting incremental benefit is small,
                    dissection and examination of 10 or more LNs should be considered for curative
                    intent resections.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    149TV&#xD;Times Cited: 0&#xD;Cited Reference Count: 28&#xD;Cited References:
                    &#xD; *AM CANC SOC, 2006, CANC FACTS FIG&#xD; *SEER PROGR, 2005, PUBL US DAT
                    1973 200&#xD; ARAIDA T, 2004, J HEPATO-BILIARY-PAN, V11, P45&#xD; COX DR, 1972,
                    J ROY STAT SOC B MET, V34, P187&#xD; CSERNI G, 2002, J SURG ONCOL, V81, P63&#xD;
                    CUSCHIERI A, 1999, BRIT J CANCER, V79, P1522&#xD; DONOHUE JH, 1998, CANCER, V83,
                    P2618&#xD; GERVASONI JE, 2000, SURG CLIN N AM, V80, P1631&#xD; GREENE FL, 2002,
                    AM JOINT COMMITTEE C&#xD; HARTGRINK HH, 2004, J CLIN ONCOL, V22, P2069&#xD; JANG
                    JY, 2005, ANN SURG, V241, P77&#xD; KAPLAN EL, 1958, AM STAT ASS J, V53,
                    P457&#xD; KITAGAWA Y, 2001, ANN SURG, V233, P385&#xD; KONDO S, 2000, BRIT J
                    SURG, V87, P418&#xD; ONOYAMA H, 2002, WORLD J SURG, V26, P1315&#xD; PAWLIK TM,
                    2005, ARCH SURG-CHICAGO, V140, P584&#xD; PAWLIK TM, 2005, ARCH SURG-CHICAGO,
                    V140, P9&#xD; PEDRAZZOLI S, 1998, ANN SURG, V228, P508&#xD; PETO R, 1973,
                    BIOMETRICS, V29, P579&#xD; SCHWARZ RE, 2002, ANN SURG ONCOL, V9, P394&#xD;
                    SCHWARZ RE, 2006, ANN SURG ONCOL, V13, P1189&#xD; SMITH DD, 2005, J CLIN ONCOL,
                    V23, P7114&#xD; YALCIN S, 2004, HEPATO-GASTROENTEROL, V51, P43&#xD; YEO CJ,
                    1999, ANN SURG, V229, P613&#xD; YEO CJ, 1999, ANN SURG, V229, P622&#xD; YEO CJ,
                    2002, ANN SURG, V236, P355&#xD; YEO CJ, 2002, ANN SURG, V236, P366&#xD; YOSHIDA
                    T, 2002, ARCH SURG-CHICAGO, V137, P69</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245170600008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>768</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">768</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1132</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Schwarz, R. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">UT Southwestern Canc Ctr, Div Surg
                    Oncol, Dallas, TX 75390 USA. City Hope Natl Med Ctr, Div Biostat, Duarte, CA
                    91010 USA.&#xD;Schwarz, RE, UT Southwestern Canc Ctr, Div Surg Oncol, 5323 Harry
                    Hines Blvd, Dallas, TX 75390
                    USA.&#xD;Roderich.Schwarz@utsouthwestern.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Clinical impact of
                        lymphadenectomy extent in resectable esophageal cancer</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Gastrointestinal
                        Surgery</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Gastrointestinal
                        Surgery</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Gastrointest. Surg.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Gastrointest Surg</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1384-1393</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">11</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">lymphadenectomy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">resectable esophageal
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">lymph nodes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">N staging</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODE DISSECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AMERICAN-JOINT-COMMITTEE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">US-POPULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DATABASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LONG-TERM SURVIVAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGNOSTIC-FACTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTROESOPHAGEAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">JUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EN-BLOC</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDIASTINAL
                        LYMPHADENECTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SURGICAL RESECTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GASTRIC-CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1091-255X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249979900002</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Esophageal cancer (EC) frequently
                    presents with advanced stages and is associated with high recurrence rates after
                    esophagectomy. The value of an extended lymph node dissection (ELND) remains
                    unclear in this setting. An EC data set was created from the Surveillance,
                    Epidemiology, and End-Results 1973-2003 database. Relationships between the
                    number of lymph nodes (LNs) examined and overall survival (OS) were analyzed.
                    From a cohort of 40,129 EC patients, 5,620 individuals were selected. The median
                    age was 65 (range: 11-102), and 75% were men. The median tumor size was 5.0 cm
                    (0.1-30). On multivariate analysis, total LN count (or negative LN count,
                    respectively) was an independent prognostic variable, aside from age, race,
                    resection status, radiation, T category, N category (all at p &lt; 0.0001), and
                    M category (p=0.0003). Higher total LN count (&gt; 30) and negative LN count
                    (&gt; 15) categories were associated with best OS and lowest 90-day mortality (p
                    &lt; 0.0001). The numeric LN effect on OS was independent from nodal status or
                    histology. Greater total and negative LN counts are associated with longer EC
                    survival. Although the mechanism remains uncertain, it does not appear to be
                    limited to stage migration. ELND during potentially curative esophagectomy for
                    EC can be supported by the data.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    217XF&#xD;Times Cited: 0&#xD;Cited Reference Count: 39&#xD;Cited References:
                    &#xD; ALTORKI N, 2002, ANN SURG, V236, P177&#xD; BIRKMEYER JD, 2003, NEW ENGL J
                    MED, V349, P2117&#xD; BIRKMEYER JD, 2007, ANN SURG, V245, P777&#xD;
                    BOLLSCHWEILER E, 2006, J SURG ONCOL, V94, P355&#xD; CENSE HA, 2006, BEST PRACT
                    RES CL GA, V20, P893&#xD; DJOURNO XB, 2005, EUR J CARDIO-THORAC, V27, P697&#xD;
                    DUTKOWSKI P, 2002, HEPATO-GASTROENTEROL, V49, P176&#xD; ELOUBEIDI MA, 2002,
                    CANCER, V95, P1434&#xD; HAGEN JA, 2001, ANN SURG, V234, P520&#xD; HEEREN PAM,
                    2005, EJSO, V31, P270&#xD; HULSCHER JBF, 2001, BRIT J SURG, V88, P715&#xD;
                    HULSCHER JBF, 2002, NEW ENGL J MED, V347, P1662&#xD; JEMAL A, 2007, CA-CANCER J
                    CLIN, V57, P43&#xD; JOHANSSON J, 2004, ARCH SURG-CHICAGO, V139, P627&#xD;
                    JOHANSSON J, 2004, ARCH SURG-CHICAGO, V139, P631&#xD; JUNGINGER T, 2006,
                    EJSO-EUR J SURG ONC, V32, P749&#xD; KANG CH, 2007, EUR J CARDIO-THORAC, V31,
                    P154&#xD; LAW S, 2007, SURG ONCOL CLIN N AM, V16, P115&#xD; LERUT T, 2004, ANN
                    SURG, V240, P962&#xD; LERUT T, 2004, ANN SURG, V240, P972&#xD; NISHIHIRA T,
                    1998, AM J SURG, V175, P47&#xD; POHL H, 2005, J NATL CANCER I, V97, P142&#xD;
                    PORTALE G, 2006, J AM COLL SURGEONS, V202, P588&#xD; PRENZEL KL, 2007, ANN SURG
                    ONCOL, V14, P954&#xD; RIZK N, 2006, J THORAC CARDIOV SUR, V132, P1374&#xD; RIZK
                    NP, 2007, J CLIN ONCOL, V25, P507&#xD; SCHURR PG, 2006, J SURG ONCOL, V94,
                    P307&#xD; SCHWARZ RE, 2006, ANN SURG ONCOL, V13, P1189&#xD; SCHWARZ RE, 2007,
                    ANN SURG ONCOL, V14, P317&#xD; SCHWARZ RE, 2007, J GASTROINTEST SURG, V11,
                    P158&#xD; SHIMADA H, 2007, AM J SURG, V193, P448&#xD; SMITH DD, 2005, J CLIN
                    ONCOL, V23, P7114&#xD; STEIN HJ, 2005, ANN SURG, V242, P566&#xD; STEIN HJ, 2005,
                    ANN SURG, V242, P573&#xD; TSURUMARU M, 2001, ANN THORAC CARDIOVAS, V7, P325&#xD;
                    VANSANDICK JW, 2002, J AM COLL SURGEONS, V194, P28&#xD; WATERMAN TA, 2004, ANN
                    THORAC SURG, V78, P1161&#xD; WIJNHOVEN BPL, 2007, ANN SURG, V245, P717&#xD;
                    WILLIAMS VA, 2006, SURG ONCOL CLIN N AM, V15, P765</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249979900002 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>799</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">799</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1129</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Scuto, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhao, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rivera, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yeatman, T. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Torres-Roca, J. F.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Beckman Res Inst, Div Mol
                    Med, Duarte, CA USA. Natl Med Ctr, Duarte, CA USA. H Lee Moffitt Canc Ctr &amp;
                    Res Inst, Dept Interdisciplinary Oncol, Tampa, FL USA.&#xD;Torres-Roca, JF, H
                    Lee Moffitt Canc Ctr &amp; Res Inst, 12902 Magnolia Dr,SRB-3, Tampa, FL 33612
                    USA.&#xD;Javier.torresroca@moffitt.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">RbAp48 regulates cytoskeletal
                        organization and morphology by increasing k-ras activity and signaling
                        through mitogen-activated protein kinase</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">10317-10324</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">21</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">INTEGRIN-LINKED KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HISTONE DEACETYLASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIN CYTOSKELETON</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEGATIVE REGULATOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHOSPHOINOSITIDE
                        3-KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATHWAY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHROMATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">YEAST</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSFORMATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Nov</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250700200029</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">RbAp48 is a WD-40 protein that plays
                    an important role in chromatin metabolism and regulates Ras signaling. Here, we
                    report that RbAp48 is involved in the regulation of cytoskeletal organization, a
                    novel function. First, we show that transfection of RbAP48 into Hs-578T breast
                    cancer cells (Hs-RbAp48-hi) leads to cell size reduction, a rounded cell shape,
                    decreased cellular protrusions, and a higher nuclear/cytoplasmic ratio.
                    Furthermore, we observed cytoskeletal F-actin organization disruption with loss
                    of actin stress fibers and formation of membranous F-actin rings in Hs-RbAp48-hi
                    cells. These morphologic changes were partially reversed by RbAp48 knockdown.
                    Interestingly, mitogen-activated protein kinase (MAPK) was activated in
                    Hs-RbAp48-hi cells, and this activity was also partly reversed by RbAp48
                    down-regulation. Furthermore, pharmacologic inhibition of MAPK led to the
                    reappearance of organized actin fibers and focal contacts, suggesting MAPK as
                    the effector pathway. Moreover, we show an increase in total Ras activity in
                    Hs-RbAp48-hi cells with K-Ras-GTP becoming the dominant isoform. This reverted
                    to baseline activity levels on RbAp48 small interfering RNA transfection, thus
                    suggesting a direct role for RbAp48 in Ras regulation. Finally, we tested the
                    model in transformed 3T3-K-Ras-G12V fibroblasts. As expected, RbAp48 knockdown
                    in 3T3-K-Ras-hi fibroblasts resulted in reappearance of an organized
                    cytoskeleton and shutdown of K-Ras activity. In conclusion, our data support a
                    model whereby RbAp48 regulates cellular morphology and cytoskeletal organization
                    by increasing K-Ras activity and signaling through MAPK.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/</style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    228AV&#xD;Times Cited: 0&#xD;Cited Reference Count: 48&#xD;Cited References:
                    &#xD; BARSAGI D, 1986, SCIENCE, V233, P1061&#xD; BARSAGI D, 2000, CELL, V103,
                    P227&#xD; CHOI JA, 2004, ONCOGENE, V23, P9&#xD; COX AD, 2003, ONCOGENE, V22,
                    P8999&#xD; DOWNWARD J, 2003, NAT REV CANCER, V3, P11&#xD; ELADSFADIA G, 2004, J
                    BIOL CHEM, V279, P34922&#xD; FURUYAMA T, 2003, GENESIS, V35, P114&#xD; GUPTA AK,
                    2001, CANCER RES, V61, P4278&#xD; HANCOCK JF, 2003, NAT REV MOL CELL BIO, V4,
                    P373&#xD; HANNIGAN G, 2005, NAT REV CANCER, V5, P51&#xD; HENIKOFF S, 2003,
                    NATURE, V423, P814&#xD; HENNIG L, 2003, DEVELOPMENT, V130, P2555&#xD; KIM IA,
                    2004, CANCER METAST REV, V23, P227&#xD; LU XW, 1998, CELL, V95, P981&#xD; MULLER
                    J, 2002, CELL, V111, P197&#xD; NARLIKAR GJ, 2002, CELL, V108, P475&#xD; NEER EJ,
                    1994, NATURE, V371, P297&#xD; NICOLAS E, 2000, J BIOL CHEM, V275, P9797&#xD;
                    PARTHUN MR, 1996, CELL, V87, P85&#xD; PAWLAK G, 2002, J BIOL CHEM, V277,
                    P26927&#xD; PAWLAK G, 2002, MOL BIOL CELL, V13, P336&#xD; POLLOCK CB, 2005,
                    CANCER RES, V65, P1244&#xD; QIAN YW, 1993, NATURE, V364, P648&#xD; QIAN YW,
                    1995, J BIOL CHEM, V270, P25507&#xD; REUVENI H, 2000, J CELL BIOL, V151,
                    P1179&#xD; RIDLEY AJ, 1992, CELL, V70, P389&#xD; RODRIGUEZVICIANA P, 1997, CELL,
                    V89, P457&#xD; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778&#xD; SAHAI E,
                    2001, EMBO J, V20, P755&#xD; SHIELDS JM, 2000, TRENDS CELL BIOL, V10, P147&#xD;
                    SONDEK J, 1996, NATURE, V379, P369&#xD; TANG Y, 2003, ONCOGENE, V22, P5866&#xD;
                    TAUNTON J, 1996, SCIENCE, V272, P408&#xD; TONG JK, 1998, NATURE, V395, P917&#xD;
                    TORRESROCA JF, 2005, CANCER RES, V65, P7169&#xD; URNOV FD, 2001, CURR TOP
                    MICROBIOL, V254, P1&#xD; VERREAULT A, 1996, CELL, V87, P95&#xD; VERREAULT A,
                    1998, CURR BIOL, V8, P96&#xD; VOICE JK, 1999, J BIOL CHEM, V274, P17164&#xD;
                    WADE PA, 1998, CURR BIOL, V8, P843&#xD; WADE PA, 1999, NAT GENET, V23, P62&#xD;
                    WOLFFE AP, 2000, BIOCHEM SOC T 4, V28, P379&#xD; WU CY, 2001, J CELL BIOL, V155,
                    P505&#xD; XUE YT, 1998, MOL CELL, V2, P851&#xD; YAN J, 1998, J BIOL CHEM, V273,
                    P24052&#xD; ZHANG Y, 1998, CELL, V95, P279&#xD; ZHONG CL, 1997, MOL BIOL CELL,
                    V8, P2329&#xD; ZONDAG GCM, 2000, J CELL BIOL, V149, P775</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250700200029 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>396</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">396</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1127</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Seibel, N. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Krailo, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chen, Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Healey, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Breiffeld, P. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Drachtman, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Greffe, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nachman, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nadel, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sato, J. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Meyers, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reaman, G. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">George Washington Univ, Sch Med,
                    Childrens Natl Med Ctr, Washington, DC 20052 USA. Univ So Calif, Childrens Oncol
                    Grp, Los Angeles, CA 90089 USA. Univ So Calif, Dept Prevent Med, Los Angeles, CA
                    90089 USA. Childrens Oncol Grp, Arcadia, CA USA. Mem Sloan Kettering Canc Ctr,
                    Dept Surg, New York, NY 10021 USA. Duke Univ, Durham, NC 27706 USA. Univ Med
                    &amp; Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
                    Childrens Hosp, Dept Hematol Oncol, Denver, CO 80218 USA. Univ Chicago, Comers
                    Childrens Hosp, Dept Pediat, Chicago, IL 60637 USA. British Columbia Childrens
                    Hosp, Dept Radiol, Vancouver, BC V6H 3V4, Canada. City Hope Natl Med Ctr, Div
                    Pediat, Duarte, CA USA. Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY
                    10021 USA.&#xD;Seibel, NL, 111 Michigan Ave NW, Washington, DC 20010
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Upfront window trial of
                        topotecan in previously untreated children and adolescents with poor
                        prognosis metastatic osteosarcoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1646-1653</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">109</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">osteosarcoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">topotecan</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">metastatic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">window</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ifosfamide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">carboplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">etoposide</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">doxorubicin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cisplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">treatment</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PEDIATRIC-ONCOLOGY-GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLONY-STIMULATING
                        FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SOLID TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NEOADJUVANT CHEMOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OSTEOGENIC-SARCOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IFOSFAMIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPERIENCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARBOPLATIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RHABDOMYOSARCOMA</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-543X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245570900026</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">BACKGROUND. Patients with metastatic
                    osteosarcoma have a poor prognosis. The objectives of the study were to
                    determine the antitumor activity and toxicity of topotecan (daily x5) in newly
                    diagnosed patients with metastatic osteosarcoma followed by chemotherapy
                    (ifosfamide, carboplatin, etoposide [ICE], alternating with cisplatin and
                    doxorubicin [CD]). METHODS. Newly diagnosed patients (&lt;= 30 years of age)
                    with extensive metastatic disease (primary and &gt;= 5 pulmonary nodules and/or
                    bone metastases) with normal hepatic, renal, and cardiac function were eligible.
                    Patients were eligible to receive further topotecan after standard chemotherapy
                    if they exhibited a response. Twenty-eight patients were enrolled. Seventeen had
                    metastases to the lung only and 11 had metastases to the bone or multiple sites.
                    Of 28 patients enrolled, 27 could be evaluated for response. A limited dose
                    escalation was incorporated. RESULTS. No responses were seen in the 11 patients
                    treated at 3 mg/m(2)/day One partial response (PR) and 1 clinical response (CLR)
                    were reported among 15 patients who received topotecan at 3.5 mg/m(2)/day. No
                    dose-limiting toxicity was observed. Principal nondose-limiting toxicities were
                    hematologic and gastrointestinal. The 2- and 5-year event-free survival rates
                    were low, 7% and 4%, respectively, but the 2- and 5-year overall survival rates
                    were 44% and 22%, respectively. CONCLUSIONS. Topotecan at dose of 3.5
                    mg/m(2)/day can be safely administered upfront to newly diagnosed patients
                    without excessive toxicity. Insufficient activity was seen with topotecan in
                    this schedule to warrant further studies in osteosarcoma. The combination of ICE
                    and CD was tolerable when delivered after initial topotecan therapy</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    155IK&#xD;Times Cited: 0&#xD;Cited Reference Count: 25&#xD;Cited References:
                    &#xD; BACCI G, 2003, ANN ONCOL, V14, P1126&#xD; CASTLEBERRY RP, 1994, J CLIN
                    ONCOL, V12, P1616&#xD; FERGUSON WS, 2001, J PEDIAT HEMATOL ONC, V23, P340&#xD;
                    GOORIN AM, 2002, J CLIN ONCOL, V20, P426&#xD; HARRIS MB, 1995, MED PEDIATR
                    ONCOL, V24, P87&#xD; HARRIS MB, 1998, J CLIN ONCOL, V16, P3641&#xD; HOROWITZ ME,
                    1988, J CLIN ONCOL, V6, P308&#xD; HOUGHTON PJ, 1992, CANCER CHEMOTH PHARM, V31,
                    P229&#xD; HUVOS AG, 1977, ARCH PATHOL LAB MED, V101, P14&#xD; KAGER L, 2003, J
                    CLIN ONCOL, V21, P2011&#xD; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI&#xD;
                    KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457&#xD; LONGHI A, 2001, J CHEMOTHERAPY,
                    V13, P324&#xD; MEYER WH, 1989, HAMATOL BLUTTRANSFUS, V32, P141&#xD; MEYER WH,
                    2001, J CLIN ONCOL, V19, P171&#xD; MEYERS PA, 1993, J CLIN ONCOL, V11, P449&#xD;
                    MIALOU V, 2005, CANCER, V104, P1100&#xD; PAPPO AS, 1993, CANCER, V71, P2119&#xD;
                    ROWINSKY EK, 1996, J CLIN ONCOL, V14, P1224&#xD; SALTZ L, 1993, J NATL CANCER I,
                    V85, P1499&#xD; SANTANA VM, 2003, CLIN CANCER RES, V9, P633&#xD; SMITH MA, 2001,
                    J PEDIAT HEMATOL ONC, V23, P334&#xD; STEWART CF, 1996, INVEST NEW DRUG, V14,
                    P37&#xD; TUBERGEN DG, 1996, J PEDIAT HEMATOL ONC, V18, P352&#xD; VANWINKLE P,
                    2005, PEDIATR BLOOD CANCER, V44, P338</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245570900026 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>769</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">769</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1126</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Seidel, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schagdarsurengin, U.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blumke, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wurl, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pfeifer, G. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hauptmann, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Taubert, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dammann, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Halle Wittenberg, AWG Tumor
                    Genet Med Fac, Halle, Germany. Univ Halle Wittenberg, Inst Pathol, Halle,
                    Germany. Univ Ulm, Surg Clin, Ulm, Germany. City Hope Canc Ctr, Dept Biol,
                    Duarte, CA USA.&#xD;Dammann, R, Univ Halle Wittenberg, Inst Human Genet,
                    Magdeburger Str 2, D-06097 Halle, Germany.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Frequent hypermethylation of
                        MST1 and MST2 in soft tissue sarcoma</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Carcinogenesis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Carcinogenesis</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Carcinog.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Carcinog</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">865-871</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">46</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">sarcoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA methylation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RASSF1A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MST1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MST2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hippo pathway</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE
                        LYMPHOBLASTIC-LEUKEMIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-SUPPRESSOR RASSF1A</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-RELATED</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL-CYCLE EXIT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROMOTER
                        HYPERMETHYLATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOWN-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FAMILY PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POOR-PROGNOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MULTIPLE GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0899-1987</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250072900006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The RASSF1A tumor suppressor is
                    involved in regulation of apoptosis and cell cycle progression. RASSF1A is
                    localized to microtubules and binds the apoptotic kinases MST1 and MST2. It has
                    been shown that this interaction is mediated by the Sav-RASSF-Hpo domain, which
                    is an interaction domain characterized for the Drosophila proteins Sav (human
                    WW45), Hpo (human MST1 and MST2) and Warts/LATS (large tumor suppressor).
                    Previously, we have reported that RASSF1A hypermethylation occurs frequently in
                    soft tissue sarcoma and is associated with an unfavorable prognosis for cancer
                    patients. In our study, we performed methylation analysis of the CpG island
                    promoter of MST1, MST2, WW45, LATS1 and LATS2 in soft tissue sarcomas by
                    methylation-specific PCR. No or a very low methylation frequency was detected
                    for WW45, LATS1 and LATS2 (&lt; 7%). In 19 out of 52 (37%) sarcomas, a
                    methylated promoter of MST1 was detected and 12 out of 60 (20%) samples showed
                    methylation of the MST2 promoter. Methylation status of MST1 was confirmed by
                    bisulfite sequencing. In tumors harboring a methylated promoter of MST1, a
                    reduction of MST1 expression was observed by RT-PCR. In leiomyosarcomas, MST1
                    and MST2 or RASSF1A methylation were mutually exclusive (P=0.007 and P=0.025,
                    respectively). Surprisingly, a significantly increased risk for tumor-related
                    death was found for patients with an unmethylated MST1 promoter (P=0.036). In
                    summary, our results suggest that alteration of the Sav-RASSF1-Hpo tumor
                    suppressor pathway may occur through hypermethylation of the CpG island promoter
                    of MST1, MST2 and/or RASSF1A in human sarcomas. (c) 2007 Wiley-Liss,
                    Inc.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    219GO&#xD;Times Cited: 0&#xD;Cited Reference Count: 29&#xD;Cited References:
                    &#xD; AGATHANGGELOU A, 2005, CANCER RES, V65, P3497&#xD; CHAN EH, 2005,
                    ONCOGENE, V24, P2076&#xD; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990&#xD;
                    DAMMANN R, 2000, NAT GENET, V25, P315&#xD; DAMMANN R, 2005, HISTOL HISTOPATHOL,
                    V20, P645&#xD; HARADA K, 2002, ONCOGENE, V21, P4345&#xD; HARVEY KF, 2003, CELL,
                    V114, P457&#xD; HAY BA, 2003, DEV CELL, V5, P361&#xD; HISAOKA M, 2002, LAB
                    INVEST, V82, P1427&#xD; HOU P, 2006, CANCER, V106, P1602&#xD; JIMENEZVELASCO A,
                    2005, LEUKEMIA, V19, P2347&#xD; JONES PA, 2002, NAT REV GENET, V3, P415&#xD;
                    KAWAGUCHI K, 2006, MODERN PATHOL, V19, P106&#xD; KHOKHLATCHEV A, 2002, CURR
                    BIOL, V12, P253&#xD; LEHTINEN MK, 2006, CELL, V125, P987&#xD; MCPHERSON JP,
                    2004, EMBO J, V23, P3677&#xD; OH HJ, 2006, CANCER RES, V66, P2562&#xD;
                    PANTALACCI S, 2003, NAT CELL BIOL, V5, P921&#xD; PRASKOVA M, 2004, BIOCHEM J 2,
                    V381, P453&#xD; ROMANGOMEZ J, 2004, BLOOD, V104, P2492&#xD; SCHEEL H, 2003, CURR
                    BIOL, V13, R899&#xD; SEIDEL C, 2005, INT J CANCER, V114, P442&#xD; STJOHN MAR,
                    1999, NAT GENET, V21, P182&#xD; TAKAHASHI Y, 2005, CLIN CANCER RES, V11,
                    P1380&#xD; TAPON N, 2002, CELL, V110, P467&#xD; TOMMASI S, 2005, CANCER RES,
                    V65, P92&#xD; UDAN RS, 2003, NAT CELL BIOL, V5, P914&#xD; VANUNNIK JAM, 1993,
                    EUR J CANCER A, V29, P2089&#xD; WU S, 2003, CELL, V114, P445</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250072900006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>397</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">397</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1125</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shankar, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carter, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Francisco, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Baker, K. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gurney, J. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Weisdorf, D. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Robison, L. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grant, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatia, S.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Of Hope Canc Ctr, Duarte, CA
                    91010 USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Univ Minnesota,
                    Minneapolis, MN 55455 USA. Univ Michigan, Ann Arbor, MI 48109 USA. St Jude
                    Childrens Hosp, Memphis, TN 38105 USA.&#xD;Bhatia, S, City Of Hope Canc Ctr,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;sbhltia@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Health care utilization by adult
                        long-term survivors of hematopoietic cell transplant: Report from the bone
                        marrow transplant survivor study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Epidemiology Biomarkers
                        &amp; Prevention</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol. Biomarkers
                        Prev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Epidemiol Biomarkers
                        Prev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">834-839</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">16</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER SURVIVORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHILDHOOD-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FUNCTIONAL STATUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MORTALITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SERVICES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Apr</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1055-9965</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245732600030</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The high intensity of therapy and
                    prolonged immune suppression after hematopoietic cell transplantation (HCT)
                    increase the risk of long-term complications and health care needs among
                    survivors. The aim of this study was to evaluate the current status of health
                    care utilization by longterm HCT survivors and to identify factors associated
                    with lack of utilization. A total of 845 individuals who had undergone HCT
                    between 1974 and 1998 at age 21 years or older and survived 2 or more years
                    after HCT participated in the study. Health care utilization was assessed
                    through a mailed questionnaire in three domains: general contact with health
                    care system, general physical examination, and cancer/HCT -related visit. The
                    median age at HCT was 38.2 years, and the median length of follow-up was 6.4
                    years. Overall, 98% of allogeneic and 94% of autologous HCT survivors reported
                    medical contact 11+ years after HCT. Cancer/HCT-related visits decreased with
                    increasing time from HCT (allogeneic HCT, 98-57%; autologous HCT, 9463%). The
                    prevalence of general physical examination increased with time (allogeneic HCT,
                    56-74%; autologous HCT, 72-81%). Primary care physicians provide health care for
                    an increasing number of adult long-term survivors of HCT, emphasizing the need
                    for increased awareness of the long-term follow-up needs of the HCT survivors by
                    the health care providers.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    157PN&#xD;Times Cited: 0&#xD;Cited Reference Count: 19&#xD;Cited References:
                    &#xD; ANDRYKOWSKI MA, 1990, BONE MARROW TRANSPL, V6, P269&#xD; ANDRYKOWSKI MAA,
                    2005, J CLIN ONCOL, V23, P599&#xD; BHATIA S, 2005, BLOOD, V105, P4215&#xD; COOL
                    VA, 1996, BONE MARROW TRANS S3, V18, S45&#xD; DEEG HJ, 2004, THOMAS
                    HEMATOPOIETIC, P944&#xD; DUELL T, 1997, ANN INTERN MED, V126, P184&#xD; HEWITT
                    M, 2003, J GERONTOL A-BIOL, V58, P82&#xD; JOHNSON R, 2004, ARCH DIS CHILD, V89,
                    P374&#xD; KRAMER JH, 1997, BONE MARROW TRANSPL, V19, P607&#xD; NORD C, 2005, INT
                    J CANCER, V114, P307&#xD; OEFFINGER KC, 2000, J FAM PRACTICE, V49, P689&#xD;
                    OEFFINGER KC, 2004, ANN FAM MED, V2, P61&#xD; PHIPPS S, 2000, J CLIN ONCOL, V18,
                    P1004&#xD; RIZZO JD, 2006, BIOL BLOOD MARROW TR, V12, P138&#xD; SEO PH, 2004,
                    CANCER, V101, P2276&#xD; SHAW AK, 2006, CANCER, V106, P1829&#xD; SOCIE G, 1999,
                    NEW ENGL J MED, V341, P14&#xD; WINGARD JR, 1991, ANN INTERN MED, V114, P113&#xD;
                    ZEBRACK BJ, 2004, CANCER, V100, P843</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245732600030 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 05/07 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>486</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">486</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1661</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shi, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Neurosciences, Center
                    for Gene Expression and Drug Discovery, Beckman Research Institute of City of
                    Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA. yshi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Orphan nuclear receptors in drug
                        discovery</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Drug Discov Today</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Drug Discovery Today</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Drug Discov. Today</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Drug Discov Today</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">440-5</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">12</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11-12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Animals</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-Binding Proteins/drug
                        effects/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Design</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Ligands</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Peroxisome
                        Proliferator-Activated Receptors/drug effects/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pharmacology/ trends</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Cytoplasmic and
                        Nuclear/ drug effects/genetics/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Trans-Activators/drug
                        effects/genetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription Factors/drug
                        effects/genetics</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1359-6446 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17532527</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Orphan nuclear receptors provide a
                    unique resource for uncovering novel regulatory systems that impact human health
                    and also provide drug targets for a variety of human diseases. Ligands of
                    nuclear receptors have been used in several important therapeutic areas, such as
                    breast cancers, skin disorders and diabetes. Orphan nuclear receptors,
                    therefore, represent a tremendous opportunity in understanding and treating
                    human diseases. Here, I highlight recent advances in the use of orphan nuclear
                    receptors and their potential as targets for drug discovery in diabetes,
                    obesity, neurodegenerative diseases and other related disorders.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>208</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">208</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1120</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shibata, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chow, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Frankel, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Juhasz, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Leong, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lim, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Margolin, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Morgan, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Newman, E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somlo, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yen, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gandara, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenz, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Doroshow, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Med
                    Oncol &amp; Therapeut, Duarte, CA 91010 USA. Univ Calif Davis, Ctr Canc,
                    Sacramento, CA 95817 USA. Univ So Calif, Norris Canc Ctr, Los Angeles, CA 90089
                    USA.&#xD;Shibata, S, City Hope Natl Med Ctr, Dept Med Oncol &amp; Therapeut,
                    1500 E Duarte Rd, Duarte, CA 91010 USA.&#xD;sshibata@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">A phase I study of oxaliplatin
                        in combination with gemcitabine: correlation of clinical outcome with gene
                        expression</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Chemotherapy and
                        Pharmacology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Chemotherapy and
                        Pharmacology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Chemother.
                        Pharmacol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Chemother
                        Pharmacol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">549-557</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">59</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">oxaliplatin</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">gemcitabine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ribonucleotide reductase</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">pharmacokinetics</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELL LUNG-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA MISMATCH REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METASTATIC
                        PANCREATIC-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DYSFUNCTION WORKING
                        GROUP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA EXPRESSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RIBONUCLEOTIDE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REDUCTASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OVARIAN-CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">III TRIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REPLICATIVE BYPASS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLORECTAL-CANCER</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0344-5704</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243554600015</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: Oxaliplatin has in vitro
                    activity similar to or higher than other platinum agents. Preclinically,
                    gemcitabine has demonstrated synergy when combined with platinum compounds.
                    These facts formed the rationale for determining the maximum tolerated dose
                    (MTD) of gemcitabine in combination with oxaliplatin. Methods: Eligible patients
                    with advanced incurable solid tumors were given oxaliplatin 130 mg/m(2) as a 2-h
                    infusion on day 1 followed by escalating doses of gemcitabine given over 30 min
                    on day 1 and 8 of a 21-day cycle. Results: A total of 43 patients were enrolled,
                    including 30 patients at the MTD in an expanded cohort. At a gemcitabine dose of
                    800 mg/m(2), 1/6 patients had a dose limiting toxicity (DLT) (grade 3 blurred
                    vision and memory loss). At 1,000 mg/m(2), 1/6 patients had a DLT (grade 3
                    increase in AST). At 1,200 mg/m(2), 2/3 patients had a DLT (grade 4
                    thrombocytopenia and grade 3 confusion). The MTD of gemcitabine with 130 mg/m(2)
                    of oxaliplatin was therefore 1,000 mg/m(2). The clearances of gemcitabine and
                    ultrafilterable platinum are within the ranges previously reported for single
                    agents. A patient with colon cancer had a partial response, and 21 patients had
                    a best response of stable disease. In patients with tumor biopsies treated at
                    the MTD, decreased ribonucleotide reductase M2 expression correlated with
                    response. Conclusion: Treatment with gemcitabine and oxaliplatin was well
                    tolerated with primarily hematologic toxicity at the MTD. Study of biochemical
                    correlates of response remain of interest althought current results remain
                    exploratory.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    126ZP&#xD;Times Cited: 0&#xD;Cited Reference Count: 55&#xD;Cited References:
                    &#xD; ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491&#xD; AEBI S, 1996, CANCER RES,
                    V56, P3087&#xD; ALBERTS SR, 2002, ANN ONCOL, V13, P553&#xD; ALBERTS SR, 2003,
                    ANN ONCOL, V14, P580&#xD; ANDRE T, 2004, ANN ONCOL, V15, P1339&#xD; ANDRE T,
                    2004, NEW ENGL J MED, V350, P2343&#xD; BEPLER G, 2004, J CLIN ONCOL, V22,
                    P1878&#xD; BERGMAN AM, 1996, CLIN CANCER RES, V2, P521&#xD; BIDOLI P, 2004, LUNG
                    CANCER-J IASLC, V43, P203&#xD; CASSIDY J, 2002, SEMIN ONCOL S15, V29, P11&#xD;
                    CHOLLET P, 1996, ANN ONCOL, V7, P1065&#xD; COLUCCI G, 2002, CANCER, V94,
                    P902&#xD; DOROSHOW JH, 2000, P AN M AM SOC CLIN, V19, A155&#xD; DOROSHOW JH,
                    2003, SEMIN ONCOL S15, V30, P14&#xD; DUENASGONZALEZ A, 2003, AM J CLIN
                    ONCOL-CANC, V26, P22&#xD; ELLIS RE, 1961, PHYS MED BIOL, V5, P255&#xD; FAIVRE S,
                    1999, ANN ONCOL, V10, P1125&#xD; FAIVRE S, 1999, CANCER CHEMOTH PHARM, V44,
                    P117&#xD; FAIVRE S, 2002, ANN ONCOL, V13, P1479&#xD; FINK D, 1996, CANCER RES,
                    V56, P4881&#xD; FINK D, 1997, CANCER RES, V57, P1841&#xD; FRANCIOSI V, 2003,
                    LUNG CANCER-J IASLC, V41, P101&#xD; FREEMAN KB, 1995, J CHROMATOGR B, V665,
                    P171&#xD; GARUFI C, 2001, ANN ONCOL, V12, P179&#xD; GOAN YG, 1999, CANCER RES,
                    V59, P4204&#xD; GOLDBERG RM, 2004, J CLIN ONCOL, V22, P23&#xD; GRAHAM MA, 2000,
                    CLIN CANCER RES, V6, P1205&#xD; JUHASZ A, 2003, J CLIN LAB ANAL, V17, P184&#xD;
                    KIDANI Y, 1980, GANN, V71, P637&#xD; LOUVET C, 2005, J CLIN ONCOL, V23,
                    P3509&#xD; MAMENTA EL, 1994, CANCER RES, V54, P3500&#xD; MAVROUDIS D, 2003, ANN
                    ONCOL, V14, P304&#xD; MONNET I, 1998, EUR J CANCER, V34, P1124&#xD; PAVLAKIS N,
                    1997, CANCER, V80, P286&#xD; PECTASIDES D, 2004, ANN ONCOL, V15, P493&#xD;
                    PENDYALA L, 1995, CANCER LETT, V97, P177&#xD; PLUNKETT W, 1996, SEMIN ONCOL S10,
                    V23, P3&#xD; POPLIN E, P ASCO, V24&#xD; PORTA C, 2004, CANCER, V100, P2132&#xD;
                    RASPAGLIESI F, 2004, ONCOLOGY-BASEL, V67, P376&#xD; RAYMOND E, 1998, SEMIN ONCOL
                    S5, V25, P4&#xD; RIXE O, 1996, BIOCHEM PHARMACOL, V52, P1855&#xD; ROSELL R,
                    2004, CLIN CANCER RES, V10, P1318&#xD; ROTHENBERG ML, 2003, J CLIN ONCOL, V21,
                    P2059&#xD; SANDLER AB, 2000, J CLIN ONCOL, V18, P122&#xD; SCHMIDT W, 1993,
                    CANCER RES, V53, P799&#xD; SCHUTTE W, 2003, CLIN LUNG CANCER, V4, P294&#xD;
                    SOULIE P, 1997, EUR J CANCER, V33, P1400&#xD; TAKIMOTO CH, 2003, J CLIN ONCOL,
                    V21, P2664&#xD; VAISMAN A, 1998, CANCER RES, V58, P3579&#xD; VANMOORSEL CJA,
                    1999, BRIT J CANCER, V80, P981&#xD; VENOOK AP, 2000, J CLIN ONCOL, V18,
                    P2780&#xD; VONDERMAASE H, 2000, J CLIN ONCOL, V18, P3068&#xD; WOYNAROWSKI JM,
                    1998, MOL PHARMACOL, V54, P770&#xD; ZHOU BS, 1998, BIOCHEM PHARMACOL, V55,
                    P1657</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243554600015 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>859</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">859</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1117</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shih, C. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chu, P. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Slovak, M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Hematol
                    Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. City Hope Natl Med Ctr,
                    Dept Anat Pathol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Cytogenet,
                    Duarte, CA 91010 USA.&#xD;Shih, CC, City Hope Natl Med Ctr, Div Hematol
                    Hematopoiet Cell Transplantat, Fox N Res Bldg,1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;cshih@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Human embryonic stem cells are
                        prone to generate primitive, undifferentiated tumors in engrafted human
                        fetal tissues in severe combined immunodeficient mice</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Stem Cells and
                        Development</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Stem cells and
                        development</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Stem Cells Dev.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Stem Cells Dev</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">893-902</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">16</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">SCID-HU MOUSE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN BLASTOCYSTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEMATOPOIETIC LINEAGES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN FEEDERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">B-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DIFFERENTIATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LINES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1547-3287</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000252031000003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Embryonic stem (ES) cells are
                    uniquely endowed with the capacity of self-renewal and the potential to give
                    rise to all possible cell types. Their dirferentiation potential has raised hope
                    that these cells could be used as a renewable source for cell transplantation in
                    severe degenerative diseases. However, progress in this direction is still
                    limited. Using two human embryonic stem (ES) cell lines, HI and HSF-6, and three
                    types of human fetal tissues-thymus, lung and pancreas-we investigated whether
                    engrafted human fetal tissues in severe combined immunodeficient mice (SCID)
                    mice could provide a physiologically-relevant microenvironment for human ES
                    cells to differentiate into mature cells of corresponding tissues. Surprisingly,
                    we observed an aggressive growth of tumors when human ES cells were injected
                    into engrafted. human fetal tissues in SCID mice. These tumors displayed
                    histological characteristics of primitive, undifferentiated tumors rather than
                    differentiated teratomas. Additionally, these tumors exhibited a normal
                    karyotype and did not express the characteristic antigens of embryonic
                    carcinomas. We also found differences among human fetal tissue types in their
                    abilities to support the growth or these primitive tumors. Our study supports
                    and validates a previously reported phenomenon in mouse that tumorigenesis of ES
                    cells is host dependent. Our study is also the first report to demonstrate that
                    human ES cells are prone to generate primitive, undifferentiated tumors in human
                    fetal tissue grafts in SCID mice and raises a potential safety concern for using
                    human ES cell-derived cell products in humans.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    246TU&#xD;Times Cited: 0&#xD;Cited Reference Count: 59&#xD;Cited References:
                    &#xD; AI C, 2007, IN PRESS STEM CELLS, V16&#xD; ANDREWS PW, 1996, INT J CANCER,
                    V66, P806&#xD; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804&#xD; BEHFAR A,
                    2007, J EXP MED, V204, P405&#xD; BJORKLUND A, 2000, NAT NEUROSCI, V3, P537&#xD;
                    BJORKLUND LM, 2002, P NATL ACAD SCI USA, V99, P2344&#xD; BODNAR MS, 2004, STEM
                    CELLS DEV, V13, P243&#xD; BRIMBLE SN, 2004, STEM CELLS DEV, V13, P585&#xD;
                    BRUSTLE O, 1999, SCIENCE, V285, P754&#xD; CHEN BP, 1994, BLOOD, V84, P2497&#xD;
                    CHEVILLE JC, 2000, AM J CLIN PATHOL, V113, P583&#xD; COOKE MJ, 2006, STEM CELLS
                    DEV, V15, P254&#xD; COWAN CA, 2004, NEW ENGL J MED, V350, P1353&#xD; DELPLANQUE
                    A, 2000, J CELL SCI, V113, P767&#xD; DRAPER JS, 2004, NAT BIOTECHNOL, V22,
                    P3&#xD; ERDO F, 2003, J CEREBR BLOOD F MET, V23, P780&#xD; GERTOW K, 2004, STEM
                    CELLS DEV, V13, P421&#xD; HERSZFELD D, 2006, NAT BIOTECHNOL, V24, P351&#xD;
                    ITSKOVITZELDOR J, 2000, MOL MED, V6, P88&#xD; KAWASAKI H, 2000, NEURON, V28,
                    P311&#xD; KELLER G, 2005, GENE DEV, V19, P1129&#xD; KELLER GM, 1995, CURR OPIN
                    CELL BIOL, V7, P862&#xD; KIM JH, 2002, NATURE, V418, P50&#xD; KLIMANSKAYA I,
                    2006, NATURE, V444, P481&#xD; KLUG MG, 1996, J CLIN INVEST, V98, P216&#xD;
                    LAFLAMME MA, 2005, AM J PATHOL, V167, P663&#xD; LAVOIR MC, 1998, REPROD FERT
                    DEVELOP, V10, P557&#xD; LEBIEN TW, 1990, LEUKEMIA, V4, P354&#xD; LI M, 1998,
                    CURR BIOL, V8, P971&#xD; MAITRA A, 2005, NAT GENET, V37, P1099&#xD; MARQUARDT H,
                    1981, J BIOL CHEM, V256, P6859&#xD; MASSAGUE J, 1985, J BIOL CHEM, V260,
                    P4551&#xD; MCCUNE JM, 1988, SCIENCE, V241, P1632&#xD; MCKAY R, 2000, NATURE,
                    V406, P361&#xD; MENARD C, 2005, LANCET, V366, P1005&#xD; NAKANO T, 1996,
                    SCIENCE, V272, P722&#xD; NAMIKAWA R, 1990, J EXP MED, V172, P1055&#xD; NISHIKAWA
                    S, 1998, DEVELOPMENT, V125, P1747&#xD; ODORICO JS, 2001, STEM CELLS, V19,
                    P193&#xD; PEAR WS, 1998, BLOOD, V92, P3780&#xD; PRZYBORSKI SA, 2005, STEM CELLS,
                    V23, P1242&#xD; REUBINOFF BE, 2000, NAT BIOTECHNOL, V18, P399&#xD; RICHARDS M,
                    2002, NAT BIOTECHNOL, V20, P933&#xD; RICHARDS M, 2003, STEM CELLS, V21,
                    P546&#xD; SCHULZE D, 2000, IMECHE CONF TRANS, V2000, P97&#xD; SHAMBLOTT MJ,
                    1998, P NATL ACAD SCI USA, V95, P13726&#xD; SHAMBLOTT MJ, 2001, P NATL ACAD SCI
                    USA, V98, P113&#xD; SHIH CC, 1999, BLOOD, V94, P1623&#xD; SHIH CC, 2000, BLOOD,
                    V95, P1957&#xD; SHIH CC, 2001, BLOOD, V98, P24&#xD; SMITH AG, 1987, DEV BIOL,
                    V121, P1&#xD; SPERGER JM, 2003, P NATL ACAD SCI USA, V100, P13350&#xD; STOJKOVIC
                    M, 2004, STEM CELLS, V22, P790&#xD; TERAOKA S, 1995, JPN J CANCER RES, V86,
                    P419&#xD; THOMSON JA, 1998, SCIENCE, V282, P1145&#xD; TUCH BE, 1984, DIABETES,
                    V33, P1180&#xD; VILLABLANCA JG, 1990, J EXP MED, V172, P325&#xD; WILES MV, 1991,
                    DEVELOPMENT, V111, P259&#xD; YAM PY, 2002, MOL THER, V5, P479</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000252031000003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>639</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">639</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1116</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shiina, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Briles, W. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goto, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hosomichi, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yanagiya, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shimizu, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Inoko, H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miller, M. M.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Mol Biol, Duarte, CA 91010 USA. Tokai Univ, Sch Med, Dept Mol Life
                    Sci, Div Basic Med Sci &amp; Mol Med, Kanagawa 2591100, Japan. No Illinois Univ,
                    Dept Biol Sci, De Kalb, IL 60115 USA.&#xD;Miller, MM, City Hope Natl Med Ctr,
                    Beckman Res Inst, Div Mol Biol, 1450 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;mamiller@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Extended gene map reveals
                        tripartite motif, C-type lectin, and Ig superfamily type genes within a
                        subregion of the chicken MHC-B affecting infectious disease</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">7162-7172</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">178</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">11</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">MAJOR HISTOCOMPATIBILITY
                        COMPLEX</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLASS-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RFP-Y</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPARATIVE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENOMICS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SEQUENCE-ANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANCIENT ORIGIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MAREKS-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CD1 GENES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">G-PROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">REGION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-1767</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246896300057</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">MHC haplotypes have a remarkable
                    influence on whether tumors form following infection of chickens with oncogenic
                    Marek&apos;s disease herpesvirus. Although resistance to tumor formation has
                    been mapped to a subregion of the chicken MHC-B region, the gene or genes
                    responsible have not been identified. A full gene map of the subregion has been
                    lacking. We have expanded the MHC-B region gene map beyond the 92-kb core
                    previously reported for another haplotype revealing the presence of 46 genes
                    within 242 kb in the Red Jungle Fowl haplotype. Even though MHC-B is structured
                    differently, many of the newly revealed genes are related to loci typical of the
                    MHC in other species. Other MHC-B loci are homologs of genes found within MHC
                    paralogous regions (regions thought to be derived from ancient duplications of a
                    primordial immune defense complex where genes have undergone differential
                    silencing over evolutionary time) on other chromosomes. Still others are similar
                    to genes that define the NK complex in mammals. Many of the newly mapped genes
                    display allelic variability and fall within the MHC-B subregion previously shown
                    to affect the formation of Marek&apos;s disease tumors and hence are candidates
                    for genes conferring resistance.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    173TV&#xD;Times Cited: 0&#xD;Cited Reference Count: 56</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246896300057 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>380</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">380</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1658</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shively, J. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Division of Immunology, Beckman
                    Research Institute of the City of Hope, Duarte, California 91010, USA.
                    jshively@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">18F labeling for immuno-PET:
                        where speed and contrast meet</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Nucl Med</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Nuclear
                        Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Nucl. Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Nucl Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">170-2</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">48</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Fluorine
                        Radioisotopes/chemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Half-Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunochemistry</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Immunoconjugates/
                        chemistry/diagnostic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Isotope Labeling</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Positron-Emission Tomography/
                        methods</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Radiopharmaceuticals/
                        chemistry/diagnostic use</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0161-5505 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17268009</style>
            </accession-num>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%"> PubMed 07/04</style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>371</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">371</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1114</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Shor, A. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Keschman, E. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, F. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Muro-Cacho, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Letson, G. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Trent, J. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Pledger, W. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst City Hope, Duarte, CA 91010 USA. Univ Texas, MD Anderson Canc Ctr, Dept
                    Sarcoma Med Oncol, Houston, TX 77030 USA. Univ Miami, Leonard M Miller Sch Med,
                    Miami, FL 33152 USA. Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ
                    08543 USA. Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL USA. Univ S
                    Florida, Coll Med, Gonzmart Lab, Sarcoma Program, Tampa, FL USA. Univ S Florida,
                    Coll Med, Mol Oncol Program, H Lee Moffit Canc Ctr &amp; Res Inst, Tampa, FL
                    USA.&#xD;Jove, R, City Hope Natl Med Ctr, Beckman Res Inst City Hope, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;Rjove@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Dasatinib inhibits migration and
                        invasion in diverse human sarcoma cell lines and induces apoptosis in bone
                        sarcoma cells dependent on Src kinase for survival</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2800-2808</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">67</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">FOCAL-ADHESION KINASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOUSE SKIN
                        CARCINOGENESIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LUNG-CANCER CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GROWTH-FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">YOUNG-ADULTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BMS-354825</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMATINIB</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADOLESCENTS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Mar</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0008-5472</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000245019100051</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Sarcomas are rare malignant
                    mesenchyrnal tumors for which there are limited treatment options. One potential
                    molecular target for sarcoma treatment is the Src tyrosine kinase. Dasatinib
                    (BMS-354825), a small-molecule inhibitor of Src kinase activity, is a promising
                    cancer therapeutic agent with p.o. bioavailability. Dasatinib exhibits antitumor
                    effects in cultured human cell lines derived from epithelial tumors, including
                    prostate and lung carcinomas. However, the action of dasatinib in mesenchymally
                    derived tumors has yet to be shown. Based on our previous findings of Src
                    activation in human sarcomas, we evaluated the effects of dasatinib in 12
                    cultured human sarcoma cell lines derived from bone and soft tissue sarcomas.
                    Dasatinib inhibited Src kinase activity at nanomolar concentrations in these
                    sarcoma cell lines. Downstream components of Src signaling, including focal
                    adhesion kinase and Crk-associated substrate (P130(CAS)), were also inhibited at
                    similar concentrations. This inhibition of Src signaling was accompanied by
                    blockade of cell migration and invasion. Moreover, apoptosis was induced in the
                    osteosarcoma and Ewing&apos;s subset of bone sarcomas at nanomolar
                    concentrations of dasatinib. Inhibition of Src protein expression by small
                    interfering RNA also induced apoptosis, indicating that these bone sarcoma cell
                    lines are dependent on Src activity for survival. These results show that
                    dasatinib inhibits migration and invasion of diverse sarcoma cell types and
                    selectively blocks the survival of bone sarcoma cells. Therefore, dasatinib may
                    provide therapeutic benefit by preventing the growth and metastasis of sarcomas
                    in patients.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Prostate/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    147RC&#xD;Times Cited: 0&#xD;Cited Reference Count: 47&#xD;Cited References:
                    &#xD; 2004, CANC BIOL THER, V3, P700&#xD; ALBRITTON KH, 2005, HEMATOL ONCOL CLIN
                    N, V19, P527&#xD; BAKER B, 1978, NATL CANC I MONOGR, V48, P219&#xD; BLEYER A,
                    2005, CANCER, V103, P1891&#xD; BLEYER WA, 1996, J REGISTRY MANAGEMEN, V23,
                    P114&#xD; BLEYER WA, 1997, J ADOLESCENT HEALTH, V21, P366&#xD; BOUTON AH, 2001,
                    ONCOGENE, V20, P6448&#xD; BOWMAN T, 2000, ONCOGENE, V19, P2474&#xD; BROWN MT,
                    1996, BBA-REV CANCER, V1287, P121&#xD; CANCE WG, 2000, CLIN CANCER RES, V6,
                    P2417&#xD; CHEN ZM, 2006, MOL PHARMACOL, V69, P1527&#xD; COPLAND M, 2006, BLOOD,
                    V107, P4532&#xD; DEFILIPPI P, 2006, TRENDS CELL BIOL, V16, P257&#xD; DOGGRELL
                    SA, 2005, EXPERT OPIN INV DRUG, V14, P89&#xD; ERIKSON RL, 1980, J CELL BIOL,
                    V87, P319&#xD; FRAME MC, 2002, BBA-REV CANCER, V1602, P114&#xD; GONDA TJ, 1982,
                    MOL CELL BIOL, V2, P617&#xD; HANKS SK, 2003, FRONT BIOSCI, V8, P982&#xD; HELMAN
                    LJ, 2003, NAT REV CANCER, V3, P685&#xD; HU SSF, 1978, J VIROL, V27, P667&#xD;
                    JERNAL A, 2004, CA CANC J CLIN, V54, P8&#xD; JOHNSON FM, 2005, CLIN CANCER RES
                    1, V11, P6924&#xD; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31&#xD; LARK AL, 2003,
                    CLIN CANCER RES, V9, P215&#xD; LOMBARDO LJ, 2004, J MED CHEM, V47, P6658&#xD;
                    MCCORMACK SJ, 1997, ONCOGENE, V15, P265&#xD; MCLEAN GW, 2001, CANCER RES, V61,
                    P8385&#xD; MCLEAN GW, 2004, GENE DEV, V18, P2998&#xD; MCLEAN GW, 2005, NAT REV
                    CANCER, V5, P505&#xD; NAM S, 2005, CANCER RES, V65, P9185&#xD; NEET K, 1996,
                    GENES CELLS, V1, P147&#xD; OHARE T, 2006, CURR OPIN GENET DEV, V16, P92&#xD;
                    PARSONS JT, 1997, CURR OPIN CELL BIOL, V9, P187&#xD; QUINTANILLA M, 1986,
                    NATURE, V322, P78&#xD; ROUS P, 1911, J EXP MED, V13, P397&#xD; SCHALLER MD,
                    2001, BBA-MOL CELL RES, V1540, P1&#xD; SCHITTENHELM MM, 2006, CANCER RES, V66,
                    P473&#xD; SHAH NP, 2005, HEMATOLOGY, V1, P183&#xD; SHAH NP, 2006, BLOOD, V108,
                    P286&#xD; SILVA CM, 2004, ONCOGENE, V48, P8017&#xD; SONG LX, 2006, CANCER RES,
                    V66, P5542&#xD; THOMAS SM, 1997, ANNU REV CELL DEV BI, V13, P513&#xD; TOKARSKI
                    JS, 2006, CANCER RES, V66, P5790&#xD; TREMBLAY L, 1996, INT J CANCER, V68,
                    P164&#xD; VARMUS H, 1989, PRINCESS TAKAMATSU S, V20, P63&#xD; YEATMAN TJ, 2004,
                    NAT REV CANCER, V4, P470&#xD; YU H, 2004, NAT REV CANCER, V4, P97</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000245019100051 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/04 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>447</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">447</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1112</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Siddiquee, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Guida, W. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Blaskovich, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Greedy, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lawrence, H. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yip, M. L. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">McLaughlin, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lawrence, N. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sebti, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Turkson, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Cent Florida, Biomol Sci Ctr,
                    Orlando, FL 32826 USA. Univ Cent Florida, Dept Mol Biol &amp; Microbiol,
                    Orlando, FL 32826 USA. Univ S Florida, Coll Med, Translat Res Lab, Tampa, FL
                    33612 USA. Univ S Florida, Coll Med, Drug Discovery Program, Tampa, FL 33612
                    USA. Univ S Florida, Coll Med, High Throughput Screening &amp; Chem Core Facil,
                    H Lee moffitt Canc Ctr, Tampa, FL 33612 USA. Univ S Florida, Coll Med, Res Inst,
                    Tampa, FL 33612 USA. Univ S Florida, Coll Med, Dept Interdisciplinary Oncol,
                    Tampa, FL 33612 USA. Univ S Florida, Coll Med, Dept Chem &amp; Mol Med, Tampa,
                    FL 33612 USA. City Hope Comphrens Ctr, Duarte, CA 91010 USA.&#xD;Turkson, J,
                    Univ Cent Florida, Biomol Sci Ctr, 12722 Res Pkwy, Orlando, FL 32826
                    USA.&#xD;jturkson@mail.ucf.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Selective chemical probe
                        inhibitor of Stat3, identified through structure-based virtual screening,
                        induces antitumor activity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">7391-7396</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">18</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-BINDING ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSTITUTIVE ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSCRIPTION FACTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNAL TRANSDUCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULAR TARGETS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACCURATE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOCKING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">APOPTOSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SRC</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246239400018</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">S31-201 (NSC 74859) is a chemical
                    probe inhibitor of Stat3 activity, which was identified from the National Cancer
                    Institute chemical libraries by using structure-based virtual screening with a
                    computer model of the Stat3 SH2 domain bound to its Stat3 phosphotyrosine
                    peptide derived from the x-ray crystal structure of the Stat3 beta homodimer.
                    S31-201 inhibits Stat3-Stat3 complex formation and Stat3 DNA-binding and
                    transcriptional activities. Furthermore, S31-201 inhibits growth and induces
                    apoptosis preferentially in tumor cells that contain persistently activated
                    Stat3. Constitutively climerized and active Stat3C and Stat3 SH2 domain rescue
                    tumor cells from S31-201-induced apoptosis. Finally, S31-201 inhibits the
                    expression of the Stat3-regulated genes encoding cyclin D1, BcI-xL, and survivin
                    and inhibits the growth of human breast tumors in vivo. These findings strongly
                    suggest that the antitumor activity of S31-201 is mediated in part through
                    inhibition of aberrant Stat3 activation and provide the proof-of-concept for the
                    potential clinical use of Stat3 inhibitors such as S31-201 in tumors harboring
                    aberrant Stat3.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    164MY&#xD;Times Cited: 0&#xD;Cited Reference Count: 35&#xD;Cited References:
                    &#xD; BECKER S, 1998, NATURE, V394, P145&#xD; BLASKOVICH MA, 2003, CANCER RES,
                    V63, P1270&#xD; BOWMAN T, 2000, ONCOGENE, V19, P2474&#xD; BROMBERG J, 2000,
                    BREAST CANCER RES, V2, P86&#xD; BROMBERG J, 2000, ONCOGENE, V19, P2468&#xD;
                    BROMBERG JF, 1999, CELL, V98, P295&#xD; CATLETTFALCONE R, 1999, IMMUNITY, V10,
                    P105&#xD; DARNELL JE, 2002, NAT REV CANCER, V2, P740&#xD; DARNELL JE, 2005, NAT
                    MED, V11, P595&#xD; FRIESNER RA, 2004, J MED CHEM, V47, P1739&#xD; GALBAUGH T,
                    2006, BMC CELL BIOL, V7&#xD; GARCIA R, 2001, ONCOGENE, V20, P2499&#xD; GOUILLEUX
                    F, 1995, ENDOCRINOLOGY, V136, P5700&#xD; HALGREN TA, 2004, J MED CHEM, V47,
                    P1750&#xD; JING N, 2003, DNA CELL BIOL, V22, P685&#xD; JOHNSON PJ, 1985, MOL
                    CELL BIOL, V5, P1073&#xD; KURIYAN J, 1997, ANNU REV BIOPH BIOM, V26, P259&#xD;
                    LEE TR, 2000, J MED CHEM, V43, P1173&#xD; MORA LB, 2002, CANCER RES, V62,
                    P6659&#xD; NAGELWOLFRUM K, 2004, MOL CANCER RES, V2, P170&#xD; SEIDEL HM, 1995,
                    P NATL ACAD SCI USA, V92, P3041&#xD; SHAO H, 2004, J BIOL CHEM, V279,
                    P18967&#xD; SHEINERMAN FB, 2003, J MOL BIOL, V334, P823&#xD; SHUAI K, 1994,
                    CELL, V76, P821&#xD; SONG H, 2005, P NATL ACAD SCI USA, V102, P4700&#xD; TURKSON
                    J, 1998, MOL CELL BIOL, V18, P2545&#xD; TURKSON J, 2000, ONCOGENE, V19,
                    P6613&#xD; TURKSON J, 2001, J BIOL CHEM, V276, P45443&#xD; TURKSON J, 2004, MOL
                    CANCER THER, V3, P1533&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P261&#xD;
                    TURKSON J, 2005, J BIOL CHEM, V280, P32979&#xD; WAGNER M, 1999, PANCREAS, V19,
                    P370&#xD; YU CL, 1995, SCIENCE, V269, P81&#xD; YU H, 2004, NAT REV CANCER, V4,
                    P97&#xD; ZHANG Y, 2000, J BIOL CHEM, V275, P24935</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246239400018 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/06/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>860</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">860</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1111</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Siddiquee, K. A. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gunning, P. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Glenn, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Katt, W. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zhang, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Schroeck, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sebti, S. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jove, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamilton, A. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Turkson, J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Cent Florida, Coll Med, Biomol
                    Sci Ctr, Orlando, FL 32826 USA. Univ Cent Florida, Dept Mol Biol &amp;
                    Microbiol, Orlando, FL 32826 USA. Yale Univ, Dept Chem, New Haven, CT 06520 USA.
                    Univ S Florida, Coll Med, Tampa, FL 33612 USA. Univ S Florida, Coll Med, H Lee
                    Moffitt Canc Ctr &amp; Res Inst, Drug Discovery Programs, Tampa, FL 33612 USA.
                    Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.
                    Univ S Florida, Coll Med, Dept Biochem &amp; Mol Biol, Tampa, FL 33612 USA. City
                    Hope Comprehens Canc Ctr, Dev Canc Therapeut Program, Duarte, CA 91010 USA.
                    Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA.&#xD;Turkson, J, Univ Cent
                    Florida, Coll Med, Biomol Sci Ctr, Orlando, FL 32826
                    USA.&#xD;jturkson@mail.ucf.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An oxazole-based small-molecule
                        Stat3 inhibitor modulates Stat3 stability and processing and induces
                        antitumor cell effects</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Acs Chemical Biology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">ACS Chemical Biology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">ACS Chem. Biol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">ACS Chem Biol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">787-798</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">2</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">UBIQUITIN-PROTEASOME
                        SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN PANCREATIC-CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BREAST-CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-BINDING ACTIVITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CONSTITUTIVE ACTIVATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SIGNAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSDUCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENE-REGULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">AGGRESOME FORMATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SRC ONCOPROTEIN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRUG</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISCOVERY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1554-8929</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251905100014</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Stat3 is hyperactivated in many
                    human tumors and represents a valid target for anticancer drug design. We
                    present a novel small-molecule Stat3 inhibitor, S3I-N12001, and describe the
                    dynamics of intracellular processing of activated Stat3 within the context of
                    the biochemical and biological effects of the Stat3 inhibitor. S3I-M2001 is an
                    oxazole-based peptidomimetic of the Stat3 Src homology (SH) 2 domain-binding
                    phosphotyrosine peptide that selectively disrupts active Stat3:Stat3 dimers.
                    Consequently, hyperactivated Stat3, which hitherto occurs as
                    &apos;&apos;dotlike&apos;&apos; structures of nuclear bodies, undergoes an early
                    aggregation into nonfunctional perinuclear aggresomes and a late-phase
                    proteasome-mediated degradation in malignant cells treated with S3I-M2001. Thus,
                    S3I-M2001 inhibited Stat3-dependent transcriptional regulation of tumor survival
                    genes, such as Bcl-xL. Furthermore, Stat3-dependent malignant transformation,
                    survival, and migration and invasion of mouse and human cancer cells harboring
                    persistently activated Stat3 were inhibited by S3I-M2001. Finally, S3I-M2001
                    inhibited growth of human breast tumor xenografts. The study identifies a novel
                    Stat3 inhibitor, S3I-M2001, with antitumor cell effects mediated in part through
                    a biphasic loss of functional Stat3. The study represents the first on
                    intracellular Stat3 stability and processing following inhibition by a small
                    molecule that has significant antitumor activity.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Breast/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    244ZX&#xD;Times Cited: 0&#xD;Cited Reference Count: 41&#xD;Cited References:
                    &#xD; BECKER S, 1998, NATURE, V394, P145&#xD; BENCE NF, 2001, SCIENCE, V292,
                    P1552&#xD; BENNETT EJ, 2005, MOL CELL, V17, P351&#xD; BOWMAN T, 2000, ONCOGENE,
                    V19, P2474&#xD; BROMBERG JF, 1998, MOL CELL BIOL, V18, P2553&#xD; BUETTNER R,
                    2002, CLIN CANCER RES, V8, P945&#xD; CATLETTFALCONE R, 1999, IMMUNITY, V10,
                    P105&#xD; CIECHANOVER A, 2000, BIOESSAYS, V22, P442&#xD; DARNELL JE, 1996,
                    RECENT PROG HORM RES, V51, P391&#xD; DARNELL JE, 1997, SCIENCE, V277, P1630&#xD;
                    DARNELL JE, 2005, NAT MED, V11, P595&#xD; GARCIA R, 1997, CELL GROWTH DIFFER,
                    V8, P1267&#xD; GARCIA R, 2001, ONCOGENE, V20, P2499&#xD; GARCIAMATA R, 1999, J
                    CELL BIOL, V146, P1239&#xD; GELMAN MS, 2002, J BIOL CHEM, V277, P11709&#xD;
                    HAURA EB, 2005, NAT CLIN PRACT ONCOL, V2, P315&#xD; HERRMANN A, 2004, J CELL
                    SCI, V117, P339&#xD; HUANG C, 2006, CANCER SCI, V97, P1417&#xD; JING N, 2003,
                    DNA CELL BIOL, V22, P685&#xD; JOHNSTON JA, 1998, J CELL BIOL, V143, P1883&#xD;
                    JONES G, 1997, J MOL BIOL, V267, P727&#xD; LEE TR, 2000, J MED CHEM, V43,
                    P1173&#xD; NAGELWOLFRUM K, 2004, MOL CANCER RES, V2, P170&#xD; NAM S, 2005, P
                    NATL ACAD SCI USA, V102, P5998&#xD; SCHOLZ A, 2003, GASTROENTEROLOGY, V125,
                    P891&#xD; SHUAI K, 1994, CELL, V76, P821&#xD; SIDDIQUEE K, 2007, P NATL ACAD SCI
                    USA, V104, P7391&#xD; SONG H, 2005, P NATL ACAD SCI USA, V102, P4700&#xD;
                    SZEBENYI G, 2007, BMC CELL BIOL, V8&#xD; TURKSON J, 1998, MOL CELL BIOL, V18,
                    P2545&#xD; TURKSON J, 1999, MOL CELL BIOL, V19, P7519&#xD; TURKSON J, 2000,
                    ONCOGENE, V19, P6613&#xD; TURKSON J, 2001, J BIOL CHEM, V276, P45443&#xD;
                    TURKSON J, 2004, EXPERT OPIN THER TAR, V8, P409&#xD; TURKSON J, 2004, MOL CANCER
                    THER, V3, P1533&#xD; TURKSON J, 2004, MOL CANCER THER, V3, P261&#xD; TURKSON J,
                    2005, J BIOL CHEM, V280, P32979&#xD; WIPF P, 1993, J ORG CHEM, V58, P3604&#xD;
                    YU CL, 1995, SCIENCE, V269, P81&#xD; YU H, 2004, NAT REV CANCER, V4, P97&#xD;
                    ZHANG BL, 2001, ORG LETT, V3, P275</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251905100014 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/02/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>234</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">234</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1110</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Singh, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Camazine, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jadhav, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gupta, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mukhopadhyay, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Khan, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Reddy, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zheng, Q.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, D. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Khodel, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhatt, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Bhat, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yaqub, Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shah, R. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharma, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sikkal, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Erickson, R. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Cent Texas Vet Hlth Care Syst, Div
                    Gastroenterol, Temple, TX 76504 USA. Cent Texas Vet Hlth Care Syst, Dept Radiol,
                    Temple, TX 76504 USA. Cent Texas Vet Hlth Care Syst, Dept Internal Med, Temple,
                    TX 76504 USA. Cent Texas Vet Hlth Care Syst, Div Pulm &amp; Crit Care, Temple,
                    TX 76504 USA. Cent Texas Vet Hlth Care Syst, Div Oncol, Temple, TX 76504 USA.
                    Henderson Mem Hosp, Dept Surg, Henderson, TX USA. Texas A&amp;M Univ, Sch Rural
                    &amp; Publ Hlth, Dept Epidemiol &amp; Biostat, College Stn, TX USA. City Hope
                    Natl Med Ctr, Dept Biostat, Duarte, CA 91010 USA. VA Boston Healthcare Syst, Div
                    Gastroenterol, Boston, MA USA. Scott &amp; White Mem Hosp &amp; Clin, Div
                    Gastroenterol &amp; Hepatol, Temple, TX 76508 USA.&#xD;Singh, P, Cent Texas Vet
                    Hlth Care Syst, Div Gastroenterol, 1901 S 1st St, Temple, TX 76504
                    USA.&#xD;pankaj1110@hotmail.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Endoscopic ultrasound as a first
                        test for diagnosis and staging of lung cancer - A prospective study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">American Journal of Respiratory
                        and Critical Care Medicine</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">American Journal of Respiratory
                        and Critical Care Medicine</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Am. J. Respir. Crit. Care
                        Med.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Am J Respir Crit Care
                        Med</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">345-354</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">175</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">lung cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">non-small cell lung
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">celiac lymph nodes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">endoscopic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ultrasound-guided fine needle
                        aspiration</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">survival</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >POSITRON-EMISSION-TOMOGRAPHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FINE-NEEDLE-ASPIRATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MEDIASTINAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPH-NODE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EUS-GUIDED FNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SQUAMOUS-CELL CARCINOMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LEFT</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADRENAL-GLAND</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPUTED-TOMOGRAPHY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESOPHAGEAL CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FDG PET</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NONDIAGNOSTIC
                        BRONCHOSCOPY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1073-449X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244263600010</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Rationale: Multiple tests are
                    required for the management of lung cancer. Objectives: Endoscopic
                    ultrasound-guided fine needle aspiration (EUS-FNA) was evaluated as a single
                    test for the diagnosis and staging (thoracic and extrathoracic) of lung cancer.
                    Methods: Consecutive subjects with computed tomography (CT) findings of a lung
                    mass were enrolled for EUS and results were compared with those from CT and
                    positron emission tomography scans. Results: Of 113 subjects with lung cancer,
                    EUS was performed as a first test (after CT scan) for diagnosis in 93 (82%) of
                    them. EUS-FNA established tissue diagnosis in 70% of cases. EUS-FNA, CT, and
                    positron emission tomography detected metastases to the mediastinal lymph nodes
                    with accuracies of 93, 81, and 83%, respectively. EUS-FNA was significantly
                    better than CT at detecting distant metastases (accuracies of 97 and 89%,
                    respectively; p = 0.02). Metastases to lymph nodes at the celiac axis (CLNs)
                    were observed in 11% of cases. The diagnostic yields of EUS-FNA and CT for
                    detection of metastases to the CLNs were 100 and 50%, respectively (p &lt;
                    0.05). EUS was able to detect small metastases (less than 1 cm) often missed by
                    CT. Metastasis to the CLNs was a predictor of poor survival of subjects with
                    non-small cell lung cancer, irrespective of the size of the CLNs. Of 44 cases
                    with resectable tumor on CT scan, EUS-FNA avoided thoracotomy in 14% of cases.
                    Conclusions: EUS-FNA as a first test (after CT) has high diagnostic yield and
                    accuracy for detecting lung cancer metastases to the mediastinum and distant
                    sites. Metastasis to the CLNs is associated with poor prognosis. EUS-FNA is able
                    to detect occult metastasis to the CLNs and thus avoids thoracotomy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    136ZW&#xD;Times Cited: 1&#xD;Cited Reference Count: 61&#xD;Cited References:
                    &#xD; ANNEMA JT, 2005, JAMA-J AM MED ASSOC, V294, P931&#xD; ANNEMA JT, 2005,
                    LUNG CANCER-J IASLC, V48, P357&#xD; ANTOCH G, 2003, RADIOLOGY, V229, P526&#xD;
                    ARROLIGA AC, 1993, CLIN CHEST MED, V14, P87&#xD; BLOCK MI, 1997, ANN THORAC
                    SURG, V64, P770&#xD; CHANG KJ, 1996, GASTROINTEST ENDOSC, V44, P568&#xD; CHOI
                    JY, 2000, J NUCL MED, V41, P808&#xD; COUGHLIN M, 1985, ANN THORAC SURG, V40,
                    P556&#xD; DUNAGAN DP, 2001, CHEST, V119, P333&#xD; DWAMENA BA, 1999, RADIOLOGY,
                    V213, P530&#xD; ELOUBEIDI MA, 2004, GASTROINTEST ENDOSC, V59, P627&#xD;
                    ELOUBEIDI MA, 2005, ANN THORAC SURG, V79, P263&#xD; ELOUBEIDI MA, 2005, ANN
                    THORAC SURG, V80, P1231&#xD; ERASMUS JJ, 1997, AM J ROENTGENOL, V168, P1357&#xD;
                    FERNANDEZESPARRACH G, 2006, LUNG CANCER, V54, P35&#xD; FRITSCHERRAVENS A, 1999,
                    RESPIRATION, V66, P150&#xD; FRITSCHERRAVENS A, 2003, AM J RESP CRIT CARE, V168,
                    P1293&#xD; FRITSCHERRAVENS A, 2003, CHEST, V123, P442&#xD; GIOVANNINI M, 1999,
                    ENDOSCOPY, V31, P536&#xD; GREENE FL, 2002, AJCC CANC STAGING MA&#xD; GRESS FG,
                    1997, ANN INTERN MED 1, V127, P604&#xD; GUPTA NC, 2000, CHEST, V117, P773&#xD;
                    GUPTA NC, 2001, CHEST, V120, P521&#xD; HABERKORN U, 2001, LUNG CANCER-J IAS S3,
                    V34, S13&#xD; HERTH FJF, 2005, AM J RESP CRIT CARE, V171, P1164&#xD; IKEJOE J,
                    1990, J COMPUT ASSIST TOMO, V14, P340&#xD; KAZEROONI EA, 1996, RADIOLOGY, V198,
                    P371&#xD; KRAMER H, 2003, ANN SURG, V238, P180&#xD; KRAMER H, 2004, THORAX, V59,
                    P596&#xD; LANDIS SH, 1998, CA-CANCER J CLIN, V48, P6&#xD; LEBLANC JK, 2005, AM J
                    RESP CRIT CARE, V171, P177&#xD; LEWIS JW, 1990, ANN THORAC SURG, V49, P591&#xD;
                    LUKETICH JD, 1997, ANN THORAC SURG, V64, P765&#xD; LUKETICH JD, 1997, J THORAC
                    CARDIOV SUR, V114, P817&#xD; MAROM EM, 1999, RADIOLOGY, V212, P803&#xD; MAUREA
                    S, 1999, AM J ROENTGENOL, V173, P25&#xD; MOUNTAIN CF, 1997, CHEST, V111,
                    P1710&#xD; NEDINA JF, 1992, AM REV RESPIR DIS, V146, P1210&#xD; NGUYEN P, 1999,
                    GASTROINTEST ENDOSC, V50, P357&#xD; PANNELI F, 2001, AM J GASTROENTEROL, V96,
                    P401&#xD; PARMAR KS, 2002, ANN THORAC SURG, V73, P916&#xD; PRASAD P, 2004,
                    GASTROINTEST ENDOSC, V59, P49&#xD; PRENZEL KL, 2003, CHEST, V123, P463&#xD;
                    REDDY RM, 2005, J CLIN ONCOL, V23&#xD; REED CE, 1999, ANN THORAC SURG, V67,
                    P319&#xD; ROBERTS PF, 2000, ANN THORAC SURG, V70, P1154&#xD; SAVIDES TJ, 2004,
                    GASTROINTEST ENDOSC, V60, P340&#xD; SAWHNEY MS, 2006, CLIN GASTROENTEROL H, V4,
                    P846&#xD; SAWHNEY MS, 2006, GASTROINTEST ENDOSC, V63, P959&#xD; SCHAWARTZ DA,
                    2002, GASTROINTEST ENDOSC, V56, P868&#xD; SINGH P, 2005, GASTROINTEST ENDOSC,
                    V61, AB301&#xD; SINGH P, 2005, J CLIN ONCOL, V23&#xD; SINGH P, 2006, ENDOSCOPY,
                    V38&#xD; SINGH P, 2006, GASTROINTEST ENDOSC, V63, AB255&#xD; TENBERGE J, 2002,
                    GASTROINTEST ENDOSC, V55, P859&#xD; TOLOZA EM, 2003, CHEST S, V123, S137&#xD;
                    VILMANN P, 2005, ENDOSCOPY, V37, P833&#xD; VONHAAG DW, 2002, J SURG RES, V103,
                    P160&#xD; WALLACE MB, 2001, ANN THORAC SURG, V72, P1861&#xD; WALLACE MB, 2004,
                    ANN THORAC SURG, V77, P1763&#xD; YOON YC, 2003, RADIOLOGY, V227, P764</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244263600010 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>284</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">284</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1108</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Singh, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Zheng, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chavez, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qiu, J. Z.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shen, B. H.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Radiat
                    Biol, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Shen,
                    BH, City Hope Natl Med Ctr, Dept Radiat Biol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;bshen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Concerted action of exonuclease
                        and gap-dependent endonuclease activities of FEN-1 contributes to the
                        resolution of triplet repeat sequences (CTG)(n)- and (GAA)(n)-derived
                        secondary structures formed during maturation of Okazaki fragments</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Biological
                        Chemistry</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Biol. Chem.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Biol Chem</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3465-3477</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">282</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN FLAP
                        ENDONUCLEASE-1</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SACCHAROMYCES-CEREVISIAE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FRIEDREICHS-ATAXIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRINUCLEOTIDE REPEATS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VITRO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MISMATCH REPAIR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-SEQUENCES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STICKY DNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPANSION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0021-9258</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244481900009</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">There is much evidence to indicate
                    that FEN-1 efficiently cleaves single-stranded DNA flaps but is unable to
                    process double-stranded flaps or flaps adopting secondary structures. However,
                    the absence of Fen1 in yeast results in a significant increase in trinucleotide
                    repeat (TNR) expansion. There are then two possibilities. One is that TNRs do
                    not always form stable secondary structures or that FEN-1 has an alternative
                    approach to resolve the secondary structures. In the present study, we test the
                    hypothesis that concerted action of exonuclease and gap-dependent endonuclease
                    activities of FEN-1 play a role in the resolution of secondary structures formed
                    by (CTG)(n) and (GAA)(n) repeats. Employing a yeast FEN-1 mutant, E176A, which
                    is deficient in exonuclease (EXO) and gap endonuclease (GEN) activities but
                    retains almost all of its flap endonuclease (FEN) activity, we show severe
                    defects in the cleavage of various TNR intermediate substrates. Precise knock-in
                    of this point mutation causes an increase in both the expansion and fragility of
                    a (CTG), tract in vivo. Taken together, our biochemical and genetic analyses
                    suggest that although FEN activity is important for single-stranded flap
                    processing, EXO and GEN activities may contribute to the resolution of
                    structured flaps. A model is presented to explain how the concerted action of
                    EXO and GEN activities may contribute to resolving structured flaps, thereby
                    preventing their expansion in the genome.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    140CW&#xD;Times Cited: 0&#xD;Cited Reference Count: 54&#xD;Cited References:
                    &#xD; BAMBARA RA, 1997, J BIOL CHEM, V272, P4647&#xD; BIDICHANDANI SI, 1998, AM
                    J HUM GENET, V62, P111&#xD; CALLAHAN JL, 2003, MOL CELL BIOL, V23, P7849&#xD;
                    CAMPUZANO V, 1996, SCIENCE, V271, P1423&#xD; CHEN XA, 1995, P NATL ACAD SCI USA,
                    V92, P5199&#xD; CLEARY JD, 2003, CYTOGENET GENOME RES, V100, P25&#xD; FRANK G,
                    2001, J BIOL CHEM, V276, P36295&#xD; FREUDENREICH CH, 1997, MOL CELL BIOL, V17,
                    P2090&#xD; FREUDENREICH CH, 1998, SCIENCE, V279, P853&#xD; GACY AM, 1995, CELL,
                    V81, P533&#xD; GACY AM, 1998, MOL CELL, V1, P583&#xD; GATCHEL JR, 2005, NAT REV
                    GENET, V6, P743&#xD; GORDENIN DA, 1997, NAT GENET, V16, P116&#xD; HARRINGTON JJ,
                    1994, EMBO J, V13, P1235&#xD; HEIDENFELDER BL, 2003, J BIOL CHEM, V278,
                    P2425&#xD; HENRICKSEN LA, 2000, J BIOL CHEM, V275, P16420&#xD; JOHNSON RE, 1995,
                    SCIENCE, V269, P238&#xD; KAO HI, 2002, J BIOL CHEM, V277, P14379&#xD; KAO HI,
                    2004, J BIOL CHEM, V279, P15014&#xD; KOKOSKA RJ, 1998, MOL CELL BIOL, V18,
                    P2779&#xD; KRASILNIKOVA MM, 2004, MOL CELL BIOL, V24, P2286&#xD; LEA DE, 1949, J
                    GENET, V49, P264&#xD; LIU R, 2006, NUCLEIC ACIDS RES, V34, P1772&#xD; LIU Y,
                    2003, J BIOL CHEM, V278, P13728&#xD; LIU Y, 2004, MOL CELL BIOL, V24, P4049&#xD;
                    MARIAPPAN SVS, 1999, J MOL BIOL, V285, P2035&#xD; MARSISCHKY GT, 1996, GENE DEV,
                    V10, P407&#xD; MCMURRAY CT, 1999, P NATL ACAD SCI USA, V96, P1823&#xD; MIRET JJ,
                    1997, MOL CELL BIOL, V17, P3382&#xD; MIRET JJ, 1998, P NATL ACAD SCI USA, V95,
                    P12438&#xD; MOORE H, 1999, P NATL ACAD SCI USA, V96, P1504&#xD; MURANTE RS,
                    1995, J BIOL CHEM, V270, P30377&#xD; NEGRITTO MC, 2001, MOL CELL BIOL, V21,
                    P2349&#xD; PARRISH JZ, 2003, EMBO J, V22, P3451&#xD; POLLARD LM, 2004, NUCLEIC
                    ACIDS RES, V332, P5962&#xD; REAGAN MS, 1995, J BACTERIOL, V177, P364&#xD;
                    RICHARD GF, 2000, EMBO J, V19, P2381&#xD; RUGGIERO BL, 2004, J BIOL CHEM, V279,
                    P23088&#xD; SAKAMOTO N, 1999, MOL CELL, V3, P465&#xD; SCHERER S, 1979, P NATL
                    ACAD SCI USA, V76, P4951&#xD; SCHWEITZER JK, 1998, HUM MOL GENET, V7, P69&#xD;
                    SCHWEITZER JK, 1999, GENETICS, V152, P953&#xD; SHARMA R, 2002, HUM MOL GENET,
                    V11, P2175&#xD; SHEN BH, 1996, J BIOL CHEM, V271, P9173&#xD; SHEN BH, 2005,
                    BIOESSAYS, V27, P717&#xD; SPIRO C, 1999, MOL CELL, V4, P1079&#xD; SUBRAMANIAN J,
                    2005, GENETICS, V171, P427&#xD; TISHKOFF DX, 1997, CELL, V88, P253&#xD; TOM S,
                    2000, J BIOL CHEM, V275, P10498&#xD; TOTH G, 2000, GENOME RES, V10, P967&#xD;
                    VETCHER AA, 2004, J BIOL CHEM, V279, P6434&#xD; WACH A, 1994, YEAST, V10,
                    P1793&#xD; WELLS RD, 1998, J BIOL CHEM, V273, P19532&#xD; ZHENG L, 2005, EMBO
                    REP, V6, P83</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244481900009 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/03 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>571</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">571</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1655</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Slatkin, N. E.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Supportive Care, Pain
                    and Palliative Medicine, City of Hope National Medical Center, 1500 E. Duarte
                    Road, Duarte, CA 91010, USA. nslatkin@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Cannabinoids in the treatment of
                        chemotherapy-induced nausea and vomiting: beyond prevention of acute
                        emesis</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Support Oncol</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">1-9</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">5</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5 Suppl 3</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Acute Disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antiemetics/adverse
                        effects/pharmacology/therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Antineoplastic Agents/ adverse
                        effects</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cannabinoids/adverse
                        effects/pharmacology/ therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Nausea/ chemically
                        induced/physiopathology/ prevention &amp; control</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/drug therapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Quality of Life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Serotonin,
                        5-HT3/antagonists &amp; inhibitors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Vomiting/ chemically
                        induced/physiopathology/ prevention &amp; control</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1544-6794 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17566383</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Chemotherapy-induced nausea and
                    vomiting (CINV) remains a significant problem in the care of cancer patients.
                    Although the use of serotonin (5-HT3) receptor antagonists, as well as
                    neurokinin-1 inhibitors, has reduced rates of acute emesis, many patients still
                    experience acute vomiting; moreover, these agents have reduced efficacy in
                    preventing nausea, delayed CINV, and breakthrough CINV. Nausea, in particular,
                    continues to have a major--and often overlooked--impact on patients&apos;
                    quality of life. Optimizing the treatment for CINV likely will involve
                    combinations of agents that inhibit the numerous neurotransmitter systems
                    involved in nausea and vomiting reflexes. Cannabinoids are active in many of
                    these systems, and two oral formulations, dronabinol (Marinol) and nabilone
                    (Cesamet), are approved by the US Food and Drug Administration for use in CINV
                    refractory to conventional antiemetic therapy. Agents in this class have shown
                    superiority to dopamine receptor antagonists in preventing CINV, and there is
                    some evidence that the combination of a dopamine antagonist and cannabinoid is
                    superior to either alone and is particularly effective in preventing nausea. The
                    presence of side effects from the cannabinoids may have slowed their adoption
                    into clinical practice, but in a number of comparative clinical trials, patients
                    have expressed a clear preference for the cannabinoid, choosing its efficacy
                    over any undesired effects. Improvement in antiemetic therapy across the entire
                    spectrum of CINV will involve the use of agents with different mechanisms of
                    action in concurrent or sequential combinations, and the best such combinations
                    should be identified. In this effort, the utility of the cannabinoids should not
                    be overlooked.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/08/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>727</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">727</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1654</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Slatkin, N. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Xie, F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Messina, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Segal, T. J.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Department of Supportive Care, Pain
                    and Palliative Medicine, City of Hope National Medical Center, Duarte,
                    California 91010, USA. nslatkin@gmail.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Fentanyl buccal tablet for
                        relief of breakthrough pain in opioid-tolerant patients with cancer-related
                        chronic pain</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">J Support Oncol</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">327-34</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">5</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">7</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Administration, Buccal</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Analgesics,
                        Opioid/administration &amp; dosage/ therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Chronic Disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Drug Tolerance</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Female</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Fentanyl/administration &amp;
                        dosage/ therapeutic use</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Male</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Middle Aged</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neoplasms/
                        complications/physiopathology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pain/ drug
                        therapy/etiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Pain Measurement</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Treatment Failure</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jul-Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1544-6794 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17708123</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Fentanyl buccal tablet (FBT) is a
                    new opioid formulation providing rapid-onset analgesia for the treatment of
                    breakthrough pain (BTP). This study evaluated FBT for BTP in opioid-tolerant
                    patients with chronic cancer pain. The study had a randomized, double-blind,
                    placebo-controlled design and was conducted at 30 outpatient treatment centers
                    in the United States. Following open-label titration, patients were randomly
                    assigned to 1 of 18 double-blind dose sequences (7 FBT tablets, 3 placebo) to
                    treat 10 BTP episodes. Pain intensity was measured on an 11-point scale (0 = no
                    pain; 10 = worst pain). The primary efficacy measure was the sum of pain
                    intensity differences (PIDs) for the first 60 minutes (SPID60); secondary
                    efficacy measures included PIDs and pain relief (PR) measured from 5 minutes
                    through 2 hours. Adverse events (AEs) were recorded. Of 129 patients enrolled,
                    87 entered the double-blind phase. SPID60 significantly favored FBT versus
                    placebo (mean +/- SE, 9.7 +/- 0.63 vs 4.9 +/- 0.50; P &lt; 0.0001). Secondary
                    measures also favored FBT: PIDs and PR showed significant differences versus
                    placebo at 10 minutes (0.9 vs 0.5; 0.815 vs 0.606, respectively, P &lt; 0.0001)
                    and all subsequent time points (P &lt; 0.0001). AEs were typical of opioids (eg,
                    nausea, dizziness, fatigue). In conclusion, in this study of opioid-tolerant
                    patients with chronic cancer pain and BTP, FBT was efficacious, well tolerated,
                    demonstrated rapid onset of analgesia (within 10 minutes), and had a sustained
                    effect.</style>
            </abstract>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/10/ </style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>829</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">829</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">948</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Soifer, H. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rossi, J. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Saetrom, P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Beckman Res Inst City Hope, Div Mol
                    Biol, Duarte, CA 91010 USA. Interagon AS, Trondheim, Norway. Norwegian Univ Sci
                    &amp; Technol, Dept Canc Res &amp; Mol Med, Trondheim, Norway.&#xD;Rossi, JJ,
                    Beckman Res Inst City Hope, Div Mol Biol, 1450 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;jrossi@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">MicroRNAs in disease and
                        potential therapeutic applications</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Molecular Therapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Mol. Ther.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Mol Ther</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2070-2079</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">15</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA-POLYMERASE-II</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SARCOMA-ASSOCIATED
                        HERPESVIRUS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SMALL INTERFERING</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DOUBLE-STRANDED-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SHORT HAIRPIN RNAS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUSCLE-SPECIFIC MICRORNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">X MENTAL-RETARDATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MESSENGER-RNA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IN-VIVO</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MICROPROCESSOR COMPLEX</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Dec</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1525-0016</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000251266800005</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">MicroRNAs (miRNAs) are 21-24
                    nucleotide (nt) duplex RNAs that are created from precursor transcripts by
                    subsequent processing steps mediated by members of the RNAseIII family, Drosha
                    and Dicer. One of the two strands is incorporated into the active sites of the
                    Argonaute family of proteins, where it serves as a guide for Watson-Crick base
                    pairing with complementary sequences in target messenger RNAs (mRNAs). In
                    mammals, the majority of miRNAs guide the RNA-induced silencing complex (RISC)
                    to the 3&apos; untranslated regions (UTRs) of mRNA targets, with the consequence
                    that translation of the target mRNAs is inhibited. The importance of miRNAs in
                    normal cellular development and metabolism is only now being realized. miRNA
                    deficiencies or excesses have been correlated with a number of clinically
                    important diseases ranging from myocardial infarction to cancers. The loss or
                    gain of miRNA function can be caused by a single point mutation in either the
                    miRNA or its target or by epigenetic silencing of primary miRNA transcription
                    units. This review summarizes miRNA biogenesis and biology, explores the
                    potential roles miRNAs can play in a variety of diseases, and suggests some
                    therapeutic applications for restoring or inhibiting miRNA function.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    235XE&#xD;Times Cited: 0&#xD;Cited Reference Count: 161&#xD;Cited References:
                    &#xD; AAGAARD L, 2007, MOL THER, V15, P938&#xD; ABELSON JF, 2005, SCIENCE, V310,
                    P317&#xD; ALTUVIA Y, 2005, NUCLEIC ACIDS RES, V33, P2697&#xD; BAGGA S, 2005,
                    CELL, V122, P553&#xD; BASKERVILLE S, 2005, RNA, V11, P241&#xD; BENNASSER Y,
                    2006, METH MOL B, V342, P241&#xD; BENNASSER Y, 2006, RETROVIROLOGY, V3&#xD;
                    BITKO V, 2005, NAT MED, V11, P50&#xD; BODEN D, 2004, NUCLEIC ACIDS RES, V32,
                    P1154&#xD; BOHNSACK MT, 2004, RNA, V10, P185&#xD; BORCHERT GM, 2006, NAT STRUCT
                    MOL BIOL, V13, P1097&#xD; BRENNECKE J, 2005, PLOS BIOL, V3, P404&#xD;
                    BRUMMELKAMP TR, 2002, CANCER CELL, V2, P243&#xD; CAI XZ, 2005, P NATL ACAD SCI
                    USA, V102, P5570&#xD; CAI XZ, 2006, J VIROL, V80, P2234&#xD; CALIN GA, 2004, P
                    NATL ACAD SCI USA, V101, P11755&#xD; CALIN GA, 2006, NAT REV CANCER, V6,
                    P857&#xD; CARE A, 2007, NAT MED, V13, P613&#xD; CASTANOTTO D, 2007, NUCL ACIDS
                    RES&#xD; CAUDY AA, 2002, GENE DEV, V16, P2491&#xD; CHAN JA, 2005, CANCER RES,
                    V65, P6029&#xD; CHEN CF, 2005, NUCLEIC ACIDS RES, V33&#xD; CHEN CZ, 2004,
                    SCIENCE, V303, P83&#xD; CHENDRIMADA TP, 2005, NATURE, V436, P740&#xD; CHIOSEA S,
                    2006, AM J PATHOL, V169, P1812&#xD; CHIOSEA S, 2007, CANCER RES, V67, P2345&#xD;
                    CHU TC, 2006, NUCLEIC ACIDS RES, V34&#xD; CHUNG KH, 2006, NUCLEIC ACIDS RES,
                    V34&#xD; CIMMINO A, 2005, P NATL ACAD SCI USA, V102, P13944&#xD; CLOP A, 2006,
                    NAT GENET, V38, P813&#xD; COSTINEAN S, 2006, P NATL ACAD SCI USA, V103,
                    P7024&#xD; CUMMINS JM, 2006, P NATL ACAD SCI USA, V103, P3687&#xD; DAVIS S,
                    2006, NUCLEIC ACIDS RES, V34, P2294&#xD; DENLI AM, 2004, NATURE, V432, P231&#xD;
                    DIDIANO D, 2006, NAT STRUCT MOL BIOL, V13, P849&#xD; DOENCH JG, 2003, GENE DEV,
                    V17, P438&#xD; DOENCH JG, 2004, GENE DEV, V18, P504&#xD; DUAN RH, 2007, HUM MOL
                    GENET, V16, P1124&#xD; DUNN W, 2005, CELL MICROBIOL, V7, P1684&#xD; DYKXHOORN
                    DM, 2006, ANNU REV BIOMED ENG, V8, P337&#xD; ESAU C, 2006, CELL METAB, V3,
                    P87&#xD; ESQUELAKERSCHER A, 2006, NAT REV CANCER, V6, P259&#xD; FALLER M, 2007,
                    NAT STRUCT MOL BIOL, V14, P23&#xD; FIRE A, 1998, NATURE, V391, P806&#xD;
                    FORSTEMANN K, 2005, PLOS BIOL, V3, P1187&#xD; GAIDATZIS D, 2007, BMC
                    BIOINFORMATICS, V8&#xD; GREGORY RI, 2004, NATURE, V432, P235&#xD; GREGORY RI,
                    2005, CELL, V123, P631&#xD; GREGORY RI, 2006, METH MOL B, V342, P33&#xD; GRIMM
                    D, 2006, NATURE, V441, P537&#xD; GRIMSON A, 2007, MOL CELL, V27, P91&#xD; HAASE
                    AD, 2005, EMBO REP, V6, P961&#xD; HALEY B, 2004, NAT STRUCT MOL BIOL, V11,
                    P599&#xD; HAN JJ, 2004, GENE DEV, V18, P3016&#xD; HAN JJ, 2006, CELL, V125,
                    P887&#xD; HANNON GJ, 2004, NATURE, V431, P371&#xD; HAYASHITA Y, 2005, CANCER
                    RES, V65, P9628&#xD; HE HL, 2005, P NATL ACAD SCI USA, V102, P19075&#xD; HE L,
                    2005, NATURE, V435, P828&#xD; HOUBAVIY HB, 2005, RNA, V11, P1245&#xD;
                    HULIESKOVAN S, 2005, CANCER RES, V65, P8984&#xD; HUTVAGNER G, 2004, PLOS BIOL,
                    V2, P465&#xD; JIN P, 2004, NAT CELL BIOL, V6, P1048&#xD; JIN P, 2004, NAT
                    NEUROSCI, V7, P113&#xD; KARUBE Y, 2005, CANCER SCI, V96, P111&#xD; KAY MA, 2001,
                    NAT MED, V7, P33&#xD; KIM DH, 2005, NAT BIOTECHNOL, V23, P222&#xD; KIM DH, 2007,
                    NAT REV GENET, V8, P173&#xD; KLOOSTERMAN WP, 2004, NUCLEIC ACIDS RES, V32,
                    P6284&#xD; KREK A, 2005, NAT GENET, V37, P495&#xD; KRUTZFELDT J, 2005, NATURE,
                    V438, P685&#xD; KRUTZFELDT J, 2007, NUCLEIC ACIDS RES, V35, P2885&#xD;
                    KULSHRESHTHA R, 2007, MOL CELL BIOL, V27, P1859&#xD; KURIHARA Y, 2004, P NATL
                    ACAD SCI USA, V101, P12753&#xD; LAGOSQUINTANA M, 2002, CURR BIOL, V12, P735&#xD;
                    LAGOSQUINTANA M, 2003, RNA, V9, P175&#xD; LAI EC, 2002, NAT GENET, V30,
                    P363&#xD; LANDTHALER M, 2004, CURR BIOL, V14, P2162&#xD; LEE CT, 2007, DNA CELL
                    BIOL, V26, P209&#xD; LEE RC, 1993, CELL, V75, P843&#xD; LEE Y, 2004, EMBO J,
                    V23, P4051&#xD; LEE Y, 2006, EMBO J, V25, P552&#xD; LEWIS BP, 2003, CELL, V115,
                    P787&#xD; LEWIS BP, 2005, CELL, V120, P15&#xD; LIM LP, 2005, NATURE, V433,
                    P769&#xD; LIU CG, 2004, P NATL ACAD SCI USA, V101, P9740&#xD; LU J, 2005,
                    NATURE, V435, P834&#xD; LU SH, 2004, J VIROL, V78, P12868&#xD; LUKIW WJ, 2007,
                    NEUROREPORT, V18, P297&#xD; LUND E, 2004, SCIENCE, V303, P95&#xD; MA JB, 2005,
                    NATURE, V434, P666&#xD; MANAMARA JO, 2006, NAT BIOTECHNOL, V24, P1005&#xD;
                    MANIATAKI E, 2005, GENE DEV, V19, P2979&#xD; MATSUBARA H, 2007, ONCOGENE&#xD;
                    MEISTER G, 2004, RNA, V10, P544&#xD; MEISTER G, 2005, CURR BIOL, V15, P2149&#xD;
                    MORRIS KV, 2004, SCIENCE, V305, P1289&#xD; MORRIS KV, 2006, HUM GENE THER, V17,
                    P479&#xD; MORRISSEY DV, 2005, NAT BIOTECHNOL, V23, P1002&#xD; NELSON PT, 2004,
                    NAT METHODS, V1, P155&#xD; ODONNELL KA, 2005, NATURE, V435, P839&#xD; OKAMURA K,
                    2004, GENE DEV, V18, P1655&#xD; OKAMURA K, 2007, CELL, V130, P89&#xD; OLSEN PH,
                    1999, DEV BIOL, V216, P671&#xD; OMOTO S, 2004, RETROVIROLOGY, V1, P44&#xD; OROM
                    UA, 2006, GENE, V372, P137&#xD; PADDISON PJ, 2002, GENE DEV, V16, P948&#xD;
                    PALLISER D, 2006, NATURE, V439, P89&#xD; PARK MY, 2005, P NATL ACAD SCI USA,
                    V102, P3691&#xD; PARKER JS, 2005, NATURE, V434, P663&#xD; PERKINS DO, 2007,
                    GENOME BIOL, V8&#xD; PFEFFER S, 2004, SCIENCE, V304, P734&#xD; PFEFFER S, 2005,
                    NAT METHODS, V2, P269&#xD; PLANTE I, 2006, J BIOMED BIOTECHNOL, P6437&#xD; RANA
                    TM, 2007, NAT REV MOL CELL BIO, V8, P23&#xD; REINHART BJ, 2000, NATURE, V403,
                    P901&#xD; RHOADES MW, 2002, CELL, V110, P513&#xD; ROBB GB, 2005, NAT STRUCT MOL
                    BIOL, V12, P133&#xD; ROBSON T, 2003, J BIOMED BIOTEC 0421, P110&#xD; RODRIGUEZ
                    A, 2004, GENOME RES, V14, P1902&#xD; RUBY JG, 2007, NATURE, V44, P83&#xD;
                    SAETROM O, 2005, RNA, V11, P995&#xD; SAETROM P, 2006, OLIGONUCLEOTIDES, V16,
                    P115&#xD; SAETROM P, 2007, NUCLEIC ACIDS RES, V35, P2333&#xD; SAITO Y, 2006,
                    CANCER CELL, V9, P435&#xD; SAMOLS MA, 2005, J VIROL, V79, P9301&#xD; SCHMITTGEN
                    TD, 2004, NUCLEIC ACIDS RES, V32&#xD; SHEN J, 2006, GENE THER, V13, P225&#xD;
                    SHIOHAMA A, 2003, BIOCHEM BIOPH RES CO, V304, P184&#xD; SIOLAS D, 2005, NAT
                    BIOTECHNOL, V23, P227&#xD; SNOVE O, 2006, NAT METHODS, V3, P689&#xD; SONG EW,
                    2005, NAT BIOTECHNOL, V23, P709&#xD; SOUTSCHEK J, 2004, NATURE, V432, P173&#xD;
                    STERNGINOSSAR N, 2007, SCIENCE, V317, P376&#xD; SULLIVAN CS, 2005, NATURE, V435,
                    P682&#xD; SULLIVAN KE, 2004, CURR OPIN ALLERGY CL, V4, P505&#xD; THOMSON JM,
                    2006, GENE DEV, V20, P2202&#xD; TRIBOULET R, 2007, SCIENCE, V315, P1579&#xD;
                    VANROOIJ E, 2006, P NATL ACAD SCI USA, V103, P18255&#xD; VELLA MC, 2004, CHEM
                    BIOL, V11, P1619&#xD; VELLA MC, 2004, GENE DEV, V18, P132&#xD; VERMEULEN A,
                    2007, RNA, V13, P723&#xD; VOLINIA S, 2006, P NATL ACAD SCI USA, V103, P2257&#xD;
                    VOORHOEVE PM, 2006, CELL, V124, P1169&#xD; WANG YM, 2007, NAT GENET, V39,
                    P380&#xD; WU LG, 2006, P NATL ACAD SCI USA, V103, P4034&#xD; XIE XH, 2005,
                    NATURE, V434, P338&#xD; YANG BF, 2007, NAT MED, V13, P486&#xD; YEKTA S, 2004,
                    SCIENCE, V304, P594&#xD; YEOM KH, 2006, NUCLEIC ACIDS RES, V34, P4622&#xD; YI R,
                    2003, GENE DEV, V17, P3011&#xD; ZALFA F, 2003, CELL, V112, P317&#xD; ZAMORE PD,
                    2000, CELL, V101, P25&#xD; ZENG Y, 2002, MOL CELL, V9, P1327&#xD; ZENG Y, 2005,
                    METHOD ENZYMOL, V392, P371&#xD; ZHAO JJ, 2006, CHILD NERV SYST, V22, P1419&#xD;
                    ZHAO Y, 2005, NATURE, V436, P214&#xD; ZHAO Y, 2007, CELL, V129, P303&#xD; ZHOU
                    HX, 2005, NUCLEIC ACIDS RES, V33&#xD; ZHOU XF, 2007, PLOS COMPUT BIOL, V3,
                    P412&#xD; ZIMMERMANN TS, 2006, NATURE, V441, P111</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Review</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000251266800005 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2008/01/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>489</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">489</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1102</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Song, G. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gibson, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Haq, W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Huang, E. C. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Srivasta, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hollstein, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Daftarian, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wang, Z. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Diamond, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ellenhorn, J. D. I.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Comprehens Canc Ctr, Div
                    Surg, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Gen &amp; Oncol Surg,
                    Duarte, CA USA. City Hope Natl Med Ctr, Lab Vaccine Res, Duarte, CA USA. German
                    Canc Res Ctr, Div Genet Alterat Carcinogenesis, Heidelberg,
                    Germany.&#xD;Ellenhorn, JDI, City Hope Comprehens Canc Ctr, Div Surg, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;jellenhorn@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">An MVA vaccine overcomes
                        tolerance to human p53 in mice and humans</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Cancer Immunology
                        Immunotherapy</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Cancer Immunology
                        Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Cancer Immunol.
                        Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Cancer Immunol
                        Immunother</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1193-1205</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">56</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">8</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">animal models of cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immune response to
                        cancer</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">p53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cancer vaccines</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CYTOTOXIC T-LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WILD-TYPE P53</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KNOCK-IN MICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER-PATIENTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VIRUS ANKARA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ANTITUMOR IMMUNITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR-ERADICATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MURINE TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TARGETING P53</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0340-7004</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246561900007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Background The cellular regulatory
                    protein p53 is overexpressed by almost 50% of all malignancies making it an
                    attractive target for a vaccine approach to cancer. A number of immunotherapy
                    approaches targeting p53 have been evaluated successfully in murine models, but
                    translation of these preclinical findings to the clinic has been unsuccessful.
                    Prior studies in our laboratory employing murine models demonstrated that a
                    modified vaccinia virus Ankara (MVA) vaccine expressing murine p53 could
                    stimulate p53 specific immunity. Systemic administration of the MVA vaccine was
                    able to effect the rejection of established tumors. To better understand the
                    immunologic mechanisms that underlie the vaccine function of human p53, we
                    utilized a murine model in which the murine germ line copy of p53 was replaced
                    with a modified human one. These mice, referred to as Hupki, were evaluated as a
                    tolerant model to explore the capacity of MVA expressing human p53 to overcome
                    tolerance and reject human p53-expressing tumors. Results MVAp53 immunization of
                    Hupki mice resulted in the generation of p53-specific CD8(+) T cells and the
                    rejection of a highly aggressive murine mammary carcinoma cell line 4T1(H-2d)
                    transfected with human p53 (4T1p53). An immunologic correlate of tumor
                    protection was evaluated utilizing an overlapping peptide library spanning the
                    full length of human p53. This reagent was also used in combination with MVAp53
                    to stimulate p53-specific CD8(+) T cell responses in cancer patients. Conclusion
                    These studies demonstrate the potential of MVAp53 to overcome tolerance to p53
                    for cancer immunotherapy.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    168ZG&#xD;Times Cited: 0&#xD;Cited Reference Count: 46&#xD;Cited References:
                    &#xD; ANTONIA SJ, 2006, CLIN CANCER RES 1, V12, P878&#xD; ASLAKSON CJ, 1992,
                    CANCER RES, V52, P1399&#xD; BERTHOLET S, 1997, EUR J IMMUNOL, V27, P798&#xD;
                    CARBONE DP, 2005, J CLIN ONCOL, V23, P5099&#xD; COSMA A, 2003, VACCINE, V22,
                    P21&#xD; DAFTARIAN P, 2004, CANCER RES, V64, P5407&#xD; DORRELL L, 2006, J
                    VIROL, V80, P4705&#xD; ESPENSCHIED J, 2003, J IMMUNOL, V170, P3401&#xD;
                    GABRILOVICH DI, 1996, J IMMUNOTHER, V19, P414&#xD; GOONETILLEKE N, 2006, J
                    VIROL, V80, P4717&#xD; HAINAUT P, 2000, ADV CANCER RES, V77, P81&#xD; HARRIS CC,
                    1993, NEW ENGL J MED, V329, P1318&#xD; HERNDON RM, 2000, INT J MS CARE, V2,
                    P1&#xD; HILBURGER RM, 2001, CANCER IMMUNOL IMMUN, V49, P603&#xD; HOFFMANN TK,
                    2000, J IMMUNOL, V165, P5938&#xD; HURPIN C, 1998, VACCINE, V16, P208&#xD; KERN
                    F, 2000, EUR J IMMUNOL, V30, P1676&#xD; KUBALL J, 2002, GENE THER, V9, P833&#xD;
                    LANE DP, 1999, BRIT J CANCER S1, V80, P1&#xD; LAROSA C, 2006, EXP HEMATOL, V34,
                    P497&#xD; LUO JL, 2001, CANCER RES, V61, P8158&#xD; LUO JL, 2001, ONCOGENE, V20,
                    P320&#xD; MAYORDOMO JI, 1996, J EXP MED, V183, P1357&#xD; MCCONKEY SJ, 2003, NAT
                    MED, V9, P729&#xD; MOLDOVEANU Z, 1998, VACCINE, V16, P1216&#xD; MOORTHY VS,
                    2003, VACCINE, V21, P2004&#xD; NOGUCHI Y, 1995, P NATL ACAD SCI USA, V92,
                    P2219&#xD; ODIN L, 2001, CANCER GENE THER, V8, P87&#xD; PANTUCK AJ, 2004, J
                    IMMUNOTHER, V27, P240&#xD; PARAJULI P, 2001, CANCER RES, V61, P8227&#xD; ROTH J,
                    1996, P NATL ACAD SCI USA, V93, P4781&#xD; SHERMAN LA, 1992, J EXP MED, V175,
                    P1221&#xD; SHERMAN LA, 1998, CRIT REV IMMUNOL, V18, P47&#xD; STICKL H, 1974,
                    DEUT MED WOCHENSCHR, V99, P2386&#xD; STITTELAAR KJ, 2001, VACCINE, V19,
                    P3700&#xD; SVANE IM, 2004, CANCER IMMUNOL IMMUN, V53, P633&#xD; THEOBALD M,
                    1995, P NATL ACAD SCI USA, V92, P11993&#xD; THEOBALD M, 1997, J EXP MED, V185,
                    P833&#xD; TUTING T, 1997, EUR J IMMUNOL, V27, P2702&#xD; VANDERBURG SH, 2002,
                    CLIN CANCER RES, V8, P1019&#xD; VIERBOOM MPM, 1997, J EXP MED, V186, P695&#xD;
                    VIERBOOM MPM, 2000, CANCER RES, V60, P5508&#xD; VIERBOOM MPM, 2000, INT J
                    CANCER, V87, P253&#xD; WANG ZD, 2004, BLOOD, V104, P847&#xD; YU ZW, 1997, J SURG
                    RES, V69, P337&#xD; ZHU X, 2006, J IMMUNOL, V176, P3223</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246561900007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>800</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">800</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1100</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Stastny, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Brown, C. E.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ruel, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Canc
                    Immunotherapeut &amp; Tumor Immunol, Duarte, CA 91010 USA. City Hope Natl Med
                    Ctr, Dept Informat Sci, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept
                    Pediat Hematol Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Beckman Res
                    Inst, Duarte, CA 91010 USA.&#xD;Jensen, MC, City Hope Natl Med Ctr, Div Canc
                    Immunotherapeut &amp; Tumor Immunol, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;mjensen@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Medulloblastomas expressing IL1
                        3R alpha 2 are targets for IL1 3-zetakine(+) cytolytic T cells</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Pediatric Hematology
                        Oncology</style>
                </secondary-title>
            </titles>
            <pages>
                <style face="normal" font="default" size="100%">669-677</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">29</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">medulloblastoma</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">cytotoxic T lymphocytes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IL13R alpha 2</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IL13-zetakine</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRIMITIVE NEUROECTODERMAL
                        TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CENTRAL-NERVOUS-SYSTEM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BRAIN-TUMORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-13 RECEPTOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ADOPTIVE IMMUNOTHERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EFFECTOR FUNCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERFERON-GAMMA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LAK</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1077-4114</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250453100001</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Central nervous system loco-regional
                    disease relapse is a common etiology of treatment failure for medulloblastoma
                    (MB)/primitive neuroectodermal tumors. Therapeutic targeting of primary disease
                    and the adjacent craniospinal cerebral spinal fluid pathways should decrease
                    relapse rates and allow for the curtailed use of radiation therapy. The adoptive
                    transfer of tumor-specific cytolytic T cells (CTLs) to the tumor bed and
                    cerebral spinal fluid is an attractive strategy, but limited in its clinical
                    application owing to the paucity of defined antigens consistently expressed by
                    these tumors and their potential to escape T-cell recognition by expressing low
                    level surface human leukocyte antigen. Here, we describe the human leukocyte
                    antigen-independent recognition of MB cell-surface IL13R alpha 2 by genetically
                    modified CTLs expressing an IL13-zetakine chimeric immunoreceptor. We found that
                    IL13-zetakine(+) CTLs exhibit potent cytolytic activity toward IL13Ra2(+) Daoy
                    cells, and are activated to secrete proinflammatory cytokines such as
                    interferon-gamma. By employing an orthotoplic NOD-scid murine model in which
                    intraventricularly seeded Daoy cells form tumors on leptomeningeal surfaces,
                    regression of established ffLuc(+) Daoy xenografts in response to
                    intraventricularly delivered IL13-zetakine(+) CD8(+) CTLs was observed using
                    biophotonic imaging. These studies support the rationale for exploring the
                    clinical utility of targeted iminunotherapy using adoptively transferred
                    IL13-zetakine redirected CTLs as a therapeutic component for treating IL13R
                    alpha 2(+) MB/primitive neuroectodennal tumors.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    224NG&#xD;Times Cited: 0&#xD;Cited Reference Count: 34&#xD;Cited References:
                    &#xD; APPAY V, 2002, NAT MED, V8, P379&#xD; BERNARD J, 2001, LAB INVEST, V81,
                    P1223&#xD; BIERIE B, 2006, NAT REV CANCER, V6, P506&#xD; BOIARDI A, 1994, CANCER
                    IMMUNOL IMMUN, V39, P193&#xD; COOPER LJ, 2005, CANC CHEMOTHER BIOL, V22,
                    P293&#xD; COOPER LJN, 2003, BLOOD, V101, P1637&#xD; DAINES MO, 2002, J BIOL
                    CHEM, V277, P10387&#xD; DEBINSKI W, 2000, MOL MED, V6, P440&#xD; FICHTNERFEIGL
                    S, 2006, NAT MED, V12, P99&#xD; GAMBHIR SS, 2000, P NATL ACAD SCI USA, V97,
                    P2785&#xD; GEYER JR, 1994, J CLIN ONCOL, V12, P1607&#xD; GONZALEZ S, 2004, J
                    GENE MED, V6, P704&#xD; HAYAKAWA Y, 2006, SEMIN IMMUNOL, V18, P176&#xD; HEMMATI
                    HD, 2003, P NATL ACAD SCI USA, V100, P15179&#xD; IKEDA H, 2002, CYTOKINE GROWTH
                    F R, V13, P95&#xD; JAKACKI RI, 2005, J NEUROSURG S, V102, P44&#xD; JENSEN MC,
                    2000, MOL THER, V1, P49&#xD; JENSEN MC, 2003, CYTOTHERAPY, V5, P131&#xD; KAHLON
                    KS, 2004, CANCER RES, V64, P9160&#xD; KAWAKAMI K, 2001, BLOOD, V97, P2673&#xD;
                    KAWAKAMI M, 2004, CANCER, V101, P1036&#xD; LIN WS, 2004, J NEUROSCI, V24,
                    P10074&#xD; MCKENZIE ANJ, 2003, J EXP MED, V197, P675&#xD; MOELLER M, 2005,
                    BLOOD, V106, P2995&#xD; MOLENAAR WM, 1994, CRIT REV ONCOL HEMAT, V17, P1&#xD;
                    MORGAN RA, 2006, SCIENCE, V314, P126&#xD; OKAMOTO Y, 1988, ACTA NEUROCHIR WIEN,
                    V94, P47&#xD; PACKER RJ, 1999, CURR TREAT OPTIONS N, V1, P395&#xD; PILKINGTON
                    GJ, 2005, CELL PROLIFERAT, V38, P423&#xD; PITTET MJ, 2000, J IMMUNOL, V164,
                    P1148&#xD; RADCLIFFE J, 1994, INT J DEV NEUROSCI, V12, P327&#xD; SANKHLA SK,
                    1996, J NEURO-ONCOL, V27, P133&#xD; SINGH SK, 2003, CANCER RES, V63, P5821&#xD;
                    UPSHAW JL, 2006, SEMIN IMMUNOL, V18, P167</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250453100001 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>209</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">209</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1099</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Strassberg, S. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Cristea, I. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Qian, D. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parton, L. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept
                    Biostat, Duarte, CA 91010 USA.&#xD;Strassberg, SS, New York Med Coll, Dept
                    Pediat Neonatol, Valhalla, NY 10595 USA.&#xD;strassbergs@wcmc.com</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Single nucleotide polymorphisms
                        of tumor necrosis factor-alpha and the susceptibility to bronchopulmonary
                        dysplasia</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Pediatric Pulmonology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Pediatric Pulmonology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Pediatr. Pulmonol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Pediatr Pulmonol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">29-36</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">42</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">1</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">bronchopulmonary
                        dysplasia</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">single nucleotide
                        polymorphism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">tumor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">necrosis factor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CHRONIC LUNG-DISEASE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >RESPIRATORY-DISTRESS-SYNDROME</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PRETERM INFANTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HAPLOTYPE RECONSTRUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GENETIC SUSCEPTIBILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TNF-ALPHA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERLEUKIN-6</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POPULATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">VENTILATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ASSOCIATION</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jan</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">8755-6863</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243285600006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Bronchopulmonary dysplasia (BPD) is
                    the most common chronic lung disease of infancy A &quot;New&quot; BPD has been
                    characterized in preterm infants that may begin in utero, and then progress
                    post-natally, resulting in arrested lung development and alveolar hypoplasia.
                    Foundations for this &quot;New&quot; BPD may be derived from pro-inflammatory
                    genes including tumor necrosis factor-alpha (TNF alpha). The hypothesis of the
                    current study is that single nucleotide polymorphisms (SNPs) of the
                    pro-inflammatory TNF alpha gene place preterm infants at increased risk for BPD.
                    Preterm infants (105 in number) with birthweights &lt;= 1 kg, who survived to at
                    least 36 weeks postmenstrual age (PMA) or discharge were enrolled into this
                    study They were stratified for BPD according to their need for supplemental
                    oxygen at 28 days and at 36 weeks PMA (non-, mild-, moderate-, or severe-BPD).
                    DNA was extracted from these infants and subjected to analyses for the TNF alpha
                    SNPs: -1,031, -863, -857, -308, and -238, The PHASE software (version 2.1) was
                    used to reconstruct haplotypes and estimate their frequencies within the study
                    population. Differences in birth weight (P &lt; 0.001) and gestational age (P
                    &lt; 0.001), but not in racial distribution between the groups were found.
                    Haplotype-specific analysis revealed no significant association between BPD
                    severity and any of the 5-marker common haplotypes with 10 or more copies in
                    this study population. Additionally, no significant association was observed in
                    any three SNP haplotypes at -1,031, -863, and -857, and two SNP haplotypes at
                    -308 and -238. We observed no association between BPD severity and the five TNF
                    alpha SNPs investigated.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    123GY&#xD;Times Cited: 0&#xD;Cited Reference Count: 52&#xD;Cited References:
                    &#xD; ADCOCK K, 2003, GENES IMMUN, V4, P420&#xD; ALLCOCK RJN, 2004, HUM MUTAT,
                    V24, P517&#xD; ALLEN J, 2003, AM J RESP CRIT CARE, V168, P356&#xD; BAGCHI A,
                    1994, PEDIATR RES, V36, P244&#xD; BHANDARI V, 2002, FRONT BIOSCI, V7, D1624&#xD;
                    BHANDARI V, 2006, PEDIATRICS, V117, P1901&#xD; BOURBON J, 2005, PEDIATR RES 2,
                    V57, R38&#xD; BRINKMAN BMN, 1997, BRIT J RHEUMATOL, V36, P516&#xD; CAMARENA A,
                    2001, AM J RESP CRIT CARE, V163, P1528&#xD; COALSON JJ, 1995, AM J RESP CRIT
                    CARE, V152, P640&#xD; COPLAND IB, 2002, AM J RESP CELL MOL, V26, P261&#xD; GITTO
                    E, 2004, J PINEAL RES, V36, P250&#xD; HEDRICK PW, 1987, GENETICS, V117,
                    P331&#xD; HERNANDEZPACHECO G, 2003, J AUTOIMMUN, V21, P59&#xD; HIGUCHI T, 1998,
                    TISSUE ANTIGENS, V51, P605&#xD; HOLDEN AL, 2004, 2004 TSC&#xD; HUANG HC, 2005,
                    PEDIATR RES, V58, P216&#xD; HULL J, 2001, AM J HUM GENET, V69, P413&#xD; IKEGAMI
                    M, 2003, AM J PHYSIOL-LUNG C, V285, L121&#xD; JANG WH, 2001, CANCER LETT, V166,
                    P41&#xD; JOBE AH, 2001, AM J RESP CRIT CARE, V163, P1723&#xD; JONSSON B, 1997,
                    ARCH DIS CHILD, V77, F198&#xD; KAZZI SN, 2004, PEDIATRICS, V114, E243&#xD;
                    KOTECHA S, 1995, ARCH DIS CHILD, V72, P90&#xD; LIN HC, 2005, ARCH DIS CHILD,
                    V90, F93&#xD; LISTA G, 2004, PEDIATR PULM, V37, P510&#xD; MAKRI V, 2002, EUR J
                    PEDIATR, V161, P604&#xD; MANAR MH, 2004, J PERINATOL, V24, P30&#xD; MUNSHI UK,
                    1997, PEDIATR PULM, V24, P331&#xD; NEBEN K, 2002, BLOOD, V100, P2263&#xD;
                    NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357&#xD; PARKER RA, 1996, SEMIN
                    PERINATOL, V20, P206&#xD; PARTON LA, 2006, FRONT BIOSCI, V11, P1854&#xD; PERL
                    AK, 2004, CLIN GENET, V56, P14&#xD; ROVA M, 2004, HUM MOL GENET, V13, P1095&#xD;
                    SHEU WHH, 2001, METABOLISM, V50, P1447&#xD; SOGA Y, 2002, J CLIN PERIODONTOL,
                    V30, P524&#xD; STEPHENS M, 2001, AM J HUM GENET, V68, P978&#xD; STEPHENS M,
                    2003, AM J HUM GENET, V73, P1162&#xD; TULLUS K, 1996, EUR J PEDIATR, V155,
                    P112&#xD; VANMARTER LJ, 2000, PEDIATRICS, V105, P1194&#xD; VARUGHESE R, 2003,
                    LUNG, V181, P335&#xD; WAGENAAR GTA, 2004, FREE RADICAL BIO MED, V36, P782&#xD;
                    WALSH MC, 1986, PEDIATR CLIN N AM, V33, P179&#xD; WARBURTON D, 2004, PAEDIAT
                    RESP REV SA, V5, S283&#xD; WATERER GW, 2001, AM J RESP CRIT CARE, V163,
                    P1599&#xD; WEBER B, 2000, TURKISH J PEDIATR, V42, P181&#xD; WILSON AG, 1997, P
                    NATL ACAD SCI 07/01 USA, V94, P3195&#xD; YANG G, 2004, J CLIN INVEST, V114,
                    P669&#xD; YODER BA, 2000, AM J RESP CRIT CARE, V162, P1867&#xD; YOON BH, 1997,
                    AM J OBSTET GYNECOL, V177, P825&#xD; ZAYKIN DV, 2002, HUM HERED, V53,
                    P79</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243285600006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>801</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">801</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1098</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, C. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yuan, J. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koh, W. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lee, H. P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, M. C.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Populat
                    Sci, Duarte, CA 91010 USA. Beckman Res Inst, Duarte, CA 91010 USA. Univ
                    Minnesota, Ctr Canc, Minneapolis, MN 55455 USA. Natl Univ Singapore, Yong Loo
                    Lin Sch Med, Dept Community Occupat &amp; Family Med, Singapore 117597,
                    Singapore.&#xD;Sun, CL, City Hope Natl Med Ctr, Div Populat Sci, 1500 E Duarte
                    Rd, Duarte, CA 91010 USA.&#xD;casun@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Green tea and black tea
                        consumption in relation to colorectal cancer risk: the Singapore Chinese
                        Health Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Carcinogenesis</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">2143-2148</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">28</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">10</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >2-AMINO-1-METHYL-6-PHENYLIMIDAZO&lt;4,5-B&gt;PYRIDINE PHIP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">POSTMENOPAUSAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">WOMEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DNA-ADDUCTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">F344 RATS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COLON</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">METAANALYSIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HYPOXIA</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ESTROGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TUMOR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MUTAGENICITY</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0143-3334</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250676400012</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The relationships between green tea
                    and black tea consumption and colorectal cancer risk were examined within the
                    Singapore Chinese Health Study, a prospective cohort study of diet and cancer
                    involving 60 000 men and women. Intake of green tea and black tea was assessed
                    through in-person interviews. Incident cancer cases and deaths among cohort
                    members were identified through record linkage of the cohort database with
                    respective databases from the nationwide Singapore Cancer Registry and the
                    Singapore Registry of Births and Deaths. The proportional hazard regression
                    method was used to examine the associations between intake of green and black
                    tea separately and colorectal cancer risk with adjustment for potential
                    confounders. After an average of 8.9 years of follow-up, 845 colorectal cancer
                    cases were identified. Subjects who drank green tea exhibited a statistically
                    non-significant increase in risk [relative risk (RR) = 1.12, 95% confidence
                    interval (CI) = 0.97-1.29] relative to non-drinkers of green tea. This risk
                    increase was mainly confined to men (RR = 1.31, 95% CI = 1.08-1.58); the
                    comparable RR in women was 0.89 (95% CI = 0.71-1.12). In men, the green tea -
                    colorectal cancer association was noted mainly in those with advanced disease
                    (Duke C or D) (RR = 1.53, 95% CI = 1.19-1.97), and the association was dose
                    dependent (P for trend = 0.0002). This latter association was especially strong
                    within the colon subsite (RR = 1.75, 95% CI = 1.24-2.46; P for trend &lt;
                    0.0001). Irrespective of gender, intake of black tea was not associated with
                    risk of colorectal cancer (RR = 0.92, 95% CI = 0.79-1.07) in this Asian
                    population.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    227RV&#xD;Times Cited: 0&#xD;Cited Reference Count: 35&#xD;Cited References:
                    &#xD; ANDERSON GL, 2004, JAMA-J AM MED ASSOC, V291, P1701&#xD; APOSTOLIDES Z,
                    1996, MUTAT RES-ENVIR MUTA, V359, P159&#xD; BALENTINE DA, 1997, CRIT REV FOOD
                    SCI, V37, P693&#xD; CHLEBOWSKI RT, 2004, NEW ENGL J MED, V350, P991&#xD; COX DR,
                    1972, J ROY STAT SOC B MET, V34, P187&#xD; DERSIMONIAN R, 1986, CONTROL CLIN
                    TRIALS, V7, P177&#xD; GOETHALS L, 2006, INT J RADIAT ONCOL, V65, P246&#xD;
                    GRAHAM HN, 1992, PREV MED, V21, P334&#xD; GRODSTEIN F, 1999, AM J MED, V106,
                    P574&#xD; HANKIN JH, 2001, NUTR CANCER, V39, P187&#xD; HEBERTCROTEAU N, 1998,
                    CANCER EPIDEM BIOMAR, V7, P653&#xD; HERNAEZ JF, 1998, MUTAT RES-FUND MOL M,
                    V402, P299&#xD; HIROSE M, 2001, CANCER LETT, V168, P23&#xD; HOCKEL M, 2001, J
                    NATL CANCER I, V93, P266&#xD; HUBER WW, 1997, MUTAT RES-FUND MOL M, V376,
                    P115&#xD; ISHIKAWA T, 1996, CANCER LETT, V107, P5&#xD; JIA XD, 2001, NUTR
                    CANCER, V39, P239&#xD; KIM M, 2005, CARCINOGENESIS, V26, P1553&#xD; METZ N,
                    2000, NUTR CANCER, V38, P60&#xD; MICHELS KB, 2005, J NATL CANCER I, V97,
                    P282&#xD; PARKIN DM, 2003, CANC INCIDENCE 5 CON&#xD; SCHUT HAJ, 2000, NUTR
                    CANCER, V36, P52&#xD; SEOW A, 2006, J NATL CANCER I, V98, P135&#xD; SUN CL,
                    2006, CARCINOGENESIS, V27, P1301&#xD; TAVANI A, 2004, CANCER CAUSE CONTROL, V15,
                    P743&#xD; THOMAS R, 2005, BIOCHEM BIOPH RES CO, V334, P543&#xD; TSONG WH, 2007,
                    BRIT J CANCER, V96, P821&#xD; WANG BK, 1994, MICROW OPT TECHN LET, V7, P12&#xD;
                    WATERHOUSE J, 1976, CANC INCIDENCE 5 CON&#xD; WEISBURGER JH, 1996, MUTAT
                    RES-GENET TOX, V371, P57&#xD; WU AH, 2005, CARCINOGENESIS, V26, P976&#xD; XU M,
                    1996, CARCINOGENESIS, V17, P1429&#xD; YUAN JM, 2006, INT J CANCER, V120,
                    P1344&#xD; ZHONG H, 1999, CANCER RES, V59, P5830&#xD; ZHOU YD, 2004, J NAT PROD,
                    V67, P2063</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250676400012 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/12/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>729</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">729</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1640</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yu, R. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Evans, R. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Shi, Y.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Neuroscience Division, Beckman
                    Research Institute of City of Hope, 1500 East Duarte Road, Duarte, CA 91010,
                    USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Orphan nuclear receptor TLX
                        recruits histone deacetylases to repress transcription and regulate neural
                        stem cell proliferation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Proceedings of the National
                        Academy of Sciences of the United States of America</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U. S.
                        A.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">15282-7</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">104</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">39</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">Amino Acid Motifs</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Amino Acid Sequence</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cell Proliferation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Cyclin-Dependent Kinase
                        Inhibitor p21/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Gene Expression
                        Regulation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Histone Deacetylases/
                        metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Humans</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Molecular Sequence Data</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Neurons/
                        cytology/metabolism</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PTEN
                        Phosphohydrolase/metabolism/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Protein Structure,
                        Tertiary</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Receptors, Cytoplasmic and
                        Nuclear/ physiology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Sequence Homology, Amino
                        Acid</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Stem Cells/ cytology</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">Transcription, Genetic</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep 25</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0027-8424 (Print)</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">17873065</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">TLX is a transcription factor that
                    is essential for neural stem cell proliferation and self-renewal. However, the
                    molecular mechanism of TLX-mediated neural stem cell proliferation and
                    self-renewal is largely unknown. We show here that TLX recruits histone
                    deacetylases (HDACs) to its downstream target genes to repress their
                    transcription, which in turn regulates neural stem cell proliferation. TLX
                    interacts with HDAC3 and HDAC5 in neural stem cells. The HDAC5-interaction
                    domain was mapped to TLX residues 359-385, which contains a conserved nuclear
                    receptor-coregulator interaction motif IXXLL. Both HDAC3 and HDAC5 have been
                    shown to be recruited to the promoters of TLX target genes along with TLX in
                    neural stem cells. Recruitment of HDACs led to transcriptional repression of TLX
                    target genes, the cyclin-dependent kinase inhibitor, p21(CIP1/WAF1)(p21), and
                    the tumor suppressor gene, pten. Either inhibition of HDAC activity or knockdown
                    of HDAC expression led to marked induction of p21 and pten gene expression and
                    dramatically reduced neural stem cell proliferation, suggesting that the
                    TLX-interacting HDACs play an important role in neural stem cell proliferation.
                    Moreover, expression of a TLX peptide containing the minimal HDAC5 interaction
                    domain disrupted the TLX-HDAC5 interaction. Disruption of this interaction led
                    to significant induction of p21 and pten gene expression and to dramatic
                    inhibition of neural stem cell proliferation. Taken together, these findings
                    demonstrate a mechanism for neural stem cell proliferation through
                    transcriptional repression of p21 and pten gene expression by TLX-HDAC
                    interactions.</style>
            </abstract>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <urls/>
            <custom1>
                <style face="normal" font="default" size="100%">PubMed 2007/10/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>596</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">596</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1097</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, J. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Dagis, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gaidulis, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Miller, M. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rodriguez, R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parker, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Falk, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenthal, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Senitzer, D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Div Hematol
                    &amp; HCT, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Informat Sci,
                    Duarte, CA 91010 USA. City Hope Natl Med Ctr, Div Mol Biol, Duarte, CA 91010
                    USA. City Hope Natl Med Ctr, Div Pediat, Duarte, CA 91010 USA. Beckman Res Inst,
                    Duarte, CA USA. Kaiser Reg BMT Program, Duarte, CA USA.&#xD;Senitzer, D, City
                    Hope Natl Med Ctr, Div Hematol &amp; HCT, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;dsenitzer@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Detrimental effect of natural
                        killer cell alloreactivity in T-replete hematopoietic cell transplantation
                        (HCT) for leukemia patients</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">197-205</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">natural killer cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">killer immunoglobulin-like
                        receptors</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">clinical outcomes</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMMUNOGLOBULIN-LIKE
                        RECEPTORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIR LIGAND
                        INCOMPATIBILITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%"
                        >BONE-MARROW-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN-LEUKOCYTE ANTIGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CLASS-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MOLECULES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA-C</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">UNRELATED DONORS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DENDRITIC CELLS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ACUTE GVHD</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NK</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000244028200007</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">In hematopoietic cell
                    transplantation (HCT), natural killer cell alloreactivity conferred by
                    inhibitory ligands of killer immunoglobulin-like receptors (iKIRLs) may result
                    in beneficial or detrimental outcomes. More data may contribute to resolution of
                    this complex issue. We analyzed 378 primary allogeneic transplants with
                    T-replete grafts for acute lymphoblastic leukemia (n = 101), acute myeloid
                    leukemia and myelodysplastic syndrome (n = 149), and chronic myeloid leukemia (n
                    = 128). The cohort was divided into 3 groups: in group 1, HLA class I matched at
                    the antigen level (n = 260); in group 2, HIA class I mismatched at the antigen
                    level (n = 57); and in group 3, HLA class I and iKIRLs mismatched (n = 61).
                    One-year overall survival (OS) across groups 1 (59%), 2 (49%), and 3 (30%) was
                    significantly different (P =.002). In contrast to group 2, group 3 had
                    statistically lower OS (P =.05) and event-free survival (P =.01). Relapse and
                    relapse-free mortality appeared to contribute to the low OS in group 3. The
                    detrimental effect of natural killer alloreactivity was also evident when
                    HLA-matched transplants were analyzed for patients lacking iKIRLs. One-year OS
                    in patients lacking the HLA-Cw group 1 or 2 iKIRL was significantly lower than
                    that in patients having the iKIRLs (55% vs 67%, n = 246, P =.01). Our
                    observations indicate that, in T-replete unrelated HCT, iKIRL mismatches and the
                    absence of iKIKLs confer higher risk to patients after HCT.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    133QT&#xD;Times Cited: 0&#xD;Cited Reference Count: 40</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000244028200007 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>771</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">771</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1096</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Sun, V. C. Y.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Borneman, T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ferrell, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Piper, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Koczywas, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Choi, K.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Beckman Res
                    Inst, Div Populat Sci, Dept Nursing Res &amp; Educ, Duarte, CA 91010 USA. City
                    Hope Natl Med Ctr, Dept Med Oncol &amp; Therapeut Res, Duarte, CA 91010 USA.
                    Univ Arizona, Virginia G Piper Canc Ctr, Scottsdale, AZ USA. Vital Res, Los
                    Angeles, CA USA.&#xD;Sun, VCY, City Hope Natl Med Ctr, Beckman Res Inst, Div
                    Populat Sci, Dept Nursing Res &amp; Educ, 1500 E Duarte Rd, Duarte, CA 91010
                    USA.&#xD;vsun@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Overcoming barriers to cancer
                        pain management: An institutional change model</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Pain and Symptom
                        Management</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of pain and symptom
                        management</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Pain Symptom Manage</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">359-369</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">34</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">4</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">pain</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">barriers</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">quality of life</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">QOL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PATIENT-RELATED BARRIERS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">OF-LIFE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INTERVENTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KNOWLEDGE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EDUCATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PROGRAM</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">NURSES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HEALTH</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Oct</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0885-3924</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000250159600006</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">The Agency for Health Care Policy
                    and Research Pain Guidelines of 1994 recognized pain as a critical symptom that
                    impacts quality of life (QOL). The barriers to optimum pain relief were
                    classified into three categories: patient, professional, and system barriers. A
                    prospective, longitudinal clinical trial is underway to test the affects of the
                    &quot;Passport to Comfort&quot; innovative intervention on pain and fatigue
                    management. This article reports on preintervention findings related to barriers
                    to pain management. Cancer patients with a diagnosis of breast, lung, colon., or
                    prostate cancer who reported a pain rating of 4 were accrued. Subjects completed
                    questionnaires to assess subjective ratings of overall QOL, barriers to pain
                    management, and pain knowledge at baseline and at one- and three-month
                    evaluations. A chart audit was conducted at one month to document objective data
                    related to pain management. The majority of subjects had moderate (4-6 on a 0-10
                    numeric rating scale) pain at the time of accrual. Patient barriers to pain
                    management existed in attitudes and knowledge regarding addiction, tolerance,
                    and not being able to control pain. Subjects who were currently receiving
                    chemotherapy were reluctant to communicate their pain with health care
                    professionals. Professional and system barriers were focused around screening,
                    documentation, reassessment, and follow-up of pain. Lack of referrals to
                    supportive care services for patients was also noted. Several well-described
                    patient, professional, and system barriers continue to hinder efforts to provide
                    optimal pain relief. Phase II of this initiative will attempt to eliminate these
                    barriers using the &quot;Passport&quot; intervention to manage cancer
                    pain.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    220MA&#xD;Times Cited: 0&#xD;Cited Reference Count: 32&#xD;Cited References:
                    &#xD; *AG HLTH CAR POL R, 1994, CLIN PRACT GUID CANC&#xD; *I MED, 1997, APPR
                    DEATH IMPR CAR&#xD; *NCCN PRACT GUID O, 2004, CANC REL PAIN VERS 1&#xD; *NIH
                    STAT SCI STAT, 2002, SYMPT MAN CANC PAIN&#xD; CLEELAND C, 1984, CANCER, V58,
                    P2635&#xD; DODD MJ, 2001, ONCOL NURS FORUM, V28, P465&#xD; ELLIOTT TE, 1995, J
                    PAIN SYMPTOM MANAG, V10, P494&#xD; FERRELL B, 1993, J PSYCHOSOC ONCOL, V10,
                    P21&#xD; FERRELL BR, 1991, ONCOL NURS FORUM, V18, P1303&#xD; FERRELL BR, 1991,
                    ONCOL NURS FORUM, V18, P1315&#xD; FERRELL BR, 1993, CANCER PRACT, V1, P185&#xD;
                    FERRELL BR, 1993, CANCER, V72, P3426&#xD; FERRELL BR, 1993, J PAIN SYMPTOM
                    MANAG, V8, P549&#xD; FERRELL BR, 1995, ONCOL NURS FORUM, V22, P1211&#xD; FERRELL
                    BR, 1995, QUAL LIFE RES, V4, P523&#xD; FERRELL BR, 1999, J PALLIAT MED, V2,
                    P185&#xD; FERRY D, 2000, P AN M AM SOC CLIN, V19, P3&#xD; GEE RE, 2003, J PAIN
                    SYMPTOM MANAG, V25, P101&#xD; GIFT AG, 2004, ONCOL NURS FORUM, V31, P202&#xD;
                    GUNNARSDOTTIR S, 2002, PAIN, V99, P385&#xD; JOHNSTONTAYLOR E, 1993, ONCOL NURS
                    FORUM, V20, P919&#xD; MCCAFFERY M, 1990, CANCER NURS, V13, P21&#xD; MCCAFFERY M,
                    2000, PAIN MANAG NURS, V1, P79&#xD; MIASKOWSKI C, 1995, ONCOL NURS FORUM, V22,
                    P791&#xD; MIASKOWSKI C, 2004, J CLIN ONCOL, V22, P1713&#xD; PAICE JA, 1998, J
                    PAIN SYMPTOM MANAG, V16, P1&#xD; PARGEON KL, 1999, J PAIN SYMPTOM MANAG, V18,
                    P358&#xD; POTTER VT, 2003, PSYCHO-ONCOL, V12, P153&#xD; RABOW MW, 2000, JAMA-J
                    AM MED ASSOC, V283, P771&#xD; RANDALLDAVID E, 2003, SUPPORT CARE CANCER, V11,
                    P660&#xD; WARD S, 2000, RES NURS HEALTH, V23, P393&#xD; WARD S, 2001, SUPPORT
                    CARE CANCER, V9, P148</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000250159600006 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/11/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>490</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">490</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1091</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Takimoto, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Doroshow, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gandara, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mani, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Remick, S. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mulkerin, D. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamilton, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharma, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ramanathan, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lenz, H. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Graham, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Longmate, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kaufman, B. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ivy, P.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Canc Therapy &amp; Res Ctr S Texas,
                    Inst Drug Dev, San Antonio, TX 78245 USA. City Hope Comprehens Canc Ctr, Duarte,
                    CA USA. Univ Calif Davis, Davis Canc Ctr, Sacramento, CA 95817 USA. Albert
                    Einstein Coll Med, Bronx, NY 10467 USA. Case Western Comprehens Canc Ctr,
                    Cleveland, OH USA. Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA. NYU,
                    Inst Canc, New York, NY USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021
                    USA. Univ Pittsburgh, Ctr Comprehens Canc, Pittsburgh, PA USA. Univ So Calif,
                    Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA. Sanofi
                    Synthelabo Inc, Dept Clin Pharmacokinet &amp; Drug Metab, Malvern, PA USA. PSI
                    Int Inc, Vienna, VA USA. NCI, Invest Drug Branch, Canc Therapy Evaluat Program,
                    Div Canc Treatment &amp; Diag, Bethesda, MD 20892 USA.&#xD;Takimoto, CH, Canc
                    Therapy &amp; Res Ctr S Texas, Inst Drug Dev, 14960 Omicron Dr, San Antonio, TX
                    78245 USA.&#xD;ctakimot@idd.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Dose-escalating and
                        pharmacologic study of oxaliplatin in adult cancer patients with impaired
                        hepatic function: A National Cancer Institute Organ Dysfunction Working
                        Group Study</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">3660-3666</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">12</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Jun</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000247336200031</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To determine the
                    toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in
                    patients with hepatic impairment and to develop formal guidelines for
                    oxaliplatin dosing in this patient population. Experimental Design: Sixty adult
                    cancer patients with variable hepatic function received i.v. oxaliplatin ranging
                    from 60 to 130 mg/m(2) every 3 weeks. Patients were stratified by levels of
                    total bilirubin, aspartate aminotransferase (AST), and alkaline phosphatase (AP)
                    into five cohorts based on the degree of hepatic dysfunction: control group A
                    [bilirubin, AST and AP &lt;= upper limit of normal (ULN)], mild dysfunction
                    group B (bilirubin &lt;= ULN, ULN &lt; AST &lt;= 2.5 x ULN, or ULN &lt; AP &lt;=
                    5 x ULN), moderate dysfunction group C (ULN &lt; bilirubin &lt;= 3.0 mg/dL, AST
                    &gt; 2.5 x ULN, or AP &gt; 5 x ULN), severe dysfunction group D (bilirubin &gt;
                    3.0 mg/dL, anyAST, and any AP), and liver transplantation group E (any
                    bilirubin, any AST, and any AP). Doses were escalated in cohorts of three
                    patients, and urine and plasma ultrafiltrates were assayed for platinum
                    concentrations. Results: Dose escalation of single-agent oxaliplatin to 130
                    mg/m(2) was well tolerated in all cohorts. Platinum clearance did not correlate
                    with any liver function test. Two of 56 assessable patients with a diagnosis of
                    laryngeal carcinoma and cervical adenocarcinoma experienced partial responses
                    lasting 3 and 5.5 months. Conclusions: Oxaliplatin at 130 mg/m(2) every 3 weeks
                    was well tolerated in all patients with impaired liver function. Dose reductions
                    of single-agent oxaliplatin are not indicated in patients with hepatic
                    dysfunction.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    180BZ&#xD;Times Cited: 0&#xD;Cited Reference Count: 10&#xD;Cited References:
                    &#xD; *FDA, 2003, GUID IND PHARM PAT I&#xD; ALLAIN P, 2000, DRUG METAB DISPOS,
                    V28, P1379&#xD; EGORIN M, 2006, CLIN ADV HEMATOL ONC, V4, P116&#xD; GRAHAM MA,
                    2000, CLIN CANCER RES, V6, P1205&#xD; MANI S, 2002, CANCER INVEST, V20,
                    P246&#xD; MISSET JL, 1998, BRIT J CANCER S4, V77, P4&#xD; OKEN MM, 1982, AM J
                    CLIN ONCOL-CANC, V5, P649&#xD; PUGH RNH, 1973, BRIT J SURG, V60, P646&#xD;
                    TAKIMOTO CH, 2003, J CLIN ONCOL, V21, P2664&#xD; WEISS L, 1986, J PATHOL, V150,
                    P195</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000247336200031 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>597</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">597</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1090</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Takahide, K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Parker, P. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wu, M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hwang, W. Y. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Carpenter, P. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Moravec, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Stehr, B.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Martin, P. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenthal, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. F.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Flowers, M. E. D.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Fred Hutchinson Canc Res Ctr, Div
                    Clin Res, Seattle, WA 98109 USA. City Hope Natl Med Ctr, Seattle, WA USA. Univ
                    Washington, Seattle, WA 98195 USA. Singapore Gen Hosp, Singapore 0316,
                    Singapore. Harvard Med Sch, Boston Fdn Sight, Boston, MA USA.&#xD;Flowers, MED,
                    Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 fairview ave N, Seattle, WA
                    98109 USA.&#xD;mflowers@fhcrc.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Use of fluid-ventilated,
                        gas-permeable scleral lens for management of severe keratoconjunctivitis
                        sicca secondary to chronic graft-versus-host disease</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Biology of Blood and Marrow
                        Transplantation</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Biol. Blood Marrow
                        Transplant.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Biol Blood Marrow
                        Transplant</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">1016-1021</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">9</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">graft-versus-host
                        disease</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">keratoconjunctivitis
                        sicca</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">allogeneic</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">hematopoietic cell
                        transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TERM FOLLOW-UP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BONE-MARROW</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DRY EYE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CELLS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1083-8791</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000249152200003</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Keratoconjunctivitis sicca (KCS)
                    occurs in 40%-60% of patients with chronic graft-versus-host-disease (cGVHD)
                    after allogeneic hematopoietic cell transplantation. Although immunosuppressive
                    therapy is the primary treatment of chronic GVHD, ocular symptoms require
                    measures to improve ocular lubrication, decrease inflammation, and maintain
                    mucosal integrity. The liquid corneal bandage provided by a fluid-ventilated,
                    gas-permeable scleral lens (SL) has been effective in mitigating symptoms and
                    resurfacing corneal erosions in patients with KCS related to causes other than
                    cGVHD. We report outcomes in 9 consecutive patients referred for SL fitting for
                    cGVHD-related severe KCS that was refractory to standard treatments. All
                    patients reported improvement of ocular symptoms and reduced the use of topical
                    lubricants after SL fitting resulting from decreased evaporation. No serious
                    adverse events or infections attributable to the SL occurred. The median Ocular
                    Surface Disease Index improved from 81 (75-100) to 21 (6-52) within 2 weeks
                    after SL fitting, and was 12 (2-53) at the time of last contact, 1-23 months
                    (median, 8.0) after SL fitting. Disability related to KCS resolved in 7 patients
                    after SL fitting. The use of SL appears to be safe and effective in patients
                    with severe cGVHD-related KCS refractory to conventional therapies. (c) 2007
                    American Society for Blood and Marrow Transplantation</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    205YX&#xD;Times Cited: 0&#xD;Cited Reference Count: 12</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000249152200003 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>609</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">609</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1089</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Takimoto, C. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Graham, M. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lockwood, G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ng, C. M.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Goetz, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Greenslade, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Remick, S. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Sharma, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mani, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ramanathan, R. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Synold, T. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Doroshow, J. H.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Hamilton, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Mulkerin, D. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Ivy, P.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Egorin, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grem, J. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Canc Therapy &amp; Res Ctr S Texas,
                    Inst Drug Dev, San Antonio, TX 78245 USA. NCI, Med Branch Navy, Natl Naval Med
                    Ctr, Bethesda, MD 20892 USA. NCI, Div Canc Treatment &amp; Ctr, Invest Drug
                    Branch, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. Dept Global Metab
                    &amp; Pharmacokinet, Malvern, PA USA. Case Western Reserve Univ, Cleveland, OH
                    44106 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NYU, San
                    Antonio, TX USA. Montefiore Hosp, Albert Einstein Coll Med, Bronx, NY USA. Univ
                    Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA USA. City Hope Natl Med Ctr,
                    Duarte, CA 91010 USA. Univ Wisconsin, Madison, WI USA.&#xD;Takimoto, CH, Canc
                    Therapy &amp; Res Ctr S Texas, Inst Drug Dev, 14960 Omicron Dr, San Antonio, TX
                    78245 USA.&#xD;ctakimot@idd.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Oxaliplatin pharmacokinetics and
                        pharmacodynamics in adult cancer patients with impaired renal
                        function</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Clinical Cancer Research</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Clin. Cancer Res.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Clin Cancer Res</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">4832-4839</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">13</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">16</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">CREATININE CLEARANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PHASE-I</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PERFORMANCE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PREDICTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">PLATINUM</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1078-0432</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248837900025</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: To characterize the
                    pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with
                    impaired renal function. Experimental Design: Thirty-four patients were
                    stratified by 24-h urinary creatinine clearance (CrCL) into four renal
                    dysfunction groups: group A (control, CrCL, &gt;= 60 mL/min), B (mild, CrCL,
                    40-59 mL/min), C (moderate, CrCL, 20-39 mL/min), and D (severe, CrCL, &lt;20
                    mL/min). Patients were treated with 60 to 130 mg/m(2) oxaliplatin infused over 2
                    h every 3 weeks. Pharmacokinetic monitoring of platinum in plasma, plasma
                    ultrafiltrates, and urine was done during cycles 1 and 2. Results: Plasma
                    ultrafiltrate platinum clearance strongly correlated with CrCL (r(2) = 0.712).
                    Platinum elimination from plasma was triphasic, and maximal platinum
                    concentrations (C-max) were consistent across all renal impairment groups.
                    However, only the beta-half-life was significantly prolonged by renal
                    impairment, with values of 14.0 +/- 4.3, 20.3 +/- 17.7, 29.2 +/- 29.6, and 68.1
                    h in groups A, B, C, and D, respectively (P = 0.002). At a dose level of 130
                    mg/m(2), the area under the concentration time curve increased in with the
                    degree of renal impairment, with values of 16.4 +/- 5.03, 39.7 +/- 11.5, and
                    44.6 +/- 14.6 mu g.h/mL, in groups A, B, and C, respectively. However, there was
                    no increase in pharmacodynamic drug-related toxicities. Estimated CrCL using the
                    Cockcroft-Gault method approximated the measured 24-h urinary CrCL (mean
                    prediction error, -5.0 mL/min). Conclusions: Oxaliplatin pharmacokinetics are
                    altered in patients with renal impairment, but a corresponding increase in
                    oxaliplatin-related toxicities is not observed.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    201ND&#xD;Times Cited: 0&#xD;Cited Reference Count: 24</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248837900025 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>640</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">640</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1075</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Tran, C. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Burton, L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Russom, D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Wagner, J. R.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Jensen, M. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Forman, S. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">DiGiusto, D. L.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Duarte, CA
                    91010 USA. City Hope Natl Med Ctr, Div Hematol, Duarte, CA 91010 USA. City Hope
                    Natl Med Ctr, Div Hematopoiet Cell Transplantat, Duarte, CA 91010 USA. Beckman
                    Res Inst, Duarte, CA USA.&#xD;DiGiusto, DL, City Hope Natl Med Ctr, 1500 E
                    Duarte Rd, Duarte, CA 91010 USA.&#xD;ddigiusto@coh.org</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Manufacturing of large numbers
                        of patient-specific T cells for adoptive immunotherapy - An approach to
                        improving product safety, composition, and production capacity</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Immunother.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunother</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Immunotherapy</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Immunother.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Immunother</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">644-654</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">30</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">6</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">adoptive immunotherapy</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">T cells</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">bioreactor</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">GMP</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FLUID MANAGEMENT DEVICE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LARGE-SCALE PRODUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">LYMPHOCYTES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXPANSION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">THERAPY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CULTURE</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">CANCER</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">BIOREACTORS</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Sep</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">1524-9557</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248353900008</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">We have developed an innovative
                    system for ex vivo processing of patient-specific cell products to produce large
                    numbers of T-lymphocytes in support of phase 2 adoptive immunotherapy trials for
                    hematologic malignancies. Extensive efforts were undertaken to close the cell
                    processing system to improve the safety profile of the process and comply with
                    new federal regulations regarding cell and tissue processing. Our results
                    demonstrate that apheresis products can be processed in a closed system
                    (Cytomate) with similar yields (approximate to 4 x 10(9) mononuclear
                    cells/apheresis) and recoveries (approximate to 60% of starting mononuclear
                    cells) to manual cell processing. Cells processed with this system could be
                    cryopreserved for up to 5 months without significant loss of recovery or
                    viability. Additionally, we have evaluated the use of gas permeable bags and
                    developed perfusion bioreactor protocols in which T cells can be rapidly
                    produced in excess of 10(10) viable cells per liter of culture. Using similar
                    methods for upfront processing, we have also developed methods for positive
                    selection and ex vivo culture of CD4(+) T cells that result in 200 to 800-fold
                    expansion of fresh or cryopreserved samples. T cells produced in these systems
                    were shown to retain activation-induced cytolytic capability and T(H)1 /T(H)2
                    cytokine production as a measure of biologic potency. These new methods allow
                    for more efficient production multiple patient-specific products by satisfying
                    the basic tenants of safety and efficacy required for early phase clinical
                    trials of cell products.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    194OO&#xD;Times Cited: 0&#xD;Cited Reference Count: 16</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248353900008 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>491</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">491</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1074</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Tran, C. N.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Davis, M. J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Tesmer, L. A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Endres, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Motyl, C. D.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smuda, C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Somers, E. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Chung, K. C.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Urquhart, A. G.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lundy, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Kovats, S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Fox, D. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Michigan, Rheumat Dis Core Ctr,
                    Ann Arbor, MI 48109 USA. Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. City
                    Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA.&#xD;Fox, DA, Univ
                    Michigan, Taubman Ctr, Room 3918,1500 E Med Ctr Dr, Ann Arbor, MI 48109
                    USA.&#xD;dfox@umich.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Presentation of arthritogenic
                        peptide to antigen-specific T cells by fibroblast-like synoviocytes</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Arthritis and Rheumatism</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Arthritis and Rheumatism</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">Arthritis Rheum.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">Arthritis Rheum</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">1497-1506</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">56</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">5</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">HUMAN CARTILAGE
                        GLYCOPROTEIN-39</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">RHEUMATOID-ARTHRITIS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">SYNOVIAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">FIBROBLASTS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">II COLLAGEN</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">INFLAMMATORY CONDITIONS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">JOINT DESTRUCTION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">DISEASE SEVERITY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MHC CLASS</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">HLA-DR</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">MODEL</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">May</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0004-3591</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000246324800016</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Objective. To assess the ability of
                    rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) to function as
                    antigen -presenting cells (APCs) for arthritogenic autoantigens found within
                    inflamed joint tissues. Methods. Human class 11 major histocompatibility complex
                    (MHC)-typed FLS were used as APCs for murine class 11 MHC-restricted CD4 T cell
                    hybridomas. Interferon-y (IFNy)-treated, antigen-loaded FLS were cocultured with
                    T cell hybridomas specific for immunodominant portions of human cartilage gp-39
                    (HC gp-39) or human type 11 collagen (CH). T cell hybridoma activation was
                    measured by enzyme-linked immunosorbent assay of culture supernatants for
                    interleukin-2. Both synthetic peptide and synovial fluid (SF) were used as
                    sources of antigen. APC function in cocultures was inhibited by using blocking
                    antibodies to human class 11 NIHG, CD54, or CD58, or to murine CD4, CD11a, or
                    CD2. Results. Human FLS could present peptides from the autoantigens HC gp-39
                    and human CH to antigen-specific MHC-restricted T cell hybridomas. This response
                    required pretreatment of FLS with IFNy, showed MHC restriction, and was
                    dependent on human class 11 MHC and murine CD4 for effective antigen
                    presentation. Furthermore, FLS were able to extract and present antigens found
                    within human SF to both the HC gp-39 and human CH T cell hybridomas in an
                    IFN-y-dependent and MHC-restricted manner. Conclusion. RA FLS can function as
                    APCs and are able to present peptides derived from autoantigens found within
                    joint tissues to activated T cells in vitro. In the context of inflamed synovial
                    tissues, FLS may be an important and hitherto overlooked subset of APCs that
                    could contribute to autoreactive immune responses.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    165SC&#xD;Times Cited: 0&#xD;Cited Reference Count: 40&#xD;Cited References:
                    &#xD; ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315&#xD; BOOTS AM, 1994,
                    IMMUNOLOGY, V8, P268&#xD; COPE AP, 1999, ARTHRITIS RHEUM, V42, P1497&#xD;
                    CORRIGALL VM, 2000, ARTHRITIS RHEUM, V43, P1606&#xD; DAVID CS, 2004, AM J MED
                    SCI, V327, P180&#xD; DZHAMBAZOV B, 2005, EUR J IMMUNOL, V35, P357&#xD; FIRESTEIN
                    GS, 1996, ARTHRITIS RHEUM, V39, P1781&#xD; GEPPERT TD, 1985, J IMMUNOL, V135,
                    P3750&#xD; GEPPERT TD, 1987, J IMMUNOL, V138, P385&#xD; GEPPERT TD, 1987, J
                    RHEUMATOL, V14, P59&#xD; GONZALEZGAY MA, 2002, SEMIN ARTHRITIS RHEU, V31,
                    P355&#xD; GORONZY JJ, 1998, INT REV IMMUNOL, V17, P339&#xD; GREGERSEN PK, 1987,
                    ARTHRITIS RHEUM, V30, P1205&#xD; HE XW, 2001, J RHEUMATOL, V28, P2168&#xD;
                    JOHANSEN JS, 1999, RHEUMATOLOGY, V38, P618&#xD; KHANIHANJANI A, 2002, J
                    RHEUMATOL, V29, P1358&#xD; KIM WU, 2004, AM J MED SCI, V327, P202&#xD;
                    KONTOYIANNIS D, 2000, ARTHRITIS RES, V2, P342&#xD; KOTZIN BL, 2000, P NATL ACAD
                    SCI USA, V97, P291&#xD; LALLY F, 2005, ARTHRITIS RHEUM, V52, P3460&#xD; MEINECKE
                    I, 2005, CURR PHARM DESIGN, V11, P563&#xD; MIRANDACARUS ME, 2004, J IMMUNOL,
                    V173, P1463&#xD; MOR A, 2005, CLIN IMMUNOL, V115, P118&#xD; PELTOMAA R, 2001,
                    RHEUMATOL INT, V20, P192&#xD; PENZOTTI JE, 1996, J AUTOIMMUN, V9, P287&#xD;
                    SEKINE T, 1999, ANN RHEUM DIS, V58, P446&#xD; SINIGAGLIA F, 2001, CURR DIRECT
                    AUTOIMMU, V3, P36&#xD; STASTNY P, 1978, NEW ENGL J MED, V298, P869&#xD;
                    STEENBAKKERS PGA, 2003, J IMMUNOL, V170, P5719&#xD; TRENTHAM DE, 1977, J EXP
                    MED, V146, P857&#xD; TSARK EC, 2002, J IMMUNOL, V169, P6625&#xD; VANBILSEN JHM,
                    2004, P NATL ACAD SCI USA, V101, P17180&#xD; VERHEIJDEN GFM, 1997, ARTHRITIS
                    RHEUM, V40, P1115&#xD; VOS K, 2000, ANN RHEUM DIS, V59, P544&#xD; VOS K, 2000,
                    RHEUMATOLOGY, V39, P1326&#xD; WEYAND CM, 1992, ANN INTERN MED, V117, P801&#xD;
                    WEYAND CM, 1995, J CLIN INVEST, V95, P2120&#xD; YAMAMURA Y, 2001, J IMMUNOL,
                    V166, P2270&#xD; YANG HY, 1999, J INVEST MED, V47, P236&#xD; ZIMMERMANN T, 2001,
                    ARTHRITIS RES, V3, P72</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000246324800016 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 07/07/ </style>
            </custom1>
            <custom3>
                <style face="normal" font="default" size="100%"> ALL BRI?</style>
            </custom3>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>636</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">636</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1073</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Trisal, V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Nademanee, A.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Lau, S. K.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Grannis, F. W.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">City Hope Natl Med Ctr, Dept Surg
                    Oncol, Duarte, CA 91010 USA. City Hope Natl Med Ctr, Dept Hematol, Duarte, CA
                    91010 USA. City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA. City Hope
                    Natl Med Ctr, Dept Thorac Surg, Duarte, CA 91010 USA.&#xD;Trisal, V, City Hope
                    Natl Med Ctr, Dept Surg Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA.</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Thymoma-associated severe
                        aplastic anemia treated with surgical resection followed by allogeneic
                        stem-cell transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </secondary-title>
                <alt-title>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </alt-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </periodical>
            <alt-periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Clinical
                        Oncology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Clin. Oncol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Clin Oncol</style>
                </abbr-2>
            </alt-periodical>
            <pages>
                <style face="normal" font="default" size="100%">3374-3375</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">25</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">22</style>
            </number>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Aug</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0732-183X</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000248744000031</style>
            </accession-num>
            <label>
                <style face="normal" font="default" size="100%">Top Tier/ </style>
            </label>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    200DL&#xD;Times Cited: 0&#xD;Cited Reference Count: 6</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000248744000031 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%">SCI 2007/08/ SCI 2007/09 </style>
            </custom1>
            <language>
                <style face="normal" font="default" size="100%">English</style>
            </language>
        </record>
        <record>
            <database name="cummulative-April2011 Copy Copy.enl"
                path="C:\Documents and Settings\alynch\Desktop\cummulative-April2011 Copy Copy.enl"
                >cummulative-April2011 Copy Copy.enl</database>
            <source-app name="EndNote" version="14.0">EndNote</source-app>
            <rec-number>210</rec-number>
            <foreign-keys>
                <key app="EN" db-id="tvdsrfez22saafe95sg5dfrrfvv2vrx09dx5">210</key>
                <key app="ENWeb" db-id="SpvuHwrtqggAACRgWhA">1068</key>
            </foreign-keys>
            <ref-type name="Journal Article">17</ref-type>
            <contributors>
                <authors>
                    <author>
                        <style face="normal" font="default" size="100%">Veale, J. L.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Yew, J.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gjertson, D. W.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Smith, C. V.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Singer, J. S.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Rosenthal, J. T.</style>
                    </author>
                    <author>
                        <style face="normal" font="default" size="100%">Gritsch, H. A.</style>
                    </author>
                </authors>
            </contributors>
            <auth-address>
                <style face="normal" font="default" size="100%">Univ Calif Los Angeles, David Geffen
                    Sch Med, Dept Urol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David
                    Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. Sharp Rees Stealy Med
                    Grp, Dept Urol, San Diego, CA USA. City Hope Natl Med Ctr, Dept Surg, Duarte, CA
                    91010 USA.&#xD;Veale, JL, Univ Calif Los Angeles, David Geffen Sch Med, Dept
                    Urol, 10833 Le Conte Ave,63-276 CHS, Los Angeles, CA 90095
                    USA.&#xD;jveale@mednet.ucla.edu</style>
            </auth-address>
            <titles>
                <title>
                    <style face="normal" font="default" size="100%">Long-term comparative outcomes
                        between 2 common ureteroneocystostomy techniques for renal
                        transplantation</style>
                </title>
                <secondary-title>
                    <style face="normal" font="default" size="100%">Journal of Urology</style>
                </secondary-title>
            </titles>
            <periodical>
                <full-title>
                    <style face="normal" font="default" size="100%">Journal of Urology</style>
                </full-title>
                <abbr-1>
                    <style face="normal" font="default" size="100%">J. Urol.</style>
                </abbr-1>
                <abbr-2>
                    <style face="normal" font="default" size="100%">J Urol</style>
                </abbr-2>
            </periodical>
            <pages>
                <style face="normal" font="default" size="100%">632-636</style>
            </pages>
            <volume>
                <style face="normal" font="default" size="100%">177</style>
            </volume>
            <number>
                <style face="normal" font="default" size="100%">2</style>
            </number>
            <keywords>
                <keyword>
                    <style face="normal" font="default" size="100%">transplantation</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">kidney</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">ureter</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">complications</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">URETEROVESICAL REIMPLANTATION
                        TECHNIQUES</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">EXTRAVESICAL</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">URETERONEOCYSTOSTOMY</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">KIDNEY-TRANSPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">COMPARING TAGUCHI</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">IMPLANTATION</style>
                </keyword>
                <keyword>
                    <style face="normal" font="default" size="100%">STRICTURES</style>
                </keyword>
            </keywords>
            <dates>
                <year>
                    <style face="normal" font="default" size="100%">2007</style>
                </year>
                <pub-dates>
                    <date>
                        <style face="normal" font="default" size="100%">Feb</style>
                    </date>
                </pub-dates>
            </dates>
            <isbn>
                <style face="normal" font="default" size="100%">0022-5347</style>
            </isbn>
            <accession-num>
                <style face="normal" font="default" size="100%">ISI:000243453900048</style>
            </accession-num>
            <abstract>
                <style face="normal" font="default" size="100%">Purpose: We compared the incidence
                    of ureteral complications between the classic (Lich-Gregoir) technique and the
                    recently popularized single stitch (Shanfield) technique in renal
                    transplantation. Materials and Methods: The charts of 721 consecutive transplant
                    recipients from May 1999 to July 2002 were retrospectively reviewed. Ureteral
                    and nonureteral complications were reviewed at 3 to 5-year followup. Results: Of
                    the 721 recipients evaluated 713 were included in the study. There were 360
                    recipients in the Lich-Gregoir group and 353 in the Shanfield group. A
                    significantly higher rate of ureteral complications occurred in the Shanfield
                    group compared to the Lich-Gregoir group (15.6% vs 3.9%, p &lt; 0.0001). The
                    Shanfield group consisted of 20 patients with ureteral leakage, 21 with
                    hematuria, 11 with strictures and 3 who had ureteral stones. The Lich-Gregoir
                    group had 8 patients with ureteral leakage, 5 with hematuria and 1 with a
                    stricture. In comparison, urinary tract infections, delayed graft function and
                    rejection rates, were not significantly different between the 2 groups (p =
                    0.76, 0.12 and 0.19, respectively). Conclusions: In contrast to other reports,
                    the Shanfield group had significantly more ureteral complications. In particular
                    the Shanfield technique may predispose patients to higher rates of hematuria and
                    stone formation. Based on this large series and published meta-analyses we
                    believe that the stented Lich-Gregoir anastomosis is the superior
                    ureteroneocystostomy technique in renal transplantation.</style>
            </abstract>
            <notes>
                <style face="normal" font="default" size="100%">ISI Document Delivery No.:
                    125PI&#xD;Times Cited: 0&#xD;Cited Reference Count: 17&#xD;Cited References:
                    &#xD; BARRY JM, 1983, J UROLOGY, V129, P918&#xD; CAPARROS J, 1996, WORLD J UROL,
                    V14, P236&#xD; GOLDFISCHER ER, 1997, J UROLOGY, V157, P770&#xD; GREGOIR W, 1962,
                    ACTA UROL BELG, V30, P286&#xD; HARIHARAN S, 2000, NEW ENGL J MED, V342,
                    P605&#xD; HARRISON JH, 1956, SURG FORUM, V6, P432&#xD; KRISTO B, 2003, UROLOGY,
                    V62, P831&#xD; KUSS R, 1991, HIST TRANSPLANTATION, P3&#xD; LICH R, 1961, J
                    UROLOGY, V86, P554&#xD; MACKINNON KJ, 1968, J UROLOGY, V99, P486&#xD; MANGUS RS,
                    2004, AM J TRANSPLANT, V4, P1889&#xD; MODLIN CS, 2000, TECH UROL, V6, P1&#xD;
                    POLITANO VA, 1958, J UROLOGY, V79, P932&#xD; SECIN FP, 2002, J UROLOGY, V168,
                    P926&#xD; SHANFIELD I, 1972, TRANSPLANT P, V4, P637&#xD; TZIMAS GN, 2003,
                    TRANSPLANT P, V35, P2420&#xD; ZARGAR MA, 2005, TRANSPLANT P, V37, P3077</style>
            </notes>
            <work-type>
                <style face="normal" font="default" size="100%">Article</style>
            </work-type>
            <urls>
                <related-urls>
                    <url>
                        <style face="normal" font="default" size="100%">&lt;Go to
                            ISI&gt;://000243453900048 </style>
                    </url>
                </related-urls>
            </urls>
            <custom1>
                <style face="normal" font="default" size="100%"> SCI 07/01</style>
            </custom1>
        </record>
    </records>
</xml>
